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Our laboratory has shown that ligands constructed using an appropriately 
substituted norbenzomorphan-derived scaffold exhibit high affinity and selectivity for the 
sigma-2 receptor (s2R) and that several of these analogs display promising activity in 
models of neurodegenerative and neurological conditions. Herein, we report the 
development of a novel set of ligands that target the s2R using a scaffold simplification 
strategy for modification of the norbenzomorphan motif to a tetralin scaffold. Systematic 
evaluation of structure-activity relationships (SAR) was conducted in four regions of the 
scaffold and across a range of substitution patterns. This effort resulted in the 
identification of critical pharmacophore elements and the development of several potent 
and selective s2R ligands. One of these, JVW-1601, displayed promising anti-
inflammatory properties in the 5XFAD mouse model of Alzheimer’s disease. In addition, 
unique structural features of the simplified scaffold and critical insight from the SAR 
 viii 
investigation were leveraged to enable the molecular identification and cloning of the 
long sought-after s2R.    
The total synthesis of (±)-alstoscholarisine E, a pentacyclic indole alkaloid, was 
completed in a longest linear sequence of seven steps from commercially available 
reagents and 15.2% overall yield, the shortest and most high-yielding synthesis reported 
to date. The approach features a unique variant of the vinylogous Mannich reaction and 
tandem intramolecular hetero Diels–Alder reaction to quickly access the core. 
Diastereoselective reduction of the cyclic vinyl ether moiety was accomplished via a 
stereoselective acyloxyacetal formation/reduction. A mild procedure to form the bridging 
aminal ring was discovered that occurs via iridium–catalyzed hydrosilylation of the 
lactam and spontaneous cyclization of the intermediate hemi-aminal with the indole 
nitrogen atom, thereby completing the total synthesis of (±)-alstoscholarisine E.   
Pierisketolide A is a rearranged ent-kaurene diterpene that possesses a 
bicyclo[3.2.1]octane ring with a fused 5,7-membered ring and a spirotetronate moiety. 
Enantioselective access to the bridged core structure was achieved using a unique 
Pauson-Khand reaction with a highly substituted cyclopentane that was prepared from   
(–)-linalool in five steps. Efforts to optimize this preliminary discovery are ongoing, and 
further elaboration of the tricyclic core is anticipated to complete the total synthesis of 
pierisketolide A. 
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THE DESIGN AND SYNTHESIS OF LIGANDS TARGETING THE 
SIGMA-2 RECEPTOR  
Chapter 1: Sigma Receptors 
1.1 JOURNEY FROM TOTAL SYNTHESIS TO SIGMA RECEPTORS 
1.1.1 Introduction 
Research in the Martin laboratories has long been focused on utilizing the 
structural complexity found in natural products and their mimics as a platform for 
broader discovery and innovation.1 These efforts have led to the development of 
interesting strategies and chemical transformations with broad utility for the construction 
of small molecules with promising biological activity. Recent work in the Martin group 
constructing small molecules that target the sigma receptors (sR) exemplifies this 
approach and highlights important discoveries that arise from challenging targets in both 
chemistry and biology.  
The path that led the Martin group to investigating sRs commenced with early 
work on the total synthesis of heteroyohimbine natural products. Challenges encountered 
during the course of that work established a key reaction sequence for the expedient 
formation of an oxahydroisoquinolne ring system.2 Ultimately, this gave rise to a more 
general strategy for accessing diverse heterocyclic scaffolds that were subsequently 
elaborated to create libraries of small molecules.3 These molecular libraries were 
subjected to a variety of assays in order to probe for potential biological activity and a 
variety of hits were identified. However, a subset of compounds constructed with a 
norbenzomorphan scaffold displayed affinity for sRs, an interesting target that piqued 
our interest.4    
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Decades of study has indicated that sRs, which are comprised of the 
pharmacologically related sigma-1 (s1R) and sigma-2 receptor (s2R) subtypes, are 
potential therapeutic targets for a broad range of diseases including cancer and 
neurological disorders.5 Yet despite extensive efforts, much remains unknown about this 
relatively enigmatic receptor class. The s1R was successfully cloned in 1996, allowing a 
more thorough investigation, and  a crystal structure was finally obtained in 2016.6 In 
contrast, when we initiated our work the s2R had not yet been cloned, thereby blocking 
access to modern tools for investigation. A wide variety of structurally diverse ligands 
bind the s1R and s2R, with substantial overlap in their binding profiles, which has 
resulted in additional challenges that are compounded by the absence of structural 
information about the protein.7 However, the potentially untapped medicinal value of the 
s2R suggested that the challenges posed by this elusive target might be an opportunity 
for much needed discovery. 
Accordingly, the Martin group forged ahead with an investigation of the 
norbenzomorphan scaffold, as well as other scaffolds derived from it, for targeting the 
s2R.4,8 These efforts revealed important structural features of the scaffold that can be 
used to affect s1R and s2R affinity.9 At the time, the s1R had been implicated in 
neurological disorders, but the s2R had largely been pursued as a target for the treatment 
and diagnosis of cancer and little was known about its role in central nervous system 
(CNS) disorders.7,10 Discoveries in the Martin group demonstrated that modulating the 
s2R can have beneficial outcomes in models of several CNS disorders including 
Alzheimer’s disease (AD), neuropathic pain, and traumatic brain injury (TBI), as well as 
alleviating symptoms of alcohol withdrawal.11-14 However, the expanding therapeutic 
potential of the s2R highlights the need for an increased understanding of its biological 
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role, which would be aided through the development of additional tool compounds and 
by access to the cloned receptor. 
1.1.2 Total Synthesis Leads to MCAP 
Research in the Martin group has long been focused on accessing a variety of 
natural product and natural product-like molecules.1 A central tactic in this endeavor has 
been to develop chemical transformations that efficiently access structural subunits that 
are common to these compounds. Among these, the hydroisoquinoline and 
oxahydroisoquinoline ring systems were identified as a shared structural feature of many  
indole alkaloids in the yohimbine family of natural products (Figure 1.1).15 A synthetic 
approach that provides efficient access to these cis-fused heterocycles would therefore be 
broadly applicable for the construction of a variety of natural products. 
 
Figure 1.1. Yohimbine natural products.  
Accordingly, the Martin group devised a strategy to access this structural motif 

























































a strategically placed amide moiety that linked the diene and dienophile (Scheme 1.1). 
Initial investigations proved the utility of this IMDA approach for accessing the 
hydroisoquinoline subunit and the transformation was extended as a key step in the total 
syntheses of reserpine (1.1) and yohimbine (1.2).16,17  In the event, propargyl alcohol 1.6 
was converted to the  benzyl amine 1.7 and subsequently acylated to afford triene 1.9. 
Consistent with preliminary studies, thermolysis of 1.9 induced cyclization to provide 
diene 1.10 in 93% yield.18,19 Refunctionalization of cycloadduct 1.10 via regioselective 
epoxidation and nucleophilic ring–opening afforded acyloxy analog 1.11, which was 
elaborated over 10 steps to yield the advanced indole intermediate 1.12. Oxidative 
cyclization with Hg(OAc)2 provided reserpine 1.1 in 35% yield after zinc mediated 
reduction of the crude reaction mixture.16,17 Acyloxy analog 1.11 was also elaborated to 
access yohimbine (1.2) through a similar reaction sequence.17,20   
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Scheme 1.1. Total synthesis of yohimbine natural products.17  
These successful total syntheses demonstrated the value of this IMDA approach 
for accessing yohimbine natural products, while related investigations suggested that the 
HDA reaction was equally effective for accessing the oxahydroisoquinoline subunit in 
tetrahydroalstonine (1.3), a heteroyohimbine natural product.20 However, deficiencies in 
the final oxidative iminium cyclization to form the C ring, as well as other lengthy 
manipulations, highlighted the need for a more efficient strategy. This led to a second-
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synthesis and subsequent refunctionalization would set the stage for a similar HDA 
reaction to construct the pentacyclic ring system of 1.3 (Figure 1.2).2         
 
 
Figure 1.2. Second generation approach to construct heteroyohimbine natural products. 
Expedient access to the HDA precursor 1.12 was critical to assess the feasibility 
of this modified approach and the known 3,4-dihydro-b-carboline (1.14), which is 
accessible in two steps from tryptamine, was identified as a promising entry point to this 
system. An interesting one-pot procedure was developed for functionalization of the 
carboline imine through treatment with an acyl chloride to form an activated N-
acyliminium with subsequent nucleophilic addition.15 In the event, treating 1.15 with 
crotonyl chloride (1.16) in the presence of the trimethylsilyloxydiene 1.17 promoted the 
vinylogous Mannich reaction to afford N-acylated triene 1.13 (Scheme 1.2).21 Refluxing 
1.13 in mesitylene induced the HDA reaction to provide the cycloadducts 1.18 in 80% 
yield. Cycloadduct 1.18 was subsequently elaborated in a few additional steps to 
























Scheme 1.2. Development of a one-pot vinylogous Mannich reaction.  
It is notable that the developed sequence provided access to the pentacyclic core 
of the heteroyohimbine alkaloids in only four steps from commercially available 
reagents. Indeed, the initial challenge of constructing the oxahydroisoquinoline subunit 
provided an opportunity to develop a concise approach to the HDA precursor reaction via 
in interesting vinylogous Mannich reaction. This endeavor highlighted the utility of 
combining a vinylogous Mannich reaction in tandem with a HDA reaction to construct 
challenging alkaloid natural products.21-26 However more generally, this demonstrated 
that nucleophilic addition to an activated N-acyliminium in tandem with a cycloaddition 
reaction might be a powerful tool for the assemblage of a variety of structurally complex 
heterocycles.1           
1.1.3 MCAP 
Early work in the Martin group to access heteroyohimbine natural products is 
representative of a target-oriented approach, in which the genesis of the synthetic strategy 



































analysis.27 Target oriented synthesis (TOS) is designed to start from readily available 
starting materials and access a finite area of chemical space. An alternative strategy is to 
efficiently access a maximum amount of unique chemical space from simple materials, 
an approach that Schreiber defined as diversity oriented synthesis (DOS) in 2000.28 This 
has been a useful strategy for drug discovery projects, in which large libraries of diverse 
and complex molecular skeletons are generated and screened for activity against a panel 
of biological targets.29 Because there is not a specific target, the screen can identify both 
a biological target of interest and a small molecule scaffold that modulates it from diverse 
chemical space, thereby avoiding some structural bias that might be present in a TOS 
approach.30 
The strategy for the preparation of DOS chemical libraries often relies on 
diversity generating processes to transform a collection of relatively similar substrates 
into a collection of more diverse products.29 The libraries should be accessible through 
efficient synthetic sequences, ideally less than five steps without protecting group 
manipulations. Thus, the sequential use of complexity generating reactions, in which the 
product of one reaction is used directly in the next complexity building step, is 
particularly valuable.  
Multi-component coupling reactions (MCRs) have emerged as a powerful 
approach to generate molecular complexity by creating multiple bonds in a single step 
from less complex inputs.31  Combining sequential transformations into a single-pot 
process is useful for increasing synthetic efficiency, as well as operational simplicity. An 
MCR that displays broad functional group tolerance can facilitate the introduction of 
orthogonal handles for a variety of transformations.32-35 This provides an opportunity for 
a multitude of tandem complexity generating reactions, including annulations and 
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refunctionalizations that are well suited for accessing numerous scaffolds in a DOS 
application, an approach that is commonly referred to as build/couple/pair.36  
Shortly after it’s conception, the Mannich-like reaction sequence that was 
developed during our efforts toward alkaloid synthesis was envisaged to provide more 
general access to heterocyclic scaffolds. The modular nature of the three-component 
reaction sequence is distinct from MCRs because introduction of the reactants must be 
synchronized to obtain the desired reactivity, rather than occurring with simultaneous 
addition.37,38 However, the efficiency of the process derives from the one-pot nature of 
the operation, as opposed to the timepoint of reagent addition. Therefore, by providing a 
similar ability to incorporate orthogonal functional handles for subsequent diversification, 
it was expected to be useful from a DOS perspective.  
An opportunity to more fully explore this utility later presented itself when the 
Martin group became involved in the National Institutes of Health (NIH) Molecular 
Libraries Initiative (MLI). The goal of the program was to facilitate downstream drug 
development using high-throughput screening (HTS) of chemically diverse, molecular 
libraries to identify small molecule modulators of thousands of biological targets.39,40 
This effort to expand HTS to the public sector, which was designed to accelerate target 
validation and identification of chemical probes, required production of chemical 
libraries that accessed unique areas of chemical space. Thus, the Martin group sought to 
generalize the tandem vinylogous Mannich and hetero Diels-Alder reaction sequence to 
provide access to structurally diverse heterocyclic scaffolds for this purpose.    
The sequence previously developed to access complex alkaloid natural products 
can be broadly characterized as the addition of a carbon nucleophile to an iminium ion 
that is generated in situ from an imine and an acylating agent. A related sequence was 
designed for application in DOS, in which the condensation of an amine 1.19 and an 
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aldehyde 1.20 afford an intermediate imine that is converted to an activated N-acyl 
iminium ion in situ via treatment with acylating agent 1.21.  Subsequent addition of a 
nucleophile (“Nu”) 1.22 provides the functionalized amide adduct 1.23 (Scheme 1.3) in a 
single reaction vessel.41,42 This one-pot, four-component coupling reaction, identified as 
the multicomponent assembly process (MCAP), generates considerable complexity from 
an assortment of simple and readily available reagents. The modular nature of the 
reaction facilitates the incorporation of orthogonal functional handles that can be used in 
sequenced annulation reactions, creating additional skeletal complexity in the resulting 
polycyclic heterocycles 1.24. Further functional group (FG) interconversions and 
diversification provide a library of unique scaffolds that are differentiated into various 
analogs 1.25. Through the judicious choice of input components, the MCAP sequence 
provides rapid access to diverse scaffolds that access unique regions of chemical space.     
 
    































 The efficiency of the one-pot MCAP sequence was leveraged to access over 900 
compounds comprised of a variety of heterocyclic scaffolds that broadly probed a range 
of chemical space.1 The structural diversity achieved with this approach is represented by 
the benzazepines (1.26-1.27), benzodiazepine (1.28), polycyclic indoles (1.29-1.30), 
isoindolinone (1.31),  tetrahydroisoquinolines (1.32-1.33), quinazolone (1.34),   2-
arylpiperidines (1.35-1.36), tetrahydrobenzonaphtheridine (1.37), benzoxazocine (1.38), 
and the norbenzomorphan (1.39) scaffolds that were accessed with this strategy (Figure 
1.3).3,43-50 The prepared compounds were screened at various NIH facilities to evaluate 
for potential biological activity as part the MLI program and indeed many of the 
compounds provided hits at various biological targets.  Because the norbenzomorphan 
framework 1.39 is structurally related to the benzomorphan subunit of morphine and has 
shown promise as a molecular framework for designing acetylcholinesterase (AChE) 
inhibitors, it was particularly interesting as a platform for HTS.51-53  
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 The Martin group prepared a library of nornbenzomorphan analogs using the 
MCAP procedure from commercially available 2-bromo-5-chlorobenzaldehyde (1.40) 
and 2-bromo-4-chlorobenzaldehyde (1.41) (Scheme 1.4).50 Condensation with allyl 
amine (1.42) provided intermediate imines 1.43 and 1.44 that were subsequently 
activated with benzyl chloroformate, followed by addition to of allyl zinc bromide to 
provide dienes 1.45 and 1.46 in 89-91% yield. Ring closing metathesis (RCM) proceeded 
smoothly to deliver 2-arylpiperidines 1.47 and 1.48, and a subsequent Heck cyclization 
furnished the bridged enecarbamates 1.49 and 1.50  in 92-94% yield.  Reduction of the 
olefin was achieved by treatment with Et3SiH in the presence of trifluoroacetic acid to 
deliver the 7-chloro-norbenzomorphan 1.51 and 8-chloro-norbenzomorphan 1.52 
scaffolds. Refunctionalization of the heterocyclic nitrogen atom and cross coupling 
reactions with the aryl chloride readily converted the norbenzomorphan core to a 




Scheme 1.4. Synthesis of norbenzomorphan analogs using the MCAP.   
The initial series of analogs was screened for activity in a range of phenotypic and 
target-based assays at the NIH Molecular Library Probe Production Center Network 
(MLPCN), the National Institute of Mental Health’s (NIMH) Psychoactive Drug 
Screening Program (PDSP), and Eli Lilly’s Open Innovation Drug Discovery (OIDD) 
Program.50 Notable activity was observed for several of the analogs across a spectrum of 
biological targets, but low nanomolar affinity for the s1R and s2R was observed among 
a subset of derivatives (Figure 1.4).54 Some early hits with distinct substitution patterns, 
including compounds 1.54-1.55, displayed little preference for either sR subtype. 
Alternatively, morpholine substituted norbenzomorphan 1.56 displayed modest 
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displayed low levels of selectivity for the s2R. It was not immediately clear how the 
substitution pattern was imparting the observed selectivity, but the results suggested that 
altering the functionality might enable modulation of sR subtype selectivity. Additional 
investigation revealed the sR to be an intriguing biological target for a range of 
therapeutic implications, but the absence of definitive characterization data for the 
receptors made them enigmatic targets.5 With the DOS initiative having identified an 
interesting biological target, as well as an easily diversifiable molecular scaffold that 
modulates it, some additional investigation was warranted.    
      
 
Figure 1.4. Representative examples of preliminary norbenzomorphan analogs with 
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1.2 THE HISTORY OF SIGMA RECEPTORS  
1.2.1 The Early Discovery of Sigma Receptors and Their Misclassification  
The receptors that have now been classified as sRs were originally discovered in 
1976 in the seminal work of Martin et al. that identified several opioid receptor subtypes 
through pharmacological evaluation of morphine and a series of structurally related 
analogs (Figure 1.5).55  The classical approach relied on observation of distinguishable 
behavioral responses to drug administration in dogs, and the receptor category was 
named according the first letter in the name of the corresponding compound it bound. 
The administration of morphine (1.58) diminished nociceptive responses with general 
apathy toward external stimuli, but notably the dogs did not sleep. This response was 
attributed to activity at mu (µ) opioid receptors and was accompanied by a depression in 
body temperature and pulse rate. In contrast, dosing with ketocyclazocine (1.59) 
produced a notable sedative effect, without altering body temperature or pulse rate, and 
was attributed to activity at the kappa (k) opioid receptors. Administration of the 
benzomorphan SKF-10,047 (1.60) produced a dose dependent increase in pulse rate, but 
did not alter body temperature. However, a pronounced change in behavior was observed 
as mania and symptoms of delirium ensued, which was associated with activity at sigma 
(s) opioid receptors. The unique physiological response to each chemically related 
compound was blocked by naloxone, an established opioid antagonist, supporting the 
hypothesis that the behavioral responses resulted from agonism of related opioid 




Figure 1.5. Compounds used to distinguish opioid receptor classes  
Following Martin’s initial discovery of sRs, there were continued 
pharmacological investigations to probe the nature of the SKF-10,047 binding site, and 
these suggested that it was a receptor class distinct from the opioid receptors.56,57 
Previous studies indicated that the levorotatory isomers of opioids had higher affinity for 
µ-opioid receptors than the corresponding dextrorotatory isomer and that the opioid l-
etorphine had non-specific high affinity for opioid receptors.58-60 However in 1982, Su et 
al. reported that the racemic, tritiated version of the prototypic sR ligand [3H]-(±)-SKF-
10,047 had affinity for a site in the guinea-pig (GP) brain that was not accessible by l-
etorphine.56 They also found that the dextrorotatory isomer of benzomorphans (1.61-
1.63) had much greater affinity for the l-etorphine inaccessible site, in contrast to the 
levorotatory isomers which interacted preferentially with opioid receptors (Figure 1.6). In 
1983, Tam provided similar evidence that dextrorotatory benzomorphans had affinity for 
a site inaccessible by the opioid antagonist naloxone in the rat brain.57 Collectively, 
evidence provided by Su and Tam indicated that the sR was distinct from opioid 





















Figure 1.6. Dextrorotatory benzomorphans with affinity for l-etorphine inaccessible site 
in GP brain using [3H]-SKF-10,047 in the presence of l-etorphine to mask 
opioid sites. 
While evidence was emerging to suggest that the sR was a unique receptor class, 
concurrent pharmacological characterization of the phenylcyclidine (PCP) receptor led to 
some speculation that sR ligands and PCP act at the same site.61 Pert and coworkers 
reported in 1981 that the binding of tritium labeled PCP ([3H]-PCP) in rat brain was not 
affected by morphine or naloxone, but was displaced by sR binding benzomorphans such 
as SKF-10,047 (1.60), even at low concentrations.62 The psychotomimetic activity and 
other behavioral responses that resulted from administration of  SKF-10,047 was similar 
to that observed with PCP, supporting the hypothesis that they acted at the same site.63-66 
However, Su and Tam both demonstrated that sR ligands did not have similar potency at 
the PCP site and Tam reported differences in regional distribution of the two receptors, 
suggesting that they were not synonymous.56,57 The PCP receptor was later revealed to be 
located within the N-methyl-D-aspartate (NMDA) receptor, and additional investigations 
with high affinity and noncompetitive radiolabeled NMDA receptor ligands found that 
these sites were separate from those labeled by the sR ligand [3H]-(±)-SKF-10,047.67-69 
Eventually, a committee at the 1987 “International Seminar on Phencyclidine and Sigma-
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classifying the PCP and sR as distinct sites based on ligand affinity and selectivity 
patterns.70   
The reports by Su and Tam helped establish that the sR was indeed a unique class 
of receptors with affinity for structurally diverse opiates (1.61-1.63) and non-opioid 
(1.64-1.69) drugs, inspiring additional investigations to characterize pharmacological 
features of the novel receptor (Figure 1.7).56,57 This aided the identification of additional 
drugs that interacted with the sR, some of which were radiolabeled for competition 
binding analysis and autoradiographic studies including haloperidol (1.64), which had the 
highest sR affinity among these early ligands.57 Unfortunately, many of these had a lack 
of specificity for sR which stymied early characterization efforts, but in 1984 Snyder 
reported that (+)-3-(3-hydroxyphenyl)-N-propylpiperidine (3-PPP) (1.68) had high 
affinity for the sR with greater selectivity.71 However, (+)-3-PPP was also a presynaptic 
dopamine autoreceptor agonist, and a truly selective sR ligand was still needed. The 
crucial advance came in 1986 when Weber et al. reported that the achiral, symmetric 
guanidine derivative 1,3-di-o-tolylguanidine (DTG) (1.69) displayed high affinity for the 
sR and that it was selective over the opioid receptors, dopamine D2 receptors, and the 
PCP binding site.72 This specificity was similar to that of (+)-3-PPP (1.68), but the 
structural simplicity of the achiral ligand made it more attractive as a prototypic sR 
selective ligand, suggesting that the radiolabeled analog [3H]-DTG (1.70) would prove 
beneficial in additional investigations.  
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Figure 1.7. Non-opioids with affinity for sR. Determined using GP brain against [3H]-
DTG unless noted otherwise. a Determined using [3H]-EKC in the presence 
of naloxone in rat spinal cord membrane.  
1.2.2 Two Sigma Receptor Subtypes  
The  sR binding site originally identified in Martin’s seminal work had become 
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characterization and misidentification that plagued early studies, but the arrival of 
selective sR ligands enabled more thorough biochemical characterization. At the time, 
the sR was pharmacologically distinguished from other receptors according to the 
binding profile against a range of established ligands.70 High affinity for (+)-
benzomorphans, such as pentazocine (1.62) and dextrallorphan (1.63) was a defining 
feature of the sR.56,57 Additionally, the sR binding site was insensitive to naloxone and l-
etorphine opioids and had much lower affinity for (-)-benzomorphans, which interacted 
preferentially with opioid receptors. Another critical defining feature of the sR was 
notably high affinity for the non-benzomorphan ligands haloperidol (1.64), as well as (+)-
3-PPP (1.68), and DTG (1.69), which were more sR selective ligands.57,71,72 After a 
decade of research that had been plagued by misidentification, this unique binding pattern 
comprised the core features of sRs, but evidence soon emerged that pointed to the 
existence of two distinct sR subtypes.  
Irradiation of opioid receptors with ultra-violet (UV) light was a known method 
for altering the protein structure and attenuating ligand affinity, leading Bowen et al. to 
pursue a similar strategy for evaluating the sR.73 In 1989 Bowen disclosed the results 
from that effort, finding that irradiation of membranes from the rat brain with 254 nM 
light for five minutes decreased affinity for the non-benzomorphan ligands [3H]-DTG and  
[3H]-(+)-3-PPP by approximately 50%.74  In contrast, irradiation with 254 nM light 
significantly enhanced affinity for the benzomorphan ligand [3H]-(+)-SKF-10,047 by 
about 190% after 10 minutes of irradiation. Additionally, exposure to UV light reduced 
the ability of the non-benzomorphan ligands to inhibit benzomorphan binding, whereas 
benzomorphan inhibition of benzomorphan binding was unaffected. The differing 
photosensitivity to binding suggested that different proteins with distinct responses to 
irradiation were binding the structurally unique compounds and that that interaction was 
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not occurring at a common binding site. Moreover, [3H]-DTG and [3H]-(+)-3-PPP each 
labeled approximately four-times the number of sites that were labeled by [3H]-(+)-SKF-
10,047.  Collectively these data supported the existence of a multiple binding site model 
with structurally distinct sR ligands. Bowen concluded with a noteworthy comment that 
the photosensitivity in rat membrane discussed in the report was different from what they 
independently observed using GP brain, a much more common tissue source for sR 
analysis, leading him to suggest that there may be a species-specific difference in the 
relative ratio of sR subtypes.74        
Bowen and Hellewell expanded on those findings in 1990 with a follow up report 
that compared the sR binding profile in tissues obtained from GP brain and 
pheochromocytoma (PC12) cells, a tumor cell line derived from the rat adrenal gland.75 
Both tissues displayed similar levels of high affinity for the prototypic sR selective 
ligand [3H]-DTG, as well as haloperidol, a defining feature of the sR. Both tissues also 
displayed high affinity for [3H]-(+)-PPP, another selective sR ligand, but in PC12 cells it 
was approximately one-third of that obtained using GP brain (i.e. KD = 86.3 ± 22 and 
27.4 ± 2, respectively). The number of sites labeled by [3H]-DTG in GP brain was also 
roughly three-times greater than the number of sites labeled by [3H]-(+)-PPP. In addition 
to differing affinities for established sR selective ligands, the two tissues displayed 
opposite stereochemical preferences for benzomorphans. The GP brain is a common 
tissue source for sR studies, and it displayed the typical preference for (+)-
benzomorphans, yet little to no affinity for those compounds was observed in PC12 cells 
that instead had a modest preference for the (-)-isomer with generally low affinity overall. 
The report also utilized an azide-modified DTG analog for photolabeling studies and 
determined that a 25 KDa protein was labeled in GP brain, but it was not observed in 
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PC12 cells. Instead, and 18 and 21 KDa protein was labeled and, in each case, the 
photolabeling was blocked by haloperidol.  
Collectively, the findings of Bowen and Hellewell in 1989 and 1990 provided 
critical evidence to suggest there were two molecular forms of the sR, which could be 
differentiated by their binding profile and molecular weight.74,75 Additional evidence 
emerged supporting this assertion, prompting leading researchers in the field to propose 
in 1992 that the sigma bind site be delineated into two subtypes, the s1R and s2R.76 The 
s1R subtype exhibits the pharmacological profile that was classically associated with 
sRs in early work by Su and Tam, including high affinity for DTG and haloperidol, as 
well as (+)-pentazocine and other (+)-benzomorphans. The s2R was defined by similar 
affinity for DTG and haloperidol, but with low affinity for (+)-benzomorphans. The 
functional role of the s1R and s2R was still largely unknown, but these critical studies 
provided important pharmacological characterization data that established the existence 
of two distinct receptor subtypes and they also identified sR selective ligands that were 
employed in decades of future research.     
1.3 THE SIGMA-1 RECEPTOR 
1.3.1 Early Characterization of the Sigma-1 Receptor  
Early investigations of sRs relied on pharmacological characterization and were 
confounded by a promiscuous binding profile among structurally diverse opioid and non-
opioid drugs that lacked specificity for the receptor. The result was more than a decade of 
confusion over the identity of the receptor, and the pharmacological effects associated 
with binding remained ambiguous. This dilemma was transformed with the emergence of 
ligands selective for the sR, but soon confounded again with the realization that there 
were in fact two sR subtypes, and many of the early sR selective ligands, such as DTG 
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and (+)-3-PPP, had high affinity for both. However, (+)-pentazocine was identified as a 
high affinity and specific s1R ligand that was selective over s2R, providing a useful tool 
for additional characterization efforts that was not yet available for the s2R.75 In fact, 
[3H]-(+)-pentazocine remains the radioligand of choice for determining s1R affinity, 
whereas s2R affinity is still commonly determined with [3H]-DTG in the presence of (+)-
pentazocine to block binding at the s1R.77  
Delineation of sR subtypes using selective radioligands for binding analysis was 
a significant milestone that was followed by efforts to obtain structural information 
regarding the molecular composition and function of the receptors. The s1R was the first 
to be successfully cloned in 1996 by purifying the receptor from GP liver homogenate 
with eight chromatographic steps while tracking the [3H]-(+)-pentazocine binding activity 
of the eluent.78 The human s1R was subsequently cloned from a human placental 
choriocarcinoma cDNA library and found to share 93% amino acid sequence similarity to 
the GP s1R.79 Shortly thereafter, the receptor was also cloned from rat and murine 
tissues.80,81  
1.3.2 Localization and Function Role of the Sigma-1 Receptor  
Determination of the s1R primary sequence fueled numerous predictions about 
the topology and function of the protein. The 25.3 KDa protein was comprised of 223 
amino acids with over 90% homology across species.78-81 The molecular weight and 
binding profile of the cloned protein were consistent with those reported by Bowen and 
Hellewell for the s1R.74,75 Interestingly, the sequence has no significant similarity to any 
known mammalian protein, but does share some similarity with the yeast C8-C7 sterol 
isomerase, ERG 2P.78 However, the cloned mammalian receptor does not possess any 
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sterol isomerase activity, and the lack of similarity to other known mammalian proteins 
has made it difficult to ascertain the functional role of the s1R.82 
Determination of the s1R amino acid sequence enabled some predictions about 
the topology of the membrane protein, but several conflicting models emerged.83 Hanner 
and coworkers applied hydrophobicity analysis to predict a single transmembrane portion 
near the N-terminus, whereas Kekuda and Seth both predicted the single transmembrane 
portion was located in the middle of the protein.78,79,81  A later model predicted that a 
hydrophobic region near the N-terminus, and also in the middle of the protein, both 
spanned the membrane to form an extracellular loop that contains approximately 50 
amino acids with the N- and C-terminus located intracellularly.84,85  This two-pass 
transmembrane model gained more acceptance and would form the foundation of 
additional modeling studies that attempted to ascertain a structural basis for ligand 
binding.86,87 However, 20 years after the s1R was successfully cloned, a crystal structure 
was finally obtained that suggested the original single transmembrane hypothesis was 
accurate (infra vide).6   
Access to the cloned gene also enabled expression studies, immunohistochemical, 
and immunoprecipitation techniques, in addition to radioligand analysis, that indicated 
wide distribution throughout the CNS and peripheral tissues.86,88-90 At the subcellular 
level, s1R is thought to be primarily located at the endoplasmic reticulum (ER) and 
specifically localized at the mitochondrial associated membrane (MAM).91 The MAM are 
specialized microdomains of the ER that form junctions with the mitochondria and 
regulate diverse cellular functions that are important for cell survival, including Ca2+ 
transfer and protein folding.92 At the MAM in its dormant state, the s1R is part of a 
complex with binding immunoglobulin protein (BiP), a chaperone protein that is known 
to form mass assemblies with other ER chaperones that respond to stress.91 In response to 
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either a depletion of cellular Ca2+ levels or ligand activation, the s1R dissociates from 
BiP, a critical step that allows it to exert its modulatory function with a chaperone at a 
myriad of other cellular proteins.93       
In this model, the s1R is proposed to function as a ligand-operated receptor 
chaperone at the MAM, but can also translocate to other regions within the cell to interact 
with other proteins.94 At the MAM, it serves to stabilize the conformation of the inositol 
triphosphate receptor (IP3R) and couple it to ankyrin B to control Ca2+ signaling between 
the mitochondria and the ER, which is related to ER stress and cellular survival.91 It also 
helps control transmission of ER stress to the nucleus by interacting with the inositol 
requiring enzyme 1 (IRE1), an ER stress response protein that results in enhanced 
production of antistress and antioxidant proteins.95 The s1R can also translocate to the 
plasma membrane, where it interacts with ion channels and G-protein coupled receptors 
(GPCRs).94,96 Additionally,  the s1R can also translocate to the nuclear membrane to help 
regulate gene expression.94,97   
These models notwithstanding, the precise physiological role of the s1R remains 
somewhat ambiguous given that an endogenous ligand has not yet been identified. Some 
steroid hormones have significant affinity for the s1R, most notably progesterone (1.71) 
(Ki = 55 ± 15 nM against [3H]-(+)-pentazocine for recombinant human s1R in Jurkat 
cells), which has been proposed as an endogenous ligand (Figure 1.8).98 However, a wide 
range of Ki values (30-300 nM) for progesterone in various tissues have been reported 
since it was originally proposed and the physiological relevance of the interaction 
remains unclear.5,10,83,99,100 The natural hallucinogen N,N-dimethyltryptamine (DMT) 
(1.72) has been proposed as an endogenous ligand, but its relatively low affinity for the 
s1R  (Ki = 14.75 µM) has also led to skepticism about the physiological importance of 
this interaction.5,101-103 The long chain sphingoid base D-erythro-sphingosine (1.73) (Ki = 
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140 ± 20 nM) has  also been proposed as a potential endogenous ligand, but the identity 
or existence of a specific endogenous ligand remains uncertain.104,105  
   
 
Figure 1.8. Proposed endogenous ligands for s1R.  
The status of the s1R as an orphan receptor without a relationship to other known 
proteins has complicated the determination of ligand functional activity. Instead, 
phenotypic response to ligands have generally been used to assign their functional 
activity as either agonist or antagonist. Initially, exacerbation of cocaine-induced 
convulsions in the rat was ascribed to agonist activity, whereas antagonists inhibited the 
convulsions, but had no affect when administered on their own.106,107 Later agonist 
activity was assigned to those compounds that recapitulated the genetic overexpression 
phenotype.82  Within the cell, administration of (+)-pentazocine produces agonist activity 
that results in dissociation of s1R from BiP.91 In contrast, haloperidol did not affect the 
s1R-BiP complex and blocked the dissociation caused by agonists, consequently it was 
ascribed antagonist activity. This antagonist functionality is assigned to those ligands that 
recapitulate the genetic knockdown phenotype.82 However, the molecular mechanism by 
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1.3.3 Sigma-1 Receptor as a Therapeutic Target 
Initial interest in sR as a therapeutic target undoubtedly resulted from the original 
presumption that it was an opioid receptor along with its association with 
psychotomimetic properties, but this grew as an increasing number of structurally 
diverse, pharmacologically active compounds were found to have sR activity. In the time 
since, the s1R has been implicated in a vast number of disorders that creates a complex 
picture of the receptor’s therapeutic potential. Much of the attention has focused on the 
role s1R in various neurological disorders,82,93,108 including Alzheimer’s disease (AD),109 
Parkinson’s disease (PD),110,111, Huntington’s disease (HD),112 amyotrophic lateral 
sclerosis (ALS),113,114 traumatic brain injury (TBI),115 and ischemic stroke.116,117 The s1R 
has also emerged as an intriguing, non-opioid target for the treatment of pain,118,119 as 
well as addiction.10 In fact, s1R ligands are currently in phase II clinical trials for the 
treatment of neuropathic pain120 and ischemic stroke,121 as well as  phase II clinical trials 
for PD122 and phase IIb/III trials for AD.123,124 The putative role of s1R in processes 
critical to cell survival, such as protein folding and intracellular ion regulation and signal 
transduction suggests that malfunction or mutation of the protein might have a significant 
impact even if the exact mechanisms remain unclear.91,94  
Perhaps unsurprisingly, the receptors role in cell survival has also attracted 
attention to the s1R as a potential therapeutic target for the treatment of cancer.125 Both 
s1R and s2R are overexpressed in a variety of proliferating normal cells and cancerous 
cells, but significantly higher levels of s2R expression are observed that has generated 
more attention in this area (infra vide).126 However, the role of the s1R in cell survival 
and proliferation makes it an intriguing target as well. Accordingly, early studies 
demonstrated that putative s1R antagonists are correlated with a decrease in cancer cell 
growth.127,128 Evidence does not suggest that s1R is itself an oncogene, but genetic 
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knockdown of the receptor inhibits cell growth and proliferation in breasts cancer cell 
lines with little effect on non-cancerous breast cells.129 This effect was recapitulated to a 
similar extent in the presence of s1R antagonists, indicating that small molecule 
inhibition can diminish proliferation of cancerous tissues. The upregulation of s1R has 
also been utilized for visualization with radiolabeled ligands, which could be promising 
for diagnostic imaging of tumors.130,131 The s1R is an attractive target for cancer 
treatment and imaging, but the molecular mechanisms of the receptor in tumor biology 
and its antiproliferative effects remain unclear, requiring additional investigation for 
continued advancement toward the clinic.125,126  
 The broad diversity of diseases and cellular processes impacted by the s1R 
highlights the importance of the receptor for maintenance of proper cellular function and 
viability. Numerous genetic mutations in s1R  have been correlated to a predisposition 
for disease that is generally linked to the loss of motor neuron function associated with 
ALS, distal hereditary motor neuropathy, and Silver syndrome.5 More work is needed to 
understand the molecular mechanisms at play in these diseases and the mechanism of 
action associated with its pharmacology. However, these findings emphasize the 
importance of continued investigation of the receptor as a therapeutic target. Indeed many 
approved pharmaceuticals including fluvoxamine (Luvox), sertraline (Zoloft), buproprion 
(Wellbutrin), donepezil (Aricept), and opipramol (Opipram) have s1R affinity.10,132 The 
fact that several approved drugs interact with the s1R and that ligands targeting the s1R  
have continued into phase II and III clinical trials holds promise that the receptor might 
be safely targeted in humans.  
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1.3.4 Sigma-1 Receptor Pharmacophore 
The potential of the s1R as a therapeutic target for a range of diseases with unmet 
medical needs has continued to inspire efforts to construct small molecules that are 
selective for the receptor. A number of pharmacologically active drugs with s1R affinity 
were identified early, but the receptors affinity for a range of structurally diverse ligands 
posed a challenge for pharmacological characterization. This promiscuity hindered efforts 
to identify small molecules that were selective for the s1R, as well as to elucidate the 
pharmacophore elements that contribute to structure–activity relationships (SAR) that 
might aid the ligand design process.133 With the delineation of sR subtypes, it was 
realized that much of the early binding data was confounded by unclear subtype 
specificity.133 Nonetheless, a fertile starting ground for investigation was provided by 
established ligand classes with affinity for s1R such as benzomorphan 1.62, N,N’-
disubstituted guanidine 1.69, and phenyl piperidines 1.64 and 1.68 (Figure 1.9). 56,57,75 A 
unified pharmacophore model that could bridge the structural dissimilarity among 
established ligands, connecting common molecular features for optimal s1R affinity, was 




Figure 1.9. Ligand classes that have s1R affinity.  
1.3.4.1    Sigma-1 Pharmacophore: Gilligan Model  
An extensive SAR study of substituted piperidine analogs that were structurally 
related to haloperidol led Gilligan and coworkers to report in 1992 a s1R pharmacophore 
based on the lead compound (1.74) (Figure 1.10.A).138 Analog 1.74 was characterized 
with [3H]-SKF-10,047, which is selective for s1R over s2R, and found to have high sR 
affinity (Ki = 6 nM) with selectivity over dopamine D2 (IC50 > 1,000 nM) and PCP 
receptors (Ki = > 10,000 nM). The four distinct pharmacophore elements (A-D) of 1.74 
were identified as region A containing a distal aromatic group that was connected by a 
linker group (region B) to a centrally located piperidine ring (region C). The piperidine 
ring provided a basic nitrogen atom, which is a salient feature of virtually all sR ligands 





























Figure 1.10. Pharmacophore proposed for s1R by Gilligan based on substituted 
piperidine analogs.  
A series of  analogs based on 1.74 were prepared with systematic structural 
variations in each of the regions A-D as part of an SAR study to establish a 
pharmacophore model for this ligand class.138 Computational analysis of a subset of these 
analogs with geometry optimization and energy minimization led Gilligan and coworkers 
to propose a more detailed four-component model with optimal distances between the 
critical pharmacophore elements (Figure 1.10.B).138 The model presented the basic 
nitrogen atom as the central component, flanked by two hydrophobic groups that 
extended from the center at different distances. Aliphatic and aromatic groups were 
accommodated at the proximal hydrophobic site, which was optimally positioned 3 Å 
from the nitrogen atom. However, it was noted that both the chemical nature and distance 
of this substituent from the basic amine were critical for obtaining s1R selectivity over 
D2 dopamine and 5-HT2 serotonin receptors. Heteroaromatic, aromatic and aliphatic 
carbocycles were well-tolerated at the distal hydrophobic site, optimally positioned 6 Å 
from the nitrogen center, although aromatic groups were favored for oral potency. The 
highest potency was generally obtained when the linker between the nitrogen center and 
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the distal hydrophobic site contained a hydrogen bonding center (i.e. carbonyl or ether 
moiety). While providing interesting insight into the pharmacophoric features, the author 
acknowledged that the model was limited by the structural similarity of the flexible 
piperidine analogs, and therefore likely does not define a minimal pharmacophore. The 
model also made no attempt to account for sR subtype selectivity.      
1.3.4.2    Sigma-1 Pharmacophore: Glennon and Ablordeppey Model  
In an effort to establish the minimal pharmacophore elements of the (+)-
benzomorphan scaffold, Glennon and coworkers sought to simplify the nucleus to the 
phenethylamine substructure 1.75 (Figure 1.11).139 The (+)-benzomorphan opiates are 
archetypal sR ligands, but many only displayed modest potency or suffered from off-
target activity, which Glennon hoped to overcome through derivatization of the active 
pharmacophore subunit. Accordingly, a library of phenethylamine analogs 1.75 were 
prepared that highlight several important findings from this SAR investigation. Most 
notably, a continual increase in affinity was observed as the alkyl linker between the 
nitrogen atom and the phenyl group at R2 was extended (n = 2-5). It was also noted that 
stereochemistry had a relatively minimal impact on the binding profile, although there 
was a modest preference for the S-(+)-stereoisomer. This study led to the identification of 
lead phenylethylamine analog 1.76, which exemplified the critical pharmacophore 
elements and in contrast to many benzomorphans, the phenethylamine nucleus provided 
selectivity over PCP sites. In addition, sR affinity was maintained if the nitrogen atom 
was a secondary or tertiary amine. Collectively, these findings suggested that the 
phenethylamine subunit might represent the active pharmacophore of the benzomorphan, 
but it should be pointed out that overall sR affinity was determined without 




Figure 1.11. Glennon’s benzomorphan scaffold minimization approach.   
 Glennon and Ablordeppey later expanded on the previous study to generate a 
more thorough pharmacophore model for the s1R that was generally consistent with their 
earlier observations, along with a few key points of clarification (Figure 1.12).140,141 The 
primary hydrophobic site was found to be critically important for s1R affinity and was 
generally occupied by an aryl group, although the group was not required to be aromatic 
and other aliphatic carbocycles could be accommodated. However, the absence of a 
hydrophobic group at this position considerably diminished s1R affinity. The optimal 
alkyl “y-chain” length between the central nitrogen atom and the primary hydrophobic 
groups was proposed to be 8.3 Å, but some variability could be accomodated. In contrast, 
the alkyl “x-chain” allowed more variability in length without deleterious effects and the 
phenyl group that occupied the secondary hydrophobic site was not significant for s1R 
affinity. Replacing the phenyl moiety with a methyl or naphthyl group did not have a 
considerable impact, provided that the x-chain extended to the secondary hydrophobic 






















and tertiary amine, but with variable effects. The methyl substituent alpha to the amine 
did not to contribute to s1R affinity and was removed without impact. As in Gilligan’s 
model, no attempt was made to identify features that led to  sR subtype selectivity.    
 
 
Figure 1.12. Glennon/Ablordeppey pharmacophore model.   
The pharmacophore model proposed by Gilligan was followed by Glennon and 
Ablordeppey’s proposal, and the two are quite similar. However, the Glennon and 
Ablordeppey model does not require the hydrogen bonding group that was suggested in 
Gilligan’s model, but it does allow for hydrophobic bulk at the secondary site. It should 
be noted that the s1R is quite promiscuous with affinity for structurally diverse 
compounds that are not encompassed within this model, but many with high affinity fit 
well.141 Both models are defined using conformationally flexible ligands that cannot 
account for the three-dimensional relationship of the various binding pockets and neither 
provides a mechanism for obtaining selectivity over the s2R. At the time there were few 
ligands with selectivity for the s2R over the s1R to enable this distinction, but the 
similarity in their binding profiles highlights the need for a pharmacophore model that 
can distinguish between sR subtypes.141    
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1.3.4.3    Sigma-1 Pharmacophore: Laurini Model  
The absence of a s1R  crystal structure continued to prohibit structure–based-
design strategies, but technological advances enabled more detailed computational 
predictions of pharmacophore models.133 Zampieri et al. utilized a computational 
approach in an effort to generate a predictive 3-D pharmacophore model by applying 
computational software to assess the features of 31 structural variants of the 
benzooxazolone ligand 1.77 that had a wide range of s1R affinities (Figure 1.13).142 The 
highest ranked quantitative SAR (QSAR) model correlated the predicted and empirically 
determined binding affinity values (Ki) within four-fold error for most analogs in the 




Figure 1.13. Zampieri pharmacophore model using benoxazolone ligands. Adapted with 
permission.143 Copyright (2009) American Chemical Society.  
The derived pharmacophore aligned well with the Glennon/Ablordeppey and 
Gilligan models with some variation that might be attributable to the specific structural 
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hydrophobic site from the earlier models into an aromatic and an aliphatic hydrophobic 
site at similar distances (8.5 and 7 Å, respectively) from the positive ionizable group 
represented by the central basic amine.142 An additional hydrophobic site was posited to 
exist 3.6 Å from the positive ionizable group that corresponded well with the secondary 
hydrophobic site from earlier models. Similar to the Gilligan model, the Zampieri model 
also accommodates a hydrogen bond acceptor group, which was present in the training 
set. The model was validated by comparing predicted and experimentally determined 
binding affinities for six newly developed piperidine analogs that are structurally similar 
to haloperidol (error 1.1- 4.4-fold), along with three known haloperidol analogs that have 
high s1R affinity (error 2.6-9.5 fold).142 This 3-D model expands on the spatial 
relationship of key pharmacophore elements and provides some additional basis for 
structure-based ligand design in the absence of a crystal structure, but the predictive 
power is unclear given the error observed for ligands outside of the training set. Like 
earlier models, this 3-D model focuses only on features for optimal s1R binding without 
distinguishing between  sR subtypes.   
1.3.4.4   The Sigma-1 Receptor: A 3-D Homology Model  
In 201l, Laurini and colleagues published the first 3-D model of the s1R that was 
generated and optimized using homology modeling techniques.87 The overall 3-D 
structure was constructed using four different proteins with ³30% sequence similarity to 
the s1R and their crystal structures formed templates that were linked together to build 
the transmembrane potions of the protein, along with optimization processes that created 
missing loops. The modeling relied on previous structural predictions, including two 
membrane spanning portions, an assumption that was shown to be incorrect in the 
recently obtained crystal structure.6 The homology model was then further refined by 
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leveraging data from the Zampieri 3-D pharmacophore model, along with information 
gleaned about the binding pocket from previous ligand docking studies and  mutagenesis 
experiments.142 The early site-directed mutagenesis experiments were critical for 
establishing that Asp126 and Glu172 were essential for ligand binding, likely through 
interaction with the basic amine moiety of the ligand, and therefore comprised the 
putative binding site within the recpeptor.144  
The model was validated by docking a series of ligands with binding affinities 
that spanned 4-orders of magnitude and comparing the predicted and empirically 
determined s1R affinities.87 The structurally diverse series included benzoxazocine and 
aryl piperidine analogs, as well as the traditional ligands (+)-pentazocine and haloperidol. 
Impressively, the ligand affinities were predicted in the correct order, and the calculated 
values were quite similar to the experimental values (R2 = 0.93). The 3-D homology 
model was then used for in silico characterization of a benzoxazocine ligand, and the 
protein-ligand interactions were identified as: (1) Asp126 formed a critical salt bridge 
with the basic amine site; (2) favorable van der Waals and electrostatic interactions 
between Glu172 and the benzoxazocine heterocycle, and between Arg119 and the p-Cl-
phenyl moiety; (3) hydrogen bonding between the benzoxazolone carbonyl moiety and 
the -NH donor of the THR151 and Val152; (4) stabilizing p-p interactions between the 
benzylamine aromatic ring and Trp121 as well as between the benzoxazolone phenyl ring 
and Tyr173; and (5) generally favorable hydrophobic interactions with Ile128, Thr151, 
and Val152 (Figure 1.14). It is perhaps unsurprising that these interactions were observed 
during docking given that several were predicted in the Zampieri pharmacophore model 




Figure 1.14. 2-D depiction of the predicted protein-ligand interactions in homology 
model. Adapted with permission.145 Copyright (2011) American Chemical 
Society.   
Having characterized the relevant protein interactions in the binding pocket, three 
new ligands were constructed with structural features designed to interact with the protein 
and provide a range of high, medium, and low affinity analogs.87 Indeed, the calculated 
affinities closely aligned with experimental values, which suggested that the 3-D model 
might resemble the  natural topology of the protein and might be a useful predictive tool 
for structure-based ligand design. Numerous subsequent studies by Laurini and others 
utilized this homology model in the design of structurally diverse s1R ligands with good 
agreement between the in silico and empirical binding affinities.146-151 Another study 
recapitulated in silico the effects of site directed mutagenesis among a variety of DNA-
mutant proteins variants, confirming that the protein-ligand interactions outlined in the 






















Roldan made additional progress toward structural characterization of s1R with a 
solution NMR study that revealed the secondary structure of the protein independently of 
the homology model.153  The NMR study predicted a cytosolic domain that consisted of 
three a-helices, one of which was relatively mobile (residues 81-85), as well as a second 
transmembrane helix (residues 91-107). The experimentally determined structure 
correlated well with the 3-D homology model, further supporting the validity of the 
predicted structure.133        
1.3.4.5   Summary of Sigma-1 Receptor Pharmacophore Models  
Since the s1R was first cloned in 1992, considerable progress has been made 
toward determining the overall structure of the protein and generating a predicative 
pharmacophore model for structure-based ligand design. In the absence of a crystal 
structure for the protein, there has been surprising consistency between early 
pharmacophore models that relied on extensive SAR studies and more recent 
computational efforts to generate 3-D structural information. However, definitive 
structural information remained unavailable, and much was unclear about the molecular 
mechanisms and the structural basis for agonist and antagonist activity.154 Access to the 
cloned s1R protein enabled major leaps in our understanding of the receptor topology 
and pharmacophore model, but the s2R had not yet been cloned, blocking access to 
similar biochemical tools for characterization. Thus, the predictive models did not 
provide rationale for designing ligands that were selective for s1R over s2R, a 
formidable challenge given the overlap and their binding profiles.  
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1.3.5 Sigma-1 Receptor: X-ray Crystal Structure  
In 2016, 20 years after the s1R was first cloned, Kruse et al. reported the first 
crystal structure of the protein.6 Purification and crystallization of the integral membrane 
protein had long eluded researchers, but recent advances in the area of membrane protein 
structural biology have enabled the use of lipid-based crystallization methods, along with 
mild detergents and improved X-ray diffraction methods with microcrystals.155 Kruse and 
coworkers leveraged these modern advances in a GPCR-inspired approach that utilized a 
mild maltoside detergent to extract the protein from Sf9 insect cells expressing high 
levels of a s1R  construct.6,155 Subsequent purification with antibody affinity 
chromatography provided pure and minimally altered protein that was crystallized using 
the lipidic cubic phase technique.  
 The crystal structure revealed a triangular trimeric assembly in which each 
promoter contains a single transmembrane domain (a-1, residues 6-31) at the outer 
corners (Figure 1.15.A).6 Interestingly, the single-pass transmembrane structure is 
consistent with early predictions, but is contrary to the more widely accepted two-pass 
transmembrane models.78,85,133 The cytosolic portion of the structure is comprised of a b-
barrel (residues 81-176) bordered by a-helices (a-2 to a-5) (Figure 1.15.B).6  The a-
helices that cover the b-barrel opening (a-4 and a-5, residues 177-223) adjacent to the 
membrane contain hydrophobic amino acids facing the membrane. Although the protein 
contains only one transmembrane portion, this face of the trimer is likely embedded in 
the membrane.155 The ligand-binding site is located in the center of the b-barrel portion 
of the protein, which is structurally similar to the active sites of oligomeric bacterial 
enzymes in the cupin family.6 The wider opening of the b-barrel is proximal to the 
membrane and gated by a-helices (a-4 and a-5) and the more narrow polar opening of 
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the b-barrel is blocked by Gln135. In fact, the binding pocket is entirely blocked from 
solvent and the pathway for ligand entry is unclear.6  
 
  
Figure 1.15. (A)X-ray crystal structure of s1R trimeric complex. Membrane shown in 
grey. (B) Structure of single s1R protomer. Adapted by permission from 
Springer Nature Customer Service Centre GmbH: Springer Nature Nature 
Structural & Molecular Biology] Schmidt, H.R., Betz, R.M., Dror, R.O. et 
al. Structural basis for σ1receptor ligand recognition. Nat. Struct. Mol. 
Biol. 25, 981–987 (2018). Copyright (2018).      
The s1R crystal structure was originally obtained in complex with two 
structurally distinct ligands, PD144418 (1.78) (Figure 1.16.A) and 4-IBP (not shown) and 
later reported in complex with the classical s1R ligands pentazocine (1.62) and 
haloperidol (1.64) (Figure 1.16.B).6,154  An interesting attribute of the s1R is its ability to 
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bind a wide range of structurally diverse ligands that fit into the general pharmacophore 
model described by  Glennon and Ablordeppey, most critically a basic amine site. The 
crystal structure revealed that the amine forms a salt bridge with Glu172, a highly 
conserved acidic residue that prior mutation studies confirmed was necessary for 
binding.144 Another acid residue, Asp126 is also important for binding and forms a 2.7 Å 
hydrogen bond that helps position Glu172.6,154 Aside from these polar amino acids, the 
binding pocket consists of primarily aromatic and hydrophobic residues including Val84, 
Trp,89, Met93, Leu95, Phe107, Ile124, Trp164, and Leu 182. In addition, Tyr103 
interacts with ligands via aromatic stacking, but also forms a critical hydrogen bond with 
Glu172 to help orient the acidic residue. Replacing this important residue, which was 
previously thought to be part of the second transmembrane domain, with a Y103F mutant 
resulted in a significant reduction in binding affinity, confirming its critical role in 














Figure 1.16. (A) X-ray crystal structure of s1R with PD144418. (B) X-ray crystal 
structure of s1R with (+)-pentazocine. (C) X-ray crystal structure of s1R 
with haloperidol. Adapted by permission from Springer Nature Customer 
Service Centre GmbH: [Springer Nature][Nature Structural & Molecular 
Biology] Schmidt, H.R., Betz, R.M., Dror, R.O. et al. Structural basis for 
σ1receptor ligand recognition. Nat. Struct. Mol. Biol. 25, 981–987 (2018). 
[Copyright] 2018. 
 
The initial crystal structures obtained with nonclassical s1R ligands provided for 
the first-time definitive structural information about the receptor that was critical for 
continued advancement. In 2018, Kruse expanded on this work with a more detailed 
examination of the molecular basis for ligand binding  and activity using the classical 
s1R agonist (+)-pentazocine (1.62) and antagonist haloperidol (1.64) (Figure 1.16.B).154 
The study found that agonists have a binding pose that is unique from antagonists, which 
tend to favor a more linear orientation that positions the primary hydrophobic group 
toward the space between the a-4 and a-5 helices. In contrast, agonists tended to project 
the primary hydrophobic group toward the a-4 helix, forcing the helix to shift 1.1-1.8 Å 
from the a-5 helix. The shift did not disrupt the protomer interface of the trimeric 
structure. Importantly, Kruse pointed out that crystallization favors low-energy states and 
therefore may not be representative of a fully activated state. In a higher-energy state, a 















reports of  s1R agonists biasing toward lower molecular weight oligomers.157,158 
Conversely, antagonist are associated with higher molecular weight oligomers, 
suggesting that the oligomerization state might be important for to the molecular basis of 
s1R function.159 
  A detailed view of ligand recognition has emerged that unites early 
pharmacophore models with molecular interactions that will enable true structure-based 
design efforts in the future. The discrepancy between relevant protein-ligand interaction 
observed in the 3-D homology model and the crystal structure of bound ligands 
highlights the limitations of these predictive models. The considerable structural diversity 
of  s1R ligands is attributed to the largely hydrophobic, flexible binding pocket that was 
observed in the crystal structure.6 However, a rationale for applying this information to 
structure-based design strategies that provide selectivity over the s2R remain unclear.  
The availability of definitive structural information for the s1R provides a foundation for 
continued advancement that will likely transform our understanding of the receptor’s 
molecular mechanisms and function, expanding its potential as a therapeutic target.  
1.4 THE SIGMA-2 RECEPTOR 
1.4.1 Sigma-2 Receptor: An Enigmatic Target 
The sRs have been the subject of considerable research for more that 40 years, 
during which time the s1R has benefited from significant characterization advancements 
that have furthered our understanding of the receptor and paved the way for additional 
discoveries. In contrast, the s2R had evaded characterization efforts, until the research 
outlined through the course of this work resulted in the successful cloning of the receptor 
(vide infra).160 Accordingly, the s2R has only recently entered the modern era of 
biological investigation and has instead relied on classical pharmacological approaches 
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since its initial discovery. These investigations had continued to endure many of the same 
challenges that afflicted early s1R research efforts including misidentification of the 
receptor, absence of an endogenous ligand, and a promiscuous binding profile with a 
poorly defined pharmacophore.  
The s2R was pharmacologically distinguished from the s1R in 1990 following 
consecutive reports from Bowen and coworkers outlining several characteristics that were 
unique from the s1R.74,75 As previously discussed, the s2R was defined by its high 
affinity for the classical sR ligands DTG and haloperidol and its low affinity for (+)-
benzomorphans, whereas the s1R displayed high affinity for each of these ligands. 
Bowen et al. also found the s2R to be approximately 21.5 kDa, smaller than the s1R 
which was approximately 25 kDa. Critically, this work identified the benzomorphan (+)-
pentazocine (1.62) as a s1R selective ligand, but at the time there were no selective s2R 
ligands available. In fact, many ligands that were developed were either selective for s1R 
or had high affinity for both the s1R and s2R.161,162 Consequently, tool compounds for 
continued pharmacological characterization of s1R were more readily available. 
Additionally, previous characterization efforts often relied on benzomorphans based on 
the seminal findings of Su and Tam and were likely more indicative of s1R activity.56,57 
These attributes, along with the successful cloning of the s1R and the more recently 
published crystal structure have led to a better understanding of the s1R in comparison to 
the s2R, which has been much more enigmatic.5   
Characterization of the s2R has relied almost entirely on pharmacological 
approaches in the absence of a cloned gene and with no structural information available. 
This has blocked access to modern biological techniques for elucidation of central 
features of the receptor. Protein knock-down and over-expression studies have not been 
available to assess the functional role of the receptor and ascribe the pharmacological 
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effects of various ligands.5 Lacking knowledge of the structure of the 2sR has also 
prevented the development of highly specific antibodies for unambiguous 
characterization with immunohistochemical and immunoprecipitation techniques. 
Researchers have instead relied on less selective binding assays that commonly use the 
non-sR specific ligand [3H]-DTG in the presence of (+)-pentazocine to mask s1R 
binding sites.77,83 Information gleaned about the anatomical distribution and subcellular 
localization has often had to utilize radioligand assays or other photoaffinity labeling 
approaches with molecules designed to selectively target the receptor.83 Because 
structural information for the s2R has not been available and it has not been possible to 
use structure-based design strategies for increasing sR subtype selectivity. Moreover, the 
considerable overlap in s2R and s1R ligand binding profiles, has presented a formidable 
challenge for the development of s2R selective compounds.161  
Despite the challenges associated with s2R research the receptor has continued to 
attract attention due to its potential as a therapeutic target for a range of disorders. This 
has largely focused on treatment and diagnostic imaging of cancer due to high levels of 
s2R expression in cancer cells.77 More recently, important findings from the Martin 
group11-14,163 and other contemporaneous reports,164-168 have indicated that the s2R might 
be a target for the treatment of some neurological disorders. Interestingly, the s2R and 
s1R were also recently highlighted as a potential targets for treatment of the novel 
coronavirus SARS-CoV-2, which has resulted in the current COVID-19 global pandemic 
people leading to significant loss of life, and catastrophic social and economic 
upheaval.169 Although the exact role of the s2R in these disease remains unclear, the 
receptor appears to have a critical role in cell viability that highlights the need for 
continued investigation.    
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1.4.2 Sigma-2 Receptor: Characterization   
1.4.2.1   Sigma-2 Receptor: Localization and Physiological Role   
Autoradiographic and photoaffinity labeling studies indicate that the s2R has 
wide anatomical distribution in both the CNS and peripheral organs. Labeling studies in 
brain tissue using [3H]-DTG in the presence of (+)-pentazocine have shown wide 
distribution of the s2R with higher densities observed in areas associated with posture 
control and movement such as the motor cortex, cerebellum, oculomotor nuclei, central 
gray matter, and the substantia nigra pars reticulata.170 The s2R is also found outside of 
the central nervous system with high densities in liver and kidney tissues,171 as well as 
tumors and proliferating tissues.83,172 At the subcellular level, fluorescent  ligands with 
selectivity for the s2R over s1R were found to colocalize with fluorescent markers of the 
mitochondria, lysosomes, ER, and plasma membrane suggesting distribution among 
several cellular organelles.173 The s2R has also been proposed to localize specifically 
within lipid raft microdomains of the membrane, which require harsh detergents for 
protein extraction and likely contributes to challenges associated with isolation of 
functional s2R protein.174  
The precise role of the s2R in biological systems and its molecular mechanisms 
remain unclear. Without an endogenous ligand or gene-knockout models, the effects of 
receptor agonism and antagonism can only be hypothesized based on interactions with 
synthetic compounds. Unfortunately, a standardized system has not been used, and a 
variety of physiological effects have been associated with activation of s2R (i.e. agonist 
activity).175 This seemingly makes the use of ligand descriptors such as agonist and 
antagonist somewhat arbitrary, but reliance on pharmacological characterization has 
prevented use of a less ambiguous approach. Early studies classified ligands as either 
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agonists or antagonists based on behavioral responses. For instance, Matsumoto and 
coworkers reported that the pan-sR selective ligand BD-1047 (1.79) was able to 
attenuate dystonia in the rat that was induced by DTG and haloperidol, but had no effect 
on its own (Figure 1.17).176 The authors ascribed this to antagonism at both s1R and 
s2R, although the lack of sR subtype specificity is confounding and makes this result 
unclear.   
 
 
Figure 1.17. Pan-sR selective ligand BD-1047 that was classified as an antagonist.   
1.4.2.2   Sigma-2 Receptor: Expression in Proliferating Cells 
The s2R has remained an enigmatic target since it was first delineated from the 
s1R with relatively little known about its precise physiological role and its potential as a 
therapeutic target. However, the majority of investigations have focused on the 
involvement of the s2R in cancer, inspired by early reports that it is overexpressed in 
cancer cell lines with respect to the corresponding non-malignant cell line. Indeed, high 
expression levels of the s2R in PC12 pheochromocytoma and C6 glioma rodent derived 
cancer call lines, were critical for establishing the existence of the s2R.75 Vilner et al. 
followed with a broader examination and found high expression of both sR subtypes in a 
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at much higher level.172 This suggested that the s2R might play in an integral role in 
cellular function and might also be useful for diagnostic imagining purposes.  
To expand on this potential, Wheeler et al. investigated the relationship between 
s2R expression and the proliferative status of cancerous cells.177 The ability to accurately 
ascertain the proliferative status of a tumor is useful for determining an effective 
treatment regimen in the clinic, but technical challenges associated with biopsy and assay 
methods present some difficulties.178,179 Therefore, a noninvasive assay to directly 
visualize whole tumor proliferation status with positron emission tomography (PET) 
methods would be valuable.77 Wheeler et al. examined mouse mammary adenocarcinoma 
cell in their active proliferating state (P-cells) and found that s2R expression was 
approximately ten-fold higher than in their corresponding quiescent state (Q cells), which 
was also greater than in nonmalignant cells.177 A follow up study indicated that the P:Q 
ratio in solid tumors was significantly elevated and in good agreement with the P:Q ratio 
observed in tissue culture.180 These results suggested that the overexpression of s2R in 
cancerous tissue might be effective not just for distinguishing tumors from proximal 
healthy tissue, but also for assessing the proliferative status.    
Validation of the s2R as a biomarker for the proliferative status of solid tumors 
led to a concerted effort to generate s2R selective radioligands that could be used for 
PET imaging. Relatively few selective s2R ligands were known, but while developing 
dopamine D3 ligands Mach et al. inadvertently discovered that benzamide analog 
YUN252 (1.80) had high affinity and selectivity for the s2R (Figure 1.18).181 This 
inspired the development of several structural analogs with 11C- and 18F-radiotracers 
incorporated for PET imaging, including [11C]-RHM-1 (1.81) and [18F]-ISO-1 
(1.82).7,182,183 MicroPET studies and tumor uptake imaging with the 11C analog 1.81 
provided promising initial results, although the short half-life (11C t1/2 = 20.4 min) was 
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not favorable for PET imaging in the clinic, but the 18F analog 1.82 has a half-life that is 
more favorable [18F] (t1/2 = 109.8 min).183 Subsequent analysis of [18F]-ISO-1 (1.82) 
indicated high tumor uptake with good tumor/normal tissue ratios and rapid clearance 
from the blood in the mouse. These promising results were followed with successful in 
human studies using [18F]-ISO-1 (1.82) for PET imaging of proliferative status of solid 
tumors and is currently undergoing clinical trials.184,185   
  
 
Figure 1.18. s2R ligands developed for PET imaging.      
1.4.2.3   Putative Sigma-2 Activation and Cytotoxicity in Cancerous Cells  
The s2R has notably high expression levels in cancerous tissue that attracted 
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expression level was also indicative of a role in cell viability. Putative activation of the 
s2R has been associated with modulation of intracellular calcium levels, which is 
important for signaling and regulation of cellular processes.186 Treatment with the s2R 
selective ligand CB-64D (1.83) was reported to induce a brief, but rapid release of Ca2+ 
from stores within the endoplasmic reticulum (ER) in human SK-N-SH neuroblastoma 
cells that returned to baseline levels within five minutes (Figure 1.19).187 Subsequent 
removal of the ligand produced no further changes in Ca2+ levels with no observed 
morphological changes associated with cytotoxicity. However, continued exposure for an 
additional 20 minutes led to an additional rise in Ca2+ levels that was sustained for up to 
60 minutes. This Ca2+ release was insensitive to thapsigargin, and was therfore proposed 
to be derived from the mitochondria rather than the ER. The sustained Ca2+ increase also 
led to morphological signs of apoptotic cell death, which were not observed during the 
initial transient release. This increase in cytosolic Ca2+ levels was not observed in the 
presence of s1R selective ligands and was attributed to activation of s2R, an effect that 
was blocked by the putative pan-selective sR antagonist BD-1047 (1.79).  
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Figure 1.19. s2R selective ligands investigated for modulation of intracellular Ca2+ 
levels.  
Intracellular calcium provides an important signaling mechanism for proliferation 
and cell viability,186 but its link to s2R activation and cytotoxicity is not entirely clear.188 
For instance, the high affinity s2R ligand PB28 (1.84) was found to inhibit Ca2+ release 
in SK-N-SH neuroblastoma cells, but also has potent cytotoxicity in the same cell line 
(Figure 1.19).128,189 However treatment of SK-N-SH cells with F281 (1.85), a structural 
analog of PB28, resulted in immediate and non-transient increase in intracellular Ca2+ 
concentration derived from the ER, as well as thapsigargin insensitive sites (Figure 
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be pointed out that PB28 also has high affinity for the s1R making interpretation of these 
results somewhat difficult.128 Another s2R ligand,  SN79 (1.86) has been proposed to 
have antagonist activity because it attenuates cocaine-induced convulsions and locomotor 
activity in behavioral models (Figure 1.19).192 However, treating SK-N-SH cells with 
SN79 produces a small Ca2+ signal even though no appreciable cytotoxicity is 
observed.193 These reports indicate a role for s2R in Ca2+ homeostasis, but the underlying 
mechanisms remain uncertain.  
Inhibition of proliferation and s2R mediated cytotoxicity has been observed in a 
variety of malignant cell lines and has been the most common phenotypic response 
associated with activation of s2R, but the underlying cellular mechanism requires further 
clarification .175,194-196 An early report by Bowen and coworkers revealed that treatment 
of numerous cancer cell lines of neuronal and non-neuronal origin with a variety of sR 
ligands had cytotoxic effects.194 Additional investigations found that treating MCF-7 
breast cancer cells with the putative s2R agonist CB-64D (1.83) resulted in dose 
dependent cytotoxicity. The mechanism of cell death was attributed to caspase-
independent apoptosis, as evidenced by DNA fragmentation and Annexin V binding, and 
cytotoxicity was independent of mutations in the tumor suppressor gene p53.196  Mach et 
al. developed several high affinity s2R selective ligands that also possessed micromolar 
level cytotoxicity in EMT-6 mouse breast cancer cells and MDA-MB-435 human 
melanoma cells (Figure 1.20).7,188 However, the mechanism of cell death was at least in 
part caspase-3 dependent becasue the caspase inhibitor Z-VAD-FMK partially inhibits 
DNA fragmentation and cytotoxicity. Autophagosome markers were also observed with 
each of the bicyclononane ligands, WC-26 (1.87), SV119 (1.88), and tropane analog 




Figure 1.20. Selective s2R ligands that have cytotoxic effects of malignant cell lines.  
Siramesine (1.90) is a ligand with subnanomolar affinity for the s2R that was 
originally developed for the treatment of anxiety and depression (Figure 1.21).197 
Although it ultimately lacked efficacy in clinical trials, it was well-tolerated in humans, 
and the reports of s2R mediated cytotoxicity in cancer cell lines suggested that it might 
be promising as a cancer therapeutic. This led Ostenfeld et al. to investigate tumor cell 
death in a variety of cancer cell lines, including MCF-7 human breast cancer and ME-180 
human cervix carcinoma,  upon treatment with siramesine (< 10 µM).198 Similar to some 
earlier reports, caspase-independent apoptotic cell death was observed, and cytotoxicity 
was independent of the tumor suppressor p53 protein; however, siramesine was 
significantly more potent than previously reported s2R ligands. A significant increase in 
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inhibited by the antioxidant a-tocopherol, suggesting that oxidative stress may be 
involved. Additional studies indicated an accumulation of siramesine in lysosomes that 
induced a rapid rise in pH and destabilization, resulting in lysosomal leakage and 
dysfunction that triggered caspase-independent cell death.199 In contrast, a report by Turk 
et al. found that treating HaCaT cells with an increased concentration of siramesine (> 20 
µM) resulted in rapid cell death that was not the result of lysosomal leakage.200 Instead, 
generation of ROS caused destabilization of the mitochondria by loss of mitochondrial 
membrane potential and release of cytochrome c that triggered caspase-3 mediated cell 
death.   
 
 
Figure 1.21. The s2R selective ligand siramesine that is associated with cytotoxic effects 
in malignant cell lines.  
Although the mechanisms remain unclear, s2R ligand induced cytotoxicity is 
prevalent in cancer cell lines, providing a convenient phenotypic metric for comparison. 
This led Mach et al. to proposed a system for classifying functional activity of s2R 
ligands based on cell viability in comparison to siramesine (1.90) as a standard ligand 
(Figure 1.22).201   Mach et al. refers to siramesine as a well-accepted s2R agonist, which 
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lines, a feature that has commonly been associated with s2R activation.198,201 However, it 
is worth reiterating that the functional role of s2R in cell viability is not clear, and a 
variety of mechanism could be associated with cell death that might confound results, 
which is supported by recent findings from Mach’s group.202 This notwithstanding, Mach 
et al. proposed that s2R ligands (50 µM for 24 h) that possess cytotoxicity (EC50 in 
EMT-6 or MDA-MB-435 cells) greater than 90% relative to siramesine (EC50 = 15.9 ± 
2.7 µM), are classified as full agonists. Ligands that possess cytotoxicity that is less than 
10% relative to siramesine, are classified as antagonists, and ligands that falls in the 
intermediate range are classified as partial agonists. Using this approach Mach assigned 
the azabicyclononane SV119 (1.88) and tropane RHM-138 (1.89) analogs as full 
agonists, azabicyclononane analogs WC-26 (1.87) and YUN245 (1.91) as partial 
agonists, and the azabicyclononane SV95 (1.92) and the flexible benzamide RHM-1 
(1.93) as antagonists (Figure 1.22). It is interesting that derivatives of the 
azabicyclononane scaffold elicit such a wide range of cytotoxicities, but recent findings 
suggest that this effect may not be mediated by the s2R.202  
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Figure 1.22. Functional activity assignment for s2R ligands based on cytotoxicity in 
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The cumulative results from these studies produce a complex picture of the 
functional role of s2R in cell viability and the molecular mechanisms for its cytotoxic 
effects. Modulation of the s2R appears to have an effect in Ca2+ homeostasis, which is 
known to play a critical role in cellular signaling that affects cell viability. However, 
some studies suggest that it is difficult to directly correlate s2R mediated cell death with 
an increase in intracellular Ca2+ levels.175 In addition, the s2R mediated cytotoxicity in 
cancer cell lines appears to occur through multiple pathways that can be both caspase-
dependent and independent and that the mechanism might depend on ligand 
concentration and cancer type.7 Determination of the functional role of s2R in these 
processes requires more investigation that would be aided by access to the s2R gene, but 
the receptor seems to be firmly linked to cancer biology and cell viability. The 
importance of obtaining a better understanding of the therapeutic potential of s2R is 
highlighted by the fact that the potent s2R ligand siramesine was safe for humans in 
clinical trials and many studies have found s2R mediated toxicity toward tumor cells to 
have little effect on nonmalignant tissues.203    
1.4.2.4   Sigma-2 Receptor: Putative Antagonism and Neurobiological Disorders 
Pharmacological manipulation of the s2R has long been the only mechanism for 
assessing functional activity of ligands, but selective antagonists of s2R are surprisingly 
sparse in the literature. This has been attributed to a dearth of selective s2R ligands and a 
lack of unambiguous characterization of the role of this receptor.204 Behavioral studies 
have provided one criterion for assigning functional activity, with attenuation of DTG or 
psychostimulant induced dystonic head movement in the rat being ascribed to s2R 
antagonists.176,205 This strategy was used to assign the high affinity s2R ligands SM21 
(1.94),177 benzamide 1.95,206 BD-1047 (1.79), and SN79 (1.86) as antagonists (Figure 
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1.23).192 However, among the limited number of putative s2R antagonists, many suffer 
from either modest s2R affinity or a lack of specificity.207 The limited availability of 
unambiguous s2R antagonists has resulted in relatively few studies of their biological 
effects, but some evidence is emerging that antagonist action at the s2R might be 
beneficial in the treatment of addiction and some neurological disorders.208       
 
 
Figure 1.23. Putative s2R antagonists based on behavioral models.    
 Recently, Izzo et al. discovered that some modulators of the s2R are competitive 
antagonists for b-amyloid (Ab) 1–42 oligomers at neuronal synapses.164 This study 
determined that Ab oligomers exhibit saturable binding  to neuronal synapses at a single 
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inhibition of learning and memory.164,165 Because the involvement of Ab in 
synaptotoxicity is of interest for the treatment of AD,  Izzo et al. screened a propriety 
library of small molecules for their ability to displace Ab and identified lead compounds 
CT0109 (1.96) and CT01202 (1.97) for their potent inhibition of Ab binding, which were 
subsequently determined to be potent and selective for the s2R (Figure 1.24).164 The s2R 
ligands and their structural analogs CT01344 (1.98) and CT01812 (1.99)  effectively 
blocked the downstream deficits associated with Ab binding and also restored behavioral 
deficits in the transgenic hAPPLond/Swed mouse model of AD. One of the identified 
compounds, CT1812 (1.99), was advanced and is currently undergoing phase II clinical 
trials for the treatment of AD.209 These findings highlight the promise of the s2R as a 
new therapeutic target for the treatment of AD and also corroborated independent results 
in the Martin group that pointed to similar neuroprotective attributes of ligands that 
modulate the s2R (vide infa). 
 
   































Another ligand that modulates the s2R and is thought to act as an antagonist is 
roluperidone (1.100), which was developed by Minerva for the treatment of 
schizophrenia (Figure 1.25).167,210 Rodent models with roluperidone (1.100) have 
demonstrated that it is efficacious against the negative symptoms of schizophrenia, and 
although it is essentially equipotent for both the s2R and the serotonin 5–HT2A, its 
activity at the s2R is thought to modulate relevant dopamine and glutamatergic 
pathways.167 The mechanistic role of roluperidone is not entirely clear, but it is proposed 
to act through synergistic antagonism of 5–HT2A and the s2R.210 Roluperidone is 
currently undergoing phase III clinical trials for the treatment of schizophrenia, 
suggesting that high affinity modulators of the s2R are safe in humans for the treatment 
on CNS disorders.211  
 
   
Figure 1.25. Ligand that modulates s2R undergoing clinical trials for the treatment of 
schizophrenia.     
1.4.3 Attempts to Identify the Sigma-2 Receptor Protein 
It is somewhat surprising that despite decades of research and an increasing 
number of reports highlighting its medical relevance, the identity of s2R has evaded 
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target are based almost entirely on pharmacological manipulation, which has often been 
limited by the use of less selective ligands.212 The enigmatic receptor had not yet entered 
the modern biological era and our understanding of the s2R remains underdeveloped in 
comparison to many other receptors, including the s1R.5 Despite the considerable 
importance of identifying the protein sequence and its coding gene, the literature reveals 
only two attempts prior to our successful effort disclosed herein.  
1.4.3.1   Sigma-2 Receptor: Identity Proposed as a Histone Binding Protein  
Protein identification is commonly achieved with chemical proteomic approaches 
using small molecules functionalized in a way that allows downstream analysis of the 
protein binding partner. Affinity chromatography methods are a classical technique for 
purifying the target protein from other components of the biological matrix.213 This 
strategy often relies on a small molecule with high affinity for the target that is 
immobilized on a solid support using a molecular linker. The linker must allow the small 
molecule to interact with the target without interference from the solid support and 
without deleterious effects on affinity for the target, and extensive SAR knowledge about 
the small molecule probe is often required.213 A variety of linker types and lengths have 
been used with longer and more rigid linkers providing some benefit, but increasing the 
hydrophobic surface can increase levels of non-specific interactions that might pose a 
challenge for downstream identification.214-216 After immobilization of the molecular 
probe, it is incubated with a cell lysate to capture the target and the undesired matrix is 
rinsed away. The target is then released from the immobilized probe, often with a 
competitive ligand, where it can then be processed with sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) to isolate specific protein bands for 
sequence identification using mass-spectrometry (MS).213    
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 In 2006, Colabufo et al. utilized an affinity chromatography approach in an 
attempt to purify the s2R from human SK-N-SH neuroblastoma, which had been shown 
to have high levels of s2R expression.217 A small molecule probe was inspired by the 
high affinity pan-sR ligand PB28 (1.84) that lacked chemical functionality to directly 
install a linker for immobilization (Figure 1.26). Accordingly, a nitrogen atom was 
installed on the tetralin moiety to provide 1.101, which was subsequently coupled with an 
activated ester on a stationary phase. It was posited that substitution at this position of the 
tetralin moiety would not affect s2R affinity based on previous SAR studies. However, 
that work did not evaluate amide substituents on the tetralin aromatic ring, nor did it 
incorporate any substituents at the site that was modified in this work.218 The modified 
scaffold was also not subjected to independent competition binding analysis to confirm 
affinity and selectivity.  
 65 
 
Figure 1.26. Structural modification of PB28 and for affinity purification.  
SK-N-SH cells were lysed, and a protein membrane preparation was eluted 
through an affinity column containing 1.101 while monitoring (SDS-PAGE), to isolate 
H3.3A (kDa = 15.3), H2B (kDa = 13.8), H2A.5 (kDa = 14.1), and H2.1 (kDa = 21.2) 
histone proteins.217 Saturation binding analysis of the eluted cell fractions with [3H]-DTG 
was consistent with values obtained for the crude material leading to the hypothesis that 
s2R is a histone protein. The authors conceded that the s2R ligand may also have 
affinity for the histone proteins and that they may not be synonymous, which was 
corroborated using [3H]-PB28 and reconstituted human histone protein to reveal 
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the nucleus, which was not supported by data using selective s2R fluorescent ligands that 
showed no significant accumulation in nuclei.220 Ultimately, the hypothesis had not been 
widely accepted, with some noting that the study lacked rigorous validation and that 
histone proteins lacked characteristic s2R features.77 It is plausible that the modified 
molecular probe had diminished affinity for the s2R, combined with a lack of specificity 
that contributed to unsuccessful purification. Alternatively, the immobilized ligand might 
not have the ability to interact with the s2R binding site which could have prevented 
efficient protein capture.    
1.4.3.2   Sigma-2 Receptor: A Potential Association with the PGRMC1 
The molecular identity of the s2R continued to evade researchers, leading the 
Mach group to purse an alternative approach for identifying the protein that was reported 
in 2011.221 This strategy sought to utilize the molecular probe WC-21 (1.103) that was 
based on RHM-1 (1.93), a selective s2R ligand previously developed by the group. 
Ligand 1.93 was contained an azide moiety for covalently linking the probe to the protein 
and a fluorescein isothiocyanate group (FITC) for fluorescent visualization (Figure 1.27). 
The new molecular probe WC-21 (1.103) was characterized using the atypical 
radioligand [125I]-RHM-4 (1.104) that was also developed by the group and determined to 
have high s2R affinity and specificity. Having confirmed that WC-21 (1.103) displayed 
affinity for the target, it was incubated with rat liver membrane homogenate and 
irradiated to crosslink the probe and protein complex. Subsequent western blot analysis 
with anti-FITC antibodies revealed a ~24 kDa protein band that was labeled with the 
FITC-probe. Proteomic analysis of the band with MS identified the 22kDa putative 
progesterone-binding protein and the 25 kDa protein 25-Dx, both sharing the genetic 
name, progesterone receptor membrane component 1 (PGRMC1). Notably, WC-21 
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labeling of the protein band was inhibited by classical s2R ligands DTG and haloperidol, 
as well as [125I]-RHM-4 (1.104), which supported the conclusion that the protein band 
contained the s2R.    
 
Figure 1.27. Molecular probe for photo-crosslinking with the s2R protein.  
PGRMC1 is a known protein that has been sequenced and cloned from several 
species including humans, enabling Mach to perform additional studies that assessed 
similarities between the s2R and PGRMC1.221 Competitive binding analysis using [125I]-
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PGRMC1 ligand AG-205, as well as the s2R ligands DTG (1.70), siramesine (1.90), 
SV119 (1.88), and WC-26 (1.87) in HeLa cell membrane homogenate. Additionally, the 
siRNA knockdown of PGRMC1 reduced [125I]-RHM-4 binding, whereas overexpression 
using PGRMC1 cDNA increased radioligand binding (~60%) in HeLa cells. PGRMC1 
and s2R were also found to be colocalized within the cell using confocal microscopy 
with a PGRMC1 antibody and a s2R fluorescent probe. Taken together, these data led 
Mach to conclude that the putative s2R binding site resides within a PGMRC1 protein 
complex. 
1.4.3.3   The PGRMC1   
The literature provides a number of insights into PGRMC1 that offer some 
support for Mach’s proposal. The sequenced and cloned protein has an approximate mass 
of ~25-28 kDa, notably heavier than the reported 21.5 kDa mass reported for s2R.171,222 
However, the PGRMC1 amino acid sequence is 21.54 kDa for an unmodified isoform 
without the N-terminal methionine, which is consistent with the s2R.161 PGRMC1 has 
similar anatomical distribution with high levels of expression in the liver and kidney, but 
is also found among other peripheral tissues, as well as distribution in the brain and 
CNS.223 Within the cell, PGRMC1 is found to localize in ER, microsomal, and 
mitochondrial fractions, which is consistent with s2R subcellular localization studies.77 
Importantly, PGRMC1 is overexpressed in a variety of cancer types where it has been 
associated with cell viability, a well-established s2R feature.224   
PGRMC1 is a member of the membrane associated progesterone receptor 
(MAPR) subfamily of proteins that contain cytochrome b5 (Cytb5) domain, which is 
associated with heme-binding.225 PGRMC1 is a multifunctional protein that has been 
implicated in a variety of cellular processes, and its X-ray crystal structure was recently 
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disclosed showing that the protein forms a stable dimeric species upon binding with 
heme, which is critical to its function.226,227 PGRMC-1 has been associated with 
cholesterol biosynthesis through activation of specific cytochrome P-450 (cyP450) 
enzymes involved in sterol synthesis.228 The s2R has been proposed to be a cyP450 
protein as a result of high s2R affinity among some cyP450 inhibitors and substrates 
leading Mach to suggest a PGRMC1–cyP450 protein complex might constitute the s2R 
binding site.77,229,230  
Much like the s2R, the exact functional role of PGRMC1 has been difficult to 
elucidate, although as its name implies it has been associated with binding of 
progesterone. However, while it does seem to be involved in progesterone responses, 
there is little evidence for direct progesterone binding to purified recombinant PGRMC1 
protein.231-233 Nonetheless, progesterone has been proposed as an endogenous ligand for 
PGRMC1, suggesting that in vivo binding might occur with post-translationally modified 
PGRMC1 as many high molecular weight isoforms have been identified.224 Partially 
purified PGRMC1 has been found to have high affinity for progesterone (apparent Kd = 
11-35 nM), although the discrepancy with purified recombinant protein in 
confounding.222,234 The affinity of progesterone for  s1R  and s2R in rat liver membrane 
is modest, 239 and 441 nM respectively, notably lower than partially purified PGRMC1 
even though the implications of this result are not entirely clear.235 However, the pan-sR 
ligand haloperidol was competitive with the [3H]-progesterone binding site in porcine 
liver membrane (Ki = 20 nM), whereas the s1R selective ligand (+)-pentazocine had 
much lower affinity for the same site (Ki = 1.13 µM).236    
Collectively these data provide some evidence that does not rule out the 
possibility of the s2R binding site being located in or associated with PGRCM1. The 
similar anatomical distribution, subcellular localization, and demonstrated role in cancer 
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biology provide the clearest support for the hypothesis. Indeed, the significant levels of 
overexpression of PGRMC1 in a variety of cancer types where it was shown to promote 
proliferation in tumors was consistent with a common feature of the s2R. It is perplexing 
that knockdown of PGRMC1 was associated with decreased proliferation, whereas 
activation of s2R has been correlated with the same effect.226,237 However, since the 
exact molecular mechanisms of s2R activation remain unclear and have instead been 
assigned somewhat arbitrarily, this discrepancy is not completely surprising. Taken 
together with Mach’s fluorescent labeling and proteomic studies, there was compelling 
evidence to suggest a relationship between the s2R and PGRMC1, and the hypothesis 
gained some acceptance, although unequivocal evidence from cloning of the s2R 
remained to be acquired. 
1.4.3.4   The Sigma-2 Receptor is not Synonymous with PGRMC1 
The link between the s2R and PGRMC1 was viewed as a substantial leap forward 
in s2R research that brought molecular identification and cloning closer to being 
realized. Indeed, the commonality in certain biological features was compelling, and an 
increasing number of reports ostensibly identified the two proteins as synonymous (e.g. 
s2R/PGRMC1).165,238-240 However, important questions regarding the aforementioned 
discrepancies between the two proteins remained unanswered leading to some 
controversy about the true identity of s2R.126  Most notably, the PGRMC1 was a 25 kDa 
protein that was distinctively heavier than the 21.5 kDa mass originally reported for the 
s2R. Evidence suggested that splice variants and post-translational modification of 
PGRMC1 existed with a mass that was consistent the s2R and therefore the identification 
could not be precluded based on that criteria, but it did prompt concern among some.224 
In addition, the s2R was defined by its high affinity for DTG and haloperidol, but at the 
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time the affinity of these ligands for PGRMC1 was conspicuously absent from the 
literature.241 
In an effort to provide some clarity on this issue, Abate et al. independently 
examined the s2R binding characteristics of MCF7 breast cancer cells with genetic 
knockdown and overexpression of  PGRMC1.242 Interestingly, scatchard binding analysis 
using the prototypic s2R ligand [3H]-DTG revealed no significant change in saturation 
levels between the MCF7 control cells and the MCF7 cells with altered PGRMC1 
expression levels. This suggested that the s2R binding site might be distinct from the 
PGRMC1 protein. In addition, the antiproliferative effects of six s2R ligands with known 
cytotoxic effects were evaluated in MCF7 cells overexpressing PGRMC1 and little 
change was observed in proliferation, as compared to control cells.242 The MCF7 cells 
with PGRMC1 knockdown displayed increased sensitivity to the antiproliferative effects, 
but this was attributed to the prosurvival characteristics of PGRMC1 that were 
diminished due to lower expression levels. In the presence of a known PGRMC1 
inhibitor, a synergistic effect was observed that led to increased cytotoxicity in MCF7 
control cells that also pointed to separate pathways for inducing cell death. Collectively, 
these results led Abate et al. to suggest that the s2R and PGRMC1 are unique proteins 
and that the photoaffinity label used in Mach’s study likely had affinity for both proteins.  
 The report from Abate’s group was followed by corroborating results from Ruoho 
et al. using the motor neuron-like NSC34 cell line with altered PGRMC1 expression.241  
In this study, complete knockout of PGRMC1 in NSC34 cells was enabled using 
CRISPR/Cas9 technology to remove any ambiguity that might derive from the low 
expression levels obtained with the knockdown approaches used by Mach and 
Abate.221,242 Similar to Abate, Ruoho et al. found that NSC34 cells lacking PGRMC1 
provided no reduction in s2R density according to scatchard analysis with [3H]-DTG as 
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compared to control cells.241 The photoaffinity probe [125I]-IAF (1.105) is s1R selective 
with micromolar affinity for the s2R, but after incubation with PGRMC1 knockout cells 
two DTG-sensitive protein bands were visualized at approximately 26 and 18 kDa, 
corresponding to s1R and s2R respectively (Figure 1.28).243 This suggested that the 
defining features of  s2R, namely a 18-21.5 kDa protein with high affinity for DTG, were 
still present in  cells devoid of PGRMC1, thus the two proteins must be derived from 
distinct genes as opposed to resulting from a splice variant or modified protein complex. 
The affinities of DTG and haloperidol for PGRMC1 in rat liver membrane were also 
assayed using [3H]-progesterone and determined to be lower (> 3 orders of magnitude) 
than for the s2R in the same tissue, although as previously discussed the PGRMC1 does 
not appear to directly bind progesterone so the meaning of this result is not entirely 
clear.241 However, these collective results support the conclusion that PGRMC1 and s2R 
are not synonymous and are instead genetically distinct. 
  
 
 Figure 1.28. Molecular probe for photo-crosslinking with the s1R and s2R.  
The report from Mach et al. that the s2R binding site was located within the 
PGRMC1 protein complex initially seemed to provide long sought-after clarity about the 
molecular identity of the elusive receptor. However, independent reports from other 
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using cell lines different from those originally described by Mach. The reason for the 
discrepancy between research groups is not clear, but it is possible that the photoaffinity 
probe used by Mach et al. either had off-target affinity for PGRMC1 or that the 
PGRMC1 is in close proximity to the s2R and was irreversibly labeled while the probe 
interacted with the s2R binding site.161 It is important to point out that this does not 
necessarily invalidate Mach’s original hypothesis that the binding site was part of a 
PGRMC1 protein complex and that s2R could be a partner protein in. However, it does 
seem increasingly likely based on genetic manipulation studies that the two proteins are 
not synonymous and that the s2R is not a modified form of PGRMC1. If it is a partner 
protein in a larger complex, then it remains unclear if PGRMC1 is essential for s2R 
function.13,224 This produces a rather complex picture about the relevant association of the 
s2R and PGRMC1 that requires additional investigation, but it does suggest that the true 
molecular identity of s2R had yet to be determined.   
1.4.4 Sigma-2 Receptor Pharmacophore and Selective Ligands.  
It is somewhat surprising that in spite of decades of research and an increasing 
number of reports highlighting the medical relevance of the s2R that its true identity 
continued to evade researchers. The absence of a crystal structure prevents the use of 
typical structure-based design strategies, similar to the challenges faced in s1R ligand 
design prior to 2016.6 However, unlike the s1R, 3-D homology models and mutagenesis 
studies are also not available to provide structural insights because the s2R protein has 
not been identified and the sequence is unknown. Unfortunately, there is considerable 
overlap in the s1R and s2R ligand binding profile, and neither the s1R crystal structure 
nor the previously discussed s1R pharmacophore models addressed strategies for 
obtaining subtype selectivity.133,141  
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Lack of a 3-D model for the s2R binding site has resulted in a longstanding 
challenge for designing ligands that have both high affinity for the s2R and high 
selectivity over s1R.77,162,203 In fact, the first high affinity ligands with reasonable 
selectivity for the s2R over the s1R were not reported until 1995 and some of these were 
only identified by happenstance during the course of investigations targeting other 
receptors.161,244 Since then, many high affinity s2R ligands have been developed that 
exhibit varying degrees of selectivity over the s1R and that have been derived from 
extensive SAR studies within a given ligand class.77,162,203,220 An online searchable 
database was compiled in 2017 containing known s2R ligands with selectivity over s1R 
(i.e. Ki s1R/Ki s2R > 1).245 At the time of this writing, this database contained 592 s2R 
ligands meeting this criteria, but less than half of these had greater than 10-fold 
selectivity over s1R, and only 90 had greater than 100-fold selectivity. This limited 
number of compounds with high levels of selectivity highlights the persistent and 
ongoing challenge of ligand design. In addition, the s2R binds a large variety of 
structurally diverse ligands and the lack of crystal structure has made it difficult to 
identify common pharmacophore features.162 There have been several attempts to identify 
s2R pharmacophore models, but these have generally be restricted to  structurally similar 
molecules from within specific ligand classes and do not provide broadly predictive 
information.142,246,247 In addition, these models often used ligands that lacked sufficient 
subtype selectivity so their discussion will be limited. However, a brief survey of several 
ligand classes that are selective for the s2R over the s1R and the associated SAR 
investigations of these ligands will provide some insight into structural features that have 
provided enhanced potency and selectivity.   
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1.4.4.1   Sigma-2 Receptor Ligands: The Benzomorphan-7-one Scaffold 
The benzomorphan-7-one scaffold 1.107 reported by Bowen et al. in 1995 was 
among the first s2R selective ligand classes disclosed, and it was discovered 
inadvertently.248 Initial efforts were focused on modulating the µ-opioid affinity of 3-
hydroxyphenylmorphan 1.106, a potent opioid analgesic, through the introduction of an 
E-benzylidene group on the parent scaffold to give analogs of 1.107 (Scheme 1.5). 
Notably, this structural change produced a modest decrease in opioid affinity in the 
modified scaffold that was accompanied by an increase in affinity for the s1R and s2R.  
 
 
Scheme 1.5. Introduction of an E-benzylidnene group in the 3-hydroxyphenyl-morphan 
scaffold   
Recognizing that benzomorphan-7-one (±)-1.107 represented a unique scaffold 
for targeting the sRs, a more detailed investigation of the SAR was conducted.244,249 
Initial examination of the benzomorphan-7-one stereoisomers CB-64D (1.83) and CB-
64L (1.110) revealed that levorotatory isomer 1.110 had significantly higher affinity for 
the s1R than the corresponding dextrorotatory isomer 1.83.249 In fact, the (+)-
benzomorphan-7-one displayed high affinity for the s2R and remarkable selectivity over 
the s1R, an enantiomeric preference that is opposite the preference that is typically 
observed with (+)-benzomorphans. The same trend was observed upon introduction of 
the dichlorinated benzylidenes moiety in CB-182 (1.112) and CB-184 (1.111). Indeed, 












analog CB-184 (1.111) and led to 554-fold subtype selectivity favoring the s2R.249 The 
effect of a single chlorine atom on the benzylidene aromatic ring was found to be a bit 
more pronounced at R2 (1.114) than R1 (1.113), but incorporating both had a notable 
synergistic effect in CB-184 (1.111).244 Introduction of a single iodine atom at R2 (1.115) 
was not as effective as the chlorine substituent for reduction of s1R affinity. However, 
introduction of a polar methoxy substituent at R2 (1.116) was favorable and led to 157-
fold selectivity for s2R over s1R.244 It is notable that each of the (+)-benzomorphan-7-
one analogs maintained high affinity for the s2R, and s1R affinity was modulated by 
altering the substitution pattern. The (+)-benzomorphan-7-one analog CB-184 (1.111) 
was the most s2R subtype selective ligand known at the time, although the µ-opioid 
affinity was still high detracting from its utility as a truly s2R selective ligand.248 
Nonetheless, CB-64D (1.83) and CB-184 (1.111) provided an advancement in selective 
ligand design and were used for many additional studies probing the cytotoxicity of s2R 













Table 1.1. Binding affinity of benzomorphan-7-one analogs. 
 
 Ki (nM) Ki ratio 
Compd. (name) (+)/(–) R1 R2 s1R s2R (s1R/s2R) 
1.83  (CB-64D) (+) H H 3,063 ± 78 16.5 ± 2.7 185 
1.110 (CB-64L) (–) H H 10.5 ± 1.6 154 ± 3 0.07 
1.111 (CB-184) (+) Cl Cl 7,436 ± 308 13.4 ± 2 554 
1.112 (CB-182) (–) Cl Cl 27.3 ± 2.8 35.5 ± 8.8 0.77 
1.113 (+) Cl H 759.3 ± 59.8 6.4 ± 0.4 119 
1.114 (+) H Cl 3,100 ± 350 22.4 ± 2.1 138 
1.115 (+) H I 1,620 ± 170 24.0 ± 1.5 68 
1.116 (+) H OMe 6,000 ± 750 38.2 ± 3.5 157 
 
1.4.4.2   Sigma-2 Receptor Ligands: The Tropane Scaffold 
The first tropane identified with high affinity for the s2R and selectivity over the 
s1R was BIMU-1 (1.117), discovered while probing the tropane based structure as a 
ligand for  the serotonin receptors (5-HT3 and 5-HT4 ) (Figure 1.29).250 The 200-fold s2R 
subtype selectivity possessed by BIMU-1(1.117) was an interesting discovery, and it 
represented a useful tool compound, although it maintained high affinity for the serotonin 













were first prepared by Gualtieri et al. in 1994 were found to have potent antinociceptive 
activity that was attributed to their activity as a cholinergic modulator.251,252 However, the 
sR affinity of SM-21 (1.94) was evaluated after it was discovered that the structurally 
similar tropane BIMU-1 (1.117) had high s2R affinity. In fact, Mach reported that SM-
21 (1.94) has higher affinity for s2R than the muscarinic receptor it was designed to 
target and suggested that it might serve as a lead compound for developing additional 
s2R selective ligands.253  
 
 
Figure 1.29. Tropane-based analogs with selectivity for s2R over s1R.  
 Inspired by the discovery that SM-21 displayed selectivity for the s2R, the 
tropane derivatives originally prepared by Gualtieri et al. in 1994 as potential analgesics 
or nootropics were also determined to have sR affinity.254 Three regions were identified 
among 48 tropane derivatives for construction of a computationally derived 
pharmacophore model: (1) hydrophobic region–1, (2) hydrophobic region–2, and (3) the 
positive ionizable nitrogen area that was labeled as hydrogen bond (HB) donor region 
(Figure 1.30.A).246 Interestingly, many of the derivatives displayed only modest affinity 
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restricts the utility of the model. Nevertheless, the results can be briefly summarized as 
follows: (1) There was little difference when hydrophobic region–1 contained a phenoxy 
or phenthio group (R2 = ArO–, ArS–, but an aniline group (R2 = ArNH–, ArNMe–) 
decreased s2R affinity; (2) converting the ester moiety (Y = O) to and ether linkage ( Y = 
H) increased affinity for both s1R  and s2R, thereby eliminating s2R selectivity; and (3) 
a methyl substituent was preferred in hydrophobic region–2 (Z = Me) and switching to a 
benzyl group increased s1R, again eroding selectivity.254  A pharmacophore model was 
proposed from these results using grid-independent descriptor (GRIND) computational 
methods that proposed optimal distances between the three pharmacophore elements 
(Figure 1.30.B).246 Overall, the model is similar to the s1R pharmacophore model 
proposed by Gilligan, but with modified distances to favor the s2R. However, the modest 
affinity and low s2R selectivity displayed by the tropane derivatives makes it difficult to 
extrapolate the reported distances to a more general model that can be used in the design 







Figure 1.30. (A) Pharmacophore elements of tropane derivatives. (B) s2R 
pharmacophore model for tropane derivatives proposed by Cratteri.246   
1.4.4.3   Sigma-2 Receptor Ligands: The Granatane Scaffold 
The tropane derivative BIMU-1 (1.117) was serendipitously discovered as a high 
affinity s2R ligand with selectivity over s1R, but it suffered significant off-target 
interactions leading Mach et al. to investigate structural modifications as part of an 
extensive SAR investigation (Figure 1.31).255 The N-methyl moiety of BIMU-1 was 
thought to be the source of high 5-HT3 and 5-HT4 affinity because that functionality was 
observed in several antagonists targeting those receptors, hence replacing the methyl 
group with a benzyl moiety was investigated to suppress off-target interactions. The 
benzimidazole moiety was replaced with a phenyl carbamate moiety to more easily 
evaluate a range of substituted aromatic groups in this region. The tropane core was also 
targeted for modification with a structurally similar granatane unit envisioned as an 
alternative. These structural changes were embodied in the N-benzyl tropane 1.118 and 
N-benzyl granatane 1.119 scaffolds that were designed to interrogate these key SAR 
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Figure 1.31. Structural modification of BIMU-1 leads to N-benzyl tropane and granatane 
scaffolds.  
Importantly, Mach discovered that exchange of the N-methyl substituent with an 
N-benzyl group significantly diminished affinity for 5-HT3 and 5-HT4 in most of the 
analogs, while high s2R affinity was maintained (Table 1.2).255 Additionally, the 
incorporation of aromatic substituents on the phenyl carbamate had a pronounced impact 
on s1R affinity. For example, the 2,5-dimethylcarbamate moiety on the tropane 1.120 
and granatane 1.121 scaffolds had high affinity for both the s1R and s2R with a slight 
preference for the s1R. In contrast, the methoxy substituent in tropane 1.122 and 
granatane 1.123 decreased affinity for the s1R, an effect that was more pronounced for 
granatane 1.123 leading to 30-fold selectivity for the s2R. The most s2R selective 
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Interestingly, the analogous granatane 1.125 displayed decreased s2R affinity and only 
2-fold selectivity. However, a number of the N-benzyl granatane analogs displayed 
modest levels of selectivity for the s2R over the s1R, suggesting that it was the preferred 
scaffold arrangement.  
Table 1.2. Binding affinity of N-benzyl tropane and granatane analogs.  
 
 Ki (nM) Ki ratio 
Compd.  R1 R2 R3 n s1R s2R (s1R/s2R) 
1.120  T Me Me 1 9.2 ± 1.2 14.6 ± 0.4 0.6 
1.121  G Me Me 1 6.0 ± 1.5 7.6 ± 0.2 0.8 
1.122  T OMe Me 1 14.4 ± 0.1 3.2 ± 0.4 4.5 
1.123  G OMe Me 1 92.5 ± 11 3.1 ± 0.8 30 
1.124 T OMe NO2 1 37.9 ± 3.3 5.4 ± 1.1 7 
1.125 G OMe NO2 1 67.8 ± 2.1 16.7 ± 0.4 2 
1.126 G OMe OMe 1 329.1 ± 26.1 26.8 ± 7.9 12 
1.127 G OMe Me 2 59.9 ± 4.6 1.2 ± 0.1 50 
1.128 G OMe Me 3 73.0 ± 1.6 2.0 ± 0.1 37 
1.129 G OMe Me 4 65.5 ± 4.3 2.9 ± 0.2 23 
1.130 G OMe Me 5 17.3 ± 1.2 1.8 ± 0.2 10 















This finding generated additional interest in the granatane scaffold and a variety 
of additional analogs were evaluated.203 These efforts identified granatane 1.127 in which 
the aromatic group was optimally positioned with a two-carbon spacer (n = 2) between 
the granatane nitrogen atom providing 50-fold selectivity over the s1R (Table 1.2).256  
Interestingly,  spacers up to 6-carbons in length (n = 1-6) provided high s2R affinity and 
modest selectivity over the s1R. A second basic amine at the terminus of the tethered 
group significantly decreased affinity for the s1R, providing 510-fold selectivity with 
aniline analog 1.91 and 273-fold selectivity with the primary amine analog 1.88 (Figure 
1.32).256,257 The range of spacer lengths and hydrophobic bulk that was tolerated at the 
tethered aromatic group inspired considerable investigation and led to the installation of 
fluorescent tags in this region for visualizing the s2R in tumors, as well as a tethered 
biotin unit.257 It is interesting that there are no reports attempting to pulldown the s2R 
with the biotinylated compound. Nonetheless, the granatane scaffold has been the subject 
of extensive SAR investigations, providing highly selective s2R ligands that were useful 
as tool compounds for investigating the receptor.     
 
 
Figure 1.32. Granatane analogs with a second basic amine.   
!1R Ki (nM) = 2,250 ± 73
!2R Ki (nM) = 5.0 ± 0.2
Ki ratio (!1R/!2R) = 510
1.91
yun245
!1R Ki (nM) = 1,418 ± 439
!2R Ki (nM) = 5.19 ± 0.8

















1.4.4.4   Sigma-2 Receptor Ligands: Siramesine Analogs 
Perregaard et al. reported a series of aryl piperazine analogs (1.132) in 1995 that 
were originally developed as low efficacy serotonin 5-HT1a agonists, but were also potent 
sR ligands.197 Interested in exploring this feature, an SAR strategy was devised to 
evaluate functionality that might enhance affinity and selectivity for the s2R over the 
s1R (Figure 1.33). Initially a series of aryl substituents at R1 were targeted for 
investigation, as well exchange of the aniline nitrogen with a carbon atom in 1.133. In 
addition, substitution of the nitrogen atom of the tethered indole moiety would also be 
probed.     
 
 
Figure 1.33. Modification of aryl piperazines analogs to enhance s2R affinity.     
The initial iteration of SAR revealed that each of these structural units could be 
modified to enhance the overall binding profile (Table 1.3).197 For instance, the aryl 
substituent at R1 impacted overall affinity for the sRs and switching from a 2-methoxy in 
1.134 to a 4-fluoro substituent in 1.135 increased affinity for both sR receptors with low 
selectivity for the s2R (4.3-fold). Replacement of the aniline nitrogen atom with a carbon 
atom (1.136) further increased affinity for the s1R, slightly favoring it over the s2R, 
which suffered a slight decrease in affinity. However, replacing the 4-fluoro substituent at 















with only a slight preference over the s1R (3.1 fold). Unfortunately, each of the 
unsubstituted indole analogs (1.134-1.137) had considerable off-target affinity for the 
serotonin N 5-HT1a and 5-HT2a, dopamine D2, and the a1 adrenergic receptors. However, 
introduction of the 4-fluorophenyl substituent at the indole nitrogen (1.138-1.139) greatly 
reduced these off-target interactions and also decreased s1R affinity, affording up to 100-
fold selectivity for the s2R.  
Table 1.3. Binding affinity of indole analogs 
 
 Ki (nM) Ki ratio 
Compd.  X R1 R2 s1R s2R (s1R/s2R) 
1.134  N 2-OMe H 14 21 0.67 
1.135  N 4-F H 5.6 1.3 4.3 
1.136  CH 4-F H 1.4 4.0 0.35 
1.137 CH H H 1.5 0.48 3.1 
1.138  CH 4-F 4-F-phenyl 16 0.27 59 
1.139 CH H 4-F-phenyl 44 0.44 100 
 
Inspired by reports of other sR ligands with a spirocyclic piperidine moiety, 
Perregaard et. al. next constrained the aryl group in 1.140 as a phthalane–piperidine 
spirocycle (1.141) (Figure 1.34).197 The length of the carbon chain that tethered the indole 








Figure 1.34. Introduction of the spirocyclic piperidine moiety.       
Indeed, Perregaard et al. discovered that the spirocycle 1.90 had increased s2R 
affinity to 0.12 nM, along with a modest increase in s1R affinity that resulted in a 140-
fold preference for the s2R (Table 1.4). Attempts to decrease the length of the carbon-
linker ( n = 1–4) connected to the indole moiety decreased affinity for the s2R and 
increased s1R affinity, thereby eroding selectivity (1.142-1.144). Analog 1.90, which 
came to be known as siramesine, benefits from remarkably high affinity for the s2R and 
has potent cytotoxic activity in cancer cell lines, leading to its prominent use as a 





















Table 1.4. Binding affinity of spirocyclic piperidine analogs. 
 
 Ki (nM) Ki ratio 
Cmpd.  n s1R s2R (s1R/s2R) 
1.90  4 17 0.12 140 
1.142  3 10 2.8 3.6 
1.143  2 15 3.0 5 
1.144  1 3.0 4.7 0.64 
 
1.4.4.5   Sigma-2 Receptor Ligands: Benzamide Analogs 
In 2004, the efforts of Mach and coworkers to design ligands targeting dopamine 
D3 receptors selectively over the D2 receptors and the sRs resulted in the fortuitous 
discovery of some of the most s2R selective ligands reported to date.77 Previous work 
from the group identified pyrrole analog 1.145 with modest selectivity for D3 over D2 and 
low off-target affinity for the sRs (Figure 1.35.A).258 The naphthamide analog 1.146 had 
improved selectivity for D3 over D2, but showed high affinity for the s1R and s2R 
(Figure 1.35.B).259 Accordingly, Mach sought to construct a series of hybrid ligands 
1.147 to improve D3 over D2 selectivity and reduce sR affinity  by combining the amide 






i) and tetrahydroisoquinoline (Group ii) elements from 1.145 with the 2-methoxynaphthyl 
(Group iii) moiety from 1.146 (Figure 1.35.C).181  
 
 
Figure 1.35. A) Pyrrole analog with modest D3 selectivity and low sR affinity.  B) 
Pyrrole analog with improved D3 selectivity and high sR affinity. C) Design 
of benzamide analog for optimized D3 selectivity.        
The study revealed that the benzamide analogs 1.148 typically displayed high 
affinity for the s2R, and affinity for the s1R and dopamine receptors could be modulated 
by altering the substitution pattern (Table 1.5).181 For instance, the 2-
methoxynaphthylamide (R1 = A) and the unsubstituted tetrahydroisoquinoline (R2 = H) 
separated by a two-carbon spacer (1.149) displayed high affinity for both sRs, but 
introduction of the 6,7-methoxy substituents (1.150) attenuated s1R affinity and provided 
D2 (nM) = 33
D3 (nM) = 3.9
Ki ratio (D2/D3) = 8.5
!1R Ki (nM) = >1,000
!2R Ki (nM) = 460
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D3 Ligand with Low !R affinity D3 Ligand with High !R affinity
1.145 1.146












modest selectivity (9-fold) and both 1.149 and 1.150 maintained significant affinity for 
the dopamine receptors. The same pattern in s2R selectivity was observed when the 
naphthyl group was replaced with a 2-methoxyphenylamide group (R1 = B) (1.151-
1.152), but 442-fold selectivity over the s1R was achieved. In addition, both 1.151 and 
1.152 benefited from diminished dopamine D3 receptor activity. Transitioning to the 2,3-
dimethoxyphenylamide (R1 = C) (1.153) increased affinity for s1R and the D3 receptor. 
However, when the spacer group was increased to four-carbon atoms as in 1.80 there was 
a considerable decrease in s1R affinity that produced a remarkable 1,573-fold selectivity 
for the s2R subtype and further diminished dopamine receptor affinity. Finally, 
installation of the 2-methoxy-4-methyl-phenylamide (R1 = D) as in 1.154, increased 
affinity for the s1R and the D3 receptor, eroding selectivity, but decreasing the length of 
the spacer group to 2-carbons in 1.155 attenuated this effect and provided 783-fold 













Table 1.5. Binding affinity of benzamide analogs 
 
 Ki (nM) Ki ratio 
Cmpd.  R1 R2 n s1R s2R D3 (s1R/s2R) 
1.149  A H 1 15.1 ± 1.7 47.7 ± 2.5 81.6 0.32 
1.150  A OMe 1 189.1 ± 2.6 21.2 ± 0.1 126.5 9.0 
1.151  B H 1 21.8 ± 5.6 89.4 ± 13.9 310.7 0.24 
1.152  B OMe 1 5,484 ± 266 12.4 ± 1.8 488 442 
1.153 C OMe 1 2,932 ± 28  16.4 ± 2.0 21.4 179 
1.80 C OMe 3 12,900 ± 28 8.2 ± 1.4 627 1,573 
1.154 D OMe 3 3,078 ± 87 10.3 ± 1.5 313 299 
1.155 D OMe 1 10,412 ± 462 13.3 ± 0.1 3,760 783 
 
The remarkable levels of s2R selectivity achieved with the benzamide scaffold 
led to the construction of a variety of analogs that were used extensively in biological 
investigations of the receptor.77 Some follow up SAR investigations revealed the 
importance of the conformationally constrained amine of the tetrahydroisoquinoline. For 
example, the ring-opened analog 1.156 displayed substantially reduced affinity for the 























substituents of the tetrahydroisoquinoline moiety was also revealed through replacement 
with a constrained ethylenedioxy ring (1.157) that resulted in a dramatic increase in s1R 
affinity (Figure 1.36.B).260 Further investigations of the 2,3-dimethoxyphenyl amide 
substitution pattern identified the 2-methoxy substituent to play an important role that 
was hypothesized to result from a hydrogen bonding interaction with the amide N-H that 
forced a coplanar orientation of the aromatic ring (Figure 1.36.C).261 This inspired the 
constrained cyclic amide 1.159 with a conformational constraint that forces a coplanar 
orientation and delivered good levels of s2R selectivity.      
 
 
Figure 1.36. A) Benzamide analog with ring-opened tetrahydroisoquinoline. B) 
Benzamide analog with ethylenedioxy ring. C) Proposed hydrogen bond 
with ortho-methoxy group that promotes coplanar orientation.  
1.156
!1R Ki (nM) = 709 ± 133
!2R Ki (nM) = 4.84 ± 0.74
Ki ratio (!1R/!2R) = 147
1.157
!1R Ki (nM) = 338
!2R Ki (nM) = 21.7
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1.4.4.6   Sigma-2 Receptor Ligands: Cyclohexylpiperazine Analogs 
Analogs constructed with a cyclohexylpiperazine motif have also been well-
studied due to their high affinity for both the s1R and s2R, but most members of this 
family do not achieve meaningful levels of subtype selecitvity.220 This is exemplified by 
the prototypic member of this ligand class PB-28 (1.84), which achieves subnanomolar 
affinities for the s1R and s2R and has potent antiproliferative activity (Figure 1.37).262 
The cyclohexylpiperazine moiety is important for maintaining s2R affinity, but unlike 
siramesine, replacing it with a piperidine ring (1.160) has a deleterious effect on s2R 
affinity and high s1R affinity is maintained.262 The particularly high affinity of PB-28 
(1.84) for the s2R has attracted attention for additional SAR studies, but attempts to 
prepare structural analogs of PB-28 with enhanced selectivity for the s2R have been 
generally unsuccessful.261,262 A notable exception is F281 (1.85) wherein the 5-
methoxytetraline group of 1.84 is replaced with a carbozole moiety that diminishes 
affinity for both sRs, but because this effect is less pronounced at s2R there is 274-fold 
selectivity for the s2R. Despite the modest reduction in s2R affinity, F281 has more 
potent antiproliferative activity in SK-N-SH cells than 1.84.190,262 In addition, exchange 
of the 5-methoxytetraline group in 1.84 with the 2(3H)-benzothiazolone moiety to give 
1.161 led to higher affinity for the s2R and a modest decrease for s1R, affording 11-fold 
selectivity. Although unremarkable for s2R selectivity the cyclohexylpiperazine motif 
does afford high potency and, in some cases, the tethered aromatic group can be altered 




Figure 1.37. Cyclohexylpiperazine analogs.   
1.4.4.7   Sigma-2 Receptor Ligands: Summary 
There are relatively few ligand classes that achieve high levels of selectivity for 
the s2R over the s1R and frequently such selective compounds were discovered by 
happenstance during extensive SAR investigations. A unifying pharmacophore model 
that is predictive for ligand design has not yet emerged. However, comparing the ligands 
discussed above reveals several principles that might guide future design strategies 
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has a hydrophobic substituent. This basic group is frequently either a piperidine or a 
piperazine ring that might be bridged by another carbocycle. The basic amine is typically 
flanked by two hydrophobic/aromatic groups, one that that is relatively close in proximity 
and another that is more distant. This model is quite similar to pharmacophore models 
proposed for the s1R, and the structural diversity accommodated by both receptors 
increases the complexity of designing  s2R-selective ligands. Indeed, many ligands with 
high affinity for s2R also have high affinity for the s1R and obtaining selectivity relies 
on relatively subtle structural changes that disfavor interaction with the s1R.    
 
 
Figure 1.38. Hypothetical 2-D representation of a s2R pharmacophore.  
High affinity for the s2R can be obtained with either a flexible or rigid linker that 
connects the distal hydrophobic/aromatic group to the amino group and shifting its 
position can have a dramatic effect on s1R affinity. The optimal distance is not entirely 
clear and seems to exist within a variable range as demonstrated by the benzamide ligand 
class. A significant decrease in s1R affinity was observed as the linker for 2,3-
dimethoxybenzamide 1.153 was extended from two to four carbon atoms in 1.80. In 
contrast, the structurally similar 2-methoxybenazmide 1.155 displayed an equally 
substantial decrease in s1R affinity when the linker was shortened from four to two 
carbon atoms in 1.154. During the SAR investigations of potential s2R ligands, 












obtaining selectivity, even if the preferred position is not necessarily obvious or 
predictable.  
The position of the proximal hydrophobic group is also important for obtaining 
high s2R affinity and selectivity over the s1R, although it is again difficult to predict the 
optimal distance. Conformational restriction of this hydrophobic group seems to be 
somewhat more important and many ligands that display selectivity over the s1R impart 
conformational rigidity with a carbocycle. This can be seen in the tetrahydroisoquinoline 
moiety of benzamide analogsthe spirocyclic ring fusion of siramesine (1.90), and the 
benzylidene moiety of (+)-benzomorphan-7-one analogs. However, the existence of 
multiple binding modes has been proposed and might present a challenge for discerning 
between the hydrophobic sites based on their relative position.247 During the design of 
s2R ligands, subtle perturbations in positioning of the proximal hydrophobic group and 
employing conformational restrictions can significantly impact subtype selectivity.  
Variations in the substituents on these aromatic groups also significantly impacts 
s1R affinity. For instance, incorporation of the 6,7-dimethoxy substituents on the 
tetrahydroisoquinoline of benzamide analogs produced a significant reduction in s1R 
affinity as compared to the corresponding unsubstituted analog. Likewise, introduction of 
two chlorine atoms on the benzylidene moiety of the (+)-benzomorphan-7-one analogs 
had a synergistic effect that afforded a considerable decrease in s1R affinity. Probing 
aryl substitution patterns is an important consideration during an SAR investigation of 
ligands targeting the s2R.  
These trends are unfortunately somewhat speculative and vague because they are 
based on general observations among the few selective s2R ligands available. Structural 
information about the s2R remains elusive, access to the cloned gene would facilitate 
mutation studies and homology models based upon the predicted structure of s2R would 
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provide additional insights.  However, the lack of s2R selective ligands and an 
understanding of how they modulate biological pathway justifies additional efforts to 
design potent and selective s2R binding ligands with favorable drug–like properties.  
1.5 THE NORBENZOMORPHAN: A NEW CLASS OF SIGMA LIGANDS    
1.5.1 Identification of Lead Compound Classes 
As previously discussed, the Martin group developed a rapid process for 
construction of the halogenated norbenzomorphan scaffold 1.162, and preliminary 
investigations revealed that some analogs had affinity for the  sRs with selectivity 
favoring either s2R or s1R being observed in some instances.  Intrigued by the 
medicinal relevance of the s2R and the relative ambiguity of the protein, along with 
historical challenges of developing selective ligands, the possibility of developing a new 
molecular scaffold that selectivity targets the s2R warranted additional investigations. 
Accordingly, the Martin group expanded the SAR study to probe diverse substitution 
patterns that might provide enhanced affinity and selectivity for the s2R. The easily 
diversifiable core allowed for the incorporation of varied functionality via cross-coupling 
reactions with the aryl halide and nitrogen refunctionalization reactions, similar to the 
approach previously discussed (Scheme 1.6).  
 
 















Among the ligands screened as part of the preliminary investigation, a subset 
emerged with discernable substitution patterns that provided favorable results, 
particularly with the piperazine substituted norbenzomorphans (1.163-1.165) (Figure 
1.39). Installation of N-methylpiperazine at C-8 in 1.163 provided high affinity for the 
s2R (<100 nM) with modest selectivity over the s1R. The requisite basic nitrogen atom 
is located on the piperazine rather than the nitrogen atom of the norbenzomorphan core, 
which is instead acylated.  Notably, the benzyl carbamate of 1.163 that was originally 
installed as a nitrogen protecting group provides similar levels of s2R potency as the 3-
chlorobenzamide derivative 1.164, but with lower s1R affinity that affords 9.3-fold 
selectivity. This might be attributed to minor changes in the positioning of the distal 
aromatic group in relation to the basic amine, similar to observations among known s2R 
selective ligands. In addition, when the core nitrogen atom was functionalized as a benzyl 
carbamate, installation of the N-methylpiperazine at C-7 in 1.165 resulted in a significant 
increase in affinity for the s1R, that is accompanied by a modest decrease in s2R 
affinity. This reversed the sR selectivity preference to favor the s1R, an interesting 
feature that might also result from the subtle changes in the position of the distal aromatic 
group with respect to the substituted basic nitrogen atom.   
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Figure 1.39. Piperazine substituted norbenzomorphans with sR subtype selectivity.   
Another series of norbenzomorphan analogs emerged, in which the core nitrogen 
atom served as the requisite basic amine (1.166-1.170) (Figure 1.40). In a subset of these 
derivatives the nitrogen atom was substituted with a benzyl group and variation of the 
substituent on the core arene ring had a significant effect on sR affinity. The 
unsubstituted arene 1.166 was nearly equipotent at s1R and s2R, but installation of a 
morpholine substituent at C–7 (1.167) increased affinity for the s1R and decreased 
affinity for the s2R. In contrast, incorporating the morpholine substituent at C–8 in 
dicholobenzyl analog 1.168 provided a considerable reduction in s1R affinity in relation 
to unsubstituted analog 1.166 and afforded 32-fold selectivity for the s2R. A similar 
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preference for the s1R, whereas introduction of an aromatic group at C–8 in the N–
methyl analog 1.170 increased affinity for the s2R and provided some selectivity.  
 
 
Figure 1.40. Norbenzomorphans analogs with a basic amine in the core.  
This preliminary SAR study highlighted several key structural features in lead 
compounds that inspired additional investigations. Critically, the scaffold existed in two 
distinct categories in which the requisite basic nitrogen atom was incorporated either as 
an substituent on the benzene ring of the norbenzomorphan scaffold or by the 
norbenzomorphan nitrogen atom. In both cases, substitution at the C–8 position favored 
the s2R, whereas substitution at C–7 favored the s1R. Substitution of the 
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particularly when the core nitrogen was functionalized as a benzyl carbamate, as 
exemplified by lead compound 1.163. Alternatively, substitution on the arene ring with a 
morpholine or aryl group also provided high s2R affinity and modest selectivity as 
demonstrated by compounds 1.168 and 1.170. 
The Martin group was particularly interested in pursuing the s2R because little 
was known about its role in neuroscience and it therefore presented fertile ground for 
discovery. The optimal structural arrangement for favoring the s2R was not clear, but 
preliminary investigations revealed that subtle changes in substitution patterns and spatial 
orientation of these groups could have a dramatic effect on subtype selectivity. 
Accordingly, a multifaceted SAR study was devised for continued investigation of the 
norbenzomorphan substitution pattern to favor the s2R.  In addition, a concurrent 
scaffold simplification initiative to assess the importance of some norbenzomorphan 
structural features and to provide alternative lead scaffolds that might have more 
favorable properties was also conducted.    
1.5.2 SAR of the Piperazine Substituted Norbenzomorphan Scaffold 
The piperazine substituted norbenzomorphan scaffold presented several 
opportunities for this SAR effort (Figure 1.41).  The basic nitrogen is a critical 
pharmacophore element of ligands that bind sRs, thus it stands to reason that 
modifications to the nitrogen substituent might have considerable impact on sR 
selectivity. Interestingly, relatively little information is available from the literature about 
systematic alteration of N-substituents in s2R selective ligands because it has typically 
been part of a constrained ring system and substituted with an alkyl spacer group that 
connects to the distal hydrophobic/aromatic group.203 The cyclohexylpiperazine analogs 
provide the closest comparison (Figure 1.37), but those analogs displayed little s2R 
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selectivity. Early results suggested that the position of the piperazine substituent on the 
arene core is important with placement at C–8 favoring the s2R.  
 
 
Figure 1.41. Strategy for SAR investigation of piperazine substituted norbenzomorphan 
scaffold  
The nitrogen atom of the norbenzomorphan core is functionalized with a 
carbamate linker attached to aromatic group that presented several areas for an SAR 
investigation (Figure 1.41). Many s2R selective ligands have a hydrogen bond acceptor 
(HBA) group such as the benzyl carbamate of 1.17, but assessing its contribution to the 
binding profile would require additional investigation. The distal hydrophobic/aromatic 
group is known to have a significant effect on the binding profile suggesting that both the 
position and nature of that group should be examined. Likewise, substituents on the distal 
aromatic group have been previously observed to impart selectivity and were therefore 
targeted for further SAR analysis.  A large number of compounds were prepared, but this 
discussion will summarize general trends from the SAR investigation as represented by a 

















1.5.2.1   Investigation of the Linker and Distal Aromatic Group  
The SAR investigation commenced with evaluation of the distal aromatic group 
and the linker that connects it to the scaffold. The N–methylpiperazine from lead 
compound 1.163 was maintained for comparison (Figure 1.39). The C–8 halogenated 
norbenzomorphan 1.51 was prepared according to the previously discussed MCAP 
procedure and then diversified to a variety of analogs for analysis. Subsequent Buchwald-
Hartwig cross-coupling of 1.51 using Pd(OAc)2 and JohnPhos with an excess of 
piperazine (1.172) afforded the substituted norbenzomorphan 1.173 in 72% yield,50 
followed by reductive amination with paraformaldehyde to provide the N–methylated 
analog 1.163 (Scheme 1.7).4 Reductive removal of the Cbz-protecting group in 1.163 
produced impurities that were difficult to separate.263 Alternatively stirring a solution of 
1.163 in CH2Cl2 with TMSI followed by acidic workup provided the deprotected product 
1.174 in 88% yield. The core nitrogen atom was subjected to a variety of N-
functionalization reactions including acylation with acyl chlorides, chloroformates, and 





Scheme 1.7. General strategy for diversification of the norbenzomorphan core nitrogen.  
The SAR investigation of  the distal aromatic group of the and the linker 
connecting it to the norbenzomorphan scaffold indicated the significance of this group for 
maintaining high affinity and selectivity for the s2R (Table 1.6).263  The carbamate 
functionality of the linker in 1.163 was first examined by replacing the benzylic oxygen 
atom with a nitrogen atom and a carbon in 1.176 and amide 1.177, respectively. Both 
suffered similar decreases in s2R affinity in comparison to carbamate 1.163, but amide 
1.177 also displayed increased affinity for the s1R. Decreasing the length of the linker in 
the amide group also had a negative effect on s2R selectivity. Compared with the two-
carbon spacer in amide 1.177, the single methylene linker 1.178 provided reduced 
affinity for the s2R and increased affinity for s1R, whereas potency was diminished for 






































affinity for both sRs, as compared to benzyl carbamate 1.163 with an additional 
methylene spacer. Replacement of the benzyl carbamate moiety with an alloc group 
(1.183) also diminished sR affinity indicating the importance of the aromatic group, as 
opposed to an alternative unsaturated alkyl group. Likewise, removal of the benzyl 
carbamate functionality eliminated detectable sR binding in acetamide analog 1.184 and 
unsubstituted amine analog 1.174.  
Table 1.6. Binding affinity of N-methylpiperazine-norbenzomorphan analogs. 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R s1R s2R (s1R/s2R) 
1.163 
 
841 89.7 9.4 
1.176 
 
935 360 2.6 
1.177 
 
294 357 0.82 
1.178 
 













Table 1.6. Binding affinity of N-methylpiperazine-norbenzomorphan analogs. 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R s1R s2R (s1R/s2R) 
1.179 
 
1,875 1,642 1.1 
1.180 
 
>10,000 445 > 22 
1.181 
 
428 31 14 
1.182 
 
264 37 7.1 
1.183 
 
2,105 442 4.8 
1.184 
 



















Table 1.6. Binding affinity of N-methylpiperazine-norbenzomorphan analogs. 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R s1R s2R (s1R/s2R) 
1.174  >10,000 >10,000 N/A 
1.185 
 
>10,000 764 >13 
1.186 
 
476 309 1.5 
1.187 
 
664 301 2.2 
1.188 
 






















Table 1.6. Binding affinity of N-methylpiperazine-norbenzomorphan analogs. 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R s1R s2R (s1R/s2R) 
1.189 
 
442 27 16 
Ki values determined from non-linear regression of radioligand competition binding isotherms by PDSP. 
Unless indicated otherwise, s1R was sourced from guinea pig brain and s2R was sourced from rat PC12 
cells.  
The positional requirements of the distal aromatic group could also be satisfied if 
the core nitrogen atom was functionalized as an aryl sulfonamide, although a sensitivity 
to aryl substituents was evident within this series (Table 1.6). Namely, s2R binding of 
the unsubstituted aryl sulfonamide 1.185 was much less favorable than the benzyl 
carbamate 1.163. However, the corresponding substituted analogs 1.186 and 1.187 were 
more potent for both sRs than 1.185, with little subtype selectivity. Interestingly, the 3,5-
dichloro analog 1.189 increased affinity for the s2R and provided 16-fold selectivity. The 
trifluoromethyl–substituted analog 1.188 exhibited s2R affinity that was similar to 1.189, 
but also increased affinity for the s1R leading to little selectivity. The same trend was 
observed for the benzyl carbamate series in which the 3,5-dichlorobenzyl analog 1.181 
had a notable increase in s2R affinity relative to 1.163 with a less pronounced change at 
s1R that afforded 14-fold selectivity. Likewise, the fluorobenzyl carbamate analog 1.182 











optimal aromatic substitution pattern requires more investigation, but consistent with 
other selective s2R ligands, dichlorination at this site appears to be favorable.     
Collectively, these data indicate that the distal aromatic group is a key 
pharmacophore element of the piperazine substituted norbenzomorphan scaffold. 
Relatively minor changes in its position that result from alterations in the length and 
composition of the linker can lead to large shifts in s1R and s2R affinity, although the 
exact orientation of the aryl group that is preferred is not clear. Additonally, aryl 
substituents on the distal aromatic group can also lead to increased affinity for the s1R 
and s2R that can either enhance or diminish s2R selectivity. Among the N-acylated 
analogs, functionalization of the core nitrogen atom as a benzyl carbamate seems to 
provide the favorable s2R affinity and selectivity.    
1.5.2.2   Investigation of Piperazine Substituents   
Having identified that the benzyl carbamate functionality on the 
norbenzomorphan core nitrogen atom delivered generally favorable s2R selectivity, 
attention turned toward the piperazine nitrogen-substituent. The unsubstituted piperazine 
1.173, previously prepared by cross-coupling with the halogenated norbenzomorphan 
core, was subjected to a variety of N–functionalization reactions including reaction with 
alkyl halides, reductive alkylation, and conjugate addition to various Michael acceptors to 
access a series of analogs to assess the effects of different aliphatic substituents at the 
piperazine nitrogen atom.4,9,263   
  A trend emerged in which an increase in size of the aliphatic substituent led to 
higher affinity for the s1R and s2R (Table 1.7).4,9,263 For example, as the length of the 
linear alkyl group was increased from methyl (1.163) to propyl (1.191),  the affinity 
increased for both sRs, but the increase was more pronounced for s2R, achieving 5.1 nM 
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affinity and 45-fold selectivity over the s1R for the propyl piperazine analog 1.191.  The 
same trend was observed for analogs with branched alkyl groups (1.192-1.193). 
Similarly, cyclic alkyl groups (1.194-1.196) displayed high affinity for the sRs that 
favored s2R selectivity, but larger carbocycles also increased affinity for the s1R, 
thereby eroding selectivity.  Thus, the cyclobutyl 1.194 and cyclopentyl 1.195 analogs 
were 42 and 36–fold selective for s2R, respectively, whereas the cyclohexyl analog 
1.196 was only 2.4–fold selective. Aliphatic substituents from three to five–carbon atoms 



















Table 1.7. Binding affinity of saturated piperazine substituents 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R s1R s2R (s1R/s2R) 
1.163  841 89.7 9.4 
1.190  600 32.5 18 
1.191  230 5.1 45 
1.192 
 
473 14.5 33 
1.193  111 1.8 62 
1.194  208 5.0 42 
1.195 
 
130 3.6 36 
1.196 
 
29.8 12.5 2.4 
Ki values determined from non-linear regression of radioligand competition binding isotherms by PDSP. 
Unless indicated otherwise, s1R was sourced from guinea pig brain and s2R was sourced from rat PC12 
cells.  
A similar series was prepared to assess the effects of unsaturated N-alkyl 
substituents (Table 1.8).4,9,263  The introduction of unsaturation in 1.197 decreased 













provided results that were similar to the propyl piperazine analog 1.191, although 
somewhat less potent and selective. Introduction of a benzyl group (1.200) was also less 
favorable, leading to an increase in s1R affinity and eroding selectivity to 1.5–fold, 
which again suggests that large hydrophobic groups in this region favor the s1R. 
Table 1.8. Binding affinity of unsaturated piperazine substituents 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R s1R s2R (s1R/s2R) 
1.191  230 5.1 45 
1.197  931 76.4 12 
1.198  413 17.5 24 
1.199 
 
62 23 2.7 
1.200 
 
119 80.8 1.5 
Ki values determined from non-linear regression of radioligand competition binding isotherms by PDSP. 
Unless indicated otherwise, s1R was sourced from guinea pig brain and s2R was sourced from rat PC12 
cells.  
 A series of analogs that incorporated polar functional groups on the aliphatic 
substituent was also evaluated (Table 1.9).4,9,263 Interestingly, many of these analogs 
displayed dramatically lower affinity for the s1R. For instance, both the ethyl alcohol 










to the corresponding aliphatic analogs 1.190 and 1.163, respectively, but affinities for the 
s2R were relatively in comparison, thereby increasing selectivity. A similar effect was 
noted for the substituents with a carbonyl moiety, such as ethyl ester analog 1.203, which 
achieved micromolar affinity for the s1R and 280-fold s2R selectivity, albeit with a 
modest decrease in s2R affinity. Similar results were obtained with amide 1.204 and 
nitrile 1.205, although with some reduction in s2R affinity. Introduction of cyclic alkyl 
substituents containing a heteroatom, such as tetrahydropyran 1.206 and N-
methylpiperidine 1.207, led to a more modest reduction in s1R affinity, but these analogs 

















Table 1.9. Binding affinity of polar piperazine substituents 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R s1R s2R (s1R/s2R) 
1.191  230 5.1 45 
1.201  1,1216 39 31 
1.202  524 5 105 
1.203 
 
6,660 23.8 280 
1.204 
 
3,919 45 87 
1.205  5,890 414 14 
1.206 
 
121 3.5 35 
1.207 
 
150 26 5.8 
Ki values determined from non-linear regression of radioligand competition binding isotherms by PDSP. 


















Investigation of substituents at the piperazine nitrogen atom revealed several 
interesting trends for modulating sR selectivity. Generally high affinity for the s2R is 
observed for a variety of groups at this position, and there is more variability in affinity 
for the s1R. There are limits with respect to the size of the hydrophobic group, and as the 
size increases the s2R selectivity is eroded by increasing s1R affinity. The optimal s2R 
selectivity seems to be obtained with saturated aliphatic substituents that contain three-to 
five–carbon atoms. Incorporating polar functional groups on the nitrogen substituent 
produces a pronounced reduction in binding at the s1R and represents a significant 
mechanism for modulating s2R selectivity. The effect was particularly favorable with 
alcohol or ester functional groups positioned two to three carbon-atoms from the amine. 
The specific negative interaction with the s1R binding site that produces this effect is not 
clear, but the close proximity of the polar functional group to the essential basic amine 
site of the ligand suggests that it might be disrupting this key ligand-protein interaction is 
some way. For instance, the electron withdrawing nature of this group likely results in 
decreased basicity of the nitrogen atom that might weaken the formation of the critical 
salt-bridge that was previously observed in the crystal structure of the s1R.6,154,264 While 
the exact mechanism requires additional investigation, the fact that the reduction in 
potency in more pronounced for the s1R than the s2R is a meaningful finding and it 
might allow for additional optimization in the future.          
1.5.2.3   Site of Piperazine Installation on the Norbenzomorphan Core    
As previously discussed, installation of the piperazine ring at the C–8 position of 
the norbenzomorphan core seemed to provide enhanced selectivity for the s2R over the 
s1R. However, after a more thorough investigation of the SAR revealed optimal 
piperazine substituents, this hypothesis was again tested with several sets of C–7 and C–8 
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substituted analogs (Table 1.10).9 Interestingly, installing the N-substituted piperazine at 
the C–7 position resulted in a  a modest decrease in s2R affinity that was accompanied 
by a significant increase in s1R affinity. The result was a reversal in the subtype 
preference that switched from favoring the s2R at the C–8 position to favoring the s1R 
at the C–7 position for each analog tested (1.208-1.211). This was even true for C–7 ethyl 
ester analog 1.211 that displays a slight preference for the s1R, but the corresponding C–



















Table 1.10. Binding affinity of unsaturated piperazine substituents 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R C–7/C–8 s1R s2R (s1R/s2R) 
1.208 
 
C–7 8.7 29.3 0.30 
1.163 C–8 230 5.1 45 
1.209 
 
C–7 4.6 11.1 0.41 
1.195 C–8 130 3.6 36 
1.210 
 
C–7 18.5 46.7 0.40 
1.198 C–8 413 17.5 24 
1.211 
 
C–7 108 111 0.97 
1.203 C–8 6,660 23.8 280 
Ki values determined from non-linear regression of radioligand competition binding isotherms by PDSP. 
Unless indicated otherwise, s1R was sourced from guinea pig brain and s2R was sourced from rat PC12 
cells.  
The discovery that the orientation of a substituent on the norbenzomorphan 
scaffold leads to changes in sR subtype selectivity is highly notable. It was somewhat 
surprising that merely changing the position of the substituent could have such a dramatic 
effect. Although limited in predictive power, the pharmacophore models that have been 












and distal hydrophobic sites in relation to the basic amine site. In this case, shifting the 
basic amine site to the C–7 position of the norbenzomorphan scaffold alters its relative 
position in relation to the distal hydrophobic site in a way that is more favorable for the 
s1R. Indeed, a related trend was observed within the benzamide ligand class, in which 
changing the length of the spacer group between the benzamide moiety and the 
tetrahydroisoquinoline by two methylene groups produced a remarkable decrease in s1R 
affinity, while s2R was relatively unaffected (Table 1.5). This likely represents a similar 
alteration in the position of the distal hydrophobic group relative to the basic amine site. 
It is interesting that the s2R seems to be less sensitive to this change, suggesting that this 
is a structural feature that can be used to bias against s1R interaction. If this speculation 
is correct, then the rigidity of the norbenzomorphan scaffold might provide a useful 
mechanism to control the position of these groups and might be optimized in future 
studies.  
1.5.2.4   Enantiomeric Preference of The Piperazine-Substituted Norbenzomorphan  
The s2R was defined based on the preference of (+)-benzomorphans to bind the 
s1R, but not the s2R. It is therefore not surprising that some ligand classes have 
displayed enhanced s2R selectivity for a particular enantiomer. As previously discussed, 
the (-)–benzomorphan-7-one CB-182 (1.112) possessed high affinity for both sR 
subtypes, but the (+)-enantiomer CB-184 (1.111) had greatly reduced s1R affinity and 
achieved 554-fold selectivity for the s2R. It therefore stands to reason that the 
norbenzomorphan scaffold might also display an enantiomeric preference. Accordingly, 
the enantiomers of the N-propylpiperazine analog 1.191 were separated via chiral HPLC 
and evaluated individually.263 Both enantiomers (1.212-1.213) possessed nearly identical 
affinity for the  s1R, which was relatively unchanged from the racemic mixture (s1R Ki 
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= 230 nM) (Figure 1.42). However, 1.212 showed a modest decrease in affinity for the 
s2R as compared to the racemic mixture (s2R Ki = 5.1 nM), the affinity of 1.213 for the 
s2R was nearly identical to the racemic mixture. It is interesting that a more pronounced 
difference was not observed. However, this might be because the source of chirality is not 
in close proximity to the basic amine site of the piperazine-substituted norbenzomorphan 
as it is in the benzomorphan-7-one ligands. 
 
 
Figure 1.42. Binding affinity of enantiomerically pure N-propylpiperazine analogs.   
1.5.2.5   Other Structural Features of the Piperazine-Substituted Norbenzomorphan  
Having investigated a wide variety of substitution patterns on the piperazine-
substituted norbenzomorphan, a few analogs were prepared to interrogate structural 
features of the scaffold. As previously discussed, many high affinity s2R ligands contain 
a basic nitrogen atom within a constrained ring system, commonly a piperidine nitrogen 
atom. The contribution of the less basic, aniline nitrogen of the piperazine substituted 
norbenzomorphan was not clear as it may not be involved in interactions with acidic 
residues of the protein.  Accordingly, the aniline nitrogen atom in 1.191 was removed in 
piperidine analog 1.214, which maintained high affinity for the s2R (Figure 1.43). 








!1R Ki (nM) = 250 
!2R Ki (nM) = 20








!1R Ki (nM) = 251 
!2R Ki (nM) = 2.7
Ki ratio (!1R/!2R) = 93
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This finding suggests that the aniline nitrogen of the piperazine ring is beneficial for 
enhancing s2R selectivity and thus was maintained in ongoing SAR studies.    
 
 
Figure 1.43. A propylpiperidine analog of the norbenzomorphan scaffold.   
The norbenzomorphan scaffold possessing a bridged 7-membered ring system 
was the primary subject of SAR investigations. As part of ongoing efforts in the Martin 
group to assess the effect of different structural modifications of the norbenzomorphan 
scaffold, compounds having the expanded methanobenzazocine ring in 1.215 were also 
evaluated (Figure 1.44). The ring expanded analog maintained high s2R affinity, but an 
increase in s1R affinity was also observed that eroded selectivity.  
 
 






!1R Ki (nM) = 132 
!2R Ki (nM) = 9.7




!1R Ki (nM) = 230 
!2R Ki (nM) = 5.1





!1R Ki (nM) = 70 
!2R Ki (nM) = 8.3







!1R Ki (nM) = 230 
!2R Ki (nM) = 5.1
Ki ratio (!1R/!2R) = 45
Cbz
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1.5.3 The Aryl-Substituted Norbenzomorphan Scaffold 
An alternative substitution pattern of the norbenzomorphan core is one in which 
the nitrogen atom of the norbenzomorphan ring provides the requisite basic amine site 
and was also evaluated during early investigations of the scaffold. Thus, a brief overview 
of SAR features of this scaffold is also warranted. As previously discussed, substitution 
of the norbenzomorphan core with an aryl substituent at C–8 provided high affinity s2R 
ligands. Specifically, the 4-trifluoromethylphenyl substituent led to high s2R affinity and 
selectivity and inspired examination of an expanded series in which the N-alkyl group 


















Table 1.11. Binding affinity of biaryl analogs.  
 
 
 Ki (nM) Ki ratio 
Cmpd. (name)  R n s1R s2R (s1R/s2R) 
1.170  1 156 43 3.6 
1.216 
 
1 609a 82b 7.4 
1.217 (DKR-1051) 
 
2 556 61 9.1 
1.218  1 154 a 19 b 8.1 
1.219 (UKH-1114)  2 1,279 46 28 
1.220 
 
2 3,049 59 52 
1.221  2 27 a 21 b 1.3 
Ki values determined from non-linear regression of radioligand competition binding isotherms by PDSP. 
Unless indicated otherwise, s1R was sourced from guinea pig brain and s2R was sourced from rat PC12 
cells. a determined using HEK293 cells expressing recombinant human s1R. b determined using HEK293 
cells expressing recombinant human s2R/TMEM97.  
The N-methyl analog 1.170 displayed modest affinity for the s2R, but low 
selectivity over the s1R. An N–cyclopentyl group in 1.216 reduced affinity for both sRs, 












favoring the s2R.4 A similar trend was observed for the corresponding ring-expanded 
methanobenzazocine DKR-1051 (1.217) as compared to 1.170.11 Introduction of a propyl 
alcohol substituent on norbenzomorphan 1.218 increased affinity for both sRs, but 
retained 8.1-fold selectivity favoring the s2R. The corresponding methanobenzazocine 
UKH-1114 (1.219) showed a considerable reduction in s1R affinity that afforded 28-fold 
selectivity for the s2R.11 The reason for the difference between the two ring sizes is not 
clear, but the methanobenzocine provides higher levels of selectivity. The ring expanded 
analog with an ester substituent (1.220) also displayed decreased s1R affinity with 52-
fold selectivity for the s2R. The importance of an N-alkyl substituent at this position was 
confirmed with the unsubstituted analog 1.221 which achieves high potency for both 
sRs, but is not subtype selective.  
It is interesting that similar SAR trends are observed for norbenzomorphan and 
methanobenzazocine analogs that possesses the basic amine moiety within the 
heterocyclic scaffold or as a substituent on the arene core. In both cases, hydrophobic 
substituents at the basic nitrogen are increase  sR affinity and incorporation of a polar 
functional group on those substituents diminshes s1R affinity. Likewise, each displays 
optimal s2R selectivity when the piperazine or aryl group is installed at the C–8 position 
of the scaffold. Although the methanobenzazocine JVW-1034 (1.222) also achieves high 
affinity for the s2R with modest selectivity over s1R, when a chlorine is installed at the 




Figure 1.45. Binding affinity of the chloro-substituted methanobenzazocine analog.    
1.5.4 Norbenzomorphan Ligands in Neuropsychiatric Disorders  
1.5.4.1   The Sigma-2 Receptor as a Therapeutic Target for Neurological Disorders  
It is unsurprising that the s2R has attracted considerable attention with respect to 
a role in cancer given its significant overexpression in malignant cells, but its 
demonstrated role in cell survival and wide expression in the CNS suggests that it might 
also be an intriguing target for neurological disorders.170 It is therefore somewhat 
perplexing that this area of research has received significantly less attention, particularly 
since the pharmacologically similar s1R has been implicated in a variety of CNS 
disorders. Indeed the s2R was defined by its ability to bind some neuroleptic drugs and 
psychotomimetic compounds.75,76 However more recently, evidence has emerged that the 
s2R might be a target for a range of difficult-to-treat neurological disorders, and the 
Martin group has been at the forefront of this area of research with pioneering studies that 




!1R Ki (nM) = 248 
!2R Ki (nM) = 23
Ki ratio (!1R/!2R) = 11
N
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1.5.4.2   Norbenzomorphan Ligands and APP Induced Neurodegeneration  
Because the s1R is associated with a range of CNS disorders, but little was 
known about the role of the s2R in neurological disorders, and the recent discovery that 
norbenzomorphan analogs were capable of selectively modulating the s2R, the Martin 
group was inspired to investigate the effects of these compounds in models of 
neurodegeneration. A Caenorhabditis elegans (C. elegans) model that mimics age-related 
neurodegeneration associated with AD was recently developed by the Pierce-Shimomura 
group at the University of Texas at Austin, providing a promising assay for assessing 
ligands that bind the s2R as potential neuroprotective agents.12 In humans, the amyloid 
precursor protein (APP) is produced in large quantities in neurons and processed to 
produce b-amyloid protein (Ab), but genetic mutation of the human APP gene gives rise 
to Ab accumulation that is correlated with AD progression.265 C. elegans have orthologs 
for approximately two-thirds of all human genes and work by the Pierce-Shimomura 
group revealed that inserting a single copy of the human amyloid precursor protein 
(SC_APP) 695 gene into the worm genome results in age-dependent degeneration of 
cholinergic neurons, similar to AD progression in humans.12,266 These neurons can be 
labeled with green fluorescent protein for visualization of progressive neurodegeneration.    
The gene that codes for the s2R was not known and thus, an ortholog had not 
been identified in C. elegans, but the worm possesses the PGRMC1 ortholog vem–1.267 
The increase in neurodegeneration associated with SC_APP in the worm model was 
reduced to control levels upon genetic knockout of vem-1, suggesting that PGRMC1 
might be involved in the SC_APP associated degenerative pathway.12 As previously 
discussed, evidence indicated that the PGRCM1 and s2R are not synonymous and the 
true genetic identity of the s2R was unknown, but work by Mach et al. suggested the two 
proteins might be associated to some extent.221 As a result, the worm model could 
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provide some insights on the ability of s2R ligands to recapitulate the diminished 
neurodegenerative effects of vem-1 knock out.    
The Martin group pursued a collaboration with the Pierce-Shimomura group to 
assess the effects of s2R selective norbenzomorphans in the SC_APP worm model. 
Gratifyingly, treating the SC_APP worm with SAS-0132 (1.163) and JVW-1009 (1.55) 
reduced neurodegeneration as compared to the control SC_APP worm that was 
administered vehicle only (Figure 1.46).12 Conversely, DKR-1051 (1.217) and DKR-
1005 (1.168) led to enhanced neurodegeneration relative to the control SC_APP worm. 
Genetic knockdown of vem-1 with RNAi, both in the presence and absence of SAS-0132 
(1.163) and JVW-1009 (1.55), provided similar levels of diminished neurodegeneration, 
thus supporting a hypothesis that the s2R binding ligands acted through the vem-1 
pathway.12 Moreover, SAS-0132 (1.163) improved cognitive performance, and rescued 
AD–related behavioral deficits in the Thy-1 hAPPLond/Swe+  transgenic mouse model of 
AD. Interestingly, it also provided enhanced cognitive performance in healthy wild-type 
mice.12 Collectively these result suggest that ligands that modulate the s2R can alleviate 
Ab–induced neurodegeneration and improve cognitive deficits associated with animal 




Figure 1.46. A) Norbenzomorphan analogs that decreased neurodegeneration in SC_APP 
C. elegans model. B) Norbenzomorphan analogs that increased 
neurodegeneration in SC_APP C. elegans model.    
At the time of this initial discovery there were no other reports that linked 
modulation of s2R with attenuation of Ab–related neurodegeneration, although Izzo et 
al. soon reported that putative s2R antagonists could block Ab oligomer–induced 
synaptotoxicity.164,165 The exact mechanism of s2R–associated neuroprotection remains 
to be clarified, but the report from Izzo et al. corroborates these early findings from the 
Martin group and suggests that more investigation is warranted. The promising results of 
the SAS-0132 (1.163) in this early study, along with pharmacokinetic properties that 
!1R Ki (nM) = 556 ± 99
!2R Ki (nM) = 61 ± 23
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supported good bioavailability and brain/plasma ratio, led the Martin group to pursue the 
piperazine-substituted norbenzomorphan scaffold in a number of continuing studies.12   
1.5.4.3   Norbenzomorphan Analogs and Neuropathic Pain  
Neuropathic pain is a troubling medical condition that is associated with pain 
caused by damage or disease of the somatosensory system, which is responsible for the 
perception of pain, pressure, temperature, vibration, and touch.268 The pain arises from 
altered transmission of sensory signals into the CNS and is mechanistically distinct from 
pain attributed to inflammation making treatment more challenging. Common first-line 
treatment options include gabapentinoids and various antidepressants, but low efficacy is 
associated with these therapeutic options that are effective in less than 50% of patients 
with chronic neuropathic pain.269 As previously discussed, antinociceptive properties are 
associated with the s1R, and ligands that modulate this receptor are currently in phase II 
clinical trials for the treatment of neuropathic pain, but the s2R had not been investigated 
for this purpose .118,270 However, the s2R is expressed in the mouse and human dorsal 
root ganglion, which contain the cell bodies of sensory neurons, as well as the spinal 
cord, suggesting that the s2R might be a therapeutic target for this condition.11 
The Martin group in collaboration with the Price group at The University of 
Texas at Dallas selected several norbenzomorphan and methanobenzazocine analogs for 
evaluation in the mouse spared nerve injury (SNI) model, which generates persistent and 
robust neuropathic pain via lesions on the sciatic nerve while leaving the sural nerve 
intact (Figure 1.47).271 This nerve injury results in increased responsiveness to 
mechanical sensitivity that was assayed after intrathecal injection (10 µg dose) of the test 
compounds.11 Significant antimechanical hypersensitivity was observed 24 h after 
injection of DKR-1005 (1.168) and DKR-1051 (1.217), peaking at 48 h. In addition, 
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further enhanced antimechanical hypersensitivity was observed for the more potent and 
s2R selective analog UKH-1114 (1.219) at the same time points. The effects of UKH-
1114 (1.219) could be blocked by SAS-0132 (1.163), which displayed neuroprotective 
activity that was opposite to that observed with DKR-1005 (1.168) and DKR-1051 
(1.217) in the SC_APP C. elegans model of neurodegeneration. This suggests that the 
two compounds might act through differing functional activity pathways at the s2R.  
 
 
Figure 1.47. Norbenzomorphan and methanobenzazocine analogs with antinociceptive 
effects.  
Encouraged by these behavioral results, UKH-1114 (1.219) was advanced as the 
lead compound for additional analysis with systemic dosing (10 mg/kg) and compared to 
!1R Ki (nM) = 556 ± 99
!2R Ki (nM) = 61 ± 23
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Ki ratio (!1R/!2R) = 14
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gabapentin, a standard treatment for neuropathic pain.11 Treating mice after SNI with 
gabapentin (100 mg/kg), fully alleviated mechanical hypersensitivity between 1 and 3 h 
after administration. Interestingly, UKH-1114 (1.219) also ameliorated hypersensitivity 
with an equivalent level of efficacy, but with longer duration that peaked between 24 and 
48 h, which may point to a unique mechanism of action. UKH-1114 (1.219) displays 28-
fold selectivity for the s2R over the s1R and negligible affinity for a panel of 55 other 
targets, strongly implicating the s2R in the observed antinociceptive activity.11 This is 
the first study identifying the s2R as a potential therapeutic target for the treatment of 
neuropathic pain and might offer a mechanism of action that is unique from current 
treatment options. More investigation is needed to fully understand the role of s2R in 
pain and its cellular mechanisms, but this work expands upon the medical value of the 
receptors and highlights the need for additional investigation of the s2R in CNS 
disorders.  
1.5.4.4   Norbenzomorphan Analogs and Traumatic Brain Injury 
Traumatic brain injury (TBI) is associated with a primary injury to the brain that 
then gives rise to secondary, non-mechanical mechanisms of injury that can result in 
progressive neuronal death, leading to cognitive decline and numerous psychological 
problems.272 Unfortunately, the condition is widespread, with 1.7 million cases reported 
annually in the United States, but there are currently no FDA–approved treatments that 
prevent TBI–induced neurodegeneration.273,274 Accumulating evidence indicates that 
norbenzomorphan-derived modulators of the s2R are neuroprotective and this finding 
prompted the Martin group to investigate s2R ligands in models of TBI.  
The piperazine-substituted norbenzomorphan DKR-1677 (1.191) is structurally 
related to SAS-0132 (1.163), which had promising neuroprotective attributes in animal 
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models of AD, but DKR-1677 is more potent at the s2R and has enhanced selectivity for 
the s1R (Figure 1.48).14 The increased s2R selectivity of this structural congener along 
with its ability to achieve effective brain exposure suggested that it was a good candidate 
for analysis in animal models of TBI.  Because TBI can occur through numerous 
pathways and give rise to a variety of secondary injury mechanisms, both a blast and 
cortical controlled impact (CCI) models were assessed.14   
 
 
Figure 1.48. Norbenzomorphan analog DKR-1677 and its pharmacological 
characteristics  
 The blast injury model applies a pressure wave to the head of a mouse that leads 
to impaired performance in behavioral models that assess hippocampal-dependent 
learning and memory functions, as well as widespread axonal degeneration.275 Treatment 
with DKR-1677 (1.191) 30 min after the blast injury and continuing daily for seven days 
revealed dose dependent (1, 3, 10 mg/kg/day) preservation of memory in the Morris 
water maze model of memory and learning.14 The improved memory functions were 
correlated with diminished axonal degeneration for the 10 mg/kg dose regimen as 
compared to the control group, which displayed significant axonal degeneration after the 







!1R Ki (nM) = 5.1
!2R Ki (nM) = 230
Ki ratio (!1R/!2R) = 45
t1/2 (IP, 3 mg/kg) = 1.2 h
Tmax (IP) = 5 min
brain conc. (IP, 4 h) = 32 nM 
brain/plasma ration (4 h) = 3.5
P-gp ration = 0.6
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The CCI model applies a direct impact to the exposed cortex with an accelerated 
metal rod to mimic a concussive injury that causes localized cell death.276 The resulting 
loss of neurons and oligodendrocytes was partially mitigated by treatment with DKR-
1677 (1.191) 1 h after the injury and continuing daily for 7 days (3 mg/kg/day).14 
Collectively, these data point to the neuroprotective properties associated with 
modulation of the s2R by DKR-1677 (1.191) and for the first time indicate that the 
receptor might present a therapeutic opportunity for the treatment of TBI. Although the 
mechanism for protection remains to be clarified, it provides further support for the role 
of the s2R in CNS disorders.      
1.5.4.5   Norbenzomorphan Analogs and Alcohol Withdrawal 
Alcohol use disorder is a common problem, but FDA approved drugs that treat 
alcohol addiction suffer from low success rates that often result in relapse.277,278 During 
the course of chronic alcohol use the neurocircuitry associated with positive 
reinforcement is altered and might be associated with the symptoms of withdrawal.279 
The duration of abstinence can be affected by a patient’s ability to tolerate the symptoms, 
which can range in severity.280 This suggests that treatments targeting withdrawal  
symptoms might be a useful approach for treating alcohol use disorder. Ligands that 
modulate the s2R have previously been associated with an ability to attenuate the 
behavioral responses and toxic effects of cocaine in rodent models and ligands that target 
the s1R have shown promise for the treatment addiction.10,192,281,282 Therefore, we 
queried whether s2R ligands might also be effective for modifying alcohol-related 
behaviors.   
The effects of alcohol withdrawal have been modeled in C. elegans behavioral 
studies to assess performance upon removal of alcohol following chronic exposure.283,284 
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The model evaluates C. elegans in a food-race assay, in which the target area contains an 
attractant and a paralytic for immobilization upon reaching the target. Following 
preconditioning of C. elegans with ethanol and subsequent cessation, a withdrawal period 
ensues in which impaired navigation in the food-race is observed.283 Performance can be 
recovered if sufficient time is allowed in the withdrawal period, prior to the race, and also 
with low-dose administration of alcohol, suggesting that the compromised performance is 
the result of withdrawal symptoms.283 The number of C. elegans that navigate to the 
endpoint during the course of the race enable a comparison of withdrawal effects under 
various conditions. Although the system does not fully mimic the complexity of alcohol 
abuse in humans, it does provide a convenient platform for screening compounds that 
target withdrawal symptoms, and C. elegans have previously been used to identify genes 
that affect alcohol-related behaviors.285   
In collaboration with the Pierce group at the University of Texas at Austin, we 
selected a small series of methanobenazocine derived analogs with high s2R affinity and 
selectivity over the s1R in order to assess their ability to modulate alcohol related 
behaviors (Figure 1.49).13 As previously discussed, analogs substituted with a 4-
trifluoromethylphenyl group on the benzene ring, such as UKH-1114 (1.219) and DKR-
1051 (1.217), reduced mechanical hypersensitivity in models of neuropathic pain.11 
Therefore these analogs, along with several similarly substituted derivates (not shown) 
were included in the screen. Several structurally related methanobenzazocine analogs 
with a chlorine substituent on the benzene ring (1.222–1.224) were discovered to have 
high s2R affinity with modest selectivity over the s1R and were also included in the 




Figure 1.49. Methanobenzazocine analogs evaluated in C. elegans model of alcohol 
abuse. 
The Peirce group conducted the assay by removing ethanol conditioned C. 
elegans from alcohol exposure onto plates seeded with the test ligands (100-200 µM) for 
one hour, during which time the internal alcohol level returned to baseline levels.13 After 
the one-hour withdrawal period, C. elegans were evaluated in the food-race. Similar to 
the reported protocol, significant impairment was observed in the nematodes treated with 
vehicle alone (DMSO) and the fraction on target was greatly reduced as compared to 
nematodes naive to ethanol.13,283  Administration of UKH-114 (1.219) and DKR-1051 
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analogs. In contrast, the chlorine substituted analogs 1.222 and 1.223 did reduce 
behavioral deficits in the assay, and notably JVW-1034 (1.222) improved performance to 
levels observed with the naive nematode.13 Administration of these compounds to C. 
elegans that were not exposed to ethanol had no effect on their behavior, suggesting that 
these s2R ligands may reduce alcohol withdraw symptoms.  
Having identified novel analogs that modulate alcohol-related behaviors, the 
effect was compared to the well-characterized sR ligands siramesine and opipramol. 
Administration of siramesine, which possesses high s2R affinity (0.12 nM) and 
selectivity over the s1R (142-fold), also recovered behavioral deficits in C. elegans 
preconditioned to ethanol. However, the behavior of ethanol-naïve nematodes was also 
altered, with some performance enhancement observed in the food-race. This provides 
additional support using a structurally distinct ligand that the s2R may be involved in 
alleviating symptoms of alcohol withdrawal. Opipramol has low nanomolar affinity for 
the s1R (0.2 nM) and is selective over the s2R (280-fold) and did not provide any 
notable effect in the assay, indicating the s1R may not be responsible for the activity. 
The results from the C. elegans food-race assay were corroborated in higher order 
animals using a rodent model of alcohol dependence.286  The voluntary ethanol 
consumption of the ethanol-dependent rats during the withdrawal period was significantly 
attenuated by administration of JVW-1034 (1.222). These findings provide evidence for 
the first time, that modulation of s2R with small molecules effects behaviors associated 
with alcohol withdrawal. This expands the therapeutic potential of the s2R and suggests 
that small molecules targeting the receptor might be useful for treating alcohol-abuse 
disorder.  
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1.6 SCAFFOLD MODIFICATION OF THE NORBENZOMORPHAN 
1.6.1 Scaffold Simplification   
These studies show that the norbenzomorphan scaffold is a promising molecular 
template for the construction of ligands that selectively target the s2R and have 
promising activity in animal models of neurological disorder. Motivated by the 
underexplored therapeutic potential of the receptor and the longstanding challenges 
associated with the protein, SAR investigations of various substitution patterns were 
performed. However, despite the obvious merits of norbenzomorphan–derived s2R 
modulators, it was not clear if this scaffold presented the optimal orientation of 
substituents or pharmacological properties for continued advancement. Accordingly, an 
investigation was initiated to modify the scaffold using a structural simplification 
approach. The hit-to-lead development process can frequently result in an increased 
number of rings and atoms that increase molecular complexity, as well as the molecular 
weight and lipophilicity, as a result of efforts to enhance potency.287 The structural 
simplification process attempts to remove nonessential groups as part of lead 
optimization and generally focuses on reducing the number of rings.288 This approach can 
provide alternative lead compounds that have shed unnecessary complexity and might 
exhibit pharmacokinetic (PK) properties that are more favorable than the parent scaffold. 
Indeed, it is often strategically important to identify multiple diverse structures with 
suitable potency, selectivity, and PK profiles to increase the likelihood of successful lead 
optimization and advancement during development.289     
Analysis of the norbenzomorphan structure revealed the bridged ring system as an 
obvious source of structural complexity, but it was unknown if the feature was necessary 
for the pharmacological profile. Accordingly, a simplified scaffold was envisioned that 
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would arise from excision of bridging methylene in 1.53 to afford the tetrahydro-2-
benzazepine ring system in 1.225 (Figure 1.50).8 Further evaluation of 1.225 would 
involve contraction of the heterocyclic ring to assess various ring sizes in 1.226 (n = 1-3). 
Of course, the bridged ring system imparts conformational rigidity to the 
norbenzomorphan that will be absent in the modified scaffold.  
 
 
Figure 1.50. Scaffold simplification via excision of the bridging carbon atom.   
The halogenated regioisomers of 1.226 (R =  Br, n = 1-2) are known and  
accessible with slight modification of literature procedures, whereas hydrobenzazepine 
1.225 (R = Cl ) was prepared in a five-step procedure from the commercially available 
dihalogenated aldehydes 1.227-1.228 (Scheme 1.8).8 In the event, Suzuki cross-coupling 
of 1.227-1.228 with potassium vinyltrifluoroborate provided the styrenes 1.229-1.230 
that were subjected to reductive amination with allylamine followed by installation of the 
benzyl carbamate to afford dienes 1.231-1.232.  Ring closing metathesis of 1.231-1.232 
with Grubbs 2nd generation catalyst (Grubbs II) and subsequent hydrogenation of the 
resultant olefin with Adam’s catalyst delivered the halogenated hydrobenzazepines 



















Scheme 1.8. Synthesis of the halogenated hydrobenzazepine scaffold.  
These halogenated scaffolds 1.233-1.234 were easily diversified in a manner 
similar to the norbenzomorphan, as previously discussed. A series of substituted 
piperazine analogs that corresponded to s2R selective norbenzomorphans were prepared, 
revealing that excision of the bridging methylene had a pronounced effect on the binding 
profile (Table 1.12).8 In addition, the size of the heterocyclic ring system (n = 1-3), as 
well as the nature of the alkyl substituents on the piperazine affected affinity and 
selectivity. For instance, the propyl piperazine substituent provided high s2R affinity and 
45-fold selectivity with norbenzomorphan 1.91. However, the same substituent on the 
simplified scaffolds (1.235-1.237) provided less than 2-fold s2R selectivity resulting 
from increased s1R affinity and diminished s2R affinity. Increasing the ring size in 
1.235-1.237 (n = 1-3) increased the s2R affinity, and the lowest s1R affinity was 
obtained with the tetrahydroisoquinoline scaffold 1.236 (n = 2). A similar trend was 
observed with an unsaturated alkyl substituent on the piperazine (1.238-1.240), and in 






1.227:  R1 = Cl, R2 = H
1.228:  R1 = H, R2 = Cl







1.229:  R1 = Cl, R2 = H  (80%)
1.230:  R1 = H, R2 = Cl  (75%)
1. allylamine, CH2Cl2
    then NaBH4, MeOH
2. CbzCl, i–Pr2NEt





1.231:  R1 = Cl, R2 = H  (76%)
1.232:  R1 = H, R2 = Cl  (80%)
1. Grubbs II, CH2Cl2





1.233:  R1 = Cl, R2 = H  (79%)
1.234:  R1 = H, R2 = Cl  (65%)
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greatest s2R affinity (Ki = 2.7 nM) was obtained for tetrahydroisoquinoline scaffold 
1.242 with a cyclopentyl substituent at the piperazine nitrogen atom, a notable increase 
that provided 19-fold selectivity over the s1R. Previously, introduction of an alkyl 
substituent bearing an ester moiety delivered a considerable decrease in s1R affinity with 
norbenzomorphan 1.203, but little effect was observed at the s2R. Interestingly, this 
effect was not as pronounced for the simplified scaffold (1.244-1.246) and was 



















Table 1.12. Binding affinities of the piperazine substituted-simplified scaffold. 
 
 Ki (nM) Ki ratio 
cmpd. n scaffold R s1R s2R (s1R/s2R) 
1.191 N/A A 
 
230 5.1 45 
1.235 1 B 19 77 0.25 
1.236 2 B 85 50 1.7 
1.237 3 B 15 14 1.1 
1.210 N/A A 
 
413 17.5 24 
1.238 1 B 92 153 0.6 
1.239 2 B 245 25 10 
1.240 3 B 48 19 3 
1.209 N/A A 
 
130 3.6 36 
1.241 1 B 44 8.2 5 
1.242 2 B 52 2.7 19 
1.243 3 B 49 13 4 
1.203 N/A A 
 
6,660 23.8 280 
1.244 1 B 352 134 3 
1.245 2 B 407 198 2 



















Relatively minor changes in the position of the distal aromatic group with respect 
to the more basic nitrogen atom of the piperazine ring were previously demonstrated to 
have a significant impact on s1R affinity. Indeed, the norbenzomorphan scaffold 
displayed much lower affinity for the s1R when the piperazine was installed at C–8, as 
opposed to C–7.9 The isoindoline scaffold 1.226 (n = 1) has a symmetry element that 
prevents examination of a similar regioisomeric preference. However, the orientation of 
the piperazine on 1.247 and 1.249 provides a slight preference for the s2R, whereas 
1.248 has a modest preference for the s1R (Figure 1.51).8 The bridging methylene group 
of the norbenzomorphan scaffold seems to plays a role in obtaining  selectivity for the 
s2R. Excision of this group in hydrobenzazepine scaffold 1.249 likely altered the 
orientation of the core nitrogen atom and the distal aromatic group that is attached at this 
site in a manner that favors  s1R binding. In order to examine alternative linkers to the 
distal aromatic group, the benzyl carbamate of 1.249 was exchanged with an aryl 
sulfonamide in 1.250, which provided increased affinity for both sRs, but with little 






Figure 1.51. A) Regioisomers of piperazine substituted tetrahydroisoquinoline. B) 
Variations in the aryl substituent on the hydrobenzazepine nitrogen atom.  
The norbenzomorphan scaffold demonstrated an ability to obtain s1R selectivity, 
when substituted at the C–7 and this proved to be effective strategy for accessing s1R 
selective ligands using the simplified scaffold (Table 1.13).8,9  The morpholine 
substituted scaffolds (1.251-1.253) achieved low nanomolar affinity for the s1R, and 
isoindoline 1.251 achieved 28-fold selectivity over the s2R. Likewise, the aryl 
substituted scaffold displayed high affinity for the s1R, with isoindoline 1.254 obtaining 
4.1 nM for the s1R and 16-fold selectivity over the s2R. In both cases, the modified 
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that removal of the bridging methylene is an effective simplification strategy for 
developing s1R selective ligands.  
Table 1.13. Binding affinity of simplified scaffold with s1R selectivity.  
 
 Ki (nM) Ki ratio 
cmpd. n scaffold R s1R s2R (s2R/s1R) 
1.56 N/A A 
 
16.5 562.3 34 
1.251 1 B 5.9 166 28 
1.252 2 B 1.7 33 19 
1.253 3 B 6.1 81 13 
1.169 N/A A 
 
11.1 121 11 
1.254 1 B 4.1 65 16 
1.255 2 B 4.9 57 12 
1.256 3 B 21 440 21 
Ki values determined from non-linear regression of radioligand competition binding isotherms by PDSP.  
Collectively, these results provide additional evidence that the relative position of 
the basic nitrogen and the distal aromatic group are important pharmacophore elements 
for obtaining s2R selectivity. Moreover, the bridging methylene group appears to be an 
important structural feature for preferential s2R binding and this simplification strategy 
suggests that excision of this group had a deleterious effect in the bicyclic heterocycles. 
Modest s2R selectivity was achieved in some in some instances with the bicyclic 










substitution patterns, suggesting that it provides a more favorable orientation of key 
pharmacophore elements.   
1.7 CONCLUSION 
The s1R and s2R are intriguing receptors that have been implicated in a broad 
range of diseases, and ligands that modulate the sRs are currently undergoing clinical 
trials. This expanding medicinal relevance highlights the need for a thorough 
understanding of the cellular mechanism of action involving these receptors, but the s2R 
has been an enigmatic target that has relied on pharmacological characterization and 
remains poorly defined. Identification of the s2R protein and access to the cloned gene 
will provide access to modern tools for investigation that should enable much needed 
advancement. This underscores the need for molecular tools with high specificity for the 
s2R, but ligands that are selective over the s1R have been elusive in the absence of 
structure-based-design strategies.  
The Martin group has developed a new sR ligand class using an efficient an 
easily diversifiable synthetic strategy that enabled an extensive SAR investigation and 
identified substitution patterns that modulate s1R and s2R affinity. Some of these 
norbenzomorphan derived analogs show promising activity in models of several 
neurological disorders that were previously unknown, suggesting that continued 
development is warranted. Structural features of the norbenzomorphan nucleus that 
contribute to the binding profile were interrogated using a scaffold simplification strategy 
as part of ongoing hit-to-lead development aimed at optimizing pharmacological activity 
and discovering alternative lead scaffolds with unique PK profiles. This effort revealed 
that the bridged ring system of the norbenzomorphan might play an important role as a 
conformational constraint to provide selectivity over the s1R. However, it also suggests 
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that selectivity can be obtained using other scaffolds if the proper orientation of critical 
substituents can be obtained. Thus, continued investigation of molecular variants of the 
norbenzomorphan scaffold might provide useful tool compounds that elucidate key 
features of the SAR and potentially provide alternative lead compounds with improved 















Chapter 2: Structural Modification of the Norbenzomorphan Scaffold 
for Targeting the s2R and the Molecular Identification of the s2R as 
TMEM971 
2.1 SCAFFOLD SIMPLIFICATION: AN ALTERNATIVE APPROACH 
2.1.1 Introduction 
In the time since their initial discovery, the sRs have generated considerable 
interest that revealed the enigmatic nature of the protein, but also their promising 
therapeutic potential.5 Following their early mischaracterization as an opioid receptor 
subtype, the sRs were delineated into the s1R and s2R receptor subtypes that were 
unique from opioid receptors.55,75 Molecular identification and cloning of the s1R 
followed shortly thereafter, enabling significant advancements, and more recently the 
structure of the protein was finally revealed via X-ray crystallography.6,78 Increased 
access to these characterization data improved our understanding of the cellular role  of 
the s1R and have implicated it in the regulation of cellular processes important for cell 
viability.10 Genetic mutations of the s1R have been linked to disorders associated with 
neuronal decline,5 and it has been implicated in a variety of conditions that range from 
cancer to neuropsychiatric disorders. Ligands that modulate the s1R are currently in 
clinical trials for the treatment of neuropathic pain, AD, and stroke.10,108,119-124  
 In contrast, the s2R has proved to be a much more elusive target and the protein 
was only recently identified and cloned through the course of the work presented 
herein.160 As a result, pharmacological characterization has been the primary mechanism 
                                               
1 Sections of this chapter are based on previously published work from Michael D. Wood that Prof. 
Stephen F. Martin served as an advisor for. See Alon, A.; Schmidt, H. R.; Wood, M.D.; Sahn, J. J.; Martin 
S. F.; Kruse, A. C. Identification of the Gene that Codes for the s2 Receptor. Proc. Natl. Acad. Sci. U.S.A. 
2017, 114, 7160-7165. Contributions from Michael D. Wood include the development and synthesis of the 
ligand used for affinity purification of the s2 receptor. 
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for investigation of the s2R, and although numerous studies posit promising therapeutic 
potential of the receptor, the molecular mechanism remained unclear.7 These challenges 
notwithstanding, the s2R had attracted considerable attention for treatment and 
diagnostic imaging of cancer.77,161,203 More recently, important findings from the Martin 
group11-14,163 and others have indicated that the s2R might be a target for the treatment of 
some neurological and addiction disorders, and ligands that modulate the receptor are 
currently undergoing clinical trials for the treatment of AD and schizophrenia.164-168,211  
The Martin group recently discovered that derivatives of the norbenzomorphan 
scaffold can have high affinity for the s2R. Importantly, a SAR investigation revealed 
that affinity for the s1R can be effectively modulated through several unique variations 
in substitution pattern (Figure 2.1).263 Among the key findings, the position of the 
piperazine moiety on the core arene and alterations to the position of the distal aromatic 
group had a pronounced impact on affinity, particularly with respect to the s1R.9,263 
Several of the compounds developed during the course of these investigations displayed  
promising neuroprotective activity in animal models of some CNS disorders that inspired 
continued investigation as part of hit-to-lead development.11-14,163  However, the SAR 
studies focused on identifying substitution patterns on norbenzomorphans that enhanced 
potency and selectivity for the s2R, but the importance of specific structural features of 
the norbenzomorphan nucleus itself required additional clarification. 
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Figure 2.1. Summary of SAR for piperazine-substituted norbenzomorphan.  
Scaffold simplification , which is a common strategy during hit-to-lead 
development, aims to achieve a similar orientation of key pharmacophore elements with 
an alternative scaffold arrangement that is less structurally complex.288 This tactic can 
potentially provide alternative lead scaffolds that possess unique physiochemical or PK 
properties that might be beneficial, and it also allows the importance of various structural 
characteristics of the scaffold to be assessed. During the course of ongoing studies that 
probed the effects of various substitution patterns on the norbenzomorphan scaffold, there 
were also concurrent efforts to assess structural modifications via a scaffold 
simplification approach. As discussed in the preceding chapter, the bridged ring system 
was identified as a potential source of unnecessary structural complexity. Thus, one 
scaffold simplification approach involved excision of the bridging methylene, but 
interestingly, this generally enhanced affinity for the s1R and eroded selectivity for the 
s2R (Figure 2.2).8 These results suggested that the bridged ring system might play an 
important role, possibly through conformationally constraining the scaffold in an 
orientation that was less favorable for interaction with the s1R. However, if this 
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alternative scaffold, provided that critical pharmacophore elements are constrained in a 




Figure 2.2. Summary of SAR for piperazine-substituted scaffolds with the bridging 
methylene removed. 
2.1.2 Development of an Aminotetralin Scaffold 
During the course of these investigations, an alternative strategy for scaffold 
simplification of the bridged ring system was devised. In this unique approach, scission 
of the seven-membered ring in 1.53 and ring-expansion of the bridging five-membered 
ring gives rise to the aminotetralin scaffold 2.1 (Figure 2.3.A). Importantly, this tactic 
transitioned the benzylic nitrogen atom to an exocyclic position that is less 
conformationally restricted. As evidenced by preliminary studies of the 
norbenzomorphan, seemingly minor alterations in substitution at this position can have a 
considerable impact on s2R selectivity, indicating that it is an important pharmacophore 
element. This suggests that the proposed structural modification in the simplified scaffold 










 1) aliphatic groups (R1) 
     – increase !1R and !2R affinity
     – cyclopentyl favors !2R affinity
 2) polar groups (R1) 
     – decrease !1R and !2R affinity
increase n (1-3)
= increase !2R affinity
 n = 2 provides optimal selectivity
Modified scaffold possess increased σ1R affinity and diminished σ2R selectivity 
relative to similarly substituted norbenzomorphan congeners
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In addition, aminotetralin 2.1 presents a new site of substitution at the exocyclic nitrogen 
atom (R3), thereby allowing access to unexplored chemical space that might be leveraged 
to enhance the binding profile or other physiochemical properties.   
 
 
Figure 2.3. A) Strategy for scaffold simplification via a tetralin based scaffold.  
 B) Structural configurations of the norbenzomorphan that will be  
 mimicked on the tetralin scaffold.   
In order to assess the effects of these structural changes, an initial evaluation was 
devised to incorporate substitution patterns that were favored the s2R on the 
norbenzomorphan scaffold. At the time, initial SAR results with the norbenzomorphan 
scaffold pointed toward unique structural configurations that provided reasonable levels 
of s2R selectivity in addition to promising activity in models of neurodegeneration 
(Figure 2.3.B). One such construction was the piperazine-substituted norbenzomorphan 
2.2, in which the core nitrogen atom was functionalized as a benzyl carbamate, and the 
requisite basic amine moiety was incorporated as a substituent on the aromatic ring.  An 
alternative arrangement presented the core nitrogen atom as the basic amine site and the 






























could be mimicked on aminotetralin scaffold 2.1 for direct comparison to their 
norbenzomorphan derived congeners in order to assess the impact of these structural 
changes on the binding profile. Because the position of the substituent on the aromatic 
ring of the norbenzomorphan nucleus 1.53 significantly impacted affinity for the s1R and 
s2R, we foresaw an investigation of substituents at C–6 and C–7 of the tetralin scaffold 
2.1. However, an initial emphasis was placed on installation of the substituent at the C–7 
position because it corresponded to the norbenzomorphan C–8 position that was more 
favorable for s2R selectivity (Figure 2.3.A). A methyl group was envisioned at the newly 
accessible site of substitution on the nitrogen atom (R3) in 2.2 to resemble the substitution 
present in the parent scaffold, while also avoiding added hydrophobic bulk and 
unnecessary complexity. 
A synthetic strategy that provides efficient access to the core tetralin moiety and 
is readily diversifiable was required for a systematic investigation. The initial approach 
was inspired by the MCAP that was used to construct the norbenzomorphan scaffold 
because of the synthetic versatility that it provided.3,4,9,43,48,50 The halogenated aldehydes 
1.227 and 1.228 are commercially available and represented convenient starting materials 
for an MCAP approach (Scheme 2.1). Suzuki cross-coupling of 1.227 and 1.228 with 
potassium vinyltrifluoroborate (2.4) was catalyzed by palladium acetate (5 mol%) and 
triphenylphosphine according to slight modification of a literature procedure and 
occurred selectively at the arylbromide to afford styrene intermediates 1.229 and 1.230 in 
72% and 79% yield, respectively.290-292 Subsequent addition of an ethanolic solution of 
methylamine to a mixture containing the aldehyde intermediate 1.229 or 1.230 and 
MgSO4 in CH2Cl2 delivered 2.5 and 2.6 in 99% yield, and these compounds were used 




Scheme 2.1. Synthesis of the halogenated imine as MCAP precursor.   
With imines 2.5 and 2.6 in hand, the stage was set for installation of the 
homoallylic benzyl carbamate using the one-pot MCAP according to established 
protocol.3,50 In the event, stirring a solution of imine 2.6 and benzyl chloroformate 
(CbzCl) in THF at 60 °C for three hours followed by addition of allyl zinc bromide at -78 




Suspecting that formation of an activated N-acyliminium ion in the presence of 
the styrene moiety might be problematic, the one-pot reaction was divided into a related 
two-step sequence.  Thus, allyl zinc bromide was added directly to imine intermediates 
2.5 and 2.6 to afford the homoallylic amines 2.8 and 2.9 in 80% and 88%, respectively 
(Scheme 2.2). The amines 2.8 and 2.9 were subsequently acylated with benzyl 
chloroformate to deliver 2.10 and 2.11 in 99% and 92% yield, respectively. RCM 
proceeded smoothly by treating dienes 2.10 and 2.11 with Grubbs II catalyst to afford 












1.229:  X = H, Y = Cl (72%)
1.230:  X = Cl, Y = H (79%)
1.227:  X = H, Y = Cl





2.5:  X = H, Y = Cl (99%)














resulting olefin was accomplished via catalytic hydrogenation using Adam’s catalyst to 
afford the halogenated aminotetralin scaffolds 2.14 and 2.15.   
 
 
Scheme 2.2. Synthesis of the halogenated aminotetralin scaffolds.    
2.1.3 Preliminary Validation of the Aminotetralin Scaffold 
With halogenated scaffold 2.14 in hand, attention was shifted toward the 
preparation of a small series of analogs for direct comparison to corresponding 
norbenzomorphan derivatives. The aryl chloride moiety provided a convenient handle for 
cross-coupling using Buchwald-Hartwig amination reactions that were established for 
derivatization of the norbenzomorphan core 1.53.4,9 Thus, heating a toluene solution of 
2.14 and excess piperazine (1.172) at 100 °C in the presence of palladium acetate (5 
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reductive alkylation of 2.16 with paraformaldehyde provided N-methylpiperazine analog 
2.17 in 52% yield.  
 
 
Scheme 2.3. Synthesis of N-methylpiperazine analog. 
The binding profile was determined by the National Institutes of Health (NIH) 
Psychoactive Drug Screening Program (PDSP) at UNC-Chapel Hill via competition 
binding analysis.54 The s1R binding affinity was determined for a range of test ligand 
concentrations (0.1 nM – 10 µM) using [3H]-(+)-pentazocine with tissue typically 
sourced from guinea pig unless indicated otherwise. A modified protocol was recently 
established using membrane preparations from HEK293T cells transfected with human 
s1R to obtain high levels of protein expression.  The s2R binding affinity was 
determined with the same range of ligand concentrations using [3H]-DTG in the presence 
of (+)-pentazocine to block s1R binding sites with membrane preparations from rat PC12 
cells. Following the molecular identification and cloning of the s2R discussed in this 
work, a modified protocol using membrane preparations from HEK293T cells transfected 
with human s2R was established. The IC50 was calculated from dose-response curves 




























Cheng-Prusoff equation and is reported as the common measure of binding affinity.293 
All Ki values for tetralin derived analogs were determined from a single experiment using 
non-linear regression.  
Gratifyingly, binding analysis revealed that the piperazine-substituted 
aminotetralin 2.17 displayed 10-fold selectivity for the s2R over the s1R, which is 
similar to the corresponding norbenzomorphan 1.163 (Figure 2.4). Although the affinities 
of aminotetralin 2.17 for the s1R and s2R were somewhat diminished, this preliminary 
result suggested that the modified scaffold might be a viable alternative to the more 
structurally complex norbenzomorphan. However, a more thorough SAR investigation of 
the simplified scaffold was needed for determination of preferred substitution patterns.   
 
 
Figure 2.4. Comparison of the piperazine-substituted aminotetralin scaffold and the 
similarly substituted norbenzomorphan.    
To further evaluate alternative scaffold substitutions, an analog of the 4-
trifluoromethylphenyl substituted methanobenzazocine 1.219 was also prepared (Scheme 
2.4). Suzuki cross-coupling of halogenated aminotetralin 2.14 with arylboronic acid 2.18 
in the presence of Pd(t-Bu3P)2  delivered the biaryl substrate 2.19 in 78% yield.11 
Reductive removal of the Cbz-group in 2.19 provided the secondary amine 2.20 in 91% 












!1R Ki (nM) = 841
!2R Ki (nM) = 90
Ki ratio (!1R/!2R) = 9.3
!1R Ki (nM) = 2,944
!2R Ki (nM) = 284




analog 2.22 in 75% yield. Reduction of the ester moiety of 2.22 with lithium borohydride 
gave the 4-trifluoromethylphenyl analog 2.23 in 50% yield.   
 
Scheme 2.4. Synthesis of the 4-trifluoromethylphenyl-substituted aminotetralin analog.    
Comparison of the sR binding profile of the aminotetralin 2.23 with the 
corresponding methanobenzazocine 1.219 revealed close similarities (Figure 2.5). 
Namely, the affinity of 2.23 for the s2R of 50 nM was similar to the related 
methanobenzazocine congener 1.219. Likewise, affinity for the s1R of the aminotetralin 
2.23 was 1,268 nM, leading to a 25-fold preference for the s2R, which is comparable to 






































Figure 2.5. Comparison of the 4-trifluoromethylphenyl-substituted tetralin scaffold and 
the corresponding methanobenzazocine.  
 Preliminary analysis of analogs having the aminotetralin scaffold revealed 
binding profiles that were commensurate with similarly substituted norbenzomorphans. 
Importantly, this observation suggested that this simplified ring system maintains a 
similar orientation of critical pharmacophore elements. However, more data were needed 
to assess the merits of this modified scaffold.  
2.2 EXPANDED SAR OF THE PIPERAZINE-SUBSTITUTED AMINOTETRALIN SCAFFOLD 
Norbenzomorphans, in particular those bearing a piperazine group, that modulate 
the s2R yielded encouraging results in some models of neurodegeneration.12,14 A 
preliminary study showed that the piperazine-substituted aminotetralin scaffold 2.17 
possessed a binding profile that was similar to the corresponding norbenzomorphan 
derivatives, suggesting that the modified scaffold might also possess similar activity in 
neurodegenerative models. As a result, we embarked on an expanded SAR investigation 
to elucidate trends in the binding profile and hopefully to identify useful tool compounds 
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Interrogation of the aminotetralin SAR was conducted concurrently with the 
norbenzomorphan 1.53 and hydrobenzazepine 1.226 derived scaffolds, and trends in 
substitution pattern that favor the s2R were just beginning to emerge. However, the 
piperazine moiety was identified as a preferred ligand subtype. The presence of a basic 
amine is a mandatory requirement for high affinity sR ligands, and the s1R crystal 
structure demonstrated a critical interaction between a basic site on the molecule and 
acidic residues within the s1R binding pocket.6 The existence of related interactions in 
the binding pocket of the s2R were not known because the protein had not been 
identified, but the ubiquitous nature of this functional group among ligands that bind the 
s2R suggests that salt bridges might also play an important role for s2R ligand 
binding.220  
Based on these considerations, it seemed reasonable that variations in substituents 
at the piperazine nitrogen atom of aminotetralin 2.24 may modulate affinity for the s1R 
and s2R, which was the subject of SAR region A (Figure 2.6). At the time, the 
importance of the distal aromatic group in SAR region D was not entirely clear, although 
the benzyl carbamate did appear to be favorable on the norbenzomorphan. Thus, the intial 
SAR investigation would retain the benzyl N-methylcarbamate functionality in region D 
present in 2.17. Likewise, the position of the piperazine was fixed at the C–7 position in 





Figure 2.6. SAR regions targeted on the aminotetralin scaffold.  
2.2.1 The C–7 Piperazine-Substituted Aminotetralin Scaffold 
2.2.1.1 Synthesis of C-7 Piperazine Analogs 
The first-generation synthesis of the aminotetralin scaffold (Scheme 2.2) provided 
both C–6 and C–7 halogenated scaffolds that were easily diversifiable, but six steps were 
needed to access the key intermediate 2.14. Given our interest in more thoroughly 
exploring piperazine substituents at the C–7 position, a more expedient approach to that 
regioisomer was developed. Tetralone 2.25 possesses the bicyclic ring system present in 
the aminotetralin scaffold, but incorporation of a halogen substituent on the aromatic ring 
was first needed. Direct bromination of tetralone 2.25 was accomplished according to a 
literature protocol via addition of bromine to a mixture of 2.25 and excess AlCl3 that had 
been heated at 70 °C for 1 hour to deliver a separable mixture of 2.26 and 2.27 in 76% 
combined yield (ca. 1:1) (Equation 2.2).294 The C–7 regioisomer 2.26 is commercially 
available, although somewhat costly; notably this protocol also provides efficient access 

















     
With 7-bromotetralone (2.26) in hand, the next step required introduction of the 
benzyl carbamate moiety. Initial attempts to install the amine via reductive amination of 
tetralone 2.26 with MeNH3Cl in the presence of sodium cyanoborohydride resulted in 
poor conversion, and amine 2.28 was isolated in only 38% yield (Equation 2.3). 
However, efficient conversion to the amine 2.28 was realized by stirring a solution of 
2.26, MeNH3Cl, triethylamine, and Ti(Oi-Pr)4 in ethanol for 22 hours followed by 
addition of NaBH4 to afford amine 2.28 in 79% yield (Equation 2.4).295 Subsequent 
treatment of 2.28 with benzyl chloroformate at 0 °C delivered the halogenated scaffold 






With an efficient route to 7-bromotetralin scaffold 2.29 in hand, a piperazine 




























 Et3N, EtOH, 22 h,
















JohnPhos (1.176) at 100 °C, following a protocol reported for the norbenzomorphan 
scaffold (Scheme 2.5).4,9 However, 2.16 was obtained in only 37% yield. Concurrent 
investigations with similar substrates revealed that low and variable yields were often 
obtained using these conditions and loss of the Cbz-group was frequently observed upon 
analysis of the crude reaction mixtures. Investigation of more mild conditions using 
Pd2dba3 and RuPhos (2.30), a phosphine ligand with improved reactivity, in the presence 
of excess piperazine (1.172) in THF at 70 °C afforded 2.16 in 91% yield.296,297       
 
 
Scheme 2.5. Buchwald-Hartwig amination conditions.  
The secondary amine intermediate 2.16 was easily diversified using a variety of 
N–alkylation reactions to access a range of substituted analogs. For instance, reductive 
alkylation of 2.16 with an aldehyde or ketone delivered analogs 2.31-2.35 in high yields 
(Equation 2.5). Alternatively, reaction of 2.16 with alkyl halides delivered analogs 2.36-












Pd(OAc)2, JohnPhos, NaOt-Bu, PhMe, 100 °C (37%)















conjugate addition of 2.16 with an appropriate acrylate (Equation 2.7). Finally, the ether 
analog 2.44 was obtained directly from Buchwald-Hartwig amination of the halogenated 
aminotetralin 2.14 with the commercially available piperazine 2.45 (Equation 2.8). These 














2.31:  R = n-propyl (80%)
2.32:  R = isopropyl (65%)
2.33:  R = cyclobutane (89%)
2.34:  R = cyclopentane (79%)















2.36:  R = ethyl (70%)
2.37:  R = allyl (30%)
2.38:  R = CH2CH2CH2OH (34%)
2.39:  R = CH2CH2CH2CO2Et (55%)
2.40:  R = CH2CO2Et (62%)











2.42:  R = CH2CH2CO2Et (86%)




2.2.1.2 Effect of Varying Hydrophobic Piperazine Substituents 
The first series of analogs were designed to assess the effect of hydrophobic 
substituents of increasing size at the piperazine nitrogen atom on binding affinity for the 
s1R and s2R (Table 2.1). The N-methylpiperazine analog 2.17 had modest affinity and 
selectivity for the s2R. Interestingly, the unsubstituted piperazine analog 2.16 showed 
increased affinity for both the s1R and s2R relative to 2.17, but the selectivity for the 
two compounds was similar. However, increasing the length of a linear alkyl group from 
one to three carbon atoms (2.17, 2.36, 2.31) increased affinity for both sRs. The observed 
increase generally favored the s2R as illustrated by the n-propyl analog 2.31, which has 
5.5 nM affinity for the s2R and 36-fold selectivity over the s1R. Branching in the 
aliphatic substituent had comparatively little effect as reflected in the isopropyl analog 
2.32, but introduction of unsaturation with the allyl group in 2.37 resulted in a nearly 20-





















Table 2.1. Binding affinity of aminotetralins with aliphatic piperazine substituents. 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R Scaffold s1R s2R (s1R/s2R) 
2.16 
 
AT 280a 32b 8.8 
1.173 NB 1,624 25 65 
2.17 
 
AT 2,944 284 10 
1.163 NB 841 90 9.3 
2.36 
 
AT 887 35 25 
1.190 NB 600 32.5 18 
2.31 
 
AT 200 5.5 36 
1.191 NB 230 5.1 45 
2.32 
 
AT 223 8.3 27 
1.192 NB 473 14.5 33 
2.37 
 
AT 820 105b 7.8 
1.197 NB 931 76.4 12 
Ki values for aminotetralin analogs (single point) determined from non-linear regression of radioligand 
competition binding isotherms by PDSP. Unless indicated otherwise, s1R was sourced from guinea pig 
brain and s2R was sourced from rat PC12 cells. a Determined using HEK293T transfected with human 
s1R. b Determined using HEK293T cells transfected with human s2R/TMEM97. 
The ligands in this aminotetralin (AT) series were also compared to similarly 




















for each pair was remarkably consistent across the entire range of alkyl groups that were 
tested. These results provided compelling evidence that the simplified aminotetralins are 
viable replacements for norbenzomorphans. The unsubstituted piperazine analog 2.16 is 
the lone exception with s2R affinity similar to norbenzomorphan 1.173, but considerably 
higher s1R affinity. However, it is notable that s1R affinity for 2.16 was determined 
using HEK293T cells transfected with human s1R, as opposed to the classical assay 
using GP tissue that was utilized with other ligands. This difference makes a direct 
comparison more challenging.   
Having established that linear aliphatic substituents of increasing size were 
associated with increased affinity, attention shifted toward N-cycloalkyl analogs (Table 
2.2). As the ring size is increased from four to six-carbons (2.33-2.35) affinity for both 
sRs increases. Among the cyclic hydrocarbon substituents, the cyclopentyl group in 2.34 
provides the greatest affinity for the s2R (2.1 nM) and selectivity (41-fold) for the s2R 
over the s1R. Expanding the ring size to a cyclohexyl group in 2.35 produces a notable 
increase in s1R affinity with no change in s2R affinity, resulting in a more modest 7.6-
fold preference for the s2R. Hydrophobic bulk appears to be well tolerated near the basic 
nitrogen atom by both the s1R and s2R, and sR affinity is enhanced as the group size 
increases. Similar to linear aliphatic groups, there is a high level of consistency between 
analogs derived from the simplified aminotetralin scaffold and similarly substituted 







Table 2.2. Binding affinity of aminotetralins with carbocyclic piperazine substituents. 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R Scaffold s1R s2R (s1R/s2R) 
2.33 
 
AT 266 12 22 
1.194 NB 208 5.0 42 
2.34 
 
AT 86 2.1 41 
1.195 NB 130 3.6 36 
2.35 
 
AT 16 2.1 7.6 
1.196 NB 29.8 12.5 2.4 
Ki values for aminotetralin analogs (single point) determined from non-linear regression of radioligand 
competition binding isotherms by PDSP. Unless indicated otherwise, s1R was sourced from guinea pig 
brain and s2R was sourced from rat PC12 cells. 
2.2.1.3 Polar Functional Groups on the Piperazine Substituent 
Having assessed a range of aliphatic groups on the piperazine nitrogen atom, 
attention turned toward incorporating polar functionality on these substituents. Large 
hydrophobic groups in close proximity to the basic nitrogen atom appear to be readily 
accommodated by the s1R and s2R. However, the data indicate that high s2R affinity 
can be obtained with or without large hydrophobic groups, whereas such groups are 
imperative for high s1R affinity. This observation suggested that introducing polar 














region by the s1R, but perhaps with less impact on s2R binding, thereby enhancing s2R 
selectivity.    
 To examine this hypothesis, a series of analogs with several polar functional 
groups at various locations on the N–alkyl substituent were evaluated (Table 2.3). In 
comparison to propyl piperazine analog 2.31, each compound had diminished affinity for 
the s1R, but the impact on s2R potency was generally more subtle. For instance, the 
incorporation of an ethyl ester in 2.42 resulted in an 8-fold decrease in s1R affinity, but 
potency for the s2R was virtually unchanged, affording a remarkable 366-fold preference 
for the s2R. Extending the length of the carbon chain between the basic amine and the 
carbonyl moiety from two to three-carbons in 2.39 provided a modest decrease in s2R 
affinity that resulted in a more modest 68-fold preference for s2R. In contrast, decreasing 
the length of the aliphatic chain from two to one-carbon atoms in 2.40 significantly 
reduced affinity for both sRs. It is notable that a structurally related amine with an a-
ester moiety similar to 2.40 has significantly reduced basicity as compared to a b-ester 
moiety similar to 2.42  (DpKa ca. -1.5).264 Thus, the diminished sR affinity of 2.40 might 
be attributed to a decrease in basicity that mitigates formation of a strong salt-bridge 
interaction in the receptor binding site.  Decreasing the length of the alkoxy-carbon chain 
in methyl ester analog 2.43 provided similarly diminished s1R, although with a more 
pronounced decrease in s2R affinity. A similarly positioned carbonyl moiety in 
diethylamide analog 2.41 reduced s1R affinity to micromolar levels, but low nanomolar 
affinity was retained for the s2R, resulting in a 292-fold preference over the s1R. The 
propyl alcohol analog 2.38 displayed a modest reduction in s1R affinity (ca. 2-fold), 
accompanied by decreased s2R affinity (ca. 4-fold) and a similar effect was observed in 
methyl ether analog 2.44 with a more prominent reduction in potency at both the s1R and 
s2R. As observed with hydrophobic groups, the binding profile of the aminotetralin and 
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norbenzomorphan analogs are generally similar, although with somewhat more 
variability that might be attributed to an increased sensitivity toward minor changes in the 
position of polar functionality.298  
Table 2.3. Binding affinity of aminotetralins with polar substituents at the piperazine. 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R Scaffold s1R s2R (s1R/s2R) 
2.31 
 
AT 200 5.5 36 
1.191 NB 230 5.1 45 
2.38 
 
AT 474 21 23 
1.202 NB 524 5 105 
2.44 
 
AT 1,054 128 8 
2.46 NB 583 26 22 
2.40 
 
AT >10,000 894 >11 
– NB N/A N/A N/A 
2.42 
 
AT 1,649 4.5 366 
1.203 NB 6,660 23.8 280 
2.39 
 
AT 1,369 20b 68 
– NB N/A N/A N/A 
2.43 
 
AT 2,864 43 67 

























Table 2.3. Binding affinity of aminotetralins with polar substituents at the piperazine. 
 
 
 Ki (nM) Ki ratio 
Cmpd.  R Scaffold s1R s2R (s1R/s2R) 
2.41 
 
AT 2,101 7.2 292 
2.48 NB 963a 7.7b 125  
Ki values for aminotetralin analogs (single point) determined from non-linear regression of radioligand 
competition binding isotherms by PDSP. Unless indicated otherwise, s1R was sourced from guinea pig 
brain and s2R was sourced from rat PC12 cells. aDetermined using HEK293T transfected with human 
s1R. bDetermined using HEK293T cells transfected with human s2R/TMEM97. 
 
Among the analogs tested, those with an alkyl substituent installed at the 
piperazine nitrogen atom possessing a carbonyl moiety that is separated from the amine 
by a two-carbon chain achieved approximately 300-fold selectivity for the s2R over the 
s1R. This represents an important discovery for modulating s2R selectivity that is not 
clearly demonstrated among structurally unrelated s2R ligands. It is important to note 
that a carbonyl group at this position has minimal impact on s2R affinity, while 
significantly disfavoring interaction with the s1R. As previously discussed, many of the 
more s2R selective ligands incorporate some HBA group or other polar functionality, but 
a relationship with respect to its proximity to the basic amine site has not been clearly 
estabilished.162,203,220 This provides support for the hypothesis that the s1R requires a 
















can disrupt binding. These results represent a valuable observation that could potentially 
be further optimized to enhance selectivity for the s2R.        
2.2.1.4 Nitrogen Containing Heterocycles in SAR Region A 
During lead optimization, lipophilic bulk is often accumulated on molecules and 
such changes can frequently give rise to enhanced potency. However, increased 
lipophilicity can also result in physiochemical properties that are not ideal, contributing 
to downstream attrition of drug candidates.299 It is therefore important to more broadly 
consider molecular attributes that are favorable not just for potency, but also for 
adsorption, distribution, metabolism, excretion, and toxicity (ADMET). The lipophilicity 
of a compound is often related in terms of its computed n-octanol and water partition 
coefficient (cLogP) with higher values corresponding to increased lipophilicity. This 
parameter is a particularly important component in many factors associated with drug 
properties.298,300 Indeed, cLogP values greater than five were associated with a decreased 
likelihood of oral bioavailability by Lipinksi.301 Later, nearly 30,000 compounds were 
profiled by GlaxoSmithKline (GSK) finding that on average those with cLogP values less 
than four and molecular weights below 400 exhibited more favorable ADMET 
profiles.302  
The propensity of basic compounds to inhibit the human ether-a-go-go related 
gene (hERG) potassium ion channels, a particularly promiscuous protein that is 
associated with life-threatening heart arrhythmias, is magnified with increased 
lipophilicity.303 In fact, among the basic molecules reviewed by GSK, those with cLogP 
values greater than four had, on average, a higher likelihood of hERG inhibition along 
with lower solubility and lower bioavailability, as compared to compounds with cLogP 
values less than four.302 The balance of these molecular features is certainly more 
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nuanced than these general parameters, but they provide guidelines that can be applied 
during development.298  
The discovery that polar functional groups in region A significantly attenuate 
affinity for the s1R with little disruption in s2R affinity was an intriguing finding and 
provides a useful strategy for augmenting selectivity. This was particularly effective with 
either an ester or amide moiety positioned two to three-carbons from the basic amine 
group. The investigation of aliphatic substituents in this region revealed that considerable 
hydrophobic bulk was also well-tolerated by the s2R. However, the series of analogs that 
probed polar functional groups was limited to flexible, linear substituents. These 
observations raised the possibility that more bulky heterocycles possessing similar 
functionality in this region, but with potentially unique physiochemical properties, might 
also provide a similar effect. Thus, the incorporation of polar heterocycles in region A 
could potentially decrease lipophilicity and enhance s2R.    
The previous investigation of substituents in this region revealed that an amide 
moiety provided low nanomolar affinity for the s2R and 292-fold selectivity over the 
s1R in analog 2.41, suggesting that structural variants might also be promising. A lactam 
was envisioned as a heterocyclic replacement that would provide similar functionality in 
region A as part of a conformationally constrained ring system. Accordingly, heating a 
solution of piperazine analog 2.16 and the known lactam 1-(chloroethyl)-2-pyrolidinone 
(2.49) at 65 °C for 72 h provided 2.50, albeit in only 25% yield along with significant 
unreacted starting material (Equation 2.9).304 However, a sufficient quantity of material 





Alternatively, a common strategy during development of drug candidates is the 
replacement of a functional group with a bioisosteric equivalent that elicits a similar 
biological effect, but is structurally unique. This strategy is often employed to exchange 
metabolically labile groups with more robust groups or as a means of modulating 
physiochemical and ADMET properties.305 Ester and amide groups are frequently 
targeted for bioisostere replacement, and many functional groups have been established 
for this purpose, particularly azole heterocycles.305 Exchanging the carbonyl moiety in 
ester 2.42 and amide 2.41 with a known heterocyclic bioisostere might provide similarly 
potent and selective s2R ligands, but with decreased cLogP values and more favorable 
ADMET properties.  
To test this hypothesis, a small series of analogs was desinged to probe the effects 
of heterocyclic isosteres in this region. The 1,2,4-oxadiazole ring system is a well-
established bioisostere for amide and ester functional groups that can be accessed via a 
nitrile intermediate.305,306 Accordingly, a solution of piperazine analog 2.16 in methanol 
at 0 °C was treated with acrylonitrile (2.51) to deliver the 1,4-addition product 2.52 in 
70% yield (Scheme 2.6). Nucleophilic addition of hydroxylamine to nitrile 2.52 delivered 
amide-oxime 2.53 in 45% yield. Notably, significant formation of piperazine 2.16 was 
observed in the crude reaction mixture, presumably resulting from retro-Michael addition 























amide-oximes with either an acid chloride or anhydride followed by base promoted 
condensation to form the heterocycle.307 However, refluxing 2.53 with acetic anhydride 
in pyridine delivered in intractable mixture containing only a trace amount of oxazole 
2.54.308 An alternative two-step sequence was conducted according to a reported protocol 
by first acylating amide-oxime 2.53 with acetyl chloride then treating the crude reaction 
mixture with tetrabutylammonium fluoride (TBAF) to promote cyclization afforded trace 
quantities of oxazole 2.54 as part of a complex mixture that was could not be purified.309   
 
 
Scheme 2.6. Synthesis 1,2,4-oxadiazole analog.  
The assemblage of 1,2,4-oxadiazole 2.54 through a nitrile precursor proved 
somewhat challenging and suffered from low yields during formation of the amide-oxime 
intermediate. As a result, an alternative approach was devised utilizing ester analog 2.42 
as a potential divergent intermediate for accessing structurally distinct oxazoles. In the 
event, ester 2.42 was heated under reflux with amide-oxime 2.55 to deliver 1,2,4-








































Ac2O, pyridine, 0 °C to reflux  (trace)
AcCl, i-Pr2NEt, CH2Cl2, then TBAF THF (trace)
2.51
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of hydrazine to ester 2.42 provided the hydrazide intermediate 2.57 accompanied by 
formation of the retro-Michael addition product 2.16 that could not be separated (Scheme 
2.7.B).312 Thus, the crude reaction mixture was subjected to microwave irradiation with 
excess trimethyl orthorformate to afford 1,3,4-oxadiazole analog 2.58 in 63% yield over 
two-steps.        
 
 
Scheme 2.7. A) Synthesis 1,2,4-oxadiazole analog. B) Synthesis of 1,3,4-oxadiazole 
analog. 
Analogs 2.50, 2.56, and 2.58 were submitted to the PDSP but are still awaiting 
complete binding analysis (Table 2.4). Interestingly, lactam 2.50 suffered from a 


























































increase in s1R potency. This is a profound shift that highlights a potential unforeseen 
sensitivity to polar groups in this region. Binding analysis of oxazoles 2.56 and 2.58 has 
been delayed due to COVID-19, but a preliminary single point assay (10 µM test-ligand) 
yielded encouraging results. Oxazole analog 2.56 displayed high levels of s2R inhibition 
(94%) and lower inhibition at the s1R (88%), a notable decrease at such a high test-
ligand concentration. Oxazole analog 2.58 exhibited much lower inhibition of s1R 
(64%), and retained high levels of s2R inhibition (96%). These preliminary results are 
encouraging, but determination of inhibition constants will be necessary before the results 
can be interpreted. Nonetheless, it is interesting that lactam 2.50 suffered complete loss of 
s2R inhibition in a single point assay (10 µM), whereas oxazoles 2.56 and 2.58 displayed 
significant inhibition suggesting that heterocyclic ester and amide isosteres in this region 
may be promising. In addition, comparison of cLogP values for these compounds reveals 
that analogs 2.56 and 2.58 with oxazole substituents attained cLogP values below four, a 
notable reduction as compared to amide analog 2.41. While these are merely predicted 
values, it suggests that physiochemical properties might be effectively modulated with 










Table 2.4. Binding affinity of aminotetralins with polar heterocycles in region A.  
 
 
 Ki (nM) Ki ratio 
Cmpd.  R cLogPc s1R s2R (s1R/s2R) 
2.41 
 
5.7 2,101 7.2 292 
2.50 
 
4.4 188 >10,000b < 0.019 
2.56 
 
3.4 pending pending pending 
2.58 
 
3.3 pending pending pending 
Ki values for aminotetralin analogs (single point) determined from non-linear regression of radioligand 
competition binding isotherms by PDSP. Unless indicated otherwise, s1R was sourced from guinea pig 
brain and s2R was sourced from rat PC12 cells. aDetermined using HEK293T transfected with human 
s1R. bDetermined using HEK293T cells transfected with human s2R/TMEM97. c cLogP values calculated 
using BioByte with ChemDraw Professional 16.0.  
2.2.1.5 Summary of Piperazine Substituents in SAR Region A 
Collectively, the investigation of SAR region A helped elucidate several 
important findings on the aminotetralin scaffold (Figure 2.7). A broad range of 






















sufficient, but not necessary to obtain high affinity for the s2R and that a secondary 
nitrogen atom can provide modest selectivity over the s1R. However, enhanced s2R 
potency is obtained with aliphatic groups that are either linear or cyclic and that optimally 
contain three to five-carbon atoms. Within this size range, potency for the s2R increases 
as the size increases, providing reasonable selectivity over the s1R that is diminished as 
the size is further increased. The discovery that substituents with polar HBA or HBD 
groups disfavor interaction with the s1R is significant. Critically, a carbonyl moiety 
positioned two to three-carbons from the basic amine was established as an effective 
tactic for disfavoring the s1R with little impact on s2R potency. Thus, varying the 
substitution pattern on the piperazine nitrogen atom in region A delivered analogs with 
low nanomolar affinity for the s2R that are capable of obtaining up to 366-fold 
selectivity over the s1R.     
          
 
Figure 2.7. Summary of SAR observation in region A.      
Most importantly, this SAR investigation validated the aminotetralin scaffold as a 









 1) aliphatic groups 
     – increase !2R affinity
     – 3-5 carbons preferred
 2) increased 
     hydrophobic  bulk
     – increase !1R affinity
     – diminished selectivity
 3) polar groups 
     – decrease !1R affinity
     – enhance selectivity
     – carbonyl is optimal 2-3   




ligands constructed around this template are quite similar to the norbenzomorphan with a 
broad range of linear and cyclic hydrophobic groups in region A, as well as substituents 
with polar functionality. This suggests that the modified scaffold provides similar 
orientations of critical pharmacophore elements among ligands with diverse substitution 
patterns in this region. Critically, this strategy has resulted in a new scaffold that might 
possess altered physicochemical or ADMET properties that could be useful during 
ongoing hit-to-lead development.     
2.2.2 Position of the Piperazine on the Aminotetralin Core 
A range of hydrophobic and polar substituents were installed in region A that 
elucidated several important trends, but was restricted to the C–7 piperazine-substituted 
scaffold, which corresponds to C–8 substituted norbenzomorphans. However, it was not 
clear if the simplified scaffold would offer a sR binding profile that was similar to the 
norbenzomorphan when the substituents were repositioned on the core benzene ring, thus 
we explored the SAR in region B (Figure 2.8).   
 
Figure 2.8. Investigation of the position of piperazine ring in region B.       
We first prepared the C–6 halogenated aminotetralin scaffold 2.15 using an 
MCAP inspired approach as previously discussed. The chlorine provided a convenient 
functional handle for probing the effect of positioning the piperazine at this site. 











aforementioned bromination protocol to provide access to the 5-substituted analogs. 
Based on the SAR derived from region A, compounds corresponding to N-
propylpiperazine analog 2.31 and ester analog 2.42 were targeted for comparison.  
The synthesis of C–5 and C–6 analogs was similar to that employed for related C–
7 analogs. Namely, Buchwald-Hartwig amination of the halogenated scaffolds 2.15 and 
2.27 with excess piperazine (1.172) was catalyzed by palladium acetate and JohnPhos to 
afford the piperazine-substituted products 2.60 and 2.61 in 57% and 35% yield, 
respectively (Equation 2.10). Reductive alkylation of 2.60 and 2.61 with propionaldehyde 
(2.62) delivered the C–5 N-propylpiperazine analog 2.63 and the corresponding C–6 
analog 2.64 in 71% and 68% yield, respectively (Equation 2.11). Alternatively, treating 
2.60 and 2.61 with ethyl acrylate (2.21) in ethanol at 40 °C provided the C–5 substituted 
ester analog 2.65 and the corresponding C–6 analog 2.66 in 84% and 59% yield 

















2.27:  C–5 = Br









2.60:  C–5 piperazine (57%)













2.63:  C–5 piperazine (71%)
2.64:  C–6 piperazine (68%)
2.62
(2.11)
2.60:  C–5 piperazine





Compounds 2.63-2.66 were submitted to the PDSP to determine their sR binding 
profile and comparison of these binding affinities with those of the corresponding C–7 
analog confirmed that substitution at C–7 imparts the greatest s2R potency with the 
lowest levels of s1R affinity (Table 2.5). For example, the C–7 N-propylpiperazine in 
2.31 exhibited 200 nM affinity for the s1R, but the C–6 substituted analog 2.64 was 5-
fold more potent, whereas the C–5 derivative 2.63 had 17-fold higher affinity for s1R.  In 
contrast, less-pronounced reductions in s2R affinity were observed for the C–6 and C–5 
congeners 2.64 and 2.63. Thus, repositioning the piperazine ring from C–7 in 2.31 to the 
C–5 position in 2.63 switches the sR that is favored from s2R preferring in 2.31 (36-
fold) to s1R in 2.63 (2.2-fold). As discussed in the preceding chapter, the 
norbenzomorphan 1.163 that possessed an N-propylpiperazine at C–8 favored the s2R 
(45-fold), but the same substituent at C–7 in 1.208 switched the sR preference to favor 
the s1R (3.4-fold) (Table 1.10). A similar trend is observed in s1R potency for ester 
analogs 2.65-2.66, but the carbonyl group appears to still attenuate interaction at s1R, 
again highlighting the effect of this functional group. A more pronounced decrease in 
s2R affinity is also observed with ester analogs 2.65-2.66, and the lowest s2R potency is 















2.65:  C–5 piperazine (84%)





2.60:  C–5 piperazine
2.61:  C–6 piperazine
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Table 2.5. Binding affinity of aminotetralins with varied substitution on the core 
arene.  
 
 Ki (nM) Ki ratio 
Cmpd.  R position s1R s2R (s1R/s2R) 
2.31 
 
C–7 200 5.5 36 
2.64 C–6 40 13 3.1 
2.63 C–5 12 26 0.46 
2.42 
 
C–7 1,649 4.5 366 
2.66 C–6 647 91 7.1 
2.65 C–5 303 34 8.9 
Ki values for aminotetralin analogs (single point) determined from non-linear regression of radioligand 
competition binding isotherms by PDSP. Unless indicated otherwise, s1R was sourced from guinea pig 
brain and s2R was sourced from rat PC12 cells.  
The probe of SAR region B demonstrated that the optimal position for the 
piperazine substituent on the aminotetralin scaffold for s2R binding is C–7. Importantly, 
this trend was confirmed using two dissimilar groups on the piperazine nitrogen atom, 
suggesting that the effect was not limited to hydrophobic groups. As previously 
discussed, a related trend was observed with the norbenzomorphan scaffold.  Therefore, 
collectively these data highlight a useful strategy for disfavoring interaction with the s1R 
by tuning the position of key pharmacophore elements around the rigid tetralin and 














2.2.3 Summary of the Scaffold Simplification Strategy: SAR Regions A and B 
The SAR investigation of regions A and B revealed several important 
characteristics (Figure 2.9). Examination of the cumulative data set reveals that many of 
the aminotetralin derived ligands displayed high affinity for the s2R, with greater than 
100 nM affinity being observed for the majority of analogs constructed using a range of 
substitution patterns in both regions A and B.  This illustrates the promiscuous nature of 
the s2R and its ability to accommodate considerable structural diversity. However, the 
s1R appears to be more sensitive to variations in substitution pattern on the aminotetralin 
scaffold. Seemingly minor alterations in functional groups or substituent position lead to 
large shifts in s1R potency that can range from nanomolar to micromolar levels.  
 
 
Figure 2.9. Summary of SAR trends in regions A and B.       
Examination of the SAR in region A revealed that most hydrophobic substituents 
provided greater the 35 nM affinity for the s2R with increasing size leading to enhanced 
potency for both s1R and s2R that results in low nanomolar affinity for both receptors. 
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increases in s1R affinity, but high s2R potency is retained. Installation of alkyl 
substituents with a carbonyl moiety that is separated from the basic amine by two-carbon 
atoms decreased affinity for the s1R to micromolar levels, with relatively little change in 
s2R affinity as compared to related hydrophobic substituents. This provides a useful 
strategy for disfavoring interaction with the s1R and enhancing s2R selectivity. In 
addition, evaluation of the SAR in region B demonstrates that installation of the 
piperazine at C–7 disfavors binding at the s1R and provides the highest levels of s2R 
selectivity. This trend is consistent with observations for the norbenzomorphan and 
establishes an effective strategy for modulating sR subtype selectivity through the 
positioning of key pharmacophore elements around the rigid scaffold.           
As discussed in the preceding chapter, the pharmacophore models available for 
the s1R and s2R lack predictive power for selective ligand design, but the relative 
positions of the basic amine and the distal aromatic group have been highlighted as 
important pharmacophore elements.138,140,246 In the aminotetralin, the distal aromatic 
group is represented by the benzyl group of the carbamate moiety (Figure 2.10). It stands 
to reason that installation of the piperazine moiety at C–7 constrains the basic amine in an 
orientation relative to the benzylcarbamate that disfavors the s1R, but remains favorable 
for the s2R. If this hypothesis is correct, then it suggests that structural changes that alter 
the relative orientation of these pharmacophore elements can significantly impact affinity 
for the s1R and either enhance or erode s2R selectivity.  
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Figure 2.10. The relative orientation of the basic amine and distal aromatic group is a 
critical pharmacophore feature.         
The aminotetralin scaffold was born of a multifaceted scaffold simplification 
strategy that was aimed at probing the s2R pharmacophore, while potentially developing 
alternative leads having improved ADMET and PK profiles. The initial goal of this effort 
was a comparison of the binding profiles of aminotetralins with that of similarly 
substituted norbenzomorphan analogs. A high degree of similarity was observed between 
the norbenzomorphan and the aminotetralin scaffolds in nearly every ligand pair over a 
range of substitution patterns and structural configurations. These results signify that the 
orientation of critical pharmacophore elements on the aminotetralin scaffold and the 
norbenzomorphan is similar. The significance of the position of the distal aromatic group 
with respect to the basic amine likely indicates that the aminotetralin achieves a similar 
orientation of these group without the need for a bridged ring system. This highlights the 
utility of this scaffold simplification strategy for removal of unnecessary structural 
complexity and validates the aminotetralin as a viable alternative scaffold. 
The scaffold simplification strategy that led to the aminotetralin scaffold 2.67 was 
conducted concurrently with an alternative strategy that delivered the hydrobenzazapine 













relative orientation is 
critical for disfavoring  !1R
2.67
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bridged ring system in norbenzomorphan 2.69, but the heterocycles 2.68 (n = 0-2) 
retained a nitrogen atom in the ring and these analogs were generally less selective and 
less potent for both sRs. Collectively, these results indicate that the relative orientation of 
the piperazine and the distal aromatic group is more favorable in norbenzomorphan 2.69 
and aminotetralin 2.67 scaffolds than in bicyclic heterocycles 2.68. It also suggests that 
the aminotetralin and norbenzomorphan might provide similar orientations of these 




Figure 2.11. Comparison of the scaffold simplification strategies.  
Following the elucidation of critical pharmacophore features of the 
norbenzomorphan and its structurally simplified variants, a picture emerges that might 
explain the differences observed in the two simplification strategies (Figure 2.10).  The 
bridged ring system of the norbenzomorphan 2.69 projects the core nitrogen atom out the 
plane of the aromatic ring. Excision of the bridging methylene removes that 
conformational constraint, providing a more flexible system in which the nitrogen atom 
preferentially adopts an orientation more in plane with the aromatic ring. The resultant 
alteration in the position of the benzyl carbamate moiety likely disrupts the relative 
orientation of the basic amine and distal aromatic group that is critical for disfavoring the 
s1R and favoring the s2R. In contrast, the position of the norbenzomorphan nitrogen 


















atom is directed out of the plane of the aromatic ring to minimize steric interactions with 
hydrogen atom of the aromatic ring.313,314   
2.2.4 Evaluation of the Core Nitrogen Atom 
2.2.4.1 Substituents on the Carbamate Nitrogen Atom 
The structural modifications to the norbenzomorphan that delivered the 
aminotetralin scaffold significantly altered the nature of the core nitrogen atom from a 
heterocyclic motif to and exocyclic amine. This modification generated a newly 
accessible site of substitution in 2.70 (R2) that had not yet been explored (Figure 2.12). 
Accordingly, a brief evaluation of substituents at this position was necessary to determine 
the optimal substitution pattern of this nitrogen atom. Indeed, investigation of polar and 
hydrophobic substituents in SAR region A identified trends in nitrogen substituents that 
delivered considerable enhancements in s2R selectivity. Therefore, region C was devised 
to assess a series of hydrophobic and polar substituents installed at the core nitrogen atom 
(R2), while structural features that favored the s2R in regions A and B were retained. 
 
 
Figure 2.12. SAR region C.  
Analogs with hydrophobic groups in region C were first prepared via reductive 
amination of tetralone 2.26 with a primary amine in the presence on sodium 











proceeded slowly with significant amounts of starting material being present. The amine 
intermediate was separated from the crude reaction mixture via acid extraction and the 
crude residue was treated directly with benzyl chloroformate to delivery halogenated 
aminotetralin scaffolds 2.71 and 2.72 in 51% and 44% yield over two steps, respectively. 
Subsequent Buchwald-Hartwig amination with excess piperazine (1.172) catalyzed by 
palladium acetate and JohnPhos delivered the piperazine-substituted scaffolds 2.73 and 
2.74 in 73% and 70% yield, respectively. 
 
 
Scheme 2.8. Synthesis of piperazine substituted aminotetralin scaffold with aliphatic 
group at the benzyl carbamate nitrogen atom.   
Similarly, a solution of tetralone 2.26 and ammonium acetate in methanol was 
heated at 60 °C in the presence of sodium cyanoborohydride to give an intermediate 
amine that was separated from the crude reaction mixture via acid extraction and the 
crude residue was treated directly with benzyl chloroformate to deliver the halogenated 
aminotetralin 2.75 in 63% yield over two steps (Scheme 2.9). Buchwald-Hartwig 







2.71:  R = Et (51%)







2.73:  R = Et (73%)




    DCE, 48 h
2. CbzCl, i-Pr2NEt, 
    CH2Cl2, 0 °C
Cbz
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piperazine-substituted scaffold 2.76, albeit in 43% yield with loss of Cbz-group observed 
as a considerable side-product in the crude reaction mixture.  
 
 
Scheme 2.9. Synthesis of piperazine substituted aminotetralin scaffold.  
The synthesis of final analogs was completed through alkylation of the piperazine 
nitrogen atom with an n-propyl group or ethyl ester group to enable comparison to the 
parent compounds 2.31 and 2.42. Thus, reductive amination of 2.73-2.74 and 2.76 with 
propionaldehyde (2.62) afforded 2.77-2.79 in good yield (Equation 2.13). Alternatively, 
reaction of 2.73-2.74 and 2.76 with ethyl acrylate (2.21) at 40 °C delivered 2.80-2.82 in 
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2.77:  R = H (84%)
2.78:  R = Et (77%)










2.76:  R = H
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Compounds 2.77-2.79 and 2.80-2.82 were submitted to the PDSP for 
determination of sR binding affinity according to the protocol previously discussed. 
Increasing the size of the hydrophobic substituent at the carbamate nitrogen atom (R2) 
had relatively little impact on the binding profiles for N-propylpiperazine analogs 2.78-
2.79, with less the 2-fold change observed in both s1R and s2R affinity as compared to 
benzyl N-methylcarbamate analog 2.31 (Table 2.6). A similar trend was observed for the 
corresponding ester analogs 2.81-2.82, although with a more notable decrease in s2R 
affinity was observed with increased size of the N–alkyl group (ca. 4-fold). The lowest 
s1R affinity was observed with an ethyl group installed at the carbamate nitrogen atom 
(R2) in 2.78 and 2.81, but the reduction was modest as compared to the corresponding 
methyl substituent. In both cases, the secondary carbamate was not well tolerated with 
2.77 and 2.80 suffering from diminished  s2R affinity as compared to the corresponding 
benzyl N-methylcarbamate analogs 2.31 and 2.42, perhaps pointing toward a modest 









2.80:  R = H (80%)
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2.76:  R = H
2.73:  R = Et 
2.74:  R = n-Pr
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Table 2.6. Binding affinity of benzyl N-substituted carbamates.  
 
 Ki (nM) Ki ratio 
Cmpd.  R1 R2 s1R s2R (s1R/s2R) 
2.77  H 174 56 3.1 
2.31 
 
Me 200 5.5 36 
2.78 Et 321 4.6 70 
2.79 n-Pr 199 9.4 21 
2.80  H 2,256 80 28 
2.42 
 
Me 1,649 4.5 366 
2.81 Et 3,315 20 166 
2.82 n-Pr 2,364 19 124 
Ki values for aminotetralin analogs (single point) determined from non-linear regression of radioligand 
competition binding isotherms by PDSP. Unless indicated otherwise, s1R was sourced from guinea pig 
brain and s2R was sourced from rat PC12 cells.  
Because varying the size of the hydrophobic groups at the carbamate nitrogen 
atom had little effect attention shifted toward incorporating polar functional groups in 
region C. However, we recognized that a more divergent approach was needed to enable 
an efficient investigation of substituents on the core nitrogen atom.  Installation of a 
substituted piperazine moiety prior to incorporation of the amino moiety was envisioned 
to provide more rapid access to greater structural diversity. Accordingly, 7-
bromotetralone (2.26) was subjected directly to Buchwald-Hartwig amination with 











Because 7-bromotetralone (2.26) possesses an enolizable ketone, the reaction conditions 
were modified using cesium carbonate in tert-butanol rather than sodium tert-butoxide, 
which can be problematic in the presence of acidic protons.296 Earlier studies revealed 
that the tetralone ketone moiety was reticent to undergo reductive amination at room 
temperature, suggesting that reductive alkylation of the piperazine nitrogen atom should 
occur preferentially. In the event, treating piperazine substituted tetralone 2.83 with 
excess propionaldehyde (5 eq.) in the presence of sodium triacetoxyborohydride 
delivered alkylated product 2.84, but in only 33% yield. Interestingly, considerable 
formation of a mixture of a side products that were consistent with an aldol side-reaction 
to provide 2.85 as a mixture of diastereomers. Reducing the equivalents of 
propionaldehyde (1.1 eq.) provided modest improvement, affording 2.84 in 55% yield. 
Ultimately, slow addition of a solution of propionaldehyde (2.62) in dichloroethane to a 
stirred solution of tetralone 2.83 and sodium triacetoxyborohydride delivered 2.84 in 77% 
yield on a multigram scale. With efficient access to this key intermediate, tetralone 2.84 
was subjected to reductive amination with an appropriate amine in the presence of Ti(Oi-
Pr)4, followed by addition of sodium borohydride to afford aminoteralins 2.86-2.88 in 




Scheme 2.10. Synthesis of a piperazine-substituted tetralone divergent intermediate.  
The primary amine 2.86 was then diversified to probe the effects of ester, ether, 
and alcohol functional groups in region C.  Conjugate addition of 2.86 with ethyl acrylate 
(2.21) followed by treatment with benzyl chloroformate delivered ester 2.89, albeit in 
only 21% yield over two steps (Equation 2.15). Alternatively, treating 2.86 with 3-
oxetanone (2.90) in the presence of Ti(Oi-Pr)4 followed by addition of sodium 
borohydride and subsequent treatment with benzyl chloroformate afforded 2.91 (Equation 
2.16). Notably, reductive amination of tetralone 2.86 with 2.20 in the presence of sodium 
triacetoxyborohydride failed to deliver the desired product. Lastly, 2.88 was treated with 
benzyl chloroformate predicting that the amine might react preferentially react over the 
alcohol moiety, but perhaps unsurprisingly a mixture of products was obtained and 2.92 


























2.86:  R = H (54%)
2.87:  R = Me (78%)












but importantly considerable structural diversity was accessed through the common 
divergent intermediate 2.86 to provide analogs for preliminary analysis. Because our 
primary interest was determining the effect of polar functional groups in this region on 








Binding analysis of the prepared analogs was conducted by the PDSP revealing 
that polar groups in SAR region C were generally less favorable (Table 2.7). For 
example, the impact on s1R was relatively minimal for ester analog 2.89 and alcohol 
analog 2.92 as compared to the methyl group in 2.31, but each suffered from diminished 
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reduction in s2R affinity (ca. 24-fold) as compared to benzyl N-methylcarbamate 2.31, 
whereas ester analog 2.89 suffered a more modest decrease (ca 6-fold). The cyclic ether 
analog 2.91 also suffered from diminished s2R affinity (ca. 10-fold) that was 
accompanied by a modest increase in s1R affinity. Collectively, these data suggest that 
polar functional groups in region C have a deleterious effect on s2R affinity and 
selectivity.   
Table 2.7. Binding affinity of analogs with polar groups in region C. 
 
 Ki (nM) Ki ratio 
Cmpd.  R s1R s2R (s1R/s2R) 
2.31  200 5.5 36 
2.89 
 
187 35b 5.3 
2.92  254 135b 1.0 
2.91  105
a 57b 1.8 
Ki values for aminotetralin analogs (single point) determined from non-linear regression of radioligand 
competition binding isotherms by PDSP. Unless indicated otherwise, s1R was sourced from guinea pig 
brain and s2R was sourced from rat PC12 cells. aDetermined using HEK293T transfected with human 
s1R. bDetermined using HEK293T cells transfected with human s2R/TMEM97. 
2.2.4.2 Evaluation of the Benzyl Carbamate Functionality  
Previous SAR investigations of the aminotetralin retained the benzyl carbamate 











in this region of the norbenzomorphan had been limited, but studies had shown that the 
benzyl carbamate group could be replaced with an aryl sulfonyl group, but not amide 
groups, without a loss of potency. Additionally, substituents on the aromatic ring of this 
groups provided enhanced potency. Hence, a number of analogs were designed in which 
substitution in region D was varied (Figure 2.13).   
 
 
Figure 2.13. SAR region D.  
The propyl piperazine 2.87 was efficiently accessed in three steps as previous 
described (Scheme 2.10) and this served as the key intermediate for preparing a range of 
N–substituted derivatives. In the event, stirring a solution of 2.87 in dichloromethane 
with an appropriate acyl chloride delivered a series of N–acylated analogs 2.93-2.94 




Analogs 2.93-2.95 were assayed by the PDSP revealing that different acyl groups 



















2.93:  R = cinnamyl (66%)
2.94:  R = hydrocinnamyl (61%)






cinnamamide moiety in analog 2.93 resulted in relatively minimal change in s1R and 
s2R affinities. Interestingly, the affinity of the related hydrocinnamamide analog 2.94 for 
the s1R decreased by 4.9-fold as compared to benzyl carbamate 2.31, leading to 
increased s2R selectivity (57-fold). This notable increase in selectivity for the more 
conformationally restricted cinnamamide analog 2.93 highlights the importance of the 
orientation of the distal aromatic group. Reducing the length of the spacer by one-carbon 
atom in amide analog 2.95, which had similar s1R potency as the benzyl carbamate 
analog 2.31, reduced s2R affinity (9.6-fold). These results suggest that at least a three-
atom linker between the nitrogen atom and the aromatic ring is needed for significant 














Table 2.8. Binding affinity of aminotetralins with varied N-acyl groups.   
 
 Ki (nM) Ki ratio 
Cmpd.  R1 s1R s2R (s1R/s2R) 
2.31 
 
200 5.5 36 
2.93 
 
196a 9.6b 20 
2.94 
 
973 17b 57 
2.95 
 
188a 53b 3.5 
Ki values for aminotetralin analogs (single point) determined from non-linear regression of radioligand 
competition binding isotherms by PDSP. Unless indicated otherwise, s1R was sourced from guinea pig 
brain and s2R was sourced from rat PC12 cells. aDetermined using HEK293T transfected with human 
s1R. bDetermined using HEK293T cells transfected with human s2R/TMEM97. 
We then worked to assess the importance of the nitrogen atom itself to determine 
if it was essential, or if it was merely an atom in the linker that might be replaced with 
another atom, such as an oxygen atom. To probe this question, tetralone 2.84 was treated 
with NaBH4 to afford benzylic alcohol intermediate 2.96 for diversification (Scheme 
2.11). Reaction of 2.96 with sodium hydride followed by alkylation with several alkyl 
bromides (2.97-2.98) delivered analogs 2.99 and 2.100 for analysis. In addition, catalytic 









hydrocinnamyl ether 2.101 (Equation 2.19). Alternatively, treatment of alcohol 2.96 with 

























2.99:  R = benzyl (58%)























Interestingly, each of the oxygen analogs 2.99-2.101 and 2.103 displayed a 
considerable increase in s1R affinity relative to the parent benzyl carbamate analog 2.31 
and a modest reduction in s2R affinity (Table 2.9). For example, hydrocinnamic ether 
and ester analogs 2.101 and 2.103, were approximately equipotent for both sRs. 
However, introduction of an olefin in the side chain of 2.100 diminished s1R affinity and 
restored modest levels of s2R selectivity (9-fold). This is a particularly interesting result 
because it suggests for the first time that the nitrogen atom is not necessary for s2R 
selectivity and again points to a dependence on the precise positioning of the distal 
aromatic group as a critical pharmacophore element. Similar to the nitrogen derived 
compounds, shortening the length of the carbon chain in benzyl ether analog 2.99 was 















Table 2.9. Binding affinity of oxygenated tetralin analogs.  
 
 Ki (nM) Ki ratio 
Cmpd.  R1 s1R s2R (s1R/s2R) 
2.103 
 
33 25 1.3 




140 15b 9 
2.99 
 
104 50 2.1 
Ki values for aminotetralin analogs (single point) determined from non-linear regression of radioligand 
competition binding isotherms by PDSP. Unless indicated otherwise, s1R was sourced from guinea pig 
brain and s2R was sourced from rat PC12 cells. aDetermined using HEK293T transfected with human 
s1R. bDetermined using HEK293T cells transfected with human s2R/TMEM97. 
Intrigued by the discovery that the nitrogen atom is not be a required structural 
feature, two additional analogs were prepared (Scheme 2.12). Treating a solution of 
tetralone 2.84 and potassium hydroxide in ethanol with benzaldehyde (2.104) resulted in 
aldol condensation to deliver benzylidene analog 2.105 in 59% yield as a mixture of E/Z 
isomers (ca. 8:1). Interestingly, analysis of this mixture revealed that s1R and s2R 
affinities were remarkably similar to the cinnamyl ether analog 2.100 with a modest 







2-benzyl tetralone 2.106, albeit in only 28% yield due to competitive reduction of the 
benzylic ketone moiety that was observed in analysis of the crude reaction mixture. 
Binding studies of 2.106 showed a notable increase in s1R potency relative to 2.105 
resulting in a slight preference for the  s1R over the s2R. These results again suggested 
that the specific positioning of the distal aromatic group, which can be controlled with a 
conformational constraint, is required to disfavor binding at the s1R.  
 
 
Scheme 2.12. Synthesis of benzylidene derived analogs.  
As discussed in the proceeding chapter, substituents on the distal aromatic ring of 
s2R ligands, including the norbenzomorphan scaffold, have been observed to 
significantly alter potency and selectivity.203,220 Accordingly, we sought to evaluate the 
effect of placing halogen atoms and more polar methoxy groups on the aromatic ring of 
this group on the aminotetralin scaffold. In order to access a range of substituents on the 
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carbamate 2.107 in 75% yield (Scheme 2.13). Subsequent condensation of 2.107 with 
MeNH3Cl in the presence of Ti(Oi-Pr)4  followed by addition of sodium borohydride 
afforded amintotetralin 2.108. A solution of 4-fluorobenzyl alcohol (2.109) in a mixture 
of toluene and THF (1:1) was treated with phosgene at 0 °C to generate a chloroformate 
that was allowed to react with aminotetralin 2.108 to deliver the 4-fluorobenzylcarbamate 
intermediate 2.110 in 73% yield. Removal of the Boc-protecting group with 
trifluoroacetic acid provided the unsubstituted piperazine analog 2.111. Reductive 
alkylation of 2.111 with propionaldehyde (2.62) provided N-propylpiperazine analog 
2.112 (Equation 2.21), and alkylation with the known alkyl bromide 2.113 provided 
diethylamide analog 2.114 in 94% yield (Equation 2.22).315  
 
 

















 Et3N, EtOH, 22 h,
































Binding analysis of the 4-fluorobenzyl analogs 2.111-2.112 and 2.114 revealed 
that they had s2R affinities similar to their benzyl carbamate analogs (Table 2.10). 
Interestingly, the affinities of analogs 2.112 and 2.114, which possess an alkyl substituent 
at the piperazine nitrogen atom, for the s1R increased, thereby eroding selectivity. In 
contrast, the s1R affinity of unsubstituted piperazine analog 2.111 was relatively 
unchanged. These results suggest that incorporation of a fluorine substituent at the 4-
position of the benzyl group generally has a deleterious effect on s2R selectivity with the 
aminotetralin scaffold, whereas the same group in norbenzomorphan 1.182 provided an 




































Table 2.10. Binding affinity of 4-fluorobenzyl N-substituted carbamates.  
 
 Ki (nM) Ki ratio 
Cmpd.  R1 R2 s1R s2R (s1R/s2R) 
2.16 
 
H 280a 32b 8.8 
2.111 F 237a 35b 6.8 
2.31 
 
H 200 5.5 36 
2.112 F 52a 4.4b 12 
2.41 
 
H 2,101 7.2 292 
2.114 F 355a 3.1b 115 
Ki values for aminotetralin analogs (single point) determined from non-linear regression of radioligand 
competition binding isotherms by PDSP. Unless indicated otherwise, s1R was sourced from guinea pig 
brain and s2R was sourced from rat PC12 cells. aDetermined using HEK293T transfected with human 
s1R. bDetermined using HEK293T cells transfected with human s2R/TMEM97. 
 
A series of aminotetralin analogs was also designed to probe the effects of more 
polar methoxy substituents on the aromatic ring. Because the cinnamamide analog 2.93 
displayed nearly identical binding affinity for the s1R and s2R as the benzyl carbamate 
analog 2.31, we decided to study the effect of methoxy-substituted cinnamamides. (Table 
2.7). Thus, the aminotetralin 2.87 was coupled with the appropriate cinnamic acid using 
EDCI to deliver the 2-methoxy, 3-methoxy, and 4-methoxy analogs 2.116-2.118 in good 
yields (Equation 2.23). A similar tactic was used to exchange the phenyl group with a 














aromatic group that is more polar in nature (Equation 2.24). Binding analysis of these 
analogs has been delayed due to COVID-19, but is anticipated to provide insight into the 





2.2.5 Investigation of the Aminotetralin Enantiomers 
It is well established that some some ligands in their optically pure form 
preferentially bind either the s1R or s2R. As outlined in the preceding chapter, the sRs 
were originally defined based on their preference for (+)-benzomoprhans, a feature that 
was later attributed specifically to the s1R.56,57 The s2R was later defined in part, by its 
low affinity for the (+)-benzomoprhans.75 A related trend was observed with the 
benzomorphan-7-one  s2R ligand classes, in which (+)-CB-184 (1.111) displayed greater 
than 500-fold selectivity for the s2R over the s1R, whereas as the enantiomer displayed 
a modest preference for the s1R (Table 1.1).249 However, little difference was observed 














2.116:  2–OMe (70%)
2.117:  3–OMe (75%)
















1.213 and the corresponding racemate 1.191, although 1.212 did show a modest reduction 
in s2R affinity (3.9-fold) (Figure 1.42). However, it remained to be determined if the 
enantiomers of the aminotetralin scaffold exhibited preferential binding for the s2R that 
might enhance selectivity.  
 A common tactic for resolving enantiomers is through formation of 
diastereomeric salts from a racemic mixture by selective crystallization of a particular 
diastereomeric form.316 The proximity of the basic amine moiety to the chiral center of N-
methyl aminotetralin 2.28 suggested that it was an ideal intermediate for optical 
resolution using this strategy. Fortunately, Welch and Williams of Pfizer disclosed the 
resolution of (R)-2.122 during their preparation of sertraline in greater than 99% 
enantiomeric excess (ee) by crystallization of the N-acetyl-L-phenylalanine salt.317 In 
accordance with the reported protocol, a solution of N-acetyl-L-phenylalanine and 2.28 
was stirred in hot ethanol and allowed to cool whereupon crystallization occurred 
(Scheme 2.14). The collected solids were recrystallized again from ethanol to deliver S-
enriched salt (> 97:3 dr) along with the mother liquors containing R-enriched salt. The R-
enriched residue obtained from the mother liquors was converted to the free base and 
subjected to the same procedure using N-acetyl-D-phenylalanine to afford the R-enriched 
salt  (> 97:3 dr). Treatment of the salts thus obtained with aqueous sodium hydroxide 
afforded aminotetralins (S)-2.121 and (R)-2.122 in 32% and 25% overall yield, 




Scheme 2.14. Synthesis enantioenriched analogs through chiral resolution of 2.28.  
The enantiomers (S)-2.121 and (R)-2.122 were subsequently converted to N-
propylpiperazine analogs for comparison to the racemic mixture (Scheme 2.14). Similar 
to the previously discussed protocol, (S)-2.121 and (R)-2.122 were treated with benzyl 
chloroformate to deliver (S)-2123 and (R)-2.124 in 98% yield. Subsequent Buchwald-
Hartwig amination of (S)-1.123 and (R)-2.124 with piperazine (1.172) catalyzed by 
Pd2(dba)3 and RuPhos afforded intermediates (S)-2.125 and (R)-2.126 in 68% and 60% 
yield, respectively. Reductive alkylation of (S)-2.125 and (R)-2.126 with 
propionaldehyde (2.62) provided (S)-2.127 and (R)-2.128 in greater than 99% ee.  
The enantioenriched analogs were submitted to the PDSP for binding analysis, 
that indicated that the two enantiomers had different binding profiles (Table 2.11). The 
effect toward the s1R was the most pronounced, with a 5.3-fold increase in s1R affinity 
in (R)-2.128, as compared to (S)-2.127. Interestingly, (S)-2.127 possessed similar s1R 
affinity as the racemate. The s2R potency of (R)-2.128 and (S)-2.127 was relatively 
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to the racemate. However, it is worth noting that different protocols were used for the 
s1R binding assay of the racemate and the enantiomers that makes a direct comparison 
more challenging. Somewhat surprisingly, the difference in s1R affinity for the 
aminotetralin enantiomers is distinct from the similarly substituted norbenzomorphan 
enantiomers, which had nearly identical affinity for the s1R.  
Table 2.11. Binding affinity of enantioenriched analogs.   
 
 Ki (nM) Ki ratio 
Cmpd.  s1R s2R (s1R/s2R) 
(±)-2.31 200 5.5 36 
(R)-2.128 37a 8.4b 4.4 
(S)-2.127 195a 5.5b 35 
Ki values for aminotetralin analogs (single point) determined from non- 
linear regression of radioligand competition binding isotherms by PDSP.  
Unless indicated otherwise, s1R was sourced from guinea pig brain and  
s2R was sourced from rat PC12 cells. aDetermined using HEK293T  
transfected with human s1R. bDetermined using HEK293T cells transfected  
with human s2R/TMEM97. 
2.2.6 Summary of the Aminotetralin SAR Investigation  
A scaffold simplification strategy applied to the norbenzomorphan framework 
gave rise to the aminotetralin scaffold (Figure 2.14). SAR investigations in region A and 
B suggest that compounds that have the aminotetralin scaffold had similar binding 







high affinity and selectivity for the s2R over the s1R when a piperazine ring was 
installed at the C–7 position in region B. The highest levels of s2R selectivity, up to 366-
fold, were obtained with aliphatic substituents possessing a carbonyl moiety installed on 
the piperazine nitrogen atom in region A. Hydrophobic groups in this region that were 
between three and five- carbon atoms provide optimum s2R selectivity if a carbonyl 
group is not present. The relative orientation of the substituted piperazine moiety and the 
distal aromatic group appear to be critical for achieving selectivity for the s2R over the 
s1R. Indeed, Further investigation of the aminotetralin scaffold in region D revealed that 
the position of the aromatic group appears to be a significant component for disfavoring 
binding to the s1R. A linker of at least three atoms connecting the distal aromatic group 
is important for retaining high s2R affinity, and selectivity over the s1R is achieved with 
carbamate, amide, and ether heteroatom configurations in the chain. However, the 
hydrocinnamamide group provided the highest levels of s2R selectivity among similarly 
substituted analogs.  The newly accessible site of substitution on the nitrogen atom in 
SAR region C provided no benefit, with minimal change observed from hydrophobic 
groups of increasing size and polar groups leading to enhanced  s1R affinity. However, 




Figure 2.14. Summary of the aminotetralin SAR.   
2.3 SIGMA-2 MODULATION IN THE 5XFAD TRANSGENIC MOUSE MODEL 
2.3.1 Introduction 
Alzheimer’s Disease (AD) is an age-related neurodegenerative disorder that is 
clinically characterized by progressive loss of cognitive function and deficits in learning 
and memory that are associated with dementia.318  Typical pathological characteristics of 
the disease include extracellular buildup of Ab plaques and formation of intracellular 
neurofibrillary tangles, along with chronic neuroinflammation that collectively contribute 
to synaptic loss and ultimately neuronal death.319-321  Current FDA approved drugs for the 
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and  donepezil, as well as the NMDA receptor antagonists memantine, but these only 
provide temporary symptomatic relief.318 There are currently no disease altering 
treatment options that are capable of slowing or halting the progressive neuronal death 
associated with AD, which currently impacts more than five million people in the United 
States and is expected to increase in prevalence as the population ages.318 This dire 
situation highlights the need for continued development of novel therapeutic strategies 
for the treatment of AD.  
The s2R has recently emerged as a potential target for the treatment of several 
neuropsychiatric disorders, and neuroprotective properties in some disease models 
suggest that modulating this receptor might provide a unique approach for treating AD. 
As discussed in the preceding chapter, the Martin group discovered that SAS-0132 
(1.163) was neuroprotective in a C. elegans model of age related neurodegeneration.12 
Administration of SAS-0132 also improved cognitive performance, rescuing AD-related 
behavioral deficits in a Thy-1 hAPPLond/Swe+  transgenic mouse model of AD.12 Notably, 
reduced levels of the proinflammatory cytokine IL1b, which is associated with the 
neuroinflammatory response and AD progression, were observed in the transgenic mice 
relative to control levels following the dosing regimen.322,323 In addition, the structurally 
related analog DKR-1677 (1.191), which possesses enhanced s2R potency and 
selectivity over the s1R, provided decreased axon degeneration and improved behavioral 
deficits in mouse models of TBI (Figure 2.15)..14 A structurally unique ligand class that 
modulates the s2R was observed to displace Ab oligomers from the neuronal synapse 
leading to reduced synaptotoxicity an improved memory in mouse models of AD.164,165 
This led to the development of Elayta (CT1812), which is currently undergoing phase II 




Figure 2.15. Norbenzomorphan analogs with neuroprotective properties.   
Because of the promising activity of SAS-0132 and DKR-1677 in models of 
neurodegeneration, we queried whether the corresponding aminotetralin JVW-1601 
(2.31) might also possess similar neuroprotective activity (Figure 2.16). Accordingly, we 
evaluated DKR-1677 and JVW-1601 in the FXFAD transgenic mouse model.  
 
 
Figure 2.16. Aminotetralin analog selected for evaluation in 5XFAD model.    
Transgenic 5XFAD mice are derived from overexpression of mutated versions of 
three human amyloid precursor protein (APP)  genes and two human presenilin-1 
(PSEN1) genes associated with early onset familial AD.324 This gives rise to increased 
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Although there is much about the underlying mechanism and its role in the disease that 
remain unclear, the amyloid cascade hypothesis suggests that an accumulation of Ab 
oligomers that results from in imbalance in Ab production and clearance is correlated 
with AD onset.319,325,326 The predominant forms of Ab consist of 40 (Ab40) and 42 (Ab42) 
amino acid residues; they are soluble in their monomeric form, but readily aggregate into 
a variety of assemblies that can lead to soluble oligomers or insoluble plaques that are 
associated with AD.327 However, soluble oligomers possess more potent neurotoxicity.328 
The rapid accumulation of Ab in the 5XFAD mouse model provides a useful assay for 
evaluating the ability of small molecules to alleviate the negative effects associated with 
this pathological feature of AD.324  Because compounds that modulate the s2R have 
demonstrated an ability to mitigate Ab oligomer synaptotoxicity, the 5XFAD mouse 
model was selected in collaboration with the Shamloo group at Stanford University to 
assess the neuroprotective attributes of JVW-1601 and DKR-1677.  
2.3.2 Bioavailability and Specificity  
Prior to evaluation in the 5XFAD transgenic mouse study, JVW-1601 and DKR-
1677 were assessed for metabolic stability and bioavailability (Quintara Discovery, Inc.  
Hayward, CA) (Figure 2.17). Both displayed low metabolic stability (t1/2 < 5 min) upon 
incubation with liver microsome, indicating similar metabolic liabilities for both 
scaffolds that would eventually limit their potential for oral administration. The P-
glycoprotein (P-gp) is an efflux transporter that is widely expressed in major organs, but 
specifically in the capillaries of the blood brain barrier (BBB) where it can restrict brain 
penetration of potential CNS drugs.329 Madin Darby canine kidney (MDCK) cells with 
the MDR1 gene (ABCB1) that encodes for P-glycoprotein (P-gp)  provide a useful assay 
to assess permeability and P-gp efflux liability.330 Analysis of known CNS drugs suggests 
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that a P-gp efflux ratio greater than 2.5 is considered a P-gp liability, but JVW-1601  and 
DKR-1677  display efflux ratios of 1.0 and 0.6 respectively, suggesting that good brain 
penetration is anticipated.330  The PK properties of JVW-1601  and DKR-1677  were also 
assessed in vivo and found to be bioavailable and to readily cross the BBB in mice. The 
brain concentrations four hours after a single intraperitoneal (IP) dose of JVW-1601 (10 
mg/kg) and DKR-1677 (3 mg/kg) were 95 nM and 32 nM, respectively.  In the same 
experiment, the brain to plasma ratio was 2.8 for JVW-1601 and 3.5 for DKR-1677.  
 
 
Figure 2.17. Bioavailability of analogs.     
Because obtaining selectivity for the s2R over the s1R has been historically 
challenging, the initial SAR investigation of the aminotetralin scaffold placed emphasis 
on that particular parameter. However, JVW-1601 was also screened against a panel of 
more than 50 proteins relevant to the CNS by the PDSP and greater than 100-fold 
selectivity was obtained against targets other than the s2R (Supplements Table S.1). The 
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fold), and the histamine-1 receptor (4-fold). This is similar to DKR-1677, which had 
greater than 100-fold selectivity for many of the same targets with the exception of the 
s1R (45-fold), alpha-2A adrenergic receptor (69-fold), and histamine-1 receptor (20-
fold). This suggest that JVW-1601 and DKR-1677 share similar binding profile with 
respect to sRs and also other CNS proteins.  
2.3.3 Administration in the 5XFAD Model 
In collaboration with the Shamloo laboratory at Stanford University, age-matched 
wildtype (N = 6–7) and 5XFAD transgenic (N = 6–7) mice were assigned to vehicle and 
drug groups and administered JVW-1601 or DKR-1677 (10 mg/kg) daily via IP for 60 
days beginning at approximately four weeks of age. The animals were weighed daily and 
no adverse effects were observed on body weight for the duration of the dosing regimen 
(Figure 2.18). At the completion of the 60-day dosing schedule, the animals were 
sacrificed and the blood and major organs were harvested. No significant alterations in 
the mass of these organs (brains, heart, lungs, livers, spleens, kidneys, testes, intestines) 
was observed. Additionally, analysis of the blood for 22 chemical biomarkers revealed no 
notable discrepancies between the vehicle and drug groups. Collectively, this suggests 
that chronic dosing with JVW-1601 or DKR-1677 presents no obvious toxic effect.   
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Figure 2.18. Body weight of wildtype and 5XFAD transgenic mice in vehicle and drugs 
groups measured daily.      
AD is characterized by Ab and tau pathologies, along with neuroinflammation 
and neurodegeneration. The 5XFAD transgenic mouse model rapidly accumulates Ab 
and gives rise to plaque formation and neurodegeneration associated with disease 
progression.319 Therefore, the effect of JVW-1601 or DKR-1677 on Ab burden in cortical 
tissues of the 5XFAD group was assessed. Soluble Ab40 and Ab42 was extracted with tris-
buffered saline (TBS) and quantified using an enzyme-linked immunosorbent assay 
(ELISA) kit revealing that administration of JVW-1601 and DKR-1677 led to decreased 
levels of soluble Ab40 and Ab42, as compared to the vehicle-treated group (Figure 2.19). 
In both cases, the reduction was much more pronounced for the norbenzomorphan 
compound DKR-1677 than the aminotetralin JVW-1601. A similar trend was observed 
for insoluble Ab40 and Ab42 with reduced solubility that was extracted from the same 
homogenized tissue with guanidine HCl (GdHCl) buffer and quantified. Minor reduction 
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in insoluble Ab40 and Ab42 levels was observed with administration of JVW-1601 as 
compared to the vehicle-treated group, whereas DKR-1677 provided a more pronounced 
reduction. These preliminary result point toward diminished Ab burden following 
chronic dosing with DKR-1677 and its simplified variant JVW-1601, although additional 
testing is needed to confirm statistical significance.   
 
 
Figure 2.19. Levels of soluble Ab40 and Ab42 determined by TBS extraction of cortical 
tissues. Levels of insoluble Ab40 and Ab42 determined by extraction of the 
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The role of neuroinflammation in AD is not well-defined, but it is considered a 
symptom of neurodegeneration that might result from Ab and tau pathologies, as well as 
a cause of additional neuron damage that can contribute to progression of the disease.321 
Immune responses in recognition of damage gives rise to the activation of microglial 
cells that secrete a variety of inflammatory components including the pro-inflammatory 
cytokines interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a). Enhanced 
expression of pro-inflammatory cytokines has been observed in AD patients, and there is 
evidence that mRNA expression of these neuroinflammatory markers is elevated in the 
5XFAD transgenic model and is accompanied by increased neurodegeneration.331,332 
Moreover, compounds that are neuroprotective and restore behavioral deficits in models 
of AD, including the norbenzomorphan SAS-0132, have provided decreased mRNA 
expression of neuroinflammatory cytokines.12,332  
The mRNA expression level of several inflammatory markers in the cortex were 
assessed by quantitative real-time polymerase chain reaction (qRT-PCR). Consistent with 
previous results, some elevated expression of the pro-inflammatory cytokines TNF-a and 
IL-1b were observed in 5XFAD transgenic mice as compared to wildtype (Figure 
2.20).332 Wildtype mice treated with JVW-1601 and DKR-1677 possessed similar 
expression levels of TNF-a as compared to the control group, whereas IL-1b expression 
was suppressed in the same wildtype groups. The elevated gene expression of TNF-a and 
IL-1b that was observed in 5XFAD transgenic mice was suppressed in groups that were 
subjected to chronic dosing of JVW-1601 and DKR-1677. In both instances the reduction 
was more pronounced with the norbenzomorphan DKR-1677 than with aminotetralin 
JVW-1601. These preliminary results show there is a reduction of neuroinflammatory 
markers resulting from administration of JVW-1601 and DKR-1677 that is consistent 
with an anti-inflammatory effect.12,332 
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Figure 2.20. Relative mRNA expression of pro-inflammatory cytokines.  
Increased levels of inflammatory cytokines such as TNF-a and IL-1b activate 
astrocytes as part of the neuroinflammatory response, resulting in gliosis that is 
characterized by an upregulation of glial fibrillary acidic protein (GFAP).333 An increase 
in gliosis and corresponding GFAP is observed in neurodegenerative disorders, including 
Alzheimer’s disease, although the contribution of gliosis is complex and requires further 
clarifiaction.334 Gliosis levels were measured by immunohistochemical staining of GFAP 
that indicated increased gliosis in the striatal and hippocampal region of the vehicle-
treated 5XFAD transgenic group, as compared to the vehicle-treated wildtype group 
(Figure 2.21). Chronic dosing with JVW-1601 and DKR-1677 in 5XFAD transgenic 
mice diminished gliosis as compared to the vehicle-treated 5XFAD group, although the 












































































































































































































































































































































































































































































Figure 2.21. Hippocampal regions of the brain stained with GFAP (red). Cell nuclei 
stained with 4’,6-diamino-2-phenylindole (blue).    
2.3.4 Summary  
These studies were conducted to determine if the norbenzomorphan analog DKR-
1677 and its simplified variant JVW-1601 mitigated the negative effects associated with 
Ab pathology in 5XFAD transgenic mice and to compare the properties these scaffolds. 
Analysis of the PK profile and bioavailability in vitro and in vivo revealed that JVW-
1601 and DKR-1677 were similarly susceptible to rapid metabolism by liver microsome. 
In addition, they possessed similar half-life times (IP), and both displayed a favorable 
















liability. The off-target profile against a range of CNS related proteins was also generally 
similar.   
Chronic dosing with JVW-1601 and DKR-1677 indicated that they were well 
tolerated, and no signs of toxicity or variation of chemical biomarkers was observed. At 
the completion of the 60-day dosing regimen, both JVW-1601 and DKR-1677 displayed 
anti-inflammatory properties in 5XFAD transgenic mice as observed through a reduction 
in pro-inflammatory cytokines and diminished gliosis. In addition, some reduction of 
soluble and insoluble Ab was observed suggesting that each of these compounds 
decreased Ab burden in this model. In each instance, the effect was more pronounced 
with DKR-1677 than JVW-1601, which may indicate that the norbenzomorphan scaffold 
is more advantageous in this system. Collectively, the anti-inflammatory properties 
exhibited by these compounds suggest that they may help mitigate the negative effects of 
Ab pathology, but further experiments are needed to confirm statistical significance and 
to probe their ability to rescue cognition in behavioral models.  
2.4 MOLECULAR IDENTIFICATION OF THE SIGMA-2 RECEPTOR AS TMEM97  
2.4.1 Introduction 
The s2R has been an enigmatic target since it was initially distinguished from the 
s1R in 1990, but it has continued to attract considerable interest due to its implication in 
a range of disorders.75 During this time, the s2R had evaded all attempts to identify its 
molecular structure and its coding gene.212 As a result, pharmacological characterization 
methods have been the primary mechanism for investigating the s2R, which has greatly 
limited our understanding of its biological role.5 As previously discussed, the s2R has 
recently emerged as a potential target for the treatment of several neurodegenerative 
disorders including AD, neuropathic pain, and TBI.11-14 Moreover, ligands that modulate 
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the s2R are currently undergoing clinical trials for the treatment of AD, schizophrenia, 
and for the diagnostic imaging of cancer.166,184,185,209,211 The increasing medicinal 
potential of the s2R highlights the critical need to understand the cellular mechanisms 
and biological role of this protein.  
Given the decades of research focused on the s2R, it is rather surprising that the 
molecular identity of the protein has proven to be so evasive. Recently, Mach et al. 
reported that the s2R binding site resides within a PGRMC1 protein complex.221 
However, follow up studies revealed that modulation of PGRMC1 expression levels did 
not affect [3H]-DTG binding, indicating that the proteins were not synonymous and that 
the true identity remained unknown.224,241,242 Because the need for identification of the 
protein was critical for continued advancement, efforts in the Martin group shifted toward 
molecular identification of the s2R in a collaboration with the Kruse group at Harvard 
University.    
2.4.2 Aminotetralin Analogs for Affinity Purification of the Sigma-2 Receptor  
Our plan to identify the s2R was a classical affinity purification approach that 
required immobilization of a high affinity ligand on a solid support to enable separation 
of the target protein from the biological matrix. This is similar to other approaches 
undertaken that attempted to purify the s2R.217,221 However, because the small molecule 
is a central component in the purification strategy, we hypothesized that different 
structural arrangements available on high affinity s2R ligands developed in our 
laboratories might prove useful. As discussed in preceding chapter, the linker for 
immobilization must be installed on the small molecule in manner that allows the ligand 
to interact with the binding pocket of the receptor without interference from the solid 
support and without a deleterious impact on potency.213 This task requires thorough 
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knowledge of the small molecule’s SAR and an ability to install a range of linkers at 
several unique positions on the scaffold.213  
Our SAR investigation of a range of aminotetralin analogs provided this relevant 
insight and the readily diversifiable scaffold could easily be modified for installation of 
linkers at several locations. Analysis of the SAR for the four regions investigated (A-D), 
revealed that regions A and C tolerated hydrophobic groups of increasing size with only 
modest changes in s2R affinity (Figure 2.22.A). This observation suggested that linkers 
installed at these sites might not disrupt ligand affinity, and the nitrogen present in each 
region provided a function handle for linker attachment. Linker groups that possessed an 
aldehyde or primary amine at one terminus could readily be installed on the scaffold in a 
manner similar to other diversification strategies that were previously developed, whereas 
a Boc-protected amine at the other linker terminus could easily be deprotected to enable 
immobilization on a solid surface that possessed activated ester sites (Figure 2.22.B).  
 
   
Figure 2.22. (A) Regions targeted for linker installation. (B) Strategy for incorporating a 
range of linkers at scaffold nitrogen atoms.  
Because the length and nature of the linker that would enable the small molecule 
to effectively interact with the s2R binding site after immobilization was not known, we 
sought to install a short (six-carbon atoms) and long (11-carbon atoms) linker at each site. 
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modified literature procedure wherein amino acid 2.129 was treated with Boc-anhydride 
to afford the N-Boc amino acid 2.130 (Scheme 2.15). The crude reaction mixture was 
treated with lithium aluminum hydride to afford the primary alcohol 2.131 that was 
subjected to Swern oxidation without purification to deliver the known aldehyde 2.132 in 
67% yield over three steps.335,336      
 
 
Scheme 2.15. Synthesis of the six-carbon linker bearing an aldehyde functional group. 
A slightly modified procedure was used to construct the 11-carbon linker bearing 
an aldehyde functional group (Scheme 2.16). In the even, amino acid 2.133 was treated 
with Boc-anhydride to afford N-Boc amino acid 2.134. The crude reaction mixture was 
reduced according to a reported protocol by treating 2.134 with isobutyl chloroformate 
(2.135) to generate the mixed anhydride in situ followed by addition of sodium 
borohydride and subsequent dropwise addition of methanol to afford alcohol 2.136.337 
The operational simplicity and mildness of this reduction strategy was preferred to 
lithium aluminum hydride reduction. The crude reaction mixture thus obtained was 
subjected to Swern oxidation to deliver the known aldehyde 2.137 in 71% yield over 
three steps.338   
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Scheme 2.16. Synthesis of the six-carbon linker bearing an aldehyde functional group. 
The aldehyde functionality on the aliphatic chains of 2.132 and 2.139 proved to 
be an effective handle for attachment to 2.16 via reductive amination, as a variety of 
groups were previously appended in this manner. Stirring a solution of 2.16 in 
dichloroethane with 2.132 or 2.137 in the presence of sodium triacetoxyborohydride 




A related tactic was employed to attach these linking groups at the carbamate 
nitrogen atom. Accordingly, reductive amination of 7-bromotetralone (2.26) with 
ammonium acetate delivered aminotetralin 2.140 (Scheme 2.17). Condensation of 2.140 
with aldehyde 2.132 provided an intermediate imine that was reduced in situ with sodium 
H2N OH
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borohydride, and the resultant amine was treated with benzyl chloroformate to deliver 
2.141 with a six-carbon spacer between the carbamate nitrogen and the Boc-protected 
amine, in 67% yield over two steps. Buchwald-Hartwig amination of 2.141 with excess 
piperazine (1.172) using the same conditions as previously discussed delivered 2.142, and 
subsequent reductive alkylation with propionaldehyde (2.62) delivered 2.143.  
 
 
Scheme 2.17. Synthesis of aminotetralin analog with a six-carbon linker at the 
carbamate. 
This strategy enabled late-stage diversification of the substituent at the piperazine 
nitrogen atom if needed, but the high s2R affinity of the related N-propylpiperazine 
analog 2.31 suggested that a propyl group at that position should be sufficient. However, 
this synthesis of 2.143 required introduction of the aliphatic linker at an early stage of the 
synthetic sequence, a significant drawback for evaluating a range of linkers. Because the 
nature and the length of the linker that would prove most effective for application to 
affinity chromatography was not known, a more divergent strategy was devised in order 
to increase efficiency of analog preparation. An aliphatic linker with a primary amine 
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intermediate 2.84. Therefore 11-aminoundecanoic acid (2.133) was Boc-protected, and 
the acid was subsequently reduced via activation as a mixed anhydride to deliver the 
known alcohol intermediate 2.136 in 92% yield over two steps (Scheme 2.18).339  A 
solution of 2.136 in toluene was treated with methansulfonyl chloride followed by 
addition of sodium azide to afford intermediate 2.144, and the crude reaction mixture was 
subjected to catalytic hydrogenation to provide the known mono-Boc-protected 
diaminoalkane 2.145 in 50% yield over two steps.340 
 
Scheme 2.18. Synthesis of mono-Boc-protected diaminoalkane 2.145.  
 
After some experimentation, we discovered that heating a solution of 2.84 and 
2.145 in ethanol in the presence of excess Ti(Oi-Pr)4 provided full conversion to the 
imine intermediate that was reduced in situ by addition of sodium borohydride to deliver 
the secondary amine 2.146 in 87% yield (Scheme 2.19). Notably, this transformation 
required the use of excess Ti(Oi-Pr)4 (10 eq.) for efficient conversion to the imine 
intermediate. The use of three equivalents of Ti(Oi-Pr)4 resulted in only partial 
conversion  (ca. 1:1) after 15 h and heating provided little benefit. Treating 2.146 with 







































Scheme 2.19. Synthesis of pull-down analog 2.147.  
The putative pull-down ligands 2.138-2.139, 2.143, and 2.147 were then assessed 
for their ability to bind the s2R.  Single point binding analysis with the test ligands 
(1µM) was conducted by the Kruse group at Harvard University using PC-12 cell 
membrane preparations and [3H]-DTG (30 nM) in the presence of SKF-10,047 (2 µM) to 
mask the s1R binding site (Figure 2.23.A). The single point assay included the related 
norbenzomorphan analog 2.148 possessing a six-carbon aliphatic group at the piperazine 
nitrogen atom, as well as haloperidol (s2R Ki = 48.7 nM) and the aminotetralin 2.42 
(s2R Ki = 4.5 nM) as standards for comparison.75 Several of the ligands performed well 
in the assay with competitive [3H]-DTG binding that were similar to or less than 
haloperidol. However, 2.147 possessing an 11-carbon linker at the carbamate nitrogen 
atom, displayed notably lower levels of competitive [3H]-DTG binding that suggested 
higher affinity for the s2R. Thus, 2.147 was progressed as a lead compound, along with 
the norbenzomorphan analog 2.148, which provided an alternative scaffold with a unique 
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possessed 0.4 nM affinity for the s2R and that norbenzomorphan 2.148 displayed 3.1 nM 
s2R affinity, indicating that introduction of the aliphatic chain at these positions did not 




Figure 2.23. (A) Single point binding analysis of test ligand at 1 µM with PC12 cells 
using [3H]-DTG (30 nM) in the presence of SKF-10,047 (2 µM) (B) Ki 
values (single experiment) for lead analogs.   
The lead analogs 2.147 and 2.148 were next assessed for their ability to capture 
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removal of the Boc-protecting group was accomplished by treating 2.147 with a solution 
of HCl in dioxane to deliver JVW-1625 (2.149) with the requisite primary amine for 
immobilization. Competition binding analysis confirmed that JVW-1625 possessed 16.6 
nM affinity for the s2R (Equation 2.26). An affinity resin was prepared by coupling  
JVW-1625 (2.149) to affi-gel 10 resin at a range of coupling densities (50-2,000 µM) for 
use in preparing affinity columns (Figure 2.24).160 Calf liver membrane extract was 
flowed onto the column, and s2R capture was assessed by determination of [3H]-DTG 
binding in the column flow through. Critically, the affinity resin prepared with JVW-
1625 (2.149) demonstrated efficient depletion of radioligand binding at all coupling 
densities examined, and no [3H]-DTG binding was observed at a 2,000 µM coupling 
density.160  A similar analysis with an affinity resin prepared using the norbenzomorphan 
analog 2.148 revealed that protein capture was much less effective. It is not clear if the 
reduction in protein capture derives from the decreased length of the linker used for 

























Figure 2.24. Affinity column prepared with JVW-1625 coupled to affi-gel 10 resin at the 
specified coupling density. Binding assay performed on column flowthrough 
of calf liver membrane extract with  [3H]-DTG (25 nM). Copyright (2017) 
National Academy of Sciences / modified from original to show only 
binding depletion assay (A) and JVW-1625 coupled to bead.160 
Longer linkers can often provide superior results by projecting the small molecule 
further away from the stationary phase, but additional hydrophobicity in the linker can 
create challenges with solubility and non-specific binding.214,216 During the course of the 
binding depletion assay, some clumping was observed in the resin that was attributed to 
the hydrophobicity of JVW-1625, and this clumping posed a potential problem for scale 
up during isolation studies. An effort was made to prepare a similar analog that possessed 
a PEG-linker that might provide improved solubility. Therefore, the known diamino-
PEG-chain 2.150 was installed on tetralone 2.84 via reductive amination according to the 
previously discussed protocol to afford 2.151 in 69% yield (Scheme 2.20).341 Subsequent 





















































































2.152 by the PDSP revealed diminished s2R affinity, which is consistent with prior 
observations in SAR region C, suggesting that 2.152 might not be a suitable candidate.         
 
 
Scheme 2.20. Synthesis of an amainoteralin analog with a PEG-linker at the carbamate.  
Fortunately, efficient protein capture was observed using an affinity resin 
prepared with JVW-1625 even at low coupling densities. Thus, scaled up affinity 
purification was conducted by the Kruse lab using the JVW-1625 affinity resin (2 mL) at 
100 µM coupling density.160 Solubilized s2R from calf liver homogenate was flowed 
through the column in order to wash away undesired components of  the biological 
matrix, followed by eluent containing DTG (100 µM) to release the desired protein. The 
obtained protein was processed with SDS-PAGE, and the portion of the gel that was 
consistent with a mass range of 15-25 kDa was analyzed via LCMS/MS at Harvard’s 
Faculty of Arts and Sciences Mass Spectrometry and Proteomics Resource Laboratory 
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Known protein candidates were selected from the identified proteins for follow up 
analysis because their molecular weight was consistent with the range predicted for the 
s2R, in addition to PGRMC1 due to its association with the s2R. Each was 
overexpressed in HEK293 cells and assayed for [3H]-DTG binding, but only the 
transmembrane protein 97 (TMEM97) displayed significant activity (Figure 2.25).160 
Notably, mRNA expression of Tmem97 was reduced by approximately 60% in PC-12 
cells using siRNA knockdown, which produced a similar reduction in s2R expression as 
determined with [3H]-DTG saturation binding studies. This discovery supported the 




Figure 2.25. Single point binding assay performed in triplicate on membrane 
preparations of expi293 cells expressing hits identified via LCMS/MS with 
[3H]-DTG (10-30 nM). Shown as means ± SEM. Copyright (2017) National 
Academy of Sciences / modified from original to show only binding assay 
results.160 
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Additional validation studies were conducted by the Kruse lab to confirm the 
potential identification of the s2R as TMEM97 based on the well characterized s2R 
binding profile.160 The Sf9 insect cells line does not possess a TMEM97 ortholog and 
does no display affinity for [3H]-DTG.342 However, upon overexpression of human 
TMEM97, these cells exhibited saturable [3H]-DTG binding with 11.3 nM affinity, which 
is within the range of reported values (17.9-37.6 nM).75,172,242 Having discovered that the 
expression of TMEM97 in Sf9 cells imparted an ability to bind [3H]-DTG, a central 
pharmacological characteristic that defined the s2R and was otherwise absent, a range of 
well-characterized s2R  ligands were assessed in the same cell line (Table 2.12).75 
Notably, the inhibition constant of each liagnd was consistent with the values reported in 
the literature. For example, high s2R affinity was observed for DTG, haloperidol, and 
PB-28, as well as the norbenzomorphan analog SAS-1121. However, low or 
nondetectable affinity was displayed by the (+)-benzomorphans (+)-SKF-10,047 and (+)-
pentazocine, another defining characteristic of the s2R. In addition, the s2R possessed 
similar affinities for Elacridar and Ro 48-8071, which were recently reported as 










Table 2.12. Binding affinities of known ligands at recombinant TMEM97 and 
native s2R expressed in cell membranes.   
 Ki (nM) 
entry ligand TMEM97 in sf9 cells s2R 
1 DTG 19.6 ± 3.0 21.2a 
2 haloperidol 54.1 ± 6.7 48.7 a 
3 PB-28 2.0 ± 0.3 1.8b 
4 (+)-pentazocine 2,467 ± 436 1,402 – 3,890b 
5 (+)-SKF 10,047 >10,000 no inhibitiona 
6 SAS-1121 25.2 ± 3.8 23.8c 
7 Elacridar 6.5 ± 1.1 4.7 ± 0.7 
8 Ro 48-8071 971 ± 228 817 ± 226 
The inhibition constants were determined by the Kruse group with  sf9 cells expressing recombinant 
TMEM97 and MCF-7 cell membranes expressing native s2R using [3H]-DTG in the presence of (+)-SKF-
10,047 (1.8 µM). a Values reported by Hellewell and Bowen.75 b Values reported by Colabufo et al.128 c 
Values reported by Sahn et al.9 Copyright (2017) National Academy of Sciences / modified from original to 
reformat table.160 
2.4.3 The Sigma-2 Receptor is Synonymous with TMEM97 
The s2R was pharmacologically distinguished from the s1R in 1990 based on a 
unique ligand binding profile that was distinct from the s1R.75 The defining features of 
the s2R were high affinity for the classical sR liagnds DTG and haloperidol, as well as 
low affinity for (+)-benzomorphans. Following affinity purification of calf liver 
membrane extract using the high affinity s2R ligand JVW-1625 that was developed 
through an extensive SAR investigation of the aminotetralin scaffold, TMEM97 was 
identified as a candidate protein a search for the molecular identity of the s2R. 
Subsequent expression studies confirmed that TMEM97 expression is necessary and 
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sufficient for [3H]-DTG binding. Moreover, the ligand binding profile that 
pharmacologically defined the s2R was recapitulated in cells expressing recombinant 
TMEM97. Collectively, this led us to conclude that the s2R and TMEM97 are 
synonymous and will henceforth be referred to as TMEM97/s2R.160 This identification 
resolves a mystery that had evaded researchers for decades and should enable more 
thorough characterization of the biological functions and cellular mechanisms of 
TMEM97/s2R.  
Successful identification of the elusive of TMEM97/s2R protein was enabled by 
the discovery and development of the aminotetralin scaffold as a new s2R ligand class. 
The unique structural features of the aminotetralin scaffold provided the pivotal 
attachment point for immobilization of the ligand that facilitated efficient protein capture. 
This highlights the utility of this scaffold simplification strategy for the development of 
alternative lead scaffolds as tool compounds that aid the study of challenging biological 
targets.  
2.5 TMEM97/s2R OVERVIEW AND NEW DISCOVERIES 
2.5.1  TMEM97/s2R Structure and Function 
As the name suggests, TMEM97 is an integral membrane protein and it was 
originally identified in 1993 as a gene with altered expression in meningiomas that was 
referred to as meningioma-associated protein (MAC30).344 The membrane protein, is 
comprised of 176 amino acids and high expression levels were observed in a several 
cancers prior to its identification as TMEM97/s2R, although little is known about its 
molecular function.345,346 However, increased expression of TMEM97/s2R in tumors was 
correlated with poor prognosis in cancer patients and inhibition of cancer cell migration 
and proliferation in vitro was observed upon downregulation of TMEM97/s2R.347-350  
 236 
TMEM97/s2R has also been proposed as a sterol response element binding 
protein (SREBP) target gene located at the ER and lysosomes that is involved in 
regulation of cellular cholesterol levels.351 In addition, TMEM97/s2R interacts with 
NPC1, which is required for shuttling cholesterol out of lysosomes and its dysfunction 
results in an accumulation of lysosomal lipids that is associated with Niemann-Pick 
disease type C (NP-C).352 Reduction of TMEM97 levels was observed to increase levels 
of NPC1 and also  increase cholesterol and lipid transport from lysosomes, suggesting 
that TMEM97/s2R might be a target for the treatment of NP-C disease, a fatal 
neurodegenerative disorder that is associated with cognitive decline.352 The sRs were 
previously implicated in cholesterol metabolism and the TMEM97/s2R identification 
provides conformation of this important cellular role.353,354  
As part of our effort to identify and clone TMEM97/s2R, computational and 
mutagenic analysis were conducted to predict the structure of the protein (Figure 
2.26.A).160 A four-pass transmembrane topology is predicted with an ER retention 
sequence at the C-terminus, which is located in the cytosolic domain. With respect to 
interactions occurring within the binding pocket, a ubiquitous structural feature of ligands 
with high affinity for TMEM97/s2R is the presence of a basic amine site, which 
indicates that a pivotal salt-bridge interaction might be present that is similar to those 
observed in the s1R crystal strucutre.6,155 To further probe the structural basis for 
TMEM97/s2R ligand recognition, each Glu and Asp residue was subjected to site 
directed mutagenesis and its ability to bind [3H]-DTG was assessed.160 Mutation of both 
D29N and D56N abolished binding and ab initio structural prediction indicated that both 
acid residues were located in close proximity (Figure 2.26.B).355 This supports the 
hypothesis that a hydrogen bond complex, similar to the one observed in the s1R, might 
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be involved in ligand binding, but this remains be determined definitively by an X-ray 
structure of a TMEM97/s2R ligand complex. 
 
 
Figure 2.26. (A) Overlay of top four ranked molecular models generated from 
evolutionary coupling analysis. Asp29 and Asp56 are represented as red 
spheres. (B) Single point [3H]-DTG (10-30 nM) binding assay of membrane 
preparations from Expi293 cells expressing TMEM97 with point mutation at 
specified residue number. Copyright (2017) National Academy of Sciences / 
modified from original to show only molecular models (A) and mutation 
study (B).160  
Following our report on the molecular identification and cloning of 
TMEM97/s2R, several studies that have been aided by access to Crisper-Cas9 gene 
editing technology have been disclosed in which TMEM97/s2R expression is modulated 
in order to examine its cellular role. For example, an interaction between TMEM97/s2R 
and low-density lipoprotein (LDL) was recently demonstrated.356  In this study, 









































































suggested to derive from a ternary protein complex involving PGRMC1, TMEM97/s2R, 
and the LDL receptor.356 Another study utilized TMEM97/s2R ligands that were 
previously associated with cytotoxic activity and discovered that knockout of 
TMEM97/s2R did not change the ligand concentration required to achieve 50% cell 
death.202 This finding was particularly interesting because it suggested that the cytotoxic 
effects that had long been associated with TMEM97/s2R agonism in cancer cells might 
not be mediated by TMEM97/s2R.188,201    
In collaboration with the Pierce group at the University of Texas at Austin, we 
recently utilized the molecular identification and cloning of TMEM97/s2R to expand on 
our earlier findings that ligands that modulate the receptor mitigate negative effects of 
alcohol withdrawal in C. elegans.13 In order to assess the effect of genetic manipulation, 
Y38H6C.16 was identified as a potential TMEM97/s2R ortholog in C. elegans that 
shared 30% sequence similarity to TMEM97/s2R and possessed a similar predicted 
secondary structure along with partial conservation of the aspartate residues that were 
identified as critical for ligand binding.13,160  The putative TMEM97/s2R ortholog was 
required for activity of JVW-1034 in the C. elegans model with no recovery of 
performance being observed in the Y38H6C.16 null strain.13 Critically, the activity of 
these compounds was rescued upon reintroduction of endogenous Y38H6C.16 or the 
human TMEM97/s2R  gene. This supports the role of TMEM97/s2R in modulation of 
alcohol withdrawal symptoms and points to a conserved TMEM97/s2R signaling 
pathway that could be useful for additional studies. This is also the first report that 
utilizes genetic modulation of TMEM97/s2R in a behavioral study to assess its function. 
Interestingly, the PGRMC1 ortholog, VEM-1, was also required for activity of JVW-
1034, providing additional support for its hypothesized involvement in the 
TMEM97/s2R signaling mechanism.356,357   
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2.6 SUMMARY 
The enigmatic nature of TMEM97/s2R has posed a considerable challenge to 
researchers for decades and has stymied critical advancement for elucidation of its 
function and therapeutic potential.  Even basic strategies for the design of selective 
TMEM97/s2R ligands has been surprisingly elusive. Through the course of the work 
described herein, a new molecular scaffold was developed that possesses high affinity 
and selectivity for TMEM97/s2R relative to the s1R. This aminotetralin scaffold was 
derived from the norbenzomorphan scaffold via a simplification strategy to remove 
structural complexity and provide an alternative scaffold for hit-to-lead development. 
This tactic proved successful, given that the simplified scaffold exhibits a binding profile 
and biological properties that are generally quite similar to corresponding 
norbenzomorphan analogs.  
Despite the numerous studies that highlight the therapeutic potential of 
TMEM97/s2R, including ongoing clinical trials for the treatment of several CNS 
disorders, the role of the receptor in these diseases has been unclear due to a reliance on 
pharmacological characterization. However, as a direct result of the work described 
herein, the research landscape has now changed dramatically. The SAR studies 
conducted with the aminotetralin scaffold identified structural features unique to this 
scaffold that were leveraged to enable the molecular identification and cloning of the 
long sought-after TMEM97/s2R. This discovery will now enable access to a suite of 
modern biological tools that should increase our understanding of the role of 
TMEM97/s2R in a range of neurodegenerative disorders. In the time since this 
discovery, genetic manipulation of TMEM97/s2R expression has already linked the 
receptor to a potential role in LDL and cholesterol transport that was previously unknown 
and enabled unambiguous characterization of ligands that were previously thought to 
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mediate cytotoxic effects in cancer cells, an effect that now seems less likely.202,356 
Moreover, it permitted the first study that utilized genetic manipulation in a behavior 
model to confirm that TMEM97/s2R plays a role in modulating the effects of alcohol 
withdrawal.13 The identification of TMEM97/s2R also facilitates work to obtain a crystal 
structure of the TMEM97/s2R protein, which is the focus of continuing efforts in the 
Martin and Kruse groups that should enable structure-based ligand design strategies in 
the future. Application of the aminotetralin scaffold for the molecular identification and 
cloning of TMEM97/s2R was not envisioned at the outset of this work, but it is perhaps 
the most significant component of this research that has resolved a longstanding mystery 










THE STEREOSELECTIVE TOTAL SYNTHESIS OF 
ALSTOSCHOLARISINE E 
Chapter 3: Isolation and Previous Syntheses 
3.1 ISOLATION AND BIOLOGICAL ACTIVITY 
Progressive neuronal decline is a feature associated with a range of CNS 
disorders, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral 
sclerosis.358 There are currently no disease altering treatment options for these disorders 
that attenuate the neuronal deficits associated with disease progression. However, stem-
cell based therapies have emerged as a potentially useful strategy for the development of 
novel therapeutic remedies and several are undergoing phase I and II clinical trials for the 
treatment of Alzheimer’s disease.359 Because small molecules have been shown to 
influence neural stem cell proliferation, natural products that possess this ability have 
garnered increasing attention as privileged molecular scaffolds for further exploration of 
treatment options.360,361  
Alstoscholarisines A-E (3.1-3.5) are unique monoterpenoid indole alkaloids, 
isolated from the leaves of Alstonia scholaris in the Yunnan Province of China by Luo et 
al. in 2014, that were reported to promote neuronal stem cell (NSC) proliferation (Figure 
3.1).362 Each of these alkaloids 3.1-3.5 (10 µg/mL) were found to enhance adult NSC 
proliferation relative to control cells treated with DMSO.362 Alstoscholarisines A (3.1) 
and E (3.5), respectively were among the most potent and 3.1 provided a dose dependent 
response (0.1 – 20 µg/mL). Furthermore, alstoscholarisine A (3.1) promoted NSC sphere 
formation and neuronal fate commitment. Because these natural products appear to 
modulate NSC proliferation and neurogenic fate they are intriguing candidates for 
additional analysis in neurodegenerative models.    
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Figure 3.1. The structures of (–)-Alstoscholarisines A-E.  
The alstoscholarisine alkaloids 3.1-3.5 are comprised of a similar pentacyclic 
structure that contains a cis–fused oxahydroisoquinolone ring system bearing five 
contiguous stereocenters. Notably, the indole nitrogen forms a cyclic aminal with the 
piperidine ring of the cis-oxahydroisoquinolone, bridging the tetrahydropyran ring and 
forming a highly caged structure. The core scaffolds of 3.1-3.5 differ in their orientation 
of the methyl group at the C–19 center and the substituent at the C-19 bridgehead carbon. 
An equatorial methyl group is exhibited by 3.1 and 3.2, whereas 3.3-3.5 possess an axial 
methyl group at this position. Additionally 3.2-3.4 contain a carboxylic acid or ester 
group at the C–16 bridgehead center, whereas 3.1 and 3.5 possess a tertiary bridgehead 
(R = H).  
The structural complexity of these natural products and their intriguing biological 
activity quickly captured the interest of the synthetic community. The first synthesis of 
racemic alstoscholarisine A was reported by Bihelovic and Ferjancic in 2016,363 followed 
shortly thereafter by an enantioselective approach disclosed the same year by Yang.364 
Weinreb achieved a synthesis of (±)-alstoscholarisines B and C in 2017 via a divergent 
approach that was also utilized to access (±)-alstoscholarisines A, D, and E in 2018.365,366 
















3.1 (–)-alstoscholarisine A  R = H
3.2 (–)-alstoscholarisine B  R = CO2Me
3.3 (–)-alstoscholarisine C  R = CO2Me
3.4 (–)-alstoscholarisine D  R = CO2H




3.2 PREVIOUS SYNTHESES OF THE ALSTOSCHOLARISINE ALKALOIDS  
3.2.1 Bihelovic and Ferjancic Synthesis of (±)-Alstoscholarisine A 
The first successful synthesis of (±)-alstoscholarisine A was achieved by 
Bihelovic and Ferjancic in 2016 using a domino-enamine cyclization as a key step to 
assemble the core.363 The synthesis commenced with preparation of the starting material 
3.9 according to a reported protocol via oxidative radical alkylation of 3-methylindole 
(3.6) with the xanthate ester 3.7 to deliver the known 2,3-disubstituted indole 3.8 in 63% 
yield (Scheme 3.1).368 Subsequent treatment of 3.8 with Boc-anhydride afforded indole 
ester 3.9 in 60% yield. Treating a solution of 3.9 in THF with lithium diisopropylamide 
(LDA) generated the corresponding ester enolate followed by addition of the known N-
protected aldehyde 3.10 to generate the aldol product 3.11.369 Subsequent dehydration of 
the crude reaction mixture with sodium hydride resulted in migration of the N-Boc 
protecting group to the oxygen atom generating a carbonate that was spontaneously 
eliminated to afford 3.12 as a single isomer in 75% yield. Palladium mediated removal of 
the allyloxycarbonyl (alloc) protecting group in 3.12 provided secondary amine 3.13 and 




Scheme 3.1. Synthesis of the domino-cascade reaction precursor. 
In the event, a solution of amine 3.13 with 4-(phenylselanyl)butanal (3.14) in 
acetonitrile was heated under reflux in the presence of  4 Å molecular sieves (MS) 
resulting in condensation to generate enamine 3.15 that underwent an intramolecular 
Michael addition to the a,b-unsaturated ester moiety to generate the cyclic iminium ion 
in intermediate 3.16 (Scheme 3.2). Subsequent spontaneous cyclization with the indole 
nitrogen atom formed the aminal ring in the tetracyclic product 3.17 as a mixture of 


























































and DBU resulted in thermodynamic equilibration of the ester moiety, and 3.18 was 
isolated in 71% yield over two steps.  
 
 
Scheme 3.2. Enamine–Michael cascade reaction sequence.  
The axial orientation of the alkylselenide side chain in 3.18 was not predicted at 
the outset and inversion at this center would ultimately be required. The stereochemical 
outcome was rationalized to occur through equilibration of enamine 3.19 under the 
reaction conditions (Scheme 3.3). The equatorial sidechain in 3.20 was posited to be less 
favorable due to gauche interactions that were alleviated upon equilibration to the axial 
position in 3.16, which might be favored because the presence of the nitrogen atom in the 


















































Scheme 3.3. Equilibration of alkylselenide side chain in 3.20 and 3.16.  
Having successfully executed the key domino reaction in the assemblage of 
tetracyclic core 3.18, attention turned toward late-stage construction of the 
tetrahydropyran ring. Oxidation of the selenide moiety of 3.18 was accomplished via 
treatment with meta-chloroperoxybenzoic acid (m-CPBA) to generate the selenoxide that 
was eliminated in–situ to afford the terminal alkene in 3.21 in 83% yield (Scheme 3.4). 
The ester moiety of 3.21 was reduced with diisobutylaluminum hydride (DIBAL-H) to 
deliver the primary alcohol intermediate 3.22. Subsequent Upjohn dihydroxylation of the 
terminal olefin in 3.22 followed by oxidative cleavage with lead tetraacetate generated 
aldehyde 3.23 that was used directly, without purification. Upon treatment of 3.23 with 
DBU, epimerization of the aldehyde to the equatorial position occurred, resulting in 
spontaneous cyclization to deliver hemiacetal intermediate 3.24 that was oxidized in–situ 
with Dess–Martin periodinane (DMP) to afford lactone 3.25 in 34% yield, over three 
steps. Addition of methyllithium to lactone 3.25 yielded the hemiketal intermediate 3.26 
in 66% yield. Lewis acid-catalyzed reduction of the hemiketal in 3.26 using triethylsilane 
in the presence of trimethylsilyl trifluoromethansulfonate (TMSOTf) resulted in 
diastereoselective, axial  delivery of the hydride from the convex face to complete the 






















Scheme 3.4. Construction of the tetrahydropyran ring of (±)-alstoscholarisine A  
The route to (±)-alstoscholarisine A developed by Bihelovic and Ferjancic was 
accomplished in 13 steps and 2.7% overall yield from the known 2,3-disubstituted indole 
3.9.  The key step involved an enamine–Michael addition and aminal cyclization cascade 
that assembled a portion of the core structure in six steps, in its longest linear sequence 
(LLS). Unfortunately, the strategy for late-stage construction of the tetrahydropyran ring 
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the overall efficiency of the synthesis.  Despite this shortcoming, the synthesis is notable 
as the first reported synthesis of an alkaloid from this family of natural products. 
3.2.2 The Yang Synthesis of (±)-Alstoscholarisine A 
The first synthesis of (–)-alstoscholarisine A was reported by Yang et al. shortly 
after  the report from Bihelovic and Ferjancic .364 The synthesis began from known 
butyrolactone 3.30, which was prepared in two steps from the commercially available 
ester 3.27 according to a reported protocol via ozonolysis and subsequent addition of 
vinylmagnesium chloride to provide the cyclized product 3.30  (Scheme 3.5).370 
Butyrolactone 3.30 was then used in a Lewis acid promoted acylation of 3-methylindole 
(3.6) to form the N-acylated product 3.31 in 75% yield. This intermediate set the stage for 
the key iridium-catalyzed enantioselective Friedel-Crafts cyclization at the 2-position of 
indole 3.31 using Carreira’s chiral ligand 3.32 and scandium triflate to afford the lactam 




Scheme 3.5. The asymmetric Friedel-Crafts cyclization in Yang’s synthesis of (–)-
alstoscholarisine A. 
With the critical stereocenter established in 3.33, the terminal olefin was then 
dihydroxylated with osmium tetroxide to afford diol 3.34 as a mixture (5:1) of 
diastereomers (Scheme 3.6). The crude mixture thus obtained was converted to the 
corresponding acetonide with 2,2,-dimethoxypropane (3.35) and the major diastereomer 
3.36 was separated in 75% yield over two steps. Deprotonation of lactam 3.36 with 
lithium bis(trimethylsilyl)amide (LiHMDS) followed by addition of phenylselenyl 
bromide provided the selenide intermediate 3.37 that was then oxidized and eliminated to 













































Scheme 3.6. Yang’s synthesis of 3.38. 
With 3.38 in hand, the subsequent copper iodide mediated conjugate addition of 
vinylmagnesium bromide (3.39) proceeded smoothly with substrate-controlled 
stereoselective addition from the most accessible face (Scheme 3.7). The resulting 
enolate was trapped with acetaldehyde to afford 3.40 as the major diastereomer (8:1) in 
75% yield. Stirring a solution of 3.40 in methanol with aqueous HCl revealed the diol 
intermediate 3.41 that was oxidatively cleaved in-situ by addition of sodium periodate 
(NaIO4) to give aldehyde 3.42 that spontaneously cyclized to deliver lactol 3.43 in 86% 
yield as an inconsequential mixture (1:1) of diastereomers. Subsequent Lewis acid-
promoted ionic reduction of 3.43 with triethylsilane completed construction of the 













































Scheme 3.7. Completion of the total synthesis of (–)-alstoscholarisine A. 
Attention next turned toward construction of the cyclic aminal ring. Thus, 
hydroboration and oxidation of the terminal olefin in 3.44 provided the primary alcohol 
intermediate 3.45 and subsequent oxidization with Dess–Martin periodinane yielded 
MgBr








































































aldehyde 3.46 (Scheme 3.7). The aldehyde moiety in 3.46 was converted to an imine via 
condensation with methylamine, followed by reduction with lithium aluminum hydride 
that also reduced the indole lactam resulting in aminal formation and completing the 
synthesis of (–)-alstoscholarisine A.  
Yang and coworkers achieved the first synthesis of (–)- alstoscholarisine A in 12 
steps (LLS) from known starting material 3.30 and 5.9% overall yield.364 A critical 
stereocenter was established early in the synthesis using Carreira’s methodology for 
iridium-catalyzed polyene cyclization to forge the lactam ring in 3.33. This enabled 
sufficient substrate control in subsequent transformations. In contrast to other strategies, 
late-stage construction of the aminal ring was used to complete the enantioselective 
synthesis. 
3.2.3 The Weinreb Synthesis of (±)-Alstoscholarisine B and C 
Weinreb later developed a more divergent approach to access several of the 
alstoscholarisine alkaloids.365,366  The synthesis commenced with preparation of known 
N-sulfonylvalerolactam 3.48 from commercially available valerolactam 3.47  according 
to a reported protocol (Scheme 3.8).372 Deprotonation of 3.48 with excess LiHMDS (2.2 
eq.) followed by sequential addition of allyl chloroformate (AllocCl) and phenylselenyl 
bromide delivered the b-ketoester intermediate 3.49 in 71% yield.365 Oxidation and 
elimination of the selenide in 3.49 provided a,b-unsaturated lactam 3.50, which was not 
stable to purification and was used directly as a Michael acceptor in the conjugate 
addition with known 2,3-disubstituted indole 3.8 to afford Michael–adduct 3.51 in 69% 





Scheme 3.8. Synthesis of Michael-adduct 3.51.  
The next task involved constructing the appropriately substituted cyclic aminal 
ring system.365 A one-pot process involving alkylation of b-ketoester 3.51 with allyl 
iodide, followed by palladium catalyzed decarboxylation delivered lactam 3.52 in 74% 
yield as a mixture of C–16 diastereomers (Scheme 3.9). The direct palladium–mediated 
decarboxylation and allylation of 3.51 proved to be lower yielding than the sequential 
one-pot sequence. Chemoselective partial reduction of N-sulfonyl lactam 3.52 to 
hemiaminal intermediate 3.53 was accomplished with diisobutylaluminum hydride 
(DIBAL-H) in 78% yield. Treating 3.53 with trifluoroacetic acid removed of the Boc-
protecting group and induced cyclization of the indole nitrogen atom with the hemiaminal 
moiety to afford the aminal ring system in 3.54. This served as the key divergent 
intermediate that possessed four of the five ring systems and would be used to complete 
the alstoscholarisines via late-stage construction of the tetrahydropyran ring in Weinreb’s 














































Scheme 3.9. Synthesis of Weinreb’s divergent intermediate.  
Treatement of 3.54 with potassium bis(trimethylsilyl) amide (KHMDS) followed 
by addition of formaldehyde from the convex face afforded the aldol adduct 3.55 in 94% 
yield as a single diastereomer (Scheme 3.10).365 The primary alcohol of 3.55 was 
protected as a tert-butyldimethylsilyl (TBS) ether in 3.56. Formation of the 
tetrahydropyran ring required isomerization of the terminal olefin of 3.56 to a 2-propenyl 
group. Initial attempts at transition metal catalyzed isomerization were unsuccessful and 
led to an alternative strategy that transposed the olefin via a thermal ene–reaction with 
diethyl diazocarboxylate (DEAD) to afford the allylic hydrazide intermediate 3.57 in 
77% yield.366 Subsequent dihydroxylation of the olefin in 3.57 followed by oxidative 













































Scheme 3.10. Weinreb’s synthesis of 3.58.  
Continuing toward alstoscholarisine C, the TBS-protecting group was next 
removed from aldehyde 3.58 under acidic conditions to deliver the primary alcohol 3.59 
(Scheme 3.11). Similar to the tactic used by Bihelovic and Ferjancic, aldehyde 3.59 was 
epimerized via treatment with DBU, resulting in spontaneous cyclization to the lactol 
intermediate that was then acylated in situ to afford 3.60 in 77% overall yield from 3.58. 
Stirring a solution of 3.60 in dichloromethane in the presence of TMSOTf and 
trimethylaluminum provided axial delivery of a methyl group to a presumed 
oxocarbenium intermediate in 75% yield, thereby completing the construction of the 
tetrahydropyran ring 3.61. Subsequent removal of the N-tosyl protecting group and 
reductive methylation of the resulting secondary amine completed the synthesis of (±)-
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Scheme 3.11. Completion of the total synthesis of (±)-alstoscholarisine C.  
A related strategy was used to complete the synthesis of alstoscholarisine B.365 
Removal of the silyl protecting group from 3.58 followed by epimerization of the 
aldehyde with DBU gave lactol intermediate 3.59,  which was oxidized in situ using 
iodobenzene diacetate and TEMPO to afford lactone 3.63  in 73% yield over two steps 
(Scheme 3.12) . Addition of methyllithium to lactone 3.63 afforded the hemiketal 
intermediate 3.64 as a single diastereomer (configuration not determined) in 66% yield. 
Subsequent ionic reduction of 3.64 with triethylsilane and TMSOTf resulted in axial 
delivery of the hydride to the oxocarbenium intermediate, thereby establishing the correct 






































3.60:  R = Ac
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N-tosyl protecting group from 3.65 and reductive methylation of the nitrogen atom 
completed the synthesis of (±)-alstoscholarisine B.   
 
 
Scheme 3.12. Completion of (±)-alstoscholarisine B.  
3.2.4 The Weinreb Synthesis of (±)-Alstoscholarisines A–E 
After Weinreb’s initial syntheses of (±)-alstoscholarisines B and C in 2017, a 
follow up report in 2018 disclosed the synthesis of (±)-alstoscholarisines A–E using a 
slightly improved route.366 The first generation approach relied on a thermal ene–reaction 


































































the transition metal catalyzed isomerization, it was discovered that heating a solution of 
3.56 and Grubbs II catalyst (10 mol%) in methanol at 60 °C according to a protocol 
reported by Hanessian et al. provided the 2-propenyl intermediate 3.67 in 89% yield as an 
inconsequential mixture (ca. 2.8:1 E/Z) of isomers (Scheme 3.13).373 This alternative 
tactic improved atom economy and obviated the need to protect the primary alcohol in 
3.56.366   
 
 
Scheme 3.13. Isomerization of the allyl group using Grubbs II catalyst.  
With improved access to a slightly modified divergent intermediate 3.67, a similar 
sequence was applied to complete the synthesis of alstoscholarisine alkaloids (Scheme 
3.14). A two-step oxidative cleavage of the olefin revealed the aldehyde in 3.59 that was 
isomerized with DBU and trapped as the acylated lactol intermediate 3.60, which was 
prepared in the first-generation approach. Thus, application of the same sequence 
completed the synthesis of (±)-alstoscholarisine C (3.3) in 14 steps from known N-
sulfonylvalerolactam 3.48 and 5.7% overall yield. Basic hydrolysis of the ester in 3.3 to 
the carboxylic acid afforded (±)-alstoscholarisine D (3.4) in 15 steps from 3.48 and 4.9% 
overall yield. Alternatively, isomerization of aldehyde intermediate 3.59 with DBU and 
oxidation of the resulting lactol provided lactone 3.63 that was also accessed in the first-




























completed the synthesis of (±)-alstoscholarisine B (3.2) in 15 steps from known N-
sulfonylvalerolactam 3.48 and 3.6% overall yield. 
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Toward the synthesis of alstoscholarisines A and E, which do not possess the 
carbonyl moiety at the C–16 bridgehead, the previously constructed aminal intermediate 
3.54 which existed as a mixture of diastereomers was epimerized with sodium methoxide 
to afford 3.68 as a single diastereomer in 95% yield (Scheme 3.15). Isomerization of the 
allyl group using Grubbs II catalyst proceeded smoothly to afford 3.69 and subsequent 
reduction of the ester was accomplished via treatment with lithium aluminum hydride to 
provide primary alcohol 3.70.  
 
 
Scheme 3.15. Weinreb’s synthesis of 3.70 en route to (±)-alstoscholarisines A and E.  
Having accessed divergent intermediate 3.70, the tetrahydropyran ring was 
constructed in a similar fashion as the previous approach (Scheme 3.16). Namely, 
oxidative cleavage of the olefin in 3.70 and epimerization of the resultant aldehyde 


































oxidized in situ to lactone 3.73. Notably, this sequence was less effective using divergent 
intermediate 3.70 that lacked a fully substituted C–16 center and proceeded in only 31% 
and 41% yield over three steps, respectively. The same sequence previously used to 
complete the syntheses (±)-alstoscholarisines B–D was applied to 3.72 and 3.73 to 
complete the synthesis of (±)-alstoscholarisine A (3.1) in 16 steps from known N-
sulfonylvalerolactam 3.48 and 1.8% overall yield, as well as the synthesis of (±)-
alstoscholarisine E (3.5) in 15 steps from 3.48 and 3.1% overall yield.   
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Scheme 3.16. Completion of the syntheses of (±)-alstoscholarisines A and E.  
Weinreb and coworkers reported the first synthesis of (±)-alstoscholarisines B-D, 
as well as the first synthesis of (±)-alstoscholarisines E.365,366 Their route shares some 
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indole starting material was used to construct the cyclic aminal ring system early in the 
synthesis. Additionally, the tactic for late-stage construction of the tetrahydropyran ring 
was related. While the synthesis did not require the development of new chemistry, it is 
notable for its divergent nature that enabled the construction of multiple alstoscholarisine 
alkaloids. This does seem to come at the cost of efficiency, as preparation of (±)-
alstoscholarisine A is more lengthy and lower yielding than previously developed routes.  
3.2.5 The Liao Synthesis of (–)-Alstoscholarisine A and E 
An enantioselective synthesis of (–)-alstoscholarisines A and E was recently 
reported by Liao and coworkers utilizing the known chiral lactam 3.78.367 The staring 
material was prepared in three steps from commercially available 1-N-Boc-2-piperidone 
(3.74) according to a reported protocol via deprotonation of 3.74 with LiHMDS and 
addition of phenylselenyl chloride to deliver 3.75 (Scheme 3.17).374 Subsequent oxidation 
and elimination of the selenide provided a,b-unsaturated lactam 3.76 in 55% yield over 
two steps. The rhodium catalyzed asymmetric conjugate addition of 
alkynl(diphenyl)methanol 3.77 to a,b-unsaturated lactam 3.76 was previously reported 
by Hayahsi to proceed in 86% yield (95% ee).375 Removal of the triisopropylsilyl (TIPS) 
protecting group with TBAF generated the terminal alkyne substrate 3.79.367 Treating 
3.79 with dibutylboron triflate (n-Bu2BOTf) and N,N-diisopropylethylamine followed by 
acetaldehyde delivered the aldol adduct 3.80 as a mixture of isomers that were not 
isolated. The crude reaction mixture was subjected to rhodium catalyzed 
cycloisomerization according to the protocol developed by Trost to afford 
oxahydroisoquinolones 3.81 in 22% yield and 3.82 as a mixture of diastereomers in 53% 
yield.376 The authors indicated that obtaining this mixture was critical to the divergent 




Scheme 3.17. Liao’s synthesis of oxahydroisoquinolone ring system.   
Continuing toward (–)-alstoscholarisine A, attention turned toward introduction of 
the indole moiety via a cross-coupling reaction (Scheme 3.18). Thus, 
oxahydroisoquinolone 3.81 was converted to vinyl iodide 3.83 using N-iodosuccinimide 
(NIS) and catalytic silver nitrate (20 mol%) according to a reported protocol for the 
conversion of glycals to 2-iodoglycals.377  A variety of conditions were screened for the 
Suzuki–Miyaura coupling of vinyl iodide 3.83 with indole boronic acid 3.84, a 
challenging substrate that is well-known to easily undergo protodeboronation under the 
reaction conditions.378 Ultimately, they found that slight modification of conditions 
reported by Buchwald and coworkers for the Suzuki-Miyaura coupling of related 2-
heterocyclic boronic acids worked well.379,380 In the event, heating a solution of 






























































and water (5:1) at 60 °C in the presence of the palladium precatalyst Pd SPhos G2 (5 
mol%) and K3PO4 provided the cross-coupled product 3.85 in 97% yield.367 
 
 
Scheme 3.18. Liao’s synthesis of (–)-alstoscholarisine A.    
With 3.85 in hand, the next challenge was formation of the bridging aminal ring. 

















































































(1:1) resulted in global Boc-deprotection to afford 3.86 (Scheme 3.18). The crude 
reaction mixture was subjected to hydrogenation using Pearlman’s catalyst (100 mol%) 
to provide the reduced product 3.87 with the correct stereochemistry in 76% yield over 
two steps. Common conditions for the reduction of lactams to hemiaminal intermediates, 
including Schwartz reagent and DIBAL-H, were assessed with only small quantities of 
the cyclized product 3.88 observed. Eventually it was discovered that subjecting  3.87 to 
conditions developed by Movassaghi, using trifluoromethanesulfonic anhydride (Tf2O) 
and tributyltin hydride provided the cyclic aminal 3.88.381 The volatiles were removed 
and the crude product was subjected to reductive alkylation with formaldehyde to afford 
(–)-alstoscholarisine A in 76% yield over two steps.  
 Attention next turned toward the synthesis of (–)-alstoscholarisine E from the 
mixture of oxahydroisoquinolone diastereomers 3.82 previously obtained using the same 
reaction sequence. Frist, treating the mixture of 3.82 with potassium hydride at -78 °C 
resulted in epimerization and the desired enantiomer 3.89 was isolated in 61% yield 
(Scheme 3.19). The same protocol outlined previously was used to convert 3.89 to vinyl 
iodide 3.90 and subsequent Suzuki–Miyaura coupling with indole boronic acid 3.84 
proceeded in 80% yield. Interestingly, the global Boc-deprotection and hydrogenation 
sequence that was used previously, delivered a mixture of diastereomers 3.39 and 3.94 in 
30% and 65% yield, respectively. The authors hypothesized that the axial methyl group 
in 3.85 provided enhanced selectivity by further blocking the concave face of the 
molecule, an effect that was absent in 3.84, resulting in diminished selectivity. The 
desired diastereomer 3.94 was subjected to Movassaghi’s conditions to form the cyclic 
aminal 3.95 followed by reductive alkylation to afford (–)-alstoscholarisine E in 64% 



































































































10 steps from 3.78 
8.9% overall yield
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Liao completed the first enantioselective synthesis of (–)-alstoscholarisine E (3.5), 
as well as the synthesis of (–)-alstoscholarisine A (3.1).367 The strategy utilized the 
known chiral lactam 3.78 that is accessible in three steps from commercially available 
materials to establish a critical stereocenter in the oxahydroisoquinolone ring system. 
However, several of the subsequent transformations were plagued by a lack of 
stereoselectivity. This was most notable in the tandem aldol–cycloisomerization sequence 
to convert 3.79 to oxahydroisoquinolones 3.81 and 3.89, which were isolated in 22% and 
32% yield respectively, after epimerization to the cis-fused ring system. The authors 
leveraged the lack of selectivity in this sequence to access both (–)-alstoscholarisine A 
(3.1) and (–)-alstoscholarisine E (3.5), but it decreases the overall efficiency of the 
synthesis. In addition, the reduction of 3.92 to 3.94, in route to (–)-alstoscholarisine E 
(3.5), resulted in a mixture (2.2:1) of diastereomers during the construction of another 
critical stereocenter. Overall, the synthesis is relatively concise from known materials, 
but the additional steps required for preparation of the starting chiral lactam 3.78 and the 
lack of stereoselectivity in the ensuing steps detract from the efficiency of this approach. 
Despite these shortcomings, the synthesis highlighted late-stage installation of the indole 
moiety and subsequent aminal cyclization as a convenient tactic for accessing the caged 
scaffold.   
3.3 SUMMARY 
The intriguing biological activity and the structural complexity of the 
alstoscholarisine alkaloids motivated numerous synthetic endeavors in the short time 
since their isolation was reported in 2014.362 Bihelovic and Ferjancic first reported  the 
synthesis of (±)-alstoscholarisine A in 2016 using an interesting enamine–Michael 
addition and aminal cyclization cascade to quickly access a portion of the core 
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structure.363 Unfortunately, the late-stage construction of the tetrahydropyran ring was 
lengthy and detracted from the synthetic efficiency. The enantioselective synthesis of (–)-
alstoscholarisine A by Yang followed in close succession using methodology develop by 
Carreira to establish a critical stereocenter.  This alternative approach also required 
multiple synthetic manipulations to establish the tetrahydropyran ring. Nonetheless the 
synthesis was accomplished in 12 steps from known staring materials. Weinreb achieved 
the first synthesis of (±)-alstoscholarisines B and C in 2017 and in 2018 extended this 
approach to the first synthesis of (±)-alstoscholarisines E and D, as well as other 
members of this family of natural products. The divergent nature of the synthesis was 
notable, but the divergent intermediate was accessed early in the synthesis and required 
numerous transformations to prepare each natural product. In addition, the synthesis of 
(±)-alstoscholarisines A and E were lower yielding and required 16 and 15 steps to 
prepare from known starting material in 1.8 and 3.1% overall yield, respectively. The 
recent synthesis of (–)-alstoscholarisines A and E reported by Liao was more concise, 
accessing the natural products in 9 and 10 steps from a known chiral starting material, 
respectively. Unfortunately, the starting material required several steps to prepare and 
multiple transformations in the sequence lacked stereoselectivity, detracting from the 







Chapter 4: The Total Synthesis of (±)-Alstoscholarisine E2 
4.1 MARTIN GROUP APPROACH TO (±)-ALSTOSCHOLARISINE E 
Research in the Martin group has long been focused on the efficient total 
syntheses of indole alkaloids and we were intrigued by the structural complexity of the 
alstoscholarisine natural products. We therefore set out to devise a strategy to access 
alstoscholarisine E (3.5), as a representative member of this family of natural products. 
At the outset of our planning, a successful synthesis of alstoscholarisines A–E had not yet 
been achieved, although shortly thereafter the racemic and enantioselective synthesis of 
alstoscholarisine A (3.1) was reported.363,364,382 Only recently was the synthesis of 
alstoscholarisine E (3.5) disclosed.366,367 Despite these recent successes, the reported 
syntheses have been somewhat lengthy from commercially available reagents (13-18 
steps LLS). We therefore continued forward to develop a concise and high yielding 
synthesis of alstoscholarisine E.    
We envisioned a convergent approach to alstoscholarisine E (3.5), in which the 
advanced intermediate 4.1 would be converted to 3.5 through a selective reduction and 
cyclization sequence (Scheme 4.1).383 Stereoselective reduction of the enol ether in 4.1 
would be achieved from the convex face. Subsequent selective reduction of the lactam in 
4.1 to the cyclic hemiaminal intermediate was expected to result in transannular 
cyclization with the indole nitrogen atom to form the bridging aminal in 3.5. The 
advanced intermediate 4.1 would be accessed by joining an appropriately substituted 3-
methylindole 4.2 (Z = ZnCl, B(OH)2, SnBu3) with the halogenated cis-
                                               
2 This chapter is based on previously published work from Michael D. Wood that Prof. Stephen F. Martin 
served as an advisor for. See Wood, M.D.; Klosowski, D. W.; Martin S. F. Stereoselective Total Synthesis 
of (±)-Alstoscholarisine E. Org. Lett. 2020, 22, 786-790. Michael D. Wood contributed to complete the full 
synthetic sequence and optimization therein that delivered alstoscholarisine E. 
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oxahydroisoquinolone 4.3 (X = Br, I) via a Negishi, Suzuki, or Stille coupling. Facile 
halogenation of cis-oxahydroisoquinolone 4.3 (X = H) was anticipated, which in turn 
would be accessed via a hetero Diels–Alder (HDA) reaction of 4.4 in accord with prior 
work from our group that has been showcased as a key step in the synthesis of several 
natural products.15,22,384,385 Expedient access to HDA precursor 4.4 was envisioned to 
occur using a vinylogous Mannich reaction, a reaction discovered and pioneered in the 
Martin group and used in the assemblage of a range of alkaloid natural products.21,23-26,386-
388 A vinylogous Mannich reaction of trimethylsiloxydiene 1.17 (~9:1 E/Z) and an N-
acyliminium ion that might arise from treating hexahydrotriazine 4.6 with crotonyl 
chloride (1.16). Each of these reagents, 1.16-1.17 and 4.5, are commercially available, 





Scheme 4.1. Retrosynthetic analysis of (±)-alstoscholarisine E.  
4.2 CONSTRUCTION OF THE OXAHYDROISOQUINOLONE RING SYSTEM 
As discussed in the first chapter, the Martin group recognized that the 
hydroisoquinoline and oxahydroisoquinolone ring system is a common structural subunit 
of many natural products and developed an efficient strategy for their construction using 
an intramolecular Diels–Alder (IMDA) and hetero Diels-Alder reactions (IMHDA).2,15-
18,20,385,389-394 As part of this endeavor targeting a general entry point to the yohimbine 
family of natural products, a novel IMHDA reaction between an a,b-unsaturated 
aldehyde and an a,b-unsaturated amide was developed (Scheme 4.2).20,389 The synthesis 
commenced with preparation of  the IMHDA precursor 4.13 from protected propargyl 




















Z = ZnCl, B(OH)2, 







































delivered homopropargyl alcohol 4.7 and subsequent partial hydrogenation using Lindlar 
catalyst provided 4.8. Successive tosylation of alcohol 4.8 and reaction with benzylamine 
generated the homoallylic amine 4.10. Amine 4.10 was subsequently acylated with crotyl 
anhydride 4.11 to afford benzyl amide 4.12. After removal of the methoxymethyl (MOM) 
acetal protecting group from 4.12, the resulting alcohol was subjected to Swern oxidation 
to deliver the IMDA precursor 4.13 in eight steps from commercially available reagents. 
Thermolysis of 4.13 in xylenes at 190 °C delivered the cycloadducts 4.14 and 4.15 (ca. 
5:1), and the cis-oxahydroisoquinolone 4.14 was isolated in 73% yield. A few additional 





Scheme 4.2. Formal synthesis of tetrahydroalstonine using IMHDA.  
The use of an IMHDA reaction with heterotiene 4.13 for the assemblage of an 
oxahydroisoquinolone ring system was unique at the time because the cycloaddition 
occurred between an electron deficient a,b-unsaturated aldehyde as the diene partner and 
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are better electronically matched for cycloaddition with a,b-unsaturated aldehydes was 
more common, particularly for the construction of dihydropyrans.395 Therefore, this work 
established an IMDHD as a useful tool for accessing these fused heterocyclic ring 
systems, particularly within the context of natural product synthesis.1 The preference for 
the cis-fused ring system attained using heterotrienes related to 4.13 was the subject of 
computational studies from our group,15 as well as Tanitillo and Houk.396  The models 
generated from these studies were in agreement that the endo, boat-like transition state is 
favored, giving rise to the cis-fused ring system. The favorability of the boat-like 
transition state has been attributed to the amides ability to maintain planarity in this 
conformation, whereas the chair-like transition state requires considerable rotation out of 
planarity to achieve proper orbital overlap for the cycloaddition (Figure 4.1). Thus, the 
energetic penalty associated with steric interactions in the boat-like transition state is 
offset by the planar conformation of the amide that is lower in energy. The experimental 








Figure 4.1. Endo and exo-transition states leading to IMDA cycloadducts.  
The heterotriene 4.13 that was used in these seminal studies is notably quite 
similar in structure to 4.4, which was targeted for construction of the 
oxahydroisoquinolone ring system of alstoscholarisine E. This provides encouraging 
precedent that the cis-fused cycloadduct would be expected from thermolysis of 4.4. 
Unfortunately, the synthesis of the IMHDA precursor 4.13 in earlier work from our group 
required eight steps to prepare.20,389 Because we required a more expedient approach for 
this synthetic endeavor, our attention turned to related work from the Martin group for 
further inspiration. The Martin group previously recognized the value of the IMHDA 
reaction for the construction of the oxahydroisoquinolone subunit, but were aware that 
more efficient access to the heterotriene precursor would expand the utility of this 
methodology for natural product synthesis. Specifically, in their quest to access the 
heteroyohimbine alkaloid core 1.18, the IMHDA precursor 1.13 was envisioned to 
provide a more direct approach (Figure 4.2).2,15 However, a clear tactic for the concise 




































Figure 4.2. Retrosynthetic analysis of heteroyohimbine core structure accessed from 
advanced IMHDA precursor 1.13.   
Eventually it was discovered that a vinylogous variant of the venerable Mannich 
reaction was uniquely suited to access the d-acrylamide-a,b-unsaturated aldehyde motif 
present in 1.13.2,15 In this newly developed vinylogous Mannich reaction sequence, 
stirring a solution of 3,4-dihydro-b-carboline (1.15), which is accessible in two steps 
from commercially available tryptamine (1.13), in THF with crotonyl chloride (1.16) in 
the presence of 1-(trimethylsiloxy)-1,3-butadiene (1.17) provided 1.13 in 78% yield 
(Scheme 4.3).15 The reaction is thought to proceed through formation of an N-acyl 
iminium ion that is activated for nucleophilic attack, but notably there was no observation 
of products that might arise from attack at the a-carbon of 1.17.21 Subsequent thermolysis 
of 1.13 in refluxing mesitylene provided the cis-fused cycloadduct 1.18 in 80% yield.2,15 
Critically, the vinylogous Mannich reaction developed through the course of this work 
provided access to the pentacyclic heteroyohimbine core in just four steps from 
commercially available materials and only a few additional steps were required to 
complete the total synthesis of tetrahydroalstonine (1.3), cathenamine (1.4), and 




















Scheme 4.3. Development of the vinylogous Mannich reaction to access IMHDA 
precursors.  
4.3 THE VINYLOGOUS MANNICH REACTION FOR PREPARATION OF THE HETERO 
DIELS–ALDER PRECURSOR  
4.3.1 Hexahydrotriazines as a Formaldehyde Equivalent in the Mannich Reaction 
The reaction sequence developed above demonstrated the utility of combining a 
tandem vinylogous Mannich reaction and IMHDA reaction for the efficient construction 
of alkaloid natural products and inspired a wide range of additional investigations from 
our laboratory, including the development of the MCAP.1,21 We queried whether we 
might utilize a related strategy to access the IMHDA substrate 4.4 that was targeted for 































































shown to fragment upon treatment with an acyl chloride 4.20 to generate N-substituted-
N-(chloromethyl)amides 4.22, that might provide a synthon for N-acyliminium ion 4.21 
(Scheme 4.4).397 Furthermore, intermediate 4.22 has been reacted with a range of 
nucleophilic partners to afford N-substituted amides.397-401 This suggests that 1-
(trimethylsiloxy)-1,3-butadiene (1.17) might be a suitable nucleophile to react with either 
the N-acyl iminium 4.21 or N-(chloromethyl)amide 4.22 that is generated upon acyl 
chloride mediated breakdown of hexahydrotriazine 4.19 in order to access the IMHDA 
precursor 4.4.   
 
 
Scheme 4.4. Acyl chloride mediated breakdown of hexahydrotriazines.  
We are not aware of any reports applying the N-acylation of hexahydrotriazines 
such as 4.5 in a vinylogous Mannich reaction with p–nucleophiles such as 1.17.  A 
related Mannich reaction using hexahydrotriazine 4.5 and a series of silyl enol ether 
analogs was disclosed by Ikeda et al. in 1981.401 In a representative example, a solution 
of hexahydrotriazine 4.5 in dichloromethane at 0 °C was treated with acetyl chloride 
(4.24) (3 molar eq.), and after stirring at room temperature for one hour, silyl enol ether 
4.26 (2.7 molar eq.) and titanium tetrachloride were added at 0 °C to afford the Mannich 
reaction product 4.27 in 40% yield (Scheme 4.5). Although this example provides a proof 
of concept for a related approach, the yields were quite low, ranging from 23-55% with 





























using a silyl enol ether vinylogue, which suggested that modifications might be required 
with our planned substrates.  
 
 
Scheme 4.5. Reported Mannich reaction of hexahydrotriazine 4.5 upon acyl chloride 
mediated breakdown.   
4.3.2 Development of a Hexahydrotriazine Vinylogous Mannich Reaction 
Our preliminary investigation was conducted by Dr. Klosowski and began with 
exploration of vinylogous Mannich conditions that were previously reported by our 
group.382 Accordingly, crotonyl chloride (1.16) was added dropwise to a solution of 
hexahydrotriazine 4.5 and 1-(trimethylsiloxy)-1,3-butadiene (1.17) in THF at -78 °C 
(Equation 4.1). Gratifyingly, these conditions did lead to the formation of 4.4, albeit in 





The optimization process began by first assessing the acyl chloride mediated 














































resonance (NMR) spectroscopy of aliquots taken directly from the reaction mixture. 
Interestingly, treating a solution of hexahydrotriazine 4.5 in THF at -78 °C did not lead to 
significant formation of N-methyl-N-(chloromethyl)amide 4.28, rather a by-product 
whose structure  is consistent with 4.29 based was observed as the major product  based 
on crude LCMS and NMR analysis (Scheme 4.6). Among related examples of acyl 
chloride mediated breakdown of hexahydrotriazines, dichloromethane has commonly 
been used as the solvent and the reaction has been performed at 0 °C, although a report 
by Siver et al. acknowledged the formation of a bis-adduct related to 4.29 using these 
conditions.397-401 Thus, a range of solvents and temperatures were screened to assess the 
transformation of 4.5 to 4.28 (Scheme 4.6). Performing the reaction in THF at elevated 
temperatures (0 °C to reflux) led to intractable mixtures. Switching the solvent to 
dichloromethane was beneficial and a positive correlation between increased 
temperatures and the formation of 4.28 was observed, but bis-adduct 4.29 remained 
prevalent. Switching the solvent to toluene resulted in an intractable mixture. However, 
when crotonyl chloride (1.16) was added to a solution of hexahydrotriazine 4.5 in 
acetonitrile at 0 °C and then heated to 70 °C for two hours, complete conversion to 
putative N-methyl-N-(chloromethyl)amide 4.28 was observed based on NMR analysis of 
an aliquot from the reaction mixture .382 It should be noted that this result stands in 
contrast to the report from Siver et al., which indicated that maintaining a low 
temperature was critical for suppressing formation of the bis-adduct.400 Taken together, 





Scheme 4.6. Solvent and temperature screen for acyl chloride mediated breakdown of 
4.5.  
Applying these conditions for the quantitative formation of N-methyl-N-
(chloromethyl)amide 4.28 followed by sequential addition of 1-(trimethylsiloxy)-1,3-
butadiene (1.17) and catalytic (10 mol%) trimethysilyl trifluoromethane sulfonate 
(TMSOTF) at 0 °C provided the IMHDA precursor 4.4 in 62% yield (Equation 4.2).382 
Interestingly, the regioisomer 4.30 that results from nucleophilic addition at the a-carbon 
of 1.17 was also isolated in 10% yield. We were encouraged that the alkylated products 
4.4 and 4.30 were isolated in a combined 72% yield, enabling continued progress toward 





























4.5 THF, -78 °C
THF, 0 °C to reflux
CH2Cl2, 0 °C to relfux
PhMe, 0 °C to reflux
MeCN, 0 °C to reflux






1.16, MeCN, 0 to 80 °C


















Solvent choice proved to be important for breakdown of hexahydrotriazine 4.5 to 
putative N-methyl-N-(chloromethyl)amide 4.28 during preliminary studies and was the 
subject of a more extensive evaluation in the full reaction sequence (Table 4.1). 
Exchanging acetonitrile for dichloromethane decreased the yield of 4.4 and 4.30 to 29% 
and 6%, respectively, which was consistent with the decreased formation of the N-
methyl-N-(chloromethyl)amide 4.28 observed in our earlier studies (entry 1). A similar 
result was obtained using dichloroethane (entry 2). Switching the solvent to THF 
provided further diminished yields of 4.4 and 4.30 and none of the desire product was 
observed when DMF was used as the solvent (entries 4-5). These studies supported the 
















Table 4.1. Solvent screen in the vinylogous Mannich reaction.  
 
entry solvent temp (°C) % yield 4.4 % yield 4.30 
1 MeCN 0 to 80 62a 10 a 
2 DCM 0 to reflux 29b 6b 
3 DCE 0 to 80 30b 13b 
4 THF 0 to reflux 13b 3b 
5 DMF 0 to 80 0b 0b 
a Isolated yield after chromatographic purification. b Yield determined by NMR with internal standard.   
Results from our preliminary investigation of the vinylogous Mannich reaction 
with hexahydrotriazine 4.5 provided some indication that the addition of a Lewis acid 
provided enhanced yields, but it remained to be determined if it was an important 
component using these optimized reaction conditions (Table 4.2).382 Indeed, performing 
the reaction in the absence of a Lewis acid resulted in significantly diminished yields, as 
compared to the reaction conducted in the presence of TMSOTf (entries 1-2). 
Exchanging TMSOTf for ethylaluminum dichloride did not result in a significant change 
(entry 3). However, the use of boron trifluoride diethyl etherate (BF3•OEt2) was not as 
favorable and 4.4 was only obtained in 29% yield (entry 4). These results confirmed that 








1.16 (3 eq.) 
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Table 4.2. Lewis acid screen in the vinylogous Mannich reaction.  
 
entry Lewis acid % yield 4.4 % yield 4.30 
1 none 7b 3b 
2 TMSOTf  62a 10 a 
3 EtAlCl2 57b 12b 
4 BF3•OEt2 29b 5b 
a Isolated yield after chromatographic purification. b Yield determined by NMR with internal standard.   
Our initial experiments utilized hexahydrotriazine 4.5 as the limiting reagent 
assuming acyl chloride mediated breakdown generated three molar equivalents of N-
methyl-N-(chloromethyl)amide 4.28. Because it was not clear that three equivalents of 
4.28 would actually be generated in this process, the reaction was also attempted using 1-
(trimethylsiloxy)-1,3-butadiene (1.17) as the limiting reagent (Table 4.3). However, 
reducing the quantity of 1.17 (4 to 2 eq.) had minimal impact on the yield of 4.4 and 4.30 
(entries 1-2). Likewise, increasing the amount of 1.17 (6 eq.) did not provide any benefit 
(entry 3). Based on these results, four equivalents of 1-(trimethylsiloxy)-1,3-butadiene 
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then 1.17 (4 eq) 
















Table 4.3. Molar equivalents of 1-(trimethylsiloxy)-1,3,butadiene (1.17) in the 
vinylogous Mannich reaction.  
 
entry 1.17 (eq.) % yield 4.4 % yield 4.30 
1 2 56b 11b 
2 4 62a 10 a 
3 6 58b 9b 
a Isolated yield after chromatographic purification. b Yield determined by NMR with internal standard.   
The optimized reaction sequence furnished the alkylated products 4.4 and 4.30 in 
72% combined yield. Formation of the regioisomer 4.30 that resulted from nucleophilic 
addition at the a-carbon of 1-(trimethylsiloxy)-1,3-butadiene (1.17) was somewhat 
surprising because this had not been observed in previous studies of the vinylogous 
Mannich reaction from our group.21 We hypothesized that increasing the size of the silyl 
group on the diene might suppress nucleophilic addition at the a-carbon and increase the 
yield of the desired product 4.4. Therefore the optimized sequence was conducted using 
the known TBS-analog 4.31 (Equation 4.3).402 Gratifyingly, 4.4 and 4.30 were obtained 
in 63% and 6% yield, respectively suggesting that by-product formation could be 
suppressed with this tactic. However, because 1-(trimethylsiloxy)-1,3-butadiene (1.17) 
was commercially available, we elected to utilize this readily available reagent in the 
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4.4 INTRAMOLECULAR HETERO DIELS–ALDER REACTION 
Having developed an optimized one-step procedure to access the IMHDA 
precursor 4.4 4.4 in 62% on a gram scale, attention turned toward the IMHDA reaction. 
Consistent with previous work from our group, heating a solution of 4.4 in degassed 
mesitylene under reflux afforded a separable mixture (5.4:1) of the cis– and trans–fused 




The thermally induced IMHDA reaction provided reliable access to the racemic 
cis–fused core 4.31, but we queried whether the cyclization might be catalyzed by a 
chiral Lewis acid to provide 4.31 enantioselectively. As previously discussed, the 
IMHDA substrate 4.4 is somewhat challenging in that both the diene and dieneophile are 
electron deficient and contain a carbonyl moiety that might interact with catalyst. Indeed, 
preliminary attempts to induce Lewis–acid catalyzed cyclizations with substrates similar 
to 4.4 in our earlier work were unsuccessful.15 Thus, we were cognizant that realization 
of this strategy might be challenging particularly since many of the known methods for 
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4.31: 65% 4.32: 12%
(4.4)
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predisposed to cyclization.403 These concerns notwithstanding, a brief evaluation of the 
chiral Lewis acids 4.33-4.35, which are known to promote hetero Diels–Alder reactions, 
was conducted (Scheme 4.7).404-406 However, treating 4.4 with each of these catalysts 
failed to produce detectable quantities of cycloadducts 4.31 and 4.32, so we were 
relegated to using racemic 4.31 to complete the synthesis of (±)-alstoscholarisine E.   
 
 
Scheme 4.7. Chiral Lewis acids evaluated in the IMHDA reaction.   
4.5 CROSS-COUPLING OF THE OXAHYDROISOQUINOLONE AND SUBSTITUTED INDOLE 
4.5.1 Halogenation of the Oxahydroisoquinolone 
With gram-scale access to the oxahydroisoquinolone core in two steps from 
commercially available reagents, the next challenge was cross-coupling of the 3-
methylindole moiety. This first required installation of a halogen atom at the b-position 









































4.33, PhMe, 4 Å MS rt to 50 °C
4.44, PhMe, 4 Å MS,  0 to 50 °C
4.45, CH2Cl2, 0 to 50 °C
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cross-coupling reactions. A protocol for the one-step conversion of glycals to 2-
iodoglycals was disclosed by Dharuman et al. in 2014 using NIS and catalytic silver 
nitrate (20 mol%) (Scheme 4.8).377 Earlier work reported that treating a solution of 4.36 
with NIS in the absence of other additives results in stereoselective addition to the vinyl 
ether moiety to afford 4.37 in 95% yield.407 Alternatively, Dharuman et al. discovered 
that including  catalytic silver nitrate (20 mol%) provided 2-iodoglycal 4.38 in 72% yield.  
 
 
Scheme 4.8. Previously reported reaction of NIS with glycals.377,407  
 The authors proposed a mechanism that involves activation of NIS with silver 
nitrate via coordination to the carbonyl in 4.40 and subsequent nucleophilic attack by the 
vinyl ether 4.39 to generate the oxocarbenium intermediate 4.41 (Figure 4.3).377 The 
intermediate 4.41 is subsequently captured by the nitrate anion, rather than the silver 
succinimide 4.42. Subsequent intramolecular elimination in 4.43 generates vinyl iodide 
4.44 and nitric acid (HNO3), which protonates the silver succinimide intermediate 4.42 






























Figure 4.3. Proposed mechanism for conversion of glycals to 2-iodoglycals.377  
Oxahydroisoquinolone 4.31 was thus treated with NIS and catalytic silver nitrate 
(20 mol%), according to the protocol reported by Dharuman et al., to deliver the vinyl 
iodide 4.46 in 79% yield (Equation 4.5). In an effort to further improve the yield, the 
silver nitrate catalyst loading was varied (10-35 mol%). Interestingly, increasing the 
catalyst loadings (> 20 mol%) resulted in diminished yields of 4.46, although analysis of 
the crude reaction mixture by NMR, LCMS, or GCMS analysis did not identify the 
formation of any significant by-product that could be isolated for further analysis. Indeed, 
in each instance the crude reaction mixture was surprisingly clean, suggesting that 
reduced yields might result from diminished recovery. Decreasing the catalyst loading 







































4.5.2 Oxahydroisoquinolone Cross-Coupling with 3-Methylindole  
With reliable access to the halogenated oxahydroisoquinolone 4.46, the stage was 
set for the cross-coupling of 4.46 with an appropriately substituted 3-methylindole (4.2). 
We first targeted a Negishi coupling in initial work performed by Dr. Daniel Klosowski,  
because the transformation could be conducted in a single step.382 After numerous 
attempts at the Negishi coupling of 4.46 with 3-methylindole 4.47 failed to furnish 4.48, 
we pursued an alternative cross-coupling strategy (Equation 4.6).382   
 
 
Our attention next turned to Suzuki–Miyaura coupling of the halogenated 
oxahydroisoquinolone 4.31 with 3-methylindole boronic acid 4.2 (R = B(OH)2). 
NIS, AgNO3































Pd(PPh)3, THF, rt to 125 °C
Pd(dba)2, P(o-fur)3, THF, tr to 125 °C
Pd(dba)2, RuPhos, THF, 80 °C
Pd(PPh)3, DMAc, 80 °C
Pd(OAc)2, RuPhos, DMAc, 80 °C
Pd(OAc)2, DMAc, 80 °C
conditions
* performed by Dr. Daniel Klosowski
4.48
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Although 2-heterocyclic boronic acids such as 4.2 (R = B(OH)2) are known to be 
problematic substrates in Suzuki–Miyaura coupling reactions due to competitive 
protodeboronation under the reaction conditions, innovations in catalyst design by 
Buchwald have overcome these challenges.378 One such catalyst is the XPhos Pd G2 
precatalyst 4.53, which was reported to work well for substrates that are prone to 
protodeboronation based on their ability to undergo rapid reduction to the active 
phosphine ligated Pd(0) complex using mild conditions, along with their inherent high 
level of catalytic activity.379,380,408 It is notable that Buchwald reported a Suzuki–Miyaura 
coupling of the related indole boronic acid 4.50 and 6-chloro-1-indanone (4.49) to afford 
4.51 in 88% yield using the XPhos Pd G2 precatalyst with aqueous K3PO4 in THF at 
room temperature (Scheme 4.9).379  
 
Scheme 4.9. Reported Suzuki–Miyaura couple of an indole boronic acid.   
We were pursuing this catalyst system for the Suzuki–Miyaura coupling of indole 























disclosed a related coupling strategy using the SPhos Pd G2 precatalyst in the synthesis 
of (–)-alstoscholarisine A and E.367,382 Cognizant of the similarities between the coupling 
partners, we elected to utilize the coupling conditions reported by Liao. The indole 
boronic acid 3.84 was prepared through slight modification of a reported protocol by 
treating a solution of 3-methylindole 4.54 in THF at -78 °C with tert-butyllithium, 
followed by rapid addition of trimethyl borate to the cooled solution and subsequent 
hydrolysis using aqueous ammonium chloride to afford the indole boronic acid 
3.84.409,410 Analysis of the crude reaction mixture indicated near quantitative conversion, 
but because of the reported instability of 3.84, it was not isolated and was instead used 
directly in the Suzuki–Miyaura coupling.409 In the event, heating a solution of indole 
boronic acid 3.84 (ca. 3 eq.) and oxahydroisoquinolone 4.31 at 60 °C in the presence of 
the SPhos Pd G2 precatalyst (5 mol%) delivered the cross-coupled product, albeit in only 
18% yield (Scheme 4.10). Suspecting that the instability of boronic acid 3.84 was the 
cause of the low yield, the experiment was repeated with an increased quantity of 3.84 
(ca 4 eq.), which provided some improvement, but further increasing the equivalents of 
3.84 (ca 5 eq.) did not further enhance the yield. Ultimately, we discovered that 
increasing the loading of the Pd SPhos G2 precatalyst (10 mol%) and indole 4.54 (4 eq.), 





Scheme 4.10. Suzuki–Miyaura coupling of indole boronic acid 3.84 and 
oxahydroisoquinolone 4.31. 
4.6 COMPLETION OF THE TOTAL SYNTHESIS OF (±)-ALSTOSCHOLARISINE E 
4.6.1 Stereoselective Reduction of the Cyclic Vinyl Ether 
With 4.55 in hand, we next investigated strategies for the stereoselective 
reduction of the cyclic vinyl ether moiety. Liao reported a tandem Boc-deprotection and 
hydrogenation sequence using a related substrate that resulted in a mixture of 
diastereomers (2.2:1) and notably the Boc-deprotected intermediate was not isolated.367 
Initially, the same sequence was attempted using oxahydroisoquinolone 4.55, but 
somewhat surprising, the crude residue obtained following treatment of 4.55 with 
methanesulfonic acid contained a complex mixture of products (Equation 4.7). The 
mixture was subjected to hydrogenation using Pearlman’s catalyst (100 mol%) according 
to the reported protocol to furnish a complex mixture. Analysis of the crude residue with 
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product 4.58 (ca. 3:2) were present, accompanied by a variety of by-products that were 
not readily identifiable.  
 
Given that an unexpected mixture of products was observed following the 
treatment of 4.55 with methanesulfonic acid, alternative conditions were attempted for 
removal of the Boc-protecting group prior to hydrogenation. Thus, trifluoroacetic acid 
(15 eq.) was added to a solution of oxahydroisoquinolone 4.55 in dichloromethane and 
stirred at room temperature for 90 minutes (Scheme 4.11). Monitoring the reaction by 
thin layer chromatography (TLC) suggested smooth conversion of the starting material 
4.55, but again the NMR spectra of the crude reaction revealed a complex mixture of 
unanticipated by-products. Nonetheless, the crude residue was subjected to 
hydrogenation with Pearlman’s catalys. However, none of the reduced product 4.58 was 
observed and instead a mixture of products that had a mass consistent with 4.60, was 
observed. Cognizant that the addition of methanol to the tetrahydropyran of 4.55 might 
be expected in the presence of acid, it was somewhat perplexing that the solvent used in 























Scheme 4.11. Attempted Boc-deprotection and catalytic hydrogenation sequence.   
Intrigued by this finding, we recognized that Lewis acid mediated reduction of the 
acetal moiety in 4.60 might also be possible and therefore attempted to form the acetal 
4.60 directly.   Thus, oxahydroisoquinolone 4.55 was treated with methanol under a 
variety of acidic conditions, that only provided returned starting material (Equation 4.8). 
Notably, addition of acetyl chloride to a solution of 4.55 in methanol also provided 
predominantly returned starting material, but was accompanied by a minor by-product 
(ca. 10%). At the time, the identity of the by-product was not clear, but its discovery 








































Having encountered difficulties during the tandem Boc-deprotection and 
hydrogenation sequence, we briefly attempted the direct hydrogenation of 
oxahydroisoquinolone 4.55 (Equation 4.8). Unfortunately, none of the hydrogenation 
conditions screened led to reduced product 4.58. Only returned starting material was 
obtained using palladium on carbon. Use of Pearlman’s catalyst and Adam’s catalyst 
appeared to provide a mixture of returned starting material and some reduction of the 
indole double bond.  
 
 
In light of these challenges, our attention next turned toward ionic reduction as an 
alternative tactic, aware that chemoselective reduction of the cyclic vinyl ether moiety 




















p-TsOH (1 eq), MeOH, rt RSM
TFA (15 eq), MeOH, rt RSM
PPTS, DCM/MeOH (1:1) 0 °C to reflux RSM
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removed under the reaction conditions.411 We first attempted conditions that were 
previously reported for the reduction of a structurally related cyclic vinyl ether that were 
not anticipated to remove the Boc-protecting group.412 Accordingly, a solution of 
oxahydroisoquinolone 4.55 in acetic acid was treated with sodium cyanoborohydride, but 
only returned starting material was obtained (Equation 4.9).  
 
 
We next examined other conditions known to reduce stabilized carbocations.413 
Surprisingly, stirring a solution of oxahydroisoquinolone 4.55 in dichloromethane with 
triethylsilane and trifluoroacetic acid (5 eq) did not provide the reduced product 4.58 or 
significant quantities of Boc-deprotected starting material (Scheme 4.12). Instead, the 
starting material was completely consumed and a mixture of two predominant by-
products that were tentatively assigned as the bicyclic acetals 4.61 and 4.62 (ca. 1:1) 





















Scheme 4.12. Unanticipated formation of acyloxy acetals.   
The exact stereochemistry of the isolated bicyclic acyloxy acetals 4.61 and 4.62 
remained to be determined, but it suggested that under acidic conditions, the Boc-
carbamate cyclized onto the vinyl ether moiety rather than undergo acid mediated 
cleavage as expected.  The discovery of this unanticipated product enabled a critical 
review of the challenges that led up to this point. In hindsight, this provided an 
explanation for the complex mixture of products obtained from the tandem Boc-
deprotection and catalytic hydrogenation sequences. Moreover, closer analysis of the 
mixture obtained from the previous Boc-deprotection reaction using trifluoracetic acid 
(15 eq, 90 min) indicated that these conditions favored the formation of one diastereomer 
(ca. 1:3) prior to catalytic hydrogenation. Replicating those conditions confirmed this 
finding with 4.61 and 4.62 (ca. 1:3) isolated in 95% combined yield (Scheme 4.13). In 
contrast, the by-product that was observed (ca. 10%) upon stirring oxahydroisoquinolone 
4.55 in methanolic HCl appeared to be a single diastereomer. Repeating that reaction 
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products, but analysis of the crude reaction mixture confirmed that only a single acyloxy 
acetal diastereomer was present and it was later revealed to be 4.61.  
 
 
Scheme 4.13. Acid catalyzed formation of acyloxy acetal intermediates.  
We recognized that the cyclic carbamate moiety of 4.61 and 4.62 could 
potentially be reductively cleaved with concomitant decarboxylation to deliver the 
reduced product 4.58. Therefore, the fortuitous discovery that the predominant bicyclic 
acetal diastereomer formed in the cyclization could be modulated through variation of the 







































































reduction sequence. Thus, conditions for the diastereoselective formation of the bicyclic 
acetal using HCl were further explored (Scheme 4.14). Gratifyingly, we found that 
stirring a solution of oxahydroisoquinolone 4.55 in dioxane with HCl (2 M) furnished 
4.61 as a single diastereomer in 59% yield. Reducing the concentration of HCl (0.4 M) 
and increasing the reaction time suppressed undesired Boc-deprotection of 4.55, 
affording 4.61 in 77% yield and the structure of which was unambiguously confirmed by 
X-ray crystallography. Notably, 4.61 possesses the same stereochemistry at the indole–
oxahydroisoquinolone carbon center as is present in alstoscholarisine E. Stirring 
oxahydroisoquinolone with trifluoroacetic acid in dioxane provided only unreacted 
starting material, confirming that that nature of the acid and solvent is important for this 
transformation.     
 
 
Scheme 4.14. Stereoselective acyloxy acetal formation.  
We speculated that 4.61 might be thermodynamically favored over 4.62 and that 
thermodynamic equilibration under the reaction conditions results in the exclusive 




















HCl (2 M), dioxane, 3 h 59
HCl (1 M), dioxane, 7 h 71
HCl (0.4 M), dioxane, 30 h 77
TFA/dioxane (1:3), 31 h RSM
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dichloromethane was stirred with trifluoroacetic acid (5 eq.) for 13 h, at which time the 
starting material was consumed (Scheme 4.15). Analysis of the crude residue confirmed 
the formation of mixture of 4.62 and 4.61 (ca. 1.2:1). The crude residue thus obtained 
was subsequently stirred with HCl (0.5 M) in dioxane for 25 h. Examination of the crude 
product mixture revealed that 4.61 was the major product and that diastereomer 4.62 was 
no longer observed. This preliminary experiment supports the hypothesis that 
thermodynamic equilibration favors the formation of 4.61.  
 
 
Scheme 4.15. Putative thermodynamic equilibration of acyloxy acetals 4.61 and 4.62. 
Attention next shifted to the reductive opening of bicyclic acetal moiety of 4.61 at 
the anomeric center, which proved to surprisingly unreactive to a range of conditions. A 
variety of Lewis acids have been used for the reductive opening of acetals in the presence 
of triethylsilane, but an example that was analogous to the bicyclic carbamate acetal in 
4.61 was not readily identified.414 However, previous work demonstrated that TiCl4, 
TMSOTf, and Sc(OTf)3 were effective for the ring opening of structurally related bicyclic 











































the presence of triethylsilane only returned starting material (Equation 4.10). BF3•OEt2 
also failed to provide any conversion of the starting material. Fortunately, we discovered 
that treating 4.61 with excess ethylaluminum dichloride (7 eq.) in the presence of 
triethylsilane led to smooth reductive opening at the anomeric center with subsequent 
decarboxylation to afford the desired product 4.63 in 97% yield. Attempted reductive 
opening using less of the Lewis acid (< 5 eq.) provided incomplete conversion of the 
starting material. The reduction was also found to be slow at lower temperatures, but 
proceeded rapidly at 0 °C.  The diastereoselective reduction of 4.55 developed in this 
two-step sequence is notable given that catalytic hydrogenation resulted in a mixture of 
diastereomers. 
      
 
4.6.2 Formation of the Bridging Aminal Ring  
All that remained to complete the synthesis of (±)-alstoscholarisine E (3.5) was 
partial reduction of the lactam moiety of 4.63 to the N,O-hemiaminal followed by 
cyclization to generate the bridging aminal ring in 3.5. Such cyclizations are well 


















TiCl4 (20 eq), CH2Cl2, -78 to rt RSM
BF3•OEt2, (10 eq), CH2Cl2, 0 °C RSM
TMSOTF (5 eq), MeCN, -40 °C to rt RSM
Sc(OTf)3, (1.5 eq), CH2Cl2, 0 °C to rt RSM




amides; however avoiding overreduction to the amine can sometimes be challenging and 
substrate specific.364-367,418 At the outset of this work, encouraging precedent for the 
feasibility of this transformation was found in the total synthesis of (±)-goniomitine 
(4.66)  reported by Mizutani et al., in which an N-benzyl lactam 4.64 was partially 
reduced with DIBAL-H, resulting in spontaneous cyclization with the indole nitrogen 
atom to form the aminal ring of 4.65 in 87% yield (Scheme 4.16).419 Although, the 
transannular cyclization of oxahydroisoquinolone 4.63 to form the bridging aminal ring 
in 3.5 was anticipated to be more challenging, this report suggested that using a 2,3-




Scheme 4.16. Precedent for formation of a cyclic aminal with and indole nitrogen atom.  
We initiated our investigation by screening conditions that were reported for 
related transformations. Thus, a solution of oxahydroisoquinolone 4.63 in THF was 
treated with DIBAL-H at -78 °C according to the protocol reported by Mizutani et al., but 
analysis of the crude reaction indicated that over reduction of the lactam to the amine was 
the major product (Equation 4.11).419 Switching the solvent to dichloromethane, 
according to the protocol reported by Weinreb provided similar results.365,366 The 



















substrate that relied on activation of the amide using trifluoromethanesulfonic anhydride 
in the presence of tributyltinhydride, but using these conditions with 




With methodology from the prior art having failed to deliver quantifiable 
quantities of the natural product, our focus turned toward other known methods for partial 
reduction of amides. The hydrozirconation of amides using Schwartz’s reagent 
(Cp2ZrHCl) is a well-established method for partial reduction of amides under mild 
conditions, but this too only delivered trace quantities of the cyclized product 3.5 based 
on LCMS analysis of the crude reaction mixture (Equation 4.12).420   
 
 
Alternatively, hydrosilylation has emerged as a particularly useful strategy for 
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amides to aldehydes was reported by the Buchwald group in 1996 using titanium(IV) 
isopropoxide and diphenylsilane (Ph2SiH2).422 The active reducing agent was postulated 
to be a titanium hydride-like complex that reduced amide 4.67 to hemiaminal 4.68, which 
underwent spontaneous elimination to the enamine 4.69 and upon aqueous work-up, the 
aldehyde 4.70 was obtained in good yields (Equation 4.13). As a result, the reaction was 
limited to secondary and tertiary amides that possessed an a-hydrogen atom.  More 
recently, a related procedure was reported by Lemaire and coworkers using titanium(IV) 
isopropoxide and 1,1,3,3-tetramethyldisiloxane (TMDS) as an alternative organosilane 
reagent.423 Notably, this protocol was not restricted to enolizable amides and worked well 




A related iridium–catalyzed process was reported by Nagashima in 2009 for the 
partial reduction and dehydrogenation of amides to enamines (Figure 4.4.A).424  The 
procedure was highly efficient, and using catalytic (0.05 mol%) Vaska’s complex 
(IrCl(CO)(PPh3)2) with TMDS, a range of aliphatic tertiary amides were converted to the 
corresponding enamines in high yield. This methodology has been adapted for the 
reductive functionalization of amides with a variety of carbon nucleophiles by the Dixon 
group, as well as others.425-435 For example, Dixon and coworkers discovered that stirring 
a solution of the tertiary amide 4.74 with Vaska’s complex in dichloromethane resulted in 
full conversion to the partially reduced intermediate 4.75 followed by addition of 
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Dixon group found that stirring a toluene solution of lactam 4.77 with Vaska’s complex 
for five minutes, followed by addition of trimethylsilyl cyanide afforded the reductive 
Strecker product 4.78 in 86% yield (Figure 4.4.C).433 The reactions were shown to work 
well with aliphatic amides and aromatic amides indicating that nucleophilic capture can 
outcompete enamine formation. Alternatively, Chida and coworkers reported that partial 
reduction of lactam 4.79 with Vaska’s complex and TMDS delivered the enamine 
intermediate 4.80 that was then subjected to a vinylogous Mannich reaction with 4.81 in 
the presence of acid to afford 4.82 in 73% yield (Figure 4.4.D).427  
 308 
 
Figure 4.4. Reported examples for the hydrosilylation of amides and their nucleophilic 
capture. 
Encouraged by these promising reports, we focused our attention on the 
hydrosilylation of oxahydroisoquinolone 4.63 (Scheme 4.17). In the event, treating 4.63 
with titanium(IV) isopropoxide and diphenylsilane according to the protocol reported by 








































































product.422 A preliminary reaction of 4.63 with titanium(IV) isopropoxide and TMDS 
according to the procedure reported by Lemaire was observed to provide some product 
formation, but was slow to react at room temperature.423 Fortunately, we discovered that 




Scheme 4.17. Hydrosilylation of oxahydroisoquinolone 4.63 and aminal formation. 
Transitioning to catalytic conditions, treating a solution of 4.63 in toluene with 
catalytic Vaska’s complex and TMDS according to the protocol reported by Nagashima, 
the natural product was isolated in 56% yield.424 Gratifyingly, merely switching the 
reaction solvent to dichloromethane delivered (±)-alstoscholarisine E (3.5) in 77% yield. 
The partial reduction of amides using Vaska’s complex and TMDS is well-established, 
but this is the first report we are aware of, in which the intermediate is captured by a 
nitrogen nucleophile to furnish an aminal. Therefore, this discovery provides a useful 

















Ph2SiH2, Ti(Oi-Pr)4, THF, 50 °C trace
TMDS, Ti(Oi-Pr)4, PhMe, 50 °C 56
TMDS, IrCl(CO)(PPh3)2, PhMe, rt 56
TMDS, IrCl(CO)(PPh3)2, CH2Cl2, rt 77
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4.7 SUMMARY 
In summary, the total synthesis of (±)-alstoscholarisine E was achieved in a mere 
seven steps (LLS) from commercially available reagents and 15.2% overall yield 
(Scheme 4.18). The synthesis features a novel variant of the vinylogous Mannich reaction 
and a tandem IMHDA reaction to rapidly access the cis-oxahydroisoquinolone core in 
just two steps from commercially available reagents. The diastereoselective reduction of 
the cyclic vinyl ether in 4.55 was accomplished via the fortuitous discovery of a 
stereoselective acid–catalyzed cyclization and the subsequent Lewis acid–promoted 
hydride reduction. Mild conditions were developed for aminal formation in an iridium–
catalyzed amide reduction and cyclization sequence to complete the synthesis. Notably, 
the route developed is considerably shorter and more efficient than previously reported 
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PROGRESS TOWARD THE ENANTIOSPECIFIC TOTAL 
SYNTHESIS OF PIERISKETOLIDE A 
Chapter 5: Approach to Pierisketolide A 
5.1 ISOLATION AND BIOACTIVITY    
Pieris Formosa (Wall) D.Don is a shrub belonging to the Ericaceae family that is 
found in south and southwest China, and it has a history of use in traditional Chinese 
medicine for the treatment of tinea and scabies.436,437 The genus Pieris is smaller than 
some other members of the family, but is a rich source of diterpenoid natural products.438 
Recently, as part of their effort to discover biologically interesting natural products from 
traditional Chinese medicines, Niu et al. reported the isolation of three pierisketane 
terpenoids (5.1–5.3) from P. Formosa that are thought to be derived from ent-kaurene 
(5.4) (Figure 5.1).437 While 5.1–5.3 possess a bicyclo[3.2.1]octane ring that is common 
among ent-kaurenoids, they contain an unusual rearranged A-homo-B-nor-framework.439 
Pierisketones B (5.2) and C (5.3) are comprised of a tetracyclic skeleton, whereas 
pierisketolide A (5.1) contains a bridged spirotetronate moiety that adds structural 
complexity. Similar to other natural products isolated from P. Formosa, pierisketolide A  
(5.1) exhibits analgesic activity, with a 45% writhe inhibition rate at 10.0 mg/kg an no 
observable cytotoxicity at  10 µM concentration.437,440 In contrast, 5.2 and 5.3 did not 
provide any analgesic effect, suggesting that the unique structural features of 
pierisketolide A are linked to its bioactivity. Thus, the development of a synthetic 
strategy to access pierisketolide A might be useful to further evaluate its biological 





Figure 5.1. The pierisketanes 5.1-5.3 derived from ent-kaurene.  
5.2 SYNTHETIC STRATEGY  
Inspired by the structural complexity of pierisketolide A (5.1) and its intriguing 
biological activity, we sought to develop an enantiospecific approach toward 5.1 that 
would forge the critical bicyclo[3.2.1]octane ring early in the synthesis (Scheme 5.1). 
Accordingly, we envisioned that the late stage intermediate 5.6 could be transformed into 
5.1 via lactonization of a b–ketoester moiety that would arise from the C–acylation and 
methylation of ketone 5.6. The seven-membered ring of 5.6 could be formed via a SmI2 
mediated pinacol coupling of a tethered carbonyl moiety in ketone 5.7, which might be 
installed through a stereoselective Mukaiyama aldol of aldehyde 5.8 with the tricyclic 
core 5.9 (R = Me or H) following a 1,4-reduction of the enone moiety.441-444 Key to this 
approach was expedient access to the tricyclic core 5.9 through a unique Pauson-Khand 














































precedent that related bridged tricycles can be formed using a similar approach.445-448 
Critically, the substituted methylenecyclopentane 5.10, which possessed the chiral 
tertiary hydroxyl group, was targeted as the PKR precursor to obviate the need for late–
stage redox manipulations. The cyclopentane precursor 5.10 could be readily accessed 
from methylenation of the known cyclopentenone 5.11 following 1,4-addition addition of 
alkyne 5.12 (R = Me of TMS).449 
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5.2.1 A Model System for the Pauson–Khand Reaction 
5.2.1.1   Preparation of the Pauson-Khand Reaction Precursor  
Because there was little direct evidence that the bicyclo[3.2.1]octane of 5.9 could 
be constructed using the devised PKR approach, we initially targeted a simplified model 
system to assess the feasibility of this transformation.  Therefore, our attention first 
directed toward the known 4-siloxy-2-cyclopentenone 5.15 for preliminary studies. 
Convenient access to 5.15 was achieved according to a reported protocol for the 
microwave promoted Piancatelli rearrangement of furfuryl alcohol (5.13) (Equation 
5.1).450 The reaction was reported to proceed in up to 80% yield with full conversion of 
the starting material within four minutes, but in our hands 5.14 was obtained in only 46% 
yield. The modest yield notwithstanding, the short reaction time enabled rapid access to 
multi-gram quantities of 5.14 and subsequent protection of the alcohol as a tert-
butyldimethylsilyl (TBS) ether provided 5.15 in two-steps from commercially available 




With 5.15 in hand, the next challenge was identification of conditions for the 1,4-
addition of alkyne 5.12 (R = Me or TMS). Related transformations are well precedented 
using organocopper reagents, particularly in the area of prostaglandin synthesis.449,451-453 
A survey of copper sources reported for the conjugate addition of organocuprates to 
similar 4-siloxy-2-cyclopentenone substrates was conducted using n-butyllithium as a 
convenient surrogate for 5.12 (Equation 5.2).449,454-456 In the event, n-butyllithium (3 eq.) 
O












was added to a solution of THF containing the copper salt (1.5 eq) at -78 °C and the 
reaction was warmed to -40 °C, and cyclopentenone 5.15 was added at -78 °C. Both CuI 
and freshly prepared CuBr•DMS provided only unreacted starting material, whereas 
CuCN resulted in full consumption of 5.15 and provided the conjugate addition product 
5.16 in 46% yield along with a variety of unidentified by-products. It is well established 
that TMSCl and hexamethylphosphoramide (HMPA) are effective additives for 
increasing the rate of organocuprate addition to enones to provide the silyl enol ether 
intermediate.457,458 Moreover, trapping the intermediate enolate was discovered as an 
effective strategy to prevent enolate equilibration and the irreversible elimination of the 
TBS ether group with related 4-silyloxy-2-cyclopentenone substrates.453,456,459 
Fortunately, including these additives with the organocuprate generated from 





We next sought to apply these conditions to the 1,4–addition of the organolithium 
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commercially available alcohol.460 Accordingly, iodoalkyne 5.17 was converted to 
organolithium 5.18 via treatment with tert-butyllithium, followed by addition of a THF 
solution containing a soluble copper iodide–dimethylsulfide complex. Subsequent 
addition of 4-silyloxy-2-cyclopentenone 5.15 and TMSCl afforded the silyl enol ether 
intermediate 5.19 (Scheme 5.2).449,461 The crude reaction mixture was hydrolyzed with 
aqueous acetic acid to provide 5.20 in 62% yield.  
 
 
Scheme 5.2. Conjugate addition of iodoalkyne 5.17 with 4-silyloxy-cyclopentenone 5.15.    
Unfortunately, this initial result proved difficult to reproduce and subsequent 
attempts provided only unreacted starting material. In order to identify the source of this 
problem, it was necessary to evaluate individual steps of the multi-step reaction. Because 
the reaction was successful using a commercially available organolithium reagent, we 
hypothesized that the lithium-halogen exchange of 5.17 might be the culprit. To further 
examine this transformation, a solution of iodoalkyne 5.17 in diethyl ether was treated 
with tert-butyllithium and after stirring for one hour, the reaction was quenched with 
freshly distilled benzaldehyde (5.21) (Scheme 5.3). Interestingly, none of the addition 
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appeared to be a major by-product. This indicated that dissolved oxygen in the solvent 
might be consuming the intermediate organolithium. Although the diethyl ether was 
sparged with N2 prior to being passed through neutral alumina according to the procedure 
reported by Grubbs, more rigorous degassing might be required.462  Thus, the reaction 
was repeated after deassing the solvent via several freeze-pump-thaw cycles, as well as 
with diethyl ether distilled from sodium benzophenone ketyl, and the addition product 
5.22 was obtained in 69% and 82% yield respectively.  
 
 
Scheme 5.3. Lithium-halogen exchange using degassed solvent.  
After establishing conditions for successful lithium-halogen exchange with 5.17, 
the conjugate addition was further optimized to reduce the quantity of alkyne required for 
the transformation by including 2-thienyllithium as a nontransferable ligand. Thus, a 
slightly modified protocol was developed using TMS-alkyne 5.23, which was also 
targeted for investigation in the PKR (Scheme 5.4). In the event, treating 5.23 with tert-
butyllithium in degassed diethyl ether induced lithium-halogen exchange, and was 
transferred to a solution of diethyl ether containing CuI•0.75DMS and 2-thienyllithium. 
Subsequent addition of cyclopentenone 5.15 and TMSCl afforded silyl enol ether 5.25, 
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Scheme 5.4. Optimized conditions for the 1,4-addition with cyclopentenone 5.26.    
With substituted cyclopentenones 5.20 and 5.26 in hand, it was necessary to  
methylenate the carbonyl moiety. Wittig olefination of structurally related b-siloxy– and 
b-alkoxy–cyclopentanones have been reported to be unsuccessful due to their propensity 
to undergo b–elimination.463,464 Accordingly, we examined Petasis reagent for 
methylenation.465,466 Thus, treating 5.20 and 5.21 with Petasis reagent afforded the 
methylenated products 5.27 and 5.28 in 46% and 57% yield, respectively (Scheme 5.5). 
Although the yields were modest, additional optimization of the reaction was delayed 
until the feasibility of the PKR could be evaluated. The TMS group in 5.27 was easily 
removed to deliver the terminal alkyne in 5.29.      
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5.20: R = Me




5.27: R = Me (46%)




5.2.1.2   A Preliminary Evaluation of the Pauson-Khand Reaction  
The PKR is formally a [2+2+1] cycloaddition of an alkene, an alkyne, and carbon 
monoxide to form a cyclopentenone product (Scheme 5.6).467 The putative mechanism, 
originally proposed by Magnus, involves the initial formation of a stable cobalt-alkyne 
complex 5.31 upon treatment of an alkyne with dicobalt octacarbonyl.468,469 A reacting 
alkene then coordinates with this complex in a ligand substitution step, followed by 
cobaltacycle formation in 5.34. Migratory insertion of CO and reductive elimination of 
the homologated intermediate 5.35 forms the cyclopentenone 5.36. The traditional 
conditions typically require high temperatures to promote this transformation, which is 
thought to be related to decarbonylation in the ligand substitution step.469,470 However, 
since its initial discovery a variety of advancements have been made to promote this 
transformation using more mild conditions, particularly with respect to oxidative and 
Lewis basic promoters that are thought to increase the rate of the ligand substitution 
step.470   
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The intramolecular variant represents a valuable strategy for accessing fused ring 
systems possessing considerable molecular complexity from comparatively simple enyne 
starting materials and has recently been has featured as a key step in the total synthesis of 
a variety complex natural products.471-477 Among the numerous reports that use the PKR 
to assemble fused ring systems, there are few examples in which a bridged ring system is 
constructed and the carbon bond formation that occurs between the alkene and alkyne 
establish a newly formed bridgehead center. One example was reported by Pauson and 
coworkers for construction of the cedrane skeleton 5.38, toward the formal and total 
syntheses of several cedrane natural products (Equation 5.3).445-447 The cycloaddition of 
the 1,6-enyne proceeded using the oxidative promoters trimethylamine N-oxide 
(TMANO) and 4-methylmorpholine N-oxide (NMO), as well as the Lewis basic promoter 
n-butyl methylsulfide to provide 5.38 in high yield under mild reaction conditions. 
Another example reported by Chirkin et al. utilized Z-enyne 5.39 in a molybdenum 
hexacarbonyl–promoted hetero Pauson-Khand reaction to create the bicyclo[3.2.1]octane 
of 5.40 in 50% yield (Equation 5.4).448 Each of these examples generate a bridged ring 
system that is structurally related to the bicyclo[3.2.1]octane of pierisketolide A, although 
both 5.37 and 5.39 possess structural features that might make cyclization more 
favorable. Thus, it remained to be determined if a related PKR with enyne 5.27 and 5.29 








Inspired by these examples, we focused our attention first on the PKR using the 
internal alkyne substrate 5.27. Enyne 5.27 was first treated with dicobalt octacarbonyl to 
generate the cobalt alkyne complex that was subjected directly to a range of conditions 
known to promote the PKR (Equation 5.5).470 Gratifyingly, GCMS analysis of the crude 
reaction mixtures revealed that trace quantities of the desired adduct 5.41 were formed 
after refluxing the mixture in toluene. Similarly, trace quantities of 5.41 were also 
observed when the reaction was conducted in refluxing dichloroethane in the presence of 
n-BuSMe as a Lewis basic promoter.478 Alternatively, in the presence of 
cyclohexylamine only alkyne 5.27 was observed, resulting from competitive 
demetallation.479 Likewise, the well-established oxidative promoter NMO•H2O only 
returned enyne 5.27. Competitive demetallation of the cobalt-alkyne is a known 
challenge when using these PKR conditions with less reactive substrates, which indicates 
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Nonetheless, we were encouraged by these preliminary findings indicating that 
the cyclized product was formed in small quantities, and we next evaluated the terminal 
alkyne substrate 5.29 using similar conditions. We were pleased to discover that stirring a 
solution of enyne 5.29 and dicobalt octacarbonyl at room temperature for 2 h, followed 
by heating under reflux for 22 h afforded the PKR adduct in 8% yield, along with some 
unreacted starting material (Equation 5.6). Given the modest success of the PKR with 
standard heating conditions, microwave irradiation was pursued as an alternative method 
for promoting the PKR.447,481 Enyne 5.29 was treated with dicobalt octacarbonyl and 
filtered through a short silica plug to afford 5.43 in 91% yield based on mass recovery. 
Gratifyingly, microwave irradiation of a toluene solution of 5.43 at 130 °C provided 
increased consumption of the starting material and 5.42 was isolated in 20% yield 
(Equation 5.7). This suggested that heating under microwave irradiation was superior to 
standard heating methods.  Similar to the reactions conducted with the internal alkyne 
5.27, all attempts to induce the cyclization using known Lewis basic (n-BuSMe, 
tetramethylthiourea, and DMSO) and oxidative promoters (NMO•H2O) did not produce 
detectable quantities of PKR product 5.42. These initial results provided some 
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preliminary experiments and it was clear that additional optimization was required. We 
therefore turned to the desired substrate rather than the model system   
 
 
    
 
 
5.2.2 The Enantiospecific Approach  
We thus focused upon accessing the chiral PKR precursor 5.10 using conditions 
that were developed with the model system. The synthesis commenced with preparation 
of known cyclopentenone 5.11 from commercially available (–)-linalool (5.44) according 
to the reported protocol.449 In the event, ring closing metathesis of 5.44 was catalyzed by 
Hoveyda-Grubbs second generation catalyst (HG II) using solvent-free conditions 
followed by silylation of the intermediate alcohol with TBSCl gave 5.45 (Equation 5.8). 
Subsequent ruthenium catalyzed allylic oxidation afforded cyclopentenone 5.11 in 30% 
yield over two-steps. However, with 5.11 in hand, we pressed ahead toward the PKR 




























Unlike the model system, the carbon center adjacent to the Michael acceptor in 
5.11 is fully substituted, and it was unclear if high levels of diastereoselectivity would be 
achieved in the 1,4–addition.449 Following lithium-halogen exchange of iodoalkyne 5.23, 
the  organolithium was added to a solution of  diethyl ether containing CuI•0.75DMS and 
2-thienyllithium, followed by addition of 5.11 and TMSCl to afford silyl enol ether 5.46 
(Scheme 5.7). Acidic hydrolysis of 5.46 delivered 5.47 in 67% yield along with the minor 
diastereomer in just 3% yield. The stereochemistry was confirmed based analysis of the 
NOESY spectra for the two diastereomers. Presumably the stereochemical outcome of 
the reaction is dictated by the steric bulk of the TBS group on the bottom face of the 
molecule. Subsequent methylenation of 5.47 with Petasis reagent provided enyne 5.48 in 
64% yield and removal of the TMS group delivered the PKR precursor 5.49 in 92% 
yield. 
MeHO
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Scheme 5.7. Synthesis of the enantiopure Pauson-Khan precursor.      
With reliable access to 5.49 thus established, the PKR was first assessed using 
conditions that showed promise in preliminary studies with the model substrate. Enyne 
5.49 was treated with dicobalt octacarbonyl and after filtration through a silica gel plug, 
the cobalt alkyne complex 5.50 was dissolved in toluene and subjected to microwave 
irradiation at 130 °C. Most of the starting material was consumed after heating for four h 
based on GCMS analysis of the crude reaction mixture and the major peak was consistent 
with the molecular weight of cyclized product 5.51, but 5.51 was isolated in only 14% 
yield (Equation 5.9). Alternatively, after stirring a solution of enyne 5.51 and dicobalt 
octacarbonyl in mesitylene at room temperature to generate the cobalt–alkyne complex in 
situ, the solution was directly heated to 130 °C for four h (Equation 5.10). Unlike the 
reaction conducted with microwave irradiation, considerable starting material remained 
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°C and the reaction was stirred for an additional 15 h, at which point the starting material 
was no longer observed, yet 5.51 was isolated in only 7% yield. The yields for each of 
these reactions were consistent with results obtained using the model system and again 
suggested heating with microwave irradiation was somewhat better than conventional 






In an attempt to further optimize the reaction, a brief survey of alternative 
conditions was conducted (Equation 5.11). Microwave irradiation was attempted using 
dichloroethane as a more polar solvent, but this resulted in diminished yields of 5.51 were 
obtained. Heating enyne 5.49 at 130 °C in the presence of n-BuSMe as a Lewis basic 
promoter provided only trace quantities of 5.51. Turning to other metal mediators of 
PKR–like reactions, heating a solution of enyne 5.49 in a mixture of DMF and toluene at 
140 °C in the presence of molybdenum hexacarbonyl, according to the protocol reported 
by Chirkin et al. delivered an intractable mixture.448 Likewise the rhodium–catalyzed 
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produced an intractable mixture.482 Thus, while initial results provided some 
encouragement, it is clear that the PKR with this substrate will require a more extensive 




5.3 SUMMARY  
In summary, we have investigated a novel approach to the  enantiospecific 
synthesis of pierisketolide A that begins from readily available chiral starting materials. 
Conditions were developed for the 1,4-addition of iodoalkyne 5.23 to cyclopentenone 
5.11 that achieved high levels of diastereoselectivity (Scheme 5.8). The PKR precursor 
was accessed in just one to two additional steps, providing a facile entry point for 
additional optimization studies. In addition, enyne 5.49 was shown to be converted 
directly to the bicyclo[3.2.1]octane core of pierisketolide A, providing an initial proof–
of–concept, but additional optimization of this transformation is still needed. Although 
our efforts to improve the yields of the PKR have so far been unsuccessful, we remain 
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Scheme 5.8. Summary of progress towards the total synthesis of pierisketolide A.        
5.4 FUTURE DIRECTIONS 
The rapid assembly of the pierisketolide A core using a PKR from enyne 5.49 
remains a promising entry point to this natural product and a variety of tactics to improve 
this transformation remain to be investigated. For instance, we have shown that 
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thorough screen of solvents and known promoters is needed to determine optimum 
conditions. Similarly, an initial evaluation with the oxidative promoter NMO indicated 
that competitive demetallation was problematic, but recent studies have shown that the 
addition of ethylene glycol can help stabilize the metal-alkyne complex to allow 
coordination of the alkene prior to decomposition.483 There remains an extensive body of 
literature on the PKR including a range of other metal mediators that might also be 
evaluated.484  
Alternatively, a strategy can be envisioned that incorporates a Z-olefin as a 
conformational constraint similar to the strategy utilized in the hetero–PKR reported by 
Chirkin et al. (Scheme 5.9).448 It is plausible that the low reactively observed using 5.49 
stems from the unfavorable conformation that must be adopted for cyclization to occur. 
Thus, preorganization of the substrate in the reactive conformation might be a useful 
tactic to promote cyclization. Although somewhat less direct, this approach might allow 
rapid construction of the tricyclic core and provides a potential path forward.  
 
 




















Chapter 6: Supplementary Information 
6.1 GENERAL EXPERIMENTAL  
Solvents were purified unless otherwise noted before use as follows. 
Tetrahydrofuran (THF) was dried by filtration through two columns of activated, neutral 
alumina according to the procedure described by Grubbs.462 Toluene (PhMe) was filtered 
through one column of activated, neutral alumina and Q5 reactant. Acetonitrile (MeCN) 
was dried by filtration through two columns of activated molecular sieves. These solvents 
were determined to have less than 50 ppm H2O by Karl Fischer coulometric moisture 
analysis. Methylene chloride (CH2Cl2), mesitylene, and 1,3,5-trimethylhexahydro-1,3,5-
triazine were distilled from CaH2, and N-Iodosuccinimide (NIS) was recrystallized from 
dioxane and hexane prior to use. All other reagents and solvents were reagent grade and 
were used as received unless otherwise noted. Dioxane was determined to have less than 
1000 ppm H2O by Karl Fischer coulometric moisture analysis. For air sensitive reactions, 
solvents were sparged with nitrogen or argon for at least 15 min. Reactions were 
performed under a nitrogen or argon atmosphere in round-bottom flasks sealed under 
rubber septa with magnetic stirring. Volatile solvents were removed under reduced 
pressure using a Büchi rotary evaporator at a water-bath temperature of 25–30 °C. Water 
sensitive reactions were performed with flame- or oven-dried glassware, stir-bars, and 
steel needles. Reaction temperatures are reported as the temperatures of the bath 
surrounding the vessel. Sensitive reagents and solvents were transferred using plastic 
syringes and steel needles using standard techniques.  
Analytical HPLC separations were performed using a Chiralcel OD (Daicel 
Chemical Industries, Ltd.) column. Proton nuclear magnetic resonance (1H NMR) and 
carbon nuclear magnetic resonance (13C NMR) spectra were acquired in CDCl3 unless 
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otherwise noted. Chemical shifts are reported in parts per million (ppm, δ), downfield 
from tetramethylsilane (TMS, δ = 0.00 ppm) and are referenced to residual solvent 
(CDCl3, δ = 7.26 ppm (1H) and 77.16 ppm (13C)). Coupling constants (J) are reported in 
hertz (Hz), and the resonance multiplicity abbreviations used are: s, singlet; d, doublet; t, 
triplet; q, quartet; dt, doublet of triplets; dd, doublet of doublets; ddd, doublet of doublet 
of doublets; dddd, doublet of doublet of doublet of doublets; m, multiplet; comp, 
overlapping multiplets of magnetically non-equivalent protons. The abbreviations br and 
app stand for broad and apparent, respectively. Infrared (IR) spectra were obtained with a 
Thermo Nicolet 380 spectrometer. Melting points were determined using a Thomas-
Hoover Uni-melt capillary melting point apparatus. Thin-layer chromatography (TLC) 
was performed on EMD 60 F254 glass- backed pre-coated silica gel plates and were 
visualized using one or more of the following methods: UV light (254 nm) and staining 
with basic potassium permanganate (KMnO4), acidic p-anisaldehyde (PAA), or CAM. 
Flash chromatography was performed using glass columns and with Silicycle® SiliaFlash 
F60® (40-63 µm) silica gel eluting with the solvents indicated according to the procedure 
of Still.485  
1-(Trimethylsiloxy)-1,3-butadiene (ca 9:1 E/Z) is commercially available from 
Sigma-Aldrich or can be prepared according to literature procedure.486 N-Boc-3-
methylindole was prepared according to literature procedure and the 1H and 13C NMR 







6.2 EXPERIMENTAL PROCEDURES  
 
 
5-Chloro-2-vinylbenzaldehyde (1.229) (MDW-4-223). A flask was charged with 
2-bromo-5-chlorobenzaldehyde (2.033 g, 9.314 mmol), potassium vinyltrifluoroborate 
(1.372 g, 10.24 mmol), Cs2CO3 (9.103 g, 27.94 mmol), Pd(OAc)2 (104 mg, 0.463 mmol), 
and PPh3 (244 mg, 0.930 mmol). The flask was evacuated and backfilled with N2 three 
times, whereupon degassed THF (42 mL) and H2O (5 mL) were added sequentially and 
the mixture was stirred at room temperature for 2 min. The flask was transferred to an oil 
bath preheated to 80° C and the reaction was heated under reflux for 6 h. Upon cooling, 
the reaction was diluted with saturated aqueous NaHCO3 (15 mL) and extracted with 
Et2O (3 x 30 mL). The combined organic extracts were washed with brine (1 x 30 mL), 
dried (MgSO4), and concentrated under reduced pressure. The crude residue was purified 
via flash chromatography (SiO2) eluting with hexanes/Et2O (100:1 to 20:1) to afford 
1.222 g (79%) of 1.229 as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 10.25 (s, 1H), 
7.82 – 7.79 (m, 1H), 7.53 – 7.50 (comp, 2H), 7.44 (dd, J = 17.4, 11.0 Hz, 1H), 5.70 (dd, J 
= 17.4, 1.0 Hz, 1H), 5.55 (dd, J = 11.0, 1.0 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
190.9, 139.0, 134.3, 134.0, 133.9, 132.2, 130.4, 129.1, 120.4. HRMS (CI) m/z calcd for 




















NMR Assignments (1.229). 1H NMR (400 MHz, CDCl3) δ 10.25 (s, 1H, 9), 7.82 
– 7.79 (m, 1H, 2), 7.53 – 7.50 (comp, 2H, 3, 6), 7.44 (dd, J = 17.4, 11.0 Hz, 1H, 10), 5.70 
(dd, J = 17.4, 1.0 Hz, 1H, 11), 5.55 (dd, J = 11.0, 1.0 Hz, 1H, 11). 13C NMR (126 MHz, 
CDCl3) δ 190.9 (7), 139.0 (4), 134.3 (5), 134.0 (1), 133.9 (6), 132.2 (10), 130.4 (2), 129.1 
(3), 120.4 (11). 
 
4-Chloro-2-vinylbenzaldehyde (1.230) (MDW-4-222). A flask was charged with 
2-bromo-4-chlorobenzaldehyde (1.531 g, 6.976 mmol), potassium vinyltrifluoroborate 
(0.935 g, 6.98 mmol), Cs2CO3 (6.821 g, 20.93 mmol), Pd(OAc)2 (78 mg, 0.35 mmol), and 
PPh3 (183 mg, 0.698 mmol). The flask was evacuated and backfilled with N2 three times, 
whereupon degassed THF (32 mL) and H2O (4 mL) were added sequentially and the 
mixture was stirred at room temperature for 2 min. The flask was transferred to an oil 
bath preheated to 80° C and the reaction was heated under reflux for 6 h. Upon cooling, 
the reaction was diluted with saturated aqueous NaHCO3 (15 mL) and extracted with 
Et2O (3 x 30 mL). The combined organic extracts were washed with brine (1 x 30 mL), 
dried (MgSO4), and concentrated under reduced pressure. The crude residue was purified 
via flash chromatography (SiO2) eluting with hexanes/Et2O (100:1 to 20:1) to afford 
0.834 g (72%) of 1.230 as a colorless solid: mp 37–40 °C. 1H NMR (400 MHz, CDCl3 ) δ 
10.24 (s, 1H), 7.77 (d, J = 8.3 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.48 (dd, J = 17.4, 11.0 
Hz, 1H), 7.40 (dd, J = 8.3, 2.0 Hz, 1H), 5.73 (dd, J = 17.4, 0.9 Hz, 1H), 5.57 (dd, J = 
11.0, 0.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 191.1, 142.2, 140.4, 132.6, 132.3, 








NMR Assignments (1.230).  1H NMR (400 MHz, CDCl3) δ 10.24 (s, 1H, 9), 7.77 
(d, J = 8.3 Hz, 1H, 6), 7.54 (d, J = 2.1 Hz, 1H, 3), 7.48 (dd, J = 17.4, 11.0 Hz, 1H, 10), 
7.40 (dd, J = 8.3, 2.0 Hz, 1H, 1), 5.73 (dd, J = 17.4, 0.9 Hz, 1H, 11), 5.57 (dd, J = 11.0, 
0.9 Hz, 1H, 11). 13C NMR (126 MHz, CDCl3) δ 191.1 (7), 142.2 (4), 140.4 (5), 132.6 (6), 
132.3 (10), 131.3 (2), 128.3 (1), 127.6 (3), 120.8 (11). 
 
1-(5-Chloro-2-vinylphenyl)-N-methylmethanimine (2.5) (MDW-4-228). A 
solution of MeNH3 (33% in EtOH, 0.32 mL) was added to a solution of 1.229 (0.286 g, 
1.72 mmol) in CH2Cl2 (11 mL) containing MgSO4 (620 mg, 5.51 mmol) and was stirred 
for 11 h. The reaction was filtered, washing with CH2Cl2 (10 mL). The filtrate was 
concentrated under reduced pressure to afford 0.305 g (99%) of 2.5 as a colorless oil that 
was used directly without purification. 1H NMR (400 MHz, CDCl3) δ 8.56 (q, J = 1.7 Hz, 
1H), 7.85 (d, J = 2.3 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.33 (dd, J = 8.4, 2.3 Hz, 1H), 
7.15 (dd, J = 17.4, 11.0 Hz, 1H), 5.62 (dd, J = 17.4, 1.1 Hz, 1H), 5.43 (dd, J = 11.0, 1.1 
Hz, 1H), 3.54 (d, J = 1.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.5, 136.5, 134.7, 
134.1, 133.0, 130.3, 128.3, 127.4, 118.4, 48.8. HRMS (ESI) m/z calcd for C10H10ClN 




















NMR Assignments (2.5). 1H NMR (400 MHz, CDCl3) δ 8.56 (q, J = 1.7 Hz, 1H, 
9), 7.85 (d, J = 2.3 Hz, 1H, 6), 7.40 (d, J = 8.4 Hz, 1H, 3), 7.33 (dd, J = 8.4, 2.3 Hz, 1H, 
2), 7.15 (dd, J = 17.4, 11.0 Hz, 1H, 10), 5.62 (dd, J = 17.4, 1.1 Hz, 1H, 11), 5.43 (dd, J = 
11.0, 1.1 Hz, 1H, 11), 3.54 (d, J = 1.7 Hz, 3H, 13). 13C NMR (126 MHz, CDCl3) δ 159.5 




1-(4-Chloro-2-vinylphenyl)-N-methylmethanimine (2.6) (MDW-4-227). A 
solution of MeNH3 (33% in EtOH, 0.29 mL) was added to a solution of 1.230 (0.256 g, 
1.54 mmol) in CH2Cl2 (10 mL) containing MgSO4 (550 mg, 4.57 mmol) and was stirred 
for 11 h. The reaction was filtered, washing with CH2Cl2 (10 mL). The filtrate was 
concentrated under reduced pressure to afford 0.274 g (99%) of 2.6 as a pale yellow oil 
that was used directly without purification. 1H NMR (400 MHz, CDCl3) δ 8.57 – 8.53 (m, 
1H), 7.78 (d, J = 8.4 Hz, 1H), 7.45 (d, J = 2.2 Hz, 1H), 7.28 (app dd, J = 8.4, 2.1 Hz, 1H), 
7.18 (dd, J = 17.3, 11.0 Hz, 1H), 5.65 (dd, J = 17.3, 1.0 Hz, 1H), 5.46 (dd, J = 11.0, 1.1 
Hz, 1H), 3.53 (d, J = 1.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 159.8, 139.6, 136.4, 
133.0, 131.8, 129.2, 128.1, 126.8, 119.0, 48.8. HRMS (ESI) m/z calcd for C10H10ClN 
























NMR Assignments (2.6). 1H NMR (400 MHz, CDCl3) δ 8.57 – 8.53 (m, 1H, 9), 
7.78 (d, J = 8.4 Hz, 1H, 6), 7.45 (d, J = 2.2 Hz, 1H, 3), 7.28 (dd, J = 8.4, 2.1 Hz, 1H, 1), 
7.18 (app dd, J = 17.3, 11.0 Hz, 1H, 10), 5.65 (dd, J = 17.3, 1.0 Hz, 1H, 11), 5.46 (dd, J = 
11.0, 1.1 Hz, 1H, 11), 3.53 (d, J = 1.7 Hz, 3H, 13). 13C NMR (126 MHz, CDCl3) δ 159.8 




1-(5-Chloro-2-vinylphenyl)-N-methylbut-3-en-1-amine (2.8) (MDW-4-230). A 
solution of allylzinc bromide (0.83 M in THF, 5.0 mL, 4.2 mmol) was added dropwise to 
a solution of crude 2.5 (0.305 g, 1.70 mmol) in THF (8.5 mL) cooled to -78 °C and the 
reaction was stirred at -78 °C for 6 h. The cooling bath was removed and the reaction was 
stirred for 30 min at room temperature. The solution was diluted with saturated aqueous 
NH4Cl (15 mL) and extracted with Et2O (3 x 20 mL). The combined organic extracts 
were washed with brine (1 x 20 mL), dried (MgSO4), and concentrated under reduced 
pressure. The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/Et2O/Et3N (100:5:1 to 100:10:1) to afford 0.303 g (80% from 1.229) of 2.8 as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 2.3 Hz, 1H), 7.37 (d, J = 8.3 Hz, 
1H), 7.18 (ddd, J = 8.3, 2.3, 0.6 Hz, 1H), 7.04 (dd, J = 17.3, 11.0 Hz, 1H), 5.78 – 5.66 



















(comp, 2H), 3.90 (dd, J = 8.3, 4.9 Hz, 1H), 2.44 – 2.35 (m, 1H), 2.31 – 2.21 (comp, 4H), 
1.44 (brs, 1H). 13C NMR (126 MHz, CDCl3) δ 142.8, 135.6, 135.1, 134.1, 133.7, 127.9, 
127.1, 126.4, 118.1, 116.9, 59.6, 42.0, 34.7. HRMS (ESI) m/z calcd for C13H16ClN 
(M+H)+, 222.1044; found 222.1048. 
 
 
NMR Assignments (2.8). 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 2.3 Hz, 1H, 
6), 7.37 (d, J = 8.3 Hz, 1H, 3), 7.18 (ddd, J = 8.3, 2.3, 0.6 Hz, 1H, 2), 7.04 (dd, J = 17.3, 
11.0 Hz, 1H, 10), 5.78 – 5.66 (m, 1H, 13), 5.58 (dd, J = 17.3, 1.3 Hz, 1H, 11), 5.32 (dd, J 
= 11.0, 1.3 Hz, 1H, 11), 5.14 – 5.05 (comp, 2H, 14), 3.90 (dd, J = 8.3, 4.9 Hz, 1H, 7), 
2.44 – 2.35 (m, 1H, 9), 2.31 – 2.21 (comp, 4H, 9, 15), 1.44 (brs, 1H, 8).13C NMR (126 
MHz, CDCl3) δ 142.8 (1), 135.6 (4), 135.1 (13), 134.1 (5), 133.7 (10), 127.9 (3), 127.1 
(2), 126.4 (6), 118.1 (14), 116.9 (11), 59.6 (7), 42.0 (9), 34.7 (15). 
 
 
1-(4-Chloro-2-vinylphenyl)-N-methylbut-3-en-1-amine (2.9) (MDW-4-229). A 
solution of allylzinc bromide (0.83 M in THF, 4.4 mL, 3.7 mmol) was added dropwise to 
a solution of crude 2.6 (0.274 g, 1.52 mmol) in THF (7.4 mL) cooled to -78 °C and the 
reaction was stirred at -78 °C for 6 h. The cooling bath was removed and the reaction was 
stirred for 30 min at room temperature. The solution was diluted with saturated aqueous 























were washed with brine (1 x 20 mL), dried (MgSO4), and concentrated under reduced 
pressure. The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/Et2O/Et3N (100:5:1 to 100:10:1) to afford 0.301 g (88% from 1.230) of 2.9 as a 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.39 (comp, 2H), 7.24 (app dd, J = 
8.3, 2.3 Hz, 1H), 7.06 (dd, J = 17.3, 11.0 Hz, 1H), 5.77 – 5.64 (m, 1H), 5.60 (dd, J = 
17.3, 1.3 Hz, 1H), 5.35 (dd, J = 10.9, 1.3 Hz, 1H), 5.13 – 5.04 (comp, 2H), 3.89 (dd, J = 
8.1, 5.2 Hz, 1H), 2.43 – 2.35 (m, 1H), 2.32 – 2.22 (comp, 4H), 1.46 (brs, 1H). 13C NMR 
(126 MHz, CDCl3) δ 139.2, 138.9, 135.1, 133.6, 132.6, 128.0, 128.0, 126.4, 118.0, 117.5, 




NMR Assignments (2.9). 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.39 (comp, 2H, 
3, 6), 7.24 (app dd, J = 8.3, 2.3 Hz, 1H, 1), 7.06 (dd, J = 17.3, 11.0 Hz, 1H, 10), 5.77 – 
5.64 (m, 1H, 13), 5.60 (dd, J = 17.3, 1.3 Hz, 1H, 11), 5.35 (dd, J = 10.9, 1.3 Hz, 1H, 11), 
5.13 – 5.04 (comp, 2H, 14), 3.89 (dd, J = 8.1, 5.2 Hz, 1H, 7), 2.43 – 2.35 (m, 1H, 9), 2.32 
– 2.22 (comp, 4H, 9, 15), 1.46 (brs, 1H, 8). 13C NMR (126 MHz, CDCl3) δ 139.2 (2), 
138.9 (4), 135.1 (13), 133.6 (10), 132.6 (5), 128.0 (3), 128.0 (1), 126.4 (6), 118.0 (14), 




















Representative Procedure A: Reaction of an amine with benzyl chloroformate. 
 
 
Benzyl (1-(5-chloro-2-vinylphenyl)but-3-en-1-yl)(methyl)carbamate (2.10) 
(MDW-4-236). A solution of 2.8 (0.278 g, 1.25 mmol) and i-Pr2NEt (0.33 g, 0.44 mL 2.5 
mmol) in CH2Cl2 (6 mL) was cooled to 0 ° C. CbzCl (0.31 g, 0.26 mL, 1.8 mmol) was 
added dropwise to the cooled solution and the reaction was stirred for 5 h at 0 °C. The 
cooling bath was removed and the solution was stirred at room temperature for 2 h. The 
reaction was quenched with 1 N HCl (10 mL) and the aqueous layer was extracted with 
CH2Cl2 (1 x 10 mL). The organic extract was washed with saturated aqueous NaHCO3 (1 
x 15 mL) and the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined 
organic extracts were washed with brine (1 x 20 mL), dried (Na2SO4), and concentrated 
under reduced pressure. The crude residue was purified via flash chromatography (SiO2) 
eluting with hexanes/EtOAc (20:5) to afford 0.443 g (99%) of 2.10 as a colorless oil. 1H 
NMR (500 MHz, 130 °C, DMSO-d6) δ 7.50 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 2.2 Hz, 1H), 
7.38 – 7.28 (comp, 6H), 6.94 (dd, J = 17.2, 11.0 Hz, 1H), 5.81 – 5.71 (m, 1H), 5.58 (dd, J 
= 17.3, 1.4 Hz, 1H), 5.47 (dd, J = 8.8, 6.5 Hz, 1H), 5.22 (dd, J = 11.0, 1.3 Hz, 1H), 5.17 – 
5.09 (m, 3H), 5.02 (dd, J = 10.3, 1.7 Hz, 1H), 2.78 – 2.65 (m, 2H), 2.63 (s, 3H). 13C NMR 
(126 MHz, 130 °C, DMSO-d6) δ 154.8, 138.1, 136.4, 135.8, 134.0, 132.7, 131.7, 127.5, 
127.5, 126.9, 126.9, 126.8, 126.4, 116.4, 116.2, 65.9, 54.0, 33.9, 28.4. HRMS (ESI) m/z 









NMR Assignments (2.10). 1H NMR (500 MHz, 130 ° C, DMSO-d6) δ 7.50 (d, J 
= 8.3 Hz, 1H, 3), 7.40 (d, J = 2.2 Hz, 1H, 6), 7.38 – 7.28 (comp, 6H, 2, 15, 16, 17, 18, 
20), 6.94 (dd, J = 17.2, 11.0 Hz, 1H, 10), 5.81 – 5.71 (m, 1H, 13), 5.58 (dd, J = 17.3, 1.4 
Hz, 1H, 11), 5.47 (dd, J = 8.8, 6.5 Hz, 1H, 7), 5.22 (dd, J = 11.0, 1.3 Hz, 1H, 11), 5.17 – 
5.09 (comp, 3H, 14, 21), 5.02 (dd, J = 10.3, 1.7 Hz, 1H, 21), 2.78 – 2.65 (m, 2H, 9), 2.63 
(s, 3H, 25). 13C NMR (126 MHz, 130 ° C, DMSO-d6) δ 154.8 (23), 138.1 (1), 136.4 (4), 
135.8 (5), 134.0 (13), 132.7 (10), 131.7 (19), 127.5 (18, 20), 127.5 (16), 126.9 (3), 126.9 




Benzyl (1-(4-chloro-2-vinylphenyl)but-3-en-1-yl)(methyl)carbamate (2.11) 
(MDW-4-235). Prepared from 2.9 (0.276 g, 1.24 mmol) and CbzCl according to 
representative procedure A. The crude residue was purified via flash chromatography 
(SiO2) eluting with hexanes/EtOAc (20:5) to afford 0.409 g (92%) of 2.11 as a colorless 
oil. 1H NMR (500 MHz, 80 °C, DMSO-d6) δ 7.52 (d, J = 2.3 Hz, 1H), 7.44 (d, J = 8.4 
Hz, 1H), 7.40 – 7.29 (comp, 6H), 6.93 (dd, J = 17.2, 11.0 Hz, 1H), 5.78 – 5.71 (m, 1H), 
5.68 (dd, J = 17.2, 1.2 Hz, 1H), 5.48 (dd, J = 9.0, 6.4 Hz, 1H), 5.23 (d, J = 11.0 Hz, 1H), 


































NMR (126 MHz, DMSO-d6) δ 154.8, 139.1, 136.4, 134.8, 134.1, 132.6, 132.1, 128.5, 
127.5, 127.0, 126.8, 126.5, 125.3, 116.9, 116.4, 65.9, 53.8, 34.1, 28.2. HRMS (ESI) m/z 
calcd for C21H22ClNO2 (M+Na)+, 378.1231; found 378.1234. 
 
 
NMR Assignments (2.11). 1H NMR (500 MHz, 80 °C, DMSO-d6) δ 7.52 (d, J = 
2.3 Hz, 1H, 3), 7.44 (d, J = 8.4 Hz, 1H, 6), 7.40 – 7.29 (comp, 6H, 1, 15, 16, 17, 18, 20), 
6.93 (dd, J = 17.2, 11.0 Hz, 1H, 10), 5.78 – 5.71 (m, 1H, 13), 5.68 (dd, J = 17.2, 1.2 Hz, 
1H, 11), 5.48 (dd, J = 9.0, 6.4 Hz, 1H, 7), 5.23 (d, J = 11.0 Hz, 1H, 21), 5.16 – 5.09 
(comp, 3H, 14, 21), 5.03 – 4.98 (m, 1H, 11), 2.76 – 2.62 (comp, 2H, 9), 2.55 (s, 3H, 25). 
13C NMR (126 MHz, 130 ° C, DMSO-d6) δ 154.8 (23), 139.1 (2), 136.4 (4), 134.8 (5), 
134.1, 132.6, 132.1 (19), 128.5 (3), 127.5 (18, 20), 127.0 (16), 126.8 (15, 17), 126.5 (1), 
125.3 (6), 116.9 (14), 116.4 (11), 65.9 (21), 53.8 (7), 34.1 (9), 28.2 (25). 
 
 
Benzyl (7-chloro-1,2-dihydronaphthalen-1-yl)(methyl)carbamate (2.12) 
(MDW-1-156). Grubbs second generation catalyst (0.163 g, 0.192 mmol) was added to a 
solution of 2.10 (1.36 g, 3.83 mmol) in CH2Cl2 (77 mL) and the reaction was stirred at 
room temperature for 2 h. DMSO (0.7 mL) was added to the reaction and the solution 
































hexanes/EtOAc (85:15) and the filtrate was concentrated under reduced pressure. The 
crude residue was purified via flash chromatography (SiO2) eluting with hexanes/EtOAc 
(92:8) to afford 1.11 g (88%) of 2.12 as a pale yellow oil. 1H NMR (500 MHz, 130 °C, 
DMSO-d6) δ 7.39 – 7.35 (comp, 4 H), 7.34 – 7.29 (m, 1 H), 7.26 (ddd, J = 8.1, 2.2, 0.8 
Hz, 1 H), 7.15 (d, J = 8.1 Hz, 1 H), 7.06 – 7.03 (m, 1 H), 6.50 – 6.45 (m, 1 H), 6.12 – 
6.07 (m, 1 H), 5.44 (t, J = 9.2 Hz, 1 H), 5.18 (s, 2 H), 2.77 (s, 3 H), 2.58 – 2.53 (comp, 2 
H). 13C NMR (126 MHz, 130 °C, DMSO-d6) δ 154.9, 136.4, 134.9, 132.3, 131.3, 127.6, 
127.3, 127.0, 126.8, 126.7, 126.7, 125.0, 125.0, 66.0, 51.9, 29.4, 26.5. HRMS (ESI) m/z 
calcd for C19H18ClNO2 (M+Na)+,  350.0918; found 350.0922. 
 
 
NMR Assignments (2.12). 1H NMR (500 MHz, 130 °C, DMSO-d6) δ 7.39 – 7.35 
(comp, 4H, 13, 15, 16, 18), 7.34 – 7.29 (m, 1H, 14), 7.26 (ddd, J = 8.1, 2.2, 0.8 Hz, 1H, 
2), 7.15 (d, J = 8.1 Hz, 1H, 3), 7.06 – 7.03 (m, 1H, 6), 6.50 – 6.45 (m, 1H, 10), 6.12 – 
6.07 (m, 1H, 11), 5.44 (t, J = 9.2 Hz, 1H, 7), 5.18 (s, 2H, 19), 2.77 (s, 3H, 23), 2.58 – 
2.53 (comp, 2H, 9). 13C NMR (126 MHz, 130 °C, DMSO-d6) δ 154.9 (21), 136.4 (1), 
134.9 (4), 132.3 (5), 131.3 (17), 127.6 (16, 18), 127.3 (11), 127.0 (3), 126.8 (10), 126.7 

































Benzyl (7-chloro-1,2-dihydronaphthalen-1-yl)(methyl)carbamate (2.13) 
(MDW-1-74). Grubbs second generation catalyst (20 mg, 0.024 mmol) was added to a 
solution of 2.11 (163 mg, 0.458 mmol) in CH2Cl2 (23 mL) and the reaction was stirred at 
room temperature for 2 h. The reaction was filtered through a short SiO2 plug rinsing with 
CH2Cl2 and the filtrate was concentrated under reduced pressure. The crude residue was 
purified via flash chromatography (SiO2) eluting with hexanes/EtOAc (92:82 to 90:10) to 
afford 134 mg (89%) of 2.13 as a pale yellow oil. 1H NMR (500 MHz, 80 °C, DMSO-d6) 
δ 7.40 – 7.30 (comp, 5H), 7.25 – 7.21 (comp, 2H), 7.06 (d, J = 7.9 Hz, 1H), 6.48 (dt, J = 
9.7, 2.0 Hz, 1H), 6.17 – 6.12 (m, 1H), 5.43 (t, J = 9.2 Hz, 1H), 5.15 (s, 2H), 2.73 (s, 3H), 
2.57 – 2.52 (comp, 2H). 13C NMR (126 MHz, 80 °C, DMSO-d6) δ 155.1, 136.6, 135.7, 
131.9, 131.5, 128.3, 127.9, 127.3, 127.3, 127.0, 126.7, 125.5, 125.3, 66.2, 51.6, 29.4, 
26.9.  
 
NMR Assignments (2.13). 1H NMR (500 MHz, 80 °C, DMSO-d6) δ 7.40 – 7.30 
(comp, 5H, 13, 14, 15, 16, 18), 7.25 – 7.21 (comp, 2H, 1, 3), 7.06 (d, J = 7.9 Hz, 1H, 6), 
6.48 (dt, J = 9.7, 2.0 Hz, 1H, 10), 6.17 – 6.12 (m, 1H, 11), 5.43 (t, J = 9.2 Hz, 1H, 7), 
5.15 (s, 2H, 19), 2.73 (s, 3H, 23), 2.57 – 2.52 (comp, 2H, 9). 13C NMR (126 MHz, 80 °C, 
DMSO-d6) δ 155.1 (21), 136.6 (2), 135.7 (4), 131.9 (5), 131.5 (17), 128.3 (3), 127.9 (16, 
18), 127.3 (11), 127.3 (14), 127.0 (13, 15), 126.7 (1), 125.5 (10), 125.3 (6), 66.2 (19), 



























Benzyl (7-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)(methyl)carbamate (2.14) 
(MDW-1-158). A solution of ethanol (9 mL) containing 2.12 (0.300 g, 0.915 mmol) and 
PtO2 (10.3 mg, 0.0440 mmol) was sparged with H2 gas for 5 min and then stirred under 
an atmosphere of H2 (1 atm) for 2 h. The reaction was filtered through a pad of Celite and 
the filter cake was washed with CH2Cl2 (20 mL). The filtrate was concentrated under 
reduced pressure and the crude residue was purified via flash chromatography (SiO2) 
eluting with hexanes/EtOAc (4:1) to afford 0.240 g (78%) of 2.14 as a colorless oil. 1H 
NMR (500 MHz, DMSO-d6) δ 7.39 – 7.29 (comp, 5H), 7.17 (dd, J = 8.2, 2.1 Hz, 1H), 
7.13 (d, J = 8.2 Hz, 1H), 7.02 – 6.99 (m, 1H), 5.24 (dd, J = 9.8, 5.9 Hz, 1H), 5.18 (s, 2H), 
2.76 – 2.70 (comp, 2H), 2.68 (s, 3H), 2.03 – 1.91 (comp, 2H), 1.89 – 1.82 (m, 1H), 1.79 – 
1.70 (m, 1H). 13C NMR (126 MHz, DMSO) δ 155.4, 137.2, 136.5, 130.1, 130.1, 127.6, 
127.0, 126.6, 126.0, 125.3, 103.6, 65.9, 54.3, 29.5, 27.6, 26.2, 20.6. HRMS (ESI) m/z 
calcd for C19H20ClNO2 (M+Na)+, 352.1075; found 352.1079.   
 
 
NMR Assignments (2.14). 1H NMR (500 MHz, DMSO-d6) δ 7.39 – 7.29 (comp, 
5H, 13, 14, 15, 16, 18), 7.17 (dd, J = 8.2, 2.1 Hz, 1H, 2), 7.13 (d, J = 8.2 Hz, 1H, 3), 7.02 
– 6.99 (m, 1H, 6), 5.24 (dd, J = 9.8, 5.9 Hz, 1H, 7), 5.18 (s, 2H, 19), 2.76 – 2.70 (comp, 
































1.70 (m, 1H, 11). 13C NMR (126 MHz, DMSO) δ 155.4 (21), 137.2, 136.5, 130.1, 130.1, 
127.6, 127.0, 126.6, 126.0 (14), 125.3 (6), 103.6, 65.9 (19), 54.3 (7), 29.5 (23), 27.6 (10), 
26.2 (9), 20.6 (11). 
 
 
Benzyl (6-chloro-1,2,3,4-tetrahydronaphthalen-1-yl)(methyl)carbamate (2.15) 
(MDW-1-121). A solution of ethanol (20 mL) containing 2.13 (0.639 g, 1.95 mmol) and 
PtO2 (22.1 mg, 0.0973 mmol) was sparged with H2 gas for 5 min and then stirred under 
an atmosphere of H2 (1 atm) for 2 h. The reaction was filtered through a pad of Celite and 
the filter cake was washed with CH2Cl2 (20 mL). The filtrate was concentrated under 
reduced pressure and the crude residue was purified via flash chromatography (SiO2) 
eluting with hexanes/EtOAc (4:1) to afford 0.575 g (89%) of 2.15 as a colorless oil. 1H 
NMR (500 MHz, 130 °C, DMSO-d6) δ 7.40 – 7.29 (comp, 5H), 7.17 – 7.14 (comp, 2H), 
7.04 – 7.00 (m, 1H), 5.26 – 5.21 (m, 1H), 5.17 (s, 2H), 2.81 – 2.68 (comp, 2H), 2.65 (s, 
3H), 2.03 – 1.91 (comp, 2H), 1.89 – 1.70 (comp, 2H). 13C NMR (126 MHz, 130 °C, 
DMSO-d6) δ 155.4, 139.9, 136.5, 133.8, 130.7, 127.7, 127.7, 127.6, 126.9, 126.6, 125.2, 
65.8, 54.0, 29.4, 28.0, 26.4, 20.5. HRMS (ESI) m/z calcd for C19H20ClNO2 (M+Na)+, 
































NMR Assignments (2.15). 1H NMR (500 MHz, 130 °C, DMSO-d6) δ 7.40 – 
7.29 (comp, 5H, 13, 14, 15, 16, 18), 7.17 – 7.14 (comp, 2H, 1, 3), 7.04 – 7.00 (m, 1H, 6), 
5.26 – 5.21 (m, 1H, 7), 5.17 (s, 2H, 19), 2.81 – 2.68 (comp, 2H, 10), 2.65 (s, 3H, 23), 
2.03 – 1.91 (comp, 2H, 9, 11), 1.89 – 1.70 (comp, 2H, 9, 11). 13C NMR (126 MHz, 130 
°C, DMSO-d6) δ 155.4 (21), 139.9 (4), 136.5 (17), 133.8 (5), 130.7 (2), 127.7 (3), 127.7 
(1), 127.6 (16, 18), 126.9 (14), 126.6 (13, 15), 125.2 (6), 65.8 (19), 54.0 (7), 29.4 (10), 
28.0 (9), 26.4 (23), 20.5 (11). 
Representative Procedure B: Buchwald-Hartwig amination using Pd(OAc)2 and  




yl)carbamate (2.16) (MDW-1-164). A sealable tube was charged with 2.14 (0.679 g, 
2.06 mmol), NaOt-Bu (0.296 g, 3.09 mmol), and piperazine (0.887 g, 10.3 mmol). The 
tube was evacuated and backfilled with N2 three times, whereupon degassed PhMe (4.1 
mL) was added and the mixture was stirred for 5 min. A freshly prepared PhMe solution 
containing Pd(OAc)2 (22 mg, 0.096 mmol) and JohnPhos (29 mg, 0.096 mmol) that had 
been stirred at room temperature for 30 min was added. The tube was sealed, and the 
reaction was stirred at 100 °C for 5 h. After cooling to room temperature, the mixture was 
filtered through Celite and the filter cake was washed with CH2Cl2 (20 mL). The filtrate 
was concentrated and the residue was dissolved in CH2Cl2 (20 mL), washed saturated 








acidic extracts were made basic with 6 N NaOH and extracted with CH2Cl2 (3 x 50 mL), 
after which the combined organic extracts were dried (Na2SO4) and concentrated. The 
crude residue was purified via flash chromatography (SiO2) eluting with 
CH2Cl2/MeOH/Et3N (100:0:1 to 100:4:1) to afford 0.439 g (56%) of 2.16 as an orange 
yellow oil. 1H NMR (400 MHz, CDCl3) (rotamers) δ 7.43 – 7.23 (comp, 5H), 6.97 (d, J = 
8.4 Hz, 1H), 6.77 – 6.71 (m, 1H), 6.60 (dd, J = 10.8, 2.1 Hz, 1H), 5.51 – 5.31 (m, 1H), 
5.31 – 5.09 (comp, 2H), 3.06 – 2.92 (comp, 8H), 2.73 – 2.59 (comp, 5H), 2.09 – 1.87 
(comp, 3H), 1.83 – 1.64 (comp, 2H). 13C NMR (101 MHz, CDCl3) (rotamers) δ 157.1, 
156.8, 150.4, 150.4, 137.1, 137.0, 135.7, 135.6, 130.0, 129.8, 129.8, 129.6, 128.5, 127.9, 
127.8, 127.7, 115.6, 115.4, 114.5, 114.2, 67.0, 67.0, 55.5, 55.3, 50.7, 50.6, 46.1, 30.2, 
29.6, 28.7, 28.6, 28.1, 27.6, 22.2, 22.1. HRMS (ESI) m/z calcd for C24H31N3O2 (M+H)+,  
380.233; found 380.2335. 
 
 
NMR Assignments (2.16). 1H NMR (400 MHz, CDCl3) rotamers δ 7.43 – 7.23 
(comp, 5H, 19, 20, 21, 22, 24), 6.97 (d, J = 8.4 Hz, 1H, 3), 6.77 – 6.71 (m, 1H, 6), 6.60 
(dd, J = 10.8, 2.1 Hz, 1H, 2), 5.51 – 5.31 (m, 1H, 7), 5.31 – 5.09 (comp, 2H, 25), 3.06 – 
2.92 (comp, 8H, 14, 15, 17, 18), 2.73 – 2.59 (comp, 5H, 10, 13), 2.09 – 1.87 (comp, 3H, 
9, 12, 16), 1.83 – 1.64 (comp, 2H, 9, 12). 13C NMR (101 MHz, CDCl3) rotamers δ 157.1 
(27), 156.8 (27), 150.4 (1), 150.4 (1), 137.1 (5), 137.0 (5), 135.7 (23), 135.6 (23), 130.0 
(4), 129.8 (3), 129.8 (3), 129.6 (4), 128.5 (19, 21), 127.9 (22, 24), 127.8 (22, 24), 127.7 


































50.7 (14, 18), 50.6 (14, 18), 46.1 (15, 17), 30.2 (13), 29.6 (13), 28.7 (10), 28.6 (10), 28.1 
(9), 27.6 (9), 22.2 (12), 22.1 (12). 
Representative Procedure C: Buchwald-Hartwig amination using Pd2(dba)3 and  




yl)carbamate (2.16) (MDW-2-283). A sealable tube was charged with 2.29 (1.494 g, 
3.949 mmol), NaOt-Bu (0.572 g, 5.95 mmol), and piperazine (1.708 g, 19.83 mmol). The 
tube was evacuated and backfilled with N2 three times, whereupon degassed THF (22 
mL) was added and the mixture was stirred at 50 °C for 10 min. A freshly prepared THF 
solution containing Pd2(dba)3 (73 mg, 0.080 mmol) and RuPhos (74 mg, 0.16 mmol) that 
had been stirred at 50 °C for 30 min was added. The tube was sealed, and the reaction 
was stirred at 70 °C for 6 h. After cooling to room temperature, the mixture was filtered 
through Celite and the filter cake was washed with CH2Cl2 (100 mL). The filtrate was 
concentrated and the residue was dissolved in CH2Cl2 (30 mL), washed with 1 N NaOH 
(3 x 30 mL), and brine (1 x 30 mL). The organic layer was dried (Na2SO4) and 
concentrated. The crude residue was purified via flash chromatography (SiO2) eluting 
with CH2Cl2/MeOH/Et3N (97:2:) to afford 1.365 g (91%) of 2.16 as an orange yellow oil. 











yl)carbamate (2.17) (MDW-4-233). Paraformaldehyde (64 mg, 2.1 mmol) and 
CH3CO2H (20 µL) were added to a solution of 2.16 (27 mg, 0.071 mmol) in DCE (1.4 
mL) and the reaction was stirred for 20 h. Additional paraformaldehyde (64 mg, 2.1 
mmol) was added and the reaction was stirred for 3 h until the starting material was 
consumed by TLC. The reaction was diluted with saturated aqueous NaHCO3 (5 mL) and 
extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried (Na2SO4), 
and concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with EtOAc/hexanes/Et3N (70:29:1) to afford 15 mg 
(54%) of 2.17 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.28 (comp, 5H), 
6.99 (d, J = 8.4 Hz, 1H), 6.76 (dt, J = 8.4, 2.9 Hz, 1H), 6.62 (dd, J = 9.9, 2.6 Hz, 1H), 
5.50 – 5.31 (m, 1H), 5.31 – 5.10 (comp, 2H), 3.22 – 3.05 (comp, 4H), 2.75 – 2.56 (comp, 
9H), 2.43 – 2.37 (comp, 2H), 2.07 – 1.91 (comp, 2H), 1.85 – 1.68 (comp, 2H). 13C NMR 
(101 MHz, CDCl3) δ 157.4, 157.1, 149.8, 149.7, 137.2, 137.1, 136.0, 135.9, 130.5, 130.0, 
130.0, 128.6, 128.1, 127.9 127.9, 115.7, 115.4, 114.9,114.6, 67.3, 67.2, 55.7, 55.5, 55.1, 
55.0, 49.3, 49.2, 46.0, 30.4, 29.8, 28.9, 28.8, 28.2, 27.7, 22.3, 22.2. HRMS (ESI) m/z 











































NMR Assignments (2.17) 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.28 (comp, 5H, 
13, 14, 15, 16, 18), 6.99 (d, J = 8.4 Hz, 1H, 3), 6.76 (dt, J = 8.4, 2.9 Hz, 1H, 6), 6.62 (dd, 
J = 9.9, 2.6 Hz, 1H, 2), 5.50 – 5.31 (m, 1H, 7), 5.31 – 5.10 (comp, 2H, 19), 3.22 – 3.05 
(comp, 4H, 24, 26), 2.75 – 2.56 (comp, 9H, 10, 23, 27, 28), 2.43 – 2.37 (comp, 2H, 29), 
2.07 – 1.91 (comp, 2H, 9, 11), 1.85 – 1.68 (comp, 2H, 9, 11). 13C NMR (101 MHz, 
CDCl3) δ 157.4 and 157.1 (21), 149.8 and 149.7 (1), 137.2 and 137.1 (5), 136.0 and 135.9 
(17), 130.5 (4), 130.0 and 130.0 (3), 128.6 (13, 15), 128.1 (14), 127.9, 127.9 (16, 18), 
115.7 and 115.4 (6), 114.9 and 114.6 (2), 67.3 and 67.2 (19), 55.7, and 55.5 (7), 55.1 and 
55.0 (23, 27), 49.3 and 49.2 (24, 26), 46.0 (29), 30.4 and 29.8 (28), 28.9 and 28.8 (10), 




yl)carbamate (2.19) (MDW-2-133). A sealable tube was charged with 2.14 (0.220 g, 
0.667 mmol), 4-trifluoromethylphenylboronic acid (0.254 g, 1.34 mmol), cesium 
carbonate (0.435 g, 1.34 mmol), and Pd(t-Bu3P)2 (0.17 g, 0.033 mmol). The flask was 
evacuated and backfilled with N2 three times, whereupon degassed 1,4-dioxane (1.7 mL) 
was added. The tube was sealed and the reaction was stirred at 100 °C for 6 h. After 
cooling to room temperature, the reaction was diluted with CH2Cl2 (20 mL) and washed 
with1 N NaOH (1 x 20 mL). The organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (2 x 20 mL). The combined organic extracts were dried (Na2SO4) 
and concentrated under reduced pressure. The crude residue was purified via flash 





2.19 as a pale yellow oil. 1H NMR (400 MHz, CDCl3)) δ 7.76 – 7.57 (comp, 4 H), 7.52 – 
7.31 (comp, 7 H), 7.25 (d, J = 8.0 Hz, 1 H), 5.72 – 5.19 (comp, 3 H), 2.96 – 2.71 (comp, 
5 H), 2.22 – 2.03 (comp, 2 H), 1.99 – 1.80 (comp, 2 H). 13C NMR (101 MHz, CDCl3) 
rotamers δ 157.3, 156.9, 144.6, 144.3, 138.8, 138.5, 137.8, 137.7, 137.0, 137.0, 136.2, 
136.1, 130.0, 130.0, 129.4, 129.3, 129.0, 129.0, 128.5, 128.5, 128.0, 127.9, 127.8, 127.8, 
127.3, 127.2, 125.8, 125.7, 125.7, 125.7, 125.6, 123.0, 67.3, 55.5, 55.3, 30.3, 29.7, 29.3, 




NMR Assignments (2.19). 1H NMR (400 MHz, CDCl3) rotamers δ 7.76 – 7.57 
(comp, 4H, 13, 14, 16, 17), 7.52 – 7.31 (comp, 7H, 2, 6, 18, 19, 20, 21, 23), 7.25 (d, J = 
8.0 Hz, 1H, 3), 5.72 – 5.19 (comp, 3H, 7, 24), 2.96 – 2.71 (comp, 5H, 9, 32), 2.22 – 2.03 
(comp, 2H, 11, 12), 1.99 – 1.80 (comp, 2H, 11, 12). 13C NMR (101 MHz, CDCl3) 
rotamers δ 157.3 and 156.9 (26), 144.6 and 144.3 (10), 138.8 and 138.5 (1), 137.8 and 
137.7 (5), 137.0 and 137.0 (4), 136.2 and 136.1 (22), 130.0 and 130.0 (3), 129.2 (d, J = 
32.4, rotamers) (15), 128.5 and 128.5 (18, 20), 128.0 (21, 23), 127.9 (19), 127.8 and 
127.8 (6), 127.3 and 127.2 (13, 17), 125.8 (2), 125.7 (JC-F = comp, rotamers) (14, 16), 
123.0 (28), 67.3 (24), 55.5 and 55.3 (7), 30.3 and 29.7 (32), 29.3 and 29.3 (9), 28.0 and 






































amine hydrate (2.20) (MDW-1-275). A solution of ethanol (6 mL) containing 2.19 
(0.130 g, 0.296 mmol) and 10% Pd/C (47 mg) was sparged with H2 gas for 5 min and 
then stirred under an atmosphere of H2 (1 atm) for 14 h. The reaction was filtered through 
a pad of Celite and the filter cake was washed with CH2Cl2 (20 mL) to provide 0.085 g 
(94%) of 2.20 as a colorless oil that was of sufficient purity to use without additional 
purification. 1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.97 (d, J = 1.9 Hz, 1H), 7.80 
(d, J = 8.1 Hz, 2H), 7.60 (d, J = 8.1 Hz, 2H), 7.43 (dd, J = 8.0, 1.8 Hz, 1H), 7.15 (d, J = 
8.0 Hz, 1H), 4.23 (t, J = 5.1 Hz, 1H), 2.93 – 2.64 (m, 2H), 2.48 (s, 3H), 2.20 – 2.03 (m, 




1-yl)amino)propanoate (2.22) (MDW-2-34). A solution of crude 2.20 (65 mg, 0.21 
mmol) and ethyl acrylate (0.21 g, 0.23 mL, 2.1 mmol) in CH2Cl2 (1.1 mL) was stirred at 
40 °C for 21 h. The reaction was concentrated and the crude residue was purified via 
flash chromatography (SiO2) eluting with hexanes/Et3N (99:1) affording 64 mg (74%) of 
2.22 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.90 (dd, J = 2.3, 1.0 Hz, 1H), 7.74 
– 7.63 (comp, 4H), 7.36 (dd, J = 7.9, 2.2 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 4.08 (qd, J = 







2H), 2.59 – 2.44 (comp, 2H), 2.24 (s, 3H), 2.09 – 1.95 (comp, 2H), 1.76 – 1.65 (comp, 
2H), 1.18 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.0, 145.2, 139.5, 138.6, 
137.3, 129.5, 129.0 (d, J = 32.5), 127.4, 127.0, 125.7 (q, J = 3.8, 14, 16), 125.1, 123.5, 
62.7, 60.4, 49.7, 37.0, 34.5, 29.8, 22.2, 21.0, 14.4. HRMS (ESI) m/z calcd for 
C23H26F3NO2 (M+H)+, 406.1988; found 406.1991. 
 
 
NMR Assignments (2.22). 1H NMR (400 MHz, CDCl2) δ 7.90 (dd, J = 2.3, 1.0 
Hz, 1H, 6), 7.74 – 7.63 (comp, 4H, 13, 14, 16, 17), 7.36 (dd, J = 7.9, 2.2 Hz, 1H, 2), 7.15 
(d, J = 7.9 Hz, 1H, 3), 4.08 (qd, J = 7.2, 1.3 Hz, 2H, 29), 3.97 – 3.89 (m, 1H, 7), 2.86 (td, 
J = 7.1, 3.6 Hz, 2H, 18), 2.83 – 2.74 (comp, 2H, 9), 2.59 – 2.44 (comp, 2H, 19), 2.24 (s, 
3H, 22), 2.09 – 1.95 (comp, 2H, 11, 12), 1.76 – 1.65 (comp, 2H, 11, 12), 1.18 (t, J = 7.1 
Hz, 3H, 28). 13C NMR (126 MHz, CDCl3) δ 173.0 (20), 145.2 (10), 139.5 (1), 138.6 (5), 
137.3 (4), 129.5 (3), 129.0 (d, J = 32.5) (15), 127.4 (13, 17), 127.0 (6), 125.7 (q, J = 3.8) 
(14, 16), 125.1 (2), 123.5 (23), 62.7 (7), 60.4 (29), 49.7 (18), 37.0 (22), 34.5 (19), 29.8 











































solution of 2.22 (29 mg, 0.702 mmol) in THF (0.7 mL) cooled to 0 °C. The reaction was 
stirred at 0 °C for 1 h and the cooling bath was removed. The reaction was stirred for 24 
h at room temperature and quenched with saturated aqueous NH4Cl (1 mL). The aqueous 
layer was extracted with CH2Cl2 (3 x 5 mL), and the combined organic extracts were 
dried (Na2SO2) and concentrated under reduced pressure. The crude residue was purified 
via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (79:20:1) affording 
12.8 mg (50%) of 2.23 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.81 (m, 
1H), 7.74 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.2 Hz, 3H), 7.41 (dd, J = 7.9, 2.0 Hz, 1H), 
7.18 (d, J = 7.9 Hz, 1H), 4.15 – 4.07 (m, 1H), 3.87 – 3.71 (comp, 2H), 2.82 – 2.74 (comp, 
4H), 2.34 (s, 3H), 2.07 – 1.98 (comp, 2H), 1.87 – 1.66 (comp, 5H). 13C NMR (126 MHz, 
CDCl3) δ 144.6, 139.1, 138.0, 137.6, 129.8, 129.2 (d, J = 32.3), 127.2 (13, 17), 127.1 (6), 
125.9 (q, J = 3.9), 125.4, 124.5 (d, J = 271.4), 64.3, 63.1, 53.9, 37.1, 29.9, 28.1, 21.9, 
20.7. HRMS (ESI) m/z calcd for C21H24F3NO (M+H)+, 364.1883; found 364.1888. 
 
 
NMR Assignments (2.23). 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.81 (m, 1H, 6), 
7.74 (d, J = 8.4 Hz, 2H, 13, 17), 7.67 (d, J = 8.2 Hz, 3H, 14, 16), 7.41 (dd, J = 7.9, 2.0 
Hz, 1H, 2), 7.18 (d, J = 7.9 Hz, 1H, 3), 4.15 – 4.07 (m, 1H, 7), 3.87 – 3.71 (comp, 2H, 
20), 2.82 – 2.74 (comp, 4H, 9, 18), 2.34 (s, 3H, 26), 2.07 – 1.98 (comp, 2H, 11, 12), 1.87 
– 1.66 (comp, 5H, 11, 12, 19, 21). 13C NMR (126 MHz, CDCl3) δ 144.6 (10), 139.1 (1), 






























(q, J = 3.9) (14, 16), 125.4 (2), 124.5 (d, J = 271.4) (22), 64.3 (20), 63.1 (7), 53.9 (18), 
37.1 (26), 29.9 (9), 28.1 (19), 21.9 (12), 20.7 (11). 
Representative Procedure D: Reduction amination using Ti(Oi-Pr)4 and an N- 
alkylammonium salt.  
 
7-Bromo-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine (2.28) (MDW-2-
260). TiO(i-Pr)4 (9.6 g, 10 mL, 34 mmol) and Et3N (6.8 g, 9.3 mL, 67 mmol) were 
sequentially added to a solution of 7-bromotetralone (3.00 g, 13.3 mmol) and MeNH3Cl 
(4.50 g, 66.6 mmol) in EtOH (27 mL) and the reaction was stirred at room temperature 
for 17 h. The reaction was cooled to 0 °C and NaBH4 (0.506, 13.4 mmol) was added in a 
single portion. The reaction was stirred for 30 min and the cooling bath was removed. 
The solution was stirred for 4 h at room temperature and poured into 2 M aq. NH4OH (20 
mL). Celite was added to the mixture and it was filtered, washing with CH2Cl2 (100 mL). 
The filtrate was concentrated under reduced pressure to remove volatile organics and the 
mixture obtained was diluted with CH2Cl2 (20 mL). The organic layer was separated and 
the aqueous layer was extracted with CH2Cl2 (2 x 10 mL). The combined organic extracts 
were washed with saturated aqueous NH4Cl (2 x 30 mL) and extracted with 1 N HCl (3 x 
40 mL). The combined acidic extracts were made basic with 6 N NaOH and extracted 
with CH2Cl2 (3 x 50 mL). The combined organic extracts were dried (Na2SO4) and 
concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (94:5:1 to 79:20:1) affording 
2.15 g (67%) of 2.28 as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 2.2 Hz, 





2.61 (comp, 2H), 2.49 (s, 3H), 1.98 – 1.82 (comp, 3H), 1.79 – 1.67 (m, 1H), 1.08 (brs, 
1H). 13C NMR (126 MHz, CDCl3) δ 141.5, 136.4, 131.7, 130.9, 129.8, 119.3, 57.0, 34.1, 




NMR Assignments (2.28). 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 2.2 Hz, 
1H, 6), 7.27 – 7.23 (m, 1H, 2), 6.95 (dd, J = 8.2, 1.0 Hz, 1H, 3), 3.62 (t, J = 4.9 Hz, 1H, 
10), 2.79 – 2.61 (comp, 2H, 7), 2.49 (s, 3H, 13), 1.98 – 1.82 (comp, 3H, 8, 9), 1.79 – 1.67 
(m, 1H, 8), 1.08 (brs, 1H, 12). 13C NMR (126 MHz, CDCl3) δ 141.5 (5), 136.4 (4), 131.7 




(2.29) (MDW-2-132). Prepared from 2.28 (1.267 g, 5.274mmol) and CbzCl according to 
representative procedure A. The crude residue was purified via flash chromatography 
(SiO2) eluting with hexanes/EtOAc (9:1) to afford 1.954 g (98%) of 2.29 as a white waxy 
solid. 1H NMR (400 MHz, CDCl3) rotamers δ 7.47 – 7.29 (comp, 5H), 7.28 – 7.23 
(comp, 2H), 6.99 – 6.93 (m, 1H), 5.54 – 5.30 (m, 1H), 5.29 – 5.19 (comp, 2H), 2.78 – 
2.60 (comp, 5H), 2.09 – 1.94 (comp, 2H), 1.85 – 1.69 (comp, 2H). 13C NMR (101 MHz, 





















129.9, 129.7, 129.6, 128.5, 127.9, 127.7, 119.9, 119.8, 55.1, 54.9, 30.3, 29.5, 28.9, 28.9, 




NMR Assignments (2.29). 1H NMR (400 MHz, CDCl3) rotamers δ 7.47 – 7.29 
(comp, 5H, 14, 15, 16, 17, 19), 7.28 – 7.23 (comp, 2H, 2, 6), 6.99 – 6.93 (m, 1H, 3), 5.54 
– 5.30 (m, 1H, 10), 5.29 – 5.19 (comp, 2H, 20), 2.78 – 2.60 (comp, 5H, 7, 13), 2.09 – 
1.94 (comp, 2H, 8, 9), 1.85 – 1.69 (comp, 2H, 8, 9). 13C NMR (101 MHz, CDCl3) 
rotamers δ 157.0 and 156.5 (22), 137.7 and 137.6 (5), 137.3 and 137.0 (18), 136.8 and 
136.7 (4), 130.9 (6), 129.9 and 129.9 (1), 129.7 and 129.6 (3), 128.5 (14, 16), 127.9 (15), 
127.7 (17, 19), 119.9 and 119.8 (2), 55.1 and 54.9 (10), 30.3 and 29.5 (7), 28.9 and 28.9 
(13), 27.5 and 27.0 (9), 21.8 and 21.7 (8). 
Representative Procedure E: Reductive amination of the piperazine nitrogen atom 




yl)carbamate (2.31) (MDW-2-286). A solution of 2.16 (0.454 g, 1.20 mmol), 


































DCE (12 mL) were stirred for 1 h at room temperature. The reaction was diluted with 
saturated aqueous NaHCO3 (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were washed with brine (1 x 10 mL), dried (Na2SO4), and concentrated 
under reduced pressure. The combined organic extracts were dried (Na2SO4) and 
concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (84:15:1) affording 0.404 g 
(80%) of 2.31 as a colorless oil. 1H NMR (500 MHz, CDCl3) rotamers δ 7.46 – 7.28 
(comp, 5H), 6.99 (d, J = 8.4 Hz, 1H), 6.82 – 6.74 (m, 1H), 6.62 (dd, J = 12.3, 2.6 Hz, 
1H), 5.51 – 5.32 (m, 1H), 5.32 – 5.12 (comp, 2H), 3.16 – 3.03 (comp, 4H), 2.76 – 2.62 
(comp, 4H), 2.62 – 2.54 (comp, 4H), 2.39 – 2.32 (comp, 2H), 2.07 – 1.91 (comp, 2H), 
1.84 – 1.70 (comp, 2H), 1.61 – 1.50 (comp, 2H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 157.3, 157.1, 150.1, 150.1, 137.2, 137.1, 135.9, 135.8, 130.2, 130.0, 
129.9, 129.7, 128.6, 128.0, 127.9, 127.9, 115.7, 115.4, 114.7, 114.3, 67.2, 67.2, 60.9, 
55.7, 55.5, 53.4, 53.3, 49.7, 49.5, 30.3, 29.8, 28.8, 28.7, 28.2, 27.7, 22.3, 22.2, 20.2, 12.1. 
HRMS (ESI) m/z calcd for C26H35N3O2 (M+H)+, 422.2802; found 422.2808. 
 
 
NMR Assignments (2.31). 1H NMR (500 MHz, CDCl3) rotamers δ 7.46 – 7.28 
(comp, 5H, 13, 14, 15, 16, 18), 6.99 (d, J = 8.4 Hz, 1H, 3), 6.82 – 6.74 (m, 1H, 2), 6.62 
(dd, J = 12.3, 2.6 Hz, 1H, 6), 5.51 – 5.32 (m, 1H, 10), 5.32 – 5.12 (comp, 2H, 19), 3.16 – 
3.03 (comp, 4H, 23, 27), 2.76 – 2.62 (comp, 4H, 7, 31), 2.62 – 2.54 (comp, 4H, 24, 26), 



































1.61 – 1.50 (comp, 2H, 29), 0.93 (t, J = 7.4 Hz, 3H, 30). 13C NMR (126 MHz, CDCl3) 
rotamers δ 157.3 and 157.1 (21), 150.1 and 150.1 (1), 137.2 and 137.1 (5), 135.9 and 
135.8 (17), 130.2 and 130.0 (4), 129.9 and 129.7 (3), 128.6 (13, 15), 128.0 (14), 127.9 
and 127.9 (16, 18), 115.7 and 115.4 (2), 114.7 and 114.3 (6), 67.2 and 67.2 (19), 60.9 
(28), 55.7 and 55.5 (10), 53.4 and 53.3 (24, 26), 49.7 and 49.5 (23, 27), 30.3 and 29.8 
(31), 28.8 and 28.7 (7), 28.2 and 27.7 (9), 22.3 and 22.2 (8), 20.2 (29), 12.1 (30). 





yl)(methyl)carbamate (2.33) (MDW-1-162). A solution of 2.16 (25 mg 0.066 mmol), 
Na(OAc)3BH (28 mg, 0.13 mmol), cyclobutanone (23 mg, 25 µL, 0.33 mmol), and 
CH3CO2H (8 mg, 8 µL, 0.1 mmol)   in DCE (0.7 mL) were stirred for 6 h at room 
temperature. The reaction was diluted with saturated aqueous NaHCO3 (5 mL) and 
extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were washed with 
brine (1 x 10 mL), dried (Na2SO4), and concentrated under reduced pressure. The crude 
residue was purified via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N 
(74:25:1) affording 25 mg (89%) of 2.33 as a pale yellow oil. 1H NMR (499 MHz, 
CDCl3) rotamers δ 7.43 – 7.28 (comp, 5H), 6.98 (d, J = 8.2 Hz, 1H), 6.80 – 6.74 (m, 1H), 
6.62 (dd, J = 8.3, 2.2 Hz, 1H), 5.50 – 5.31 (m, 1H), 5.30 – 5.12 (comp, 2H), 3.15 – 3.05 








1.80 – 1.68 (comp, 4H). 13C NMR (126 MHz, CDCl3) rotamers δ 157.3, 157.1, 150.1, 
137.3, 137.1, 135.9, 135.8, 130.3, 130.0, 129.9, 128.6, 128.0, 127.9, 115.9, 115.5, 114.8, 
114.5, 67.3, 67.2, 60.4, 55.7, 55.5, 49.5, 49.5, 49.3, 30.4, 29.8, 29.8, 28.9, 28.8, 28.2, 






yl)(methyl)carbamate (2.34) (MDW-2-235). Prepared from 2.16 (28 mg 0.074 mmol) 
and cyclopentanone according to representative procedure F. The crude residue was 
purified via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (74:25:1) to 
afford 26 mg (79%) of 2.34 as a colorless oil. 1H NMR (499 MHz, CDCl3) rotamers δ 
7.44 – 7.27 (comp, 5H), 6.99 (d, J = 8.3 Hz, 1H), 6.79 – 6.74 (m, 1H), 6.62 (dd, J = 7.7, 
2.5 Hz, 1H), 5.49 – 5.32 (m, 1H), 5.28 – 5.11 (comp, 2H), 3.16 – 3.05 (comp, 4H), 2.72 – 
2.60 (comp, 9H), 2.55 (t, J = 8.3 Hz, 1H), 2.05 – 1.88 (comp, 4H), 1.81 – 1.68 (comp, 
4H), 1.63 – 1.53 (comp, 2H), 1.52 – 1.41 (comp, 2H). 13C NMR (126 MHz, CDCl3) 
rotamers δ 157.3, 157.0, 150.0, 137.2, 137.1, 135.9, 135.8, 130.3, 130.0, 129.9, 129.8, 
128.6, 128.0, 127.9, 127.9, 115.7, 115.4, 114.7, 114.4, 67.6, 67.2, 67.2, 55.7, 55.5, 52.4, 
49.6, 49.4, 30.5, 30.3, 29.8, 28.8, 28.8, 28.2, 27.7, 24.3, 22.3, 22.2. HRMS (ESI) m/z 










NMR Assignments (2.34). 1H NMR (499 MHz, CDCl3) rotamers δ 7.44 – 7.27 
(comp, 5H, 20, 21, 22, 23, 25), 6.99 (d, J = 8.3 Hz, 1H, 3), 6.79 – 6.74 (m, 1H, 2), 6.62 
(dd, J = 7.7, 2.5 Hz, 1H, 6), 5.49 – 5.32 (m, 1H, 7), 5.28 – 5.11 (comp, 2H, 26), 3.16 – 
3.05 (comp, 4H, 14, 18), 2.72 – 2.60 (comp, 9H, 10, 13, 15, 17), 2.55 (t, J = 8.3 Hz, 1H, 
19), 2.05 – 1.88 (comp, 4H, 9, 12, 31, 32), 1.81 – 1.68 (comp, 4H, 9, 12, 30, 33), 1.63 – 
1.53 (comp, 2H, 30, 33), 1.52 – 1.41 (comp, 2H, 31, 32). 13C NMR (126 MHz, CDCl3) 
rotamers δ 157.3 (28), 157.0 (28), 150.0 (1), 137.2 (5), 137.1 (5), 135.9 (24), 135.8 (24), 
130.3 (4), 130.0 (3), 129.9 (3), 129.8 (4), 128.6 (20, 22), 128.0 (21), 127.9 (23, 25), 127.9 
(23, 25), 115.7 (2), 115.4 (2), 114.7 (6), 114.4 (6), 67.6 (19), 67.2 (26), 67.2 (26), 55.7 
(7), 55.5 (7), 52.4 (15, 17), 49.6 (14), 49.4 (14, 18), 30.5 (30, 33), 30.3 (13), 29.8 (13), 




yl)(methyl)carbamate (2.35) (MDW-1-205). Prepared from 2.16 (30 mg 0.079 mmol) 
and cyclohexanone according to representative procedure F. The crude residue was 
purified via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (77:22:1) to 














































7.46 – 7.27 (comp, 5H), 6.98 (d, J = 8.4 Hz, 1H), 6.81 – 6.75 (m, 1H), 6.62 (dd, J = 11.3, 
2.5 Hz, 1H), 5.50 – 5.32 (m, 1H), 5.31 – 5.10 (comp, 2H), 3.15 – 3.03 (comp, 4H), 2.76 – 
2.60 (comp, 9H), 2.34 – 2.25 (m, 1H), 2.07 – 1.89 (comp, 4H), 1.85 – 1.69 (comp, 4H), 
1.68 – 1.61 (m, 1H), 1.30 – 1.21 (comp, 4H), 1.18 – 1.09 (m, 1H). 13C NMR (126 MHz, 
CDCl3) rotamers δ 157.3, 157.1, 150.2, 137.3, 137.1, 135.9, 135.8, 130.2, 129.9, 129.9, 
129.6, 128.6, 128.0, 127.9, 115.8, 115.5, 114.7, 114.3, 67.2, 67.2, 63.6, 55.7, 55.5, 50.2, 
50.0, 49.1, 49.1, 30.3, 29.8, 29.1, 28.9, 28.8, 28.2, 27.8, 26.4, 26.0, 22.4, 22.2. HRMS 
(ESI) m/z calcd for C29H39N3O2 (M+Na)+, 484.2934; found 484.2942. 
 
 
NMR Assignments (2.35). 1H NMR (499 MHz, CDCl3) rotamers δ 7.46 – 7.27 
(comp, 5H, 25, 26, 27, 28, 30), 6.98 (d, J = 8.4 Hz, 1H, 3), 6.81 – 6.75 (m, 1H, 6), 6.62 
(dd, J = 11.3, 2.5 Hz, 1H, 2), 5.50 – 5.32 (m, 1H, 10), 5.31 – 5.10 (comp, 2H, 31), 3.15 – 
3.03 (comp, 4H, 14, 18), 2.76 – 2.60 (comp, 9H, 7, 12, 15, 17), 2.34 – 2.25 (m, 1H, 19), 
2.07 – 1.89 (comp, 4H, 8, 9, 20, 24), 1.85 – 1.69 (comp, 4H, 8, 9, 21, 23), 1.68 – 1.61 (m, 
1H, 22), 1.30 – 1.21 (comp, 4H, 20, 21, 23, 24), 1.18 – 1.09 (m, 1H, 22). 13C NMR (126 
MHz, CDCl3) rotamers δ 157.3 (33), 157.1 (33), 150.2 (1), 137.3 (5), 137.1 (5), 135.9 
(29), 135.8 (29), 130.2 (4), 129.9 (3), 129.9 (3), 129.6 (4), 128.6 (25, 27), 128.0 (26), 
127.9 (28, 30), 115.8 (6), 115.5 (6), 114.7 (2), 114.3 (2), 67.2 (31), 67.2 (31), 63.6 (19), 
55.7 (10), 55.5 (10), 50.2 (14, 18), 50.0 (14, 18), 49.1 (15, 17), 49.1 (15, 17), 30.3 (12), 
29.8 (12), 29.1 (20, 24), 28.9 (7), 28.8 (7), 28.2 (9), 27.8 (9), 26.4 (22), 26.0 (21, 23), 










































yl)(methyl)carbamate (2.32) (MDW-1-167). Prepared from 2.16 (25 mg 0.066 mmol) 
and acetone according to representative procedure F. The crude residue was purified via 
flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (64:35:1) to afford 18 mg 
(65%) of 2.32 as a pale yellow oil. 1H NMR (499 MHz, CDCl3) rotamers δ 7.45 – 7.28 
(m, 5H), 6.99 (d, J = 8.3 Hz, 1H), 6.80 – 6.75 (m, 1H), 6.63 (dd, J = 10.1, 2.2 Hz, 1H), 
5.50 – 5.32 (m, 1H), 5.30 – 5.11 (m, 2H), 3.15 – 3.05 (m, 4H), 2.75 – 2.61 (m, 10H), 2.07 
– 1.91 (m, 2H), 1.83 – 1.70 (m, 2H), 1.09 (d, J = 6.5 Hz, 6H). 13C NMR (126 MHz, 
CDCl3) rotamers δ 157.3, 157.1, 150.2, 137.3, 137.2, 135.9, 135.8, 130.2, 130.0, 129.9, 
129.7, 128.6, 128.0, 127.9, 127.9, 115.8, 115.5, 114.8, 114.4, 67.3, 67.2, 55.7, 55.5, 54.6, 
50.1, 49.9, 48.9, 48.9, 30.3, 29.8, 28.9, 28.8, 28.3, 27.8, 22.4, 22.2, 18.8, 18.8. HRMS 
(ESI) m/z calcd for C26H35N3O2 (M+Na)+, 444.2641; found 444.2630. 




yl)(methyl)carbamate (2.36) (MDW-1-161). A solution of 2.16 (30 mg, 0.079 mmol), 














mL) was stirred for 24 hours at room temperature. The reaction was diluted with 
saturated aqueous NaHCO3 (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were washed with brine (1 x 10 mL), dried (Na2SO4), and concentrated 
under reduced pressure. The crude residue was purified via flash chromatography (SiO2) 
eluting with hexanes/EtOAc/Et3N (69:30:1) affording 23 mg (70%) of 2.36 as a colorless 
oil. 1H NMR (499 MHz, CDCl3) rotamers δ 7.45 – 7.28 (comp, 5H), 6.99 (d, J = 8.3 Hz, 
1H), 6.81 – 6.75 (m, 1H), 6.63 (dd, J = 11.1, 2.6 Hz, 1H), 5.51 – 5.32 (m, 1H), 5.32 – 
5.11 (comp, 2H), 3.18 – 3.06 (comp, 4H), 2.72 – 2.56 (comp, 9H), 2.49 (q, J = 7.2 Hz, 
2H), 2.07 – 1.91 (comp, 2H), 1.84 – 1.69 (comp, 2H), 1.14 (t, J = 7.2 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) rotamers δ 157.3, 157.0, 150.0, 150.0, 137.3, 137.1, 135.9, 135.8, 
130.7, 130.2, 130.0, 129.9, 129.7, 128.7, 128.6, 128.1, 128.0, 127.9, 127.9, 127.9, 115.7, 
115.4, 114.8, 114.4, 67.2, 67.2, 55.7, 55.5, 52.9, 52.5, 49.6, 49.5, 30.3, 29.8, 29.8, 28.8, 
28.8, 28.2, 27.7, 22.3, 22.2, 12.1. HRMS (ESI) m/z calcd for C25H33N3O2 (M+Na)+, 




yl)(methyl)carbamate (2.37) (MDW-2-131). Prepared from 2.16 (55 mg 0.14 mmol) 
and allyl bromide according to representative procedure G. The crude residue was 
purified via flash chromatography (SiO2) eluting with hexanes/Et2O/Et3N (39:60:1) to 
afford 18 mg (30%) of 2.37 as a colorless oil. 1H NMR (499 MHz, CDCl3) δ 7.45 – 7.27 
rotamers (comp, 5H), 6.99 (d, J = 8.3 Hz, 1H), 6.80 – 6.74 (m, 1H), 6.65 – 6.59 (m, 1H), 








9H), 2.08 – 1.91 (comp, 2H), 1.83 – 1.66 (comp, 2H). 13C NMR (126 MHz, CDCl3) 
rotamers δ 157.3, 157.0, 150.1, 150.0, 137.3, 137.1, 135.9, 135.8, 135.0, 135.0, 130.2, 
130.0, 129.9, 129.7, 128.6, 128.0, 127.9, 127.9, 118.3, 115.7, 115.4, 114.7, 114.4, 67.2, 
67.2, 61.9, 61.9, 55.7, 55.5, 53.2, 53.2, 49.7, 49.5, 30.5, 30.3, 29.8, 29.8, 28.8, 28.8, 28.2, 





1-yl)(methyl)carbamate (2.38) (MDW-1-177). Prepared from 2.16 (100 mg 0.264 
mmol) and 3-bromo-1-propanol according to representative procedure G. The crude 
residue was purified via flash chromatography (SiO2) eluting with CH2Cl2/MeOH/Et3N 
(97:2:1) to afford 39 mg (34%) of 2.38 as a colorless oil. 1H NMR (499 MHz, CDCl3)  
rotamers δ 7.44 – 7.28 (comp, 5H), 6.98 (d, J = 8.3 Hz, 1H), 6.78 – 6.71 (m, 1H), 6.59 
(dd, J = 12.4, 2.6 Hz, 1H), 5.49 – 5.31 (m, 1H), 5.30 – 5.10 (comp, 2H), 3.82 (t, J = 5.2 
Hz, 2H), 3.13 – 3.01 (comp, 4H), 2.74 – 2.61 (comp, 12H), 2.05 – 1.91 (comp, 2H), 1.82 
– 1.68 (comp, 4H). 13C NMR (126 MHz, CDCl3) rotamers δ 157.3, 157.0, 149.8, 149.8, 
137.2, 137.1, 135.9, 135.8, 130.4, 130.0, 129.9, 129.9, 128.6, 128.0, 128.0, 127.9, 127.9, 
115.8, 115.4, 114.7, 114.5, 67.2, 67.2, 64.7, 58.9, 55.6, 55.4, 53.4, 49.7, 49.6, 30.3, 29.8, 
28.8, 28.7, 28.2, 27.7, 27.3, 22.3, 22.1. HRMS (ESI) m/z calcd for C26H35N3O3 (M+H)+, 










NMR Assignments (2.38). 1H NMR (499 MHz, CDCl3) rotamers δ 7.44 – 7.28 
(comp, 5H, 23, 24, 25, 26, 28), 6.98 (d, J = 8.3 Hz, 1H, 3), 6.78 – 6.71 (m, 1H, 6), 6.59 
(dd, J = 12.4, 2.6 Hz, 1H, 2), 5.49 – 5.31 (m, 1H, 10), 5.30 – 5.10 (comp, 2H, 29), 3.82 (t, 
J = 5.2 Hz, 2H, 21), 3.13 – 3.01 (comp, 4H, 14, 18), 2.74 – 2.61 (comp, 12H, 7, 12, 15, 
17, 19, 22), 2.05 – 1.91 (comp, 2H, 8, 9), 1.82 – 1.68 (comp, 4H, 8, 9, 20). 13C NMR (126 
MHz, CDCl3) rotamers δ 157.3 (31), 157.0 (31), 149.8 (1), 149.8 (1), 137.2 (5), 137.1 
(5), 135.9 (27), 135.8 (27), 130.4 (4), 130.0 (3), 129.9 (4), 129.9 (3), 128.6 (23, 25), 
128.0 (24), 128.0 (24), 127.9 (26, 28), 127.9 (26, 28), 115.8 (2), 115.4 (2), 114.7 (6), 
114.5 (6), 67.2 (29), 67.2 (29), 64.7 (21), 58.9 (19), 55.6 (10), 55.4 (10), 53.4 (15, 17), 
49.7 (14, 18), 49.6 (14, 18), 30.3 (12), 29.8 (12), 28.8 (7), 28.7 (7), 28.2 (9), 27.7 (9), 




tetrahydronaphthalen-2-yl)piperazin-1-yl)butanoate (2.39) (MDW-2-130). Prepared 
from 2.16 (55 mg 0.14 mmol) and ethyl 4-bromobutyrate according to representative 
procedure G. The crude residue was purified via flash chromatography (SiO2) eluting 
with hexanes/Et2O/Et3N (24:75:1) to afford 39 mg (55%) of 2.39 as a colorless oil. 1H 











































6.80 – 6.73 (m, 1H), 6.65 – 6.58 (m, 1H), 5.51 – 5.32 (m, 1H), 5.32 – 5.10 (comp, 2H), 
4.14 (q, J = 7.1 Hz, 2H), 3.13 – 3.02 (comp, 4H), 2.75 – 2.61 (comp, 5H), 2.60 – 2.53 
(comp, 4H), 2.42 (t, J = 7.3 Hz, 2H), 2.37 (t, J = 7.4 Hz, 2H), 2.08 – 1.91 (comp, 2H), 
1.90 – 1.67 (comp, 4H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 173.7, 
157.3, 157.0, 150.1, 150.0, 137.2, 137.1, 135.9, 135.8, 130.1, 129.9, 129.9, 129.7, 128.6, 
128.0, 127.9, 127.9, 115.7, 115.4, 114.6, 114.3, 67.2, 67.2, 60.4, 57.8, 57.8, 55.7, 55.5, 
53.2, 49.7, 49.5, 32.4, 30.4, 30.3, 29.8, 28.8, 28.7, 28.2, 27.7, 22.3, 22.3, 22.2, 14.4. 




tetrahydronaphthalen-2-yl)piperazin-1-yl)acetate (2.40) (MDW-1-169). Prepared 
from 2.16 (25 mg 0.066 mmol) and ethyl bromoacetate according to representative 
procedure G. The crude residue was purified via flash chromatography (SiO2) eluting 
with hexanes/EtOAc/Et3N (69:30:1) to afford 20 mg (62%) of 2.40 as a pale yellow oil. 
1H NMR (499 MHz, CDCl3) rotamers δ 7.45 – 7.27 (comp, 5H), 6.99 (d, J = 8.4 Hz, 1H), 
6.80 – 6.74 (m, 1H), 6.62 (dd, J = 12.4, 2.0 Hz, 1H), 5.49 – 5.32 (m, 1H), 5.31 – 5.10 
(comp, 2H), 4.25 – 4.17 (comp, 2H), 3.26 (s, 2H), 3.18 – 3.07 (comp, 4H), 2.74 – 2.62 
(comp, 9H), 2.06 – 1.92 (comp, 2H), 1.83 – 1.67 (comp, 2H), 1.29 (td, J = 7.2, 2.0 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 170.3, 157.3, 157.1, 150.0, 150.0, 137.2, 137.1, 
136.0, 135.9, 130.4, 130.0, 129.9, 129.9, 128.6, 128.1, 127.9, 127.9, 115.8, 115.5, 114.8, 










28.8, 28.2, 27.7, 22.3, 22.2, 14.4. HRMS (ESI) m/z calcd for C27H35N3O4 (M+H)+, 




tetrahydronaphthalen-1-yl)(methyl)carbamate (2.41) (MDW-1-213). Prepared from 
2.16 (30 mg 0.079 mmol) and known 3-bromo-N,N-diethylpropanamide, according to 
representative procedure G.315 The crude residue was purified via flash chromatography 
(SiO2) eluting with EtOAc/i-PrOH/Et3N (98:1:1) to afford 14 mg (36%) of 2.41 as a pale 
yellow oil. 1H NMR (499 MHz, CDCl3) rotamers δ 7.45 – 7.28 (comp, 5H), 6.99 (d, J = 
8.4 Hz, 1H), 6.79 – 6.74 (m, 1H), 6.64 – 6.59 (m, 1H), 5.49 – 5.32 (m, 1H), 5.30 – 5.11 
(comp, 2H), 3.42 – 3.30 (comp, 4H), 3.14 – 3.04 (comp, 4H), 2.84 – 2.77 (comp, 2H), 
2.74 – 2.61 (comp, 9H), 2.59 – 2.53 (comp, 2H), 2.07 – 1.92 (comp, 2H), 1.80 – 1.71 
(comp, 2H), 1.19 (td, J = 7.2, 2.0 Hz, 3H), 1.12 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) rotamers δ 170.6, 157.2, 156.9, 149.9, 149.8, 137.1, 137.0, 135.8, 135.7, 130.2, 
129.8, 129.8, 129.7, 128.5, 127.9, 127.7, 127.7, 115.6, 115.4, 114.6, 114.2, 67.1, 67.1, 
55.6, 55.3, 54.4, 53.3, 53.3, 49.5, 49.4, 42.0, 40.1, 30.8, 30.2, 29.7, 28.7, 28.6, 28.1, 27.6, 












NMR Assignments (2.41). 1H NMR (499 MHz, CDCl3) δ 7.45 – 7.28 (comp, 5H, 
28, 29, 30, 31, 33), 6.99 (d, J = 8.4 Hz, 1H, 3), 6.79 – 6.74 (m, 1H, 2), 6.64 – 6.59 (m, 
1H, 6), 5.49 – 5.32 (m, 1H, 7), 5.30 – 5.11 (comp, 2H, 34), 3.42 – 3.30 (comp, 4H, 24, 
25), 3.14 – 3.04 (comp, 4H, 14, 18), 2.84 – 2.77 (comp, 2H, 19), 2.74 – 2.61 (comp, 9H, 
10, 13, 15, 17), 2.59 – 2.53 (comp, 2H, 20), 2.07 – 1.92 (comp, 2H, 9, 12), 1.80 – 1.71 
(comp, 2H, 9, 12), 1.19 (td, J = 7.2, 2.0 Hz, 3H, 26, 27), 1.12 (t, J = 7.1 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 170.6 (21), 157.2 (36), 156.9 (36), 149.9 (1), 149.8 (1), 137.1 
(5), 137.0 (5), 135.8 (32), 135.7 (32), 130.2 (4), 129.8 (3), 129.8 (3), 129.7 (4), 128.5 (28, 
30), 127.9 (29), 127.7 (31, 33), 127.7 (31, 33), 115.6 (2), 115.4 (2), 114.6 (6), 114.2 (6), 
67.1 (34), 67.1 (34), 55.6 (7), 55.3 (7), 54.4 (19), 53.3 (15, 17), 53.3 (15, 17), 49.5 (14, 
18), 49.4 (14, 18), 42.0 (24, 25), 40.1 (24, 25), 30.8 (20), 30.2 (13), 29.7 (13), 28.7 (10), 
28.6 (10), 28.1 (9), 27.6 (9), 22.2 (12), 22.0 (12), 14.4 (26, 27), 13.1 (26, 27). 




tetrahydronaphthalen-2-yl)piperazin-1-yl)propanoate (2.42) (MDW-2-120). Ethyl 





















































in EtOH (1.1 mL). The reaction was heated at 40 °C for 18 h. The reaction was cooled to 
room temperature and the concentrated under reduced pressure. The crude residue was 
purified via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (64:35:1) 
affording 90 mg (86%) of 2.42 as a colorless oil. 1H NMR (400 MHz, CDCl3) rotamers δ 
7.45 – 7.27 (comp, 5H), 6.98 (d, J = 8.4 Hz, 1H), 6.81 – 6.72 (m, 1H), 6.61 (dd, J = 10.8, 
2.6 Hz, 1H), 5.51 – 5.31 (m, 1H), 5.32 – 5.10 (comp, 2H), 4.16 (q, J = 7.2 Hz, 2H), 3.15 
– 2.99 (comp, 4H), 2.75 (t, J = 7.4 Hz, 2H), 2.72 – 2.49 (comp, 11H), 2.07 – 1.92 (comp, 
2H), 1.85 – 1.68 (comp, 2H), 1.30 – 1.24 (comp, 3H). 13C NMR (126 MHz, CDCl3) δ 
172.6, 157.4, 157.1, 150.0, 137.3, 137.2, 136.0, 135.9, 130.3, 130.0, 129.9, 129.8, 128.6, 
128.1, 127.9, 127.9, 115.8, 115.5, 114.7, 114.4, 67.2, 67.2, 60.6, 55.7, 55.5, 53.7, 53.0, 
49.7, 49.5, 32.5, 30.3, 29.8, 29.8, 28.9, 28.8, 28.2, 27.8, 22.4, 22.2, 14.4. HRMS (ESI) 
m/z calcd for C28H37N3O4 (M+H)+, 480.2857; found 480.2860 
 
 
NMR Assignments (2.42). 1H NMR (400 MHz, CDCl3) rotamers δ 7.45 – 7.27 
(comp, 5H, 21, 22, 23, 24, 26), 6.98 (d, J = 8.4 Hz, 1H, 3), 6.81 – 6.72 (m, 1H, 2), 6.61 
(dd, J = 10.8, 2.6 Hz, 1H, 6), 5.51 – 5.31 (m, 1H, 10), 5.32 – 5.10 (comp, 2H, 27), 4.16 
(q, J = 7.2 Hz, 2H, 33), 3.15 – 2.99 (comp, 4H, 13, 17), 2.75 (t, J = 7.4 Hz, 2H, 18), 2.72 
– 2.49 (comp, 11H, 7, 14, 16, 19, 35), 2.07 – 1.92 (comp, 2H, 8, 9), 1.85 – 1.68 (comp, 
2H, 8, 9), 1.30 – 1.24 (comp, 3H, 34). 13C NMR (126 MHz, CDCl3) δ 172.6 (20), 157.4 
and 157.1 (29), 150.0 (1), 137.3 and 137.2 (5), 136.0 and 135.9 (25), 130.3 and 130.0 (4), 







































(2), 114.7 and 114.4 (6), 67.2 and 67.2 (27), 60.6 (33), 55.7 and 55.5 (10), 53.7, 53.0 (14, 
16), 49.7 and 49.5 (13, 17), 32.5 (19), 30.3 (18), 29.8 and 29.8 (35), 28.9 and 28.8 (7), 





tetrahydronaphthalen-2-yl)piperazin-1-yl)propanoate (2.43) (MDW-1-166). Methyl 
acrylate (0.16 g, 0.17 mL, 1.6 mmol) was added to a solution of 2.16 (60 mg, 0.16 mmol) 
in MeOH (0.8 mL). The reaction was heated at 40 °C for 18 h. The reaction was cooled 
to room temperature and the concentrated under reduced pressure. The crude residue was 
purified via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (59:40:1) 
affording 56 mg (75%) of 2.43 as a colorless oil. 1H NMR (499 MHz, CDCl3) rotamers δ 
7.45 – 7.28 (comp, 5H), 6.98 (dd, J = 8.4, 1.5 Hz, 1H), 6.80 – 6.73 (m, 1H), 6.61 (dd, J = 
13.7, 2.6 Hz, 1H), 5.50 – 5.32 (m, 1H), 5.31 – 5.12 (comp, 2H), 3.70 (d, J = 1.5 Hz, 3H), 
3.13 – 3.01 (comp, 4H), 2.76 (t, J = 7.4 Hz, 2H), 2.72 – 2.53 (m, 11H), 2.08 – 1.92 
(comp, 2H), 1.84 – 1.68 (comp, 2H). 13C NMR (126 MHz, CDCl3) rotamers δ 173.0, 
157.3, 157.0, 150.0, 150.0, 137.2, 137.1, 135.9, 135.8, 130.2, 130.0, 129.9, 129.8, 128.6, 
128.0, 127.9, 127.9, 115.7, 115.5, 114.7, 114.3, 67.2, 67.2, 55.7, 55.4, 53.6, 53.0, 53.0, 
51.8, 49.6, 49.5, 32.2, 30.3, 29.8, 28.8, 28.7, 28.2, 27.7, 22.3, 22.1. HRMS (ESI) m/z 










NMR Assignments (2.43). 1H NMR (499 MHz, CDCl3) δ 7.45 – 7.28 (comp, 5H, 
21, 22, 23, 24, 26), 6.98 (dd, J = 8.4, 1.5 Hz, 1H, 3), 6.80 – 6.73 (m, 1H, 2), 6.61 (dd, J = 
13.7, 2.6 Hz, 1H, 6), 5.50 – 5.32 (m, 1H, 10), 5.31 – 5.12 (comp, 2H, 27), 3.70 (d, J = 1.5 
Hz, 3H, 33), 3.13 – 3.01 (comp, 4H, 13, 17), 2.76 (t, J = 7.4 Hz, 2H, 18), 2.72 – 2.53 
(comp, 11H, 7, 14, 16, 19, 34), 2.08 – 1.92 (m, 2H, 8, 9), 1.84 – 1.68 (m, 2H, 8, 9). 13C 
NMR (126 MHz, CDCl3) rotamers δ 173.0 (20), 157.3 and 157.0 (29), 150.0 and 150.0 
(1), 137.2 and 137.1 (5), 135.9 and 135.8 (25), 130.2 and 130.0 (4), 129.9 and 129.8 (3), 
128.6 (21, 23), 128.0 (22), 127.9 and 127.9 (24, 26), 115.7 and 115.5 (2), 114.7 and 114.3 
(6), 67.2 and 67.2 (27), 55.7 and 55.4 (10), 53.6 (18), 53.0 and 53.0 (14, 16), 51.8 (33), 
49.6 and 49.5 (13, 17), 32.2 (19), 30.3 and 29.8 (34), 28.8 and 28.7 (7), 28.2 and 27.7 (9), 




1-yl)(methyl)carbamate (2.44) (MDW-1-219). Prepared from 2.14 (70 mg 0.19 mmol) 
and piperazine according to representative procedure B. The crude residue was purified 
via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (59:40:1) to afford 40 
mg (49%) of 2.44 as a pale yellow oil. 1H NMR (499 MHz, CDCl3) δ 7.45 – 7.27 (comp, 














































1H), 5.31 – 5.11 (comp, 2H), 3.56 (t, J = 5.5 Hz, 2H), 3.38 (s, 3H), 3.17 – 3.06 (comp, 
4H), 2.76 – 2.59 (comp, 11H), 2.07 – 1.91 (comp, 2H), 1.83 – 1.68 (comp, 2H). 13C NMR 
(126 MHz, CDCl3) δ 157.3, 157.0, 150.1, 150.0, 137.3, 137.1, 135.9, 135.8, 130.2, 130.0, 
129.9, 129.7, 128.6, 128.0, 127.9, 115.7, 115.4, 114.7, 114.4, 70.3, 70.2, 67.2, 67.2, 59.1, 
58.1, 55.7, 55.5, 53.7, 53.7, 49.5, 49.4, 30.3, 29.8, 28.8, 28.8, 28.2, 27.7, 22.3, 22.2. 
HRMS (ESI) m/z calcd for C26H35N3O3 (M+H)+, 438.2751; found 438.2767. 
 
 
NMR Assignments (2.44). 1H NMR (499 MHz, CDCl3) δ 7.45 – 7.27 (comp, 5H, 
23, 24, 25, 26, 28), 6.98 (d, J = 8.4 Hz, 1H, 3), 6.79 – 6.74 (m, 1H, 2), 6.65 – 6.58 (m, 
1H, 6), 5.50 – 5.31 (m, 1H, 7), 5.31 – 5.11 (comp, 2H, 29), 3.56 (t, J = 5.5 Hz, 2H, 20), 
3.38 (s, 3H, 22), 3.17 – 3.06 (comp, 4H, 14, 18), 2.76 – 2.59 (comp, 11H, 10, 13, 15, 17, 
19), 2.07 – 1.91 (comp, 2H, 9, 12), 1.83 – 1.68 (comp, 2H, 9, 12). 13C NMR (126 MHz, 
CDCl3) δ 157.3 (31), 157.0 (31), 150.1 (1), 150.0 (1), 137.3 (5), 137.1 (5), 135.9 (27), 
135.8 (27), 130.2 (4), 130.0 (3), 129.9 (3), 129.7 (4), 128.6 (23, 25), 128.0 (24), 127.9 
(26, 28), 115.7 (2), 115.4 (2), 114.7 (6), 114.4 (6), 70.3 (20), 70.2 (20), 67.2 (29), 67.2 
(29), 59.1 (22), 58.1 (19), 55.7 (7), 55.5 (7), 53.7 (15, 17), 53.7 (15, 17), 49.5 (14, 18), 











































tetrahydronaphthalen-1-yl)carbamate (2.50) (MDW-2-149). A solution of 2.16 (40 
mg, 0.11 mmol), K2CO3 (29 mg, 0.21 mmol), and known 1-(2-Chloroethyl)-2-
pyrrolidinone (20 mg, 0.14 mmol) in MeCN/THF (2:1, 1.1 mL) was heated at 45 °C for 
15 h and then heated at 65 °C for 48 h.304 The reaction was diluted with saturated 
aqueous NaHCO3 (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were washed with brine (1 x 10 mL), dried (Na2SO4), and concentrated under 
reduced pressure.  The crude residue was purified via flash chromatography (SiO2) 
eluting with EtOAc/MeOH/Et3N (97:2:1 to 94:5:1) to afford 13 mg (25%) of 2.50 as a 
pale yellow oil. 1H NMR (499 MHz, CDCl3) rotamers δ 7.44 – 7.29 (comp, 5H), 6.98 (d, 
J = 8.4 Hz, 1H), 6.78 – 6.72 (m, 1H), 6.64 – 6.56 (m, 1H), 5.49 – 5.31 (m, 1H), 5.31 – 
5.13 (comp, 2H), 3.52 – 3.42 (comp, 4H), 3.12 – 3.00 (comp, 4H), 2.74 – 2.54 (comp, 
11H), 2.38 (t, J = 8.1 Hz, 2H), 2.05 – 1.92 (comp, 4H), 1.83 – 1.68 (comp, 2H). 13C NMR 
(126 MHz, CDCl3) rotamers δ 175.2, 157.3, 157.0, 150.0, 149.9, 137.2, 137.1, 135.9, 
135.8, 130.3, 130.0, 129.9, 129.9, 128.6, 128.6, 128.0, 128.0, 127.9, 115.7, 115.6, 114.7, 
114.3, 67.2, 67.2, 55.7, 55.6, 55.5, 53.2, 49.6, 49.6, 47.9, 47.8, 39.8, 39.8, 31.1, 30.4, 
29.8, 28.8, 28.8, 28.2, 27.7, 22.3, 22.2, 18.2. HRMS (ESI) m/z calcd for C29H38N4O3 












NMR Assignments (2.50). 1H NMR (499 MHz, CDCl3) rotamers δ 7.44 – 7.29 
(comp, 5H, 21, 22, 23, 24, 26), 6.98 (d, J = 8.4 Hz, 1H, 3), 6.78 – 6.72 (m, 1H, 2), 6.64 – 
6.56 (m, 1H, 6), 5.49 – 5.31 (m, 1H, 10), 5.31 – 5.13 (comp, 2H, 27), 3.52 – 3.42 (comp, 
4H, 19, 34''), 3.12 – 3.00 (comp, 4H, 14, 16), 2.74 – 2.54 (comp, 11H, 7, 13, 17, 18, 36), 
2.38 (t, J = 8.1 Hz, 2H, 32), 2.05 – 1.92 (comp, 4H, 8, 9, 33), 1.83 – 1.68 (comp, 2H, 8, 
9). 13C NMR (126 MHz, CDCl3) δ 175.2 (31), 157.3 and 157.0 (29), 150.0 and 149.9 (1), 
137.2 and 137.1 (5), 135.9 and 135.8 (25), 130.3 and 130.0 (4), 129.9 and 129.9 (3), 
128.6 and 128.6 (21, 23), 128.0 and 128.0 (22), 127.9 (24, 26), 115.7 and 115.6 (2), 114.7 
and 114.3 (6), 67.2 and 67.2 (27), 55.7 (18), 55.6 and 55.5 (10), 53.2 (14, 16), 49.6 and 
49.6 (13, 17), 47.9 and 47.8 (34), 39.8 and 39.8 (19), 31.1 (32), 30.4 and 29.8 (36), 28.8 




yl)(methyl)carbamate (2.52)  (MDW-2-213). Acrylonitrile (61 mg, 75 µL, 1.1 mmol) 
was added to a solution of 2.16 (0.289 g, 0.762 mmol) in MeOH (3.8 mL) at 0 °C. The 
reaction was stirred at 0 °C for 1 h and the cooling bath was removed. The reaction was 















































crude residue was purified via flash chromatography (SiO2) eluting with hexanes/EtOAc 
(1:1 to 3:7) to afford 0.230 g (70%) of 2.52 as a pale yellow oil. 1H NMR (500 MHz, 
CDCl3) δ 7.48 – 7.28 (comp, 5H), 6.99 (d, J = 8.3 Hz, 1H), 6.81 – 6.73 (m, 1H), 6.66 – 
6.58 (m, 1H), 5.52 – 5.33 (m, 1H,), 5.32 – 5.12 (comp, 2H), 3.18 – 3.03 (comp, 4H), 2.83 
– 2.59 (comp, 11H), 2.58 – 2.52 (comp, 2H), 2.11 – 1.92 (comp, 2H), 1.85 – 1.68 (comp, 
2H). 13C NMR (126 MHz, CDCl3) rotamers δ 157.2, 156.9, 149.8, 149.7, 137.1, 137.0, 
135.9, 135.8, 130.3, 129.9, 129.9, 129.9, 128.5, 127.9, 127.8, 127.8, 118.7, 118.7, 115.8, 
115.5, 114.7, 114.4, 67.1, 67.1, 55.6, 55.4, 53.4, 53.4, 52.7, 49.5, 49.4, 30.2, 29.7, 28.7, 
28.7, 28.1, 27.6, 22.2, 22.1, 16.0. HRMS (ESI) m/z calcd for C26H32N4O2 (M+Na)+, 
455.2417; found 455.2434. 
 
 
NMR Assignments (2.52). 1H NMR (500 MHz, CDCl3) rotamers δ 7.48 – 7.28 
(comp, 5H, 13, 14, 15, 16), 6.99 (d, J = 8.3 Hz, 1H, 3), 6.81 – 6.73 (m, 1H, 2), 6.66 – 
6.58 (m, 1H, 6), 5.52 – 5.33 (m, 1H, 10), 5.32 – 5.12 (comp, 2H, 19), 3.18 – 3.03 (comp, 
4H, 24, 28), 2.83 – 2.59 (comp, 11H, 7, 12, 25, 27, 29), 2.58 – 2.52 (comp, 2H, 30), 2.11 
– 1.92 (comp, 2H, 8, 9), 1.85 – 1.68 (comp, 2H, 8', 9'). 13C NMR (126 MHz, CDCl3) 
rotamers δ 157.2 and 156.9 (21), 149.8 and 149.7 (1), 137.1 and 137.0 (5), 135.9 and 
135.8 (17), 130.3 and 129.9 (3), 129.9 and 129.9 (4), 128.5 (13, 15), 127.9 (16, 18), 127.8 
(14), 127.8 (16, 18), 118.7 and 118.7 (31), 115.8 and 115.5 (2), 114.7 and 114.4 (6), 67.1 
and 67.1 (19), 55.6 and 55.4 (10), 53.4 and 53.4 (29), 52.7 (25, 27), 49.5 and 49.4 (24, 








































1,2,3,4-tetrahydronaphthalen-1-yl)carbamate (2.56)  (MDW-2-255). A stirred solution 
of 2.42 (24 mg, 0.051 mmol), K2CO3 (14 mg, 0.10 mmol), and acetamide oxime (7.5 mg, 
0.10 mmol) in PhMe (0.5 mL) was heated at 110 °C in sealed vial for 44 h. The reaction 
was diluted with 1 N NaOH (5 mL) and extracted with CH2Cl2 (3 x 10 mL). The 
combined organic extracts were washed with brine (1 x 10 mL), dried (Na2SO4), and 
concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (59:40:1) to afford 18 mg 
(71%) of 2.56 as a colorless oil. 1H NMR (400 MHz, CDCl3) rotamers δ 7.46 – 7.26 
(comp, 5 H), 7.02 – 6.96 (m, 1 H), 6.79 – 6.72 (m, 1 H), 6.63 – 6.57 (m, 1 H), 5.51 – 5.11 
(comp, 3 H), 3.14 – 3.00 (comp, 6 H), 2.95 – 2.87 (comp, 2 H), 2.75 – 2.58 (comp, 9 H), 
2.39 (s, 3 H), 2.07 – 1.91 (comp, 2 H), 1.81 – 1.67 (comp, 2 H). 13C NMR (126 MHz, 
CDCl3) rotamers δ 178.2, 167.2, 157.3, 157.0, 149.9, 149.9, 137.2, 137.1, 135.9, 135.8, 
130.4, 130.0, 129.9, 128.6, 128.6, 128.0, 127.9, 127.9, 115.8, 115.5, 114.7, 114.4, 67.2, 
67.2, 55.7, 55.5, 54.8, 52.9, 49.6, 49.5, 30.3, 29.8, 28.8, 28.7, 28.2, 27.7, 24.8, 22.3, 22.2, 














NMR Assignments (2.56). 1H NMR (400 MHz, CDCl3) rotamers δ 7.46 – 7.26 
(comp, 5 H, 13, 14, 15, 16, 18), 7.02 – 6.96 (m, 1 H, 3), 6.79 – 6.72 (m, 1 H, 2), 6.63 – 
6.57 (m, 1 H, 6), 5.51 – 5.11 (comp, 3 H, 10, 19), 3.14 – 3.00 (comp, 6 H, 25, 27, 30), 
2.95 – 2.87 (comp, 2 H, 29), 2.75 – 2.58 (comp, 9 H, 7, 12, 24, 28), 2.39 (s, 3 H, 36), 2.07 
– 1.91 (comp, 2 H, 8, 9), 1.81 – 1.67 (comp, 2 H, 8, 9). 13C NMR (126 MHz, CDCl3) 
rotamers δ 178.2 (31), 167.2 (34), 157.3 and 157.0 (21), 149.9 and 149.9 (1), 137.2 and 
137.1 (5), 135.9 and 135.8 (17), 130.4 (4), 130.0 and 129.9 (3), 128.6 and 128.6 (13, 15), 
128.0 (14), 127.9 and 127.9 (16, 18), 115.8 and 115.5 (2), 114.7 and 114.4 (6), 67.2 and 
67.2 (19), 55.7 and 55.5 (10), 54.8 (29), 52.9 (24, 28), 49.6 and 49.5 (25, 27), 30.3 and 




1,2,3,4-tetrahydronaphthalen-1-yl)carbamate (2.58)  (MDW-2-251). A mixture of c.a. 
80% N2H4·H2O in water (70 µL) was added to a solution of 2.42 (58 mg, 0.12 mmol) in 
EtOH (1.2 mL), and the reaction was heated under reflux for 21 h. The reaction mixture 
was concentrated under reduced pressure and dissolved in CH2Cl2 (5 mL), whereupon it 



















































layer was extracted with CH2Cl2 (2 x 5 mL). The combined organic extracts were dried 
(Na2SO4), and concentrated under reduced pressure. The crude residue was dissolved in 
triethyl orthoacetate (1.0 mL) and CH3CO2H (2 drops) was added. The reaction was 
heated at 125 °C under microwave irradiation for 1 h. The reaction was cooled to room 
temperature and concentrated under reduced pressure. The crude crude residue was 
dissolved in CH2Cl2 (5 mL) and washed with 1 N NaOH (5 mL). The organic layer was 
separated, and the aqueous layer was extracted with CH2Cl2 (2 x 5 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated under reduced pressure. The crude 
residue was purified via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N 
(29:70:1 to 0:99:1) to afford 37 mg (63%) of 2.58 as a colorless oil. 1H NMR (400 MHz, 
CDCl3) rotamers δ 7.46 – 7.27 (comp, 5 H), 7.02 – 6.95 (m, 1 H), 6.79 – 6.72 (m, 1 H), 
6.64 – 6.57 (m, 1 H), 5.50 – 5.11 (comp, 3 H), 3.15 – 3.00 (comp, 6 H), 2.91 – 2.83 
(comp, 2 H), 2.72 – 2.59 (comp, 9 H), 2.53 – 2.49 (comp, 3 H), 2.08 – 1.90 (comp, 2 H), 
1.84 – 1.67 (comp, 2 H). 13C NMR (126 MHz, CDCl3) rotamers δ 165.7, 163.9, 157.3, 
157.0, 149.9, 149.9, 137.2, 137.1, 135.9, 135.8, 130.4, 130.0, 129.9, 129.9, 128.6, 128.6, 
128.0, 127.9, 127.9, 115.8, 115.5, 114.7, 114.4, 67.2, 67.2, 55.7, 55.4, 54.7, 52.9, 49.6, 
49.5, 30.3, 29.8, 28.8, 28.7, 28.2, 27.7, 23.6, 22.3, 22.1, 11.1. HRMS (ESI) m/z calcd for 













































NMR Assignments (2.58). 1H NMR (400 MHz, CDCl3) rotamers δ 7.46 – 7.27 (comp, 5 
H, 13, 14, 15, 16, 18), 7.02 – 6.95 (m, 1 H, 3), 6.79 – 6.72 (m, 1 H, 2), 6.64 – 6.57 (m, 1 
H, 6), 5.50 – 5.11 (comp, 3 H, 10, 19), 3.15 – 3.00 (comp, 6 H, 25, 27, 30), 2.91 – 2.83 
(comp, 2 H, 29), 2.72 – 2.59 (comp, 9 H, 7, 12, 24, 28), 2.53 – 2.49 (comp, 3 H, 36), 2.08 
– 1.90 (comp, 2 H, 8, 9), 1.84 – 1.67 (comp, 2 H, 8, 9). 13C NMR (126 MHz, CDCl3) 
rotamers δ 165.7 (33), 163.9 (31), 157.3 and 157.0 (21), 149.9 and 149.9 (1), 137.2 and 
137.1 (5), 135.9 and 135.8 (17), 130.4 (4), 130.0 and 129.9 (3), 129.9 (4), 128.6 and 
128.6 (13, 15), 128.0 (14), 127.9 and 127.9 (16, 18), 115.8 and 115.5 (2), 114.7 and 114.4 
(6), 67.2 and 67.2 (19), 55.7 and 55.4 (10), 54.7 (29), 52.9 (24, 28), 49.6 and 49.5 (25, 




yl)carbamate (2.61)  (MDW-1-165). Prepared from 2.15 (0.300 g, 0.910 mmol) and 
piperazine according to representative procedure B. The crude residue was purified via 
flash chromatography (SiO2) eluting with DCM/MeOH/Et3N (97:2:1) to afford 0.114 g 
(35%) of 2.61 as a pale yellow oil. 1H NMR (400 MHz, CDCl3) rotamers δ 7.44 – 7.23 
(comp, 5H), 7.00 – 6.92 (m, 1H), 6.77 – 6.69 (m, 1H), 6.63 – 6.57 (m, 1H), 5.46 – 5.27 
(m, 1H), 5.25 – 5.13 (comp, 2H), 3.15 – 3.05 (comp, 4H), 3.04 – 2.96 (comp, 4H), 2.72 – 








CDCl3) rotamers δ 157.1, 156.9, 150.5, 150.4, 139.2, 139.0, 137.1, 137.0, 128.4, 128.2, 
128.0, 127.8, 127.8, 127.7, 127.6, 126.5, 126.4, 115.8, 114.6, 67.0, 54.8, 54.6, 50.1, 46.0, 
30.0, 30.0, 29.9, 29.4, 28.3, 27.8, 22.1, 22.0. HRMS (ESI) m/z calcd for C23H29N3O2 
(M+H)+, 380.2333; found 380.2346. 
 
 
NMR Assignments (2.61). 1H NMR (400 MHz, CDCl3) rotamers δ 7.44 – 7.23 
(comp, 5H, 13, 14, 15, 16, 18), 7.00 – 6.92 (m, 1H, 6), 6.77 – 6.69 (m, 1H, 1), 6.63 – 6.57 
(m, 1H, 3), 5.46 – 5.27 (m, 1H, 7), 5.25 – 5.13 (comp, 2H, 19), 3.15 – 3.05 (comp, 4H, 
24, 28), 3.04 – 2.96 (comp, 4H, 25, 27), 2.72 – 2.59 (comp, 6H, 10, 12, 26), 2.04 – 1.88 
(comp, 2H, 9, 11), 1.82 – 1.63 (comp, 2H, 9, 11). 13C NMR (101 MHz, CDCl3) δ 157.1 
(21), 156.9 (21), 150.5 (2), 150.4 (2), 139.2 (4), 139.0 (4), 137.1 (17), 137.0 (17), 128.4 
(13, 15), 128.2 (6), 128.0 (6), 127.8 (14), 127.8 (14), 127.7 (16, 18), 127.6 (16, 18), 126.5 
(5), 126.4 (5), 115.8 (3), 114.6 (1), 67.0, 54.8 (7), 54.6 (7), 50.1 (24, 28), 46.0 (25, 27), 












































yl)carbamate (2.60)  (MDW-1-212). Prepared from 2.27 (0.129 g, 0.339 mmol) and 
piperazine according to representative procedure B. The crude residue was purified via 
flash chromatography (SiO2) eluting with DCM/MeOH/Et3N (97:2:1) to afford 0.0735 g 
(57%) of 2.60 as a pale yellow oil. 1H NMR (400 MHz, CDCl3) rotamers δ 7.45 – 7.27 
(comp, 5H), 7.13 (t, J = 7.8 Hz, 1H), 6.95 – 6.84 (comp, 2H), 5.56 – 5.32 (m, 1H), 5.28 – 
5.14 (comp, 2H), 3.07 – 2.92 (comp, 6H), 2.81 – 2.72 (comp, 2H), 2.72 – 2.59 (comp, 
5H), 2.55 – 2.42 (m, 1H), 2.10 – 1.93 (comp, 2H), 1.86 – 1.61 (comp, 2H). 13C NMR 
(126 MHz, CDCl3) rotamers: δ 157.1, 156.8, 151.6, 151.6, 137.0, 136.9, 136.5, 136.4, 
134.0, 133.8, 128.5, 128.4, 127.9, 127.8, 127.7, 127.7, 126.4, 126.4, 122.6, 122.5, 117.8, 
117.7, 67.1, 55.7, 55.5, 53.1, 46.5, 30.2, 29.6, 27.9, 27.4, 25.3, 25.2, 22.1, 22.0. HRMS 
(ESI) m/z calcd for C23H29N3O2 (M+H)+, 380.2333; found 380.2348. 
 
 
NMR Assignments (2.60). 1H NMR (400 MHz, CDCl3) rotamers δ 7.45 – 7.27 
(comp, 5H, 13, 14, 15, 16, 18), 7.13 (t, J = 7.8 Hz, 1H, 1), 6.95 – 6.84 (comp, 2H, 2, 6), 
5.56 – 5.32 (m, 1H, 7), 5.28 – 5.14 (comp, 2H, 19), 3.07 – 2.92 (comp, 6H, 24, 25, 27, 
28), 2.81 – 2.72 (comp, 2H, 25, 27), 2.72 – 2.59 (comp, 5H, 10, 12, 26), 2.55 – 2.42 (m, 

































MHz, CDCl3) δ 157.1 (21), 156.8 (21), 151.6 (3), 151.6 (3), 137.0 (5), 136.9 (5), 136.5 
(17), 136.4 (17), 134.0 (1), 133.8 (1), 128.5 (13, 15), 128.4 (13, 15), 127.9 (14), 127.8 
(14), 127.7 (16, 18), 127.7 (16, 18), 126.4 (4), 126.4 (4), 122.6 (6), 122.5 (6), 117.8 (2), 
117.7 (2), 67.1 (19), 55.7 (7), 55.5 (7), 53.1 (24, 28), 46.5 (25, 27), 30.2 (12), 29.6 (12), 




yl)carbamate (2.64)  (MDW-1-204). Prepared from 2.61 (30 mg, 0.079 mmol) and 
propionaldehyde according to representative procedure E. The crude residue was purified 
via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (76:23:1) to afford 24 
mg (71%) of 2.64 as a pale yellow oil. 1H NMR (400 MHz, CDCl3) rotamers δ 7.45 – 
7.28 (comp, 5H), 7.01 – 6.95 (m, 1H), 6.75 (d, J = 8.6 Hz, 1H), 6.64 – 6.60 (m, 1H), 5.49 
– 5.28 (m, 1H), 5.27 – 5.11 (comp, 2H), 3.25 – 3.14 (comp, 4H), 2.82 – 2.67 (comp, 2H), 
2.67 – 2.56 (comp, 7H), 2.40 – 2.32 (comp, 2H), 2.07 – 1.90 (comp, 2H), 1.84 – 1.65 
(comp, 2H), 1.56 (h, J = 7.9, 7.4 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H).13C NMR (101 MHz, 
CDCl3) rotamers δ 157.3, 157.0, 150.2, 150.1, 139.4, 139.1, 137.2, 137.2, 128.6, 128.6, 
128.3, 128.2, 128.0, 128.0, 127.9, 127.8, 126.5, 126.4, 115.8, 114.6, 67.2, 67.2, 60.8, 
54.9, 54.8, 53.4, 49.1, 30.2, 30.1, 29.8, 29.6, 28.4, 27.9, 22.3, 22.1, 20.1, 12.1. HRMS 










NMR Assignments (2.64). 1H NMR (400 MHz, CDCl3) rotamers δ 7.45 – 7.28 
(comp, 5H, 22, 23, 24, 25, 27), 7.01 – 6.95 (m, 1H, 6), 6.75 (d, J = 8.6 Hz, 1H, 1), 6.64 – 
6.60 (m, 1H, 3), 5.49 – 5.28 (m, 1H, 10), 5.27 – 5.11 (comp, 2H, 28), 3.25 – 3.14 (comp, 
4H, 13, 17), 2.82 – 2.67 (comp, 2H, 7), 2.67 – 2.56 (comp, 7H, 14, 16, 21), 2.40 – 2.32 
(comp, 2H, 18), 2.07 – 1.90 (comp, 2H, 8, 9), 1.84 – 1.65 (comp, 2H, 8, 9), 1.56 (h, J = 
7.9, 7.4 Hz, 2H, 19), 0.93 (t, J = 7.4 Hz, 3H, 20). 13C NMR (101 MHz, CDCl3) rotamers 
δ 157.3 (30), 157.0 (30), 150.2 (2), 150.1 (2), 139.4 (4), 139.1 (4), 137.2 (26), 137.2 (26), 
128.6 (22, 24), 128.6 (22, 24), 128.3 (6), 128.2 (6), 128.0 (23), 128.0 (23), 127.9 (25, 27), 
127.8 (25, 27), 126.5 (5), 126.4 (5), 115.8 (3), 114.6 (1), 67.2, 67.2 (28), 60.8 (18), 54.9 
(10), 54.8 (10), 53.4 (14, 16), 49.1 (13, 17), 30.2 (7), 30.1 (7), 29.8 (21), 29.6, 28.4 (18), 














































propionaldehyde according to representative procedure E. The crude residue was purified 
via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (82:17:1) to afford 23 
mg (68%) of 2.63 as a pale yellow oil. 1H NMR (499 MHz, CDCl3) rotamers δ 7.43 – 
7.28 (comp, 5H), 7.13 (t, J = 7.8 Hz, 1H), 6.96 – 6.92 (m, 1H), 6.90 – 6.85 (m, 1H), 5.56 
– 5.35 (m, 1H), 5.26 – 5.11 (comp, 2H), 3.07 – 2.93 (comp, 3H), 2.87 – 2.78 (comp, 2H), 
2.70 – 2.43 (comp, 8H2.41 – 2.35 (comp, 2H), 2.10 – 1.94 (comp, 2H), 1.85 – 1.64 
(comp, 2H), 1.61 – 1.51 (comp, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 157.3, 156.9, 151.5, 151.4, 137.2, 137.1, 136.6, 136.5, 134.1, 133.9, 128.6, 
128.6, 128.0, 128.0, 127.9, 127.8, 126.6, 126.5, 122.7, 122.5, 117.8, 117.8, 67.3, 61.0, 
55.9, 55.6, 53.9, 52.0, 30.4, 29.7, 28.1, 27.6, 25.4, 25.4, 22.3, 22.2, 20.2, 12.2. HRMS 
(ESI) m/z calcd for C26H35N3O2 (M+H)+, 422.2802; found 422.2804. 
 
 
NMR Assignments (2.63).1H NMR (499 MHz, CDCl3) rotamers δ 7.43 – 7.28 
(comp, 5H, 13, 14, 15, 16, 18), 7.13 (t, J = 7.8 Hz, 1H, 1), 6.96 – 6.92 (m, 1H, 6), 6.90 – 
6.85 (m, 1H, 2), 5.56 – 5.35 (m, 1H, 7), 5.26 – 5.11 (comp, 2H, 19), 3.07 – 2.93 (comp, 
3H, 10, 24, 28), 2.87 – 2.78 (comp, 2H, 24, 28), 2.70 – 2.43 (comp, 8H, 10, 12, 25, 27), 

































1.61 – 1.51 (comp, 2H, 30), 0.94 (t, J = 7.4 Hz, 3H, 31). 13C NMR (126 MHz, CDCl3) δ 
157.3 (21), 156.9 (21), 151.5 (3), 151.4 (3), 137.2 (5), 137.1, 136.6 (17), 136.5 (17), 
134.1 (4), 133.9 (4), 128.6 (13, 15), 128.6 (13, 15), 128.0 (14), 128.0 (14), 127.9 (16, 18), 
127.8 (16, 18), 126.6 (1), 126.5 (1), 122.7 (6), 122.5 (6), 117.8 (2), 117.8 (2), 67.3 (19), 
61.0 (29), 55.9 (7), 55.6 (7), 53.9 (25, 27), 52.0, 30.4 (12), 29.7 (12), 28.1 (9), 27.6 (9), 




tetrahydronaphthalen-2-yl)piperazin-1-yl)propanoate (2.66)  (MDW-1-207).  
Prepared from 2.61 (30 mg, 0.079 mmol) and ethyl acrylate according to representative 
procedure H. The crude residue was purified via flash chromatography (SiO2) eluting 
with hexanes/EtOAc/Et3N (69:30:1) to afford 32 mg (84%) of 2.66 as a pale yellow 
oil.1H NMR (499 MHz, CDCl3) rotamers δ 7.44 – 7.26 (comp, 5H), 7.00 – 6.94 (m, 1H), 
6.76 – 6.72 (m, 1H), 6.63 – 6.59 (m, 1H), 5.47 – 5.29 (m, 1H), 5.27 – 5.15 (comp, 2H), 
4.15 (q, J = 7.1 Hz, 2H), 3.21 – 3.11 (comp, 4H), 2.79 – 2.70 (comp, 3H), 2.72 – 2.66 (m, 
1H), 2.66 – 2.58 (comp, 7H), 2.53 (t, J = 7.8, 6.9 Hz, 2H), 2.06 – 1.91 (comp, 2H), 1.83 – 
1.66 (comp, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) rotamers δ 172.6, 
157.3, 157.0, 150.1, 150.0, 139.4, 139.1, 137.2, 137.1, 128.6, 128.6, 128.3, 128.1, 128.0, 









49.1, 32.5, 30.2, 30.1, 29.8, 29.5, 28.4, 27.9, 22.2, 22.1, 14.4. HRMS (ESI) m/z calcd for 
C28H37N3O4 (M+H)+, 480.2857; found 480.2876 
 
NMR Assignments (2.66).1H NMR (499 MHz, CDCl) rotamers δ 7.44 – 7.26 
(comp, 5H, 26, 27, 28, 29, 31), 7.00 – 6.94 (m, 1H, 6), 6.76 – 6.72 (m, 1H, 1), 6.63 – 6.59 
(m, 1H, 3), 5.47 – 5.29 (m, 1H, 10), 5.27 – 5.15 (comp, 2H, 32), 4.15 (q, J = 7.1 Hz, 2H, 
24), 3.21 – 3.11 (comp, 4H, 13, 17), 2.79 – 2.70 (comp, 3H, 7, 18), 2.72 – 2.66 (m, 1H, 
7), 2.66 – 2.58 (comp, 7H, 14, 16, 21), 2.53 (t, J = 7.8, 6.9 Hz, 2H, 19), 2.06 – 1.91 
(comp, 2H, 8, 9), 1.83 – 1.66 (comp, 2H, 8, 9), 1.26 (t, J = 7.1 Hz, 3H, 25). 13C NMR 
(126 MHz, CDC3) rotamers δ 172.6 (20), 157.3 (34), 157.0 (34), 150.1 (2), 150.0 (2), 
139.4 (4), 139.1 (4), 137.2 (30), 137.1 (30), 128.6 (26, 28), 128.6 (26, 28), 128.3 (6), 
128.1 (6), 128.0 (27), 128.0 (27), 127.9 (29, 31), 127.8 (29, 31), 126.6 (5), 126.5 (5), 
115.9 (3), 114.6 (1), 67.2 (32), 67.2 (32), 60.6 (24), 54.9 (10), 54.8 (10), 53.7 (18), 53.1 
(14, 16), 49.1 (13, 17), 32.5 (19), 30.2 (7), 30.1 (7), 29.8 (21), 29.5 (21), 28.4 (9), 27.9 











































tetrahydronaphthalen-1-yl)piperazin-1-yl)propanoate (2.65)  (MDW-1-214).  
Prepared from 2.60 (30 mg, 0.079 mmol) and ethyl acrylate according to representative 
procedure H. The crude residue was purified via flash chromatography (SiO2) eluting 
with hexanes/EtOAc/Et3N (79:20:1) to afford 22 mg (59%) of 2.65 as a pale yellow oil. 
1H NMR (499 MHz, CDCl3) rotamers δ 7.43 – 7.27 (comp, 5H), 7.13 (t, J = 7.8 Hz, 1H), 
6.94 – 6.90 (m, 1H), 6.90 – 6.85 (m, 1H), 5.55 – 5.35 (m, 1H), 5.26 – 5.11 (comp, 2H), 
4.16 (q, J = 7.2 Hz, 2H), 3.04 – 2.92 (comp, 3H), 2.85 – 2.75 (comp, 4H), 2.71 – 2.41 
(comp, 10H), 2.10 – 1.93 (comp, 2H), 1.85 – 1.62 (comp, 2H), 1.27 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) rotamers δ 172.6, 157.3, 156.9, 151.3, 151.3, 137.1, 137.1, 
136.6, 136.5, 134.1, 133.9, 128.6, 128.6, 128.0, 128.0, 127.9, 127.8, 126.6, 126.5, 122.8, 
122.6, 117.8, 117.7, 67.3, 60.6, 55.8, 55.6, 53.8, 53.6, 51.9, 32.5, 30.4, 29.7, 28.1, 27.6, 












NMR Assignments (2.65).1H NMR (499 MHz, CDCl3) rotamers δ 7.43 – 7.27 
(comp, 5H, 13, 14, 15, 16, 18), 7.13 (t, J = 7.8 Hz, 1H, 1), 6.94 – 6.90 (m, 1H, 6), 6.90 – 
6.85 (m, 1H, 2), 5.55 – 5.35 (m, 1H, 7), 5.26 – 5.11 (comp, 2H, 19), 4.16 (q, J = 7.2 Hz, 
2H, 35), 3.04 – 2.92 (comp, 3H, 10, 24', 28'), 2.85 – 2.75 (comp, 4H, 24'', 28'', 29), 2.71 – 
2.41 (comp, 10H, 10, 12, 25, 27, 30), 2.10 – 1.93 (comp, 2H, 9', 11'), 1.85 – 1.62 (comp, 
2H, 9'', 11''), 1.27 (t, J = 7.1 Hz, 3H, 34). 13C NMR (126 MHz, CDCl3) δ 172.6 (31), 
157.3 (21), 156.9 (21), 151.3 (3), 151.3 (3), 137.1 (5), 137.1 (5), 136.6 (17), 136.5 (17), 
134.1 (1), 133.9 (1), 128.6 (13, 15), 128.6 (13, 15), 128.0 (14), 128.0 (14), 127.9 (16, 18), 
127.8 (16, 18), 126.6 (4), 126.5 (4), 122.8 (6), 122.6 (6), 117.8 (2), 117.7 (2), 67.3 (19), 
60.6 (35), 55.8 (7), 55.6 (7), 53.8 (29), 53.6 (24, 28), 51.9 (25, 27), 32.5 (30), 30.4 (12), 
29.7 (12), 28.1 (9), 27.6 (9), 25.4 (10), 25.3 (10), 22.3 (11), 22.1 (11), 14.4 (34). 
 
 
Benzyl (7-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)(ethyl)carbamate (2.71)  













































(1.81 g, 22.2 mmol), NaBH3CN (0.279 g, 4.44 mmol), and Et3N (2.25 g, 3.1 mL, 22.2 
mmol) was stirred at room temperature for 48 h. The reaction was diluted with Et2O (20 
mL) and extracted with 1 N HCl (3 x 30 mL).  The combined aqueous extracts were 
made basic with 6 N NaOH and extracted with CH2Cl2 (3 x 100 mL). The combined 
organic extracts were dried (Na2SO4), and concentrated under reduced pressure to afford 
0.361 g of a crude residue that was used directly. The crude residue was dissolved in 
CH2Cl2 (14 mL) and cooled to 0 °C, whereupon i-Pr2Net (0.36 g, 0.49 mL, 2.8 mmol) and 
CbzCl (0.29 g, 0.24 mL, 1.7 mmol) were added sequentially. The reaction was stirred for 
1 h and the cooling bath was removed, and the solution was stirred for 14 h at room 
temperature.   The reaction was diluted with CH2Cl2 (20 mL) and washed with 1 N HCl 
(2 x 25 mL), 1 N NaOH (2 x 25 mL), and brine (1 x 25 mL). The organic layer was dried 
(Na2SO4) and concentrated under reduced pressure. The crude residue was purified via 
flash chromatography (SiO2) eluting with hexanes/EtOAc (25:4) to afford 0.432 g (50%) 
of 2.71 as a pale yellow oil. 1H NMR (400 MHz, CDCl3) rotamers: δ 7.52 – 7.15 (comp, 
7 H), 7.01 – 6.87 (m, 1H), 5.50 – 5.01 (comp, 3 H), 3.45 – 3.19 (m, 1 H), 3.08 – 2.57 
(comp, 3 H), 2.17 – 1.92 (comp, 2 H), 1.90 – 1.64 (comp, 2 H), 1.28 – 1.07 (m, 3 H). 
HRMS (ESI) m/z calcd for C20H22BrNO2 (M+Na)+, 410.0726; found 410.0736. 
 
 
Benzyl (7-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)(propyl)carbamate (2.72)  
(MDW-1-182). A solution containing bromotetralone (0.500 g, 2.22 mmol), propylamine 
(0.40 g, 0.55 mL 6.7 mmol), Na(OAc)BH3 (0.942 g, 4.44 mmol), and acetic acid (0.24 g, 





with Et2O (20 mL) and extracted with 1 N HCl (3 x 30 mL).  The combined aqueous 
extracts were made basic with 6 N NaOH and extracted with CH2Cl2 (3 x 100 mL). The 
combined organic extracts were dried (Na2SO4), and concentrated under reduced pressure 
to afford 0.277 g of a crude residue that was used directly. The crude residue was 
dissolved in CH2Cl2 (10 mL) and cooled to 0 °C, whereupon i-Pr2Net (0.27 g, 0.36 mL, 
2.8 mmol) and CbzCl (0.22 g, 0.18 mL, 1.7 mmol) were added sequentially. The reaction 
was stirred for 1 h and the cooling bath was removed, and the solution was stirred for 14 
h at room temperature.   The reaction was diluted with CH2Cl2 (20 mL) and washed with 
1 N HCl (2 x 25 mL), 1 N NaOH (2 x 25 mL), and brine (1 x 25 mL). The organic layer 
was dried (Na2SO4) and concentrated under reduced pressure. The crude residue was 
purified via flash chromatography (SiO2) eluting with hexanes/EtOAc (25:4) to afford 
0.398 g (45%) of 2.72 as a pale yellow oil.1H NMR (400 MHz, CDCl3) rotamers δ 7.46 – 
7.14 (comp, 7H), 6.98 – 6.89 (m, 1H), 5.41 – 4.96 (comp, 3H), 3.33 – 3.14 (m, 1H), 2.99 
– 2.60 (comp, 3H), 2.14 – 1.93 (comp, 2H), 1.92 – 1.65 (comp, 3H), 1.64 – 1.47 (m, 1H), 
0.94 – 0.75 (comp, 3H). 13C NMR (101 MHz, CDCl3) δ 156.8, 156.0, 139.1, 138.6, 
137.0, 136.8, 136.6, 136.5, 130.7, 130.7, 129.7, 129.6, 129.4, 129.2, 128.4, 128.3, 127.8, 
127.6, 127.5, 119.6, 67.0, 67.0, 56.5, 56.0, 48.5, 46.7, 28.9, 28.5, 23.5, 22.5, 22.1, 22.0, 
11.4. HRMS (ESI) m/z calcd for C21H24BrNO2 (M+Na)+, 424.0883; found 424.0891. 
 
 
NMR Assignments (2.72). 1H NMR (400 MHz, CDCl3) rotamers δ 7.46 – 7.14 





























20), 3.33 – 3.14 (m, 1H, 7), 2.99 – 2.60 (comp, 3H, 7, 13), 2.14 – 1.93 (comp, 2H, 8, 9), 
1.92 – 1.65 (comp, 3H, 8, 9, 24), 1.64 – 1.47 (m, 1H, 24), 0.94 – 0.75 (comp, 3H, 25). 13C 
NMR (101 MHz, CDCl3) rotamers δ 156.8 (22), 156.0 (22), 139.1 (5), 138.6 (5), 137.0 
(18), 136.8 (18), 136.6 (4), 136.5 (4), 130.7, 130.7 (6), 129.7 (3), 129.6 (3), 129.4 (1), 
129.2 (1), 128.4 (14, 16), 128.3 (14, 16), 127.8 (15), 127.6 (17, 19), 127.5 (17, 19), 119.6 
(2), 67.0 (20), 67.0 (20), 56.5 (10), 56.0 (10), 48.5 (13), 46.7 (13), 28.9 (7), 28.5 (9), 23.5 




(2.73)  (MDW-1-185). Prepared from 2.71 (0.432 g 1.11 mmol) and piperazine according 
to representative procedure B. The crude residue was purified via flash chromatography 
(SiO2) eluting with DCM/MeOH/Et3N (97:2:1) to afford 0.320 g (73%) of 2.73 as an 
orange oil. 1H NMR (400 MHz, CDCl3) rotamers δ 7.41 – 7.17 (comp, 5H), 6.93 (d, J = 
8.4 Hz, 1H), 6.70 (dd, J = 8.4, 2.6 Hz, 1H), 6.60 – 6.55 (m, 1H), 5.46 – 4.97 (comp, 4H), 
3.35 – 3.06 (comp, 2H), 2.98 – 2.86 (comp, 8H), 2.71 – 2.56 (comp, 2H), 2.07 – 1.94 
(comp, 2H), 1.85 – 1.59 (comp, 2H), 1.12 (dt, J = 24.7, 7.0 Hz, 3H). 13C NMR (101 
MHz, CDCl3) rotamers δ 156.9, 156.0, 150.0, 149.9, 136.9, 136.8, 136.5, 136.1, 129.5, 
129.4, 129.1, 128.2, 128.1, 127.6, 127.5, 115.4, 115.2, 114.2, 113.8, 66.6, 66.5, 56.4, 
56.0, 50.4, 50.3, 45.9, 40.3, 38.8, 29.2, 28.8, 28.5, 28.4, 22.3, 22.1, 15.6, 14.5. HRMS 








NMR Assignments (2.73). 1H NMR (400 MHz, CDCl3) rotamers δ 7.41 – 7.17 
(comp, 5H, 19, 20, 21, 22, 24), 6.93 (d, J = 8.4 Hz, 1H, 3), 6.70 (dd, J = 8.4, 2.6 Hz, 1H, 
6), 6.60 – 6.55 (m, 1H, 2), 5.46 – 4.97 (comp, 4H, 7, 16, 25), 3.35 – 3.06 (m, 2H, 13), 
2.98 – 2.86 (comp, 8H, 14, 15, 17, 18), 2.71 – 2.56 (comp, 2H, 10), 2.07 – 1.94 (comp, 
2H, 9, 12), 1.85 – 1.59 (comp, 2H, 9, 12), 1.12 (dt, J = 24.7, 7.0 Hz, 3H, 29). 13C NMR 
(101 MHz, CDCl3) rotamers δ 156.9 (27), 156.0 (27), 150.0 (1), 149.9 (1), 136.9 (5), 
136.8 (5), 136.5 (23), 136.1 (23), 129.5 (4), 129.4 (3), 129.1 (4), 128.2 (19), 128.1 (21), 
127.6 (20), 127.5 (22, 24), 115.4 (2), 115.2 (2), 114.2 (6), 113.8 (6), 66.6 (25), 66.5 (25), 
56.4, 56.0 (7), 50.4 (14, 18), 50.3 (14, 18), 45.9 (15, 17), 40.3 (13), 38.8 (13), 29.2 (10), 




yl)(propyl)carbamate (2.74)  (MDW-1-186). Prepared from 2.72 (0.398 g 1.02 mmol) 
and piperazine according to representative procedure B. The crude residue was purified 
via flash chromatography (SiO2) eluting with DCM/MeOH/Et3N (97:2:1) to afford 0.284 
g (70%) of 2.74 as an orange oil. 1H NMR (400 MHz, CDCl3) rotamers δ 7.43 – 7.18 
(comp, 5H), 6.95 (d, J = 8.4 Hz, 1H), 6.73 (dd, J = 8.4, 2.6 Hz, 1H), 6.60 – 6.54 (m, 1H), 




































3H), 2.10 – 1.97 (comp, 2H), 1.97 – 1.88 (m, 1H), 1.84 – 1.60 (comp, 3H), 1.59 – 1.44 
(m, 1H), 0.77 (dt, J = 30.3, 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) rotamers δ 157.0, 
156.3, 150.1, 150.0, 137.0, 136.8, 136.3, 129.6, 129.5, 129.1, 128.2, 128.1, 127.6, 127.5, 
127.5, 115.5, 115.2, 114.1, 113.6, 66.6, 66.6, 56.7, 56.1, 50.5, 50.4, 46.3, 45.9, 29.3, 28.9, 
28.5, 28.5, 23.5, 22.4, 22.2, 11.4. HRMS (ESI) m/z calcd for C25H33N3O2 (M+H)+, 
408.2646; found 408.2661. 
 
 
NMR Assignments (2.74). 1H NMR (400 MHz, CDCl3) rotamers δ 7.43 – 7.18 
(comp, 5H, 21, 22, 23, 24, 26), 6.95 (d, J = 8.4 Hz, 1H, 3), 6.73 (dd, J = 8.4, 2.6 Hz, 1H, 
2), 6.60 – 6.54 (m, 1H, 6), 5.42 – 4.99 (comp, 3H, 7, 27), 3.26 – 3.04 (m, 1H, 10), 3.02 – 
2.87 (comp, 8H, 14, 15, 17, 18), 2.83 – 2.59 (comp, 3H, 10, 13), 2.10 – 1.97 (comp, 2H, 
9, 12), 1.97 – 1.88 (m, 1H, 19), 1.84 – 1.60 (comp, 3H, 9, 12, 19), 1.59 – 1.44 (m, 1H, 
16), 0.77 (dt, J = 30.3, 7.4 Hz, 3H, 20). 13C NMR (101 MHz, cdcl3) δ 157.0 (29), 156.3 
(29), 150.1 (1), 150.0 (1), 137.0 (5), 136.8 (5, 25), 136.3 (25), 129.6 (4), 129.5 (3), 129.1 
(4), 128.2 (21), 128.1 (21, 23), 127.6 (24, 26), 127.5 (24, 26), 127.5 (22), 115.5 (2), 115.2 
(2), 114.1 (6), 113.6 (6), 66.6 (27), 66.6 (27), 56.7 (7), 56.1 (7), 50.5 (14, 18), 50.4 (14, 
18), 46.3 (13), 45.9 (15, 17), 29.3 (10), 28.9 (10), 28.5 (9), 28.5 (9), 23.5 (12), 22.4 (19), 





































Benzyl (7-bromo-1,2,3,4-tetrahydronaphthalen-1-yl)carbamate (2.75)  
(MDW-1-193).  NH4OAc (1.71 g, 22.2 mmol), and NaBH3CN (691 mg, 11.1 mmol) were 
added to a solution of 7-bromotetralone (0.500 g, 2.22 mmol), in MeOH (11 mL) and the 
reaction was heated at 60 °C for 24 h. The reaction was concentrated under reduced 
pressure, and the crude residue was dissolved in Et2O (30 mL) and extracted with 1 N 
HCl (3 x 30 mL). The combined aqueous extracts were made basic with 6 N NaOH and 
extracted with CH2Cl2 (3 x 50 mL). The combined organic extracts were dried (Na2SO4) 
and concentrated under reduced pressure. The crude residue was dissolved in CH2Cl2 (22 
mL) and cooled to 0 °C. i-Pr2Net (0.55 g, 0.75 mL, 4.3 mmol) and CbzCl (0.44 g, 0.37 
mL, 2.6 mmol) were added sequentially to the cooled solution. The reaction was stirred 
for 1 h and the cooling bath was removed, and the solution was stirred for 14 h at room 
temperature.   The reaction was diluted with CH2Cl2 (20 mL) and washed with 1 N HCl 
(2 x 25 mL), 1 N NaOH (2 x 25 mL), and brine (1 x 25 mL). The organic layer was dried 
(Na2SO4) and concentrated under reduced pressure. The crude residue was purified via 
flash chromatography (SiO2) eluting with hexanes/EtOAc (9:1) to afford 0.502 g (59%) 
of 2.75 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.48 (dd, J = 2.1 Hz, 1H), 7.41 – 
7.28 (comp, 5H), 7.25 (dd, J = 8.4, 2.1 Hz, 1H), 6.92 (d, J = 8.2 Hz, 1H), 5.40 (d, J = 9.0 
Hz, 1H), 5.11 (s, 2H), 4.89 – 4.79 (m, 1H), 2.76 – 2.60 (comp, 2H), 2.07 – 1.95 (m, 1H), 
1.89 – 1.68 (comp, 3H). 13C NMR (101 MHz, CDCl3) δ 155.9, 139.0, 136.4, 136.1, 
131.1, 130.6, 130.1, 128.4, 128.0, 127.9, 119.5, 66.7, 49.0, 30.1, 28.6, 19.8. HRMS (ESI) 









NMR Assignments (2.75). 1H NMR (400 MHz, CDCl3) δ 7.48 (dd, J = 2.1 Hz, 
1H, 6), 7.41 – 7.28 (comp, 5H, 13, 14, 15, 16, 18), 7.25 (dd, J = 8.4, 2.1 Hz, 1H, 2), 6.92 
(d, J = 8.2 Hz, 1H, 3), 5.40 (d, J = 9.0 Hz, 1H, 11), 5.11 (s, 2H, 19), 4.89 – 4.79 (m, 1H, 
10), 2.76 – 2.60 (comp, 2H, 7), 2.07 – 1.95 (m, 1H, 9), 1.89 – 1.68 (comp, 3H, 8, 9). 13C 
NMR (101 MHz, CDCl3) δ 155.9 (21), 139.0 (5), 136.4 (4), 136.1 (17), 131.1 (6), 130.6 
(2), 130.1 (1), 128.4 (13, 15), 128.0 (14), 127.9 (16, 18), 119.5 (3), 66.7 (19), 49.0 (10), 




(2.76)  (MDW-1-197). Prepared from 2.75 (0.200 g 0.555 mmol) and piperazine 
according to representative procedure B. The crude residue was purified via flash 
chromatography (SiO2) eluting with DCM/MeOH/Et3N (97:2:1) to afford 89 mg (43%) 
of 2.76 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.28 (comp, 5H), 6.96 (d, 
J = 8.4 Hz, 1H), 6.84 (d, J = 2.6 Hz, 1H), 6.76 (dd, J = 8.4, 2.6 Hz, 1H), 5.33 (d, J = 8.7 
Hz, 1H), 5.13 (dd, J = 12.3, 8.9 Hz, 2H), 4.89 – 4.81 (m, 1H), 3.07 – 2.93 (comp, 8H), 
2.71 – 2.64 (comp, 2H), 2.61 – 2.49 (m, 1H), 2.04 – 1.94 (m, 1H), 1.87 – 1.73 (comp, 
3H). 13C NMR (101 MHz, CDCl3) δ 156.0, 150.3, 137.2, 136.7, 129.7, 128.8, 128.5, 































NMR Assignments (2.75). 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.28 (comp, 5H, 
18, 19, 20, 21, 23), 6.96 (d, J = 8.4 Hz, 1H, 3), 6.84 (d, J = 2.6 Hz, 1H, 6), 6.76 (dd, J = 
8.4, 2.6 Hz, 1H, 2), 5.33 (d, J = 8.7 Hz, 1H, 8), 5.13 (dd, J = 12.3, 8.9 Hz, 2H), 4.89 – 
4.81 (m, 1H, 7), 3.07 – 2.93 (comp, 8H, 13, 14, 16, 17), 2.71 – 2.64 (comp, 2H, 10), 2.61 
– 2.49 (m, 1H, 15), 2.04 – 1.94 (m, 1H, 9), 1.87 – 1.73 (m, 3H, 9, 12). 13C NMR (101 
MHz, CDCl3) δ 156.0 (26), 150.3 (1), 137.2 (5), 136.7 (22), 129.7 (3), 128.8 (4), 128.5 
(18, 20), 128.1 (19), 128.1 (21, 23), 116.1 (2), 116.0 (6), 66.6 (24), 50.5 (13, 17), 49.6 




yl)carbamate (2.77) (MDW-1-202). Prepared from 2.76 (30 mg, 0.082 mmol) and 
propionaldehyde according to representative procedure E. The crude residue was purified 
via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (74:25:1) to afford 28 
mg (84%) of 2.77 as a colorless oil. 1H NMR (499 MHz, CDCl3) δ 7.43 – 7.29 (comp, 
5H), 6.98 (d, J = 8.4 Hz, 1H), 6.88 (d, J = 2.6 Hz, 1H), 6.79 (dd, J = 8.4, 2.7 Hz, 1H), 
5.20 – 5.10 (comp, 2H), 5.02 (d, J = 8.7 Hz, 1H), 4.91 – 4.83 (m, 1H), 3.19 – 3.07 (comp, 
4H), 2.75 – 2.62 (comp, 2H), 2.59 (t, J = 5.1 Hz, 4H), 2.40 – 2.33 (comp, 2H), 2.10 – 




































3H). 13C NMR (126 MHz, CDCl3) δ 156.0, 150.0, 137.2, 136.8, 129.9, 128.8, 128.6, 
128.2, 116.1, 116.0, 66.8, 60.8, 53.3, 30.6, 28.5, 20.1, 20.0, 12.1. HRMS (ESI) m/z calcd 
for C25H33N3O2 (M+H)+, 408.2646; found 408.2662. 
 
 
NMR Assignments (2.77). 1H NMR (499 MHz, CDCl3) δ 7.43 – 7.29 (comp, 5H, 
21, 22, 23, 24, 26), 6.98 (d, J = 8.4 Hz, 1H, 3), 6.88 (d, J = 2.6 Hz, 1H, 6), 6.79 (dd, J = 
8.4, 2.7 Hz, 1H, 2), 5.20 – 5.10 (comp, 2H, 27), 5.02 (d, J = 8.7 Hz, 1H, 11), 4.91 – 4.83 
(m, 1H, 10), 3.19 – 3.07 (comp, 4H, 13, 17), 2.75 – 2.62 (comp, 2H, 7), 2.59 (t, J = 5.1 
Hz, 4H, 14, 16), 2.40 – 2.33 (comp, 2H, 18), 2.10 – 1.97 (comp, 2H, 8, 9), 1.82 – 1.74 
(comp, 2H, 8, 9), 1.61 – 1.51 (m, 2H, 19), 0.93 (t, J = 7.4 Hz, 3H, 20). 13C NMR (126 
MHz, CDCl3) δ 156.0 (29), 150.0 (1), 137.2 (5), 136.8 (25), 129.9 (3), 128.8 (4), 128.6 
(21, 23), 128.2 (22, 24, 26), 116.1 (2), 116.0 (6), 66.8 (27), 60.8 (18), 53.3 (14, 16), 30.6 




yl)carbamate (2.78) (MDW-1-195). Prepared from 2.73 (29 mg, 0.072 mmol) and 
propionaldehyde according to representative procedure E. The crude residue was purified 






































mg (77%) of 2.78 as a pale yellow oil. 1H NMR (499 MHz, CDCl3) rotamers δ 7.45 – 
7.22 (comp, 5H), 6.98 (d, J = 8.4 Hz, 1H), 6.77 (dd, J = 8.4, 2.5 Hz, 1H), 6.65 – 6.59 (m, 
1H), 5.47 – 5.04 (comp, 3H), 3.35 – 3.15 (m, 1H), 3.11 – 3.01 (comp, 4H), 2.98 – 2.79 
(m, 1H), 2.77 – 2.62 (comp, 2H), 2.60 – 2.52 (comp, 4H), 2.39 – 2.32 (comp, 2H), 2.11 – 
2.01 (m, 1H), 2.00 – 1.91 (m, 1H), 1.88 – 1.66 (comp, 2H), 1.55 (h, J = 7.4 Hz, 2H), 1.15 
(dt, J = 32.6, 7.0 Hz, 3H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) rotamers 
δ 157.4, 156.5, 150.0, 149.9, 137.3, 137.1, 136.5, 130.0, 129.8, 129.5, 128.6, 128.5, 
127.9, 115.8, 115.5, 114.7, 114.2, 67.1, 66.9, 60.8, 56.9, 56.4, 53.4, 49.6, 49.5, 39.2, 29.6, 
29.2, 28.9, 28.8, 22.7, 22.4, 20.2, 15.9, 14.9, 12.1. HRMS (ESI) m/z calcd for C27H37N3O2 
(M+H)+, 436.2959; found 436.2976. 
 
 
NMR Assignments (2.78). 1H NMR (499 MHz, CDCl3) rotamers δ 7.45 – 7.22 
(comp, 5H, 23, 24, 25, 26, 28), 6.98 (d, J = 8.4 Hz, 1H, 2), 6.77 (dd, J = 8.4, 2.5 Hz, 1H, 
3), 6.65 – 6.59 (m, 1H, 6), 5.47 – 5.04 (comp, 3H, 10, 29), 3.35 – 3.15 (m, 1H, 7), 3.11 – 
3.01 (comp, 4H, 14, 18), 2.98 – 2.79 (m, 1H, 7), 2.77 – 2.62 (comp, 2H, 12), 2.60 – 2.52 
(comp, 4H, 15, 17), 2.39 – 2.32 (comp, 2H, 19), 2.11 – 2.01 (m, 1H, 9), 2.00 – 1.91 (m, 
1H, 9), 1.88 – 1.66 (comp, 2H, 8), 1.55 (h, J = 7.4 Hz, 2H, 20), 1.15 (dt, J = 32.6, 7.0 Hz, 
3H, 21), 0.94 (t, J = 7.4 Hz, 3H, 22). 13C NMR (126 MHz, CDCl3) rotamers δ 157.4 (31), 
156.5 (31), 150.0 (1), 149.9 (1), 137.3 (5), 137.1 (5), 136.5 (27), 130.0 (3), 129.8 (3, 4), 
129.5 (4), 128.6 (23), 128.5 (25), 127.9 (26, 28), 115.8 (2), 115.5 (2), 114.7 (6), 114.2 




































18), 39.2 (7), 29.6 (9), 29.2 (9), 28.9 (12), 28.8 (12), 22.7 (8), 22.4 (8), 20.2 (20), 15.9 




yl)carbamate (2.79) (MDW-1-196). Prepared from 2.74 (29 mg, 0.071 mmol) and 
propionaldehyde according to representative procedure E. The crude residue was purified 
via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (76:23:1) to afford 23 
mg (72%) of 2.79 as a pale yellow oil. 1H NMR (400 MHz, CDCl3) rotamers δ 7.47 – 
7.17 (comp, 5H), 6.98 (d, J = 8.5 Hz, 1H), 6.77 (dd, J = 8.4, 2.5 Hz, 1H), 6.60 (d, J = 2.6 
Hz, 1H), 5.44 – 5.01 (comp, 3H), 3.27 – 2.99 (comp, 5H), 2.86 – 2.61 (comp, 3H), 2.60 – 
2.51 (comp, 4H), 2.35 (app t, J = 7.8 Hz, 2H), 2.11 – 2.00 (m, 1H), 2.00 – 1.91 (m, 1H), 
1.91 – 1.62 (comp, 3H), 1.61 – 1.45 (comp, 3H), 0.94 (t, J = 7.4 Hz, 3H), 0.78 (dt, J = 
31.6, 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 157.4, 156.7, 150.0, 149.9, 137.4, 
137.2, 137.1, 136.6, 129.9, 129.8, 129.4, 128.6, 128.5, 127.9, 127.9, 127.8, 115.8, 115.4, 
114.4, 114.0, 67.0, 67.0, 60.8, 57.0, 56.5, 53.4, 49.6, 49.6, 46.7, 29.6, 29.3, 28.9, 28.8, 
23.8, 22.8, 22.5, 20.2, 12.1, 11.7, 11.7. HRMS (ESI) m/z calcd for C28H39N3O2 (M+H)+, 








NMR Assignments (2.79). 1H NMR (400 MHz, CDCl3) rotamers δ 7.47 – 7.17 
(comp, 5H, 24, 25, 26, 27, 29), 6.98 (d, J = 8.5 Hz, 1H, 3), 6.77 (dd, J = 8.4, 2.5 Hz, 1H, 
2), 6.60 (d, J = 2.6 Hz, 1H, 6), 5.44 – 5.01 (comp, 3H, 10, 30), 3.27 – 2.99 (comp, 5H, 7, 
14, 18), 2.86 – 2.61 (comp, 3H, 7, 12), 2.60 – 2.51 (comp, 4H, 15, 17), 2.35 (app t, J = 
7.8 Hz, 2H, 19), 2.11 – 2.00 (m, 1H, 9), 2.00 – 1.91 (m, 1H, 9), 1.91 – 1.62 (comp, 3H, 8, 
21), 1.61 – 1.45 (comp, 3H, 8, 20), 0.94 (t, J = 7.4 Hz, 3H, 23), 0.78 (dt, J = 31.6, 7.4 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 157.4 (32), 156.7 (32), 150.0 (1), 149.9 (1), 137.4 
(5), 137.2, 137.1 (28), 136.6 (28), 129.9 (4), 129.8 (3), 129.4 (4), 128.6 (24, 26), 128.5 
(24, 26), 127.9 (27, 29), 127.9 (25), 127.8 (27, 29), 115.8 (2), 115.4 (2), 114.4 (6), 114.0 
(6), 67.0 (30), 67.0 (30), 60.8 (19), 57.0 (10), 56.5 (10), 53.4 (15, 17), 49.6 (14, 18), 49.6 
(14, 18), 46.7 (7), 29.6 (9), 29.3 (9), 28.9, 28.8 (12), 23.8 (21), 22.8, 22.5 (8), 20.2 (20), 




yl)piperazin-1-yl)propanoate (2.80) (MDW-1-206). Prepared from 2.76 (30 mg, 0.082 
mmol) and ethyl acylate according to representative procedure H. The crude residue was 
purified via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (69:30:1) to 













































7.29 (comp, 5H), 6.98 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 2.6 Hz, 1H), 6.78 (dd, J = 8.4, 2.6 
Hz, 1H), 5.21 – 5.09 (comp, 2H), 5.02 (d, J = 8.7 Hz, 1H), 4.90 – 4.83 (m, 1H), 4.16 (q, J 
= 7.1 Hz, 2H), 3.17 – 3.05 (comp, 4H), 2.75 (app t, J = 7.6, 7.1 Hz, 2H), 2.74 – 2.61 
(comp, 2H), 2.60 (t, J = 5.0 Hz, 4H), 2.54 (app t, J = 7.6, 7.2 Hz, 2H), 2.07 – 1.96 (m, 
1H), 1.88 – 1.74 (comp, 3H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
172.6, 156.0, 149.9, 137.3, 136.8, 129.9, 128.9, 128.6, 128.2, 116.1, 66.8, 60.6, 53.7, 
53.0, 49.7, 49.5, 32.5, 30.6, 28.5, 20.0, 14.4. HRMS (ESI) m/z calcd for C27H35N3O4 
(M+H)+, 466.2700; found 466.2721. 
 
 
NMR Assignments (2.80). 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.29 (comp, 5H, 
25, 26, 27, 28, 30), 6.98 (d, J = 8.4 Hz, 1H, 3), 6.86 (d, J = 2.6 Hz, 1H, 6), 6.78 (dd, J = 
8.4, 2.6 Hz, 1H, 2), 5.21 – 5.09 (comp, 2H, 31), 5.02 (d, J = 8.7 Hz, 1H, 11), 4.90 – 4.83 
(m, 1H, 10), 4.16 (q, J = 7.1 Hz, 2H, 23), 3.17 – 3.05 (comp, 4H, 13, 17), 2.75 (app t, J = 
7.6, 7.1 Hz, 2H, 18), 2.74 – 2.61 (comp, 2H, 7), 2.60 (t, J = 5.0 Hz, 4H, 14, 16), 2.54 (app 
t, J = 7.6, 7.2 Hz, 2H, 19), 2.07 – 1.96 (m, 1H, 9), 1.88 – 1.74 (comp, 3H, 8, 9), 1.27 (t, J 
= 7.1 Hz, 3H, 24). 13C NMR (101 MHz, CDCl3) δ 172.6 (20), 156.0 (33), 149.9 (1), 
137.3 (5), 136.8 (29), 129.9 (3), 128.9 (4), 128.6 (25, 27), 128.2 (28, 30), 116.1 (2, 6), 
66.8 (31), 60.6 (23), 53.7 (18), 53.0 (14, 16), 49.7 (10), 49.5 (13, 17), 32.5 (19), 30.6 (9), 











































tetrahydronaphthalen-2-yl)piperazin-1-yl)propanoate (2.81) (MDW-1-190). Prepared 
from 2.73 (30 mg, 0.076 mmol) and ethyl acylate according to representative procedure 
H. The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (69:30:1) to afford 35 mg (92%) of 2.81 as a pale yellow oil. 1H 
NMR (499 MHz, CDCl3) rotamers δ 7.45 – 7.23 (comp, 5H), 6.97 (d, J = 8.3 Hz, 1H), 
6.75 (dd, J = 8.5, 2.5 Hz, 1H), 6.63 – 6.58 (m, 1H), 5.45 – 5.04 (comp, 3H), 4.16 (q, J = 
7.1 Hz, 2H), 3.36 – 3.15 (m, 1H), 3.09 – 3.00 (comp, 4H), 2.96 – 2.79 (m, 1H), 2.75 (t, J 
= 7.4 Hz, 2H), 2.72 – 2.62 (comp, 2H), 2.61 – 2.56 (comp, 4H), 2.53 (t, J = 7.4 Hz, 2H), 
2.11 – 1.91 (comp, 2H), 1.87 – 1.67 (comp, 2H), 1.27 (t, J = 7.1 Hz, 3H), 1.15 (dt, J = 
31.7, 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.6, 157.3, 156.4, 149.9, 149.7, 
137.3, 137.1, 137.0, 136.5, 130.1, 129.8, 129.6, 128.6, 128.5, 128.0, 127.9, 115.8, 115.5, 
114.7, 114.2, 67.1, 66.9, 60.6, 56.8, 56.4, 53.7, 53.0, 49.6, 49.5, 39.2, 32.5, 29.8, 29.6, 
29.2, 28.9, 28.8, 22.7, 22.4, 15.9, 14.9, 14.4. HRMS (ESI) m/z calcd for C29H39N3O4 
















from 2.74 (30 mg, 0.074 mmol) and ethyl acylate according to representative procedure 
H. The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (69:30:1) to afford 32 mg (86%) of 2.82 as a pale yellow oil. 1H 
NMR (499 MHz, CDCl3) rotamers δ 7.43 – 7.19 (comp, 5H), 7.00 – 6.94 (m, 1H), 6.75 
(dd, J = 8.4, 2.5 Hz, 1H), 6.61 – 6.56 (m, 1H), 5.42 – 5.02 (comp, 3H), 4.16 (q, J = 7.1 
Hz, 2H), 3.25 – 2.98 (comp, 5H), 2.79 – 2.62 (comp, 5H), 2.62 – 2.51 (comp, 6H), 2.09 – 
2.00 (m, 1H), 1.99 – 1.91 (m, 1H), 1.89 – 1.61 (comp, 3H), 1.59 – 1.45 (m, 1H), 1.27 (t, J 
= 7.1 Hz, 3H), 0.78 (dt, J = 38.9, 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) rotamers δ 
172.6, 157.4, 156.6, 149.9, 149.7, 137.3, 137.2, 137.1, 136.7, 130.0, 129.8, 129.5, 128.6, 
128.5, 128.0, 127.9, 127.9, 127.8, 115.8, 115.5, 114.4, 114.0, 67.0, 67.0, 60.6, 57.0, 56.4, 
53.7, 53.0, 49.6, 49.5, 46.7, 45.9, 32.5, 29.6, 29.2, 28.9, 28.8, 23.8, 22.8, 22.7, 22.5, 14.4, 
11.7, 11.6. HRMS (ESI) m/z calcd for C30H41N3O4 (M+H)+, 508.3170; found 508.3191. 
 
 
NMR Assignments (2.82). 1H NMR (499 MHz, CDCl3) rotamers δ 7.43 – 7.19 
(comp, 5H, 28, 29, 30, 31, 33), 7.00 – 6.94 (m, 1H, 3), 6.75 (dd, J = 8.4, 2.5 Hz, 1H, 2), 
6.61 – 6.56 (m, 1H, 6), 5.42 – 5.02 (comp, 3H, 10, 34), 4.16 (q, J = 7.1 Hz, 2H, 24), 3.25 
– 2.98 (comp, 5H, 12, 14, 18), 2.79 – 2.62 (comp, 5H, 7, 12, 19), 2.62 – 2.51 (comp, 6H, 
15, 17, 20), 2.09 – 2.00 (m, 1H, 9), 1.99 – 1.91 (m, 1H, 8), 1.89 – 1.61 (comp, 3H, 8, 9, 
26), 1.59 – 1.45 (m, 1H, 26), 1.27 (t, J = 7.1 Hz, 3H, 25), 0.78 (dt, J = 38.9, 7.4 Hz, 3H, 
27). 13C NMR (126 MHz, CDCl3) δ 172.6 (21), 157.4, 156.6 (36), 149.9, 149.7 (1), 












































128.0, 127.9 (31, 33), 127.9, 127.8 (29), 115.8, 115.5 (2), 114.4, 114.0 (6), 67.0, 67.0 
(34), 60.6 (24), 57.0, 56.4 (10), 53.7 (19), 53.0 (15, 17), 49.6, 49.5 (14, 18), 46.7, 45.9 
(12), 32.5 (20), 29.6, 29.2 (9), 28.9, 28.8 (7), 23.8, 22.8 (26), 22.7, 22.5 (8), 14.4 (25), 
11.7, 11.6 (27). 
 
 
7-(Piperazin-1-yl)-3,4-dihydronaphthalen-1(2H)-one (2.83) (MDW-2-220). A 
resealable tube was charged with 7-bromotetralone (1.500 g, 6.664 mmol), piperazine 
(5.740 g, 66.63 mmol), Cs2CO3 (3.257 g, 9.99 mmol). The tube was evacuated and 
backfilled with N2 three times, whereupon degassed t-BuOH (33 mL) and the suspension 
was stirred at 45 °C for 15 min. A freshly prepared t-BuOH solution (2.0 mL) containing 
Pd2dba3 (122 mg, 0.133 mmol) and RuPhos (124 mg, 0.266 mmol) that had been stirred 
at 60 °C for 30 min was added. The tube was sealed, and the reaction was stirred at 100 
°C for 3 h. After cooling to room temperature, the mixture was filtered through Celite, 
the filter cake was washed with CH2Cl2 (200 mL), and the filtrate was concentrated. The 
residue was dissolved in Et2O (75 mL) and extracted with 1 N HCl (4 x 30 mL). The 
combined acidic aqueous extracts were made basic and extracted with CH2Cl2 (3 x 100 
mL), after which the combined organic extracts were dried (MgSO) and concentrated 
under reduced pressure. The crude material was purified via flash chromatography (SiO2) 
eluting with CH2Cl2/MeOH/Et3N (97:2:1) affording 1.3574 g (88%) of 2.83 as a red oil. 
1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 2.8 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H), 7.01 
(dd, J = 8.4, 2.8 Hz, 1H), 3.15 – 3.05 (comp, 4H), 3.00 – 2.91 (comp, 4H), 2.78 (t, J = 6.1 





(101 MHz, CDCl3) δ 198.5, 150.3, 135.8, 132.8, 129.4, 122.0, 112.8, 50.0, 45.8, 39.1, 
28.7, 23.4. HRMS (ESI) m/z calcd for C14H18N2O (M+H)+, 231.1492; found 231.1497 
 
 
NMR Assignments (2.83). 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 2.8 Hz, 
1H, 6), 7.07 (d, J = 8.4 Hz, 1H, 3), 7.01 (dd, J = 8.4, 2.8 Hz, 1H, 2), 3.15 – 3.05 (comp, 
4H, 13, 17), 3.00 – 2.91 (comp, 4H, 14, 16), 2.78 (t, J = 6.1 Hz, 2H, 9), 2.70 (brs, 1H, 
18), 2.53 (t, J = 6.3 Hz, 3H, 7), 2.01 (p, J = 6.3 Hz, 2H, 8). 13C NMR (101 MHz, CDCl3) 
δ 198.5 (10), 150.3 (1), 135.8 (5), 132.8 (4), 129.4 (3), 122.0 (2), 112.8 (6), 77.5, 77.2, 




57). A solution of propionaldehyde (1.006 g, 11.29 mmol) in DCE (25 mL) was added 
dropwise to a solution of amine 2.83 (2.363 g, 10.3 mmol) and Na(OAc)3BH (4.349 g, 
20.5 mmol) in DCE (103 mL), and the reaction was stirred at room temperature for 3 h. 
The reaction mixture was then washed with saturated aq. NaHCO3 (2 x 50 mL), dried 
(Na2SO4), and concentrated under reduced pressure. The crude material was purified via 
flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (74:25:1) affording 2.165 
g (77%) of 2.84 as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 2.7 Hz, 1 H), 
























J = 6.1 Hz, 2 H), 2.64 – 2.55 (comp, 6 H), 2.38 – 2.31 (m, 2 H), 2.09 (m, 2 H), 1.60 – 
1.48 (m, 2 H), 0.92 (t, J = 7.4 Hz, 3 H). 13C NMR (101 MHz, CDCl3) δ 198.9, 150.1, 
135.8, 133.0, 129.6, 122.0, 113.0, 60.8, 53.2, 49.1, 39.3, 28.9, 23.6, 20.1, 12.1. HRMS 
(ESI) m/z calcd for C17H24N2O (M+H)+, 273.1961; found 273.1965 
 
 
NMR Assignments (2.84). 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 2.7 Hz, 
1H, 6), 7.14 (d, J = 8.4 Hz, 1H, 3), 7.08 (dd, J = 8.5, 2.7 Hz, 1H, 2), 3.24 – 3.19 (comp, 
4H, 13, 17), 2.86 (t, J = 6.1 Hz, 2H, 9), 2.64 – 2.55 (comp, 7H, 7, 14, 16), 2.38 – 2.31 
(comp, 2H, 18), 2.09 (p, J = 6.4 Hz, 3H, 19), 1.60 – 1.48 (comp, 2H, 8), 0.92 (t, J = 7.4 
Hz, 3H, 20). 13C NMR (101 MHz, CDCl3) δ 198.9 (10), 150.1 (1), 135.8 (5), 133.0 (4), 
129.6 (3), 122.0 (2), 113.0 (6), 60.8 (18), 53.2 (13, 17), 49.1 (14, 16), 39.3 (9), 28.9 (7), 




(MDW-2-100). Prepared from 2.84 (0.213 g, 0.782 mmol) mmol) and NH4OAc 
according to representative procedure D. The crude residue was purified via flash 
chromatography (SiO2) eluting with CH2Cl2/MeOH/Et3N (94:5:1) affording 0.115 g 
(54%) of 2.86 as a red oil. 1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 2.6 Hz, 1 H), 6.94 


























(comp, 4 H), 2.75 – 2.50 (comp, 6 H), 2.34 – 2.27 (m, 2 H), 2.04 – 1.82 (comp, 2 H), 1.77 
– 1.65 (comp, 2 H), 1.58 – 1.45 (comp, 2 H), 0.90 (t, J = 7.4 Hz, 3 H). 13C NMR (101 
MHz, CDCl3) δ 149.8, 139.1, 129.7, 128.0, 115.6, 115.4, 60.7, 53.3, 49.8, 49.4, 32.4, 




NMR Assignments (2.86).1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 2.6 Hz, 1 
H, 6), 6.94 (d, J = 8.4 Hz, 1 H, 3), 6.74 (dd, J = 8.4, 2.6 Hz, 1 H, 2), 4.05 – 3.90 (comp, 3 
H, 10, 21, 22), 3.20 – 3.12 (comp, 4 H, 13, 17), 2.75 – 2.50 (comp, 6 H, 7, 14, 16), 2.34 – 
2.27 (comp, 2 H, 18), 2.04 – 1.82 (comp, 2 H, 9), 1.77 – 1.65 (comp, 2 H, 8), 1.58 – 1.45 
(comp, 2H, 19), 0.90 (t, J = 7.4 Hz, 3 H, 20).13C NMR (101 MHz, CDCl3) δ 149.8 (1), 
139.1 (5), 129.7 (4), 128.0 (3), 115.6 (6), 115.4 (2), 60.7 (18), 53.3 (13, 17), 49.8 (10), 




(2.87) (MDW-2-74). Prepared from 2.84 (0.102 g, 0.375 mmol) mmol) and MeNH3Cl 
according to representative procedure D. The crude residue was purified via flash 































of 2.87 as a pale yellow oil. 1H NMR (400 MHz, CDCl3) δ 6.97 (d, J = 8.4 Hz, 1H), 6.92 
(d, J = 2.6 Hz, 1H), 6.77 (dd, J = 8.4, 2.7 Hz, 1H), 3.61 (t, J = 4.9 Hz, 1H), 3.20 – 3.14 
(comp, 4H), 2.77 – 2.62 (comp, 2H,), 2.62 – 2.57 (comp, 4H), 2.49 (s, 3H), 2.38 – 2.32 
(comp, 2H), 1.96 – 1.80 (comp, 3H), 1.75 – 1.65 (m, 1H), 1.60 – 1.49 (comp, 2H), 1.37 
(brs, 1H), 0.92 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 149.7, 139.6, 129.7, 
128.8, 116.4, 115.4, 60.8, 57.6, 53.4, 49.8, 34.1, 28.6, 27.9, 20.1, 19.2, 12.1. HRMS 
(ESI) m/z calcd for C18H29N3 (M+H)+, 288.2434; found 288.2438. 
 
 
NMR Assignments (2.87). 1H NMR (400 MHz, CDCl3) δ 6.97 (d, J = 8.4 Hz, 
1H, 3), 6.92 (d, J = 2.6 Hz, 1H, 6), 6.77 (dd, J = 8.4, 2.7 Hz, 1H, 2), 3.61 (t, J = 4.9 Hz, 
1H, 10), 3.20 – 3.14 (comp, 4H, 13, 17), 2.77 – 2.62 (comp, 2H, 7), 2.62 – 2.57 (comp, 
4H, 14, 16), 2.49 (s, 3H, 22), 2.38 – 2.32 (comp, 2H, 18), 1.96 – 1.80 (comp, 3H, 8, 9), 
1.75 – 1.65 (m, 1H, 8), 1.60 – 1.49 (comp, 2H, 19), 1.37 (brs, 1H, 21), 0.92 (t, J = 7.4 Hz, 
3H, 20). 13C NMR (101 MHz, CDCl3) δ 149.7 (1), 139.6 (5), 129.7 (3), 128.8 (4), 116.4 
(6), 115.4 (2), 60.8 (18), 57.6 (10), 53.4 (14, 16), 49.8 (13, 17), 34.1 (22), 28.6 (7), 27.9 


























Representative Procedure I: Reduction amination using Ti(Oi-Pr)4 and an alkyl 
amine.   
 
3-((7-(4-Propylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-1-
yl)amino)propan-1-ol (2.88) (MDW-2-140). TiO(i-Pr)4 (0.73 g, 0.76 mL, 2.6 mmol) was 
added to a solution of 2.84 (70 mg, 0.256 mmol)  and 3-amino-1-propanol (0.028 g, 
0.029 mL, 0.38 mmol) in EtOH (1.7 mL), and the reaction was stirred at 45 °C for 17 h. 
The reaction was cooled to 0 °C and NaBH4 (19 mg, 50 mmol) was added in a single 
portion. The reaction was stirred for 30 min and the cooling bath was removed. The 
solution was stirred for 4 h at room temperature and poured into 2 M aq. NH4OH (2 mL). 
Celite was added to the mixture and it was filtered, washing the filter cake with CH2Cl2 
(50 mL). The filtrate was concentrated under reduced pressure to remove volatile 
organics and the mixture obtained was diluted with saturated aqueous NaHCO3 (10 mL), 
whereupon the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated. The crude residue was purified 
via flash chromatography (SiO2) eluting with CH2Cl2/MeOH/Et3N (97:2:1) affording 77 
mg (91%) of 2.88 as a yellow oil.1H NMR (499 MHz, CDCl3) δ 6.95 (d, J = 8.4 Hz, 1H), 
6.91 (d, J = 2.6 Hz, 1H), 6.77 (dd, J = 8.4, 2.6 Hz, 1H), 4.37 (brs, 2H), 3.83 – 3.75 
(comp, 3H), 3.20 – 3.10 (comp, 4H), 3.04 – 2.90 (comp, 2H), 2.72 – 2.54 (comp, 6H), 
2.37 – 2.28 (comp, 2H), 1.93 – 1.80 (comp, 3H), 1.76 – 1.65 (comp, 3H), 1.57 – 1.47 





128.8, 116.3, 115.8, 64.1, 60.8, 56.0, 53.3, 49.5, 47.0, 30.9, 28.4, 27.6, 20.1, 19.1, 12.1. 
HRMS (ESI) m/z calcd for C20H33N3O (M+H)+, 332.2696; found 332.27110. 
 
 
NMR Assignments (2.88). 1H NMR (499 MHz, CDCl3) δ 6.95 (d, J = 8.4 Hz, 
1H, 3), 6.91 (d, J = 2.6 Hz, 1H, 6), 6.77 (dd, J = 8.4, 2.6 Hz, 1H, 2), 4.37 (brs, 2H, 22, 
25), 3.83 – 3.75 (comp, 3H, 10, 24), 3.20 – 3.10 (comp, 4H, 13, 17), 3.04 – 2.90 (comp, 
2H, 7), 2.72 – 2.54 (comp, 6H, 14, 16, 21), 2.37 – 2.28 (comp, 2H, 18), 1.93 – 1.80 
(comp, 3H, 8, 9), 1.76 – 1.65 (comp, 3H, 8, 23), 1.57 – 1.47 (comp, 2H, 19), 0.90 (t, J = 
7.4 Hz, 3H, 20). 13C NMR (126 MHz, CDCl3) δ 149.7 (1), 137.9 (5), 129.8 (3), 128.8 (4), 
116.3 (6), 115.8 (2), 64.1 (24), 60.8 (18), 56.0 (10), 53.3 (14, 16), 49.5 (13, 17), 47.0 (7), 




yl)amino)propanoate (2.89) (MDW-2-123). Ethyl acrylate (35 mg, 38 µL, 0.35 mmol) 
was added to a solution of 2.86 (79 mg, 0.29 mmol) in EtOH (1.4 mL) and the reaction 


































pressure. The crude residue was filtered through a SiO2 plug rinsing with 
hexanes/EtOAc/Et3N (49:49:1), and the filtrate was concentrated under reduced pressure 
to afford a crude residue (42 mg) that was use directly. The crude residue was dissolved 
in CH2Cl2 (1.1 mL) and cooled to 0 ° C. i-Pr2NEt (29 mg, 39 µL 0.22 mmol) and CbzCl 
(45 mg, 38 µL, 0.27 mmol) we added sequentially. The reaction was stirred overnight 
allowing to slowly warm to room temperature. The reaction was diluted with CH2Cl2 (5 
mL) and washed sequentially with 1 N HCl (2 x5 mL), 1 N NaOH (2 x 5 mL), and 
saturated aqueous NaHCO3 (1x 5 mL). The organic layer was dried (Na2SO4) and 
concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (74:25:1) to afford 31 mg 
(21%) of 2.89 as a colorless oil. 1H NMR (499 MHz, CDCl3) rotamers δ 7.43 – 7.24 
(comp, 5H), 6.97 (dd, J = 8.7, 2.4 Hz, 1H), 6.76 (dd, J = 8.5, 2.5 Hz, 1H), 6.56 (brs, 1H), 
5.47 – 5.05 (comp, 3H), 4.11 – 3.99 (comp, 2H), 3.54 – 3.40 (m, 1H), 3.24 – 3.00 (comp, 
5H), 2.81 – 2.45 (comp, 8H), 2.38 – 2.31 (comp, 2H), 2.08 – 1.91 (comp, 2H), 1.81 – 
1.67 (comp, 2H), 1.60 – 1.51 (comp, 2H), 1.23 – 1.16 (comp, 3H), 0.93 (t, J = 7.4 Hz, 
3H). 13C NMR (126 MHz, CDCl3) rotamers δ 171.9, 171.7, 157.1, 156.6, 150.1, 150.0, 
137.0, 136.9, 136.0, 130.0, 129.6, 128.7, 128.6, 128.1, 128.0, 128.0, 116.0, 115.7, 114.3, 
113.9, 67.3, 67.2, 60.8, 60.6, 60.6, 56.5, 53.4, 49.6, 49.5, 40.2, 35.4, 34.3, 29.5, 29.1, 
28.8, 28.7, 22.6, 22.4, 20.2, 14.3, 12.1. HRMS (ESI) m/z calcd for C30H41N3O4 (M+H)+, 




NMR Assignments (2.89).1H NMR (499 MHz,CDCl3) rotamers δ 7.43 – 7.24 
(comp, 5H, 33, 34, 35, 36, 37), 6.97 (dd, J = 8.7, 2.4 Hz, 1H, 3), 6.76 (dd, J = 8.5, 2.5 Hz, 
1H, 2), 6.56 (brs, 1H, 6), 5.47 – 5.05 (comp, 3H, 10, 31), 4.11 – 3.99 (comp, 2H, 27), 
3.54 – 3.40 (m, 1H, 23), 3.24 – 3.00 (comp, 5H, 13, 17, 23), 2.81 – 2.45 (comp, 8H, 7, 
14, 16, 21), 2.38 – 2.31 (comp, 2H, 18), 2.08 – 1.91 (comp, 2H, 8, 9), 1.81 – 1.67 (comp, 
2H, 8, 9), 1.60 – 1.51 (comp, 2H, 19), 1.23 – 1.16 (comp, 3H, 28), 0.93 (t, J = 7.4 Hz, 
3H, 20). 13C NMR (126 MHz, CDCl3) rotamers δ 171.9 and 171.7 (24), 157.1 and 156.6 
(22), 150.1 and 150.0 (1), 137.0 and 136.9 (5), 136.0 (32), 130.0 (3), 129.6 (4), 128.7 and 
128.6 (34, 36), 128.1 and 128.0 (35), 128.0 (33, 37), 116.0 and 115.7 (2), 114.3 and 113.9 
(6), 67.3 and 67.2 (31), 60.8 (18), 60.6 and 60.6 (27), 56.5 (10), 53.4 (14, 16), 49.6 and 
49.5 (13, 17), 40.2 (23), 35.4 and 34.3 (21), 29.5 and 29.1 (9), 28.8 and 28.7 (7), 22.6 and 




amine (S.1) (MDW-2-193). TiO(i-Pr)4 (0.64 g, 0.67 mL, 2.3 mmol) was added to a 
solution of 2.86 (57 mg, 24 mmol)  and 3-oxetanone (0.0192 g, 0.017 mL, 0.27 mmol) in 















































(0.026 g, 0.41 mmol) was added to the solution and the reaction was stirred for 6 h. The 
reaction was poured into 2 M aq. NH4OH (10 mL). Celite was added to the mixture and it 
was filtered. The filter cake was washed with CH2Cl2 (100 mL). The filtrate was 
concentrated under reduced pressure to remove volatile organics and the mixture 
obtained was diluted with saturated aqueous NaHCO3 (10 mL), whereupon the aqueous 
layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated under reduced pressure. The crude residue was purified via 
flash chromatography (SiO2) eluting with CH2Cl2/MeOH/Et3N (99:0:1 to 94:5:1) 
affording 26 mg (37 %) of S.1 as an orange oil. 1H NMR (499 MHz, CDCl3) δ 6.97 (d, J 
= 8.4 Hz, 1H), 6.93 (d, J = 2.6 Hz, 1H), 6.78 (dd, J = 8.4, 2.6 Hz, 1H), 4.84 (q, J = 6.4 
Hz, 2H), 4.44 (q, J = 6.0 Hz, 2H), 4.14 (p, J = 6.8 Hz, 1H), 3.69 (t, J = 5.3 Hz, 1H), 3.23 
– 3.13 (comp, 4H), 2.77 – 2.58 (comp, 6H), 2.43 – 2.34 (comp, 2H), 2.03 – 1.50 (comp, 
7H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 149.7, 139.1, 129.8, 128.9, 
116.3, 115.8, 81.4, 81.0, 60.7, 55.2, 53.3, 52.2, 49.6, 30.1, 28.5, 20.0, 19.5, 12.1. HRMS 




1-yl)carbamate (2.91) (MDW-2-197). Prepared from S.1 (14 mg, 0.042 mmol) and 
CbzCl according to representative procedure A. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (59:40:1) affording 7 mg (35 
%) of 2.91 as a colorless oil. 1H NMR (499 MHz, CDCl3) rotamers δ 7.51 – 7.21 (comp, 







4.25 (comp, 8 H), 3.08 – 2.90 (comp, 4 H), 2.67 – 2.47 (comp, 6 H), 2.34 – 2.26 (comp, 2 
H), 2.04 – 1.94 (m, 1 H), 1.90 – 1.82 (m, 1 H), 1.71 – 1.62 (comp, 2 H), 1.53 – 1.46 
(comp, 2 H), 0.86 (t, J = 7.4 Hz, 3 H). HRMS (ESI) m/z calcd for C28H37N3O3 (M+H)+, 




tetrahydronaphthalen-1-yl)carbamate (2.92) (MDW-2-143). A solution of 2.88 (77 
mg, 0.23 mmol) and i-Pr2NEt (60 mg, 81 µL 0.47 mmol) in CH2Cl2 (6 mL) was cooled to 
0 ° C. CbzCl (43 mg, 36 µL, 0.25 mmol) was added dropwise to the cooled solution and 
the reaction was stirred for 1 h at 0 °C. The cooling bath was removed and the solution 
was stirred at room temperature for 16 h. The reaction was quenched with sequential 
addition of MeOH (3 mL) and 1 N NaOH (3 mL), and the reaction was stirred for 1 h at 
room temperature. The reaction was concentrated under reduced pressure to remove 
volatile organics and the mixture obtained was diluted with saturated aqueous 1 N NaOH 
(10 mL), whereupon the aqueous layer was extracted with CH2Cl2 (3 x 15 mL). The 
combined organic extracts were dried (Na2SO4) and concentrated under reduced pressure. 
The crude residue was purified via flash chromatography (SiO2) eluting with 
EtOAc/hexanes/MeOH/Et3N (50:44:5:1) affording 20 mg (19%) of 2.92 as a colorless 
oil. 1H NMR (499 MHz, CDCl3) rotamers δ 7.46 – 7.15 (comp, 5H), 6.98 (d, J = 8.3 Hz, 
1H), 6.75 (dd, J = 8.4, 2.5 Hz, 1H), 6.63 – 6.52 (m, 1H), 5.43 – 5.03 (comp, 3H), 3.66 – 
3.41 (comp, 3H), 3.27 – 3.06 (comp, 5H), 2.99 – 2.60 (comp, 7H), 2.59 – 2.46 (comp, 







rotamers δ 157.9, 157.3, 149.5, 137.0, 136.8, 136.6, 130.8, 130.1, 128.7, 128.6, 128.1, 
128.0, 116.2, 115.8, 114.8, 114.3, 67.5, 67.3, 60.6, 60.3, 59.4, 57.4, 56.6, 53.6, 52.9, 48.8, 
42.4, 41.8, 33.6, 32.9, 29.5, 29.0, 28.8, 28.7, 22.6, 22.4, 19.3, 19.1, 11.9. HRMS (ESI) 
m/z calcd for C28H39N3O3 (M+Na)+, 488.2884; found 488.2895. 
 
 
NMR Assignments (2.92). 1H NMR (499 MHz, CDCl3) rotamers δ 7.46 – 7.15 
(comp, 5H, 25, 26, 27, 28, 30), 6.98 (d, J = 8.3 Hz, 1H, 3), 6.75 (dd, J = 8.4, 2.5 Hz, 1H, 
2), 6.63 – 6.52 (m, 1H, 6), 5.43 – 5.03 (comp 3H, 10, 31), 3.66 – 3.41 (m, 3H, 23, 24), 
3.27 – 3.06 (comp, 5H, 12, 16, 21''), 2.99 – 2.60 (comp, 7H, 7, 13, 15, 21'), 2.59 – 2.46 
(comp, 2H, 17), 2.08 – 1.60 (comp, 8H, 8, 9, 18, 22), 0.95 (t, J = 7.3 Hz, 3H, 20). 13C 
NMR (126 MHz, CDCl3) δ 157.9 and 157.3 (33), 149.5 (1), 137.0 and 136.8 (5), 136.6 
(29), 130.8 (4), 130.1 (3), 128.7 (26), 128.6 (25, 27), 128.1 and 128.0 (28, 30), 116.2 and 
115.8 (2), 114.8 and 114.3 (6), 67.5 and 67.3 (31), 60.6 and 60.3 (17), 59.4 (23), 57.4 and 
56.6 (10), 53.6 and 52.9 (13, 15), 48.8 (12, 16), 42.4 and 41.8 (21), 33.6 and 32.9 (22), 
29.5 and 29.0 (9), 28.8 and 28.7 (7), 22.6 and 22.4 (8), 19.3 and 19.1 (18), 11.9 (20). 















































yl)cinnamamide (2.93) (MDW-2-190). A solution of 2.87 (14 mg, 0.050 mmol) and i-
Pr2NEt (13 mg, 17 µL 0.10 mmol) in CH2Cl2 (0.5 mL) was cooled to 0 ° C. Cinnamoyl 
chloride (10 mg, 0.60 mmol) was added to the cooled solution and the solution was 
stirred for 24 h allowing the reaction to slowly warm to room temperature. The reaction 
was diluted with 1 N NaOH (10 mL) and the aqueous layer was extracted with CH2Cl2 (3 
x 10 mL). The combined organic extracts were washed with brine (1 x 20 mL), dried 
(Na2SO4), and concentrated under reduced pressure. The crude residue was purified via 
flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (59:40:1) to afford 14 mg 
(66%) of 2.93 as a colorless oil. 1H NMR (400 MHz, CDCl3) rotamers δ 7.85 – 7.72 (m, 
1H), 7.63 – 7.48 (comp, 2H), 7.45 – 7.32 (comp, 3H), 7.09 – 6.93 (comp, 2H), 6.86 – 
6.76 (m, 1H), 6.71 – 6.61 (m, 1H), 6.07 – 5.18 (m, 1H), 3.23 – 3.07 (comp, 4H), 2.89 – 
2.77 (comp, 3H), 2.77 – 2.69 (comp, 2H), 2.65 – 2.55 (comp, 4H), 2.41 – 2.31 (comp, 
2H), 2.13 – 1.91 (comp, 3H), 1.88 – 1.76 (m, 1H), 1.62 – 1.48 (comp, 2H), 0.97 – 0.88 
(comp, 3H).13C NMR (126 MHz, CDCl3) rotamers δ 167.9, 167.3, 150.3, 150.2, 143.1, 
142.8, 135.8, 135.5, 135.5, 135.5, 130.5, 130.2, 130.0, 129.8, 129.7, 129.4, 129.0, 128.9, 
128.0, 127.9, 117.9, 115.7, 115.6, 114.9, 114.0, 60.7, 60.5, 57.8, 53.5, 53.3, 53.2, 49.6, 
49.4, 31.5, 30.1, 29.2, 28.9, 28.6, 27.6, 22.5, 22.2, 20.0, 12.1. HRMS (ESI) m/z calcd for 



































NMR Assignments (2.93). 1H NMR (400 MHz, CDCl3) rotamers δ 7.85 – 7.72 
(m, 1H, 24), 7.63 – 7.48 (comp, 2H, 26, 30), 7.45 – 7.32 (comp, 3H, 27, 28, 29), 7.09 – 
6.93 (comp, 2H, 3, 22), 6.86 – 6.76 (m, 1H, 2), 6.71 – 6.61 (m, 1H, 6), 6.07 – 5.18 (m, 
1H, 10), 3.23 – 3.07 (comp, 4H, 13, 17), 2.89 – 2.77 (comp, 3H, 31), 2.77 – 2.69 (comp, 
2H, 7), 2.65 – 2.55 (comp, 4H, 14, 16), 2.41 – 2.31 (comp, 2H, 18), 2.13 – 1.91 (comp, 
3H, 8, 9), 1.88 – 1.76 (m, 1H, 8'), 1.62 – 1.48 (comp, 2H, 19), 0.97 – 0.88 (m, 3H, 20). 
13C NMR (126 MHz, CDCl3) rotamers δ 167.9 and 167.3 (21), 150.3 and 150.2 (1), 143.1 
and 142.8 (24), 135.8 and 135.5 (25), 135.5 and 135.5 (5), 130.5 and 130.2 (4), 130.0 and 
129.8 (3), 129.7 and 129.4 (28), 129.0 and 128.9 (26, 30), 128.0 and 127.9 (27, 29) and 
117.9 (22), 115.7 and 115.6 (2), 114.9 and 114.0 (6), 60.7 and 60.5 (18), 57.8 and 53.5 
(10), 53.3 and 53.2 (14, 16), 49.6 and 49.4 (13, 17), 31.5 and 30.1 (31), 29.2 and 28.9 (7), 




tetrahydronaphthalen-1-yl)propenamide (2.94) (MDW-1-238). Prepared from 2.87 
(14 mg, 0.052mmol) and 3-phenylpropionyl chloride according to representative 
procedure J. The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (59:40:1) affording 13 mg (61 %) of 2.94 as a colorless oil. 1H 
NMR (499 MHz, CDCl3) rotamers  δ 7.33 – 7.17 (comp, 5H), 7.00 (t, J = 8.2 Hz, 1H), 
6.81 – 6.75 (m, 1H), 6.53 (dd, J = 9.3, 2.5 Hz, 1H), 5.94 – 4.89 (m, 1H), 3.15 – 3.00 
(comp, 6H), 2.89 – 2.52 (comp, 11H), 2.36 (td, J = 7.9, 2.7 Hz, 2H), 2.02 – 1.66 (comp, 







rotamers δ 173.0, 172.8, 150.3, 150.1, 141.7, 141.5, 135.8, 135.4, 130.4, 130.2, 129.9, 
129.4, 128.7, 128.6, 128.6, 128.6, 126.3, 126.2, 115.6, 115.6, 114.7, 113.7, 60.8, 60.8, 
57.4, 53.4, 53.3, 53.0, 49.7, 49.5, 36.0, 35.4, 31.9, 31.5, 31.2, 30.5, 29.8, 29.5, 28.9, 28.7, 
28.6, 27.6, 22.5, 22.2, 20.2, 12.1. HRMS (ESI) m/z calcd for C27H37N3O (M+H)+, 




tetrahydronaphthalen-1-yl)acetamide (2.95) (MDW-2-189). Prepared from 2.87 (17 
mg, 0.059mmol) and phenylacetyl chloride according to representative procedure J. The 
crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (59:40:1) affording 11 mg (46%) of 2.95 as a colorless oil. 1H 
NMR (499 MHz, CDCl3) rotamers δ 7.43 – 7.21 (comp, 5H), 6.96 (t, J = 9.1 Hz, 1H), 
6.78 – 6.69 (m, 1H), 6.35 (d, J = 2.7 Hz, 1H), 5.95 – 5.01 (m, 1H), 3.93 – 3.78 (comp, 
2H), 3.04 – 2.88 (comp, 4H), 2.70 – 2.60 (comp, 5H), 2.59 – 2.50 (comp, 4H), 2.41 – 
2.32 (comp, 2H), 2.05 – 1.87 (comp, 2H), 1.78 – 1.49 (comp, 4H), 0.97 – 0.90 (comp, 
3H). 13C NMR (126 MHz, CDCl3) roatmers δ 171.9, 171.8, 150.1, 149.9, 135.8, 135.6, 
135.3, 135.1, 130.1, 130.0, 129.9, 128.9, 128.9, 128.9, 128.8, 127.0, 126.9, 115.5, 115.3, 
114.0, 113.8, 60.8, 57.8, 53.3, 53.2, 53.0, 49.3, 49.3, 42.0, 41.8, 31.5, 29.8, 29.6, 28.8, 
28.6, 28.5, 27.4, 22.3, 22.2, 20.1, 20.1, 12.1, 12.1. HRMS (ESI) m/z calcd for C26H35N3O 










65). NaBH4 was added to a solution of 2.84 (150 mg, 0.551 mmol) in MeOH (2.7 mL) 
and the reaction was stirred for 2 h at room temperature. The reaction was quenched with 
1 N NaOH (5 mL) and volatile organics were removed under reduced pressure, 
whereupon the aqueous mixture was extracted with CH2Cl2 (3 x 10 mL). The combined 
organic extracts were washed with brined (1 x 10 mL) dried (Na2SO4) and concentrated 
under reduced pressure to afford 151 mg (100%) of 2.96 as a colorless oil. 1H NMR (400 
MHz, CDCl3) δ 6.98 (d, J = 2.6 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.75 (dd, J = 8.4, 2.7 
Hz, 1H), 4.68 – 4.63 (m, 1H), 3.14 – 3.07 (comp, 4H), 2.93 (brs, 1H), 2.72 – 2.50 (comp, 
6H), 2.35 – 2.27 (comp, 2H), 2.00 – 1.64 (comp, 4H), 1.58 – 1.47 (comp, 2H), 0.90 (t, J 
= 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 149.7, 139.6, 129.4, 128.3, 116.1, 115.8, 
68.3, 60.7, 53.2, 49.4, 32.6, 28.4, 19.9, 19.3, 12.0. HRMS (ESI) m/z calcd for C17H26N2O 
(M+H)+, 275.2118; found 275.2125. 
 
 
NMR Assignments (2.96). 1H NMR (400 MHz, CDCl3) δ 6.98 (d, J = 2.6 Hz, 
1H, 6), 6.94 (d, J = 8.4 Hz, 1H, 3), 6.75 (dd, J = 8.4, 2.7 Hz, 1H, 2), 4.68 – 4.63 (m, 1H, 
10), 3.14 – 3.07 (comp, 4H, 13, 17), 2.93 (brs, 1H, 12), 2.72 – 2.50 (comp, 6H, 7, 14, 16), 
2.35 – 2.27 (comp, 2H, 18), 2.00 – 1.64 (comp, 4H, 8, 9), 1.58 – 1.47 (comp, 2H, 19), 



























(3), 128.3 (4), 116.1 (2), 115.8 (6), 68.3 (10), 60.7 (18), 53.2 (14, 16), 49.4 (13, 17), 32.6 




(2.99) (MDW-1-245). NaH (6 mg of a 60% suspension in mineral oil, 0.1 mmol) was 
added to a solution of 2.96 (20 mg, 0.073 mmol) in DMF (0.4 mL) and the reaction was 
stirred at room temperature for 30 min. The reaction was cooled to 0 °C and a solution of 
benzyl bromide (12 mg, 8.6 µL, 0.073 mmol) in DMF (0.1 mL) was added. The reaction 
was stirred for 30 min at 0 °C and the cooling bath was removed. The reaction was stirred 
for 1 h at room temperature and NH4Cl (10 mL) was added, whereupon the mixture was 
extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried (Na2SO4) 
and concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (89:10:1) affording 15 mg 
(58%) of 2.99 as a pale yellow oil. 1H NMR (600 MHz, CDCl3) δ 7.43 – 7.39 (m, 1H), 
7.35 (t, J = 7.6 Hz, 2H), 7.30 – 7.26 (m, 1H), 6.99 (d, J = 8.3 Hz, 1H), 6.86 (d, J = 2.7 
Hz, 1H), 6.81 (dd, J = 8.4, 2.7 Hz, 1H), 4.70 (d, J = 12.0 Hz, 1H), 4.59 (d, J = 12.0 Hz, 
1H), 4.51 – 4.47 (m, 1H), 3.21 – 3.15 (comp, 4H), 2.79 – 2.60 (comp, 6H), 2.41 (t, J = 
7.9 Hz, 2H), 2.07 – 1.98 (comp, 2H), 1.96 – 1.89 (m, 1H), 1.76 – 1.69 (m, 1H), 1.64 – 
1.55 (comp, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 149.5, 139.3, 
137.4, 129.6, 129.4, 128.5, 128.0, 127.6, 116.8, 116.7, 75.1, 70.3, 60.7, 53.3, 49.6, 28.4, 







NMR Assignments (2.99). 1H NMR (600 MHz, CDCl3) δ 7.43 – 7.39 (m, 1H, 23, 
27), 7.35 (t, J = 7.6 Hz, 2H, 24, 26), 7.30 – 7.26 (m, 1H, 25), 6.99 (d, J = 8.3 Hz, 1H, 3), 
6.86 (d, J = 2.7 Hz, 1H, 6), 6.81 (dd, J = 8.4, 2.7 Hz, 1H, 2), 4.70 (d, J = 12.0 Hz, 1H, 
21''), 4.59 (d, J = 12.0 Hz, 1H, 21'), 4.51 – 4.47 (m, 1H, 10), 3.21 – 3.15 (comp, 4H, 13, 
17), 2.79 – 2.60 (comp, 6H, 7, 14, 16), 2.41 (t, J = 7.9 Hz, 2H, 18), 2.07 – 1.98 (comp, 
2H, 8'', 9''), 1.96 – 1.89 (m, 1H, 9'), 1.76 – 1.69 (m, 1H, 8'), 1.64 – 1.55 (comp, 2H, 19), 
0.94 (t, J = 7.4 Hz, 3H, 20). 13C NMR (151 MHz, CDCl3) δ 149.5 (1), 139.3 (22), 137.4 
(5), 129.6 (3), 129.4 (4), 128.5 (24, 26), 128.0 (23, 27), 127.6 (25), 116.8 (6), 116.7 (2), 
75.1 (10), 70.3 (21), 60.7 (18), 53.3 (14, 16), 49.6 (13, 17), 28.4 (7), 28.2 (9), 19.9 (19), 




(2.100) (MDW-2-98). A solution of 2.96 (50 mg, 0.18 mmol) in DMF (0.4 mL) was 
added to a solution of NaH (10 mg of a 60% suspension in mineral oil, 0.25 mmol) in 
DMF (0.3 mL) and the reaction was stirred for 30 min at room temperature. The reaction 
was cooled to 0 °C and a solution of cinnamyl bromide (43 mg, 0.22 mmol) in DMF 
(0.45 mL) was added. The reaction was stirred for 30 min at 0 °C and the cooling bath 






























was added, whereupon the mixture was extracted with CH2Cl2 (3 x 10 mL). The 
combined organic extracts were dried (Na2SO4) and concentrated under reduced pressure. 
The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (89:10:1) affording 22 mg (31%) of 2.100 as a pale yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 7.42 – 7.37 (comp, 2H), 7.35 – 7.29 (comp, 2H), 7.26 – 7.21 
(m, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.98 (d, J = 2.7 Hz, 1H), 6.82 (dd, J = 8.4, 2.7 Hz, 1H), 
6.66 (d, J = 16.0 Hz, 1H), 6.37 (dt, J = 15.9, 5.9 Hz, 1H), 4.50 (t, J = 4.9 Hz, 1H), 4.38 – 
4.20 (comp, 2H), 3.22 – 3.15 (comp, 4H), 2.82 – 2.57 (comp, 6H), 2.41 – 2.33 (comp, 
2H), 2.07 – 1.88 (comp, 3H), 1.78 – 1.67 (m, 1H), 1.63 – 1.50 (comp, 2H), 0.93 (t, J = 
7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 149.7, 137.4, 137.1, 131.9, 129.6, 129.3, 
128.7, 127.7, 127.2, 126.6, 116.7, 116.6, 75.5, 69.1, 60.8, 53.4, 49.7, 28.5, 28.4, 20.1, 
19.4, 12.1. HRMS (ESI) m/z calcd for C26H34N2O (M+H)+, 391.2744 found 391.2754. 
 
 
NMR Assignments (2.100). 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.37 (comp, 
2H, 25, 29), 7.35 – 7.29 (comp, 2H, 26, 28), 7.26 – 7.21 (m, 1H, 27), 7.00 (d, J = 8.4 Hz, 
1H, 3), 6.98 (d, J = 2.7 Hz, 1H, 6), 6.82 (dd, J = 8.4, 2.7 Hz, 1H, 2), 6.66 (d, J = 16.0 Hz, 
1H, 23), 6.37 (dt, J = 15.9, 5.9 Hz, 1H, 22), 4.50 (t, J = 4.9 Hz, 1H, 10), 4.38 – 4.20 
(comp, 2H, 21), 3.22 – 3.15 (comp, 4H, 13, 17), 2.82 – 2.57 (comp, 6H, 7, 14, 16), 2.41 – 
2.33 (comp, 2H, 18), 2.07 – 1.88 (comp, 3H, 8'', 9), 1.78 – 1.67 (m, 1H, 8'), 1.63 – 1.50 
(comp, 2H, 19), 0.93 (t, J = 7.4 Hz, 3H, 20). 13C NMR (101 MHz, CDCl3) δ 149.7 (1), 































(22), 126.6 (25, 29), 116.7 (6), 116.6 (2), 75.5 (10), 69.1 (21), 60.8 (18), 53.4 (14, 16), 




propylpiperazine (2.101) (MDW-2-126).  A solution of ethanol (1 mL) containing 2.100 
(18 mg, 0.045 mmol) and 10% Pd/C (5 mg) was sparged with H2 gas for 5 min and then 
stirred under an atmosphere of H2 (1 atm) for 2 h.The reaction was filtered through a pad 
of Celite and the filter cake was washed with CH2Cl2 (20 mL). The filtrate was 
concentrated under reduced pressure and the crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/Et2O/Et3N (59:30:1) to afford 9 mg (50%) 
of 2.101 as a colorless oil. 1H NMR (499 MHz, CDCl3) δ 7.30 – 7.25 (comp, 2H), 7.22 – 
7.16 (comp, 3H), 6.99 (d, J = 8.5 Hz, 1H), 6.97 (d, J = 2.6 Hz, 1H), 6.83 (dd, J = 8.4, 2.7 
Hz, 1H), 4.36 (t, J = 5.2 Hz, 1H), 3.69 – 3.62 (m, 1H), 3.54 – 3.48 (m, 1H), 3.21 – 3.13 
(comp, 4H), 2.79 – 2.71 (comp, 3H), 2.67 – 2.56 (comp, 5H), 2.39 – 2.32 (comp, 2H), 
2.03 – 1.88 (comp, 5H), 1.73 – 1.66 (m, 1H), 1.60 – 1.50 (comp, 2H), 0.93 (t, J = 7.4 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 149.8, 142.3, 137.7, 129.6, 129.1, 128.6, 128.4, 
125.9, 116.6, 116.6, 76.1, 67.7, 60.9, 53.5, 49.9, 32.7, 32.0, 28.5, 28.3, 20.2, 19.5, 12.1. 







NMR Assignments (2.101). 1H NMR (499 MHz, CDCl3) δ 7.30 – 7.25 (comp, 
2H, 25, 29), 7.22 – 7.16 (comp, 3H, 26, 27, 28), 6.99 (d, J = 8.5 Hz, 1H, 3), 6.97 (d, J = 
2.6 Hz, 1H, 6), 6.83 (dd, J = 8.4, 2.7 Hz, 1H, 2), 4.36 (t, J = 5.2 Hz, 1H, 10), 3.69 – 3.62 
(m, 1H, 21''), 3.54 – 3.48 (m, 1H, 21'), 3.21 – 3.13 (comp, 4H, 13, 17), 2.79 – 2.71 
(comp, 3H, 7'', 23), 2.67 – 2.56 (comp, 5H, 7', 14, 16), 2.39 – 2.32 (comp, 2H, 18), 2.03 – 
1.88 (comp, 5H, 8'', 9, 22), 1.73 – 1.66 (m, 1H, 8'), 1.60 – 1.50 (comp, 2H, 19), 0.93 (t, J 
= 7.4 Hz, 3H, 20). 13C NMR (126 MHz, CDCl3) δ 149.8 (1), 142.3 (24), 137.7 (5), 129.6 
(3), 129.1 (4), 128.6 (26, 28), 128.4 (25, 29), 125.9 (27), 116.6 (6), 116.6 (2), 76.1 (10), 
67.7 (21), 60.9 (18), 53.5 (14, 16), 49.9 (13, 17), 32.7 (23), 32.0 (22), 28.5 (9), 28.3 (7), 




phenylpropanoate (2.103) (MDW-1-290). A solution of 2.96 (30 mg, 0.11 mmol) and i-
Pr2NEt (14 mg, 19 µL 0.11 mmol) in CH2Cl2 (1.1 mL) was cooled to 0 ° C. 
Hydrocinnamoyl chloride (18 mg, 16 µL, 0.11 mmol) was added to the cooled solution 
and the solution was stirred for 22 h allowing the reaction to slowly warm to room 
temperature. The reaction was diluted with saturated aqueous NaHCO3 (5 mL) and 


































brine (1 x 20 mL), dried (Na2SO4), and concentrated under reduced pressure. The crude 
residue was purified via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N 
(79:40:1) to afford 14 mg (32%) of 2.103 as a colorless oil. 1H NMR (500 MHz, CDCl3) 
δ 7.29 – 7.25 (comp, 2H), 7.22 – 7.17 (comp, 3H), 7.02 (d, J = 8.4 Hz, 1H), 6.85 (dd, J = 
8.4, 2.7 Hz, 1H), 6.78 (d, J = 2.6 Hz, 1H), 5.95 (t, J = 4.2 Hz, 1H), 3.20 – 3.14 (comp, 
4H), 2.97 (t, J = 7.7 Hz, 2H), 2.80 – 2.73 (m, 1H), 2.70 – 2.60 (comp, 7H), 2.45 – 2.38 
(comp, 2H), 1.94 – 1.83 (comp, 3H), 1.79 – 1.71 (m, 1H), 1.64 – 1.54 (comp, 2H), 0.94 
(t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.8, 149.7, 140.6, 135.0, 129.8, 
129.5, 128.6, 128.4, 126.3, 117.0, 117.0, 70.5, 60.7, 53.2, 49.3, 36.4, 31.2, 29.3, 28.3, 




NMR Assignments (2.103). 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.25 (comp, 
2H, 26, 30), 7.22 – 7.17 (comp, 3H, 27, 28, 29), 7.02 (d, J = 8.4 Hz, 1H, 3), 6.85 (dd, J = 
8.4, 2.7 Hz, 1H, 2), 6.78 (d, J = 2.6 Hz, 1H, 6), 5.95 (t, J = 4.2 Hz, 1H, 10), 3.20 – 3.14 
(comp, 4H, 12, 16), 2.97 (t, J = 7.7 Hz, 2H, 24), 2.80 – 2.73 (m, 1H, 7'), 2.70 – 2.60 
(comp, 7H, 7'', 13, 15, 22), 2.45 – 2.38 (comp, 2H, 17), 1.94 – 1.83 (comp, 3H, 8', 9), 
1.79 – 1.71 (m, 1H, 8''), 1.64 – 1.54 (comp, 2H, 18''), 0.94 (t, J = 7.3 Hz, 3H, 19). 13C 
NMR (126 MHz, CDCl3) δ 172.8 (21), 149.7 (1), 140.6 (5), 135.0 (25), 129.8 (3), 129.5 








































one (2.105) (MDW-1-292). A solution of 2.84 (46 mg, 0.17 mmol) in EtOH (0.2 mL) 
was added dropwise to a 5% KOH in EtOH solution containing benzaldehyde (22 mg, 21 
µL, 0.21 mmol). The reaction was stirred for 23 h at room temperature and diluted with 
saturated aqueous NH4Cl (10 mL), whereupon the solution was extracted with CH2Cl2 (3 
x 10 mL). The combined organic extracts were washed with brine (1 x 20 mL), dried 
(Na2SO4), and concentrated under reduced pressure. The crude residue was purified via 
flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (79:40:1) to afford 36 mg 
(59%) of 2.105 as a yellow solid: MP 106-110 °C. 1H NMR (499 MHz, CDCl3) δ 7.85 
(brs, J = 1.9 Hz, 1H), 7.66 (d, J = 2.6 Hz, 1H), 7.46 – 7.38 (comp, 4H), 7.36 – 7.32 (m, 
1H), 7.15 (d, J = 8.3 Hz, 1H), 7.11 (dd, J = 8.4, 2.7 Hz, 1H), 3.30 – 3.25 (comp, 4H), 
3.09 (td, J = 6.9, 1.6 Hz, 2H), 2.88 – 2.84 (comp, 2H), 2.67 – 2.62 (comp, 4H), 2.41 – 
2.36 (comp, 2H), 1.62 – 1.53 (comp, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 188.3, 150.4, 136.5, 136.1, 135.9, 134.7, 133.9, 130.0, 129.1, 128.5, 128.5, 
121.8, 114.2, 60.7, 53.2, 49.1, 28.1, 27.5, 20.1, 12.1. HRMS (ESI) m/z calcd for 






NMR Assignments (2.105). 1H NMR (499 MHz, CDCl3) δ 7.85 (brs, J = 1.9 Hz, 
1H, 21), 7.66 (d, J = 2.6 Hz, 1H, 6), 7.46 – 7.38 (comp, 4H, 23, 24, 26, 27), 7.36 – 7.32 
(m, 1H, 25), 7.15 (d, J = 8.3 Hz, 1H, 3), 7.11 (dd, J = 8.4, 2.7 Hz, 1H, 2), 3.30 – 3.25 
(comp, 4H, 13, 17), 3.09 (td, J = 6.9, 1.6 Hz, 2H, 8), 2.88 – 2.84 (comp, 2H, 7), 2.67 – 
2.62 (comp, 4H, 14, 16), 2.41 – 2.36 (comp, 2H, 18), 1.62 – 1.53 (comp, 2H, 19), 0.94 (t, 
J = 7.4 Hz, 3H, 20). 13C NMR (126 MHz, CDCl3) δ 188.3 (10), 150.4 (1), 136.5 (21), 
136.1 (9), 135.9 (22), 134.7 (5), 133.9 (4), 130.0 (23, 27), 129.1 (3), 128.5 (25), 128.5 
(24, 26), 121.8 (2), 114.2 (6), 60.7 (18), 53.2 (14, 16), 49.1 (13, 17), 28.1 (7), 27.5 (8), 




(2.106) (MDW-1-151). A solution of ethanol (1.1 mL) containing 2.105 (19 mg, 0.054 
mmol) and 10% Pd/C (9 mg) was sparged with H2 gas for 5 min and then stirred under an 
atmosphere of H2 (1 atm) for 3 h. The reaction was filtered through a pad of Celite and 
the filter cake was washed with CH2Cl2 (20 mL). The filtrate was concentrated under 
reduced pressure and the crude residue was purified via flash chromatography (SiO2) 
eluting with hexanes/Et2O/Et3N (59:30:1) to afford 6 mg (32%) of 2.106 as a pale yellow 
oil. 1H NMR (499 MHz, CDCl3) δ 7.58 (d, J = 2.4 Hz, 1H), 7.33 – 7.27 (comp, 2H), 7.25 

































(m, 4H), 2.92 – 2.77 (comp, 2H), 2.75 – 2.68 (m, 1H), 2.67 – 2.58 (comp, 5H), 2.41 – 
2.34 (comp, 2H), 2.11 – 2.03 (m, 1H), 1.80 – 1.71 (m, 1H), 1.61 – 1.51 (comp, 2H), 0.93 
(t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 199.9, 150.2, 140.3, 135.4, 133.0, 
129.6, 129.4, 128.5, 126.2, 122.0, 113.5, 60.8, 53.3, 49.6, 49.2, 35.9, 28.0, 27.8, 20.1, 




carboxylate (2.107) (DRM-1-43). Boc2O (3.77 g, 3.97 mL, 17.3 mmol) was added to a 
solution of 2.83 (2.66 g, 11.5 mmol) and Et3N (1.75 g, 2.41 mL, 17.3 mmol) in CH2Cl2 
(60 mL) and the reaction was stirred for 20 h at room temperature. The reaction was 
diluted with 1 N NaOH (40 mL) and extracted with CH2Cl2 (3 x 40 mL). The combined 
organic extracts were washed with brine (1 x 30 mL), dried (Na2SO4), and concentrated 
under reduced pressure. The crude residue was purified via flash chromatography (SiO2) 
eluting with hexanes/EtOAc/Et3N (74:25:1) to afford 2.85 g (75%) of 2.107 as a yellow 
solid: mp 114–117 °C. 1H NMR (499 MHz, CDCl3) δ 7.54 (d, J = 2.7 Hz, 1 H), 7.16 (d, J 
= 8.4 Hz, 1 H), 7.09 (dd, J = 8.4, 2.7 Hz, 1 H), 3.57 (app t, J = 5.1 Hz, 4 H), 3.13 (app t, J 
= 5.1 Hz, 4 H), 2.87 (t, J = 6.0 Hz, 2 H), 2.62 (t, J = 6.5 Hz, 3 H), 2.13 – 2.06 (m, 2 H), 
1.47 (s, 9 H). 13C NMR (126 MHz, CDCl3) δ 198.7, 154.8, 150.1, 136.6, 133.1, 129.8, 
122.8, 113.7, 80.1, 49.5, 43.9, 43.3, 39.3, 29.0, 28.5, 23.6. HRMS (ESI) m/z calcd for 







NMR Assignments (2.107). 1H NMR (499 MHz, CDCl3) δ 7.54 (d, J = 2.7 Hz, 1 
H, 6), 7.16 (d, J = 8.4 Hz, 1 H, 3), 7.09 (dd, J = 8.4, 2.7 Hz, 1 H, 2), 3.57 (t, J = 5.1 Hz, 4 
H, 14, 16), 3.13 (t, J = 5.1 Hz, 4 H, 13, 17), 2.87 (t, J = 6.0 Hz, 2 H, 9), 2.62 (t, J = 6.5 
Hz, 3 H, 7), 2.13 – 2.06 (m, 2 H, 8), 1.47 (s, 9 H, 20, 21, 22). 13C NMR (126 MHz, 
CDCl3) δ 198.7 (10), 154.8 (23), 150.1 (1), 136.6 (5), 133.1 (4), 129.8 (3), 122.8 (2), 
113.7 (6), 80.1 (19), 49.5 (13, 17), 43.9 and 43.3 (14, 16), 39.3 (7), 29.0 (9), 28.5 (20, 21, 




1-carboxylate (2.108) (MDW-2-178). Prepared from 2.107 (0.300 g, 0.908 mmol) 
mmol) and MeNH3Cl according to representative procedure D. The crude residue was 
purified via flash chromatography (SiO2) eluting with CH2Cl2/MeOH/Et3N (99:0:1 to 
98:1:1) affording 0.266 g (85%) of 2.108 as a brown oil. 1H NMR (499 MHz, CDCl3) δ 
6.98 (d, J = 8.4 Hz, 1 H), 6.95 (d, J = 2.5 Hz, 1 H), 6.76 (dd, J = 8.4, 2.5 Hz,  1H), 3.65 – 
3.61 (m, 1 H), 3.56 (app t, J = 5.2 Hz, 4H), 3.12 – 3.04 (comp, 4 H), 2.76 – 2.59 (comp, 2 
H), 2.48 (s, 3 H), 1.96 – 1.81 (comp, 3 H), 1.73 – 1.66 (m, 1 H), 1.47 (s, 9 H). 13C NMR 


































43.4, 33.9, 28.6, 28.5, 27.7, 19.2. HRMS (ESI) m/z calcd for C20H31N3O2 (M+H)+, 
315.2067 found 315.2070. 
 
 
NMR Assignments (2.108). 1H NMR (499 MHz, CDCl3) δ 6.98 (d, J = 8.4 Hz, 1 
H, 3), 6.95 (d, J = 2.5 Hz, 1 H, 6), 6.76 (dd, J = 8.4, 2.5 Hz, 1 H, 2), 3.65 – 3.61 (m, 1 H, 
10), 3.56 (t, J = 5.2 Hz, 4 H, 13, 15), 3.12 – 3.04 (comp, 4 H, 12, 16), 2.76 – 2.59 (comp, 
2 H, 7), 2.48 (s, 3 H, 18), 1.96 – 1.81 (comp, 4 H, 8, 9, 26), 1.73 – 1.66 (m, 1 H, 8), 1.47 
(s, 9 H, 21, 22, 23). 13C NMR (126 MHz, CDCl3) δ 154.8 (24), 149.6 (1), 139.4 (5), 129.8 
(3), 129.6 (4), 117.1 (6), 116.2 (2), 57.5 (10), 50.1 (12, 16), 44.1 and 43.4 (13, 15), 33.9 




tetrahydronaphthalen-2-yl)piperazine-1-carboxylate (2.110) (DRM-1-47). A 20% 
solution of phosgene in PhME (0.8 mL) was added dropwise to a solution of 4-
fluorobenzyl alcohol (0.18 g, 0.16 mL, 1.4 mmol) and i-Pr2Net (0.29 g, 0.39 mL, 2.2 
mmol) in THF/PhMe (1:1, 1.5 mL) at 0 °C. The reaction was stirred at 0 °C for 20 min, 
whereupon a solution of 2.108 (0.258 g, 0.747 mmol) in toluene (1.2 mL) was added 








































to room temperature. The solution was diluted with 1 N NaOH (10 mL) and extracted 
with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried (Na2SO4) and 
concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with EtOAc/hexanes (3:7) affording 0.269 g (73%) of 
2.110 as a pale-yellow oil. 1H NMR (499 MHz, CDCl3) δ 7.43 – 7.30 (comp, 2 H), 7.10 – 
6.95 (comp, 3 H), 6.79 – 6.73 (m, 1 H), 6.63 – 6.51 (m, 1 H), 5.48 – 5.26 (m, 1 H), 5.27 – 
5.06 (comp, 2 H), 3.56 – 3.51 (comp, 4 H), 3.07 – 2.89 (comp, 4 H), 2.74 – 2.59 (comp, 5 
H), 2.05 – 1.91 (comp, 2 H), 1.82 – 1.66 (comp, 2 H), 1.48 (s, 9 H). 13C NMR (126 MHz, 
CDCl3) δ 163.7, 161.8, 157.3, 157.0, 154.9, 154.9, 150.2, 150.1, 136.1, 136.0, 133.2, 
133.1, 133.1, 133.1, 131.0, 130.5, 130.3, 130.2, 130.2, 130.1, 130.1, 116.5, 116.3, 115.7, 
115.6, 115.3, 114.9, 80.1, 66.7, 66.7, 55.9, 55.6, 50.1, 44.2, 43.4, 30.5, 29.9, 29.0, 28.9, 




NMR Assignments (2.110). 1H NMR (499 MHz, CDCl3) δ 7.43 – 7.30 (comp, 2 
H, 26, 28), 7.10 – 6.95 (comp, 3 H, 3, 29, 31), 6.79 – 6.73 (m, 1 H, 2), 6.63 – 6.51 (m, 1 
H, 6), 5.48 – 5.26 (m, 1 H, 10), 5.27 – 5.06 (comp, 2 H, 32), 3.56 – 3.51 (comp, 4 H, 15, 
17), 3.07 – 2.89 (comp, 4 H, 14, 18), 2.74 – 2.59 (comp, 5 H, 7, 12), 2.05 – 1.91 (comp, 2 
H, 8, 9), 1.82 – 1.66 (comp, 2 H, 8, 9), 1.48 (s, 9 H, 21, 22, 23). 13C NMR (126 MHz, 
CDCl3) δ 163.7 and 161.8 (27), 157.3 and 157.0 (34), 154.9 and 154.9 (24), 150.2 and 










































130.3 (3), 130.2 (26, 28), 130.2 (3), 130.1 and 130.1 (26, 28), 116.5 and 116.3 (2), 115.7 
and 115.6 (29, 31), 115.3 and 114.9 (6), 80.1 (20), 66.7 and 66.7 (32), 55.9 and 55.6 (10), 
50.1 (14, 18), 44.2 and 43.4 (15, 17), 30.5 and 29.9 (12), 29.0 and 28.9 (7), 28.7 (21, 22, 




yl)carbamate (2.111) (DRM-1-49). TFA (0.33 mL, 4.3 mmol) was added to a solution of 
2.110 (0.107 g, 0.215 mmol) in CH2Cl2 (2.2 mL) cooled to 0 °C. The reaction was stirred 
for 17 h, allowing to slowly warm to room.  The reaction was was diluted with 1 N 
NaOH (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts 
were dried (Na2SO4) and concentrated under reduced pressure. The crude residue was 
purified via flash chromatography (SiO2) eluting with CH2Cl2/MeOH/Et3N (99:0:1 to 
97:2:1) affording 53 mg (61%) of 2.111 as a colorless oil. 1H NMR (499 MHz, CDCl3) 
rotamers δ 7.43 – 7.31 (comp, 2 H), 7.12 – 6.95 (comp, 3 H), 6.79 – 6.73 (m, 1 H), 6.64 – 
6.53 (m, 1 H), 5.50 – 5.26 (m, 1 H), 5.26 – 5.06 (comp, 2 H), 3.06 – 2.92 (comp, 7 H), 
2.74 – 2.59 (comp, 5 H) 2.04 – 1.65 (comp, 5 H). 13C NMR (126 MHz, CDCl3) rotamers 
δ 163.5, 161.6, 157.2, 156.9, 150.6, 150.5, 135.8, 135.7, 133.1, 133.0, 133.0, 132.9, 
130.2, 130.0, 130.0, 129.9, 129.9, 129.9, 129.7, 115.8, 115.5, 115.4, 114.7, 114.3, 66.5, 
66.5, 55.7, 55.5, 50.9, 50.8, 46.2, 46.2, 30.4, 29.8, 28.8, 28.7, 28.2, 27.7, 22.3, 22.1. 










NMR Assignments (2.111). 1H NMR (499 MHz, CDCl3) rotamers δ 7.43 – 7.31 
(comp, 2 H, 13, 15), 7.12 – 6.95 (comp, 3 H, 3, 16, 18), 6.79 – 6.73 (m, 1 H, 2), 6.64 – 
6.53 (m, 1 H, 6), 5.50 – 5.26 (m, 1 H, 10), 5.26 – 5.06 (comp, 2 H, 19), 3.06 – 2.92 
(comp, 7 H, 25, 26, 28, 29), 2.74 – 2.59 (comp, 5 H, 7, 12) 2.04 – 1.65 (comp, 5 H, 8, 9, 
30). 13C NMR (126 MHz, CDCl3) rotamers δ 163.5 and 161.6 (14), 157.2 and 156.9 (21), 
150.6 and 150.5 (1), 135.8 and 135.7 (5), 133.1, 133.0, 133.0, and 132.9 (17), 130.2 and 
130.0 (3), 130.0, 129.9, 129.9, 129.9 (4, 13, 15), 129.7 (4), 115.8 (2), 115.5 and 115.4 (2, 
16, 18), 114.7 and 114.3 (6), 66.5 and 66.5 (19), 55.7 and 55.5 (10), 50.9 and 50.8 (26, 
28), 46.2 and 46.2 (25, 29), 30.4 and 29.8 (12), 28.8 and 28.7 (7), 28.2 and 27.7 (9), 22.3 




tetrahydronaphthalen-1-yl)carbamate (2.112) (DRM-1-54). Prepared from 2.111 (20 
mg, 0.051 mmol) and propionaldehyde according to representative procedure E. The 
crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (74:25:1) to afford 18 mg (81%) of 2.112 as a colorless oil. 1H 
NMR (600 MHz, CDCl3) rotamers δ 7.40 (dd, J = 8.5, 5.6 Hz, 1H), 7.33 (dd, J = 8.4, 5.5 








































(m, 1H), 5.26 – 5.07 (comp, 2H), 3.13 – 3.02 (comp, 4H), 2.74 – 2.60 (comp, 5H), 2.59 – 
2.54 (comp, 4H), 2.39 – 2.33 (comp, 2H), 2.06 – 1.91 (comp, 2H), 1.83 – 1.67 (comp, 
2H), 1.60 – 1.51 (comp, 2H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, CDCl3) 
rotamers δ 163.4, 161.8, 157.2, 156.9, 150.2, 150.1, 135.9, 135.7, 133.1, 133.1, 133.0, 
133.0, 130.2, 130.1, 130.0, 130.0, 130.0, 129.9, 129.9, 129.7, 115.8, 115.6, 115.5, 115.4, 
114.7, 114.2, 66.5, 66.5, 60.8, 60.8, 55.8, 55.5, 53.4, 53.3, 49.7, 49.6, 30.4, 29.8, 28.8, 
28.7, 28.2, 27.8, 22.4, 22.2, 20.2, 12.1. HRMS (ESI) m/z calcd for C26H34FN3O2 (M+H)+, 




NMR Assignments (2.112). 1H NMR (600 MHz, CDCl3) rotamers δ 7.40 (dd, J = 
8.5, 5.6 Hz, 1H), 7.33 (dd, J = 8.4, 5.5 Hz, 1H, 13, 15), 7.09 – 6.96 (comp, 3H, 3, 16, 18), 
6.80 – 6.74 (m, 1H, 2), 6.61 – 6.55 (m, 1H, 6), 5.48 – 5.27 (m, 1H, 10), 5.26 – 5.07 
(comp, 2H, 19), 3.13 – 3.02 (comp, 4H, 26, 28), 2.74 – 2.60 (comp, 5H, 7, 12), 2.59 – 
2.54 (comp, 4H, 25, 29), 2.39 – 2.33 (comp, 2H, 30'), 2.06 – 1.91 (comp, 2H, 8'', 9''), 1.83 
– 1.67 (comp, 2H, 8', 9'), 1.60 – 1.51 (comp, 2H, 31''), 0.93 (t, J = 7.4 Hz, 3H, 32). 13C 
NMR (151 MHz, CDCl3) rotamers δ 163.4, 161.8, 157.2, and 156.9 (21), 150.2 and 150.1 
(1), 135.9 and 135.7 (5), 133.1, 133.1, 133.0, and 133.0 (17), 130.2 and 130.1 (3), 130.0, 
130.0, 130.0, and 129.9 (13, 15), 129.9 and 129.7 (4), 115.8, 115.6, 115.5, and 115.4 (16, 


































and 53.3 (25, 29), 49.7 and 49.6 (26, 28), 30.4 and 29.8 (12), 28.8 and 28.7 (7), 28.2 and 
27.8 (9), 22.4 and 22.2 (8), 20.2 (31), 12.1. 
 
4-Fluorobenzyl (7-(4-(3-(diethylamino)-3-oxopropyl)piperazin-1-yl)-1,2,3,4-
tetrahydronaphthalen-1-yl)(methyl)carbamate (2.114) (DRM-1-53). Prepared from 
2.111 (17 mg, 0.051 mmol) and 3-bromo-N,N-diethylpropanamide, according to 
representative procedure G.315 The crude residue was purified via flash chromatography 
(SiO2) eluting with hexanes/EtOAc/Et3N (74:25:1) affording 21 mg (94%) of 2.114 as a 
colorless oil. 1H NMR (600 MHz,CDCl3) rotamers δ 7.40 (dd, J = 8.5, 5.5 Hz, 1H), 7.33 
(dd, J = 8.5, 5.5 Hz, 1H), 7.10 – 6.96 (comp, 3H), 6.79 – 6.73 (m, 1H), 6.59 – 6.52 (m, 
1H), 5.47 – 5.26 (m, 1H), 5.26 – 5.06 (comp, 2H), 3.38 (q, J = 7.1 Hz, 2H), 3.33 (q, J = 
7.0 Hz, 2H), 3.10 – 3.00 (comp, 4H), 2.83 – 2.77 (comp, 2H), 2.74 – 2.59 (comp, 9H), 
2.58 – 2.53 (comp, 2H), 2.04 – 1.90 (comp, 2H), 1.82 – 1.66 (comp, 2H), 1.19 (td, J = 
7.2, 1.9 Hz, 3H), 1.12 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) rotamers δ 170.8, 
163.4, 161.8, 157.2, 156.9, 150.0, 150.0, 135.9, 135.7, 133.1, 133.1, 133.0, 133.0, 130.3, 
130.1, 130.1, 130.0, 130.0, 130.0, 129.9, 129.8, 115.8, 115.6, 115.5, 115.4, 114.6, 114.2, 
66.5, 66.5, 55.8, 55.5, 54.5, 54.5, 53.4, 53.4, 49.7, 49.5, 42.1, 42.1, 40.3, 31.0, 30.9, 30.4, 
29.8, 28.8, 28.7, 28.2, 27.7, 22.4, 22.2, 14.5, 13. HRMS (ESI) m/z calcd for C30H41FN4O3 












NMR Assignments (2.114). 1H NMR (600 MHz, CDCl3) rotamers δ 7.40 (dd, J = 
8.5, 5.5 Hz, 1H), 7.33 (dd, J = 8.5, 5.5 Hz, 1H, 13, 15), 7.10 – 6.96 (comp, 3H, 3, 16, 18), 
6.79 – 6.73 (m, 1H, 2), 6.59 – 6.52 (m, 1H, 6), 5.47 – 5.26 (m, 1H, 10), 5.26 – 5.06 
(comp, 2H, 19), 3.38 (q, J = 7.1 Hz, 2H, 36), 3.33 (q, J = 7.0 Hz, 2H, 38), 3.10 – 3.00 
(comp, 4H, 26, 28), 2.83 – 2.77 (comp, 2H, 31), 2.74 – 2.59 (comp, 9H, 7, 12, 25, 29), 
2.58 – 2.53 (comp, 2H, 30), 2.04 – 1.90 (comp, 2H, 8', 9'), 1.82 – 1.66 (comp, 2H, 8'', 9''), 
1.19 (td, J = 7.2, 1.9 Hz, 3H, 35, 37), 1.12 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, 
CDCl3) rotamers δ 170.8 (32), 163.4 and 161.8 (14), 157.2 and 156.9 (21), 150.0 and 
150.0 (1), 135.9 and 135.7 (5), 133.1, 133.1, 133.0, and 133.0 (17), 130.3 and 130.1 (3), 
130.1, 130.0, 130.0, and 130.0 (13, 15), 129.9 and 129.8 (4), 115.8, 115.6, 115.5, and 
115.4 (16, 18), 114.6, 114.2, 66.5, and 66.5 (19), 55.8 and 55.5 (10), 54.5 and 54.5 (31), 
53.4 and 53.4 (25, 29), 49.7 and 49.5 (26, 28), 42.1, 42.1, and 40.3 (36, 38), 31.0 and 
30.9 (30), 30.4 and 29.8 (12), 28.8 and 28.7 (7), 28.2 and 27.7 (9), 22.4 and 22.2 (8), 14.5 
and 13.2 (35, 37). 
















































tetrahydronaphthalen-1-yl)acrylamide (2.116) (DRM-1-64). A solution of 2.87 (64 
mg, 0.22 mmol), 2-methoxycinnamic acid (69 mg, 0.39 mmol), EDCI·HCl (74 mg, 0.39 
mmol), and i-Pr2Net (130 mg, 18 µL, 1.0 mmol) in THF (2.6 mL) was stirred for 17 h at 
room temperature. The reaction was diluted with 1 N NaOH (15 mL) and extracted with 
Et2O (2 x 15 mL), whereupon the combined organic extracts were extracted with 1 N HCl 
(3 x 15 mL). The combined acidic aqueous extracts were made basic with 6 N NaOH and 
extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were dried (Na2SO4) 
and concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc/Et3N (54:45:1) affording 66 mg 
(70%) of 2.116 as a colorless oil. 1H NMR (400 MHz,CDCl3) rotamers δ 8.04 (dd, J = 
17.8, 15.5 Hz, 1H), 7.57 – 7.44 (m, 1H), 7.36 – 7.27 (m, 1H), 7.12 – 6.87 (comp, 4H), 
6.79 (td, J = 8.5, 2.6 Hz, 1H), 6.68 (dd, J = 20.4, 2.6 Hz, 1H), 6.11 – 5.17 (m, 1H), 3.94 – 
3.83 (comp, 3H), 3.22 – 3.05 (comp, 4H), 2.89 – 2.64 (comp, 5H), 2.63 – 2.52 (comp, 
4H), 2.41 – 2.31 (comp, 2H), 2.13 – 1.69 (comp, 4H), 1.54 (h, J = 7.3 Hz, 2H), 0.91 (td, J 
= 7.4, 2.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) rotamers δ 168.6, 167.9, 158.4, 158.2, 
150.3, 150.1, 138.6, 138.1, 136.0, 135.7, 130.8, 130.7, 130.5, 130.2, 129.9, 129.5, 129.3, 
128.9, 124.6, 124.6, 120.8, 120.7, 118.9, 118.9, 115.6, 115.5, 115.0, 114.2, 111.3, 111.2, 
60.8, 57.7, 55.6, 53.4, 53.3, 53.3, 49.7, 49.5, 31.4, 29.2, 29.0, 28.7, 27.6, 22.5, 22.2, 20.1, 









































NMR Assignments (2.116). 1H NMR (400 MHz, CDCl3) rotamers δ 8.04 (dd, J = 
17.8, 15.5 Hz, 1H, 24), 7.57 – 7.44 (m, 1H, 19), 7.36 – 7.27 (m, 1H, 21), 7.12 – 6.87 
(comp, 4H, 3, 18, 20, 25), 6.79 (td, J = 8.5, 2.6 Hz, 1H, 2), 6.68 (dd, J = 20.4, 2.6 Hz, 1H, 
6), 6.11 – 5.17 (m, 1H, 10), 3.94 – 3.83 (comp, 3H, 32), 3.22 – 3.05 (comp, 4H, 12, 16), 
2.89 – 2.64 (comp, 5H, 7, 33), 2.63 – 2.52 (comp, 4H, 13, 15), 2.41 – 2.31 (comp, 2H, 
28), 2.13 – 1.69 (comp, 4H, 8, 9), 1.54 (h, J = 7.3 Hz, 2H, 29), 0.91 (td, J = 7.4, 2.1 Hz, 
3H, 30). 13C NMR (126 MHz, CDCl3) rotamers δ 168.6 and 167.9 (26), 158.4 and 158.2 
(23), 150.3 and 150.1 (1), 138.6 and 138.1 (24), 136.0 and 135.7 (5), 130.8 and 130.7 
(21), 130.5 (4), 130.2 and 129.9 (3), 129.5 (4), 129.3 and 128.9 (19), 124.6 and 124.6 
(22), 120.8 and 120.7 (20), 118.9 and 118.9 (25), 115.6 and 115.5 (2), 115.0 and 114.2 
(6), 111.3 and 111.2 (18), 60.8 (28), 57.7 (10), 55.6 (32), 53.4 (10), 53.3 and 53.3 (13, 
15), 49.7 and 49.5 (12, 16), 31.4 (33), 29.2 and 29.0 (7), 28.7 and 27.6 (9), 22.5 and 22.2 





tetrahydronaphthalen-1-yl)acrylamide (2.117) (DRM-1-63). Prepared from 2.87 (64 
mg, 0.22 mmol) and 3-methoxycinnamic acid according to representative procedure K. 
The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (54:45:1) to afford 65 mg (94%) of 2.117 as a colorless oil. 1H 
NMR (500 MHz, CDCl3) δ 7.73 – 7.60 (m, 1H), 7.26 – 7.16 (m, 1H), 7.12 – 6.78 (comp, 







3H), 3.13 – 3.01 (comp, 4H), 2.80 – 2.60 (comp, 5H), 2.58 – 2.50 (comp, 4H), 2.33 – 
2.26 (comp, 2H), 2.03 – 1.58 (comp, 4H), 1.53 – 1.43 (comp, 2H), 0.84 (t, J = 7.3 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 167.7, 167.1, 159.9, 159.8, 150.1, 149.9, 142.9, 
142.6, 136.8, 136.8, 135.7, 135.4, 130.5, 130.2, 129.9, 129.9, 129.8, 129.5, 120.5, 120.4, 
118.1, 115.6, 115.6, 115.2, 115.2, 114.8, 114.0, 113.2, 113.0, 60.6, 60.6, 57.7, 55.4, 53.4, 
53.1, 49.4, 49.3, 31.4, 29.1, 28.8, 28.5, 27.4, 22.4, 22.1, 19.9, 19.8, 12.0. HRMS (ESI) 
m/z calcd for C28H37N3O2 (M+H)+, 448.2959; found 448.2960. 
 
 
NMR Assignments (2.117). 1H NMR (500 MHz, CDCl3) rotamers δ 7.73 – 7.60 
(m, 1H, 19), 7.26 – 7.16 (m, 1H, 15), 7.12 – 6.78 (comp, 5H, 3, 14, 16, 18, 20), 6.76 – 
6.68 (m, 1H, 2), 6.62 – 6.53 (m, 1H, 6), 5.98 – 5.09 (m, 1H, 10), 3.79 – 3.70 (comp, 3H, 
24), 3.13 – 3.01 (comp, 4H, 27, 29), 2.80 – 2.60 (comp, 5H, 7, 12), 2.58 – 2.50 (comp, 
4H, 26, 30), 2.33 – 2.26 (comp, 2H, 31), 2.03 – 1.58 (comp, 4H, 8, 9), 1.53 – 1.43 (comp, 
2H, 32), 0.84 (t, J = 7.3 Hz, 3H, 33). 13C NMR (126 MHz, CDCl3) δ 167.7 and 167.1 
(21), 159.9 and 159.8 (13), 150.1 and 149.9 (1), 142.9 and 142.6 (19), 136.8 and 136.8 
(17), 135.7 and 135.4 (5), 130.5 and 130.2 (3), 129.9 and 129.9 (15), 129.8 and 129.5 (4), 
120.5 and 120.4 (16), 118.1 (20), 115.6 and 115.6 (14), 115.2 and 115.2 (2), 114.8 and 
114.0 (6), 113.2 and 113.0 (18), 60.6 and 60.6 (31), 57.7 (10), 55.4 (24), 53.4 (10), 53.1 
(26, 30), 49.4 and 49.3 (27, 29), 31.4 (12), 29.1 and 28.8 (7), 28.5 and 27.4 (9), 22.4 and 









































tetrahydronaphthalen-1-yl)acrylamide (2.118) (DRM-1-55). Prepared from 2.87 (85 
mg, 0.30 mmol) and 4-methoxycinnamic acid according to representative procedure K. 
The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (59:40:1) affording 91 mg (69%) of 2.118 as a colorless oil. 1H 
NMR (400 MHz, CDCl3) rotamers δ 7.74 (dd, J = 16.8, 15.3 Hz, 1H), 7.49 (dd, J = 27.6, 
8.7 Hz, 2H), 7.03 (dd, J = 12.0, 8.4 Hz, 1H), 6.94 – 6.76 (comp, 4H), 6.66 (dd, J = 19.6, 
2.3 Hz, 1H), 6.06 – 5.18 (m, 1H), 3.88 – 3.79 (comp, 3H), 3.18 – 3.03 (comp, 4H), 2.86 – 
2.68 (comp, 5H), 2.62 – 2.52 (comp, 4H), 2.38 – 2.29 (comp, 2H), 2.11 – 1.69 (comp, 
4H), 1.59 – 1.47 (comp, 2H), 0.91 (td, J = 7.4, 1.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ 168.2, 167.6, 161.0, 160.9, 150.3, 150.2, 142.8, 142.5, 135.9, 135.7, 130.4, 130.2, 
129.9, 129.6, 129.5, 128.3, 128.3, 115.6, 115.5, 115.5, 115.4, 114.9, 114.4, 114.3, 114.1, 
60.8, 57.7, 55.5, 53.4, 53.3, 53.3, 49.7, 49.5, 31.5, 29.2, 29.0, 28.7, 27.6, 22.6, 22.2, 20.1, 
12.1. HRMS (ESI) m/z calcd for C28H37N3O2 (M+H)+, 448.2959; found 448.2960. 
 
 
NMR Assignments (2.118). 1H NMR (400 MHz, CDCl3) rotamers δ 7.74 (dd, J = 
16.8, 15.3 Hz, 1H, 24), 7.49 (dd, J = 27.6, 8.7 Hz, 2H, 21, 23), 7.03 (dd, J = 12.0, 8.4 Hz, 











































5.18 (m, 1H, 10), 3.88 – 3.79 (comp, 3H, 32), 3.18 – 3.03 (comp, 4H, 12, 16), 2.86 – 2.68 
(comp, 5H, 7, 33), 2.62 – 2.52 (comp, 4H, 13, 15), 2.38 – 2.29 (comp, 2H, 28), 2.11 – 
1.69 (comp, 4H, 8, 9), 1.59 – 1.47 (comp, 2H, 29), 0.91 (td, J = 7.4, 1.9 Hz, 3H, 30). 13C 
NMR (126 MHz, CDCl3) rotamers δ 168.2 and 167.6 (26), 161.0 and 160.9 (19), 150.3 
and 150.2 (1), 142.8 and 142.5 (24), 135.9 and 135.7 (5), 130.4 (4), 130.2 and 129.9 (3), 
129.6 and 129.5 (21, 23), 128.3 and 128.3 (22), 115.6 and 115.5 (2), 115.5 and 115.4 
(25), 114.9 (6), 114.4 and 114.3 (18, 20), 114.1 (6), 60.8 (28), 57.7 (10), 55.5 (32), 53.4 
(10), 53.3 and 53.3 (13, 15), 49.7 and 49.5 (12, 16), 31.5 (33), 29.2 and 29.0 (7), 28.7 and 




tetrahydronaphthalen-1-yl)acrylamide (2.120) (DRM-1-72). Prepared from 2.87 (81 
mg, 0.28 mmol) and furan-2-acrylic acid according to representative procedure K. The 
crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (59:40:1) affording 87 mg (76%) of 2.120 as a pale yellow oil. 1H 
NMR (500 MHz, CDCl3) rotamers δ 7.54 (app dd, J = 15.1, 7.5 Hz, 1H), 7.46 – 7.38 (m, 
1H), 7.00 (app dd, J = 13.1, 8.4 Hz, 1H), 6.87 (app dd, J = 28.6, 15.1 Hz, 1H), 6.81 – 
6.74 (m, 1H), 6.61 (app dd, J = 20.6, 2.5 Hz, 1H), 6.55 (app dd, J = 17.6, 3.4 Hz, 1H), 
6.47 – 6.40 (m, 1H), 6.03 – 5.19 (m, 1H), 3.19 – 3.06 (comp, 4H), 2.86 – 2.66 (comp, 
5H), 2.63 – 2.54 (comp, 4H), 2.39 – 2.31 (comp, 2H), 2.10 – 1.63 (comp, 4H), 1.58 – 
1.49 (comp, 2H), 0.89 (app td, J = 7.4, 1.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) 







130.1, 129.9, 129.7, 129.7, 129.5, 115.6, 115.5, 115.4, 115.1, 114.7, 114.1, 114.0, 113.7, 
112.3, 112.2, 60.6, 57.5, 53.4, 53.1, 49.4, 49.3, 31.3, 29.9, 29.1, 28.8, 28.5, 27.4, 22.4, 




NMR Assignments (2.87). 1H NMR (500 MHz, CDCl3) rotamers δ 7.54 (app dd, 
J = 15.1, 7.5 Hz, 1H, 16), 7.46 – 7.38 (m, 1H, 20), 7.00 (app dd, J = 13.1, 8.4 Hz, 1H, 3), 
6.87 (app dd, J = 28.6, 15.1 Hz, 1H, 14), 6.81 – 6.74 (m, 1H, 2), 6.61 (app dd, J = 20.6, 
2.5 Hz, 1H, 6), 6.55 (app dd, J = 17.6, 3.4 Hz, 1H, 18), 6.47 – 6.40 (m, 1H, 19), 6.03 – 
5.19 (m, 1H, 10), 3.19 – 3.06 (comp, 4H, 23, 27), 2.86 – 2.66 (comp, 5H, 7, 12), 2.63 – 
2.54 (comp, 4H, 24, 26), 2.39 – 2.31 (comp, 2H, 28), 2.10 – 1.63 (comp, 4H, 8, 9), 1.58 – 
1.49 (comp, 2H, 29), 0.89 (app td, J = 7.4, 1.2 Hz, 3H, 30). 13C NMR (126 MHz, CDCl3) 
rotamers δ 167.5 and 167.1 (13), 151.8 and 151.7 (17), 150.1 and 149.9 (1), 144.0 and 
143.9 (20), 135.7 and 135.4 (5), 130.4 and 130.1 (3), 129.9 and 129.7 (16), 129.7 and 
129.5 (4), 115.6 and 115.5 (2), 115.4 and 115.1 (14), 114.7 and 114.1 (6), 114.0 and 
113.7 (18), 112.3 and 112.2 (19), 60.6 (28), 57.5 and 53.4 (10), 53.1 (23, 27), 49.4 and 
49.3 (24, 26), 31.3 and 29.9 (12), 29.1 and 28.8 (7), 28.5 and 27.4 (9), 22.4 and 22.1 (8), 




































2.121/(R)-2.122) (MDW-2-105 and 2-106). According to a slightly modified protocol, a 
solution of (±)-2.28 (1.276 g, 5.312 mmol) and N-acetyl-L-phenylalanine (1.101 g, 5.312 
mmol) in EtOH (25 mL) was heated to a boil. Additional EtOH was added to the boiling 
solution until the solids were completely dissolved, whereupon the solution was allowed 
to slowly cool to room temperature. The crystalline solid that formed was isolated by 
filtration and washed sequentially with cold EtOH (20 mL) and Et2O (20 mL), and the R–
enriched filtrate was reserved. The collected solids (1.041 g) were dissolved in EtOH (20 
mL) and subjected to the same recrystallization protocol, and the R–enriched filtrate was 
reserved. The isolated white crystalline solid, [a]D33 = +71.00 (c = 1, MeOH), was 
partitioned between CH2Cl2 (30 mL) and 15% NaOH (20 mL). The organic layer was 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 30 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated under reduced pressure to afford a 
0.411 g (32%) of (S)–2.121 as a colorless oil. The 1H NMR spectrum was consistent with 
(±)-2.28 A portion was converted to the HCl salt for analysis, [a]D28 = + 63.00 (c = 1, 
MeOH).  
The combined R–enriched filtrates were concentrated under reduced pressure and 
the crude residue was partitioned between CH2Cl2 (30 mL) and 15% NaOH (20 mL). The 
organic layer was separated and the aqueous layer was extracted with extracted with 
CH2Cl2 (3 x 30 mL). The combined organic extracts were dried (Na2SO4) and 
concentrated under reduced pressure to afford the R–enriched residue (0.693 g, 2.89 










(0.598 g, 2.89 mmol) in EtOH (14 mL) was heated to a boil. Additional EtOH was added 
to the boiling solution until the solids were completely dissolved, whereupon the solution 
was allowed to slowly cool to room temperature. The crystalline solid that formed was 
isolated by filtration and washed sequentially with cold EtOH (20 mL) and Et2O (20 mL). 
The collected solids (0.879 g) were dissolved in EtOH (10 mL) and subjected to the same 
recrystallization protocol. The isolated white crystalline solid, [a]D33 =  – 61.00 (c = 1, 
MeOH), was partitioned between CH2Cl2 (30 mL) and 15% NaOH (20 mL). The organic 
layer was separated and the aqueous layer was extracted with CH2Cl2 (3 x 30 mL). The 
combined organic extracts were dried (Na2SO4) and concentrated under reduced pressure 
to afford a 0.317 g (25%) of (R)–2.122 as a colorless oil. The 1H NMR spectrum was 
consistent with (±)-2.28 A portion was converted to the HCl salt for analysis, [a]D24 = – 




((S)–2.123) (MDW-2-107). Prepared from (S)–2.121 (0.69 g, 1.54 mmol) and CbzCl 
according to representative procedure A. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc (10:1) to afford 0.571 g (98%) of 
(S)–2.123 as a colorless oil ([a]D24 = – 31.00 (c = 1, MeOH). 1H NMR (400 MHz, CDCl3) 
(rotamers) δ 7.50 – 7.19 (comp, 7 H), 6.97 – 6.90 (m, 1 H), 5.55 – 5.16 (comp, 3 H), 2.77 
– 2.61 (comp, 5 H), 2.09 – 1.92 (comp, 2 H), 1.85 – 1.67 (comp, 2 H). 13C NMR (101 
MHz, CCCl3) (rotamers) δ 156.8, 156.3, 137.6, 137.5, 137.2, 136.9, 136.6, 136.6, 130.7, 







67.1, 55.0, 54.7, 30.1, 29.4, 28.8, 28.7, 27.4, 26.9, 21.6, 21.6. HRMS (ESI) m/z calcd for 




((R)–2.124) (MDW-2-108). Prepared from (R)–2.122 (0.269 g, 1.12 mmol) and CbzCl 
according to representative procedure A. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc (10:1) to afford 0.413 g (98%) of 
(R)–2.124 as a colorless oil ([a]D24 = + 26.33 (c = 1, MeOH). 1H NMR (400 MHz, 
CDCl3) rotamers δ 7.45 – 7.21 (comp, 7 H), 6.98 – 6.91 (m, 1 H), 5.55 – 5.17 (comp, 3 
H), 2.75 – 2.62 (comp, 5 H), 2.10 – 1.92 (comp, 2 H), 1.86 – 1.64 (comp, 2 H).  13C NMR 
(101 MHz, CDCl3) rotamers δ 156.9, 156.5, 137.7, 137.6, 137.2, 137.0, 136.7, 136.6, 
130.8, 129.9, 129.8, 129.6, 129.5, 128.4, 127.9, 127.6, 119.8, 119.8, 67.2, 55.1, 54.8, 
30.2, 29.5, 28.9, 28.8, 27.5, 26.9, 21.7, 21.6. HRMS (ESI) m/z calcd for C19H20BrNO2 




yl)carbamate ((S)–2.125) (MDW-2-112). Prepared from (S)–2.123 (0.529 g, 1.40 mmol) 













via flash chromatography (SiO2) eluting with CH2Cl2/MeOH/Et3N (99:0:1 to 97:2:1) to 
afford 0.362 g (68%) of (S)–2.125 as an orange oil. 1H NMR (400 MHz, CDCl3) 
rotamers δ 7.43 – 7.22 (comp, 5 H), 7.00 – 6.93 (m, 1 H), 6.77 – 6.71 (m, 1 H), 6.64 – 
6.56 (m, 1 H), 5.49 – 5.08 (comp, 3 H), 3.05 – 2.87 (comp, 8 H), 2.72 – 2.59 (comp, 5 H), 
2.06 – 1.87 (comp, 3 H), 1.82 – 1.63 (comp, 2 H). 13C NMR (101 MHz, CDCl3) rotamers 
δ 156.9, 156.6, 150.3, 150.2, 137.0, 136.8, 135.5, 135.4, 129.8, 129.6, 129.6, 129.4, 
128.3, 127.7, 127.6, 127.5, 115.4, 115.2, 114.3, 114.0, 66.8, 66.8, 55.3, 55.1, 50.5, 50.4, 
46.0, 45.9, 30.0, 29.4, 28.5, 28.4, 27.9, 27.4, 22.0, 21.9. HRMS (ESI) m/z calcd for 




yl)carbamate ((R)–2.126) (MDW-2-113). Prepared from (R)–2.124 (0.394 g, 1.04 
mmol) and piperazine according to representative procedure C. The crude residue was 
purified via flash chromatography (SiO2) eluting with CH2Cl2/MeOH/Et3N (99:0:1 to 
97:2:1)  to afford 0.235 g (60%) of (R)–2.126 as an orange oil. 1H NMR (500 MHz, 
CDCl3) rotamers δ 7.45 – 7.25 (comp, 5H), 7.02 – 6.96 (m, 1H), 6.80 – 6.73 (m, 1H), 
6.67 – 6.58 (m, 1H), 5.53 – 5.11 (comp, 3H), 3.10 – 2.95 (comp, 8H), 2.75 – 2.63 (comp, 
5H), 2.09 – 1.91 (comp, 3H), 1.84 – 1.67 (comp, 2H). 13C NMR (126 MHz, CDCl3) 
rotamers δ 157.0, 156.7, 150.3, 150.3, 137.0, 136.9, 135.6, 135.5, 129.9, 129.7, 129.6, 
129.5, 128.3, 127.7, 127.7, 127.6, 127.6, 115.5, 115.3, 114.4, 114.1, 66.9, 66.9, 55.4, 
55.2, 50.6, 50.5, 46.0, 30.1, 29.5, 28.6, 28.5, 28.0, 27.5, 22.1, 22.0. HRMS (ESI) m/z 











1-yl)carbamate ((S)–2.127) (MDW-2-118). Prepared from (S)–2.125 (32 mg, 0.084 
mmol) and propionaldehyde according to representative procedure E. The crude residue 
was purified via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N 
(79:20:1) to afford 33 mg (91%) of (S)–2.127 (>99% ee by analytical HPLC). as a 
colorless oil. 1H NMR (500 MHz, CDCl3) rotamers δ 7.44 – 7.26 (comp, 5H), 6.99 (d, J 
= 8.3 Hz, 1H), 6.81 – 6.73 (m, 1H), 6.62 (dd, J = 11.8, 2.6 Hz, 1H), 5.50 – 5.32 (m, 1H), 
5.32 – 5.11 (comp, 2H), 3.16 – 3.03 (comp, 4H), 2.75 – 2.61 (comp, 5H), 2.61 – 2.53 
(comp, 4H), 2.39 – 2.32 (comp, 2H), 2.07 – 1.91 (comp, 2H), 1.84 – 1.68 (comp, 2H), 
1.61 – 1.51 (comp, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 157.3, 
157.1, 150.1, 150.1, 137.3, 137.2, 135.9, 135.8, 130.1, 130.0, 129.9, 129.7, 128.6, 128.0, 
127.9, 127.9, 115.7, 115.4, 114.7, 114.3, 67.2, 67.2, 60.8, 55.7, 55.5, 53.4, 53.3, 49.7, 
49.5, 30.3, 29.8, 29.8, 28.8, 28.8, 28.2, 27.8, 22.3, 22.2, 20.2, 12.1. HRMS (ESI) m/z 


















mmol) and propionaldehyde according to representative procedure E. The crude residue 
was purified via flash chromatography (SiO2) eluting with hexanes/EtOAc/Et3N 
(79:20:1) to afford 36 mg (100%) of (R)–2.128 (>99% ee by analytical HPLC) as a 
colorless oil. 1H and 13C NMR are consistent with (±)–2.31. 1H NMR (499 MHz, CDCl3) 
δ 7.45 – 7.27 (comp, 5H), 6.99 (d, J = 8.3 Hz, 1H), 6.81 – 6.74 (m, 1H), 6.62 (dd, J = 
11.9, 2.6 Hz, 1H), 5.51 – 5.32 (m, 1H), 5.32 – 5.10 (comp, 2H), 3.15 – 3.03 (comp, 4H), 
2.75 – 2.62 (comp, 5H), 2.61 – 2.52 (comp, 4H), 2.06 – 1.92 (comp, 2H), 1.83 – 1.68 
(comp, 2H), 1.56 (h, J = 7.4 Hz, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 157.3, 157.1, 150.1, 150.1, 137.3, 137.1, 135.9, 135.8, 130.1, 130.0, 129.9, 
129.7, 128.6, 128.0, 127.9, 127.9, 115.7, 115.4, 114.7, 114.3, 67.2, 67.2, 60.8, 55.7, 55.5, 
53.3, 53.3, 49.7, 49.5, 32.1, 30.3, 29.8, 29.5, 28.8, 28.7, 28.2, 27.7, 22.8, 22.3, 22.2, 20.2, 




tetrahydronaphthalen-1-yl)(methyl)carbamate (2.138) (MDW-1-276). Prepared from 
2.16 (60 mg, 0.16 mmol) and the known aldehyde 2.132 according to representative 
procedure E.335 The crude residue was purified via flash chromatography (SiO2) eluting 
with hexanes/EtOAc/Et3N (54:45:1) to afford 60 mg (65%) of 2.138 as a colorless oil. 1H 
NMR (499 MHz, CDCl3) rotamers δ 7.43 – 7.27 (comp, 5H), 6.98 (d, J = 8.4 Hz, 1H), 
6.79 – 6.74 (m, 1H), 6.62 (dd, J = 12.4, 2.5 Hz, 1H), 5.50 – 5.31 (m, 1H), 5.30 – 5.10 
(comp, 2H), 4.56 (brs, 1H), 3.15 – 3.03 (comp, 6H), 2.74 – 2.61 (comp, 5H), 2.60 – 2.52 









1.58 – 1.29 (m, 17H). 13C NMR (126 MHz, CDCl3) rotamers δ 157.3, 157.0, 156.1, 
150.1, 150.0, 137.2, 137.1, 135.8, 135.7, 130.1, 129.9, 129.9, 129.6, 128.6, 128.0, 127.8, 
127.8, 115.7, 115.4, 114.6, 114.3, 79.1, 67.2, 67.1, 58.7, 55.7, 55.4, 53.3, 49.6, 49.5, 40.6, 
30.3, 30.1, 29.8, 28.8, 28.7, 28.5, 28.2, 27.7, 27.3, 26.9, 26.8, 22.3, 22.1. HRMS (ESI) 




tetrahydronaphthalen-1-yl)(methyl)carbamate (2.139) (MDW-1-278). Prepared from 
2.16 (60 mg, 0.16 mmol) and the known aldehyde 2.137 according to representative 
procedure E.338 The crude residue was purified via flash chromatography (SiO2) eluting 
with hexanes/EtOAc/Et3N (74:25:1) to afford 62 mg (60%) of 2.139 as a colorless oil. 1H 
NMR (499 MHz, CDCl3) rotamers δ 7.44 – 7.27 (comp, 5H), 6.98 (d, J = 8.8 Hz, 1H), 
6.79 – 6.74 (m, 1H), 6.62 (dd, J = 12.0, 2.5 Hz, 1H), 5.50 – 5.31 (m, 1H), 5.31 – 5.11 
(comp, 2H), 4.54 (brs, 1H), 3.16 – 3.01 (comp, 6H), 2.74 – 2.61 (comp, 5H), 2.60 – 2.52 
(comp, 4H), 2.41 – 2.33 (comp, 2H), 2.06 – 1.91 (comp, 2H), 1.83 – 1.67 (comp, 2H), 
1.57 – 1.40 (comp, 13H), 1.33 – 1.24 (comp, 14H). 13C NMR (126 MHz, CDCl3) 
rotamers δ 157.3, 157.0, 156.1, 150.1, 150.0, 137.2, 137.1, 135.9, 135.8, 130.1, 129.9, 
129.9, 129.6, 128.6, 128.0, 127.9, 127.8, 115.7, 115.4, 114.6, 114.3, 79.1, 67.2, 67.1, 
58.9, 55.7, 55.4, 53.4, 49.6, 49.5, 40.7, 30.3, 30.2, 29.8, 29.7, 29.7, 29.6, 29.6, 29.4, 28.8, 
28.7, 28.5, 28.2, 27.7, 27.0, 26.9, 22.3, 22.1. HRMS (ESI) m/z calcd for C39H60N4O4 












7-bromo-1,2,3,4-tetrahydronaphthalen-1-amine (2.140) (MDW-1-274). 
NH4OAc (1.71 g, 22.2 mmol), and NaBH3CN (691 mg, 11.1 mmol) were added to a 
solution of 7-bromotetralone (0.500 g, 2.22 mmol), in MeOH (11 mL) and the reaction 
was heated at 60 °C for 24 h. The reaction was concentrated under reduced pressure, and 
the crude residue was dissolved in Et2O (30 mL) and extracted with 1 N HCl (3 x 30 
mL). The combined aqueous extracts were made basic with 6 N NaOH and extracted 
with CH2Cl2 (3 x 50 mL). The combined organic extracts were dried (Na2SO4) and 
concentrated under reduced pressure to afford 0.486 g (97%) of 2.140 as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 2.3 Hz, 1H), 7.24 (app dd, J = 8.2, 2.1 Hz, 
1H), 6.94 (d, J = 8.2 Hz, 1H), 3.93 (d, J = 5.9 Hz, 2H), 2.80 – 2.61 (comp, 2H), 2.06 – 
1.97 (m, 1H), 1.97 – 1.86 (m, 1H), 1.81 – 1.70 (m, 1H), 1.69 – 1.60 (m, 1H), 1.53 (brs, 
2H). 13C NMR (126 MHz, CDCl3) δ 143.6, 135.8, 131.0, 130.8, 129.7, 119.6, 49.5, 33.6, 
29.2, 19.6. HRMS (ESI) m/z calcd for C10H12BrN (M+H)+, 226.0226; found 226..0222. 
 
 
NMR Assignments (2.140). 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 2.3 Hz, 
1H, 6), 7.24 (app dd, J = 8.2, 2.1 Hz, 1H, 2), 6.94 (d, J = 8.2 Hz, 1H, 3), 3.93 (d, J = 5.9 
Hz, 2H, 10), 2.80 – 2.61 (comp, 2H, 7), 2.06 – 1.97 (m, 1H, 9'), 1.97 – 1.86 (m, 1H, 8'), 


















CDCl3) δ 143.6 (5), 135.8 (4), 131.0 (6), 130.8 (3), 129.7 (2), 119.6 (1), 49.5 (10), 33.6 




butoxycarbonyl)amino)hexyl)carbamate (2.141) (MDW-1-282). A solution of 2.140 
(85 mg, 0.37 mmol) and 2.132 (90 mg, 0.45 mmol) in MeOH (1.9 mL) was stirred with 3 
Å MS (200 mg) for 4 h at room temperature, whereupon NaBH4 (14 mg, 3.7 mmol) was 
added to the solution and the reaction was stirred overnight. The reaction was 
concentrated under reduced pressure and the crude residue was partitioned between 
CH2Cl2 (10 mL) and saturated aqueous NaHCO3 (10 mL). The organic layer was 
separated and the aqueous layer was extracted with CH2Cl2 (2 x 10 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated under reduced pressure. The crude 
residue was filtered through a SiO2 plug washing with hexanes/EtOAc/Et3N (82:17:1) to 
afford 102 mg of an oil that was used directly. The crude residue was dissolved in 
CH2Cl2 (1 mL) and cooled to 0 °C. i-Pr2Net (62 mg, 83 µL, 0.48 mmol) and CbzCl (49 
mg, 41 µL, 0.29 mmol) were added sequentially to the cooled solution. The reaction was 
stirred for 20 min and the cooling bath was removed, and the solution was stirred for 3 h 
at room temperature. The reaction was diluted with CH2Cl2 (5 mL) and washed with 1 N 
HCl (2 x 5 mL), 1 N NaOH (1 x 5 mL), and saturated aqueous NaHCO3 (1 x 10 mL). The 
organic layer was dried (Na2SO4) and concentrated under reduced pressure to afford 141 
mg of 2.141 as a colorless oil. 1H NMR (499 MHz, CDCl3) rotamers δ 7.51 – 7.08 (comp, 








2.56 (comp, 6H), 2.09 – 1.07 (comp, 21H). 13C NMR (126 MHz, CDCl3) rotamers δ 
157.0, 156.2, 156.0, 139.1, 138.6, 137.2, 136.9, 136.6, 130.9, 130.9, 129.9, 129.8, 129.7, 
129.4, 128.8, 128.6, 128.6, 128.5, 128.4, 128.1, 127.9, 127.8, 119.8, 119.7, 79.0, 67.3, 
67.2, 56.6, 56.1, 53.5, 45.0, 40.5, 30.2, 29.9, 29.3, 29.1, 28.6, 28.5, 28.5, 26.8, 26.5, 26.3, 





tetrahydronaphthalen-1-yl)carbamate (2.142) (MDW-1-284). Prepared from 2.141 
(141 mg 0.252 mmol) and piperazine according to representative procedure C. The crude 
residue was purified via flash chromatography (SiO2) eluting with CH2Cl2/MeOH/Et3N 
(99:0:1 to 97:2:1) to afford 65 mg (46%) of 2.142 as a pale yellow oil. 1H NMR (499 
MHz, CDCl3) rotamers δ 7.42 – 7.19 (comp, 5H), 7.00 – 6.93 (m, 1H), 6.78 – 6.71 (m, 
1H), 6.61 – 6.53 (m, 1H), 5.43 – 5.01 (comp, 3H), 4.69 – 4.54 (comp, 1H), 3.22 – 2.90 
(comp, 9H), 2.89 – 2.38 (comp, 5H), 2.08 – 1.03 (comp, 22H). 13C NMR (126 MHz, 
CDCl3) rotamers δ 157.2, 156.5, 155.9, 150.2, 150.1, 137.1, 136.9, 136.4, 130.0, 129.7, 
129.5, 128.5, 128.4, 127.9, 127.9, 127.8, 127.8, 115.8, 115.5, 114.5, 114.0, 78.9, 67.0, 
66.8, 56.3, 52.9, 50.6, 50.5, 46.1, 46.0, 40.4, 30.2, 29.5, 29.2, 29.1, 28.7, 28.6, 28.4, 26.7, 













1,2,3,4-tetrahydronaphthalen-1-yl)carbamate (2.143) (MDW-1-286). Prepared from 
2.142 (25 mg, 0.044 mmol) and propionaldehyde according to representative procedure 
E. The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (69:30:1) to afford 17 mg (63%) of 2/143 as a colorless oil. 1H 
NMR (499 MHz, CDCl3) rotamers δ 7.43 – 7.20 (comp, 5H), 6.98 (dd, J = 8.4, 2.2 Hz, 
1H), 6.77 (dd, J = 8.4, 2.5 Hz, 1H), 6.62 – 6.56 (m, 1H), 5.43 – 5.02 (comp, 3H), 4.62 – 
4.47 (m, 1H), 3.24 – 2.95 (comp, 7H), 2.86 – 2.50 (comp, 7H), 2.37 (d, J = 8.9 Hz, 2H), 
2.07 – 1.91 (comp, 2H), 1.83 – 1.66 (comp, 3H), 1.64 – 1.49 (comp, 3H), 1.49 – 1.37 
(comp, 11H), 1.35 – 1.25 (comp, 2H), 1.19 – 1.07 (comp, 2H), 0.94 (t, J = 7.4 Hz, 3H). 




yl)amino)undecyl)carbamate (2.146) (MDW-2-95). Prepared from 2.84 (50.8 mg, 0.186 
mmol) and mono-Boc-1,11-diaminoundecane according to representative procedure I.340 
The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (84:15:1) to afford 87.6 mg (87%) of 2.146 as a colorless oil. 1H 
NMR (499 MHz, CDCl3) δ 6.96 (d, J = 8.4 Hz, 1 H), 6.93 (d, J = 2.6 Hz, 1 H), 6.76 (dd, 













(comp, J = 6.8 Hz, 2 H), 2.75 – 2.62 (comp, 4 H), 2.61 – 2.57 (comp, 4 H), 2.37 – 2.32 
(comp, 2 H), 1.97 – 1.87 (m, 1 H), 1.86 – 1.79 (comp, 2 H), 1.72 – 1.64 (m, 1 H), 1.60 – 
1.40 (comp, 15 H), 1.38 – 1.22 (m, 15 H), 0.92 (t, J = 7.4 Hz, 3 H). 13C NMR (126 MHz, 
CDCl3) δ 156.1, 149.7, 140.1, 129.7, 129.0, 116.4, 115.5, 79.1, 60.9, 56.0, 53.4, 49.9, 
47.4, 40.7, 30.7, 30.2, 29.7, 29.7, 29.7, 29.6, 29.4, 28.7, 28.6, 28.5, 27.6, 26.9, 20.2, 19.4, 




1,2,3,4-tetrahydronaphthalen-1-yl)carbamate (2.147) (MDW-2-97). Prepared from 
2.146 (80.4 mg, 0.148 mmol) and CbzCl according to representative procedure A. The 
crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/EtOAc/Et3N (74:25:1) to afford 80.6 mg (80%) of 2.147 as a pale yellow oil. 1H 
NMR (499 MHz, CDCl3) δ 7.43 – 7.19 (comp, 5 H), 6.99 – 6.95 (m, 1 H), 6.76 (dd, J = 
8.4, 2.5 Hz, 1 H), 6.60 (d, J = 2.5 Hz, 1 H), 5.42 – 4.98 (m, 3 H), 4.51 (br s, 1 H), 3.29 – 
3.01 (comp, 7 H), 2.88 – 2.50 (comp, 7 H), 2.41 – 2.31 (comp, 2 H), 2.10 – 1.38 (comp, 
19 H), 1.32 – 1.07 (comp, 14 H) 0.93 (t, J = 7.4 3 H). 13C NMR (126 MHz, CDCl3) δ 
157.3, 156.6, 156.1, 150.0, 149.9, 137.3, 137.2, 137.1, 136.7, 130.0, 129.8, 129.5, 128.6, 
128.5, 128.0, 127.9, 127.9, 115.7, 115.4, 114.5, 114.0, 79.1, 67.1, 67.0, 60.8, 56.5, 53.3, 
49.6, 49.5, 45.0, 40.8, 30.6, 30.5, 30.2, 29.6, 29.6, 29.5, 29.4, 29.3, 29.3, 28.9, 28.8, 28.6, 
27.3, 26.9, 22.7, 22.5, 20.2, 12.1. HRMS (ESI) m/z calcd for C41H64N4O4 (M+H)+, 









tetrahydronaphthalen-1-yl)carbamate (2.149) (MDW-2-32). 2.147 (37.3 mg, 0.0551 
mmol) was dissolved in a solution of dioxane (0.4 mL) containing HCl (4 M) cooled to 0 
°C. The solution was stirred at 0 °C for 3 h and then diluted with CH2Cl2 (20 mL). The 
solution was washed with 1 N NaOH (1 x 20 mL), saturated aqueous NaHCO3 (1 x 20 
mL), dried (Na2SO4), and concentrated under reduced pressure to afford 30.6 mg of 2.149  
(96%) as a pale yellow oil. 1H NMR (499 MHz, CDCl3) δ 7.44 – 7.18 (comp, 5 H), 7.01 
– 6.94 (m, 1 H), 6.76 (dd, J = 8.4, 2.5 Hz, 1 H), 6.63 – 6.56 (m, 1 H), 5.44 – 5.01 (comp, 
3 H), 3.29 – 2.99 (comp, 5 H), 2.86 – 2.60 (comp, 5 H), 2.58 – 2.50 (comp, 4 H), 2.38 – 
2.31 (comp, 2 H), 2.07 – 1.41 (comp, 12 H), 1.32 – 1.08 (comp, 14 H), 0.93 (t, J = 7.4 
Hz, 3 H). 13C NMR (126 MHz, CDCl3) δ 157.2, 156.5, 149.8, 149.7, 137.2, 136.9, 136.5, 
129.8, 129.7, 129.3, 128.4, 128.4, 127.8, 127.8, 127.7, 115.6, 115.2, 114.3, 113.8, 66.9, 
66.8, 60.7, 56.3, 53.2, 53.2, 49.5, 44.8, 42.1, 33.5, 30.4, 29.6, 29.5, 29.5, 29.4, 29.2, 29.1, 
28.7, 28.6, 27.2, 26.9, 22.6, 22.4, 20.1, 12.0. HRMS (ESI) m/z calcd for C36H56N4O2 

















tridecanediamine according to representative procedure I.341 The crude residue was 
purified via flash chromatography (SiO2) eluting with hexanes/acetone/Et3N (44:35:1) to 
afford 118 mg (54%) of 2.151 as an orange oil containing some impurities that could not 
be separated. The residue was used in the subsequent reaction without additional 
purification. 1H NMR (400 MHz, CDCl3) δ 6.97 – 6.90 (comp, 2H), 6.73 (dd, J = 8.3, 2.7 
Hz, 1H), 5.20 – 5.10 (m, 1H), 3.66 (t, J = 5.0 Hz, 1H), 3.64 – 3.45 (comp, 13H), 3.22 – 
3.09 (comp, 6H), 2.83 – 2.46 (comp, 8H), 2.35 – 2.28 (comp, 2H), 1.96 – 1.59 (comp, 
9H), 1.52 (h, J = 7.4 Hz, 2H), 1.40 (s, 10H), 0.89 (t, J = 7.4 Hz, 3H). HRMS (ESI) m/z 





2-93). Prepared from 2.151 (0.118 g, 0.204 mmol) and CbzCl according to representative 
procedure A. The crude residue was purified via flash chromatography (SiO2) eluting 
with hexanes/acetone/Et3N (76:23:1) to afford 118 mg (81%) of 2.152 as a colorless oil. 
1H NMR (499 MHz, CDCl3) rotamers δ 7.40 – 7.11 (comp, 5H), 6.89 (d, J = 8.4 Hz, 1H), 
6.68 (dd, J = 8.4, 2.5 Hz, 1H), 6.54 – 6.46 (m, 1H), 5.39 – 4.88 (comp, 4H), 3.55 – 3.08 
(comp, 15H), 3.04 – 2.93 (comp, 4H), 2.91 – 2.74 (m, 1H), 2.66 – 2.44 (comp, 6H), 2.32 
– 2.21 (comp, 2H), 2.01 – 1.62 (comp, 8H), 1.48 (h, J = 7.5 Hz, 2H), 1.36 (s, 9H), 0.86 (t, 
J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) rotamers δ 157.2, 156.6, 156.0, 149.9, 
149.8, 137.1, 136.9, 136.4, 129.9, 129.8, 129.4, 128.5, 128.4, 127.9, 127.9, 127.8, 115.7, 








56.4, 53.2, 49.5, 49.4, 42.0, 38.6, 30.5, 29.6, 29.5, 29.4, 29.0, 28.7, 28.6, 28.5, 22.6, 22.4, 
20.0, 12.0. HRMS (ESI) m/z calcd for C40H62N4O7 (M+H)+, 711.4691; found 711.4698. 
 
 
(E)-N-Methyl-N-((E)-5-oxopent-3-en-1-yl)but-2-enamide (4.4) (MDW-4-126). 
Freshly distilled crotonyl chloride (0.998 g, 9.55 mmol) was added dropwise to a solution 
of 1,3,5-trimethylhexahydro-1,3,5-triazine (0.410 g, 3.17 mmol) in MeCN (16 mL) at 0 
°C. The reaction was stirred for 30 min at 0 °C and then transferred to an oil bath 
preheated to 80 °C and stirred for 2 h.  After cooling to 0 °C, TMSOTf (0.06 mL, 0.3 
mmol) and 1-(trimethylsiloxy)-1,3-butadiene (1.813 g, 12.74 mmol) were sequentially 
added dropwise, and the reaction was stirred at 0 °C for 16 h. The reaction was quenched 
with saturated aqueous NaHCO3 (2 mL), and the MeCN was removed under reduced 
pressure. The resulting mixture was diluted with saturated aqueous NaHCO3 (20 mL) and 
extracted with CH2Cl2 (3 x 30 mL). The combined organic extracts were dried (Na2SO4) 
and concentrated under reduced pressure, and the crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/i-PrOH (90:10 to 40:60) to give 1.073 g 
(62%) of 4.4 as a pale yellow oil and 168 mg (10%) of 4.30  as a colorless oil.  
Compound 4.4  IR (neat): nmax/cm-1 2938, 1684, 1660, 1606, 1484, 1447, 1401, 
1143, 1097, 966, 827. 1H NMR (400 MHz, CDCl3) rotamers δ 9.53 – 9.43 (comp, 1H), 
6.98 – 6.67 (comp, 2H), 6.26 – 6.05 (comp, 2H), 3.65 – 3.47 (comp, 2H), 3.08 – 2.94 
(comp, 3H), 2.66 – 2.52 (comp, 2H), 1.86 (dd, J = 6.9, 1.7 Hz, 3H). 13C NMR (126 MHz, 














121.6, 121.2, 48.3, 46.5, 35.7, 34.1, 32.2, 31.1, 18.3, 15.4.HRMS (ESI) m/z calcd for 
C10H15NO2 (M+H)+, 182.1176; found 182.1178. 
Compound 4.30. IR (neat): nmax/cm-1 2936, 1681, 1659, 1612, 1447, 1400, 1284, 
1260, 1128, 1097, 965, 947, 825. 1H NMR (400 MHz, CDCl3) δ 9.44 (s, 1H), 6.97 – 6.77 
(comp, 2H), 6.23 (d, J = 15.0 Hz, 1H), 4.34 – 4.20 (comp, 2H), 3.03 (s, 3H), 2.14 (d, J = 
7.0 Hz, 3H), 1.87 (d, J = 6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 194.9, 166.7, 
155.6, 142.0, 140.2, 121.8, 40.5, 36.2, 18.4, 15.6. HRMS (ESI) m/z calcd for C10H15NO2 
(M+Na)+, 204.0995; found 204.1002.   
 
 
NMR Assignments (4.4). 1H NMR (400 MHz, CDCl3) rotamers δ 9.53 – 9.43 (m, 
1H, 9), 6.98 – 6.67 (comp, 2H, 4, 10), 6.26 – 6.05 (comp, 2H, 5, 8), 3.65 – 3.47 (comp, 
2H, 2), 3.08 – 2.94 (comp, 3H, 12), 2.66 – 2.52 (comp, 2H, 3), 1.86 (dd, J = 6.9, 1.7 Hz, 
3H, 13). 13C NMR (126 MHz, CDCl3) δ 193.9 and 193.3 (9), 166.8 and 166.7 (6), 154.9 
and 152.8 (4), 142.4 and 142.3 (10), 134.8 and 134.4 (8), 121.6 and 121.2 (5), 48.3 and 
46.5 (2), 35.7 and 34.1 (12), 32.2 and 31.1 (3), 18.3 and 15.4 (13). 
 
 
NMR Assignments (4.30). 1H NMR (400 MHz, CDCl3) δ 9.44 (s, 1H, 4), 6.97 – 



































3H, 12), 2.14 (d, J = 7.0 Hz, 3H, 10), 1.87 (d, J = 6.5 Hz, 3H, 13). 13C NMR (126 MHz, 
CDCl3) δ 194.9 (4), 166.7 (6), 155.6 (9), 142.0 (8), 140.2 (3), 121.8 (5), 40.5 (2), 36.2 




c]pyridin-8-one (4.31) (MDW-4-127). A solution of 4.4 (1.039 g, 5.733 mmol) in 
mesitylene (385 mL) was degassed via sparging the solution with N2 for 1 h. The reaction 
flask was transferred to an oil bath preheated to 190 °C and heated under reflux for 30 h. 
Upon cooling, the solvent was removed under reduced pressure, and the crude material 
was purified via flash chromatography (SiO2), eluting with hexanes/EtOAc (70:30 to 
40:60) to afford 0.677 g (65%) of 4.31 as a colorless oil and 0.125 g of 4.32  (12%) as a 
waxy white solid.   
Compound 4.31. IR (neat): nmax/cm-1 2930, 2869, 1633, 1500, 1443, 1331, 1237, 
1097, 1049, 743. 1H NMR (400 MHz, CDCl3) δ 6.38 (dd, J = 6.2, 2.1 Hz, 1H), 4.81 (qd, 
J = 6.6, 3.7 Hz, 1H), 4.53 (dd, J = 6.3, 2.4 Hz, 1H), 3.36 (ddd, J = 12.0, 10.1, 4.5 Hz, 
1H), 3.13 (dt, J = 12.2, 4.9 Hz, 1H), 2.93 (s, 3H), 2.75 – 2.67 (m, 1H), 2.41 – 2.35 (m, 
1H), 2.02 – 1.92 (m, 1H), 1.83 – 1.73 (m, 1H), 1.33 (d, J = 6.7 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 169.0, 144.6, 100.6, 70.3, 46.8, 44.6, 35.3, 27.2, 26.1, 18.4. HRMS (ESI) 
m/z calcd for C10H15NO2 (M+H)+, 182.1176; found 182.1180. 
Compound 4.32. IR (neat): nmax/cm-1 2975, 2933, 1630, 1501, 1439, 1327, 1226, 
















J = 6.1, 1.7 Hz, 1H), 4.10 (dq, J = 9.9, 6.1 Hz, 1H), 3.40 (ddd, J = 12.4, 7.6, 2.7 Hz, 1H), 
3.30 (ddd, J = 12.4, 10.1, 7.0 Hz, 1H), 2.90 (d, J = 0.7 Hz, 3H), 2.45 – 2.36 (m, 1H), 2.05 
– 1.95 (comp, 2H), 1.67 (d, J = 6.1 Hz, 3H), 1.64 – 1.54 (m, 1H). 13C NMR (126 MHz, 
CDCl3) δ 170.1, 143.7, 102.8, 73.1, 48.6, 48.2, 34.5, 32.0, 29.5, 21.8. HRMS (ESI) m/z 
calcd for C10H15NO2 (M+H)+, 182.1176; found 182.1179. 
 
 
NMR Assignments (4.31). 1H NMR (400 MHz, CDCl3) δ 6.38 (dd, J = 6.2, 2.1 
Hz, 1H, 8), 4.81 (qd, J = 6.6, 3.7 Hz, 1H, 10), 4.53 (dd, J = 6.3, 2.4 Hz, 1H, 7), 3.36 (ddd, 
J = 12.0, 10.1, 4.5 Hz, 1H, 2''), 3.13 (dt, J = 12.2, 4.9 Hz, 1H, 2'), 2.93 (s, 3H, 14), 2.75 – 
2.67 (m, 1H, 13), 2.41 – 2.35 (m, 1H, 12), 2.02 – 1.92 (m, 1H, 3'), 1.83 – 1.73 (m, 1H, 
3''), 1.33 (d, J = 6.7 Hz, 3H, 15). 13C NMR (126 MHz, CDCl3) δ 169.0 (6), 144.6 (8), 
100.6 (7), 70.3 (10), 46.8 (2), 44.6 (5), 35.3 (14), 27.2 (3), 26.1 (4), 18.4 (15). 
 
NMR Assignments (4.32). 1H NMR (400 MHz, CDCl3) δ 6.35 (dd, J = 6.0, 2.4 
Hz, 1H, 8), 4.58 (dd, J = 6.1, 1.7 Hz, 1H, 7), 4.10 (dq, J = 9.9, 6.1 Hz, 1H, 10), 3.40 (ddd, 
J = 12.4, 7.6, 2.7 Hz, 1H, 2''), 3.30 (ddd, J = 12.4, 10.1, 7.0 Hz, 1H, 2'), 2.90 (d, J = 0.7 
Hz, 3H, 14), 2.45 – 2.36 (m, 1H, 13), 2.05 – 1.95 (comp, 2H, 3'', 12), 1.67 (d, J = 6.1 Hz, 
3H, 15), 1.64 – 1.54 (m, 1H, 3'). 13C NMR (126 MHz, CDCl3) δ 170.1 (6), 143.7 (8), 









































c]pyridin-8-one (4.46) (MDW-4-129). A foil-wrapped flask containing cis-
oxahydroisoquinolone 4.31 (0.677 g, 3.74 mmol) was evacuated and backfilled with N2 
five times, whereupon MeCN (31 mL) was added. Under a positive flow of N2, AgNO3 
(63 mg, 0.37 mmol) and recrystallized NIS (1.008 g, 4.480 mmol) were added 
sequentially. The flask was transferred to an oil bath preheated to 80 °C and stirred in the 
dark for 2.5 h. After cooling the mixture to room temperature, it was filtered through a 
pad of Celite into a foil-wrapped flask, and the filter cake was washed with MeCN (50 
mL). The filtrate was concentrated under reduced pressure, whereupon the resulting 
residue was dissolved in CH2Cl2 (30 mL) and washed with saturated aqueous Na2S2O3 (1 
x 30 mL). The organic layer was separated, and the aqueous layer was washed with 
CH2Cl2 (2 x 20 mL). The combined organic layers were washed with H2O (3 x 30 mL), 
brine, (1 x 40 mL), dried (Na2SO4), and concentrated under reduced pressure. The crude 
residue was purified via flash chromatography (SiO2) eluting with hexanes/EtOAc (80:20 
to 40:60) to give 0.954 g (83%) of 4.46 as a yellow oil. IR (neat): nmax/cm-1 2931, 1636, 
1500, 1442, 1197, 1161, 1136, 1018, 983. 1H NMR (400 MHz, CDCl3) δ 6.72 (d, J = 1.8 
Hz, 1H), 4.83 (qd, J = 6.7, 4.3 Hz, 1H), 3.33 (dt, J = 12.4, 6.9 Hz, 1H), 3.14 (dt, J = 12.4, 
5.1 Hz, 1H), 2.94 (s, 3H), 2.78 – 2.71 (m, 1H), 2.57 (dd, J = 6.2, 4.3 Hz, 1H), 2.09 – 2.02 
(m, 2H), 1.36 (d, J = 6.6 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 167.8, 148.9, 72.4, 70.9, 
46.5, 46.4, 35.4, 34.8, 27.5, 18.4. HRMS (ESI) m/z calcd for C10H14INO2 (M+H)+, 











NMR Assignments (4.46). 1H NMR (400 MHz, CDCl3) δ 6.72 (d, J = 1.8 Hz, 
1H, 8), 4.83 (qd, J = 6.7, 4.3 Hz, 1H, 10), 3.33 (dt, J = 12.4, 6.9 Hz, 1H, 2''), 3.14 (dt, J = 
12.4, 5.1 Hz, 1H, 2'), 2.94 (s, 3H, 15), 2.78 – 2.71 (m, 1H, 13), 2.57 (dd, J = 6.2, 4.3 Hz, 
1H, 12), 2.09 – 2.02 (comp, 2H, 3), 1.36 (d, J = 6.6 Hz, 3H, 16). 13C NMR (126 MHz, 
CDCl3) δ 167.8 (6), 148.9 (8), 72.4 (7), 70.9 (10), 46.5 (2), 46.4 (5), 35.4 (15), 34.8 (13), 





131). tert-BuLi (8.0 mL of a 1.8 M solution in pentane) was added dropwise over 10 min 
to a solution of N-Boc-3-methylindole487 (2.908 g, 13.38 mmol) in THF (67 mL) at -78 
°C. After stirring for 1 h at –78 °C, B(OMe)3 (3.4 g, 3.7 mL, 33 mmol) was added 
rapidly, and the reaction was stirred for 1 h at –78 °C. The reaction was transferred to a 
cooling bath at 0 °C, and stirring was continued for 30 min, whereupon saturated aqueous 






























30 min. The mixture was diluted with saturated aqueous NH4Cl (20 mL) and extracted 
with Et2O (3 x 30 mL). The combined organic extracts were dried (MgSO4) and 
concentrated under reduced pressure to afford crude boronic acid 17 that was used 
immediately. The flask containing the crude 17 was evacuated and backfilled with N2 
five times, whereupon PhMe (19 mL) was added, and N2 was bubbled through the 
solution for 10 min. The solution was transferred via cannula to a N2 flushed flask 
containing vinyl iodide 4.46 (1.017 g, 3.311 mmol), SPhos Pd G2 (0.239 g, 0.332 mmol), 
and K3PO4 (2.811 g, 13.24 mmol), rinsing with PhMe (3 x 12 mL). Degassed H2O (11 
mL) was added to the mixture, and the flask was immediately transferred to an oil bath 
preheated to 60 °C and stirred in the dark for 2 h. The reaction was cooled to room 
temperature, and the mixture was diluted with saturated aqueous NH4Cl (1 x 50 mL) and 
extracted with Et2O (3 x 50 mL). The combined organic extracts were dried (MgSO4), 
concentrated under reduced pressure, and the crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc (70:30 to 50:50) to afford 1.071 g 
(79%) of 4.55 as a pale yellow solid: mp 67-72 °C. IR (neat): nmax/cm-1 2933, 1727, 
1640,1455, 1318, 1144, 1073, 866, 747. 1H NMR (400 MHz, CDCl3) δ 8.01 (dd, J = 7.3, 
1.0 Hz, 1H), 7.50 – 7.45 (comp, 1H), 7.32 – 7.21 (m, 2H), 6.49 (d, J = 1.3 Hz, 1H), 4.64 
(p, J = 6.5 Hz, 1H), 3.14 – 2.99 (m, 3H), 2.93 (s, 3H), 2.68 (t, J = 6.2 Hz, 1H), 2.22 (s, 
3H), 1.85 – 1.67 (m, 2H), 1.66 (s, 9H), 1.53 (d, J = 6.5 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 168.8, 150.2, 144.8, 135.9, 133.2, 130.6, 124.3, 122.6, 118.8, 117.2, 115.7, 
107.3, 83.6, 70.4, 48.2, 45.5, 35.2, 31.7, 28.5, 25.9, 19.6, 9.9. HRMS (ESI) m/z calcd for 




NMR Assignments 4.55). 1H NMR (400 MHz, CDCl3) δ 8.01 (dd, J = 7.3, 1.0 
Hz, 1H, 19), 7.50 – 7.45 (m, 1H, 22), 7.32 – 7.21 (comp, 2H, 20, 21), 6.49 (d, J = 1.3 Hz, 
1H, 8), 4.64 (p, J = 6.5 Hz, 1H, 10), 3.14 – 2.99 (comp, 3H, 2, 13), 2.93 (s, 3H, 24), 2.68 
(t, J = 6.2 Hz, 1H, 12), 2.22 (s, 3H, 23), 1.85 – 1.67 (comp, 2H, 3), 1.66 (s, 9H, 28, 29, 
30), 1.53 (d, J = 6.5 Hz, 3H, 25). 13C NMR (126 MHz, CDCl3) δ 168.8 (6), 150.2 (29), 
144.8 (8), 135.9 (17), 133.2 (16), 130.6 (14), 124.3 (21), 122.6 (20), 118.8 (22), 117.2 
(15), 115.7 (19), 107.3 (7), 83.6 (25), 70.4 (10), 48.2 (2), 45.5 (5), 35.2 (31), 31.7 (13), 





dione (4.61) (MDW-4-145). A solution of HCl (4 M in dioxane, 0.75 mL) was added 
dropwise to a solution of indolyl oxahydroisoquinolone 4.55 (0.155 g, 0.378 mmol) in 















































for 31 h, whereupon it was poured into saturated aqueous NaHCO3 (10 mL) and extracted 
with CH2Cl2 (3 x 15 mL). The combined organic extracts were dried (Na2SO4), 
concentrated under reduced pressure, and the crude residue was purified via flash 
chromatography (SiO2) eluting with EtOAc/CH2Cl2 (10:90 to 30:70) affording 0.103 g 
(77%) of 4.61 as a white solid: mp 107-111 °C. IR (neat): nmax/cm-1 2925, 1724, 
1627,1461, 1378, 1336, 1317, 1183, 1131, 1089, 998, 951, 907, 755. 1H NMR (400 MHz, 
CDCl3) δ 8.31 – 8.26 (comp, 1H), 7.53 – 7.49 (comp, 1H), 7.41 – 7.31 (m, 2H), 5.84 (d, J 
= 3.6 Hz, 1H), 4.43 (dq, J = 10.5, 6.1 Hz, 1H), 3.58 (dd, J = 6.2, 3.6 Hz, 1H), 3.18 (ddd, J 
= 12.3, 6.2, 1.5 Hz, 1H), 3.07 (td, J = 12.1, 5.0 Hz, 1H), 2.88 (s, 3H), 2.73 – 2.67 (m, 
1H), 2.53 – 2.44 (comp, 1H), 2.31 – 2.17 (m, 4H), 1.48 (d, J = 6.2 Hz, 3H), 1.32 – 1.26 
(comp, 1H). 13C NMR (126 MHz, CDCl3) δ 167.4, 147.1, 134.8, 131.1, 128.2, 125.3, 
124.2, 118.8, 115.7, 114.5, 98.3, 65.5, 49.6, 47.7, 35.0, 34.7, 34.5, 21.4, 19.9, 8.5. HRMS 
(ESI) m/z calcd for C20H22N2O4 (M+Na)+, 377.1472; found 377.1474. 
An analytical sample of 4.61  was recrystallized from THF and water via slow 
evaporation to afford colorless thin needles. Crystallographic data for 19 has been 
deposited with the Cambridge Crystallographic Data Center, Deposition number 1947103 
 
 
NMR Assignments (4.61). 1H NMR (400 MHz, CDCl3) δ 8.31 – 8.26 (m, 1H, 


































4.43 (dq, J = 10.5, 6.1 Hz, 1H, 10), 3.58 (dd, J = 6.2, 3.6 Hz, 1H, 7), 3.18 (ddd, J = 12.3, 
6.2, 1.5 Hz, 1H, 2''), 3.07 (td, J = 12.1, 5.0 Hz, 1H, 2'), 2.88 (s, 3H, 27), 2.73 – 2.67 (m, 
1H, 12), 2.53 – 2.44 (m, 1H, 13), 2.31 – 2.17 (comp, 4H, 3', 22), 1.48 (d, J = 6.2 Hz, 3H, 
28), 1.32 – 1.26 (m, 1H, 3''). 13C NMR (126 MHz, CDCl3) δ 167.4 (6), 147.1 (16), 134.8 
(21), 131.1 (14), 128.2 (20), 125.3 (25), 124.2 (24), 118.8 (26), 115.7 (23), 114.5 (19), 





pyrano[3,4-c]pyridin-8-one (4.63) (MDW-4-147). Triethylsilane (0.33 g, 0.46 mL, 2.9 
mmol) was added to a solution of acetal 4.61 (0.102 g, 0.288 mmol) in CH2Cl2 (4.8 mL) 
at –40 °C. EtAlCl2 (1.1 mL of a 1.8 M solution in PhMe) was added dropwise over 5 min, 
and the reaction was stirred at –40 °C for 30 min. The reaction was transferred to a 
cooling bath at 0 °C and stirred for 3 h. The solution was poured into saturated aqueous 
NaHCO3 (10 mL), whereupon saturated aqueous Rochelle salt (10 mL) was added. The 
mixture was stirred for 2 h and then extracted with CH2Cl2 (3 x 20 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated under reduced pressure, and the 
crude residue was purified via flash chromatography (SiO2) eluting with EtOAc/CH2Cl2 
(30:60 to 60:40) to furnish 87 mg (97%) of 4.63 as a white solid: mp 107-112 °C. IR 










(400 MHz, CDCl3) δ 7.91 (s, 1H), 7.51 (d, J = 1.3 Hz, 1H), 7.29 (d, J = 1.0 Hz, 1H), 7.18 
– 7.07 (comp, 2H), 4.13 – 4.00 (comp, 3H), 3.51 (dt, J = 10.0, 4.9 Hz, 1H), 3.19 – 3.02 
(comp, 2H), 2.79 (s, 3H), 2.60 – 2.46 (comp, 2H), 2.31 – 2.16 (comp, 4H), 1.62 – 1.53 
(m, 1H), 1.44 (d, J = 6.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.1, 135.4, 132.7, 
129.0, 121.8, 119.5, 118.4, 110.6, 108.5, 70.6, 64.8, 49.2, 49.0, 37.1, 36.0, 35.0, 20.3, 
20.2, 8.9. HRMS (ESI) m/z calcd for C19H24N2O2 (M+Na)+, 335.1730; found 335.1730. 
 
 
NMR Assignments (4.63).1H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H, 18), 7.51 
(d, J = 1.3 Hz, 1H, 19), 7.29 (d, J = 1.0 Hz, 1H, 22), 7.18 – 7.07 (comp, 2H, 20, 21), 4.13 
– 4.00 (comp, 3H, 8, 10), 3.51 (dt, J = 10.0, 4.9 Hz, 1H, 24), 3.19 – 3.02 (comp, 2H, 2), 
2.79 (s, 3H, 25), 2.60 – 2.46 (comp, 2H, 12, 13), 2.31 – 2.16 (comp, 4H, 3', 23), 1.62 – 
1.53 (m, 1H, 3''), 1.44 (d, J = 6.2 Hz, 3H, 26). 13C NMR (126 MHz, CDCl3) δ 169.1 (6), 
135.4 (14), 132.7 (17), 129.0 (16), 121.8 (21), 119.5 (20), 118.4 (19), 110.6 (22), 108.5 
(15), 70.6 (8), 64.8 (10), 49.2 (5), 49.0 (2), 37.1 (7), 36.0 (4), 35.0 (25), 20.3 (3), 20.2 






































(±)-Alstoscholarisine E (3.5) (MDW-4-147). A flask containing tetrahydropyran 
4.63 (79 mg, 0.25 mmol) and IrCl(CO)(PPh3)2 (3.9 mg, 0.0050 mmol) was evacuated and 
backfilled with N2 three times, followed by addition of  CH2Cl2 (5 mL). 1,1,3,3–
Tetramethyldisiloxane (99 mg, 0.13 mL, 0.74 mmol) was added and the resulting solution 
was stirred at room temperature for 2.5 h. The reaction was concentrated under reduced 
pressure, and the crude residue was purified via flash chromatography (SiO2) eluting with 
EtOAc/hexane/Et3N (20:79:1 to 40:59:1) to provide 58 mg (77%) of 3.5 as a pale yellow 
solid: mp 119-122 °C (from MeOH) (lit488 138–140 °C). IR (neat): nmax/cm-1 2918, 1682, 
1456, 1329, 1314, 1132, 1043, 736. 1H NMR (600 MHz, CD3OD) δ 7.50 (d, J = 8.2 Hz, 
1H), 7.42 (d, J = 7.9 Hz, 1H), 7.04 (td, J = 8.2, 1.2 Hz, 1H), 6.98 (td, J = 7.9, 1.0 Hz, 
1H), 5.39 (d, J = 2.5 Hz, 1H), 4.06 (q, J = 6.8 Hz, 1H), 3.96 (dd, J = 10.4, 1.8 Hz, 1H), 
3.40 (dd, J = 10.4, 2.6 Hz, 1H), 3.13 (brs, 1H), 2.56 – 2.52 (m, 1H), 2.36 (dd, J = 11.7, 
5.9 Hz, 1H), 2.29 (s, 3H), 2.23 (s, 3H), 2.19 (brs, 1H), 2.10 – 2.03 (m, 1H), 1.90 (dd, J = 
12.5, 4.1 Hz, 1H), 1.87 – 1.82 (m, 1H), 1.35 (d, J = 6.7 Hz, 3H). 13C NMR (126 MHz, 
CD3OD) δ 138.8, 137.0, 130.3, 121.3, 119.8, 118.6, 111.6, 105.1, 73.4, 72.5, 68.9, 47.1, 
45.5, 43.5, 36.1, 31.0, 28.6, 18.4, 8.0. HRMS (ESI) m/z calcd for C19H24N2O (M+H)+, 









Table S1. Comparison of 1H-NMR for natural,488 and synthetic alstoscholarisine E (3.5) 
in CD3OD. 
 1H NMR (d in ppm, multiplicity , J in Hz) 
Atom Synthetic (600 MHz) Natural (600 MHz) 
H–18 1.35 (d, J = 6.7 Hz, 3H) 1.32 (d, J = 6.8 Hz, 3H) 
H–14' 1.87-1.82 (m, 1H) 1.81 (m, 1H) 
H–3' 1.90 (dd, J = 12.5, 4.1 Hz, 1H) 1.85 (td, J = 11.3, 4.0 Hz, 1H) 
H–14" 2.10-2.03 (m, 1H) 2.03 (m, 1 H) 
H–20 2.19 (brs, 1H) 2.16 (brs, 1H) 
H–6 2.23 (s, 3H) 2.21 (s, 3H) 
NCH3 2.29 (s, 3H) 2.26 (s, 3H) 
H–3" 2.36 (dd, J = 11.7, 5.9 Hz, 1H) 2.33 (dd, J = 11.3, 6.8 Hz, 1H) 
H–15 2.56-2.52 (m, 1H) 2.50 (m, 1H) 
H–16 3.13 (brs, 1H) 3.09 (brs, 1H) 
H–17' 3.40 (dd, J = 10.4, 2.6 Hz, 1H) 3.37 (dd, J = 10.2, 2.6 Hz, 1H) 
H–17" 3.96 (dd, J = 10.4, 1.8 Hz, 1H) 3.92 (dd, J = 10.2, 1.9 Hz, 1H) 
H–19 4.06 (q, J = 6.8 Hz, 1H) 4.04 (q, J = 6.8 Hz, 1H) 
H–21 5.39 (d, J = 2.5 Hz, 1H) 5.37 (d, J = 2.3 Hz, 1H) 
H–10 6.98 (td, J = 7.9, 1.0 Hz, 1H) 6.99 (t, J = 8.0 Hz, 1H) 
H–11 7.04 (td, J = 8.2, 1.2 Hz, 1H) 7.04 (t, J = 8.0 Hz, 1H) 
H–9 7.42 (d, J = 7.9 Hz, 1H) 7.41 (d, J = 8.0 Hz, 1H) 























Table S2. Comparison of 13C-NMR for natural,488 and synthetic alstoscholarisine E (3.5) 
in CD3OD. 
 1H NMR (d in ppm, multiplicity , J in Hz) 
Atom Synthetic (600 MHz) Natural (600 MHz) 
C–6 8.0 8.0 
 473 
C–18 18.4 18.3 
C–15 28.6 28.5 
C–14 31.0 31.0 
C–16 36.1 36.0 
C–20 43.5 43.4 
NCH3 45.5 45.5 
C–3 47.1 47.1 
C–17 68.9 68.8 
C–21 72.5 72.4 
C–19 73.4 73.3 
C–7 105.1 105.0 
C–12 111.6 111.6 
C–9 118.6 118.6 
C–10 119.8 119.8 
C–11 121.3 121.3 
C–8 130.3 130.2 
C–2 137.0 137.0 




one (5.20) (MDW-3-114). tert-BuLi (1.3 mL of a 1.5 M solution in pentane) was added 





Et2O (1.9 mL) at -78 °C and the reaction was stirred for 2 h.460 A solution of 
CuI•0.75DMS (89 mg, 0.38 mmol) and DMS (0.06 mL, 51 mg, 0.82 mmol) in THF (0.5 
mL) was added dropwise and the reaction was stirred at – 78 °C for 5 min, whereupon 
the reaction was transferred to a cooling bath at  -40 °C and the mixture was stirred for 20 
min. The reaction was cooled to -78 °C and HMPA (0.08 mL, 80 mg, 0.4 mmol) was 
added followed by dropwise addition of a solution of known 4-silyloxy-cyclopentenone 
(5.15) (50 mg, 0.24 mmol) and TMSCl (50 mg, 0.5 mmol) in THF (1.2 mL) over 20 
min.450 The reaction was stirred for 30 min at -78 °C and was quenched with sequential 
addition of a solution of saturated aqueous NH4Cl and aqueous NH4OH (9:1, 10 mL) and 
Et2O (10 mL). After warming to room temperature, the organic layer was separated and 
washed with saturated aqueous NH4Cl (1 x 10 mL). The organic layer was separated and 
the combined aqueous extracts were extracted with Et2O (2 x 10 mL). The combined 
organic extracts were dried (MgSO4) and concentrated under reduced pressure. The crude 
residue was dissolved in THF (1.0 mL) and H2O (0.1 mL) and glacial AcOH (0.1 mL) 
were added sequentially. The reaction was stirred for 8 h and was diluted with saturated 
aqueous NaHCO3 (10 mL), whereupon the solution was extracted with Et2O (3 x 10 mL). 
The combined organic extracts were dried (MgSO4) and concentrated under reduced 
pressure. The crude residue was purified via flash chromatography (SiO2) eluting with 
hexanes/Et2O (93:7 to 80:20) to afford 41 mg (61%) of 5.20 as a pale yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 4.09 (q, J = 6.0 Hz, 1H), 2.60 (ddd, J = 18.5, 8.1, 1.7 Hz, 
1H), 2.53 – 2.45 (m, 1H), 2.32 – 2.12 (comp, 4H), 1.90 – 1.79 (comp, 2H), 1.77 (t, J = 
2.5 Hz, 3H), 1.42 – 1.31 (m, 1H), 0.89 (s, 9H), 0.08 (d, J = 11.9 Hz, 6H). 1H NMR (400 
MHz, CDCl3) δ 4.09 (q, J = 6.0 Hz, 1H), 2.60 (ddd, J = 18.5, 8.1, 1.7 Hz, 1H), 2.53 – 
2.45 (m, 1H), 2.32 – 2.12 (m, 4H), 1.90 – 1.79 (m, 2H), 1.77 (t, J = 2.5 Hz, 3H), 1.42 – 
1.31 (m, 1H), 0.89 (s, 9H), 0.08 (d, J = 11.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
 475 
216.1, 78.4, 76.4, 74.6, 47.5, 44.7, 42.7, 32.3, 25.9, 18.1, 17.5, 3.6, -4.5, -4.7. HRMS 
(ESI) m/z calcd for C16H29O2Si (M+H)+, 281.1937; found 281.1934. 
 
NMR Assignments (5.20).1H NMR (400 MHz, CDCl3) δ 4.09 (q, J = 6.0 Hz, 1H, 
2), 2.60 (ddd, J = 18.5, 8.1, 1.7 Hz, 1H, 1), 2.53 – 2.45 (m, 1H, 4''), 2.32 – 2.12 (comp, 
4H, 3, 4', 8''), 1.90 – 1.79 (comp, 2H, 1, 7'), 1.77 (t, J = 2.5 Hz, 3H, 19), 1.42 – 1.31 (m, 
1H, 7''), 0.89 (s, 9H, 16, 17, 18), 0.08 (d, J = 11.9 Hz, 6H, 14, 15). 13C NMR (126 MHz, 
CDCl3) δ 216.1 (5), 78.4 (9), 76.4 (10), 74.6 (2), 47.5 (4), 44.7 (3), 42.7 (1), 32.3 (7), 




yl)cyclopentan-1-one (5.26) (MDW-3-217). tert-BuLi (8.0 mL of a 1.9 M solution in 
pentane) was added dropwise via syringe pump over 4 min to a solution of known 
iodoalkyne 5.23 (2.060 g, 8.169 mmol) in Et2O (16 mL) at -78 °C and the reaction was 
stirred for 1 h. n-BuLi (2.0 mL of a 2.6 M solution in hexanes)  was added to a solution 
of thiophene (0.39 mL, 0.41 g, 4.9 mmol) in Et2O (6.0 mL) at 0 °C and the reaction was 
stirred for 10 min, whereupon the cooling bath was removed and the reaction was stirred 
at room temperature for 30 min. The freshly prepared 2-thienyllithium solution was 























(1.161 mg, 4.898 mmol) in Et2O (6.0 mL) at -78 °C and the reaction was stirred for 10 
min. The solution of freshly prepared lithiated alkyne 5.24 was allowed to settle at -78 °C 
and the supernatant was transferred dropwise via cannula to the suspension of 
CuI•0.75DMS and the mixture was stirred at -78 °C for 10 min, whereupon the reaction 
was transferred to a cooling bath at -40 °C and the reaction was stirred for 20 min. The 
reaction was cooled to -78 °C and HMPA (1.3 mL, 1.3 g, 7.3 mmol) was added followed 
by dropwise addition of a solution of known 4-silyloxy-cyclopentenone (5.15) (0.803 g, 
3.78 mmol) and TMSCl (1.4 mL, 1.2 g, 11 mmol) in Et2O (19 mL) over 1 h via syringe 
pump.450 The reaction was stirred at -78 °C for 20 min and was quenched with glacial 
AcOH/H2O (1:1, 6 mL). The cooling bath was removed and the reaction was stirred for 
10 min. The mixture was diluted with saturated aqueous NaHCO3 (50 mL) and the 
organic layer was separated. The aqueous solution was extracted with Et2O (3 x 50 mL) 
and the combined organic extracts were dried (MgSO4) and concentrated under reduced 
pressure. The crude residue was dissolved in THF (50 mL) and a solution of glacial 
AcOH/H2O (1:1, 12 mL) was added. The reaction was stirred at room temperature for 6 h 
and diluted with saturated aqueous NaHCO3 (100 mL) and Et2O (100 mL). The organic 
layer was separated and extracted with saturated aqueous NaHCO3 (3 x 100 mL). The 
combined aqueous extracts were extracted with Et2O (2 x 200 mL) and the combined 
organic extracts were dried (MgSO4) and concentrated under reduced pressure. The crude 
residue was purified via flash chromatography (SiO2) eluting with hexanes/Et2O (95:5 to 
88:12) to afford 0.927 g (72%) of 5.26 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 
4.11 (q, J = 5.8 Hz, 1H), 2.61 (ddd, J = 18.4, 8.1, 1.7 Hz, 1H), 2.49 (dd, J = 18.0, 6.0 Hz, 
1H), 2.39 – 2.23 (comp, 3H), 2.23 – 2.14 (m, 1H), 1.92 – 1.80 (comp, 2H), 1.47 – 1.36 
(m, 1H), 0.89 (s, 9H), 0.15 (s, 9H), 0.08 (d, J = 11.9 Hz, 6H). 13C NMR (126 MHz, 
 477 
CDCl3) δ 216.1, 106.5, 85.5, 74.6, 47.4, 44.7, 42.6, 32.0, 25.9, 18.6, 18.1, 0.2, -4.4, -4.6. 
HRMS (ESI) m/z calcd for C18H35O2Si2 (M+H)+, 339.2176; found 339.2179. 
 
 
NMR Assignments (5.26).1H NMR (400 MHz, CDCl2) δ 4.11 (q, J = 5.8 Hz, 1H, 
2), 2.61 (ddd, J = 18.4, 8.1, 1.7 Hz, 1H, 1''), 2.49 (dd, J = 18.0, 6.0 Hz, 1H, 4''), 2.39 – 
2.23 (comp, 3H, 3, 8), 2.23 – 2.14 (m, 1H, 4'), 1.92 – 1.80 (comp, 2H, 1', 7''), 1.47 – 1.36 
(m, 1H, 7'), 0.89 (s, 9H, 16, 17, 18), 0.15 (s, 9H, 20, 21, 22), 0.08 (d, J = 11.9 Hz, 6H, 14, 
15). 13C NMR (126 MHz, CDCl3) δ 216.1, 106.5, 85.5, 74.6, 47.4, 44.7, 42.6, 32.0, 25.9, 




yl)cyclopentyl)oxy)silane (5.27) (MDW-3-217). Petasis reagent (0.87 mL of a 12.3% 
solution in PhMe) was added to 5.20 (50 mg, 0.18 mmol) in a foil wrapped flask and the 
reaction was transferred to an oil bath preheated to 65 °C. The reaction was stirred for 8 h 
and diluted with pentane (5 mL). The mixture was filtered through celite and the filter 
cake was washed with pentane (30 mL). The combined filtrate and washings were 
concentrated and the crude residue was purified via flash chromatography (SiO2) eluting 
with hexanes/Et2O (99:1) to afford 23 mg (46%) of 5.27 as a colorless oil. 1H NMR (500 
























2.02 (comp, 3H), 1.91 – 1.77 (comp, 2H), 1.73 (s, 3H), 1.29 – 1.16 (comp, 2H), 0.84 (s, 
9H), 0.01 (d, J = 7.2 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 148.2, 106.8, 79.3, 78.0, 
75.6, 47.0, 42.2, 36.0, 32.7, 26.0, 18.2, 17.6, 3.6, -4.3, -4.6. HRMS (ESI) m/z calcd for 
C17H31OSi (M+H)+, 279.2144; found 279.2146. 
 
 
NMR Assignments (5.27). 1H NMR (500 MHz, CDCl3) δ 4.77 (s, 2H, 10), 3.72 
(q, J = 7.1 Hz, 1H, 2), 2.59 – 2.46 (comp, 2H, 1'', 4''), 2.25 – 2.02 (comp, 3H, 1', 7), 1.91 
– 1.77 (comp, 2H, 3, 4'), 1.73 (s, 3H, 19), 1.29 – 1.16 (comp, 2H, 6), 0.84 (s, 9H, 16, 17, 
18), 0.01 (d, J = 7.2 Hz, 6H, 14, 15). 13C NMR (126 MHz, CDCl3) δ 148.2 (5), 106.8 
(10), 79.3 (8), 78.0 (2), 75.6 (9), 47.0 (3), 42.2 (1), 36.0 (4), 32.7 (6), 26.0 (16, 17, 18), 




yl)cyclopentyl)oxy)silane (5.28) (MDW-3-221). Petasis reagent (11.7 mL of a 12% 
solution in PhMe) was added to a solution of 5.26 (0.898 g, 2.65 mmol) in PhMe (1.5 
mL) in a foil wrapped flask and the reaction was transferred to an oil bath preheated to 65 
°C. The reaction was stirred for 7 h and diluted with pentane (5 mL). The mixture was 
concentrated and filtered through a SiO2 plug rinsing with  hexanes/Et2O (7:3, 100 mL). 





















chromatography (SiO2) eluting with hexanes/Et2O (99:1 to 85:15) to afford 0.473 g 
(53%) of 5.28 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.83 (brs, 2H), 3.77 (q, J 
= 6.9 Hz, 1H), 2.69 – 2.52 (comp, 2H), 2.33 – 2.14 (comp, 3H), 1.98 – 1.73 (comp, 3H), 
1.39 – 1.27 (m, 1H), 0.89 (s, 9H), 0.14 (s, 9H), 0.05 (d, J = 5.3 Hz, 6H). 13C NMR (126 
MHz, CDCl3) δ 148.2, 107.7, 106.9, 84.6, 78.0, 47.1, 42.1, 36.1, 32.2, 26.0, 18.8, 18.2, 




NMR Assignments (5.28). 1H NMR (400 MHz, CDCl3) δ 4.83 (brs, 2H, 10), 3.77 
(q, J = 6.9 Hz, 1H, 2), 2.69 – 2.52 (comp, 2H, 1'', 4''), 2.33 – 2.14 (comp, 3H, 1', 7), 1.98 
– 1.73 (comp, 3H, 3, 4', 6'), 1.39 – 1.27 (m, 1H, 6''), 0.89 (s, 9H, 20, 21, 22), 0.14 (s, 9H, 
12, 13, 14), 0.05 (d, J = 5.3 Hz, 6H, 18, 19). 13C NMR (126 MHz, CDCl3) δ 148.2 (5), 
107.7 (9), 106.9 (10), 84.6 (8), 78.0 (2), 47.1 (3), 42.1 (1), 36.1 (4), 32.2 (6), 26.0 (6, 20, 




butyl)dimethylsilane (5.29) (MDW-3-214). A solution of 5.29 (0.147 g, 0.437 mmol) 
and K2CO3 (0.121 g, 0.875 mmol) in MeOH (4.4 mL) was stirred for 15 h at room 

























was dissolved in Et2O (10 mL). The solution was washed with saturated aqueous 
NaHCO3 (1 x 10 mL). The organic layer was separated and the aqueous solution was 
extracted with Et2O (2 x 10 mL). The combined organic extracts were dried (MgSO4) and 
concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/Et2O (99:1) to afford 0.108 g (94%) of 5.29 
as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.83 (brs, 2H), 3.76 (q, J = 7.2 Hz, 1H), 
2.65 – 2.53 (comp, 2H), 2.31 – 2.13 (comp, 3H), 1.99 – 1.78 (comp, 4H), 1.40 – 1.28 (m, 
1H), 0.89 (s, 9H), 0.06 (d, J = 5.2 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 147.9, 107.0, 
84.7, 78.0, 68.4, 46.9, 42.2, 35.9, 32.1, 26.0, 18.2, 17.4, -4.3, -4.6. HRMS (ESI) m/z calcd 
for C16H29OSi (M+H)+, 265.1988; found 265.1996. 
 
 
NMR Assignments (5.29). 1H NMR (400 MHz,CDCl3) δ 4.83 (brs, 2H, 10), 3.76 
(q, J = 7.2 Hz, 1H, 2), 2.65 – 2.53 (comp, 2H, 1'', 4''), 2.31 – 2.13 (comp, 3H, 1', 7), 1.99 
– 1.78 (comp, 4H, 3, 4', 6'', 11), 1.40 – 1.28 (m, 1H, 6'), 0.89 (s, 9H, 17, 18, 19), 0.06 (d, 
J = 5.2 Hz, 6H, 15, 16). 13C NMR (126 MHz, CDCl3) δ 147.9 (5), 107.0 (10), 84.7 (8), 
78.0 (2), 68.4 (9), 46.9 (3), 42.2 (1), 35.9 (4), 32.1 (6), 26.0 (17, 18, 19), 18.2 (14), 17.4 

























methanoazulen-2(4H)-one (5.42) (MDW-3-214). A solution of 5.27 (0.159 g, 0.601 
mmol) and dicobalt octacarbonyl (0.216 g, 0.632 mmol) in pentane (6 mL) was stirred for 
2 h at room temperature and concentrated under reduced pressure. The crude residue was 
filtered through a SiO2 plug washing with hexanes/Et2O (99:1, 50 mL) and the filtrate 
was concentrated to afford 0.303 g (91% mass recovery) of 5.43 as a dark red oil that was 
used directly. A portion of the crude residue (28 mg, 0.051 mmol) was dissolved in PhMe 
(1.0 mL) and heated under microwave irradiation at 130 °C for 2.5 h. The solution was 
filtered through a SiO2 plug washing with hexanes (20 mL) and discarding the flow 
through. The SiO2 plug was then washed with hexanes/EtOAc (50 mL) and the collected 
filtrate was concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/EtOAc (95:5 to 85:15) to afford 3.0 mg 
(20%) of 5.42 as a pale yellow oil. 1H NMR (500 MHz, CDCl3) δ 5.58 (s, 1H), 4.11 (dd, 
J = 7.0, 2.9 Hz, 1H), 2.62 (dd, J = 16.0, 6.5 Hz, 1H), 2.41 – 2.31 (comp, 2H), 2.26 – 2.15 
(comp, 2H), 2.12 (q, J = 3.2, 2.5 Hz, 1H), 2.07 (ddd, J = 13.9, 6.8, 2.0 Hz, 1H), 1.78 
(ddd, J = 14.2, 7.3, 4.2 Hz, 1H), 1.68 (dd, J = 13.8, 2.9 Hz, 1H), 1.55 – 1.52 (m, 1H), 
1.28 (d, J = 11.1 Hz, 1H), 0.83 (s, 9H), 0.01 (s, 3H), -0.00 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 207.5, 185.6, 123.2, 50.6, 46.0, 44.0, 43.4, 40.4, 27.7, 24.8, 24.0, 17.1, -0.0, -
























NMR Assignments (5.42). 1H NMR (500 MHz, CDCl3) δ 5.58 (s, 1H, 9), 4.11 
(dd, J = 7.0, 2.9 Hz, 1H, 8), 2.62 (dd, J = 16.0, 6.5 Hz, 1H, 6'), 2.41 – 2.31 (comp, 2H, 7), 
2.26 – 2.15 (comp, 2H, 3'', 6''), 2.12 (q, J = 3.2, 2.5 Hz, 1H, 4), 2.07 (ddd, J = 13.9, 6.8, 
2.0 Hz, 1H, 11''), 1.78 (ddd, J = 14.2, 7.3, 4.2 Hz, 1H, 5''), 1.68 (dd, J = 13.8, 2.9 Hz, 1H, 
11'), 1.55 – 1.52 (m, 1H, 5'), 1.28 (d, J = 11.1 Hz, 1H, 3'), 0.83 (s, 9H, 18, 19, 20), 0.01 
(s, 3H, 16), -0.00 (s, 3H, 17). 13C NMR (126 MHz, CDCl3) δ 207.5 (10), 185.6 (2), 123.2 
(9), 50.6 (1), 46.0 (11), 44.0, 43.4 (7), 40.4 (3), 27.7 (5), 24.8 (18, 19, 20), 24.0 (6), 17.1 




yn-1-yl)cyclopentan-1-one (5.47) (MDW-4-206). tert-BuLi (10.2 mL of a 2.4 M 
solution in pentane) was added dropwise via syringe pump over 4 min to a solution of 
known iodoalkyne 5.23 (2.942 g, 11.67 mmol) in degassed Et2O (23 mL) at -78 °C and 
the reaction was stirred for 1 h. n-BuLi (2.2 mL of a 3.4 M solution in hexanes)  was 
added to a solution of thiophene (0.55 mL, 0.58 g, 6.9 mmol) in degassed Et2O (6.0 mL) 
at 0 °C and the reaction was stirred for 15 min, whereupon the cooling bath was removed 
and the reaction was stirred at room temperature for 30 min. The freshly prepared 2-
thienyllithium solution was cooled to -78 °C and transferred dropwise via cannula over 
10 min to a suspension of CuI•0.75DMS (1.629 g, 6.872 mmol) in degassed Et2O (8.6 
mL) at -78 °C and the reaction was stirred for 10 min. The solution of freshly prepared 










major diastereomer minor diastereomer
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dropwise via cannula to the suspension of CuI•0.75DMS and the mixture was stirred at -
78 °C for 10 min, whereupon the reaction was transferred to a cooling bath at -40 °C and 
the reaction was stirred for 20 min. The reaction was cooled to -78 °C and HMPA (1.8 
mL, 1.9 g, 10 mmol) was added, followed by dropwise addition of a solution of known 4-
silyloxy-cyclopentenone (5.11) (1.196 g, 5.283 mmol) and TMSCl (2.0 mL, 1.7 g, 16 
mmol) in degassed Et2O (23 mL) over 1.5 h via syringe pump.450 The reaction was stirred 
at -78 °C for 20 min and was diluted with THF (20 mL) followed by slow addition of 
glacial AcOH/H2O (1:1, 13 mL). The cooling bath was removed and the reaction was 
stirred for 12 h. The solution was diluted with Et2O (50 mL) and extracted with saturated 
aqueous NH4Cl/NH4OH (9:1, 3 x 50 mL). The combined aqueous extracts were extracted 
with Et2O (2 x 100 mL) and the combined organic extracts were dried (MgSO4) and 
concentrated under reduced pressure. The crude residue was filtered through a SiO2 plug 
washing with hexanes/Et2O (95:5, 200 mL) to afford 1.202 g of a residue containing the 
silyl enol ether intermediate 5.46. The SiO2 plug was washed with hexanes/Et2O (90:10, 
200 mL) to afford 0.7420 g of a residue containing 5.47 (mixture of diastereomers). The 
residue containing the silyl enol ether intermediate 5.46 (1.202 g) was dissolved in THF 
(28 mL), whereupon glacial AcOH/H2O (1:1, 4.7 mL) was added and the reaction was 
stirred for 22 h. The reaction was diluted with saturated aqueous NaHCO3 (50 mL) and 
extracted with Et2O (3 x 50 mL). The combined organic extracts were dried (MgSO4) and 
concentrated under reduced pressure. The crude residue was combined with the residue 
containing 5.47 (0.7420 g) that was previously collected and was purified via flash 
chromatography (SiO2) eluting with hexanes/Et2O (95:5 to 90:10) to afford 1.191 g 
(64%) of 5.47 as a pale yellow oil and 56 mg (3%) of S.2 as a pale yellow oil.  
Compound 5.47. 1H NMR (400 MHz, CDCl3) δ 2.58 (dd, J = 18.8, 8.4 Hz, 1H), 
2.46 – 2.29 (comp, 4H), 2.28 – 2.18 (m, 1H), 1.95 – 1.83 (comp, 2H), 1.44 – 1.31 (m, 
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1H), 1.24 (s, 3H), 0.86 (s, 9H), 0.14 (s, 9H), 0.09 (d, J = 6.8 Hz, 6H). 13C NMR (126 
MHz, CDCl3) δ 215.6, 106.6, 85.3, 79.1, 54.9, 47.7, 42.7, 28.9, 25.8, 23.3, 18.9, 18.0, 
0.2, -2.2, -2.4. HRMS (CI) m/z calcd for C19H37O2Si (M+H)+, 353.2332; found 353.2321. 
 
 
NMR Assignments (5.47). 1H NMR (400 MHz, CDCl3) δ 2.58 (dd, J = 18.8, 8.4 
Hz, 1H, 4''), 2.46 – 2.29 (comp, 4H, 1, 3, 8''), 2.28 – 2.18 (m, 1H, 8'), 1.95 – 1.83 (comp, 
2H, 4', 7'), 1.44 – 1.31 (m, 1H, 7''), 1.24 (s, 3H, 23), 0.86 (s, 9H, 16, 17, 18), 0.14 (s, 9H, 
20, 21, 22), 0.09 (d, J = 6.8 Hz, 6H, 13, 14). 13C NMR (126 MHz, CDCl3) δ 215.6 (5), 
106.6 (10), 85.3 (9), 79.1 (2), 54.9 (1), 47.7 (3), 42.7 (4), 28.9 (7), 25.8 (16, 17, 18), 23.3 

















































yn-1-yl)cyclopentan-1-one (S.2). 1H NMR (400 MHz, CDCl3) δ 2.47 – 2.40 (m, 2H), 
2.39 – 2.30 (m, 1H), 2.27 (d, J = 17.6 Hz, 1H), 2.23 – 2.13 (m, 1H), 2.12 – 2.03 (m, 2H), 
1.97 – 1.82 (m, 1H), 1.66 – 1.55 (m, 1H), 1.45 (s, 3H), 0.83 (s, 9H), 0.14 (s, 9H), 0.08 (d, 
J = 11.8 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 216.6, 107.0, 85.3, 79.7, 55.2, 47.9, 
42.5, 27.7, 25.9, 25.2, 18.9, 18.3, 0.3, -2.2, -2.5. HRMS (ESI) m/z calcd for C19H36O2Si2 













































NMR Assignments (S.2). 1H NMR (400 MHz, CDCl3) δ 2.47 – 2.40 (comp, 2H, 
1', 4'), 2.39 – 2.30 (m, 1H, 8''), 2.27 (d, J = 17.6 Hz, 1H, 1''), 2.23 – 2.13 (m, 1H, 8'), 2.12 
– 2.03 (comp, 2H, 3, 4''), 1.97 – 1.82 (m, 1H, 7'), 1.66 – 1.55 (m, 1H, 7''), 1.45 (s, 3H, 
23), 0.83 (s, 9H, 16, 17, 18), 0.14 (s, 9H, 20, 21, 22), 0.08 (d, J = 11.8 Hz, 6H, 13, 
14).13C NMR (126 MHz, CDCl3) δ 216.6 (5), 107.0 (10), 85.3 (9), 79.7 (2), 55.2 (1), 47.9 
(3), 42.5 (4), 27.7 (7), 25.9 (16, 17, 18), 25.2 (23), 18.9 (8), 18.3 (15), 0.3 (20, 21, 22), -






















































yn-1-yl)cyclopentyl)oxy)silane (5.48) (MDW-4-196). Petasis reagent (1.2 mL of a 16% 
solution in PhMe) was added to 5.47 (0.111 g, 0.315 mmol) in a foil wrapped flask and 
the reaction was transferred to an oil bath preheated to 65 °C and stirred for 8 h. The 
reaction was filtered through a SiO2 plug rinsing with  hexanes/Et2O (7:3, 100 mL). The 
filtrate was concentrated and the crude residue was purified via flash chromatography 
(SiO2) eluting with hexanes/Et2O (99:1 to 85:15) to afford 71 mg (64%) of 5.48 as a 
colorless oil. 1H NMR (400 MHz, Chloroform-d) δ 4.86 – 4.82 (m, 1H), 4.81 – 4.75 (m, 








































3H), 2.10 – 1.99 (m, 1H), 1.88 – 1.71 (comp, 2H), 1.37 – 1.27 (m, 1H), 1.08 (d, J = 0.9 
Hz, 3H), 0.86 (s, 9H), 0.15 (s, 9H), 0.08 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 147.9, 
107.5, 106.6, 84.1, 80.8, 49.5, 49.4, 35.3, 28.7, 25.6, 22.2, 18.7, 17.8, -0.0, -2.4, -2.6. 
HRMS (CI) m/z calcd for C20H38OSi2 (M+H)+, 350.2461; found 350.2452. 
 
 
NMR Assignments (5.48). 1H NMR (400 MHz, CDCl3) δ 4.86 – 4.82 (m, 1H, 
10''), 4.81 – 4.75 (m, 1H, 10'), 2.60 (dd, J = 16.8, 8.5 Hz, 1H, 4'), 2.49 (dd, J = 15.6, 2.9 
Hz, 1H, 1''), 2.37 – 2.17 (comp, 3H, 1', 7), 2.10 – 1.99 (m, 1H, 3), 1.88 – 1.71 (comp, 2H, 
4'', 6''), 1.37 – 1.27 (m, 1H, 6'), 1.08 (d, J = 0.9 Hz, 3H, 23), 0.86 (s, 9H, 16, 17, 18), 0.15 
(s, 9H, 20, 21, 22), 0.08 (s, 6H, 14, 15). 13C NMR (126 MHz, CDCl3) δ 147.9 (5), 107.5 
(9), 106.6 (10), 84.1 (8), 80.8 (2), 49.5 (3), 49.4 (1), 35.3 (4), 28.7 (6), 25.6 (16, 17, 18), 




butyl)dimethylsilane (5.49) (MDW-4-198). A solution of 5.48 (0.125 g, 0.256 mmol) 
and K2CO3 (99 mg, 0.72 mmol) in MeOH (3.6 mL) was stirred for 16 h at room 
temperature. The reaction was concentrated under reduced pressure and the crude residue 
was dissolved in Et2O (10 mL). The solution was washed with saturated aqueous 




























extracted with Et2O (2 x 10 mL). The combined organic extracts were dried (MgSO4) and 
concentrated under reduced pressure. The crude residue was purified via flash 
chromatography (SiO2) eluting with hexanes/Et2O (99:1) to afford 92 mg (92%) of 5.49 
as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.87 – 4.82 (m, 1H), 4.81 – 4.76 (m, 
1H), 2.59 (dd, J = 16.7, 8.4 Hz, 1H), 2.50 (dd, J = 15.2, 2.8 Hz, 1H), 2.35 (dq, J = 15.4, 
1.5 Hz, 1H), 2.31 – 2.14 (comp, 2H), 2.10 – 2.00 (m, 1H), 1.94 (t, J = 2.6 Hz, 1H), 1.89 – 
1.73 (comp, 2H), 1.40 – 1.31 (m, 1H), 1.09 (d, J = 1.0 Hz, 3H), 0.86 (s, 9H), 0.07 (d, J = 
0.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 148.0, 107.1, 85.0, 81.0, 68.3, 49.8, 49.7, 
35.6, 28.9, 25.9, 22.4, 18.1, 17.7, -2.1, -2.3. HRMS (CI) m/z calcd for C17H30OSi (M+H)+, 
278.2066; found 278.2064. 
 
 
NMR Assignments (5.49). 1H NMR (400 MHz, CDCl3) δ 4.87 – 4.82 (m, 1H, 
11''), 4.81 – 4.76 (m, 1H, 11'), 2.59 (dd, J = 16.7, 8.4 Hz, 1H, 4''), 2.50 (dd, J = 15.2, 2.8 
Hz, 1H, 1''), 2.35 (dq, J = 15.4, 1.5 Hz, 1H, 1'), 2.31 – 2.14 (comp, 2H, 7), 2.10 – 2.00 
(m, 1H, 3), 1.94 (t, J = 2.6 Hz, 1H, 10), 1.89 – 1.73 (comp, 2H, 4', 6''), 1.40 – 1.31 (m, 
1H, 6'), 1.09 (d, J = 1.0 Hz, 3H, 20), 0.86 (s, 9H, 17, 18, 19), 0.07 (d, J = 0.9 Hz, 6H, 14, 
15). 13C NMR (126 MHz, CDCl3) δ 148.0 (5), 107.1 (11), 85.0 (8), 81.0 (2), 68.3 (9), 



























3a,6-methanoazulen-2(4H)-one (5.51) (MDW-4-199). A solution of 5.49 (8.4 mg, 0.030 
mmol) and dicobalt octacarbonyl (13 mg, 0.038 mmol) in PhMe (0.6 mL) was stirred for 
2 h at room temperature and concentrated under reduced pressure. The crude residue was 
filtered through a SiO2 plug washing with pentane (30 mL) and the filtrate was 
concentrated to afford 13 mg (76% mass recovery) of 5.50 as a dark red oil that was used 
directly. The crude residue (13 mg, 0.022 mmol)  was dissolved in PhMe (0.6 mL) and 
heated under microwave irradiation at 130 °C for 4 h. The solution was concentrated and 
the crude residue was purified via preparative TLC eluting with hexanes/EtOAC (85:15) 
to afford 0.97 mg (11% from 5.49) of 5.51 as a pale yellow oil. 1H NMR (600 MHz, 
CDCl3) δ 5.64 (d, J = 2.0 Hz, 1H), 2.69 (dd, J = 16.6, 7.2 Hz, 1H), 2.53 (ddd, J = 11.1, 
4.8, 2.2 Hz, 1H), 2.45 – 2.35 (m, 3H), 2.10 (d, J = 3.9 Hz, 1H), 2.04 (dd, J = 14.2, 1.6 Hz, 
1H), 1.92 – 1.85 (m, 1H), 1.81 (dd, J = 14.2, 1.9 Hz, 1H), 1.66 – 1.62 (m, 1H), 1.45 (s, 
3H), 1.37 (dd, J = 11.1, 1.7 Hz, 1H), 0.87 (s, 9H), 0.10 (d, J = 11.5 Hz, 6H). 13C NMR 
(151 MHz, CDCl3) δ 208.7, 187.7, 123.7, 83.2, 52.5, 51.2, 48.9, 46.0, 43.5, 26.6, 25.9, 






























NMR Assignments (5.51). 1H NMR (600 MHz, CDCl3) δ 5.64 (d, J = 2.0 Hz, 
1H, 9), 2.69 (dd, J = 16.6, 7.2 Hz, 1H, 6''), 2.53 (ddd, J = 11.1, 4.8, 2.2 Hz, 1H, 3''), 2.45 
– 2.35 (comp, 3H, 6', 7), 2.10 (d, J = 3.9 Hz, 1H, 4), 2.04 (dd, J = 14.2, 1.6 Hz, 1H, 11'), 
1.92 – 1.85 (m, 1H, 5''), 1.81 (dd, J = 14.2, 1.9 Hz, 1H, 11''), 1.66 – 1.62 (m, 1H, 5'), 1.45 
(s, 3H, 21), 1.37 (dd, J = 11.1, 1.7 Hz, 1H, 3'), 0.87 (s, 9H, 18, 19, 20), 0.10 (d, J = 11.5 
Hz, 6H, 15, 16). 13C NMR (151 MHz, CDCl3) δ 208.7 (10), 187.7 (2), 123.7 (9), 83.2 (8), 
52.5 (11), 51.2 (1), 48.9 (4), 46.0 (7), 43.5 (3), 26.6 (5), 25.9 (18, 19, 20), 24.9 (21), 24.6 


















6.3 HPLC TRACES FOR ENANTIOENRICHED (S)-2.127 AND (R)-2.128.   





 Retention time (min) Area  (µV*sec) % area Height (µV) Int Type 
1 11.827 10907640 50.07 407227 bb 


































 Retention time (min) Area  (µV*sec) % area Height (µV) Int Type 
1 11.831 43484 0.42 1685 bb 




 Retention time (min) Area  (µV*sec) % area Height (µV) Int Type 
1 11.710 12350948 99.9 456831 bb 





















































6.4 JVW-1601 BINDING PROFILE AT NON-SIGMA RECEPTOR SITES  
Table S.1. JVW-1601 binding profile at non-sigma receptor sites.  
Target Ki (nM) Target Ki (nM) 
5HT1A 156 Beta3 >10,000 
5HT1B 362 BZP Rat Brain >10,000 
5HT1D 135 Calcium Channel >10,000 
5HT1e >10,000 D1 690 
5HT2A 315 D2 >10,000 
5HT2B 100 D3 438 
5HT2C 762 D4 6,660 
5HT3 >10,000 D5 3,964 
5HT5a NA DOR >10,000 
5HT6 778 GabaA >10,000 
5HT7 459 H1 20 
A2B2 NA H3 1,351 
A2B4 NA hERG NA 
A3B2 NA KOR >10,000 
A3B4 NA M1 >10,000 
A4B2 NA M2 >10,000 
A4B2** NA M3 >10,000 
A4B4 NA M4 >10,000 
A7 NA M5 6,621 
A7** NA MOR >10,000 
Alpha1a 2,356 NET >10,000 
Alpha1b >10,000 NMDA NA  
Alpha1d 2,595 PBR 8,325 
Alpha2a 1,031 SERT >10,000 
Alpha2b 3,326 Sig1 200 
Alpha2c > 10,000 V1A NA 
AMPA NA V1B NA 
Beta1 >10,000 V2 NA 
Beta2 >10,000   
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Appendix A: Crystallographic Data 
 
Figure A.1. Crystal structure of 4.61 Showing the atom labeling scheme. Displacement 
ellipsoids are scaled to the 50% probability level   
X-ray Experimental for C20H22N2O4:  Crystals grew as clusters of colorless 
needles by slow evaporation from THF and water.  The data crystal was cut from a 
cluster of crystals and had approximate dimensions; 0.18 x 0.048 x 0.038 mm.  The data 
were collected on an Agilent Technologies SuperNova Dual Source diffractometer using 
a µ-focus Cu Ka radiation source (l = 1.5418Å) with collimating mirror 
monochromators.  A total of 669 frames of data were collected using w-scans with a scan 
range of 1° and a counting time of 15.9 seconds per frame for frames collected with a 
detector offset of - 42.4° and 58.47 seconds per frame with frames collected with a 
 496 
detector offset of 110.8°.  The data were collected at 100 K using an Oxford Cryostream 
low temperature device.  Details of crystal data, data collection and structure refinement 
are listed in Table 1.  Data collection, unit cell refinement and data reduction were 
performed using Rigaku Oxford Diffraction’s CrysAlisPro V 1.171.40.53.489  The structure 
was solved by direct methods using SHELXT490 and refined by full-matrix least-squares 
on F2 with anisotropic displacement parameters for the non-H atoms using SHELXL-
2016/6.490  Structure analysis was aided by use of the programs PLATON491, OLEX2492 and 
WinGX.6493  The hydrogen atoms on the carbon atoms were calculated in ideal positions 
with isotropic displacement parameters set to 1.2xUeq of the attached atom (1.5xUeq for 
methyl hydrogen atoms).   
The function, Sw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(s (Fo))2 + 
(0.0759*P)2 + (0.5009*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.115, with 
R(F) equal to 0.0439 and a goodness of fit, S, = 1.05.  Definitions used for calculating 
R(F), Rw(F2) and the goodness of fit, S, are given below.494  The data were checked for 
secondary extinction effects but no correction was necessary.  Neutral atom scattering 
factors and values used to calculate the linear absorption coefficient are from the 
International Tables for X-ray Crystallography (1992).495  All figures were generated using 
SHELXTL/PC.496  Tables of positional and thermal parameters, bond lengths and angles, 








Table A.1.  Crystal data and structure refinement for 4.61. 
Empirical formula  C20 H22 N2 O4 
Formula weight  354.39 
Temperature  100(2) K 
Wavelength  1.54184 Å 
Crystal system  monoclinic 
Space group  C c 
  Unit cell dimensions a = 13.4799(5) Å a= 90°. 
 b = 10.2973(3) Å b= 111.392(4)°. 
 c = 13.3063(4) Å g = 90°. 
Volume 1719.76(11) Å3 
Z 4 
Density (calculated) 1.369 Mg/m3 
Absorption coefficient 0.785 mm-1 
F(000) 752 
Crystal size 0.180 x 0.048 x 0.038 mm3 
Theta range for data collection 5.557 to 70.060°. 
Index ranges -15<=h<=16, -12<=k<=9, -16<=l<=16 
Reflections collected 3270 
Independent reflections 2242 [R(int) = 0.0268] 
Completeness to theta = 67.684° 98.6 %  
Absorption correction Gaussian and multi-scan 
Max. and min. transmission 1.00 and 0.806 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2242 / 2 / 238 
Goodness-of-fit on F2 1.053 
Final R indices [I>2sigma(I)] R1 = 0.0439, wR2 = 0.1132 
R indices (all data) R1 = 0.0453, wR2 = 0.1154 
Absolute structure parameter 0.0(3) 
Extinction coefficient n/a 





(1) Martin, S. F. Natural Products and Their Mimics as Targets of Opportunity for 
Discovery. J. Org. Chem. 2017, 82, 10757-10794. 
(2) Martin, S. F.; Benage, B.; Hunter, J. E. A concise strategy for the syntheses of 
indole alkaloids of the heteroyohimboid and corynantheioid families. Total 
syntheses of (.+-.)-tetrahydroalstonine, (.+-.)-cathenamine and (.+-.)-
geissoschizine. J. Am. Chem. Soc. 1988, 110, 5925-5927. 
(3) Sahn, J. J.; Granger, B. A.; Martin, S. F. Evolution of a strategy for preparing 
bioactive small molecules by sequential multicomponent assembly processes, 
cyclizations, and diversification. Org. Biomol. Chem. 2014, 12, 7659-7672. 
(4) Sahn, J. J.; Hodges, T. R.; Chan, J. Z.; Martin, S. F. Norbenzomorphan 
Framework as a Novel Scaffold for Generating Sigma 2 Receptor/PGRMC1 
Subtype-Selective Ligands. ChemMedChem 2016, 11, 556-561. 
(5) Schmidt, H. R.; Kruse, A. C. The Molecular Function of σ Receptors: Past, 
Present, and Future. Trends Pharmacol. Sci. 2019, 40, 636-654. 
(6) Schmidt, H. R.; Zheng, S.; Gurpinar, E.; Koehl, A.; Manglik, A.; Kruse, A. C. 
Crystal structure of the human σ1 receptor. Nature 2016, 532, 527-530. 
(7) Zeng, C.; Mach, R. H.: The Evolution of the Sigma-2 (σ2) Receptor from Obscure 
Binding Site to Bona Fide Therapeutic Target. In Sigma Receptors: Their Role in 
Disease and as Therapeutic Targets; Smith, S. B., Su, T.-P., Eds.; Springer 
International Publishing: Cham, 2017; pp 49-61. 
(8) Linkens, K.; Schmidt, H. R.; Sahn, J. J.; Kruse, A. C.; Martin, S. F. Investigating 
isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their 
sigma receptor binding properties. Eur. J. Med. Chem. 2018, 151, 557-567. 
(9) Sahn, J. J.; Hodges, T. R.; Chan, J. Z.; Martin, S. F. Norbenzomorphan Scaffold: 
Chemical Tool for Modulating Sigma Receptor-Subtype Selectivity. ACS Med. 
Chem. Lett. 2017, 8, 455-460. 
(10) Maurice, T.; Su, T.-P. The pharmacology of sigma-1 receptors. Pharmacology & 
Therapeutics 2009, 124, 195-206. 
(11) Sahn, J. J.; Mejia, G. L.; Ray, P. R.; Martin, S. F.; Price, T. J. Sigma 2 
Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects 
in Mice. ACS Chem. Neurosci. 2017, 8, 1801-1811. 
(12) Yi, B.; Sahn, J. J.; Ardestani, P. M.; Evans, A. K.; Scott, L. L.; Chan, J. Z.; Iyer, 
S.; Crisp, A.; Zuniga, G.; Pierce, J. T.; Martin, S. F.; Shamloo, M. Small molecule 
modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits 
 499 
and neuroinflammation in experimental models of Alzheimer's disease. J. 
Neurochem. 2017, 140, 561-575. 
(13) Scott, L. L.; Sahn, J. J.; Ferragud, A.; Yen, R. C.; Satarasinghe, P. N.; Wood, M. 
D.; Hodges, T. R.; Shi, T.; Prakash, B. A.; Friese, K. M.; Shen, A.; Sabino, V.; 
Pierce, J. T.; Martin, S. F. Small molecule modulators of σ2R/Tmem97 reduce 
alcohol withdrawal-induced behaviors. Neuropsychopharmacology 2018, 43, 
1867-1875. 
(14) Vázquez-Rosa, E.; Watson, M. R.; Sahn, J. J.; Hodges, T. R.; Schroeder, R. E.; 
Cintrón-Pérez, C. J.; Shin, M.-K.; Yin, T. C.; Emery, J. L.; Martin, S. F.; Liebl, D. 
J.; Pieper, A. A. Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 
Modulator (DKR-1677) after Traumatic Brain Injury. ACS Chem. Neurosci.2019, 
10, 1595-1602. 
(15) Martin, S. F.; Hunter, J. E.; Benage, B.; Geraci, L. S.; Mortimore, M. Unified 
strategy for synthesis of indole and 2-oxindole alkaloids. J. Am. Chem. Soc. 1991, 
113, 6161-6171. 
(16) Martin, S. F.; Grzejszczak, S.; Rueeger, H.; Williamson, S. A. Total synthesis of 
(.+-.)-reserpine. J. Am. Chem. Soc. 1985, 107, 4072-4074. 
(17) Martin, S. F.; Rueger, H.; Williamson, S. A.; Grzejszczak, S. General strategies 
for the synthesis of indole alkaloids. Total synthesis of (.+-.)-reserpine and (.+-.)-
.alpha.-yohimbine. J. Am. Chem. Soc. 1987, 109, 6124-6134. 
(18) Martin, S. F.; Williamson, S. A.; Gist, R. P.; Smith, K. M. Aspects of the 
intramolecular Diels-Alder reactions of some 1,3,9-trienic amides, amines, and 
esters. An approach to the pentacyclic skeleton of the yohimboid alkaloids. J. 
Org. Chem. 1983, 48, 5170-5180. 
(19) Martin, S. F.; Desai, S. R.; Philips, G. W.; Miller, A. C. General methods for 
alkaloid synthesis via intramolecular [4 + 2] cycloaddition reactions of enamides. 
A new approach to the synthesis of Aspidosperma alkaloids. J. Am. Chem. Soc. 
1980, 102, 3294-3296. 
(20) Martin, S. F.; Benage, B. Applications of intramolecular diels-alder reactions of 
heterodienes. Facile syntheses of the heteroyohimbine alkaloids 
tetrahydroalstonine and akuammigine. Tetrahedron Lett. 1984, 25, 4863-4866. 
(21) Martin, S. F. Evolution of the Vinylogous Mannich Reaction as a Key 
Construction for Alkaloid Synthesis. Acc. Chem. Res. 2002, 35, 895-904. 
(22) Martin, S. F.; Clark, C. W.; Corbett, J. W. Applications of Vinylogous Mannich 
Reactions. Asymmetric Synthesis of the Heteroyohimboid Alkaloids (-)-
Ajmalicine, (+)-19-epi-Ajmalicine, and (-)-Tetrahydroalstonine. J. Org. Chem. 
1995, 60, 3236-3242. 
 500 
(23) Martin, S. F.; Barr, K. J.; Smith, D. W.; Bur, S. K. Applications of Vinylogous 
Mannich Reactions. Concise Enantiospecific Total Syntheses of (+)-Croomine. J. 
Am. Chem. Soc. 1999, 121, 6990-6997. 
(24) Martin, S. F.; Bur, S. K. Vinylogous Mannich reactions. Stereoselective formal 
synthesis of pumiliotoxin 251D. Tetrahedron 1999, 55, 8905-8914. 
(25) Liras, S.; Lynch, C. L.; Fryer, A. M.; Vu, B. T.; Martin, S. F. Applications of 
Vinylogous Mannich Reactions. Total Syntheses of the Ergot Alkaloids 
Rugulovasines A and B and Setoclavine. J. Am. Chem. Soc. 2001, 123, 5918-
5924. 
(26) Reichelt, A.; Bur, S. K.; Martin, S. F. Applications of vinylogous Mannich 
reactions. Total synthesis of the angiotensin converting enzyme inhibitor (−)-
A58365A. Tetrahedron 2002, 58, 6323-6328. 
(27) Corey, E. J.; Cheng, X.-m.: The logic of chemical synthesis; John Wiley: New 
York, 1989. 
(28) Schreiber, S. L. Target-Oriented and Diversity-Oriented Organic Synthesis in 
Drug Discovery. Science 2000, 287, 1964-1969. 
(29) Burke, M. D.; Schreiber, S. L. A Planning Strategy for Diversity-Oriented 
Synthesis. Angew. Chem. Int. Ed. 2004, 43, 46-58. 
(30) Galloway, W. R. J. D.; Isidro-Llobet, A.; Spring, D. R. Diversity-oriented 
synthesis as a tool for the discovery of novel biologically active small molecules. 
Nature Commun. 2010, 1, 1-13. 
(31) Biggs-Houck, J. E.; Younai, A.; Shaw, J. T. Recent advances in multicomponent 
reactions for diversity-oriented synthesis. Curr. Opin. Chem. Biol. 2010, 14, 371-
382. 
(32) Gracias, V.; Darczak, D.; Gasiecki, A. F.; Djuric, S. W. Synthesis of fused 
triazolo-imidazole derivatives by sequential van Leusen/alkyne–azide 
cycloaddition reactions. Tetrahedron Lett. 2005, 46, 9053-9056. 
(33) Kumagai, N.; Muncipinto, G.; Schreiber, S. L. Short Synthesis of Skeletally and 
Stereochemically Diverse Small Molecules by Coupling Petasis Condensation 
Reactions to Cyclization Reactions.  Angew. Chem. Int. Ed. 2006, 45, 3635-3638. 
(34) Ribelin, T. P.; Judd, A. S.; Akritopoulou-Zanze, I.; Henry, R. F.; Cross, J. L.; 
Whittern, D. N.; Djuric, S. W. Concise Construction of Novel Bridged Bicyclic 
Lactams by Sequenced Ugi/RCM/Heck Reactions. Org. Lett. 2007, 9, 5119-5122. 
(35) Banfi, L.; Basso, A.; Giardini, L.; Riva, R.; Rocca, V.; Guanti, G. Tandem Ugi 
MCR/Mitsunobu Cyclization as a Short, Protecting-Group-Free Route to 
Benzoxazinones with Four Diversity Points. Eur. J. Org. Chem. 2011, 2011, 100-
109. 
 501 
(36) Nielsen, T. E.; Schreiber, S. L. Towards the Optimal Screening Collection: A 
Synthesis Strategy.  Angew. Chem. Int. Ed. 2008, 47, 48-56. 
(37) Pellissier, H. Stereocontrolled Domino Reactions. Chem. Rev. 2013, 113, 442-
524. 
(38) Nicolaou, K. C.; Edmonds, D. J.; Bulger, P. G. Cascade Reactions in Total 
Synthesis.  Angew. Chem. Int. Ed. 2006, 45, 7134-7186. 
(39) Austin, C. P. Molecular Biology: NIH Molecular Libraries Initiative. Science 
2004, 306, 1138-1139. 
(40) Zerhouni, E. Medicine: The NIH Roadmap. Science 2003, 302, 63-72. 
(41) Sunderhaus, J. D.; Dockendorff, C.; Martin, S. F. Applications of 
Multicomponent Reactions for the Synthesis of Diverse Heterocyclic Scaffolds. 
Org. Lett. 2007, 9, 4223-4226. 
(42) Sunderhaus, J. D.; Dockendorff, C.; Martin, S. F. Synthesis of diverse 
heterocyclic scaffolds via tandem additions to imine derivatives and ring-forming 
reactions. Tetrahedron 2009, 65, 6454-6469. 
(43) Sahn, J. J.; Martin, S. F. Facile syntheses of substituted, conformationally-
constrained benzoxazocines and benzazocines via sequential multicomponent 
assembly and cyclization. Tetrahedron Lett. 2011, 52, 6855-6858. 
(44) Donald, J. R.; Martin, S. F. Synthesis and Diversification of 1,2,3-Triazole-Fused 
1,4-Benzodiazepine Scaffolds. Org. Lett. 2011, 13, 852-855. 
(45) Donald, J. R.; Wood, R. R.; Martin, S. F. Application of a Sequential 
Multicomponent Assembly Process/Huisgen Cycloaddition Strategy to the 
Preparation of Libraries of 1,2,3-Triazole-Fused 1,4-Benzodiazepines. ACS 
Combi. Sci. 2012, 14, 135-143. 
(46) Granger, B. A.; Kaneda, K.; Martin, S. F. Multicomponent Assembly Strategies 
for the Synthesis of Diverse Tetrahydroisoquinoline Scaffolds. Org. Lett. 2011, 
13, 4542-4545. 
(47) Granger, B. A.; Kaneda, K.; Martin, S. F. Libraries of 2,3,4,6,7,11b-Hexahydro-
1H-pyrido[2,1-a]isoquinolin-2-amine Derivatives via a Multicomponent 
Assembly Process/1,3-Dipolar Cycloaddition Strategy. ACS Combi. Sci. 2012, 14, 
75-79. 
(48) Sahn, J. J.; Su, J. Y.; Martin, S. F. Facile and Unified Approach to Skeletally 
Diverse, Privileged Scaffolds. Org. Lett. 2011, 13, 2590-2593. 
(49) Hardy, S.; Martin, S. F. Multicomponent, Mannich-type assembly process for 
generating novel, biologically-active 2-arylpiperidines and derivatives. 
Tetrahedron 2014, 70, 7142-7157. 
 502 
(50) Sahn, J. J.; Martin, S. F. Expedient Synthesis of Norbenzomorphan Library via 
Multicomponent Assembly Process Coupled with Ring-Closing Reactions. ACS 
Comb. Sci. 2012, 14, 496-502. 
(51) Kanematsu, K.; Takeda, M.; Jacobson, A. E.; May, E. L. Synthesis of 6,7-
benzomorphan and related nonquaternary carbon structures with marked analgetic 
activity. J. Med. Chem. 1969, 12, 405-408. 
(52) Jacobson, A. E.; Mokotoff, M. Azabicyclo chemistry. I. Synthesis of 1,5-
methano-7-methoxy-2,3,4,5-tetrahydro-1H-2-benzazepines. B-
norbenzomorphans. J. Med. Chem.1970, 13, 7-9. 
(53) Chen, Y. L.; Liston, D.; Nielsen, J.; Chapin, D.; Dunaiskis, A.; Hedberg, K.; Ives, 
J.; Johnson, J., Jr.; Jones, S. Syntheses and Anticholinesterase Activity of 
Tetrahydrobenzazepine Carbamates. J. Med. Chem. 1994, 37, 1996-2000. 
(54) [Ki determinations, receptor binding profiles, agonist and/or antagonist functional 
data, HERG data, MDR1 data, etc. as appropriate] was generously provided by 
the National Institute of Mental Health's Psychoactive Drug Screening Program, 
Contract # HHSN-271-2018-00023-C (NIMH PDSP). The NIMH PDSP is 
Directed by Bryan L. Roth at the University of North Carolina at Chapel Hill and 
Project Officer Jamie Driscoll at NIMH, Bethesda MD, USA. For experimental 
details please refer to the PDSP web site 
https://pdsp.unc.edu/ims/investigator/web/. 
(55) Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The 
effects of morphine- and nalorphine- like drugs in the nondependent and 
morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197, 517. 
(56) Su, T. P. Evidence for sigma opioid receptor: binding of [3H]SKF-10047 to 
etorphine-inaccessible sites in guinea-pig brain. J. Pharmacol. Exp. Ther.1982, 
223, 284-290. 
(57) Tam, S. W. Naloxone-inaccessible sigma receptor in rat central nervous system. 
Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 6703-6707. 
(58) Pert, C. B.; Snyder, S. H. Opiate Receptor: Demonstration in Nervous Tissue. 
Science 1973, 179, 1011-1014. 
(59) Pasternak, G. W.: Opioid Receptors: The Early Years. In The Opiate Receptors; 
Pasternak, G. W., Ed.; Humana Press: Totowa, NJ, 2011; pp 59-91. 
(60) Kosterlitz, H. W.; Paterson, S. J.; Robson, L. E. Characterization of the k-subtype 
of the opiate receptor in the guinea-pig brain. Br. J. Pharmacol. 1981, 73, 939-
949. 
(61) Mendelsohn, L. G.; Kalra, V.; Johnson, B. G.; Kerchner, G. A. Sigma opioid 
receptor: characterization and co-identity with the phencyclidine receptor. J. 
Pharmacol. Exp. Ther.  1985, 233, 597-602. 
 503 
(62) Quirion, R.; Hammer, R. P.; Herkenham, M.; Pert, C. B. Phencyclidine (angel 
dust)/sigma "opiate" receptor: visualization by tritium-sensitive film. Proc. Natl. 
Acad. Sci. U.S.A.1981, 78, 5881-5885. 
(63) Holtzman, S. G. Phencyclidine-like discriminative effects of opioids in the rat. J. 
Pharmacol. Exp. Ther.  1980, 214, 614-619. 
(64) Shannon, H. E. Evaluation of phencyclidine analogs on the basis of their 
discriminative stimulus properties in the rat. J. Pharmacol. Exp. Ther.  1981, 216, 
543-551. 
(65) Brady, K.; Balster, R.; May, E. Stereoisomers of N-allylnormetazocine: 
phencyclidine-like behavioral effects in squirrel monkeys and rats. Science 1982, 
215, 178-180. 
(66) Zukin, S. R.; Brady, K. T.; Slifer, B. L.; Balster, R. L. Behavioral and 
biochemical stereoselectivity of sigma opiate/PCP receptors. Brain Res. 1984, 
294, 174-177. 
(67) Magaros, W. F.; Chu, D. C. M.; Greenamyre, J. T.; Penney, J. B.; Young, A. B. 
High correlation between the localization of [3H]TCP binding and NMDA 
receptors. Eur. J. Pharmacol. 1986, 123, 173-174. 
(68) Wong, E. H. F.; Knight, A. R.; Woodruff, G. N. [3H]MK-801 Labels a Site on the 
N-Methyl-D-Aspartate Receptor Channel Complex in Rat Brain Membranes. J. 
Neurochem. 1988, 50, 274-281. 
(69) Majewska, M. D.; Parameswaran, S.; Vu, T.; London, E. D. Divergent ontogeny 
of sigma and phencyclidine binding sites in the rat brain. Dev. Brain Res. 1989, 
47, 13-18. 
(70) Quirion, R.; Chicheportiche, R.; Contreras, P. C.; Johnson, K. M.; Lodge, D.; 
William Tam, S.; Woods, J. H.; Zukin, S. R. Classification and nomenclature of 
phencyclidine and sigma receptor sites. Trends Neurosci. 1987, 10, 444-446. 
(71) Largent, B. L.; Gundlach, A. L.; Snyder, S. H. Psychotomimetic opiate receptors 
labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. 
Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 4983-4987. 
(72) Weber, E.; Sonders, M.; Quarum, M.; McLean, S.; Pou, S.; Keana, J. F. 1,3-Di(2-
[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for 
psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. U.S.A. 
1986, 83, 8784-8788. 
(73) Glasel, J. A.; Venn, R. F. The sensitivity of opiate receptors and ligands to short 
wavelength ultraviolet light. Life Sci. 1981, 29, 221-228. 
(74) Bowen, W. D.; Hellewell, S. B.; McGarry, K. A. Evidence for a multi-site model 
of the rat brain σ receptor. Eur. J. Pharmacol.1989, 163, 309-318. 
 504 
(75) Hellewell, S. B.; Bowen, W. D. A sigma-like binding site in rat 
pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and 
lower molecular weight suggest a different sigma receptor form from that of 
guinea pig brain. Brain Res. 1990, 527, 244-253. 
(76) Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J.; Rothman, R. 
B.; Tsung-Ping, S.; Tam, S. W.; Taylor, D. P. A proposal for the classification of 
sigma binding sites. Trends Pharmacol. Sci. 1992, 13, 85-86. 
(77) Mach, R. H.; Zeng, C.; Hawkins, W. G. The σ2 Receptor: A Novel Protein for the 
Imaging and Treatment of Cancer. J. Med. Chem. 2013, 56, 7137-7160. 
(78) Hanner, M.; Moebius, F. F.; Flandorfer, A.; Knaus, H. G.; Striessnig, J.; 
Kempner, E.; Glossmann, H. Purification, molecular cloning, and expression of 
the mammalian sigma1-binding site. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8072-
8077. 
(79) Kekuda, R.; Prasad, P. D.; Fei, Y.-J.; Leibach, F. H.; Ganapathy, V. Cloning and 
Functional Expression of the Human Type 1 Sigma Receptor (hSigmaR1). 
Biochem. Biophys. Res. Commun. 1996, 229, 553-558. 
(80) Seth, P.; Leibach, F. H.; Ganapathy, V. Cloning and Structural Analysis of the 
cDNA and the Gene Encoding the Murine Type 1 Sigma Receptor. Biochem. 
Biophys. Res. Commun. 1997, 241, 535-540. 
(81) Seth, P.; Fei, Y.-J.; Li, H. W.; Huang, W.; Leibach, F. H.; Ganapathy, V. Cloning 
and Functional Characterization of a σ Receptor from Rat Brain. J. Neurochem. 
2002, 70, 922-931. 
(82) Nguyen, L.; Lucke-Wold, B. P.; Mookerjee, S. A.; Cavendish, J. Z.; Robson, M. 
J.; Scandinaro, A. L.; Matsumoto, R. R. Role of sigma-1 receptors in 
neurodegenerative diseases. J. Pharmacol. Sci. 2015, 127, 17-29. 
(83) Guitart, X.; Codony, X.; Monroy, X. Sigma receptors: biology and therapeutic 
potential. Psychopharmacology 2004, 174. 
(84) Mei, J.; Pasternak, G. W. Molecular cloning and pharmacological characterization 
of the rat sigma1 receptor. Biochem. Pharmacol. 2001, 62, 349-355. 
(85) Aydar, E.; Palmer, C. P.; Klyachko, V. A.; Jackson, M. B. The Sigma Receptor as 
a Ligand-Regulated Auxiliary Potassium Channel Subunit. Neuron 2002, 34, 399-
410. 
(86) Sigma Receptors Chemistry, Cell Biology and Clinical Implications / edited by 
Tsung-Ping Su, Rae R. Matsumoto, Wayne D. Bowen; Springer US: Boston, MA, 
2007. 
(87) Laurini, E.; Col, V. D.; Mamolo, M. G.; Zampieri, D.; Posocco, P.; Fermeglia, 
M.; Vio, L.; Pricl, S. Homology Model and Docking-Based Virtual Screening for 
Ligands of the σ1 Receptor. ACS Med. Chem. Lett. 2011, 2, 834-839. 
 505 
(88) Alonso, G.; Phan, V. L.; Guillemain, I.; Saunier, M.; Legrand, A.; Anoal, M.; 
Maurice, T. Immunocytochemical localization of the sigma1 receptor in the adult 
rat central nervous system. Neuroscience 2000, 97, 155-170. 
(89) Zamanillo, D.; Andreu, F.; Ovalle, S.; Pérez, M. P.; Romero, G.; Farré, A. J.; 
Guitart, X. Up-regulation of sigma1 receptor mRNA in rat brain by a putative 
atypical antipsychotic and sigma receptor ligand. Neuroscience Lett. 2000, 282, 
169-172. 
(90) Shamsul Ola, M.; Moore, P.; El-Sherbeny, A.; Roon, P.; Agarwal, N.; Sarthy, V. 
P.; Casellas, P.; Ganapathy, V.; Smith, S. B. Expression pattern of sigma receptor 
1 mRNA and protein in mammalian retina. Mol. Brain Res. 2001, 95, 86-95. 
(91) Hayashi, T.; Su, T.-P. Sigma-1 Receptor Chaperones at the ER- Mitochondrion 
Interface Regulate Ca2+ Signaling and Cell Survival. Cell 2007, 131, 596-610. 
(92) Vance, J. E. MAM (mitochondria-associated membranes) in mammalian cells: 
Lipids and beyond. Biochim. Biophys. Acta 2014, 1841, 595-609. 
(93) Weng, T.-Y.; Tsai, S.-Y. A.; Su, T.-P. Roles of sigma-1 receptors on 
mitochondrial functions relevant to neurodegenerative diseases. J. Biomed. Sci. 
2017, 24, 74. 
(94) Su, T.-P.; Su, T.-C.; Nakamura, Y.; Tsai, S.-Y. The Sigma-1 Receptor as a 
Pluripotent Modulator in Living Systems. Trends Pharmacol. Sci. 2016, 37, 262-
278. 
(95) Mori, T.; Hayashi, T.; Hayashi, E.; Su, T.-P. Sigma-1 Receptor Chaperone at the 
ER-Mitochondrion Interface Mediates the Mitochondrion-ER-Nucleus Signaling 
for Cellular Survival. PLoS ONE 2013, 8, e76941. 
(96) Chu, U. B.; Ruoho, A. E. Biochemical Pharmacology of the Sigma-1 Receptor. 
Mol. Pharmacol. 2016, 89, 142-153. 
(97) Tsai, S.-Y. A.; Chuang, J.-Y.; Tsai, M.-S.; Wang, X.-F.; Xi, Z.-X.; Hung, J.-J.; 
Chang, W.-C.; Bonci, A.; Su, T.-P. Sigma-1 receptor mediates cocaine-induced 
transcriptional regulation by recruiting chromatin-remodeling factors at the 
nuclear envelope. Proc. Natl. Acad. Sci. U.S.A. 2015, 112, E6562-E6570. 
(98) Ganapathy, M. E.; Prasad, P. D.; Huang, W.; Seth, P.; Leibach, F. H.; Ganapathy, 
V. Molecular and Ligand-Binding Characterization of the Sigma-Receptor in the 
Jurkat Human T Lymphocyte Cell Line. J. Pharmacol. Exp. Ther. 1999, 289, 251-
260. 
(99) Su, T.; London, E.; Jaffe, J. Steroid binding at sigma receptors suggests a link 
between endocrine, nervous, and immune systems. Science 1988, 240, 219-221. 
(100) Waterhouse, R. N.; Chang, R. C.; Atuehene, N.; Collier, T. L. In vitro and in vivo 
binding of neuroactive steroids to the sigma-1 receptor as measured with the 
positron emission tomography radioligand [18F]FPS. Synapse 2007, 61, 540-546. 
 506 
(101) Fontanilla, D.; Johannessen, M.; Hajipour, A. R.; Cozzi, N. V.; Jackson, M. B.; 
Ruoho, A. E. The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an 
Endogenous Sigma-1 Receptor Regulator. Science 2009, 323, 934-937. 
(102) Frecska, E.; Szabo, A.; Winkelman, M. J.; Luna, L. E.; McKenna, D. J. A 
possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue 
protection, regeneration, and immunity. J. Neural Transm. 2013, 120, 1295-1303. 
(103) Nichols, D. E. N,N-dimethyltryptamine and the pineal gland: Separating fact from 
myth. J. Psychopharmacol. 2018, 32, 30-36. 
(104) Ramachandran, S.; Chu, U. B.; Mavlyutov, T. A.; Pal, A.; Pyne, S.; Ruoho, A. E. 
The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. 
Eur. J. Pharmacol. 2009, 609, 19-26. 
(105) Sigma Proteins: Evolution of the Concept of Sigma Receptors edited by Felix J. 
Kim, Gavril W. Pasternak; 1st ed. 2017. ed.; Springer International Publishing: 
Cham, 2017. 
(106) McCracken, K. A.; Bowen, W. D.; De Costa, B. R.; Matsumoto, R. R. Two novel 
σ receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and 
locomotor activity. Eur. J. Pharmacol. 1999, 370, 225-232. 
(107) Matsumoto, R. R.; McCracken, K. A.; Pouw, B.; Miller, J.; Bowen, W. D.; 
Williams, W.; De Costa, B. R. N-alkyl substituted analogs of the σ receptor ligand 
BD1008 and traditional σ receptor ligands affect cocaine-induced convulsions and 
lethality in mice. Eur. J. Pharmacol. 2001, 411, 261-273. 
(108) Maurice, T.; Goguadze, N.: Sigma-1 (σ1) Receptor in Memory and 
Neurodegenerative Diseases. In Sigma Proteins: Evolution of the Concept of 
Sigma Receptors; Kim, F. J., Pasternak, G. W., Eds.; Springer International 
Publishing: Cham, 2017; pp 81-108. 
(109) Jin, J.-L.; Fang, M.; Zhao, Y.-X.; Liu, X.-Y. Roles of sigma-1 receptors in 
Alzheimer's disease. Int. J. Clin. Exp. Med. 2015, 8, 4808-4820. 
(110) Mori, T.; Hayashi, T.; Su, T.-P. Compromising σ-1 Receptors at the Endoplasmic 
Reticulum Render Cytotoxicity to Physiologically Relevant Concentrations of 
Dopamine in a Nuclear Factor-κB/Bcl-2-Dependent Mechanism: Potential 
Relevance to Parkinson's Disease. J. Pharmacol. Exp. Ther. 2012, 341, 663-671. 
(111) Hong, J.; Sha, S.; Zhou, L.; Wang, C.; Yin, J.; Chen, L. Sigma-1 receptor 
deficiency reduces MPTP-induced parkinsonism and death of dopaminergic 
neurons. Cell Death Dis. 2015, 6, e1832-e1832. 
(112) Hyrskyluoto, A.; Pulli, I.; Törnqvist, K.; Huu Ho, T.; Korhonen, L.; Lindholm, D. 
Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced 
cell degeneration: involvement of calpastatin and the NF-κB pathway. Cell Death 
Dis. 2013, 4, e646-e646. 
 507 
(113) Fukunaga, K.; Shinoda, Y.; Tagashira, H. The role of SIGMAR1 gene mutation 
and mitochondrial dysfunction in amyotrophic lateral sclerosis. J. Pharmacol. Sci. 
2015, 127, 36-41. 
(114) Mavlyutov, T. A.; Guo, L.-W.; Epstein, M. L.; Ruoho, A. E. Role of the Sigma-1 
receptor in Amyotrophic Lateral Sclerosis (ALS). J. Pharmacol. Sci. 2015, 127, 
10-16. 
(115) Dong, H.; Ma, Y.; Ren, Z.; Xu, B.; Zhang, Y.; Chen, J.; Yang, B. Sigma-1 
Receptor Modulates Neuroinflammation After Traumatic Brain Injury. Cell. Mol. 
Neurobiol. 2016, 36, 639-645. 
(116) Zhang, X.; Wu, F.; Jiao, Y.; Tang, T.; Yang, L.; Lu, C.; Zhang, Y.; Zhang, Y.; 
Bai, Y.; Chao, J.; Teng, G.; Yao, H. An Increase of Sigma-1 Receptor in the 
Penumbra Neuron after Acute Ischemic Stroke. J. Stroke Cerebrovasc. Dis. 2017, 
26, 1981-1987. 
(117) Ruscher, K.; Shamloo, M.; Rickhag, M.; Ladunga, I.; Soriano, L.; Gisselsson, L.; 
Toresson, H.; Ruslim-Litrus, L.; Oksenberg, D.; Urfer, R.; Johansson, B. B.; 
Nikolich, K.; Wieloch, T. The sigma-1 receptor enhances brain plasticity and 
functional recovery after experimental stroke. Brain 2011, 134, 732-746. 
(118) Zamanillo, D.; Romero, L.; Merlos, M.; Vela, J. M. Sigma 1 receptor: A new 
therapeutic target for pain. Eur. J. Pharmacol.2013, 716, 78-93. 
(119) Bruna, J.; Velasco, R. Sigma-1 receptor: a new player in neuroprotection against 
chemotherapy-induced peripheral neuropathy. Neural Regen. Res. 2018, 13, 775. 
(120) Bruna, J.; Videla, S.; Argyriou, A. A.; Velasco, R.; Villoria, J.; Santos, C.; Nadal, 
C.; Cavaletti, G.; Alberti, P.; Briani, C.; Kalofonos, H. P.; Cortinovis, D.; Sust, 
M.; Vaqué, A.; Klein, T.; Plata-Salamán, C. Efficacy of a Novel Sigma-1 
Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, 
Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. Neurotherapeutics 
2018, 15, 178-189. 
(121) Urfer, R.; Moebius, H. J.; Skoloudik, D.; Santamarina, E.; Sato, W.; Mita, S.; 
Muir, K. W. Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine 
(SA4503) for Recovery Enhancement After Acute Ischemic Stroke. Stroke 2014, 
45, 3304-3310. 
(122) Anavex Life Sciences Corp. ANAVEX2-73 Study in Parkinson's Disease 
Dementia (report no. NCT03774459). 
https://clinicaltrials.gov/ct2/show/NCT03774459 (accessed May 9, 2020 2020). 
(123) Anavex Life Sciences Corp. ANAVEX2-73 for Treatment of Early Alzheimer's 
Disease (report no. NCT03790709). 
https://clinicaltrials.gov/ct2/show/study/NCT03790709 (accessed May 9, 2020 
2020). 
 508 
(124) Anavex Life Sciences Corp. An Extension Study of ANAVEX2-73 in Patients 
With Mild to Moderate Alzheimer's Disease (record no. NCT02756858). 
https://clinicaltrials.gov/ct2/show/NCT02756858 (accessed May 9, 2020 2020). 
(125) Kim, F. J.; Maher, C. M.: Sigma1 Pharmacology in the Context of Cancer. In 
Sigma Proteins: Evolution of the Concept of Sigma Receptors; Kim, F. J., 
Pasternak, G. W., Eds.; Springer International Publishing: Cham, 2017; pp 237-
308. 
(126) Van Waarde, A.; Rybczynska, A. A.; Ramakrishnan, N. K.; Ishiwata, K.; Elsinga, 
P. H.; Dierckx, R. A. J. O. Potential applications for sigma receptor ligands in 
cancer diagnosis and therapy. Biochim. Biophys. Acta - Biomembranes 2015, 
1848, 2703-2714. 
(127) Spruce, B. A.; Campbell, L. A.; McTavish, N.; Cooper, M. A.; Appleyard, M. V. 
L.; O’Neill, M.; Howie, J.; Samson, J.; Watt, S.; Murray, K.; McLean, D.; Leslie, 
N. R.; Safrany, S. T.; Ferguson, M. J.; Peters, J. A.; Prescott, A. R.; Box, G.; 
Hayes, A.; Nutley, B.; Raynaud, F.; Downes, C. P.; Lambert, J. J.; Thompson, A. 
M.; Eccles, S. Small Molecule Antagonists of the σ-1 Receptor Cause Selective 
Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor 
Growthin Vitroandin Vivo. Cancer Res. 2004, 64, 4875-4886. 
(128) Colabufo, N.; Berardi, F.; Contino, M.; Niso, M.; Abate, C.; Perrone, R.; 
Tortorella, V. Antiproliferative and cytotoxic effects of some  s2 agonists and s1 
antagonists in tumour cell lines. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 
370. 
(129) Aydar, E.; Onganer, P.; Perrett, R.; Djamgoz, M. B.; Palmer, C. P. The expression 
and functional characterization of sigma (σ) 1 receptors in breast cancer cell lines. 
Cancer Lett. 2006, 242, 245-257. 
(130) Ogawa, K.; Kanbara, H.; Kiyono, Y.; Kitamura, Y.; Kiwada, T.; Kozaka, T.; 
Kitamura, M.; Mori, T.; Shiba, K.; Odani, A. Development and evaluation of a 
radiobromine-labeled sigma ligand for tumor imaging. Nucl. Med. Biol. 2013, 40, 
445-450. 
(131) Xie, F.; Bergmann, R.; Kniess, T.; Deuther-Conrad, W.; Mamat, C.; Neuber, C.; 
Liu, B.; Steinbach, J.; Brust, P.; Pietzsch, J.; Jia, H. 18 F-Labeled 1,4-Dioxa-8-
azaspiro[4.5]decane Derivative: Synthesis and Biological Evaluation of a σ 1 
Receptor Radioligand with Low Lipophilicity as Potent Tumor Imaging Agent. J. 
Med. Chem. 2015, 58, 5395-5407. 
(132) Narita, N.; Hashimoto, K.; Tomitaka, S.-I.; Minabe, Y. Interactions of selective 
serotonin reuptake inhibitors with subtypes of σ receptors in rat brain. Eur. J. 
Pharmacol.1996, 307, 117-119. 
(133) Ossa, F.; Schnell, J. R.; Ortega-Roldan, J. L.: A Review of the Human Sigma-1 
Receptor Structure. In Sigma Receptors: Their Role in Disease and as 
 509 
Therapeutic Targets; Smith, S. B., Su, T.-P., Eds.; Springer International 
Publishing: Cham, 2017; pp 15-29. 
(134) Manallack, D. T.; Beart, P. M. Quantitative conformational analyses predict 
distinct receptor sites for PCP-like and σ drugs. Eur. J. Pharmacol. 1987, 144, 
231-235. 
(135) Manallack, D. T.; Wong, M. G.; Costa, M.; Andrews, P. R.; Beart, P. M. Receptor 
site topographies for phencyclidine-like and sigma drugs: predictions from 
quantitative conformational, electrostatic potential, and radioreceptor analyses. 
Mol. Pharmacol. 1988, 34, 863-879. 
(136) Largent, B. L.; Wikström, H.; Gundlach, A. L.; Snyder, S. H. Structural 
determinants of sigma receptor affinity. Mol. Pharmacol. 1987, 32, 772-784. 
(137) Glennon, R. A.; Yousif, M. Y.; Ismaiel, A. M.; El-Ashmawy, M. B.; Herndon, J. 
L.; Fischer, J. B.; Server, A. C.; Howie, K. J. B. Novel 1-phenylpiperazine and 4-
phenylpiperidine derivatives as high-affinity .sigma. ligands. J. Med. Chem. 1991, 
34, 3360-3365. 
(138) Gilligan, P. J.; Cain, G. A.; Christos, T. E.; Cook, L.; Drummond, S.; Johnson, A. 
L.; Kergaye, A. A.; McElroy, J. F.; Rohrbach, K. W. Novel piperidine .sigma. 
receptor ligands as potential antipsychotic drugs. J. Med. Chem. 1992, 35, 4344-
4361. 
(139) Glennon, R. A.; Smith, J. D.; Ismaiel, A. M.; El-Ashmawy, M.; Battaglia, G.; 
Fischer, J. B. Identification and exploitation of the .sigma.-opiate pharmacophore. 
J. Med. Chem. 1991, 34, 1094-1098. 
(140) Glennon, R. A.; Ablordeppey, S. Y.; Ismaiel, A. M.; El-Ashmawy, M. B.; 
Fischer, J. B.; Howie, K. B. Structural Features Important for .sigma.1 Receptor 
Binding. J. Med. Chem. 1994, 37, 1214-1219. 
(141) Ablordeppey, S. Y.; Glennon, R. A.: Pharmacophore Models for σ1 Receptor 
Binding. In Sigma Receptors: Chemistry, Cell Biology and Clinical Implications; 
Su, T.-P., Matsumoto, R. R., Bowen, W. D., Eds.; Springer US: Boston, MA, 
2007; pp 71-98. 
(142) Zampieri, D.; Mamolo, M. G.; Laurini, E.; Florio, C.; Zanette, C.; Fermeglia, M.; 
Posocco, P.; Paneni, M. S.; Pricl, S.; Vio, L. Synthesis, Biological Evaluation, and 
Three-Dimensional in Silico Pharmacophore Model for σ1Receptor Ligands 
Based on a Series of Substituted Benzo[d]oxazol-2(3H)-one Derivatives. J. Med. 
Chem. 2009, 52, 5380-5393. 
(143) Adapted with permission from Zampieri, D. M., M. G.; Laurini, E.; Florio, C.; 
Zanette, C.; Fermeglia, M.; Posocco, P.; Paneni, M. S.; Pricl, S.; Vio, L. 
Synthesis, Biological Evaluation, and Three-Dimensional in Silico 
Pharmacophore Model for σ1Receptor Ligands Based on a Series of Substituted 
 510 
Benzo[d]oxazol-2(3H)-one Derivatives. J. Med. Chem. 2009, 52, 5380-5393. 
Copyright (2009) American Chemical Society  
(144) Seth, P.; Ganapathy, M. E.; Conway, S. J.; Bridges, C. D.; Smith, S. B.; Casellas, 
P.; Ganapathy, V. Expression pattern of the type 1 sigma receptor in the brain and 
identity of critical anionic amino acid residues in the ligand-binding domain of the 
receptor. Biochim Biophys. Acta. 2001, 1540, 59-67. 
(145) Adapted with permission from Laurini, E. C., V. D.; Mamolo, M. G.; Zampieri, 
D.; Posocco, P.; Fermeglia, M.; Vio, L.; Pricl, S. Homology Model and Docking-
Based Virtual Screening for Ligands of the σ1 Receptor. ACS Med. Chem. Lett. 
2011, 2, 834-839. Copyright (2011) American Chemical Society. 
(146) Laurini, E.; Marson, D.; Dal Col, V.; Fermeglia, M.; Mamolo, M. G.; Zampieri, 
D.; Vio, L.; Pricl, S. Another Brick in the Wall. Validation of the σ 1 Receptor 3D 
Model by Computer-Assisted Design, Synthesis, and Activity of New σ 1 
Ligands. Mol. Pharmaceutics 2012, 9, 3107-3126. 
(147) Meyer, C.; Schepmann, D.; Yanagisawa, S.; Yamaguchi, J.; Dal Col, V.; Laurini, 
E.; Itami, K.; Pricl, S.; Wünsch, B. Pd-Catalyzed Direct C–H Bond 
Functionalization of Spirocyclic σ1Ligands: Generation of a Pharmacophore 
Model and Analysis of the Reverse Binding Mode by Docking into a 3D 
Homology Model of the σ1 Receptor. J. Med. Chem. 2012, 55, 8047-8065. 
(148) Rossi, D.; Marra, A.; Picconi, P.; Serra, M.; Catenacci, L.; Sorrenti, M.; Laurini, 
E.; Fermeglia, M.; Pricl, S.; Brambilla, S.; Almirante, N.; Peviani, M.; Curti, D.; 
Collina, S. Identification of RC-33 as a potent and selective σ1 receptor agonist 
potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-Scale 
synthesis, physicochemical characterization and in vitro metabolic stability. 
Bioorg. Med. Chem. 2013, 21, 2577-2586. 
(149) Zampieri, D.; Laurini, E.; Vio, L.; Golob, S.; Fermeglia, M.; Pricl, S.; Mamolo, 
M. G. Synthesis and receptor binding studies of some new arylcarboxamide 
derivatives as sigma-1 ligands. Bioorg. Med. Chem. Lett. 2014, 24, 1021-1025. 
(150) Laurini, E.; Harel, D.; Marson, D.; Schepmann, D.; Schmidt, T. J.; Pricl, S.; 
Wünsch, B. Identification, pharmacological evaluation and binding mode analysis 
of novel chromene and chromane based σ1 receptor ligands. Eur. J. Med. Chem. 
2014, 83, 526-533. 
(151) Zampieri, D.; Laurini, E.; Vio, L.; Fermeglia, M.; Pricl, S.; Wünsch, B.; 
Schepmann, D.; Mamolo, M. G. Improving selectivity preserving affinity: New 
piperidine-4-carboxamide derivatives as effective sigma-1-ligands. Eur. J. Med. 
Chem. 2015, 90, 797-808. 
(152) Brune, S.; Schepmann, D.; Klempnauer, K. H.; Marson, D.; Dal Col, V.; Laurini, 
E.; Fermeglia, M.; Wünsch, B.; Pricl, S. The Sigma Enigma: In Vitro/in Silico 
 511 
Site-Directed Mutagenesis Studies Unveil σ1 Receptor Ligand Binding. 
Biochemistry 2014, 53, 2993-3003. 
(153) Ortega-Roldan, J. L.; Ossa, F.; Amin, N. T.; Schnell, J. R. Solution NMR studies 
reveal the location of the second transmembrane domain of the human sigma-1 
receptor. FEBS Lett. 2015, 589, 659-665. 
(154) Schmidt, H. R.; Betz, R. M.; Dror, R. O.; Kruse, A. C. Structural basis for σ1 
receptor ligand recognition. Nat. Struct. Mol. Biol. 2018, 25, 981-987. 
(155) Alon, A.; Schmidt, H.; Zheng, S.; Kruse, A. C.: Structural Perspectives on Sigma-
1 Receptor Function. In Sigma Receptors: Their Role in Disease and as 
Therapeutic Targets; Smith, S. B., Su, T.-P., Eds.; Springer International 
Publishing: Cham, 2017; pp 5-13. 
(156) Yamamoto, H.; Miura, R.; Yamamoto, T.; Shinohara, K.; Watanabe, M.; 
Okuyama, S.; Nakazato, A.; Nukada, T. Amino acid residues in the 
transmembrane domain of the type 1 sigma receptor critical for ligand binding. 
FEBS Lett. 1999, 445, 19-22. 
(157) Gromek, K. A.; Suchy, F. P.; Meddaugh, H. R.; Wrobel, R. L.; Lapointe, L. M.; 
Chu, U. B.; Primm, J. G.; Ruoho, A. E.; Senes, A.; Fox, B. G. The Oligomeric 
States of the Purified Sigma-1 Receptor Are Stabilized by Ligands. J. Biol. Chem. 
2014, 289, 20333-20344. 
(158) Mishra, A. K.; Mavlyutov, T.; Singh, D. R.; Biener, G.; Yang, J.; Julie; Ruoho, 
A.; Raicu, V. The sigma-1 receptors are present in monomeric and oligomeric 
forms in living cells in the presence and absence of ligands. Biochem. J. 2015, 
466, 263-271. 
(159) Kruse, A.: Structural Insights into Sigma1 Function. In Sigma Proteins: Evolution 
of the Concept of Sigma Receptors; Kim, F. J., Pasternak, G. W., Eds.; Springer 
International Publishing: Cham, 2017; pp 13-25. 
(160) Alon, A.; Schmidt, H. R.; Wood, M. D.; Sahn, J. J.; Martin, S. F.; Kruse, A. C. 
Identification of the gene that codes for the σ2 receptor. Proc. Natl. Acad. Sci. 
U.S.A. 2017, 114, 7160-7165. 
(161) Zeng, C.; McDonald, E. S.; Mach, R. H.: Molecular Probes for Imaging the 
Sigma-2 Receptor: In Vitro and In Vivo Imaging Studies. In Sigma Proteins: 
Evolution of the Concept of Sigma Receptors; Kim, F. J., Pasternak, G. W., Eds.; 
Springer International Publishing: Cham, 2017; pp 309-330. 
(162) Georgiadis, M.-O.; Karoutzou, O.; Foscolos, A.-S.; Papanastasiou, I. Sigma 
Receptor (σR) Ligands with Antiproliferative and Anticancer Activity. Molecules 
2017, 22, 1408. 
(163) Mondal, S.; Hegarty, E.; Sahn, J. J.; Scott, L. L.; Gökçe, S. K.; Martin, C.; 
Ghorashian, N.; Satarasinghe, P. N.; Iyer, S.; Sae-Lee, W.; Hodges, T. R.; Pierce, 
 512 
J. T.; Martin, S. F.; Ben-Yakar, A. High-Content Microfluidic Screening Platform 
Used To Identify σ2R/Tmem97 Binding Ligands that Reduce Age-
Dependent Neurodegeneration in C. elegans SC_APP Model. ACS Chem. 
Neurosci. 2018, 9, 1014-1026. 
(164) Izzo, N. J.; Staniszewski, A.; To, L.; Fa, M.; Teich, A. F.; Saeed, F.; Wostein, H.; 
Walko, T.; Vaswani, A.; Wardius, M.; Syed, Z.; Ravenscroft, J.; Mozzoni, K.; 
Silky, C.; Rehak, C.; Yurko, R.; Finn, P.; Look, G.; Rishton, G.; Safferstein, H.; 
Miller, M.; Johanson, C.; Stopa, E.; Windisch, M.; Hutter-Paier, B.; Shamloo, M.; 
Arancio, O.; Levine, H.; Catalano, S. M. Alzheimer's Therapeutics Targeting 
Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific 
Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive 
Deficits. PLoS ONE 2014, 9, e111898. 
(165) Izzo, N. J.; Xu, J.; Zeng, C.; Kirk, M. J.; Mozzoni, K.; Silky, C.; Rehak, C.; 
Yurko, R.; Look, G.; Rishton, G.; Safferstein, H.; Cruchaga, C.; Goate, A.; Cahill, 
M. A.; Arancio, O.; Mach, R. H.; Craven, R.; Head, E.; Levine, H.; Spires-Jones, 
T. L.; Catalano, S. M. Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 
Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding 
and Synaptotoxicity. PLoS ONE 2014, 9, e111899. 
(166) Grundman, M.; Morgan, R.; Lickliter, J. D.; Schneider, L. S.; Dekosky, S.; Izzo, 
N. J.; Guttendorf, R.; Higgin, M.; Pribyl, J.; Mozzoni, K.; Safferstein, H.; 
Catalano, S. M. A phase 1 clinical trial of the sigma-2 receptor complex allosteric 
antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. 
Alzheimers Dement. (NY) 2019, 5, 20-26. 
(167) Davidson, M.; Saoud, J.; Staner, C.; Noel, N.; Luthringer, E.; Werner, S.; Reilly, 
J.; Schaffhauser, J.-Y.; Rabinowitz, J.; Weiser, M.; Luthringer, R. Efficacy and 
Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled 
Trial of a New Drug in Development for the Treatment of Negative Symptoms in 
Schizophrenia. Am. J. Psychiatry 2017, 174, 1195-1202. 
(168) Terada, K.; Migita, K.; Matsushima, Y.; Kamei, C. Sigma-2 receptor as a 
potential therapeutic target for treating central nervous system disorders. Neural 
Regen. Res. 2019, 14, 1893. 
(169) Gordon, D. E.; Jang, G. M.; Bouhaddou, M.; Xu, J.; Obernier, K.; White, K. M.; 
O’Meara, M. J.; Rezelj, V. V.; Guo, J. Z.; Swaney, D. L.; Tummino, T. A.; 
Huettenhain, R.; Kaake, R. M.; Richards, A. L.; Tutuncuoglu, B.; Foussard, H.; 
Batra, J.; Haas, K.; Modak, M.; Kim, M.; Haas, P.; Polacco, B. J.; Braberg, H.; 
Fabius, J. M.; Eckhardt, M.; Soucheray, M.; Bennett, M. J.; Cakir, M.; McGregor, 
M. J.; Li, Q.; Meyer, B.; Roesch, F.; Vallet, T.; Mac Kain, A.; Miorin, L.; 
Moreno, E.; Naing, Z. Z. C.; Zhou, Y.; Peng, S.; Shi, Y.; Zhang, Z.; Shen, W.; 
Kirby, I. T.; Melnyk, J. E.; Chorba, J. S.; Lou, K.; Dai, S. A.; Barrio-Hernandez, 
I.; Memon, D.; Hernandez-Armenta, C.; Lyu, J.; Mathy, C. J. P.; Perica, T.; Pilla, 
 513 
K. B.; Ganesan, S. J.; Saltzberg, D. J.; Rakesh, R.; Liu, X.; Rosenthal, S. B.; 
Calviello, L.; Venkataramanan, S.; Liboy-Lugo, J.; Lin, Y.; Huang, X.-P.; Liu, Y.; 
Wankowicz, S. A.; Bohn, M.; Safari, M.; Ugur, F. S.; Koh, C.; Savar, N. S.; Tran, 
Q. D.; Shengjuler, D.; Fletcher, S. J.; O’Neal, M. C.; Cai, Y.; Chang, J. C. J.; 
Broadhurst, D. J.; Klippsten, S.; Sharp, P. P.; Wenzell, N. A.; Kuzuoglu, D.; 
Wang, H.-Y.; Trenker, R.; Young, J. M.; Cavero, D. A.; Hiatt, J.; Roth, T. L.; 
Rathore, U.; Subramanian, A.; Noack, J.; Hubert, M.; Stroud, R. M.; Frankel, A. 
D.; Rosenberg, O. S.; Verba, K. A.; Agard, D. A.; Ott, M.; Emerman, M.; Jura, N. 
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. 
Nature 2020, 582, 459-468. 
(170) Bouchard, P.; Quirion, R. [3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine 
binding sites in the rat brain: Autoradiographic visualization of the putative sigma 
1 and sigma 2 receptor subtypes. Neuroscience 1997, 76, 467-477. 
(171) Hellewell, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.; Williams, W.; Bowen, W. 
D. Rat liver and kidney contain high densities of σ1 and σ2 receptors: 
characterization by ligand binding and photoaffinity labeling. Eur. J.  Pharmacol. 
Mol. Pharmacol. 1994, 268, 9-18. 
(172) Vilner, B. J.; John, C. S.; Bowen, W. D. Sigma-1 and Sigma-2 Receptors Are 
Expressed in a Wide Variety of Human and Rodent Tumor Cell Lines. Cancer 
Res. 1995, 55, 408-413. 
(173) Zeng, C.; Vangveravong, S.; Xu, J.; Chang, K. C.; Hotchkiss, R. S.; Wheeler, K. 
T.; Shen, D.; Zhuang, Z.-P.; Kung, H. F.; Mach, R. H. Subcellular Localization of 
Sigma-2 Receptors in Breast Cancer Cells Using Two-Photon and Confocal 
Microscopy. Cancer Res. 2007, 67, 6708-6716. 
(174) Gebreselassie, D.; Bowen, W. D. Sigma-2 receptors are specifically localized to 
lipid rafts in rat liver membranes. Eur. J. Pharmacol. 2004, 493, 19-28. 
(175) Nicholson, H. E.; Alsharif, W. F.; Comeau, A. B.; Mesangeau, C.; Intagliata, S.; 
Mottinelli, M.; McCurdy, C. R.; Bowen, W. D. Divergent Cytotoxic and 
Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity 
Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-
yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives. J. Pharmacol. Exp. Ther.  
2019, 368, 272-281. 
(176) Matsumoto, R. R.; Bowen, W. D.; Tom, M. A.; Vo, V. N.; Truong, D. D.; De 
Costa, B. R. Characterization of two novel σ receptor ligands: antidystonic effects 
in rats suggest σ receptor antagonism. Eur. J. Pharmacol. 1995, 280, 301-310. 
(177) Mach, R. H.; Smith, C. R.; Al-Nabulsi, I.; Whirrett, B. R.; Childers, S. R.; 
Wheeler, K. T. σ2 Receptors as Potential Biomarkers of Proliferation in Breast 
Cancer. Cancer Res. 1997, 57, 156-161. 
 514 
(178) Hedley, D. W.; Clark, G. M.; Cornelisse, C. J.; Killander, D.; Kute, T.; Merkel, D. 
Consensus review of the clinical utility of dna cytometry in carcinoma of the 
breast. Cytometry 1993, 14, 482-485. 
(179) Masunaga, S.-I.; Ono, K. Significance of the Response of Quiescent Cell 
Populations within Solid Tumors in Cancer Therapy. J. Rad. Res. 2002, 43, 11-
11. 
(180) Wheeler, K. T.; Wang, L. M.; Wallen, C. A.; Childers, S. R.; Cline, J. M.; Keng, 
P. C.; Mach, R. H. Sigma-2 receptors as a biomarker of proliferation in solid 
tumours. Br. J. Cancer 2000, 82, 1223-1232. 
(181) Mach, R. H.; Huang, Y.; Freeman, R. A.; Wu, L.; Vangveravong, S.; Luedtke, R. 
R. Conformationally-flexible benzamide analogues as dopamine D3 and σ2 
receptor ligands. Bioorg. Med. Chem. Lett. 2004, 14, 195-202. 
(182) Tu, Z.; Dence, C. S.; Ponde, D. E.; Jones, L.; Wheeler, K. T.; Welch, M. J.; Mach, 
R. H. Carbon-11 labeled σ2 receptor ligands for imaging breast cancer. Nucl. 
Med. Biol. 2005, 32, 423-430. 
(183) Tu, Z.; Xu, J.; Jones, L. A.; Li, S.; Dumstorff, C.; Vangveravong, S.; Chen, D. L.; 
Wheeler, K. T.; Welch, M. J.; Mach, R. H. Fluorine-18-Labeled Benzamide 
Analogues for Imaging the σ2 Receptor Status of Solid Tumors with Positron 
Emission Tomography. J. Med. Chem. 2007, 50, 3194-3204. 
(184) Dehdashti, F.; Laforest, R.; Gao, F.; Shoghi, K. I.; Aft, R. L.; Nussenbaum, B.; 
Kreisel, F. H.; Bartlett, N. L.; Cashen, A.; Wagner-Johnson, N.; Mach, R. H. 
Assessment of Cellular Proliferation in Tumors by PET Using 18F-ISO-1. J. 
Nucl. Med. 2013, 54, 350-357. 
(185) Shoghi, K. I.; Xu, J.; Su, Y.; He, J.; Rowland, D.; Yan, Y.; Garbow, J. R.; Tu, Z.; 
Jones, L. A.; Higashikubo, R.; Wheeler, K. T.; Lubet, R. A.; Mach, R. H.; You, 
M. Quantitative Receptor-Based Imaging of Tumor Proliferation with the Sigma-
2 Ligand [18F]ISO-1. PLoS ONE 2013, 8, e74188. 
(186) Berridge, M. J.; Bootman, M. D.; Lipp, P. Calcium - a life and death signal. 
Nature 1998, 395, 645-648. 
(187) Vilner, B. J.; Bowen, W. D. Modulation of Cellular Calcium by Sigma-2 
Receptors: Release from Intracellular Stores in Human SK-N-SH Neuroblastoma 
Cells. J. Pharmacol. Exp. Ther.  2000, 292, 900-911. 
(188) Zeng, C.; Rothfuss, J.; Zhang, J.; Chu, W.; Vangveravong, S.; Tu, Z.; Pan, F.; 
Chang, K. C.; Hotchkiss, R.; Mach, R. H. Sigma-2 ligands induce tumour cell 
death by multiple signalling pathways. Br. J. Cancer 2012, 106, 693-701. 
(189) Cassano, G.; Gasparre, G.; Contino, M.; Niso, M.; Berardi, F.; Perrone, R.; 
Colabufo, N. A. The sigma-2 receptor agonist PB28 inhibits calcium release from 
 515 
the endoplasmic reticulum of SK-N-SH neuroblastoma cells. Cell Calcium 2006, 
40, 23-28. 
(190) Cassano, G.; Gasparre, G.; Niso, M.; Contino, M.; Scalera, V.; Colabufo, N. A. 
F281, synthetic agonist of the sigma-2 receptor, induces Ca2+ efflux from the 
endoplasmic reticulum and mitochondria in SK-N-SH cells. Cell Calcium 2009, 
45, 340-345. 
(191) Ferorelli, S.; Abate, C.; Colabufo, N. A.; Niso, M.; Inglese, C.; Berardi, F.; 
Perrone, R. Design and Evaluation of Naphthol- and Carbazole-Containing 
Fluorescent σ Ligands as Potential Probes for Receptor Binding Studies. J. Med. 
Chem. 2007, 50, 4648-4655. 
(192) Kaushal, N.; Robson, M. J.; Vinnakota, H.; Narayanan, S.; Avery, B. A.; 
McCurdy, C. R.; Matsumoto, R. R. Synthesis and Pharmacological Evaluation of 
6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one 
(SN79), a Cocaine Antagonist, in Rodents. AAPS J. 2011, 13, 336-346. 
(193) Nicholson, H.; Mesangeau, C.; McCurdy, C. R.; Bowen, W. D. Sigma-2 
Receptors Play a Role in Cellular Metabolism: Stimulation of Glycolytic 
Hallmarks by CM764 in Human SK-N-SH Neuroblastoma. J. Pharmacol. Exp. 
Ther. 2016, 356, 434-445. 
(194) Vilner, B.; De Costa, B.; Bowen, W. Cytotoxic effects of sigma ligands: sigma 
receptor-mediated alterations in cellular morphology and viability. J. Neurosci. 
1995, 15, 117-134. 
(195) Bowen, W. D.: σ2 Receptors: Regulation of Cell Growth and Implications for 
Cancer Diagnosis and Therapeutics. In Sigma Receptors: Chemistry, Cell Biology 
and Clinical Implications; Su, T.-P., Matsumoto, R. R., Bowen, W. D., Eds.; 
Springer US: Boston, MA, 2007; pp 215-235. 
(196) Crawford, K. W.; Bowen, W. D. Sigma-2 Receptor Agonists Activate a Novel 
Apoptotic Pathway and Potentiate Antineoplastic Drugs in Breast Tumor Cell 
Lines. Cancer Res. 2002, 62, 313-322. 
(197) Perregaard, J.; Moltzen, E. K.; Meier, E.; Sanchez, C. .sigma. Ligands with 
Subnanomolar Affinity and Preference for the .sigma.2 Binding Site. 1. 3-
(.omega.-Aminoalkyl)-1H-indoles. J. Med. Chem. 1995, 38, 1998-2008. 
(198) Ostenfeld, M. S.; Fehrenbacher, N.; Høyer-Hansen, M.; Thomsen, C.; Farkas, T.; 
Jäättelä, M. Effective Tumor Cell Death by σ-2 Receptor Ligand Siramesine 
Involves Lysosomal Leakage and Oxidative Stress. Cancer Res. 2005, 65, 8975-
8983. 
(199) Ostenfeld, M. S.; Høyer-Hansen, M.; Bastholm, L.; Fehrenbacher, N.; Olsen, O. 
D.; Groth-Pedersen, L.; Puustinen, P.; Kirkegaard-Sørensen, T.; Nylandsted, J.; 
Farkas, T.; Jäättelä, M. Anti-cancer agent siramesine is a lysosomotropic 
 516 
detergent that induces cytoprotective autophagosome accumulation. Autophagy 
2008, 4, 487-499. 
(200) Hafner Česen, M.; Repnik, U.; Turk, V.; Turk, B. Siramesine triggers cell death 
through destabilisation of mitochondria, but not lysosomes. Cell Death Dis. 2013, 
4, e818-e818. 
(201) Zeng, C.; Rothfuss, J. M.; Zhang, J.; Vangveravong, S.; Chu, W.; Li, S.; Tu, Z.; 
Xu, J.; Mach, R. H. Functional assays to define agonists and antagonists of the 
sigma-2 receptor. Anal. Biochem. 2014, 448, 68-74. 
(202) Zeng, C.; Weng, C.-C.; Schneider, M. E.; Puentes, L.; Riad, A.; Xu, K.; 
Makvandi, M.; Jin, L.; Hawkins, W. G.; Mach, R. H. TMEM97 and PGRMC1 do 
not mediate sigma-2 ligand-induced cell death. Cell Death Discov. 2019, 5. 
(203) Huang, Y.-S.; Lu, H.-L.; Zhang, L.-J.; Wu, Z. Sigma-2 Receptor Ligands and 
Their Perspectives in Cancer Diagnosis and Therapy. Med. Res. Rev. 2014, 34, 
532-566. 
(204) Nicholson, H.; Comeau, A.; Mesangeau, C.; McCurdy, C. R.; Bowen, W. D. 
Characterization of CM572, a Selective Irreversible Partial Agonist of the Sigma-
2 Receptor with Antitumor Activity. J. Pharmacol. Exp. Ther.  2015, 354, 203-
212. 
(205) Ghelardini, C.; Galeotti, N.; Bartolini, A. Pharmacological identification of SM-
21, the novel σ2 antagonist. Pharmacol. Biochem. Behav. 2000, 67, 659-662. 
(206) Lever, J. R.; Miller, D. K.; Green, C. L.; Fergason-Cantrell, E. A.; Watkinson, L. 
D.; Carmack, T. L.; Fan, K.-H.; Lever, S. Z. A selective sigma-2 receptor ligand 
antagonizes cocaine-induced hyperlocomotion in mice. Synapse 2014, 68, 73-84. 
(207) Colabufo, N. A.; Berardi, F.; Contino, M.; Perrone, R.; Tortorella, V. A new 
method for evaluating  s2 ligand activity in the isolated guinea-pig bladder. 
Naunyn-Schmiedeberg’s Arch. Pharmacol. 2003, 368, 106-112. 
(208) Lin, G.; Xuechu, Z. Sigma-2 Receptor Ligands: Neurobiological Effects. Curr. 
Med. Chem. 2015, 22, 989-1003. 
(209) Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease. (report no. 
NCT02907567) https://clinicaltrials.gov/ct2/show/NCT02907567 (accessed June 
5, 2020. 
(210) Keefe, R. S. E.; Harvey, P. D.; Khan, A.; Saoud, J. B.; Staner, C.; Davidson, M.; 
Luthringer, R. Cognitive effects of MIN-101 in patients with schizophrenia and 
negative symptoms : Results from a randomized controlled trial. J. Clin. Psych. 
2018, 79, 17m11753. 
(211) Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult 
Patients With Negative Symptoms of Schizophrenia (report no. NCT03397134). 
https://clinicaltrials.gov/ct2/show/NCT03397134 (accessed June 5, 2020. 
 517 
(212) Kim, F. J.; Pasternak, G. W. Cloning the sigma2 receptor: Wandering 40 years to 
find an identity. Proc. Natl. Acad. Sci. U.S.A.2017, 114, 6888-6890. 
(213) Rix, U.; Superti-Furga, G. Target profiling of small molecules by chemical 
proteomics. Nat. Chem. Biol. 2009, 5, 616-624. 
(214) Tamura, T.; Terada, T.; Tanaka, A. A Quantitative Analysis and Chemical 
Approach for the Reduction of Nonspecific Binding Proteins on Affinity Resins. 
Bioconjug. Chem. 2003, 14, 1222-1230. 
(215) Hashimoto, M.; Yang, J.; Holman, G. D. Cell-Surface Recognition of 
Biotinylated Membrane Proteins Requires Very Long Spacer Arms: An Example 
from Glucose-Transporter Probes. ChemBioChem 2001, 2, 52-59. 
(216) Tamura, S.; Inomata, S.; Ebine, M.; Genji, T.; Iwakura, I.; Mukai, M.; Shoji, M.; 
Sugai, T.; Ueda, M. Triazoyl–phenyl linker system enhancing the aqueous 
solubility of a molecular probe and its efficiency in affinity labeling of a target 
protein for jasmonate glucoside. Bioorg. Med. Chem. Lett. 2013, 23, 188-193. 
(217) Colabufo, N. A.; Berardi, F.; Abate, C.; Contino, M.; Niso, M.; Perrone, R. Is the 
σ2Receptor a Histone Binding Protein? J. Med. Chem. 2006, 49, 4153-4158. 
(218) Berardi, F.; Ferorelli, S.; Abate, C.; Colabufo, N. A.; Contino, M.; Perrone, R.; 
Tortorella, V. 4-(Tetralin-1-yl)- and 4-(Naphthalen-1-yl)alkyl Derivatives of 1-
Cyclohexylpiperazine as σ Receptor Ligands with Agonist σ2Activity. J. Med. 
Chem. 2004, 47, 2308-2317. 
(219) Colabufo, N. A.; Abate, C.; Contino, M.; Inglese, C.; Ferorelli, S.; Berardi, F.; 
Perrone, R. Tritium radiolabelling of PB28, a potent sigma-2 receptor ligand: 
pharmacokinetic and pharmacodynamic characterization. Bioorg. Med. Chem. 
Lett. 2008, 18, 2183-2187. 
(220) Abate, C.; Niso, M.; Berardi, F. Sigma-2 receptor: past, present and perspectives 
on multiple therapeutic exploitations. Future Med. Chem. 2018, 10, 1997-2018. 
(221) Xu, J.; Zeng, C.; Chu, W.; Pan, F.; Rothfuss, J. M.; Zhang, F.; Tu, Z.; Zhou, D.; 
Zeng, D.; Vangveravong, S.; Johnston, F.; Spitzer, D.; Chang, K. C.; Hotchkiss, 
R. S.; Hawkins, W. G.; Wheeler, K. T.; Mach, R. H. Identification of the 
PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nature 
Commun. 2011, 2, 380. 
(222) Meyer, C.; Schmid, R.; Scriba, P. C.; Wehling, M. Purification and Partial 
Sequencing of High-Affinity Progesterone-Binding Site(s) from Porcine Liver 
Membranes. Eur. J. Biochem. 1996, 239, 726-731. 
(223) Ryu, C. S.; Klein, K.; Zanger, U. M. Membrane Associated Progesterone 
Receptors: Promiscuous Proteins with Pleiotropic Functions – Focus on 
Interactions with Cytochromes P450. Front. Pharmacol. 2017, 8. 
 518 
(224) Cahill, M. A.; Jazayeri, J. A.; Catalano, S. M.; Toyokuni, S.; Kovacevic, Z.; 
Richardson, D. R. The emerging role of progesterone receptor membrane 
component 1 (PGRMC1) in cancer biology. Biochim. Biophys. Acta 2016, 1866, 
339-349. 
(225) Mifsud, W.; Bateman, A. Membrane-bound progesterone receptors contain a 
cytochrome b5-like ligand-binding domain. Genome Biol. 2002, 3, 
research0068.0061. 
(226) Kabe, Y.; Nakane, T.; Koike, I.; Yamamoto, T.; Sugiura, Y.; Harada, E.; Sugase, 
K.; Shimamura, T.; Ohmura, M.; Muraoka, K.; Yamamoto, A.; Uchida, T.; Iwata, 
S.; Yamaguchi, Y.; Krayukhina, E.; Noda, M.; Handa, H.; Ishimori, K.; 
Uchiyama, S.; Kobayashi, T.; Suematsu, M. Haem-dependent dimerization of 
PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. 
Nature Commun. 2016, 7, 11030. 
(227) Kabe, Y.; Handa, H.; Suematsu, M. Function and structural regulation of the 
carbon monoxide (CO)-responsive membrane protein PGRMC1. J. Clin. 
Biochem. Nut. 2018, 63, 12-17. 
(228) Hughes, A. L.; Powell, D. W.; Bard, M.; Eckstein, J.; Barbuch, R.; Link, A. J.; 
Espenshade, P. J. Dap1/PGRMC1 Binds and Regulates Cytochrome P450 
Enzymes. Cell Metab. 2007, 5, 143-149. 
(229) Klein, M.; Canoll, P. D.; Musacchio, J. SKF 525-A and cytochrome P-450 ligands 
inhibit with high affinity the binding of [3H]dextromethorpan and σ ligands to 
guinea pig brain. Life Sci. 1991, 48, 543-550. 
(230) Ross, S. B. Heterogeneous Binding of Sigma Radioligands in the Rat Brain and 
Liver: Possible Relationship to Subforms of Cytochrome P-450. Pharmacol. 
Toxicol. 1991, 68, 293-301. 
(231) Ghosh, K.; Thompson, A. M.; Goldbeck, R. A.; Shi, X.; Whitman, S.; Oh, E.; 
Zhiwu, Z.; Vulpe, C.; Holman, T. R. Spectroscopic and Biochemical 
Characterization of Heme Binding to Yeast Dap1p and Mouse PGRMC1p. 
Biochemistry 2005, 44, 16729-16736. 
(232) Min, L.; Strushkevich, N. V.; Harnastai, I. N.; Iwamoto, H.; Gilep, A. A.; 
Takemori, H.; Usanov, S. A.; Nonaka, Y.; Hori, H.; Vinson, G. P.; Okamoto, M. 
Molecular identification of adrenal inner zone antigen as a heme-binding protein. 
FEBS J. 2005, 272, 5832-5843. 
(233) Cahill, M. A. Progesterone receptor membrane component 1: An integrative 
review. J. Steroid Biochem. Mol. Biol. 2007, 105, 16-36. 
(234) Peluso, J. J.; Romak, J.; Liu, X. Progesterone Receptor Membrane Component-1 
(PGRMC1) Is the Mediator of Progesterone’s Antiapoptotic Action in 
Spontaneously Immortalized Granulosa Cells As Revealed by PGRMC1 Small 
 519 
Interfering Ribonucleic Acid Treatment and Functional Analysis of PGRMC1 M. 
Endocrinology 2008, 149, 534-543. 
(235) Johannessen, M.; Fontanilla, D.; Mavlyutov, T.; Ruoho, A. E.; Jackson, M. B. 
Antagonist action of progesterone at σ-receptors in the modulation of voltage-
gated sodium channels. Am. J. Physiol. Cell Physiol. 2011, 300, C328-C337. 
(236) Meyer, C.; Schmieding, K.; Falkenstein, E.; Wehling, M. Are high-affinity 
progesterone binding site(s) from porcine liver microsomes members of the σ 
receptor family? Eur. J. Pharmacol. 1998, 347, 293-299. 
(237) Clark, N. C.; Friel, A. M.; Pru, C. A.; Zhang, L.; Shioda, T.; Rueda, B. R.; Peluso, 
J. J.; Pru, J. K. Progesterone receptor membrane component 1 promotes survival 
of human breast cancer cells and the growth of xenograft tumors. Cancer Biol. 
2016, 1-10. 
(238) Mir, S. U.; Schwarze, S. R.; Jin, L.; Zhang, J.; Friend, W.; Miriyala, S.; St Clair, 
D.; Craven, R. J. Progesterone receptor membrane component 1/Sigma-2 receptor 
associates with MAP1LC3B and promotes autophagy. Autophagy 2013, 9, 1566-
1578. 
(239) Mir, S. U. R.; Ahmed, I. S. A.; Arnold, S.; Craven, R. J. Elevated progesterone 
receptor membrane component 1/sigma-2 receptor levels in lung tumors and 
plasma from lung cancer patients. Int. J. Cancer 2012, 131, E1-E9. 
(240) Bali, N.; Arimoto, J. M.; Morgan, T. E.; Finch, C. E. Progesterone Antagonism of 
Neurite Outgrowth Depends on Microglial Activation via Pgrmc1/S2R. 
Endocrinology 2013, 154, 2468-2480. 
(241) Chu, U. B.; Mavlyutov, T. A.; Chu, M.-L.; Yang, H.; Schulman, A.; Mesangeau, 
C.; McCurdy, C. R.; Guo, L.-W.; Ruoho, A. E. The Sigma-2 Receptor and 
Progesterone Receptor Membrane Component 1 are Different Binding Sites 
Derived From Independent Genes. EBioMedicine 2015, 2, 1806-1813. 
(242) Abate, C.; Niso, M.; Infantino, V.; Menga, A.; Berardi, F. Elements in support of 
the ‘non-identity’ of the PGRMC1 protein with the σ2 receptor. Eur. J. 
Pharmacol. 2015, 758, 16-23. 
(243) Fontanilla, D.; Hajipour, A. R.; Pal, A.; Chu, U. B.; Arbabian, M.; Ruoho, A. E. 
Probing the Steroid Binding Domain-like I (SBDLI) of the Sigma-1 Receptor 
Binding Site Using N-Substituted Photoaffinity Labels. Biochemistry 2008, 47, 
7205-7217. 
(244) Bertha, C. M.; Vilner, B. J.; Mattson, M. V.; Bowen, W. D.; Becketts, K.; Xu, H.; 
Rothman, R. B.; Flippen-Anderson, J. L.; Rice, K. C. (E)-8-Benzylidene 
Derivatives of 2-Methyl-5-(3-hydroxyphenyl)morphans: Highly Selective 
Ligands for the .sigma.2 Receptor Subtype. J. Med. Chem. 1995, 38, 4776-4785. 
 520 
(245) Nastasi, G.; Miceli, C.; Pittalà, V.; Modica, M. N.; Prezzavento, O.; Romeo, G.; 
Rescifina, A.; Marrazzo, A.; Amata, E. S2RSLDB: a comprehensive manually 
curated, internet-accessible database of the sigma-2 receptor selective ligands. J. 
Cheminform. 2017, 9, 3. 
(246) Cratteri, P.; Romanelli, M. N.; Cruciani, G.; Bonaccini, C.; Melani, F. GRIND-
derived pharmacophore model for a series of α-tropanyl derivative ligands of the 
sigma-2 receptor. J. Comput. Aided Mol. Des. 2004, 18, 361-374. 
(247) Laurini, E.; Zampieri, D.; Mamolo, M. G.; Vio, L.; Zanette, C.; Florio, C.; 
Posocco, P.; Fermeglia, M.; Pricl, S. A 3D-pharmacophore model for σ2 receptors 
based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives. Bioorg. 
Med. Chem. Lett. 2010, 20, 2954-2957. 
(248) Bertha, C. M.; Mattson, M. V.; Flippen-Anderson, J. L.; Rothman, R. B.; Xu, H.; 
Cha, X.-Y.; Becketts, K.; Rice, K. C. A Marked Change of Receptor Affinity of 
the 2-Methyl-5-(3-hydroxyphenyl)morphans upon Attachment of an (E)-8-
Benzylidene Moiety: Synthesis and Evaluation of a New Class of .sigma. 
Receptor Ligands. J. Med. Chem. 1994, 37, 3163-3170. 
(249) Bowen, W. D.; Bertha, C. M.; Vilner, B. J.; Rice, K. C. CB-64D and CB-184: 
ligands with high σ2 receptor affinity and subtype selectivity. Eur. J. Pharmacol. 
1995, 278, 257-260. 
(250) Bonhaus, D. W.; Loury, D. N.; Jakeman, L. B.; To, Z.; DeSouza, A.; Eglen, R. 
M.; Wong, E. H. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-
108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus. J. 
Pharmacol. Exp. Ther. 1993, 267, 961-970. 
(251) Gualtieri, F.; Conti, G.; Dei, S.; Giovannoni, M. P.; Nannucci, F.; Romanelli, M. 
N.; Scapecchi, S.; Teodori, E.; Fanfani, L.; Ghelardini, C.; Giotti, A.; Bartolini, A. 
Presynaptic Cholinergic Modulators as Potent Cognition Enhancers and Analgesic 
Drugs. 1. Tropic and 2-Phenylpropionic Acid Esters. J. Med. Chem. 1994, 37, 
1704-1711. 
(252) Gualtieri, F.; Bottalico, C.; Calandrella, A.; Dei, S.; Giovannoni, M. P.; Mealli, 
S.; Romanelli, M. N.; Scapecchi, S.; Teodori, E. Presynaptic Cholinergic 
Modulators as Potent Cognition Enhancers and Analgesic Drugs. 2. 2-Phenoxy-, 
2-(Phenylthio)-, and 2-(Phenylamino)alkanoic Acid Esters. J. Med. Chem. 1994, 
37, 1712-1719. 
(253) Mach, R. H.; Wu, L.; West, T.; Whirrett, B. R.; Childers, S. R. The analgesic 
tropane analogue (±)-SM 21 has a high affinity for σ2 receptors. Life Sci. 1999, 
64, PL131-PL137. 
(254) Prezzavento, O.; Gualtieri, F.; Marrazzo, A.; Romanelli, M. N.; Ronsisvalle, G.; 
Teodori, E. Sigma Receptor Binding Profile of a Series of Analgesic Tropane 
Derivatives. Arch. Pharm. 2002, 335, 39-43. 
 521 
(255) Mach R. H., Y. B., Wu L,, Kuhner R., Whirrett B., West T. Synthesis and sigma 
receptor binding affinities of 8-azabicyclo[3.2.1]octan-3a-yl and 9-
azabicyclo[3.3.1]nonan-3a-yl phenyl carbamates. Med. Chem. Res. 2001, 10, 339-
355. 
(256) Mach R. H., V. S., Huang Y. S., Yang B., Blair J. B., Wu L. . Synthesis of N-
substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as sigma-2 
receptor ligands. Med. Chem. Res. 2003, 11, 380-398. 
(257) Vangveravong, S.; Xu, J.; Zeng, C.; Mach, R. H. Synthesis of N-substituted 9-
azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands. Bioorg. 
Med. Chem. 2006, 14, 6988-6997. 
(258) Mach, R. H.; Huang, Y.; Freeman, R. A.; Wu, L.; Blair, S.; Luedtke, R. R. 
Synthesis of 2-(5-Bromo-2,3-dimethoxyphenyl)-5-(aminomethyl)-1H-pyrrole 
analogues and their binding affinities for dopamine D2, D3, and D4 receptors. 
Bioorg. Med. Chem. 2003, 11, 225-233. 
(259) Huang, Y.; Luedtke, R. R.; Freeman, R. A.; Wu, L.; Mach, R. H. Synthesis and 
Structure−Activity Relationships of Naphthamides as Dopamine D3 Receptor 
Ligands. J. Med. Chem. 2001, 44, 1815-1826. 
(260) Xu, R.; Lever, J. R.; Lever, S. Z. Synthesis and in vitro evaluation of 
tetrahydroisoquinolinyl benzamides as ligands for σ receptors. Bioorg. Med. 
Chem. Lett. 2007, 17, 2594-2597. 
(261) Abate, C.; Ferorelli, S.; Contino, M.; Marottoli, R.; Colabufo, N. A.; Perrone, R.; 
Berardi, F. Arylamides hybrids of two high-affinity σ2 receptor ligands as tools 
for the development of PET radiotracers. Eur. J. Med. Chem. 2011, 46, 4733-
4741. 
(262) Berardi, F.; Abate, C.; Ferorelli, S.; Uricchio, V.; Colabufo, N. A.; Niso, M.; 
Perrone, R. Exploring the Importance of Piperazine N-Atoms for σ2Receptor 
Affinity and Activity in a Series of Analogs of 1-Cyclohexyl-4-[3-(5-methoxy-
1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28). J. Med. Chem. 2009, 
52, 7817-7828. 
(263) Hodges, T. R. Development of Norbenzomorphan Derived Sigma 2 Receptor 
Ligands and the Synthesis of (±) Gliocladin C and Related 
Epipolythiodiketopiperazine Alkaloids. The Univeristy of Texas at Austin 
Dissertation, 2016. 
(264) Morgenthaler, M.; Schweizer, E.; Hoffmann-Röder, A.; Benini, F.; Martin, R. E.; 
Jaeschke, G.; Wagner, B.; Fischer, H.; Bendels, S.; Zimmerli, D.; Schneider, J.; 
Diederich, F.; Kansy, M.; Müller, K. Predicting and Tuning Physicochemical 
Properties in Lead Optimization: Amine Basicities. ChemMedChem 2007, 2, 
1100-1115. 
 522 
(265) O'Brien, R. J.; Wong, P. C. Amyloid Precursor Protein Processing and 
Alzheimer's Disease. Annual. Rev. Neurosci, 2011, 34, 185-204. 
(266) Hulme, S. E.; Whitesides, G. M. Chemistry and the Worm: Caenorhabditis 
elegans as a Platform for Integrating Chemical and Biological Research.  Angew. 
Chem. Int. Ed. 2011, 50, 4774-4807. 
(267) Runko, E. Caenorhabditis elegans VEM-1, a Novel Membrane Protein, Regulates 
the Guidance of Ventral Nerve Cord-Associated Axons. J. Neurosci. 2004, 24, 
9015-9026. 
(268) Colloca, L.; Ludman, T.; Bouhassira, D.; Baron, R.; Dickenson, A. H.; Yarnitsky, 
D.; Freeman, R.; Truini, A.; Attal, N.; Finnerup, N. B.; Eccleston, C.; Kalso, E.; 
Bennett, D. L.; Dworkin, R. H.; Raja, S. N. Neuropathic pain. Nat. Rev. Dis. 
Primers 2017, 3, 17002. 
(269) Finnerup, N. B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R. 
H.; Gilron, I.; Haanpää, M.; Hansson, P.; Jensen, T. S.; Kamerman, P. R.; Lund, 
K.; Moore, A.; Raja, S. N.; Rice, A. S. C.; Rowbotham, M.; Sena, E.; Siddall, P.; 
Smith, B. H.; Wallace, M. Pharmacotherapy for neuropathic pain in adults: a 
systematic review and meta-analysis. Lancet Neurol. 2015, 14, 162-173. 
(270) Gris, G.; Portillo-Salido, E.; Aubel, B.; Darbaky, Y.; Deseure, K.; Vela, J. M.; 
Merlos, M.; Zamanillo, D. The selective sigma-1 receptor antagonist E-52862 
attenuates neuropathic pain of different aetiology in rats. Sci. Rep. 2016, 6, 24591. 
(271) Decosterd, I.; Woolf, C. J. Spared nerve injury: an animal model of persistent 
peripheral neuropathic pain. Pain 2000, 87, 149-158. 
(272) Werner, C.; Engelhard, K. Pathophysiology of traumatic brain injury. Br. J. 
Anaesth. 2007, 99, 4-9. 
(273) Corrigan, J. D.; Selassie, A. W.; Orman, J. A. The Epidemiology of Traumatic 
Brain Injury. J. Head Trauma Rehabil. 2010, 25, 72-80. 
(274) Roozenbeek, B.; Lingsma, H. F.; Maas, A. I. New considerations in the design of 
clinical trials for traumatic brain injury. Clin. Investig. 2012, 2, 153-162. 
(275) Yin, T. C.; Voorhees, J. R.; Genova, R. M.; Davis, K. C.; Madison, A. M.; Britt, 
J. K.; Cintrón-Pérez, C. J.; McDaniel, L.; Harper, M. M.; Pieper, A. A. Acute 
Axonal Degeneration Drives Development of Cognitive, Motor, and Visual 
Deficits after Blast-Mediated Traumatic Brain Injury in Mice. eneuro 2016, 3, 
ENEURO.0220-0216. 
(276) Osier, N.; Dixon, C. Mini Review of Controlled Cortical Impact: A Well-Suited 
Device for Concussion Research. Brain Sci. 2017, 7, 88. 
(277) Anton, R. F.; O’Malley, S. S.; Ciraulo, D. A.; Cisler, R. A.; Couper, D.; Donovan, 
D. M.; Gastfriend, D. R.; Hosking, J. D.; Johnson, B. A.; Locastro, J. S.; 
Longabaugh, R.; Mason, B. J.; Mattson, M. E.; Miller, W. R.; Pettinati, H. M.; 
 523 
Randall, C. L.; Swift, R.; Weiss, R. D.; Williams, L. D.; Zweben, A.; Combine 
Study Research Group, F. T. Combined Pharmacotherapies and Behavioral 
Interventions for Alcohol Dependence. JAMA 2006, 295, 2003. 
(278) Mann, K.; Lehert, P.; Morgan, M. Y. The Efficacy of Acamprosate in the 
Maintenance of Abstinence in Alcohol-Dependent Individuals: Results of a Meta-
Analysis. Alcohol Clin. Exp. Res. 2004, 28, 51-63. 
(279) Koob, G. F.; Roberts, A. J.; Schulteis, G.; Parsons, L. H.; Heyser, C. J.; Hyytia, 
P.; Merlo-Pich, E.; Weiss, F. Neurocircuitry Targets in Ethanol Reward and 
Dependence. Alcohol Clin. Exp. Res. 1998, 22, 3-9. 
(280) Winward, J. L.; Bekman, N. M.; Hanson, K. L.; Lejuez, C. W.; Brown, S. A. 
Changes in Emotional Reactivity and Distress Tolerance Among Heavy Drinking 
Adolescents During Sustained Abstinence. Alcohol Clin. Exp. Res. 2014, 38, 
1761-1769. 
(281) Garcés-Ramírez, L.; Green, J. L.; Hiranita, T.; Kopajtic, T. A.; Mereu, M.; 
Thomas, A. M.; Mesangeau, C.; Narayanan, S.; McCurdy, C. R.; Katz, J. L.; 
Tanda, G. Sigma Receptor Agonists: Receptor Binding and Effects on 
Mesolimbic Dopamine Neurotransmission Assessed by Microdialysis. Biol. 
Psychiatry 2011, 69, 208-217. 
(282) Klawonn, A. M.; Nilsson, A.; Radberg, C. F.; Lindstrom, S. H.; Ericson, M.; 
Granseth, B.; Engblom, D.; Fritz, M. The Sigma-2 Receptor Selective Agonist 
Siramesine (Lu 28-179) Decreases Cocaine-Reinforced Pavlovian Learning and 
Alters Glutamatergic and Dopaminergic Input to the Striatum. Front. Pharmacol. 
2017, 8. 
(283) Mitchell, P.; Mould, R.; Dillon, J.; Glautier, S.; Andrianakis, I.; James, C.; Pugh, 
A.; Holden-Dye, L.; O'Connor, V. A Differential Role for Neuropeptides in Acute 
and Chronic Adaptive Responses to Alcohol: Behavioural and Genetic Analysis 
in Caenorhabditis elegans. PLoS ONE 2010, 5, e10422. 
(284) Scott, L. L.; Davis, S. J.; Yen, R. C.; Ordemann, G. J.; Nordquist, S. K.; Bannai, 
D.; Pierce, J. T. Behavioral Deficits Following Withdrawal from Chronic Ethanol 
Are Influenced by SLO Channel Function inCaenorhabditis elegans. Genetics 
2017, 206, 1445-1458. 
(285) Grotewiel, M.; Bettinger, J. C. DrosophilaandCaenorhabditis elegansas Discovery 
Platforms for Genes Involved in Human Alcohol Use Disorder. Alcohol Clin. Exp. 
Res. 2015, 39, 1292-1311. 
(286) Sabino, V.; Cottone, P.; Zhao, Y.; Iyer, M. R.; Steardo, L.; Steardo, L.; Rice, K. 
C.; Conti, B.; Koob, G. F.; Zorrilla, E. P. The σ-Receptor Antagonist BD-1063 
Decreases Ethanol Intake and Reinforcement in Animal Models of Excessive 
Drinking. Neuropsychopharmacology 2009, 34, 1482-1493. 
 524 
(287) Walters, W. P.; Green, J.; Weiss, J. R.; Murcko, M. A. What Do Medicinal 
Chemists Actually Make? A 50-Year Retrospective. J. Med. Chem. 2011, 54, 
6405-6416. 
(288) Wang, S.; Dong, G.; Sheng, C. Structural simplification: an efficient strategy in 
lead optimization. Acta Pharma. Sin. B 2019, 9, 880-901. 
(289) Zhao, H. Scaffold selection and scaffold hopping in lead generation: a medicinal 
chemistry perspective. Drug Discov. Today 2007, 12, 149-155. 
(290) Jarrige, L.; Carboni, A.; Dagousset, G.; Levitre, G.; Magnier, E.; Masson, G. 
Photoredox-Catalyzed Three-Component Tandem Process: An Assembly of 
Complex Trifluoromethylated Phthalans and Isoindolines. Org. Lett. 2016, 18, 
2906-2909. 
(291) Molander, G. A.; Rivero, M. R. Suzuki Cross-Coupling Reactions of Potassium 
Alkenyltrifluoroborates. Org. Lett. 2002, 4, 107-109. 
(292) Lee, J.; Kim, H. Y.; Oh, K. Tandem Reaction Approaches to Isoquinolones from 
2-Vinylbenzaldehydes and Anilines via Imine Formation–6π-Electrocyclization–
Aerobic Oxidation Sequence. Org. Lett. 2020, 22, 474-478. 
(293) Yung-Chi, C.; Prusoff, W. H. Relationship between the inhibition constant (KI) 
and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an 
enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108. 
(294) Cornelius, L. A. M.; Combs, D. W. A Convenient Synthesis of Mono- and 
Polyhalogenated Benzocyclanones. Synthetic Commun. 1994, 24, 2777-2788. 
(295) Neidigh, K. A.; Avery, M. A.; Williamson, J. S.; Bhattacharyya, S. Facile 
preparation of N-methyl secondary amines by titanium(IV) isopropoxide-
mediated reductive amination of carbonyl compounds. J. Chem. Soc. Perkin 
Trans. 1 1998, 2527-2532. 
(296) Surry, D. S.; Buchwald, S. L. Dialkylbiaryl phosphines in Pd-catalyzed 
amination: a user's guide. Chem. Sci. 2011, 2, 27-50. 
(297) Harris, M. C.; Huang, X.; Buchwald, S. L. Improved Functional Group 
Compatibility in the Palladium-Catalyzed Synthesis of Aryl Amines. Org. Lett. 
2002, 4, 2885-2888. 
(298) Meanwell, N. A. Improving Drug Design: An Update on Recent Applications of 
Efficiency Metrics, Strategies for Replacing Problematic Elements, and 
Compounds in Nontraditional Drug Space. Chem. Res. Toxicol. 2016, 29, 564-
616. 
(299) Hann, M. M. Molecular obesity, potency and other addictions in drug discovery. 
MedChemComm 2011, 2, 349. 
 525 
(300) Hann, M. M.; Keserü, G. M. Finding the sweet spot: the role of nature and nurture 
in medicinal chemistry. Nat. Rev. Drug Discov. 2012, 11, 355-365. 
(301) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 
computational approaches to estimate solubility and permeability in drug 
discovery and development settings. Adv. Drug Deliv. Rev. 1997, 23, 3-25. 
(302) Gleeson, M. P. Generation of a Set of Simple, Interpretable ADMET Rules of 
Thumb. J. Med. Chem. 2008, 51, 817-834. 
(303) Waring, M. J.; Johnstone, C. A quantitative assessment of hERG liability as a 
function of lipophilicity. Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764. 
(304) Puetzer, B.; Katz, L.; Horwitz, L. Preparatory Method for N-Vinyl-2-pyrrolidone. 
J. Am. Chem. Soc. 1952, 74, 4959-4960. 
(305) Meanwell, N. A. Synopsis of Some Recent Tactical Application of Bioisosteres in 
Drug Design. J. Med. Chem. 2011, 54, 2529-2591. 
(306) Yang, X.; Liu, G.; Li, H.; Zhang, Y.; Song, D.; Li, C.; Wang, R.; Liu, B.; Liang, 
W.; Jing, Y.; Zhao, G. Novel Oxadiazole Analogues Derived from Ethacrynic 
Acid: Design, Synthesis, and Structure−Activity Relationships in Inhibiting the 
Activity of GlutathioneS-Transferase P1-1 and Cancer Cell Proliferation. J. Med. 
Chem. 2010, 53, 1015-1022. 
(307) Chiou, S.; Shine, H. J. A simplified procedure for preparing 3,5-disubstituted-
1,2,4-oxadiazoles by reaction of amidoximes with Acyl chlorides in pyridine 
solution. J. Heterocycl. Chem. 1989, 26, 125-128. 
(308) Borg, S.; Estenne-Bouhtou, G.; Luthman, K.; Csoeregh, I.; Hesselink, W.; 
Hacksell, U. Synthesis of 1,2,4-Oxadiazole-, 1,3,4-Oxadiazole-, and 1,2,4-
Triazole-Derived Dipeptidomimetics. J. Org. Chem. 1995, 60, 3112-3120. 
(309) Gangloff, A. R.; Litvak, J.; Shelton, E. J.; Sperandio, D.; Wang, V. R.; Rice, K. 
D. Synthesis of 3,5-disubstituted-1,2,4-oxadiazoles using tetrabutylammonium 
fluoride as a mild and efficient catalyst. Tetrahedron Lett. 2001, 42, 1441-1443. 
(310) Fortuna, C. G.; Bonaccorso, C.; Bulbarelli, A.; Caltabiano, G.; Rizzi, L.; Goracci, 
L.; Musumarra, G.; Pace, A.; Palumbo Piccionello, A.; Guarcello, A.; Pierro, P.; 
Cocuzza, C. E. A.; Musumeci, R. New linezolid-like 1,2,4-oxadiazoles active 
against Gram-positive multiresistant pathogens. Eur. J. Med. Chem. 2013, 65, 
533-545. 
(311) Amarasinghe, K. K. D.; Maier, M. B.; Srivastava, A.; Gray, J. L. One-pot 
synthesis of 1,2,4-oxadiazoles from carboxylic acid esters and amidoximes using 
potassium carbonate. Tetrahedron Lett. 2006, 47, 3629-3631. 
(312) Iyer, V. B.; Gurupadayya, B.; Koganti, V. S.; Inturi, B.; Chandan, R. S. Design, 
synthesis and biological evaluation of 1,3,4-oxadiazoles as promising anti-
inflammatory agents. Med. Chem. Res. 2017, 26, 190-204. 
 526 
(313) Hagishita, S.; Kuriyama, K. Confirmation of the Sector Rule of the Benzenoid 
Chromophore. Bull. Chem. Soc. Jpn. 1982, 55, 3216-3224. 
(314) Morin, F. G.; Horton, W. J.; Grant, D. M.; Dalling, D. K.; Pugmire, R. J. Carbon-
13 magnetic resonance of hydroaromatics. II. Conformation of Tetralin and 
tetrahydroanthracene and their methyl derivatives. J. Am. Chem. Soc. 1983, 105, 
3992-3998. 
(315) Gearien, J. E.; Liska, K. J. Synthetic Oxytocics. Derivatives of N-2-
Naphthylglycine and N-2-Naphthyl-β-alanine 1,2. J. Am. Chem. Soc. 1954, 76, 
3554-3555. 
(316) Fogassy, E.; Nogradi, M.; Kozma, D.; Egri, G.; Palovics, E.; Kiss, V. Optical 
resolution methods. Org. Biomol. Chem. 2006, 4, 3011-3030. 
(317) Welch, W. M.; Williams, M. T. Synthesis of 7-H-3-(1s,4s)-4-(3,4-
Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-L-Naphthalenamine 
Hydrochloride (7-H-3-Sertraline). J. Labelled Compd. Rad. 1993, 33, 119-125. 
(318) 2020 Alzheimer's disease facts and figures. Alzheimer's Dement. 2020, 16, 391-
460. 
(319) Hardy, J. The Amyloid Hypothesis of Alzheimer's Disease: Progress and 
Problems on the Road to Therapeutics. Science 2002, 297, 353-356. 
(320) Takahashi, R. H.; Capetillo-Zarate, E.; Lin, M. T.; Milner, T. A.; Gouras, G. K. 
Co-occurrence of Alzheimer's disease β-amyloid and tau pathologies at synapses. 
Neurobiol. Aging 2010, 31, 1145-1152. 
(321) Zhang, Z.-G.; Li, Y.; Ng, C. T.; Song, Y.-Q. Inflammation in Alzheimer’s 
Disease and Molecular Genetics: Recent Update. Arch. Immunol. Ther. Exp. 
2015, 63, 333-344. 
(322) Sly, L. M.; Krzesicki, R. F.; Brashler, J. R.; Buhl, A. E.; McKinley, D. D.; Carter, 
D. B.; Chin, J. E. Endogenous brain cytokine mRNA and inflammatory responses 
to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of 
Alzheimer’s disease. Brain Res. Bull. 2001, 56, 581-588. 
(323) Shaftel, S. S.; Griffin, W. S. T.; O'Banion, M. K. The role of interleukin-1 in 
neuroinflammation and Alzheimer disease: an evolving perspective. J. 
Neuroinflamm. 2008, 5. 
(324) Oakley, H.; Cole, S. L.; Logan, S.; Maus, E.; Shao, P.; Craft, J.; Guillozet-
Bongaarts, A.; Ohno, M.; Disterhoft, J.; Van Eldik, L.; Berry, R.; Vassar, R. 
Intraneuronal beta-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in 
Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential 
Factors in Amyloid Plaque Formation. J. Neurosci. 2006, 26, 10129-10140. 
 527 
(325) Karran, E.; Mercken, M.; Strooper, B. D. The amyloid cascade hypothesis for 
Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. 
Drug Discov. 2011, 10, 698-712. 
(326) Ricciarelli, R.; Fedele, E. The Amyloid Cascade Hypothesis in Alzheimer’s 
Disease: It’s Time to Change Our Mind. Curr. Neuropharmacol. 2017, 15. 
(327) Ferreira, S. T.; Lourenco, M. V.; Oliveira, M. M.; De Felice, F. G. Soluble 
amyloid- b oligomers as synaptotoxins leading to cognitive impairment in 
Alzheimer's disease. Front. Cell. Neurosci. 2015, 9. 
(328) Walsh, D. M.; Selkoe, D. J. A beta Oligomers–a decade of discovery. J. 
Neurochem. 2007, 101, 1172-1184. 
(329) Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; 
Troutman, M. D.; de Morais, S. M. In vitro P-glycoprotein assays to predict the in 
vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug 
Metab. Dispos. 2008, 36, 268-275. 
(330) Wager, T. T.; Chandrasekaran, R. Y.; Hou, X. J.; Troutman, M. D.; Verhoest, P. 
R.; Villalobos, A.; Will, Y. Defining Desirable Central Nervous System Drug 
Space through the Alignment of Molecular Properties, in Vitro ADME, and 
Safety Attributes. ACS Chem. Neurosci. 2010, 1, 420-434. 
(331) BlumDegen, D.; Muller, T.; Kuhn, W.; Gerlach, M.; Przuntek, H.; Riederer, P. 
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of 
Alzheimer's and de novo Parkinson's disease patients. Neuroscience Lett. 1995, 
202, 17-20. 
(332) Memar Ardestani, P.; K. Evans, A.; Bitna Yi; Tiffany Nguyen; 
Laurence Coutellier; Mehrdad Shamloo. Modulation of neuroinflammation and 
pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and 
selective beta-1 adrenergic receptor partial agonist. Neuropharmacology 2017, 
116, 371-386. 
(333) Pekny, M.; Pekna, M. Reactive gliosis in the pathogenesis of CNS diseases. 
Biochim. Biophys. Acta 2016, 1862, 483-491. 
(334) Burda, J. E.; Sofroniew, M. V. Reactive Gliosis and the Multicellular Response to 
CNS Damage and Disease. Neuron 2014, 81, 229-248. 
(335) Xiao, X.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Design, 
synthesis, and biological evaluation of cytotoxic 11-
aminoalkenylindenoisoquinoline and 11-diaminoalkenylindenoisoquinoline 
topoisomerase I inhibitors. Bioorg. Med. Chem. 2004, 12, 5147-5160. 
(336) Osada, S.; Sano, S.; Ueyama, M.; Chuman, Y.; Kodama, H.; Sakaguchi, K. 
Fluoroalkene modification of mercaptoacetamide-based histone deacetylase 
inhibitors. Bioorg. Med. Chem. 2010, 18, 605-611. 
 528 
(337) Kane, B. E.; Grant, M. K. O.; El-Fakahany, E. E.; Ferguson, D. M. Synthesis and 
evaluation of xanomeline analogs - Probing the wash-resistant phenomenon at the 
M-1 muscarinic acetylcholine receptor. Bioorg. Med. Chem. 2008, 16, 1376-1392. 
(338) Amatore, M.; Beeson, T. D.; Brown, S. P.; Macmillan, D. W. C. Enantioselective 
Linchpin Catalysis by SOMO Catalysis: An Approach to the Asymmetric α-
Chlorination of Aldehydes and Terminal Epoxide Formation.  Angew. Chem. Int. 
Ed. 2009, 48, 5121-5124. 
(339) Kong, F.; Morais, G. R.; Falconer, R. A.; Sutton, C. W. An optimized method for 
the synthesis of amino-functionalized phosphatidylcholine. Tetrahedron Lett. 
2012, 53, 546-549. 
(340) Morrell, A.; Placzek, M. S.; Steffen, J. D.; Antony, S.; Agama, K.; Pommier, Y.; 
Cushman, M. Investigation of the Lactam Side Chain Length Necessary for 
Optimal Indenoisoquinoline Topoisomerase I Inhibition and Cytotoxicity in 
Human Cancer Cell Cultures. J. Med. Chem. 2007, 50, 2040-2048. 
(341) Braun, M.; Hartnagel, U.; Ravanelli, E.; Schade, B.; Böttcher, C.; Vostrowsky, 
O.; Hirsch, A. Amphiphilic [5:1]- and [3:3]-Hexakisadducts of C60. Eur. J. Org. 
Chem. 2004, 1983-2001. 
(342) Kakumani, P. K.; Malhotra, P.; Mukherjee, S. K.; Bhatnagar, R. K. A draft 
genome assembly of the army worm, Spodoptera frugiperda. Genomics 2014, 
104, 134-143. 
(343) Micah; Kenneth; Armand; Bruno; Ichu, T.-A.; Olucha, J.; Steven; Kundu, S.; 
Piscitelli, F.; Rosen, H.; Benjamin. A Global Map of Lipid-Binding Proteins and 
Their Ligandability in Cells. Cell 2015, 161, 1668-1680. 
(344) Murphy, M.; Pykett, M. J.; Harnish, P.; Zang, K. D.; George, D. L. Identification 
and Characterization of Genes Differentially Expressed in Meningiomas. Cell 
Growth Differ. 1993, 4, 715-722. 
(345) Xu, X.-Y.; Zhang, L.-J.; Yu, Y.-Q.; Zhang, X.-T.; Huang, W.-J.; Nie, X.-C.; 
Song, G.-Q. Down-Regulated MAC30 Expression Inhibits Proliferation and 
Mobility of Human Gastric Cancer Cells. Cell Physol. Biochem. 2014, 33, 1359-
1368. 
(346) Kayed, H.; Kleeff, J.; Ding, J.; Hammer, J.; Giese, T.; Zentgraf, H.; Buchler, M. 
W.; Friess, H. Expression analysis of MAC30 in human pancreatic cancer and 
tumors of the gastrointestinal tract. Histol. Histopathol. 2004, 19, 1021-1031. 
(347) Xiao, M.; Li, H.; Yang, S.; Huang, Y.; Jia, S.; Wang, H.; Wang, J.; Li, Z. 
Expression of MAC30 protein is related to survival and clinicopathological 
variables in breast cancer. J. Surg. Oncol. 2013, 107, 456-462. 
 529 
(348) Moparthi, S.; Arbman, G.; Wallin, Å.; Kayed, H.; Kleeff, J.; Zentgraf, H.; Sun, 
X.-F. Expression of MAC30 protein is related to survival and biological variables 
in primary and metastatic colorectal cancers. Int. J. Oncol. 2007. 
(349) Zhao, Z.-R.; Zhang, L.-J.; He, X.-Q.; Zhang, Z.-Y.; Zhang, F.; Li, F.; Pei, Y.-B.; 
Hu, Y.-M.; Wang, M.-W.; Sun, X.-F. Significance of mRNA and Protein 
Expression of MAC30 in Progression of Colorectal Cancer. Chemotherapy 2011, 
57, 394-401. 
(350) Han, K.-Y.; Gu, X.; Wang, H.-R.; Liu, D.; Lv, F.-Z.; Li, J.-N. Overexpression of 
MAC30 is associated with poor clinical outcome in human non-small-cell lung 
cancer. Tumor Biol. 2013, 34, 821-825. 
(351) Bartz, F.; Kern, L.; Erz, D.; Zhu, M.; Gilbert, D.; Meinhof, T.; Wirkner, U.; Erfle, 
H.; Muckenthaler, M.; Pepperkok, R.; Runz, H. Identification of Cholesterol-
Regulating Genes by Targeted RNAi Screening. Cell Metab. 2009, 10, 63-75. 
(352) Ebrahimi-Fakhari, D.; Wahlster, L.; Bartz, F.; Werenbeck-Ueding, J.; Praggastis, 
M.; Zhang, J.; Joggerst-Thomalla, B.; Theiss, S.; Grimm, D.; Ory, D. S.; Runz, H. 
Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol 
trafficking in Niemann-pick type C1 disease cells. Human Mol. Genet. 2016, 25, 
3588-3599. 
(353) Moebius, F. F.; Striessnig, J.; Glossmann, H. The mysteries of sigma receptors: 
new family members reveal a role in cholesterol synthesis. Trends Pharmacol. 
Sci.  1997, 18, 67-70. 
(354) Hayashi, T.; Su, T.-P.: Cholesterol at the Endoplasmic Reticulum: Roles of the 
Sigma-1 Receptor Chaperone and Implications thereof in Human Diseases. In 
Cholesterol Binding and Cholesterol Transport Proteins: Structure and Function 
in Health and Disease; Harris, J. R., Ed.; Springer Netherlands: Dordrecht, 2010; 
pp 381-398. 
(355) Hopf, T. A.; Scharfe, C. P. I.; Rodrigues, J. P. G. L. M.; Green, A. G.; 
Kohlbacher, O.; Sander, C.; Bonvin, A. M. J. J.; Marks, D. S. Sequence co-
evolution gives 3D contacts and structures of protein complexes. Elife 2014, 3. 
(356) Riad, A.; Zeng, C.; Weng, C.-C.; Winters, H.; Xu, K.; Makvandi, M.; Metz, T.; 
Carlin, S.; Mach, R. H. Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the 
Rate of Internalization of LDL by LDL Receptor through the Formation of a 
Ternary Complex. Sci. Rep. 2018, 8. 
(357) Riad, A.; Lengyel-Zhand, Z.; Zeng, C.; Weng, C.-C.; Lee, V. M. Y.; Trojanowski, 
J. Q.; Mach, R. H. The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL 
Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its 
Protein Aggregates. Mol. Neurobiol. 2020. 
 530 
(358) Gan, L.; Cookson, M. R.; Petrucelli, L.; La Spada, A. R. Converging pathways in 
neurodegeneration, from genetics to mechanisms. Nat. Neurosci. 2018, 21, 1300-
1309. 
(359) Duncan, T.; Valenzuela, M. Alzheimer’s disease, dementia, and stem cell therapy. 
Stem Cell Res. Ther. 2017, 8, 111. 
(360) Johnson, T. C.; Siegel, D. Directing Stem Cell Fate: The Synthetic Natural 
Product Connection. Chem. Rev. 2017, 117, 12052-12086. 
(361) Wilson, R. M.; Danishefsky, S. J. Applications of Total Synthesis to Problems in 
Neurodegeneration:  Fascinating Chemistry along the Way. Acc. Chem. Res. 
2006, 39, 539-549. 
(362) Yang, X.-W.; Yang, C.-P.; Jiang, L.-P.; Qin, X.-J.; Liu, Y.-P.; Shen, Q.-S.; Chen, 
Y.-B.; Luo, X.-D. Indole Alkaloids with New Skeleton Activating Neural Stem 
Cells. Org. Lett. 2014, 16, 5808-5811. 
(363) Bihelovic, F.; Ferjancic, Z. Total Synthesis of (±)-Alstoscholarisine A.  Angew. 
Chem. Int. Ed. 2016, 55, 2569-2572. 
(364) Liang, X.; Jiang, S.-Z.; Wei, K.; Yang, Y.-R. Enantioselective Total Synthesis of 
(−)-Alstoscholarisine A. J. Am. Chem. Soc. 2016, 138, 2560-2562. 
(365) Mason, J. D.; Weinreb, S. M. Total Syntheses of the Monoterpenoid Indole 
Alkaloids (±)-Alstoscholarisine B and C.  Angew. Chem. Int. Ed. 2017, 56, 
16674-16676. 
(366) Mason, J. D.; Weinreb, S. M. Synthesis of Alstoscholarisines A–E, Monoterpene 
Indole Alkaloids with Modulating Effects on Neural Stem Cells. J. Org. Chem. 
2018, 83, 5877-5896. 
(367) Hu, L.; Li, Q.; Yao, L.; Xu, B.; Wang, X.; Liao, X. Enantioselective and 
Divergent Syntheses of Alstoscholarisines A, E and Their Enantiomers. Org. Lett. 
2018, 20, 6202-6205. 
(368) Reyes-Gutiérrez, P. E.; Torres-Ochoa, R. O.; Martínez, R.; Miranda, L. D. 
Synthesis of azepino[4,5-b]indolones via an intermolecular radical oxidative 
substitution of N-Boc tryptamine. Org. Biomol. Chem. 2009, 7, 1388. 
(369) Blechert, S.; Knier, R.; Schroers, H.; Wirth, T. Domino Reactions - New 
Concepts in the Synthesis of Indole Alkaloids and Other Polycyclic Indole 
Derivatives. Synthesis 1995, 1995, 592-604. 
(370) Helmboldt, H.; Aho, J. E.; Pihko, P. M. Synthetic Studies Toward Pectenotoxin 2. 
Part II. Synthesis of the CDE and CDEF Ring Systems. Org. Lett. 2008, 10, 4183-
4185. 
 531 
(371) Schafroth, M. A.; Sarlah, D.; Krautwald, S.; Carreira, E. M. Iridium-Catalyzed 
Enantioselective Polyene Cyclization. J. Am. Chem. Soc. 2012, 134, 20276-
20278. 
(372) Tlais, S. F.; Danheiser, R. L. N-Tosyl-3-Azacyclohexyne. Synthesis and 
Chemistry of a Strained Cyclic Ynamide. J. Am. Chem. Soc. 2014, 136, 15489-
15492. 
(373) Hanessian, S.; Giroux, S.; Larsson, A. Efficient Allyl to Propenyl Isomerization in 
Functionally Diverse Compounds with a Thermally Modified Grubbs Second-
Generation Catalyst. Org. Lett. 2006, 8, 5481-5484. 
(374) Villar, I. S. D.; Gradillas, A.; Domínguez, G.; Pérez-Castells, J. Nitrogen ylide-
mediated cyclopropanation of lactams and lactones. Tetrahedron Lett. 2010, 51, 
3095-3098. 
(375) Dou, X.; Huang, Y.; Hayashi, T. Asymmetric Conjugate Alkynylation of Cyclic 
α,β-Unsaturated Carbonyl Compounds with a Chiral Diene Rhodium Catalyst. 
Angew. Chem. Int. Ed. 2016, 55, 1133-1137. 
(376) Trost, B. M.; Rhee, Y. H. A Rh(I)-Catalyzed Cycloisomerization of Homo- and 
Bis-homopropargylic Alcohols. J. Am. Chem. Soc. 2003, 125, 7482-7483. 
(377) Dharuman, S.; Vankar, Y. D. N-Halosuccinimide/AgNO3-Efficient Reagent 
Systems for One-Step Synthesis of 2-Haloglycals from Glycals: Application in 
the Synthesis of 2C-Branched Sugars via Heck Coupling Reactions. Org. Lett. 
2014, 16, 1172-1175. 
(378) Cox, P. A.; Leach, A. G.; Campbell, A. D.; Lloyd-Jones, G. C. Protodeboronation 
of Heteroaromatic, Vinyl, and Cyclopropyl Boronic Acids: pH–Rate Profiles, 
Autocatalysis, and Disproportionation. J. Am. Chem. Soc. 2016, 138, 9145-9157. 
(379) Kinzel, T.; Zhang, Y.; Buchwald, S. L. A New Palladium Precatalyst Allows for 
the Fast Suzuki−Miyaura Coupling Reactions of Unstable Polyfluorophenyl and 
2-Heteroaryl Boronic Acids. J. Am. Chem. Soc. 2010, 132, 14073-14075. 
(380) Düfert, M. A.; Billingsley, K. L.; Buchwald, S. L. Suzuki-Miyaura Cross-
Coupling of Unprotected, Nitrogen-Rich Heterocycles: Substrate Scope and 
Mechanistic Investigation. J. Am. Chem. Soc. 2013, 135, 12877-12885. 
(381) Medley, J. W.; Movassaghi, M. A Concise and Versatile Double-Cyclization 
Strategy for the Highly Stereoselective Synthesis and Arylative Dimerization of 
Aspidosperma Alkaloids. Angew. Chem. Int. Ed. 2012, 51, 4572-4576. 
(382) Klosowski, D. W. Applications of Enantioselective Halolactonization Reactions, 
Synthesis of Photocaged Compounds for Identifying Neurons Based on Function, 
and Progress Towards the Total Synthesis of Alstoscholarisine E. The University 
of Texas at Austin Dissertation, 2018. 
 532 
(383) Wood, M. D.; Klosowski, D. W.; Martin, S. F. Stereoselective Total Synthesis of 
(±)-Alstoscholarisine E. Org. Lett. 2020, 22, 786-790. 
(384) Martin, S. F.; Li, W. Applications of intramolecular Diels-Alder reactions to 
alkaloid synthesis. A formal total synthesis of (.+-.)-dendrobine. J. Org. Chem. 
1991, 56, 642-650. 
(385) Ito, M.; Clark, C. W.; Mortimore, M.; Goh, J. B.; Martin, S. F. Biogenetically 
Inspired Approach to the Strychnos Alkaloids. Concise Syntheses of (±)-
Akuammicine and (±)-Strychnine. J. Am. Chem. Soc. 2001, 123, 8003-8010. 
(386) Fu, T.-H.; McElroy, W. T.; Shamszad, M.; Heidebrecht, R. W.; Gulledge, B.; 
Martin, S. F. Studies toward welwitindolinones: formal syntheses of N-
methylwelwitindolinone C isothiocyanate and related natural products. 
Tetrahedron 2013, 69, 5588-5603. 
(387) Granger, B. A.; Jewett, I. T.; Butler, J. D.; Hua, B.; Knezevic, C. E.; Parkinson, E. 
I.; Hergenrother, P. J.; Martin, S. F. Synthesis of (±)-Actinophyllic Acid and 
Analogs: Applications of Cascade Reactions and Diverted Total Synthesis. J. Am. 
Chem. Soc. 2013, 135, 12984-12986. 
(388) Bian, Z.; Marvin, C. C.; Martin, S. F. Enantioselective Total Synthesis of (−)-
Citrinadin A and Revision of Its Stereochemical Structure. J. Am. Chem. Soc. 
2013, 135, 10886-10889. 
(389) Martin, S. F.; Benage, B.; Williamson, S. A.; Brown, S. P. Applications of the 
intramolecular Diels-Alder reactions of heterodienes to the syntheses of indole 
alkaloids. Tetrahedron 1986, 42, 2903-2910. 
(390) Martin, S. F.; Clark, C. W.; Ito, M.; Mortimore, M. A Biomimetic Approach to 
the Strychnos Alkaloids. A Novel, Concise Synthesis of (±)-Akuammicine and a 
Route to (±)-Strychnine. J. Am. Chem. Soc. 1996, 118, 9804-9805. 
(391) Deiters, A.; Chen, K.; Eary, C. T.; Martin, S. F. Biomimetic Entry to the Sarpagan 
Family of Indole Alkaloids:  Total Synthesis of (+)-Geissoschizine and (+)-N-
Methylvellosimine. J. Am. Chem. Soc. 2003, 125, 4541-4550. 
(392) Martin, S. F.; Chen, K. X.; Eary, C. T. An Enantioselective Total Synthesis of 
(+)-Geissoschizine†. Org. Lett. 1999, 1, 79-82. 
(393) Martin, S. F.; Humphrey, J. M.; Ali, A.; Hillier, M. C. Enantioselective Total 
Syntheses of Ircinal A and Related Manzamine Alkaloids. J. Am. Chem. Soc. 
1999, 121, 866-867. 
(394) Humphrey, J. M.; Liao, Y.; Ali, A.; Rein, T.; Wong, Y.-L.; Chen, H.-J.; Courtney, 
A. K.; Martin, S. F. Enantioselective Total Syntheses of Manzamine A and 
Related Alkaloids. J. Am. Chem. Soc. 2002, 124, 8584-8592. 
(395) Desimoni, G.; Tacconi, G. Heterodiene syntheses with .alpha.,.beta.-unsaturated 
carbonyl compounds. Chem. Rev. 1975, 75, 651-692. 
 533 
(396) Tantillo, D. J.; Houk, K. N.; Jung, M. E. Origins of Stereoselectivity in 
Intramolecular Diels−Alder Cycloadditions of Dienes and Dienophiles Linked by 
Ester and Amide Tethers. J. Org. Chem. 2001, 66, 1938-1940. 
(397) Gronowitz, S.; Lidert, Z. A Convenient Synthesis of N-Substituted N-
Chloromethyl Carboxamides. Synthesis 1979, 1979, 810-810. 
(398) Amoroso, R.; Cardillo, G.; Tomasini, C.; Tortoreto, P. A new route to the 
synthesis of amino acids through the mercury cyclization of chiral amidals. J. 
Org. Chem. 1992, 57, 1082-1087. 
(399) Majumdar, S.; Sloan, K. B. Synthesis, hydrolyses and dermal delivery of N-alkyl-
N-alkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide 
and thiol containing drugs. Bioorg. Med. Chem. Lett. 2006, 16, 3590-3594. 
(400) Siver, K. G.; Sloan, K. B. Alkylation of 6-Mercaptopurine (6-MP) with N-Alkyl-
N-alkoxycarbonyl)aminomethyl Chlorides: S6-(N-Alkyl-N-
alkoxycarbonyl)aminomethyl-6-MP Prodrug Structure Effect on the Dermal 
Delivery of 6-MP. J. Pharm. Sci. 1990, 79, 66-73. 
(401) Ikeda, K.; Terao, Y.; Sekiya, M. New syntheses of alpha;-N-
alkylacetamidomethylated carbonyl compounds. Chem. Pharm. Bull. 1981, 29, 
1156-1159. 
(402) Trost, B. M.; Chupak, L. S.; Lübbers, T. Short preparation of (S)-(E)-1-(O-
methylmandeloxy)butadiene. J. Org. Chem. 1997, 62, 736-736. 
(403) Desimoni, G.; Faita, G.; Quadrelli, P. Forty Years after “Heterodiene Syntheses 
with α,β-Unsaturated Carbonyl Compounds”: Enantioselective Syntheses of 3,4-
Dihydropyran Derivatives. Chem. Rev. 2018, 118, 2080-2248. 
(404) Gademann, K.; Chavez, D. E.; Jacobsen, E. N. Highly enantioselective inverse-
electron-demand hetero-Diels-Alder reactions of alpha,beta-unsaturated 
aldehydes. Angew. Chem. Int. Ed. 2002, 41, 3059-3061. 
(405) Graven, A.; Johannsen, M.; Jørgensen, K. A. A highly chemo- and enantio-
selective hetero-Diels–Alder reaction catalysed by chiral aluminium complexes. 
Chem. Commun. 1996, 2373-2374. 
(406) Wang, B.; Feng, X.; Huang, Y.; Liu, H.; Cui, X.; Jiang, Y. A Highly 
Enantioselective Hetero-Diels−Alder Reaction of Aldehydes with Danishefsky's 
Diene Catalyzed by Chiral Titanium(IV) 5,5‘,6,6‘,7,7‘,8,8‘-Octahydro-1,1‘-bi-2-
naphthol Complexes. J. Org. Chem. 2002, 67, 2175-2182. 
(407) Laupichle, L.; Sowa, C. E.; Thiem, J. Synthesis and structural studies of 
asparagine-modified 2-deoxy-α-N-glycopeptides associated with the renin-
Angiotensin system. Bioorg. Med. Chem. 1994, 2, 1281-1294. 
 534 
(408) Bruno, N. C.; Tudge, M. T.; Buchwald, S. L. Design and preparation of new 
palladium precatalysts for C–C and C–N cross-coupling reactions. Chem. Sci. 
2013, 4, 916-920. 
(409) De Koning, C. B.; Michael, J. P.; Pathak, R.; Van Otterlo, W. A. L. The synthesis 
of indolo- and pyrrolo[2,1- a ]isoquinolines. Tetrahedron Lett. 2004, 45, 1117-
1119. 
(410) Ito, S.; Taguchi, T.; Yamada, T.; Ubukata, T.; Yamaguchi, Y.; Asami, M. 
Indolylbenzothiadiazoles with varying substituents on the indole ring: a 
systematic study on the self-recovering mechanochromic luminescence. RSC Adv. 
2017, 7, 16953-16962. 
(411) W. Gribble, G. Sodium borohydride in carboxylic acid media: a phenomenal 
reduction system. Chem. Soc. Rev. 1998, 27, 395. 
(412) Schwartz, B. D.; Denton, J. R.; Lian, Y.; Davies, H. M. L.; Williams, C. M. 
Asymmetric [4 + 3] Cycloadditions between Vinylcarbenoids and Dienes: 
Application to the Total Synthesis of the Natural Product (−)-5-epi-Vibsanin E. J. 
Am. Chem. Soc. 2009, 131, 8329-8332. 
(413) Larson, G. L.; Fry, J. L.: Ionic and Organometallic-Catalyzed Organosilane 
Reductions. In Organic Reactions; Denmark, S. E., Ed.; Wiley and Sons, 2008; 
Vol. 71. 
(414) Anderson, E.; Campbell, C.: Reduction of O,O-, N,O-, and S,O-Acetals to Ethers. 
Elsevier Ltd., 2014; Vol. 8; pp 339-367. 
(415) Li, W.; Mead, K. T.; Smith, L. T. Studies towards diarylheptanoid synthesis. Part 
1: Synthesis and ring cleavage reactions of hexahydro-2H,5H-pyrano[2,3-
b]pyran-2-ones. Tetrahedron Lett. 2003, 44, 6351-6353. 
(416) Gaertzen, O.; Misske, A. M.; Wolbers, P.; Hoffmann, H. M. R. Synthesis of 
Enantiopure C-Glycosides and Pseudo C-Glycosides. Lewis Acid Mediated 
Cleavage of [3.3.1] Oxabicyclic Lactones. Synlett 1999, 1999, 1041-1044. 
(417) Yin, J.; Linker, T. Stereoselective diversity-oriented syntheses of functionalized 
saccharides from bicyclic carbohydrate 1,2-lactones. Tetrahedron 2011, 67, 2447-
2461. 
(418) Volkov, A.; Tinnis, F.; Slagbrand, T.; Trillo, P.; Adolfsson, H. Chemoselective 
reduction of carboxamides. Chem. Soc. Rev. 2016, 45, 6685-6697. 
(419) Mizutani, M.; Inagaki, F.; Nakanishi, T.; Yanagihara, C.; Tamai, I.; Mukai, C. 
Total Syntheses of (−)- and (+)-Goniomitine. Org. Lett. 2011, 13, 1796-1799. 
(420) Spletstoser, J. T.; White, J. M.; Tunoori, A. R.; Georg, G. I. Mild and selective 
hydrozirconation of amides to aldehydes using Cp2Zr(H)Cl: Scope and 
mechanistic insight. J. Am. Chem. Soc. 2007, 129, 3408-3419. 
 535 
(421) Addis, D.; Das, S.; Junge, K.; Beller, M. Selective Reduction of Carboxylic Acid 
Derivatives by Catalytic Hydrosilylation. Angew. Chem. Int. Ed. 2011, 50, 6004-
6011. 
(422) Bower, S.; Kreutzer, K. A.; Buchwald, S. L. A Mild General Procedure for the 
One-Pot Conversion of Amides to Aldehydes.  Angew. Chem. Int. Ed. 1996, 35, 
1515-1516. 
(423) Laval, S.; Dayoub, W.; Favre-Reguillon, A.; Demonchaux, P.; Mignani, G.; 
Lemaire, M. A mild titanium-based system for the reduction of amides to 
aldehydes. Tetrahedron Lett. 2010, 51, 2092-2094. 
(424) Motoyama, Y.; Aoki, M.; Takaoka, N.; Aoto, R.; Nagashima, H. Highly efficient 
synthesis of aldenamines from carboxamides by iridium-catalyzed silane-
reduction/dehydration under mild conditions. Chem. Commun. 2009, 1574. 
(425) Gabriel, P.; Gregory, A. W.; Dixon, D. J. Iridium-Catalyzed Aza-Spirocyclization 
of Indole-Tethered Amides: An Interrupted Pictet–Spengler Reaction. Org. Lett. 
2019, 21, 6658-6662. 
(426) Nakajima, M.; Sato, T.; Chida, N. Iridium-Catalyzed Chemoselective Reductive 
Nucleophilic Addition to N -Methoxyamides. Org. Lett. 2015, 17, 1696-1699. 
(427) Yoritate, M.; Takahashi, Y.; Tajima, H.; Ogihara, C.; Yokoyama, T.; Soda, Y.; 
Oishi, T.; Sato, T.; Chida, N. Unified Total Synthesis of Stemoamide-Type 
Alkaloids by Chemoselective Assembly of Five-Membered Building Blocks. J. 
Am. Chem. Soc. 2017, 139, 18386-18391. 
(428) Gammack Yamagata, A. D.; Dixon, D. J. Enantioselective Construction of the 
ABCDE Pentacyclic Core of the Strychnos Alkaloids. Org. Lett. 2017, 19, 1894-
1897. 
(429) Huang, P.-Q.; Ou, W.; Han, F. Chemoselective reductive alkynylation of tertiary 
amides by Ir and Cu(i) bis-metal sequential catalysis. Chem. Commun. 2016, 52, 
11967-11970. 
(430) Hu, X.-N.; Shen, T.-L.; Cai, D.-C.; Zheng, J.-F.; Huang, P.-Q. The iridium-
catalysed reductive coupling reaction of tertiary lactams/amides with 
isocyanoacetates. Org. Chem. Front. 2018, 5, 2051-2056. 
(431) Gregory, A. W.; Chambers, A.; Hawkins, A.; Jakubec, P.; Dixon, D. J. Iridium-
Catalyzed Reductive Nitro-Mannich Cyclization. Chem. Eur. J. 2015, 21, 111-
114. 
(432) Tan, P. W.; Seayad, J.; Dixon, D. J. Expeditious and Divergent Total Syntheses of 
Aspidosperma Alkaloids Exploiting Iridium(I)-Catalyzed Generation of Reactive 
Enamine Intermediates.  Angew. Chem. Int. Ed. 2016, 55, 13436-13440. 
 536 
(433) Fuentes De Arriba, Á. L.; Lenci, E.; Sonawane, M.; Formery, O.; Dixon, D. J. 
Iridium-Catalyzed Reductive Strecker Reaction for Late-Stage Amide and Lactam 
Cyanation.  Angew. Chem. Int. Ed. 2017, 56, 3655-3659. 
(434) Xie, L.-G.; Dixon, D. J. Tertiary amine synthesis via reductive coupling of amides 
with Grignard reagents. Chem. Sci. 2017, 8, 7492-7497. 
(435) Xie, L.-G.; Dixon, D. J. Iridium-catalyzed reductive Ugi-type reactions of tertiary 
amides. Nature Commun. 2018, 9. 
(436) Wang, L.-Q.; Chen, S.-N.; Qin, G.-W.; Cheng, K.-F. Grayanane Diterpenoids 
from Pieris formosa. J. Nat. Prod. 1998, 61, 1473-1475. 
(437) Niu, C.-S.; Li, Y.; Liu, Y.-B.; Ma, S.-G.; Liu, F.; Li, L.; Xu, S.; Wang, X.-J.; 
Wang, R.-B.; Qu, J.; Yu, S.-S. Pierisketolide A and Pierisketones B and C, Three 
Diterpenes with an Unusual Carbon Skeleton from the Roots of Pieris formosa. 
Org. Lett. 2017, 19, 906-909. 
(438) Li, C.-H.; Yan, X.-T.; Zhang, A.-L.; Gao, J.-M. Structural Diversity and 
Biological Activity of the Genus Pieris Terpenoids. J. Agric. Food Chem. 2017, 
65, 9934-9949. 
(439) Riehl, P. S.; DePorre, Y. C.; Armaly, A. M.; Groso, E. J.; Schindler, C. S. New 
avenues for the synthesis of ent-kaurene diterpenoids. Tetrahedron 2015, 71, 
6629-6650. 
(440) Niu, C.-S.; Li, Y.; Liu, Y.-B.; Ma, S.-G.; Li, L.; Qu, J.; Yu, S.-S. Analgesic 
diterpenoids from the twigs of Pieris formosa. Tetrahedron 2016, 72, 44-49. 
(441) Liu, Y.; Zhang, Y. Intramolecular and intermolecular ketone–ester reductive 
coupling reactions promoted by samarium(II) iodide. Tetrahedron Lett. 2001, 42, 
5745-5748. 
(442) Szostak, M.; Fazakerley, N. J.; Parmar, D.; Procter, D. J. Cross-Coupling 
Reactions Using Samarium(II) Iodide. Chem. Rev. 2014, 114, 5959-6039. 
(443) Schiavo, L.; Lebedel, L.; Massé, P.; Choppin, S.; Hanquet, G. Access to Wieland–
Miescher Diketone-Derived Building Blocks by Stereoselective Construction of 
the C-9 Quaternary Carbon Center Using the Mukaiyama Aldol Reaction. J. Org. 
Chem. 2018, 83, 6247-6258. 
(444) Li, C.; Tu, S.; Wen, S.; Li, S.; Chang, J.; Shao, F.; Lei, X. Total Synthesis of the 
G2/M DNA Damage Checkpoint Inhibitor Psilostachyin C. J. Org. Chem. 2011, 
76, 3566-3570. 
(445) Kerr, W. J.; McLaughlin, M.; Morrison, A. J.; Pauson, P. L. Formal Total 
Synthesis of (±)-α- and β-Cedrene by Preparation of Cedrone. Construction of the 
Tricyclic Carbon Skeleton by the Use of a Highly Efficient Intramolecular Khand 
Annulation. Org. Lett. 2001, 3, 2945-2948. 
 537 
(446) Crawford, J. J.; Kerr, W. J.; McLaughlin, M.; Morrison, A. J.; Pauson, P. L.; 
Thurston, G. J. Use of a highly effective intramolecular Pauson–Khand 
cyclisation for the formal total synthesis of (±)-α- and β-cedrene by preparation of 
cedrone. Tetrahedron 2006, 62, 11360-11370. 
(447) Kerr, W. J.; McLaughlin, M.; Paterson, L. C.; Pearson, C. M. Total synthesis 2-
epi-α-cedren-3-one via a cobalt-catalysed Pauson-Khand reaction. Tetrahedron 
2018, 74, 5062-5068. 
(448) Chirkin, E.; Michel, S.; Porée, F.-H. Viability of a [2 + 2 + 1] Hetero-Pauson–
Khand Cycloaddition Strategy toward Securinega Alkaloids: Synthesis of the 
BCD-Ring Core of Securinine and Related Alkaloids. J. Org. Chem. 2015, 80, 
6525-6528. 
(449) Brill, Z. G.; Grover, H. K.; Maimone, T. J. Enantioselective synthesis of an 
ophiobolin sesterterpene via a programmed radical cascade. Science 2016, 352, 
1078-1082. 
(450) Reiser, O.; Ulbrich, K.; Kreitmeier, P. Microwave- or Microreactor-Assisted 
Conversion of Furfuryl Alcohols into 4-Hydroxy-2-cyclopentenones. Synlett 
2010, 2010, 2037-2040. 
(451) Kluge, A. F.; Untch, K. G.; Fried, J. H. Prostaglandins. X. Synthesis of 
prostaglandin models and prostaglandins by conjugage addition of a 
functionalized organocopper reagent. J. Am. Chem. Soc. 1972, 94, 7827-7832. 
(452) Alvarez, F. S.; Wren, D.; Prince, A. Prostaglandins. IX. Synthesis of (+-)-
prostaglandin E1, (+-)-11-deoxyprostaglandins E1,F1.alpha., and F1.beta., and (+-
)-9-oxo-13-cis-prostenoic acid by conjugate addition of vinylcopper reagents. J. 
Am. Chem. Soc. 1972, 94, 7823-7827. 
(453) Suzuki, M.; Yanagisawa, A.; Noyori, R. Prostaglandin synthesis. 16. The three-
component coupling synthesis of prostaglandins. J. Am. Chem. Soc. 1988, 110, 
4718-4726. 
(454) Robertson, J.; Hatley, R. J. D.; Watkin, D. J. Preparation of the tricyclic 
ketopyrrole core of roseophilin by radical macrocyclisation and Paal–Knorr 
condensation. J. Chem. Soc. Perkin Trans. 1 2000, 3389-3396. 
(455) Gu, J.; Dirr, M. J.; Wang, Y.; Soper, D. L.; De, B.; Wos, J. A.; Johnson, C. R. An 
Efficient Synthesis of 3-Hetero-13,14-dihydro Prostaglandin F1αAnalogues. Org. 
Lett. 2001, 3, 791-794. 
(456) Borrelly, S.; Paquette, L. A. Studies Directed to the Synthesis of the Unusual 
Cardiotoxic Agent Kalmanol. Enantioselective Construction of the Advanced 
Tetracyclic 7-Oxy-5,6-dideoxy Congener. J. Am. Chem. Soc. 1996, 118, 727-740. 
 538 
(457) Corey, E. J.; Boaz, N. W. The reactions of combined organocuprate-
chlorotrimethylsilane reagents with conjugated carbonyl compounds. Tetrahedron 
1985, 26, 6019-6022. 
(458) Bertz, S. H.; Miao, G.; Rossiter, B. E.; Snyder, J. P. New Copper Chemistry. 25. 
Effect of TMSCl on the Conjugate Addition of Organocuprates to .alpha.-Enones: 
A New Mechanism. J. Am. Chem. Soc. 1995, 117, 11023-11024. 
(459) Taylor, R. J. K. Organocopper Conjugate Addition-Enolate Trapping Reactions. 
Synthesis 1985, 1985, 364-392. 
(460) Hickmann, V.; Kondoh, A.; Gabor, B.; Alcarazo, M.; FüRstner, A. Catalysis-
Based and Protecting-Group-Free Total Syntheses of the Marine Oxylipins 
Hybridalactone and the Ecklonialactones A, B, and C. J. Am. Chem. Soc. 2011, 
133, 13471-13480. 
(461) Bailey, W. F.; Punzalan, E. R. Convenient general method for the preparation of 
primary alkyllithiums by lithium-iodine exchange. J. Org. Chem. 1990, 55, 5404-
5406. 
(462) Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. 
Safe and Convenient Procedure for Solvent Purification. Organometallics 1996, 
15, 1518-1520. 
(463) Huang, H.; Greenberg, M. M. Synthesis and Analysis of Oligonucleotides 
Containing Abasic Site Analogues. J. Org. Chem. 2008, 73, 2695-2703. 
(464) Bisacchi, G. S.; Chao, S. T.; Bachard, C.; Daris, J. P.; Innaimo, S.; Jacobs, G. A.; 
Kocy, O.; Lapointe, P.; Martel, A.; Merchant, Z.; Slusarchyk, W. A.; Sundeen, J. 
E.; Young, M. G.; Colonno, R.; Zahler, R. BMS-200475, a novel carbocyclic 2′-
deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in 
vitro. Bioorg. Med. Chem. Lett. 1997, 7, 127-132. 
(465) Petasis, N. A.; Bzowej, E. I. Titanium-mediated carbonyl olefinations. 1. 
Methylenations of carbonyl compounds with dimethyltitanocene. J. Am. Chem. 
Soc. 1990, 112, 6392-6394. 
(466) Hartley, R. C.; McKiernan, G. J. Titanium reagents for the alkylidenation of 
carboxylic acid and carbonic acid derivatives. J. Chem. Soc. Perkin Trans. 1 
2002, 2763-2793. 
(467) Khand, I. U.; Knox, G. R.; Pauson, P. L.; Watts, W. E.; Foreman, M. I. 
Organocobalt complexes. Part II. Reaction of acetylenehexacarbonyldicobalt 
complexes, (R1C2R2)Co2(CO)6, with norbornene and its derivatives. J. Chem. 
Soc. Perkin Trans. 1 1973, 977-981. 
(468) Magnus, P.; Principe, L. M. Origins of 1,2- and 1,3-stereoselectivity in 
dicobaltoctacarbonyl alkene-alkyne cyclizations for the synthesis of substituted 
bicyclo[3.3.0]octenones. Tetrahedron Lett. 1985, 26, 4851-4854. 
 539 
(469) Xacobe C. Cambeiro, M. A. P.: The Mechanism of the Pauson-Khand Reaction: 
Hypothesis, Experimental Facts, and Theoretical Investigations. In The Pauson-
Khand Reaction; Torres, R. R., Ed., 2012; pp 23-48. 
(470) Jeong, N.: 5.24 The Pauson–Khand Reaction. In Comprehensive Organic 
Synthesis II (2nd Ed.); Knochel, P., Ed.; Elsevier: Amsterdam, 2014; pp 1106-
1178. 
(471) Schore, N. E.; Croudace, M. C. Preparation of bicyclo[3.3.0]oct-1-en-3-one and 
bicyclo[4.3.0]non-1(9)-en-8-one via intramolecular cyclization of .alpha.,.omega.-
enynes. J. Org. Chem. 1981, 46, 5436-5438. 
(472) Chang, Y.; Shi, L.; Huang, J.; Shi, L.; Zhang, Z.; Hao, H.-D.; Gong, J.; Yang, Z. 
Stereoselective Total Synthesis of (±)-5-epi-Cyanthiwigin I via an Intramolecular 
Pauson–Khand Reaction as the Key Step. Org. Lett. 2018, 20, 2876-2879. 
(473) Chuang, K. V.; Xu, C.; Reisman, S. E. A 15-step synthesis of (+)-ryanodol. 
Science 2016, 353, 912-915. 
(474) You, L.; Liang, X.-T.; Xu, L.-M.; Wang, Y.-F.; Zhang, J.-J.; Su, Q.; Li, Y.-H.; 
Zhang, B.; Yang, S.-L.; Chen, J.-H.; Yang, Z. Asymmetric Total Synthesis of 
Propindilactone G. J. Am. Chem. Soc. 2015, 137, 10120-10123. 
(475) Liu, D.-D.; Sun, T.-W.; Wang, K.-Y.; Lu, Y.; Zhang, S.-L.; Li, Y.-H.; Jiang, Y.-
L.; Chen, J.-H.; Yang, Z. Asymmetric Total Synthesis of Lancifodilactone G 
Acetate. J. Am. Chem. Soc. 2017, 139, 5732-5735. 
(476) Miller, K. A.; Martin, S. F. Concise, Enantioselective Total Synthesis of (−)-
Alstonerine. Org. Lett. 2007, 9, 1113-1116. 
(477) Chen, J.-P.; He, W.; Yang, Z.-Y.; Yao, Z.-J. Synthesis of Tricyclo[4,3,1,0 1,5 
]decane Core of Plumisclerin A Using Pauson–Khand Annulation and SmI 2 -
Mediated Radical Cyclization. Org. Lett. 2015, 17, 3379-3381. 
(478) Sugihara, T.; Yamada, M.; Yamaguchi, M.; Nishizawa, M. The Intra- and 
Intermolecular Pauson-Khand Reaction Promoted by Alkyl Methyl Sulfides. 
Synlett 1999, 1999, 771-773. 
(479) Sugihara, T.; Yamada, M.; Ban, H.; Yamaguchi, M.; Kaneko, C. Rate 
Enhancement of the Pauson–Khand Reaction by Primary Amines. Angew. Chem. 
Int. Ed. 1997, 36, 2801-2804. 
(480) Shambayani, S.; Crowe, W. E.; Schreiber, S. L. N-oxide promoted Pauson-Khand 
cyclizations at room temperature. Tetrahedron Lett. 1990, 31, 5289-5292. 
(481) Iqbal, M.; Vyse, N.; Dauvergne, J.; Evans, P. Microwave promoted Pauson–
Khand reactions. Tetrahedron Lett. 2002, 43, 7859-7862. 
 540 
(482) Shibata, T.; Toshida, N.; Takagi, K. Rhodium Complex-Catalyzed 
Pauson−Khand-Type Reaction with Aldehydes as a CO Source. J. Org. Chem. 
2002, 67, 7446-7450. 
(483) Cabré, A.; Khaizourane, H.; Garçon, M.; Verdaguer, X.; Riera, A. Total Synthesis 
of (R)-Sarkomycin Methyl Ester via Regioselective Intermolecular Pauson–
Khand Reaction and Iridium-Catalyzed Asymmetric Isomerization. Org. Lett. 
2018, 20, 3953-3957. 
(484) Lam, F. L., Lee, H.W., Wang, J. and Kwong, F.Y.: Recent Advancement of 
Catalytic Pauson-Khand-type Reactions. In The Pauson-Khand Reaction; Torres, 
R. R., Ed., 2012; pp 181-210. 
(485) Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for 
Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923-
2925. 
(486) Cui, Y.; Jiang, H.; Li, Z. T.; Wu, N.; Yang, Z.; Quan, J. M. Unexpected 
Regioselectivity in the Synthesis of Pyranonaphthoquinone via the Diels-Alder 
Reaction. Org. Lett. 2009, 11, 4628-4631. 
(487) Kuwano, R.; Kashiwabara, M. Ruthenium-catalyzed asymmetric hydrogenation 
of N-Boc-indoles. Org. Lett. 2006, 8, 2653-2655. 
(488) Yang, X. W.; Yang, C. P.; Jiang, L. P.; Qin, X. J.; Liu, Y. P.; Shen, Q. S.; Chen, 
Y. B.; Luo, X. D. Indole Alkaloids with New Skeleton Activating Neural Stem 
Cells. Org. Lett. 2014, 16, 5808-5811. 
(489) CrysAlisPro.  Rigaku Oxford Diffraction (2019).  CrysAlicPro Software System, 
1.171.40.53. 
(490) SHELXT.  (2015).  G. M. Sheldrick.  A program for crystal structure solution. 
Acta Cryst. A71, 3-8. 
(491) Spek, A. L.  (2009).  PLATON, A Multipurpose Crystallographic Tool.  Utrecht 
University, The Netherlands. Acta Cryst. D65, 148-155. 
(492) Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. 
OLEX2: a complete structure solution, refinement and analysis program. J Appl 
Crystallogr 2009, 42, 339-341. 
(493) WinGX 1.64.  (1999).  An Integrated System of Windows Programs for the 
Solution, Refinement and Analysis of Single Crystal X-ray Diffraction Data.  
Farrugia, L. J.  J. Appl. Cryst. 32. 837-838. 
(494) Rw(F2) =  w(|Fo|2 - |Fc|2)2/ w(|Fo|)4}1/2 where w is the weight given each 
reflection. 
  R(F) =  S(|Fo| - |Fc|)/S|Fo|} for reflections with Fo > 4(s(Fo)). 
 
 541 
  S =  [Sw(|Fo|2 - |Fc|2)2/(n - p)]1/2,  where n is the number of reflections 
and p is the number of refined parameters. 
(495) International Tables for X-ray Crystallography (1992). Vol. C, Tables 4.2.6.8 and 
6.1.1.4, A. J. C. Wilson, editor, Boston: Kluwer Academic Press. 
(496) Sheldrick, G. M. (1994). SHELXTL/PC (Version 5.03). Siemens Analytical X-
ray Instruments, Inc., Madison, Wisconsin, USA. 
 
